PDF bestand Page 1. Page 2. Appendix Annual Report Vumc CCA

Transcription

Address VUmc Cancer Center Amsterdam (VUmc CCA) VU University Medical Center PK 5 Z 166 De Boelelaan 1117 1081 HV Amsterdam The Netherlands phone: (31)20 4443113 e‐mail: vumc‐cca@vumc.nl website : www.vumc.nl/afdelingen/CCA‐V‐ICI Appendix Annual Report Vumc CCA 2014 ‐ 1 of 216 List of contents Appendices 1. 2. 3.
4.
5. Organization VUmc CCA Scientific input 3 Scientific output 21 Research programs 76 8 Output indicators Research products for peers and societal target groups and outreach activities in 2014  Contributions to a directive, protocol, or policy note  Research outputs other than publications Outreach activities for societal target groups  Lectures for health care professionals, general public and patients  Contributions, based on research, to post initial education  Media attention Use of research products  International collaboration  Patents  Demonstrable marks of recognition  Invited lectures  Awards  Organization of congresses  Memberships of scientific committees, editorial boards and civil advisory bodies 6. Ongoing research projects 7. Scientific Research Committee 90 93 97 99 102 106 126 127 144 146 149 171 204 Appendix Annual Report Vumc CCA 2014 – List of contents ‐ 2 of 216 Appendix 1 – Organization VUmc CCA

Management Board The members of the Management Board are responsible for the organization, mission and tasks of VUmc CCA. The Board consists of eight members, seven members have a (bio‐)medical background in either oncology or immunology and one has a organizational background. Each board member holds a portfolio. The Management Board meets once a week. Members / portfolio: H.M.W. Verheul, Department of Medical Oncology, director VUmc CCA / Patient care and clinical cancer research Y. van Kooyk, Department of Molecular Cell Biology and Immunology / Immunology research (from January 2014) G. Kazemier, Department of Surgical Oncology / PR, communication and fundraising E. van Kessel, VUmc CCA / Finances and internal organization C.R. Leemans, Department of Head and Neck surgery / Education and training G.A. Meijer, Department of Pathology / Cancer research (till January 2014) B.J. Slotman, Department of Radiation Oncology / External affairs and regionalization P.J.F. Snijders, Department of Pathology / Cancer research (from May 2014) A.E. Voskuyl, Department of Rheumatology / Patient care and clinical immunology research 
Bureau VUmc CCA The VUmc CCA bureau consists of (senior) board assistants, fundraisers, project controllers, project manager and a secretary. The bureau supports all the portfolios of the management board. Supportive staff C. Addens (secretary) Y. Denisse (fundraiser) (from October 2014) J. van Diemen (board assistant) Y.M. Duiker (board assistant) E. van Kessel (project manager) M.A.J. Koelink (board assistant) G.K. Kuipers (senior board assistant) H. Loeffen (fundraiser) (till May 2014) D. Nunnely (project controller) (from September 2014) Annual Report VUmc CCA 2014 – Appendix 1: Organization VUmc CCA ‐ 3 of 216 

E.M. Ruhé‐Hoogervorst (senior board assistant) E. Takkenberg (fundraiser) J. Zweers (project controller) Executive Board Executive Board consists of the program leaders of VUmc CCA. The research projects of VUmc CCA are grouped in five programs, headed by three to five program leaders. The five programs are meant to overview research activities within the program in order to optimize integration and sharing of expertise within the institute. The program leaders are responsible for the organization, the coordination and the quality of the program. The Executive Board reports back to the Management Board and advices on running matters. Together, a long‐term policy is developed for the programs, covering their focus, the need for personnel and materials, their budgets and their development. These long‐term plans constitute the basis of the long‐term policy of VUmc CCA. The Executive Board meets 4 times a year. Members Program 1: Oncogenesis R.H. Brakenhoff P.J.F. Snijders (till May 2014) H. Meijers‐Heijboer (from November 2014) R.D.M. Steenbergen (from October 2014) Program 2: Immunopathogenesis R. Beelen (till May 2014) T.D. de Gruijl A.A. van de Loosdrecht (from October 2014) R. Mebius E. Hooijberg Program 3: Disease profiling G.A.M.S. van Dongen N.C.T. van Grieken O. Hoekstra (till December 2014) C. Jimenez T. Würdinger Program 4: Innovative therapy J.J.W.M. Janssen G.J. Peters S. Senan H. van der Vliet R. de Bree (till December 2014) Program 5: Quality of life J. Dekker B.D. Onwuteaka‐Philipsen I.M. Verdonck‐de Leeuw O. Visser G.J. Kaspers (till June 2014) Internal Advisory Board The internal advisory board consist of heads (or a delegate) of departments involved in cancer and immunology within VUmc. The chairman is member of the MB. The board advices about policy affairs and meets twice a year. In the meeting of the advisory board policy affairs regarding the research institute (research, education and infrastructure) will be discussed. 
Steering committee oncological care The steering committee oncological care consists of heads (or delegates) of departments involved in clinical cancer care. This committee discusses all items regarding oncological care, such as multidisciplinary care pathways, regionalization, infrastructure, finances and communication. The steering committee meets every month. Annual Report VUmc CCA 2014 – Appendix 1: Organization VUmc CCA ‐ 4 of 216 
Scientific Research Committee (CWO) The CWO is divided into a section that advises merely animal related protocols (CWO‐DEC) and a section that advises patient related protocols and other project proposals. The CWO advises about the research policy and about the feasibility of new research projects. The CWO advises specifically about the quality and the feasibility of all research proposals that need permission of the ethical committees for patient related or animal related research before they can be realized. An overview of the protocols and project proposals submitted at the CWO (DEC) in 2014 can be found in Appendix 5. CWO for patient related protocols and other project proposals Research proposals that are already approved by a Dutch METC outside VUmc are judged only on local feasibility and if the research fits into the focus of research. The CWO also advises on other research proposals for which judgment by the CWO is desired. The CWO consists to a maximum of 15 members, of which at least four clinicians (including a pathologist) and two fundamental researchers. The CWO meets twice a month. Members: A.A. van de Loosdrecht (chair till October 2014) A.J.M. van den Eertwegh (chair from October 2014) B.J.M. Braakhuis N. van de Donk (from November 2014) M. van Egmond J.M.M. den Haan N. Haasbeek N.H. Hendrikse D. de Jong M. Klein G.K. Kuipers (secretary) D.L. van der Peet (from October 2014) D.M. Pegtel J.C. Reijneveld (from October 2014) R.D.M. Steenbergen (till October 2014) W.J.J. Unger (till November 2014) Q. Waisfisz CWO for animal related protocols Animal related protocols that need approval of the animal ethical committee (DEC) of the VUmc are first evaluated by the CWO DEC committee. The protocols are judged once a month. The CWO DEC is composed of five to seven members. Members: R. Scheper (chair) B.J. Appelmelk V. van Beusechem J. den Haan G. Kraal C. Molthoff (from December 2014) D. Noske (from March 2014) Y.M. Duiker (secretary) 
Committee for Education & Training The committee for Education and Training supervises and advices about all training and education activities within VUmc CCA. These activities range from counselling of higher education students, monitoring and coordinating oncology and immunology education at the (bio)medical Bachelor’s and Master’s programmes at VU and VUmc, to coordinating graduate and postgraduate education. The committee meets at least four times a yearThe graduate training in oncology is organized within the Oncology Graduate School Amsterdam (Onderzoekschool Oncologie Amsterdam ‐ OOA). The PhD student council (ProPhD) is invited to the meting when for matters that concern them directly. Annual Report VUmc CCA 2014 – Appendix 1: Organization VUmc CCA ‐ 5 of 216 Members of the Committee for Education & Training: C.R. Leemans (chair) R.H.J. Beelen (till June 2014) M.M. van Duist A.W. Griffioen (from September 2014) E. Hooijberg (from September 2014) G.A. Meijer (till September 2014) E.M Ruhé S. Zweegman (from September 2014) Subgroups: Oncology profile committee members: B.J.M. Braakhuis I.R.H.M. Konings A.A. van de Loosdrecht N.C.T. van Grieken F.B.J.M. Thunnissen E.M. Ruhé‐Hoogervorst (profile coordinator) Immunology and Infection committee members: W. Bitter H.J. Bontkes I.E.M. Bultink G.K. Kuipers (profile coordinator) Directorate OOA (Oncology Graduate School Amsterdam) A.W. Griffioen E.M. Ruhé‐Hoogervorst, secretary (VUmc) H. te Riele (NKI) M. Spaargaren (AMC) 
PhD student committee The interests of the VUmc CCA PhD students are represented by the PhD‐student committee (Pro‐PhD). This group advises VUmc CCA about subjects like courses, meetings and communication. They meet at least three times a year with a delegation of the Management Board. All PhD students of VUmc CCA are allowed to take part of this committee. Participation is on a voluntary basis. Members: F.L.M. de Groen N. Kerkhoff M. Walraven M.Q. Wentink 
CCA research building committee The CCA research building committee takes (non financial) decisions about: items concerning the CCA building (such as requests for accommodation of new research groups) licenses labour conditions and environmental legislation logistics behavioural and admission rules use of collective equipment The CCA research building committee advices the division V management and the board of VUmc CCA about all items concerning the CCA building and finances. The CCA research building committee provides information exchange between the VUmc board and the division board on the one hand and the users of the research building on the other hand. The CCA research building committee meets once a month Members: A. Dräger (chair) R.H. Brakenhoff E. Hooijberg V.W. van Beusechem Annual Report VUmc CCA 2014 – Appendix 1: Organization VUmc CCA ‐ 6 of 216 
T. Würdinger Y.M. Duiker (secretary) Funding by stichting VUmc CCA VUmc CCA foundation generates funds to facilitate research, facilities and lifestyle care. This foundation was founded over 25 years ago to support Prof Bob Pinedo and his colleagues with their innovative cancer research. The foundation consists of dedicated boardmembers with an extensive network and knowledge. Annual Report VUmc CCA 2014 – Appendix 1: Organization VUmc CCA ‐ 7 of 216 Appendix 2 – Scientific input
Program 1: Oncogenesis
Department
Funding
FTE
Scientific core staff
Oudejans CBM
Clinical Chemistry
1
0,05
Dorsman JC
Clinical Genetics
1
0,4
Joenje H
Clinical Genetics
1
0,2
Meijers-Heijboer HE
Clinical Genetics
1
0,2
te Riele H
Clinical Genetics
1
0,2
van Hest LP
Clinical Genetics
1
0,1
Waisfisz Q
Clinical Genetics
1
0,2
Berkhof J
Epidemiology and Biostatistics
1
0,7
van de Wiel MA
1
0,2
Kenter GG
Obstetrics and Gynaecology
1
0,2
Bloemena E
Oral and Maxillofacial Surgery and Pathology
1
0,2
Forouzanfar T
1
0,05
Karagozoglu KH
1
0,1
Schulten EAJM
1
0,1
van der Waal I
1
0,1
Braakhuis BJM
Otolaryngology/Head and Neck Surgery
1
0,85
Brakenhoff RH
1
0,85
Leemans CR
1
0,05
Bleeker MCG
Pathology
1
0,2
Carvalho B
Pathology
2
0,5
Cillessen SAGM
Pathology
3
1
de Jong D
Pathology
1
0,2
Heideman DAM
Pathology
1
0,5
Hooijberg E
Pathology
1
0,6
Meijer CJLM
Pathology
2
0,4
Meijer GA
Pathology
1
0,1
Mooi WJ
Pathology
1
0,1
Pegtel DM
Pathology
3
0,45
Snijders PJF
Pathology
1
0,35
Steenbergen RDM
Pathology
1
0,4
Steenbergen RDM
Pathology
2
0,11
Uyterlinde AM
Pathology
1
0,01
van Criekinge WMR
Pathology
2
0,11
Adank M
Clinical Genetics
1
0,1
Ameziane N
Clinical Genetics
3
0,9
de Lange J
Clinical Genetics
3
1
Gille JJP
Clinical Genetics
1
0,1
Heins YM
Clinical Genetics
1
0,1
Menko FH
Clinical Genetics
1
0,07
Poddighe J
Clinical Genetics
1
0,1
Stoepker C
Clinical Genetics
1
0,25
Wolthuis RMF
Clinical Genetics
1
0,8
te Beest DE
3
0,92
de Wit M
Laboratory Medical Oncology
2
1
Other scientific staff
Annual Report VUmc CCA 2014 – Appendix 2: Scientific input - 8 of 216
Pham TV
3
1
Jordanova ES
1
0,7
de Visscher JGAM
1
0,05
Martens-de Kemp SR
3
0,76
Mes SW
2
0,63
Lalic D
Pathology
3
0,38
Rozendaal L
Pathology
1
0,1
Scheffer GL
Pathology
1
0,5
van der Stroom EMC
Pathology
3
0,06
Wilting SM
Pathology
3
0,67
Corbin M
Clinical Genetics
3
0,88
Dommering CJ
Clinical Genetics
1
0,1
Faramarz A
Clinical Genetics
2
0,75
Kooi EI
Clinical Genetics
3
0,75
Mol BM
Clinical Genetics
1
0
Pennings C
Clinical Genetics
3
0,25
Roohollahi K
Clinical Genetics
4
0
Heeren AM
3
0,75
Dekker H
1
0,2
Dekker H
4
0,25
Tan C
1
0
de Boer DV
3
0,75
Graveland APJ
1
0,03
van Harten AM
3
0,75
Babion I
Pathology
3
0,75
de Strooper LMA
Pathology
3
0,69
den Uil SH
Pathology
3
1
Donken R
Pathology
3
0,75
Hiemstra AC
Pathology
1
0,12
Hubers J
Pathology
3
0,13
Luttmer R
Pathology
3
0,75
Mendeville MS
Pathology
3
0,75
Miok V
Pathology
3
0,75
Novalic Z
Pathology
3
0,56
Polman NJ
Pathology
3
0,75
Ramayanti O
Pathology
3
0,75
Rog PSJ
Pathology
1
0,53
Schütze DM
Pathology
3
0,31
Snoek BC
Pathology
2
0,75
Uijterwaal MH
Pathology
3
0,19
van Zummeren M
Pathology
3
0,75
Verhoef VMJ
Pathology
3
0,19
Verlaat W
Pathology
3
0,75
Middeldorp JM
Pathology
1
0,5
Peeper DS
Pathology
1
PhD students
Visiting fellows
Total research staff
0
37,71
Program 2: Immunopathogenesis
Department
Funding
FTE
de Rie M
Dermatology
1
0,01
Franken SM
Dermatology
1
0,3
Gibbs S
Dermatology
1
0,25
Hoekzema R
Dermatology
1
0,1
Rustemeyer T
Dermatology
1
0,3
van Montfrans C
Dermatology
1
0,1
de Boer KHN
Gastroenterology
1
0,1
Felt-Bersma RJF
Gastroenterology
1
0,2
Mulder CJJ
Gastroenterology
1
0,06
van Nieuwkerk CMJ
Gastroenterology
1
0,2
de Gruijl TD
1
0,8
Ang W
Medical Microbiology and Infection Control
1
0,1
Appelmelk BJ
1
0,05
Bitter W
1
0,4
Kuijl CP
1
0,37
Vainio SJ
1
0,3
van der Sar AM
1
0,55
Vandenbroucke-Grauls CMJE
1
0,15
van den Eertwegh AJM
Medical Oncology
1
0,1
Beelen RHJ
Molecular Celbiology and Immunology
1
0,44
den Haan JMM
1
0,6
Dijkstra CD
1
0,05
Dijkstra CD
1
0,05
Kraal G
1
0,6
Mebius RE
1
0,8
Ulrich MM
3
0,33
Unger WWJ
2
1
van Die IM
1
0,6
van Kooyk Y
1
0,6
Farhat K
Nefrology
3
0,05
Nurmohamed SA
Nefrology
1
0,1
Mulder MF
Paediatrics
1
0,1
van der Kuip M
Paediatrics
1
0,25
van der Plas RN
Paediatrics
1
0
van Furth AM
Paediatrics
1
0,1
van den Elsen PJ
Pathology
1
0,1
von Blomberg BME
Pathology
1
0,03
van Egmond M
Surgery
1
0,8
Commandeur S
3
0,75
Ambrosini M
3
1
Bogels M
2
0,33
Boks MA
3
1
Garcia-Vallejo JJ
2
1
Gul N
3
0,8
Ilarregui JM
2
0,78
Koning JJ
2
1
Pires da Silva Baptista A
2
0,25
Reijmers RM
2
1
van der Steen LPE
3
1
van Vliet SJ
2
1
Veninga H
3
1
Douma CE
Nefrology
3
0,05
Bakema JE
1
0,71
Bontkes HJ
Pathology
1
0,1
van Hoogstraten IMW
Pathology
1
0,1
de Graaf NL
Dermatology
2
0,01
Kosten IJ
Dermatology
1
0,56
Veldhuizen R
Dermatology
2
0,01
de Groot EFJ
Gastroenterology
1
0,65
Eisden TTHD
1
0,06
Ates LS
1
0,75
Boot M
3
0,75
Burggraaf MJ
2
0,13
van de Weerd R
2
0,4
van Winden VJC
1
0,75
Lam SW
Medical Oncology
3
0,75
Aleyd E
1
0,75
Bar-Ephraim J
1
0,75
Braster R
1
0,75
Cornelissen LAM
1
0,44
Duinkerken S
2
0,19
Dusoswa SA
3
0,06
Fehres CM
3
0,5
Ferrantelli E
2
0,75
Goverse G
2
0,5
Grewal SK
2
0,2
Heineke MH
2
0,25
Horrevorst SK
2
0,69
Klaver EJ
1
0,19
Li RJE
3
0,06
Schetters STT
2
0,5
Stavenuiter AWD
3
0,38
van Dinther D
3
0,44
Vila Cuenca M
2
0,75
Walraven M
2
0,75
van den Dungen FAM
Neonatology
2
0,2
Visser DH
Neonatology
1
0,2
Broers CJM
Paediatrics
1
0,2
de Crom S
Paediatrics
1
0
el Tahir O
Paediatrics
1
0
Mason S
Paediatrics
1
0
Msoka T
Paediatrics
1
0
Norder WAJ
Paediatrics
1
0,19
Solomons R
Paediatrics
1
0
van Elsland S
Paediatrics
3
0,75
van Leeuwen LM
Paediatrics
3
0,5
Rachmawati D
Pathology
3
0
PhD students
Visiting fellows
van Egmond M
1
0
van Rooijen N
3
0
Scheper RJ
Pathology
1
0
38,82
Program 3: Disease profiling
Department
Funding
FTE
0,05
Blankenstein MA
Clinical Chemistry
1
van de Wiel MA
1
0,6
Mulder CJJ
Gastroenterology
1
0,06
Huijgens PC
Hematology
1
0
Zijlstra JM
Hematology
1
0,2
Zweegman S
Hematology
1
0,1
Jimenez CR
4
1
van Beusechem VW
1
0,4
Hekker TAM
1
0,01
Kluytmans J
1
0,2
Morré SA
1
0,5
Savelkoul PHM
1
0,15
van Dijk K
1
0,05
Vandenbroucke-Grauls CMJE
1
0,15
van der Pouw-Kraan CTM
1
0,9
Heimans JJ
Neurology
1
0,06
Postma TJ
Neurology
1
0,1
Reijneveld JC
Neurology
1
0,1
Peerdeman SM
Neurosurgery
1
0,05
Boellaard R
Nuclear Medicine and PET Research
1
0,25
Comans EFI
1
0,05
Hoekstra OS
1
0,4
Lammertsma AA
1
0,15
Molthoff CFM
1
0,7
Raijmakers PG
1
0,05
van Dongen GAMS
1
0,75
Visser GWM
1
0,1
Vugts D
1
0,23
Vugts D
3
0,68
Windhorst AD
1
0,3
de Bree R
1
0,1
Leemans CR
1
0,05
Beliën JAM
Pathology
2
0,8
Bloemena E
Pathology
1
0,3
Carvalho B
Pathology
2
0,25
Carvalho B
Pathology
2
0,25
Fijneman RJA
Pathology
1
0,9
Grunberg K
Pathology
1
0,1
Meijer GA
Pathology
1
0,1
Pegtel DM
Pathology
3
0,45
Snijders PJF
Pathology
1
0,05
Thunnissen FBJM
Pathology
1
0,1
van Criekinge WMR
Pathology
2
0,11
van Grieken NCT
Pathology
1
0,2
Verweij CL
Pathology
1
0,3
Verweij CL
Pathology
2
0,3
Wesseling P
Pathology
1
0,15
Ylstra B
Pathology
1
0,35
Ylstra B
Pathology
1
0,35
Hendrikse NH
Pharmacy
1
0,3
Marcus JT
Physics and Medical Technology
1
0,05
Pouwels PJW
1
0,05
Becker A
Pulmonology
1
0,05
Daniels JMA
Pulmonology
1
0,3
de Langen AJ
Pulmonology
1
0,6
Hashemi SMS
Pulmonology
1
0,4
Smit EF
Pulmonology
1
0,5
Castelijns JA
Radiology
1
0,2
de Graaf P
Radiology
1
0,1
Meijerink MR
Radiology
1
0,2
van Kuijk C
Radiology
1
0,05
van Waesberghe JHTM
Radiology
1
0,05
Bultink IEM
Reumatology
1
0,1
Lems WF
Reumatology
1
0,1
van der Horst-Bruinsma IE
Reumatology
1
0,4
van der Laken CJ
Reumatology
4
0,2
Voskuyl AE
Reumatology
1
0,1
Kazemier G
Surgery
1
0,3
Meijerink WJ
Surgery
1
0,2
Paul MA
Surgery
1
0,1
te Velde EA
Surgery
1
0,2
Crusius JBA
1
0,75
Kaiser AM
1
0,05
Ossenkopp YJ
1
0,01
Ouburg S
1
0,5
Pettersson Fernholm AM
1
0,01
Spaargaren J
1
0
van Houdt R
1
0,01
Frings V
3
0,25
Huisman MC
1
0,2
Poot AJ
4
0,08
van Schie A
1
0,1
Verwer E
2
0,33
Waalboer DCJ
4
1
Yaqub MM
1
0,15
Tijink BM
3
0,05
Bierkens M
Pathology
2
1
Blits M
Pathology
2
0,22
Blonde W
Pathology
2
0,8
Blonde W
Pathology
3
0,2
Bosch LJW
Pathology
3
0,89
de Bruijn FDB
Pathology
2
0,1
de Bruijn FDB
Pathology
3
0,79
Hesselink AT
Pathology
3
1
Parlayan
Pathology
1
0,5
Parlayan
Pathology
2
0,5
Rausch CR
Pathology
3
0,75
Scheffer GL
Pathology
1
0,5
Sie DLS
Pathology
1
0,5
van Denderen AC
Pathology
2
0,9
Voorham QJM
Pathology
2
0,4
Voorham QJM
Pathology
3
0,6
Vosslamber S
Pathology
3
0,75
Johannesma PC
Pulmonology
2
0,75
Schook R
Pulmonology
1
0
van den Bos IC
Radiology
1
0,2
van Tilborg A
Radiology
3
0,09
Cheng JC
Radiology & Nuclear Medicine
2
0,25
Goos JACM
3
0,69
Vink MA
3
0,75
Nijeboer P
Gastroenterology
2
0,5
van Gils T
Gastroenterology
2
0,28
Jauw YW
Hematology
3
0,2
Beekhof R
3
0,25
Budding A
2
0,05
de Waaij DJ
1
0,2
Eck Hauer A
2
0,75
Schepens MLM
2
0,55
van der Brand M
2
0,62
Koekkoek J
Neurology
4
0,1
van Dellen E
Neurology
4
0,13
van Thuijl HF
Neurology
3
0,16
Hendriks E.J.
Neurosurgery
3
0,17
Hoyng LL
3
0,75
Makris N
3
0,5
Oprea D
1
0,2
Pekosak A
3
0,75
Verbeek J
3
0,58
Flach GB
1
0,02
Veringa SJE
Paediatric Oncology
4
0,6
Meel MH
Paediatrics
3
0,7
Cordes M
Pathology
3
0,12
de Groen FLM
Pathology
1
0,63
de Jong T
Pathology
2
0,69
de Jong T
Pathology
3
0,06
de Ridder A
Pathology
2
0,75
Komór MA
Pathology
3
0,25
Lubbers J
Pathology
2
0,75
Masoumi Kouhestani N
Pathology
3
0,53
Scheinin AI
Pathology
2
0,06
van den Broek E
Pathology
1
0,75
Bahce I
Pulmonology
3
0,1
Kuiper JL
Pulmonology
3
0,75
PhD students
Mellema WW
Pulmonology
3
0,75
Paff T
Pulmonology
3
0,75
de Jong MC
Radiology
4
0,75
Duvivier KM
Radiology
1
0,1
Scheffer HJ
Radiology
3
0,75
Kramer GM
3
0,56
John MLB
Reumatology
1
0,37
John MLB
Reumatology
3
0,37
van der Waal I
Pathology
1
0
van Schaardenburg D
Reumatology
1
0,05
Visiting fellows
52,68
Program 4: Innovative therapy
Department
Funding
FTE
Perez RSGM
Anesthesiology
1
0,1
Zuurmond WWA
Anesthesiology
1
0,2
Boers M
1
0,3
Coupe VMH
1
0,9
Menezes R
1
1
Mulder CJJ
Gastroenterology
1
0,06
Chamuleau MED
Hematology
1
0,2
Huijgens PC
Hematology
1
0
Janssen JJWM
Hematology
1
0,3
Lokhorst HM
Hematology
4
0,01
Meijer E
Hematology
1
0,1
Ossenkoppele GJ
Hematology
1
0,3
van de Loosdrecht AA
Hematology
1
0,3
Visser O
Hematology
1
0,2
Zweegman S
Hematology
1
0,1
Peters EJG
Internal Medicine
1
0,1
van Agtmael MA
Internal Medicine
1
0,9
Cloos J
Laboratory Hematology
1
0,67
Martens ACM
4
0,01
Mutis T
4
0,01
Schuurhuis GJ
1
0,75
Smit L
1
0,75
Griffioen AW
1
0,8
Peters GJ
1
0,8
van Beusechem VW
1
0,4
Boven E
Medical Oncology
1
0,07
Buter J
Medical Oncology
1
0,2
Konings IRHM
Medical Oncology
1
0,1
van den Eertwegh AJM
Medical Oncology
1
0,1
van der Houven van Oordt CW
Medical Oncology
1
0,2
van der Vliet JJ
Medical Oncology
1
0,2
van der Vorst MJDL
Medical Oncology
1
0,16
Verheul HMW
Medical Oncology
1
0,2
Voortman J
Medical Oncology
1
0,2
Heimans JJ
Neurology
1
0,06
Postma TJ
Neurology
1
0,1
Reijneveld JC
Neurology
1
0,2
Baayen JC
Neurosurgery
1
0,05
de Witt Hamer PC
Neurosurgery
1
0,3
Idema S
Neurosurgery
1
0,2
Noske DP
Neurosurgery
1
0,3
Vandertop WP
Neurosurgery
1
0,1
Wurdinger T
Neurosurgery
1
1
van der Meij BS
Nutricion and dietics
1
0,06
Moll AC
Opthalmonology
1
0,05
de Bree R
1
0,1
Eerenstein SEJ
1
0,02
Leemans CR
1
0,05
Abbink F
Paediatric Oncology
1
0
Hulleman E
Paediatric Oncology
3
0,7
Israels T
Paediatric Oncology
4
0,3
Kors WA
Paediatric Oncology
1
0
Dahele MR
Radiation Oncology
1
0,05
Haasbeek CJ
Radiation Oncology
1
0,05
Lagerwaard FJ
Radiation Oncology
1
0,05
Senan S
Radiation Oncology
1
0,2
Slotman BJ
Radiation Oncology
1
0,2
Sminia P
Radiation Oncology
1
0,2
Bijlsma JWJ
Reumatology
1
0,1
Bultink IEM
Reumatology
1
0,1
Lems WF
Reumatology
1
0,1
Voskuyl AE
Reumatology
1
0,1
Bonjer HJ
Surgery
1
0,2
Tuynman JB
Surgery
1
0,1
van den Tol MP
Surgery
1
0,2
van der Peet DL
Surgery
1
0,3
van Leeuwen PAM
Surgery
1
0,1
Geldof AA
Urology
1
0,5
van Moorselaar RJA
Urology
1
0,1
Vis A
Urology
1
0,1
Peeters CFW
3
0,92
Veldhuijzen NJ
3
0,9
Issa DE
Hematology
4
0,1
Niewerth D
3
0,56
Noordhuis P
4
0,6
Noort WA
3
0,01
Prins H
3
0,1
Slot S
3
0
Smit MA
4
0,12
van Oostveen JW
1
0
Broxterman HJ
1
1
Galvani E
4
1
Giovannetti E
2
0,4
Giovannetti E
3
0,4
Giovannetti E
4
0,2
Honeywell R
1
0,81
Huijbers EJM
2
1
Piersma SR
4
1
Rovithi MN
3
0,56
van Beynum JR
3
1
van de Ven R
3
1
van Pul KM
4
0,38
Berenguer de Felipe J
Neurosurgery
2
1
Lalic D
Neurosurgery
3
0,43
van der Stoop PM
Neurosurgery
2
0,8
Zhao XW
Neurosurgery
3
0,33
Langius JAE
3
0,33
Melis GC
1
0,59
Wierdsma NJ
1
0,22
de Haas V
Paediatric Oncology
1
0
van Vuurden DG
Paediatric Oncology
1
0
Raphael MF
Paediatrics
1
0
van Battum L
1
0,02
Hopmans W
Radiation Oncology
1
0,15
Thijssen VLJL
Radiation Oncology
1
0,6
van Sörnsen de Koste JR
Radiation Oncology
1
0,2
Verbakel WFAR
Radiation Oncology
3
0,2
Al MCM
Reumatology
1
1
Jansen G
Reumatology
1
0,25
van Tuyl L
Reumatology
3
0,66
Dickhoff C
Surgery
1
0,17
van den Heuvel B
Surgery
1
0,1
Zonderhuis BM
Surgery
1
0,05
Bijnsdorp IV
Urology
3
1
Bossenga J
Urology
1
0,1
Bongers ML
3
0,65
Chaturvedi N
3
0,38
Greuter MJ
3
0,75
Rauschenberger A
1
0,75
van der Meijde E
3
0,75
de Boer YS
Gastroenterology
2
0,75
van Beurden YH
Gastroenterology
1
0,44
de Koning H
Hematology
4
0,62
Thielen N
Hematology
4
0,4
Wondergem MJ
Hematology
1
0,1
Caris MG
Internal Medicine
1
0,56
de Jonge NA
Internal Medicine
4
0,56
Sikkens JJ
Internal Medicine
3
0,75
Cremers E
4
0,75
Drent E
3
0,01
Kerkhoff N
3
0,75
van Alphen C
3
0,75
Verhagen HJMP
3
0,75
Wojtuszkiewicz A
4
0,62
Avan A
3
0,38
Blijlevens M
3
0,19
PhD students
de Bruin R
3
0,75
Hodzic J
3
0,06
Kleibeuker EA
3
0,75
le Large TYS
1
0,25
Weiss A
4
0,31
Huijts L
Medical Oncology
4
0,75
Kruger DT
Medical Oncology
4
0,75
Labots M
Medical Oncology
4
0,3
Lameris R
Medical Oncology
3
0,75
Neefjes ECW
Medical Oncology
3
0,75
Offringa T
Medical Oncology
3
0,06
Poel D
Medical Oncology
3
0,62
van den Oord R
Medical Oncology
3
0,14
van der Mijn JC
Medical Oncology
4
0,34
van Helden EJ
Medical Oncology
3
0,75
van Linde ME
Medical Oncology
1
0,2
van Zweeden AA
Medical Oncology
1
0,1
Wentink MQ
Medical Oncology
4
0,75
Westgeest HM
Medical Oncology
3
0,75
Sol N
Neurology
3
0,75
van Dellen E
Neurology
4
0,05
Best MG
Neurosurgery
3
0,31
Crommentuijn MHW
Neurosurgery
3
0,31
Hiddingh L
Neurosurgery
3
0,35
Lagerweij T
Neurosurgery
3
0,75
van Rijn S
Neurosurgery
3
0,75
Buskermolen S
3
0,75
van der Werf A
4
0,56
Mourits DL
Opthalmonology
3
0,75
Hakim S
3
0,15
Schouten CS
2
0,56
Slobbe P
3
0,75
van Weert S
1
0,1
Blufpand HN
Paediatric Oncology
3
0,3
Jansen MHA
Paediatric Oncology
4
0
Klein K
Paediatric Oncology
4
0,6
Mir SE
Paediatric Oncology
2
0
Njuguna F
Paediatric Oncology
4
0
Olbara G
Paediatric Oncology
4
0
Sewing ACP
Paediatric Oncology
3
0,75
van de Velde ME
Paediatric Oncology
3
0,5
van Vuurden DG
Paediatric Oncology
4
0,4
Veldhuijzen van Zanten SEM
Paediatric Oncology
3
0,75
Franke N
Paediatrics
2
0
Boons CCLM
Pharmacy
3
0,75
Timmers L
Pharmacy
3
0
Wilhelm AJ
Pharmacy
1
0,1
Doornaert P
Radiation Oncology
1
0,05
Griffioen GHMJ
Radiation Oncology
1
0,1
Narayan RS
Radiation Oncology
3
0,3
Tol J
Radiation Oncology
3
0,6
Verstegen NE
Radiation Oncology
3
0,01
Bruijnen STG
Reumatology
4
0,75
Chandrupatla DMSH
Reumatology
3
0,75
Gent YYJ
Reumatology
3
0,31
Konijn NPC
Reumatology
1
0,75
Rasch LA
Reumatology
4
0,75
ter Wee MM
Reumatology
4
0,37
Tsang-A-Sjoe MWP
Reumatology
1
0,37
Tsang-A-Sjoe MWP
Reumatology
3
0,37
Ankersmit M
Surgery
3
0,75
Brinkmann SJH
Surgery
3
0
Buijs N
Surgery
3
0
Deijen CL
Surgery
3
0,7
Haloua JP
Surgery
1
0,1
Nielsen K
Surgery
3
0,1
Straatman J
Surgery
1
0,75
Uyl-de Groot CA
3
0
Groen RWJ
3
0
Scheper RJ
Pathology
1
0
Louie A
Radiation Oncology
3
0,4
Verheij M
Radiation Oncology
3
0
Boers M
Reumatology
3
0,1
van Schaardenburg D
Reumatology
1
Visiting fellows
0,05
77,52
Program 5: Quality of life
Department
Funding
FTE
0,4
Klein M
Medical Psychology
1
van der Linden MHM
Medical Psychology
3
0
Heimans JJ
Neurology
1
0,06
Leemans CR
1
0,05
Verdonck-de Leeuw IM
1
0,6
Kaspers GJL
Paediatric Oncology
1
0,2
Mostert SM
Paediatric Oncology
4
0,4
van Dulmen-den Broeder E
Paediatric Oncology
4
0,2
Veening MA
Paediatric Oncology
1
0
Dekker J
Rehabilitation Medicine
1
0,1
Meuleman EJH
Urology
1
0,1
Stoker J
Medical Psychology
1
0,5
Dirven L
Neurology
1
1
Lubberding S
2
0,38
van den Berg MH
Paediatric Oncology
3
0,6
van Litsenburg R
Paediatric Oncology
4
0,4
Hopmans W
Radiation Oncology
1
0,15
Boele F
Medical Psychology
3
0,75
van Dijk EM
Medical Psychology
3
0,24
Cnossen IC
3
0,08
PhD students
Jansen F
2
0,75
Korsten L
3
0,75
Krebber AMH
2
0,06
Rinkel RNPM
1
0,05
van Gogh CDL
1
0,02
van Nieuwenhuizen AJ
3
0,56
Braam KI
Paediatric Oncology
3
0,75
Handayani K
Paediatric Oncology
4
0
Steur LMH
Paediatric Oncology
3
0,1
Susilawati D
Paediatric Oncology
4
0
Gunawan S
Paediatrics
4
0
Schuitema I
Paediatrics
3
0
van Dijk M
Paediatrics
3
0,4
Al-Itejawi H
Urology
3
0,75
Neurology
4
Visiting fellows
Taphoorn MJB
0
10,67
Total research staff Vumc CCA
217,4
Appen
ndix 3 – Scientific
c outputt
gram
Scientiific outputt per prog
Program
WpR
WpNR
W
WP
VP
PP
DI
1. Oncogenesis
102
-
1
3
-
8
2. Immun
nopathogenesis
131
1
1
4
1
7
3. Disease profiling
162
2
5
5
10
8
py
4. Therap
388
-
81
39
-
20
5. Qualityy of life
102
1
3
6
3
1
Total 201
14
885
4
91
57
14
43
Total 201
13
909
6
48
49
7
44
Total 201
12
888
3
40
67
2
36
Total 201
11
775
42
30
53
16
38
Total 201
10
645
47
9
21
6
47
Total 200
09
564
59
31
15
1
43
WpR:
WpNR:
WP:
VP:
PP:
DI:
Scieentific papers refe
ereed (former WI, WN + LE)
Scieentific papers non
n refereed (formerr WI*)
Scieentific publication
ns (book, book chapters, proceedin
ngs) (former WB, WBC,
W
RA)
Pro
ofessional publicattions
Pop
pular publicationss
Dissertations
Scientiific quality
y per prog
gram
on of peer-re
eviewed publications (Sciience Citation Index (SCI) journals)
Evaluatio
Program
5
4
3
2
1
A
B
C
1. Oncogenesis
32
46
16
6
5
3
102
405
4,0
76,5
2. Immun
nopathogenesis
34
47
28
9
14
132
474
3,6
61,4
3. Disease profiling
52
51
33
11
15
162
600
3,7
63,6
120
101
82
36
49
388
1371
3,5
57,0
33
29
22
8
11
103
374
3,6
60,2
Total 201
14
271
274
18 1
69
92
887
3224
3,6
61,4
Total 201
13
297
285
18 3
64
80
909
3282
3,7
64,0
Total 201
12
266
330
16
67
48
77
888
3324
3,7
67,1
Total 201
11
304
251
14 7
46
29
777
3106
4,0
71,3
Total 201
10
246
203
11 2
44
39
644
2505
3,9
69,7
Total 200
09
213
174
99
47
30
563
2182
3,9
68,7
4. Therap
py
5. Qualityy of life
D
Relation bettween scores and journal
5:
SCI jou
urnal belonging to
o > 90th percentile (5 points)
4:
SCI jou
urnal belonging to
o 75th – 90th perrcentile (4 points)
3:
SCI jou
urnal belonging to
o 50th - 75th perc
centile (3 points)
2:
SCI jou
urnal belonging to
o 25th – 50th perrcentile (2 points)
1:
SCI jou
urnal from lowestt quarter, publicattions in peer-revieewed journals with
hout an Impact Fa
actor (1 point)
A:
WpR to
otal
C:
Average points
s
B:
Total p
points
D:
Percentage of WpR
W SCI journals in upper quartile (4 + 5)
Annual Report V
VUmc CCA 2014 –
– Appendix 3: Scieentific output ‐ 21 of 216 Key publiccations perr program Program
m 1 ‐ Oncoggenesis 1.
2.
3.
4.
5.
Steen
nbergen RDM, SSnijders PJF, He
eideman DAM, Meijer CJLM. C
Clinical implications of (epi)gennetic changes in
n HPV‐
inducced cervical preecancerous lesio
ons. Nat Rev Caancer2014; 14: 395‐405. (5/37
7.912) Verho
oef VMJ, Bosgraaaf RP, van Kem
menade FJ, Roz endaal L, Heide
eman DAM, Hessselink AT, Bekkkers RLM, Steenbergen RDM,, Massuger LFA
AG, Melchers W
WJG, Bulten J, Ovverbeek LIH, Be
erkhof J, Snijders PJF, Meijer CCJLM. Triage by meth
hylation‐markerr testing versus cytology in woomen who test HPV‐positive on self‐collectedd cervicovaginal specimens (PROHTEECT‐3): a random
mised controlleed non‐inferioriity trial. Lancet Oncol2014; 155: 315‐322. (5/2
24.725) van B
Boerdonk RAA, Daniels JMA, Sn
nijders PJF, Grüünberg K, Thunn
nissen FBJM, va
an de Wiel M, YYlstra B, Postmu
us PE, Meijeer CJLM, Meijerr GA, Smit EF, Sutedja TG, Heiddeman DAM. DNA copy number aberrations in endobronchial lesions: a validated predicto
or for cancer. Th
horax2014; 69: 451‐457. (5/8.5
562) Holsttege H, Pfeiffer W, Sie DLS, Hulsman M, Nichoolas TJ, Lee CC, Ross T, Lin J, M
Miller MA, Ylstraa B, Meijers‐Heijboer HE, Brugm
man MH, Staal FJT, Holstege G
G, Reinders MJTT, Harkins TT, Le
evy S, Sistermans EA. Somatic mutations found in the healthy blood comp
partment of a 11
15‐yr‐old womaan demonstrate
e oligoclonal he
ematopoiesis. G
Genome Res2014; 24: 733‐7742. (5/13.852)) Rietb
bergen MM, Snijders PJF, Beekkzada D, Braakhhuis BJM, van de
en Brink A, Heid
deman DAM, H
Hesselink AT, W
Witte BI, mena E, Baaten
nburg de Jong R
RJ, Leemans CR,, Brakenhoff RH
H. Molecular characterization oof p16‐immuno
opositive Bloem
but H
HPV DNA‐ negattive oropharynggeal carcinoma s. Int J Cancer2
2014; 134: 2366
6‐2372. (4/5.0007) Program 2 ‐
P
‐ Immunopa
athogenesiss 1.
2.
3.
4.
5.
van d
de Pavert SA, Feerreira M, Domingues RG, Ribeeiro H, Molenaaar R, Moreira‐Santos L, Almeidda FF, Ibiza S, Barbosa I, Goverse G, Labao‐Almeida C, Godin
nho‐Silva C, Konnijn T, Schoone
eman D, O'Toole
e TG, Mizee MRR, Habani Y, Haak E, Santo
ori FR, Littman DR, Schul. Mate
ernal retinoids control type 3 innate lymphoiid cells and set the offspring im
mmunity. Naturre 2014; 508: 1
123‐127. (5/42.3
351) Gül N
N, Babes L, Siegm
mund K, Kortho
ouwer R, Bögelss M, Braster R, Vidarsson G, te
en Hagen TLM, Kubes P, van Egmond M. Macrrophages elimin
nate circulating tumor cells aftter monoclonal antibody thera
apy. J Clin Invesst 2014; 124: 81
12‐823. (5/133.765) Roozeendaal APBR, R
Roozendaal R, R
Reijmers RM, Kooning JJ, Unger WW, Greuter M
M, Keuning ED, , Molenaar R, G
Goverse G, Sneeb
boer MMS, den
n Haan JMM, Bo
oes M, Mebius RE. Lymph nod
de stromal cells constrain imm
munity via MHC class II self‐aantigen presenttation. eLife 201
14; 3: e04433. ((5/8.519) Ruben JM, Bontkes HJ, Westers TM
M, Hooijberg E, Ossenkoppele GJ, van de Loossdrecht AA, de Gruijl TD. In situ loading he induction of tumor‐directedd immunity. of skiin dendritic cellls with apoptotic bleb‐derivedd antigens for th
Onco
oimmunology 20
014; 3: e946360. (4/6.283) Aleyd
d E, van Hout M
MWM, Ganzevle
es SH, Hoeben KKA, Everts V, Baakema JE, van E
Egmond M. IgA Enhances NETo
osis and Releaase of Neutroph
hil Extracellularr Traps by Polym
morphonuclearr Cells via Fc alp
pha Receptor I. JJ Immunol 2014; 192: 2374‐‐2383. (4/5.362
2) Program 33 – Disease
e profiling 1.
2.
3.
4.
5.
Scheiinin I, Sie DLS, B
Bengtsson H, va
an de Wiel MA, Olshen AB, van
n Thuijl HF, van Essen HF, Eijk PP, Rustenburgg F, Meijer Reijneveld JC, W
Wesseling P, Pinkel D, Albertsoon DG, Ylstra B. DNA copy num
mber analysis of f fresh and form
malin‐fixed GA, R
specimens by shallo
ow whole‐genom
me sequencing with identification and exclussion of problem
matic regions in the genome assembly. G
Genome Res 20
014; 24: 2022‐2 032. (5/13.852) der Born D, Sew
wing C, Herscheid JDM, Windhoorst AD, Orru R
RVA, Vugts DJ. A
A Universal Proccedure for the [F‐
van d
18]Trrifluoromethylaation of Aryl Iod
dides and Aryl BBoronic Acids w
with Highly Imprroved Specific AActivity. Angew
w Chem Int Ed En
ngl 2014; 53: 11
1046‐11050. (5//11.336) Haan JC, Labots M, R
Rausch C, Koop
pman M, de Noooy‐van Tol J, Mekenkamp LJM, van de Wiel M
MA, Israeli D, va
an Essen HF, vaan Grieken NCTT, Voorham QJM
M, Bosch LJW, Q
Qu X, Kabbarah
h O, Verheul HM
MW, Nagtegaal ID, Punt CJA, Y
Ylstra B, Meijeer GA. Genomicc landscape of m
metastatic coloorectal cancer. N
Nature Communications 2014;
4; 5: 5457 (5/10.742) Cohen R, Vugts DJ, V
Visser GWM, Sttigter‐van Walsuum M, Bolijn M
M, Spiga M, Lazzzari P, Shankar SS, Sani M, Zand
da M, van Donggen GAMS. Deveelopment of No
ovel ADCs: Conjjugation of Tub
bulysin Analogues to Trastuzum
mab Monitored
d by Dual Radio
olabeling. Canceer Res 2014; 74
4: 5700‐5710. (55/9.284) Lalic D, Hackenberg M, Bijnsdorp IV
V, van Eijndhovven MAJ, Sadek P, Sie DLS, Zini N, Middeldorpp JM, Ylstra B, M
Menezes R, Wurd
dinger T, Meijerr GA, Pegtel DM
M. Nontemplateed Nucleotide A
Additions Distin
nguish the Smalll RNA Composiition in Cells from Exosomess. Cell reports 2
2014; 8: 1649‐11658. (4/7.207)
Annual Report V
VUmc CCA 2014 –
– Appendix 3: Scieentific output ‐ 22
2 of 216 Program 4 – Innovativve therapy
1.
2.
3.
4.
5.
erwen B, Plug M
M, van der Wal A, zenne‐Goette E, Song JY, dde Vries S, Dekkker M, te Wojciechowicz K, Caantelli E, Van Ge
Mismatch Repaair ‐ Deficient In
ntestinal Cryptss and Accelerate
es Riele H. Temozolomide Increases the Number of M
origenesis in a M
Mouse Model o
of Lynch Syndroome. Gastroentterology 2014; 1
147: 1064‐10722. (5/13.926) Tumo
de Leeeuw DC, Denkeers F, Olthof MC
C, Rutten AP, P ouwels W, Schuurhuis GJ, Osssenkoppele GJ, Smit L. Attenua
ation of micro
oRNA‐126 Expreession That Drivves CD34(+)38 Stem/Progenitor Cells in Acutte Myeloid Leukkemia Leads to Tumor Eradication. Cancer Res 2014; 74: 2
2094‐2105. (5/99.284) Giovaannetti E, Wangg QY, Avan A, Funel N, Lagerw
weij T, Lee J, Caretti V, van der V
Velde A, Boggi U, Wang YS, Va
asile E, Peterrs GJ, Wurdingeer T, Giaccone G
G. Role of CYB5 A in Pancreaticc Cancer Progno
osis and Autophhagy Modulatio
on. J Natl Canceer I 2014; 106: djt346. (5/15.1
161) Kirwaan JR, Boers M. Biological treatment in rheum
matoid arthritis: when to stop?
?. Lancet 2014;; 383: 288‐289 ((5 / 39.2007) de Jong T, Vosslamb
ber S, Jager W, R
Raterman H, Vooskuyl A, Gelde
erman K, Verwe
eij C. Serum Cyttokine Changes in Rituximab‐Treated R
Rheumatoid Artthritis Patients.. Ann Rheum Dis 2014; 73: A3 (5 / 9.27) Program
m 5 – Qualitty of life 1.
2.
3.
4.
5.
an der Schuere n, Verheul HMW
W, Langius JAE. 'Pre‐cachexia' : a non‐existingg Buskeermolen S, van Bokhorst‐de va
phenomenon in cancer?. Ann Onco
ol2014; 25: 16668‐1669. (5/6.57
78) Verdo
onck‐de Leeuw
w IM, Buffart LM
M, Heijmans MW
W, Rietveld DHFF, Doornaert P, de Bree R, Buteer J, Aaronson NK, Slotm
man BJ, Leeman
ns CR, Langendijjk JA. The coursse of health‐related quality of life in head andd neck cancer p
patients treateed with chemoradiation: A pro
ospective coho rt study. Radiotther Oncol2014
4; 110: 422‐4288. (5/4.857) Krebb
ber AMH, Buffaart LM, Kleijn G,, Riepma IC, de Bree R, Leemaans CR, Becker A
A, Brug J, van Sttraten A, Cuijpe
ers P, de Leeuw
w IM. Prevalence of depressio
on in cancer pattients: a meta‐aanalysis of diagnostic interview
ws and self‐report instru
uments. Psycho
o‐Oncol2014; 23
3: 121‐130. (5/44.044) Brom
m L, Pasman HRW
W, Widdershovven GAM, van dder Vorst MJDL,, Reijneveld JC, Postma TJ, Onw
wuteaka‐Philipsen BD. Patients' Preferencees for Participattion in Treatmeent Decision‐Maaking at the End
d of Life: Qualittative Interview
ws with ne2014; 9: e1000435. (4/3.534) Advanced Cancer Paatients. PLoS On
Verstteeg KS, Koninggs IR, Lagaay AM
M, van de Loosddrecht AA, Verh
heul HM. Predicction of treatmeent‐related toxxicity and outco
ome with geriattric assessmentt in elderly patieents with solid malignancies treated with cheemotherapy: a systematic review
w. Ann Oncol. 2
2014 Oct;25(10
0):1914‐8 (5/6.5578). Annual Report V
VUmc CCA 2014 –
3 of 216 Program
m 1 ‐ Oncoggenesis Scientiffic papers re
efereed 1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Ahsan
n H, Halpern J, Kibriya MG, Pie
erce BL, Tong L,, Gamazon E, M
McGuire V, Felbe
erg A, Shi JX, Jaasmine F, Roy S, Brutus R, Argoss M, Melkonian
n S, Chang‐Claude J, Andrulis I,, Hopper JL, Joh
hn EM, Malone K, Ursin G, Gam
mmon MD, Tho
omas DC, Semin
nara D, Casey G
G, Knight JA, Southey MC, Gilees GG, Santella R
RM, Lee E, Contti D, Duggan D,, Gallinger S, aile R, Jenkins M, Lindor NM
M, Newcomb P
P, Michailidou KK, Apicella C, Paark DJ, Peto J, Flletcher O, Silva ID, Lathrop M,, Hunter hanock SJ, Mein
ndl A, Schmutzler RK, Muller‐M
Myhsok B, Loch
hmann M, Beckmann L, Hein RR, Makalic E, Sch
hmidt DF, DJ, Ch
Bui Q
QM, Stone J, Flesch‐Janys D, Da
ahmen N, Nevaanlinna H, Aittomaki K, Blomqv
vist C, Hall P, Czzene K, Irwanto
o A, Rahm
man N, Turnbull C, Dunning AM
M, Pharoah P, W
Waisfisz Q, Meijers‐Heijboer H,, Uitterlinden AAG, Rivadeneira
a F, Nicolae D, Easton DF, Cox NJJ, Whittemore A
AS. A Genome‐‐wide Associatio
on Study of Earrly‐Onset Breasst Cancer Identifies PFKM as a N
Novel Breast Caancer Gene and
d Supports a Co mmon Geneticc Spectrum for B
Breast Cancer aat Any Age. Can
ncer Epideem Biomar 2014
4; 23: 658‐669. Arbyn
n M, Verdoodt F, Snijders PJF, Verhoef VMJ, SSuonio E, Dillne
er L, Minozzi S, Bellisario C, Baanzi R, Zhao FH, Hillem
manns P, Anttilaa A. Accuracy o
of human papill omavirus testin
ng on self‐colleccted versus clinnician‐collected
d samples: a metta‐analysis. Lan
ncet Oncol 2014
4; 15: 172‐183.
Bakkeer JL, Thirthagirri E, van Mil SE, Adank MA, Ikeeda H, Verheul HMW, Meijers‐‐Heijboer H, de e Winter JP, Sha
aran SK, Waisffisz Q. A Novel Splice Site Muttation in the Nooncoding Region of BRCA2: Implications for FFanconi Anemia
a and Famillial Breast Canccer Diagnostics. Hum Mutat 20014; 35: 442‐44
46. Bancrroft EK, Page EC
C, Castro E, Lilja
a H, Vickers A, SSjoberg D, Asse
el M, Foster CS, Mitchell G, Dreew K, Maehle L, Axcrona K, Evaans DG, Bulman
n B, Eccles D, M
McBride D, van A
Asperen C, Vase
en H, Kiemeney
y LA, Ringelbergg J, Cybulski C, Woko
olorczyk D, Selkkirk C, Hulick PJ, Bojesen A, Skyytte AB, Lam J, Taylor L, Olden
nburg R, Cremeers R, Verhaegh G, van Zelst‐‐Stams WA, Oosterwijk JC, Blanco I, Salinas M
M, Cook J, Rosarrio DJ, Buys S, C
Conner T, Ausem
ms MG, Ong KR
R, Hoffman J, Dom
mchek S, Powers J, Teixeira MR, Maia S, Foullkes WD, Taherian N, Ruijs M, Helderman v, I zatt L, Davidson R, Adank MA, W
Walker L, Schm
mutzler R, Tucke
er K, Kirk J, Hodggson S, Harris M
M, Douglas F, Lindeman GJ, Zggajnar J, Tischko
owitz M, Clowees VE, Susman R, Cajal TRY, Pa
atcher N, Gadeaa N, Spigelman A, Van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaaldson A, Stefan
nsdottir V, Fried
dman E, Chen‐SShtoyerman R, A
Amor DJ, Copak
kova L, Barwell J, Giri VN, Murrthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Hendersson A, McGrath
h J, Gallagher D, Aaronson N, rrdern‐Jones A, Bangma C, Dearn
naley D, Costelllo P, Eyfjord J, R
Rothwell J, Falcconer A, Gronbe
erg H, Moss SJ, Eeles R. Targetted Prostate Ca
ancer Screeening in BRCA1 and BRCA2 Mu
utation Carrierss: Results from tthe Initial Scree
ening Round of the IMPACT Sttudy. Eur Urol 22014; 66: 489‐4
499. Boerss A, Bosgraaf RP
P, van Leeuwen
n RW, Schuuringg E, Heideman DAM, Massuge
er LFAG, Verhoeef VMJ, Bulten J, Melch
hers WJG, van der Zee AGJ, Be
ekkers RLM, Wiisman GBA. DNA methylation analysis in self‐‐sampled brush
h material as a ttriage test in hrHPV‐positive w
women. Brit J Caancer 2014; 111
1: 1095‐1101.
Bosgrraaf RP, Ketelaaars PJW, Verhoef VMJ, Massugger LFAG, Meije
er CJLM, Melchers WJG, Bekkeers RLM. Reaso
ons for non‐
atten
ndance to cerviccal screening an
nd preferences for HPV self‐saampling in Dutcch women. Prevv Med 2014; 64
4: 108‐113. Braakkhuis BJM, Leem
mans CR, Visserr O. Incidence aand survival trends of head and neck squamoous cell carcinom
ma in the Netheerlands betweeen 1989 and 2011. Oral Oncol 2014; 50: 670‐675. Braakkhuis BJM, Rietbergen MM, Bu
uijze M, Snijderrs PJF, Bloemen
na E, Brakenhoff RH, Leemans CR. TP53 mutation and humaan papilloma virus status of orral squamous ceell carcinomas in young adult patients. Oral D
Dis 2014; 20: 60
02‐608. Broheet RM, Velthuizzen ME, Hogervvorst FBL, Meijeers‐Heijboer HE
EJ, Seynaeve C, Collee MJ, Verhhoef S, Ausemss MGEM, Hooggerbrugge N, van Asperen CJ, G
Garcia EG, Mennko F, Oosterwijjk JC, Devilee P, van 't Veer LJ,, van Leeuwen FE, Easton DF, Rookus MA, Anttoniou AC. Breast and ovarian cancer risks in a large series o
of clinically asceertained familie
es with a high p
proportion of B
BRCA1 and BRCA
A2 Dutch foundder mutations. J Med Genet 2014; 51: 98‐1077. Broun
ns EREA, Baart JA, Karagozoglu
u KH, Aartman IHA, Bloemenaa E, van der Waal I. Malignant ttransformation
n of oral leuko
oplakia in a well‐defined cohorrt of 144 patiennts. Oral Dis 201
14; 20: e19‐e24
4. Castrro FA, Dominguez A, Puschel K
K, van de Wyngaard V, Snijders PJF, Franceschi S, Pawlita M, FFerreccio C. Serrological prevaalence and perssistence of high
h‐risk human paapillomavirus in
nfection among
g women in Sanntiago, Chile. BM
MC Infect Dis 20014; 14: 361. Chen AA, Heideman
n DAM, Boon D, Chen ZG, Burkk RD, de Vuyst H
H, Gheit T, Snijd
ders PJF, Tomm
masino M, Francceschi S, ord GM. Human
n papillomaviruss 33 worldwidee genetic variatiion and associated risk of cervvical cancer. Virrology Cliffo
2014;; 448: 356‐362.. Chen AA, Heideman
n DAM, Boon D, Gheit T, Snijdeers PJF, Tommasino M, Franceschi S, Clifford GM. Human orldwide. J Virol 2014; 88: 45114‐4521. Papilllomavirus 45 Genetic Variation and Cervical CCancer Risk Wo
Clijsteers L, van Zon W
W, ter Riet B, Vo
oets E, Boekho ut M, Ogink J, R
Rumpf‐Kienzl C,, Wolthuis RMFF. Inefficient de
egradation of cycclin B1 re‐activaates the spindle
e checkpoint rigght after sister chromatid disju
unction. Cell Cyycle 2014; 13: 2
2370‐2378. Clijsteers L, Wolthuis RMF. PIP‐box‐m
mediated degraadation prohibits re‐accumula
ation of Cdc6 duuring S phase. JJ Cell Sci 2014;; 127: 1336‐134
45. Annual Report V
VUmc CCA 2014 –
4 of 216 16. Comb
bes JD, Pawlita M, Waterboer T, Hammouda D, Rajkumar T, Vanhems P, Sn
nijders PJF, Herrrero R, Francesschi S, Cliffo
ord G. Antibodiees against high‐‐risk human pappillomavirus proteins as marke
ers for invasivee cervical cancer. Int J Canceer 2014; 135: 2453‐2461. 17. de Ko
ock L, Sabbaghiaan N, Druker H,, Weber E, Ham
mel N, Miller S, Choong CS, Gotttardo NG, Keees UR, Rednam SP, van Hest LP, Jongmans M
MC, Jhangiani SS, Lupski JR, Zaccharin M, Bouro
on‐Dal Soglio D,, Huang A, Priesst JR, Perry A, M
Mueller S, Albreecht S, Malkin D
D, Grundy RG, Foulkes WD. Geerm‐line and som
matic DICER1 m
mutations in pinneoblastoma. A
ACTA Neuro
opathol 2014; 1
128: 583‐595. 18. de Strooper LMA, Heesselink AT, Berkhof J, Meijer CJLM, Snijders PJF, Steenberg
gen RDM, Heideeman DAM. Combined CADM
M1/MAL methyylation and cyto
ology testing fo r colposcopy trriage of high‐risk HPV‐positive women. Cance
er Epidem Biomar 2014; 23: 19
933‐1937. 19. de Strooper LMA, M
Meijer CJLM, Berrkhof J, Hesseli nk AT, Snijders PJF, Steenberg
gen RDM, Heideeman DAM. Me
ethylation Analyysis of the FAM19A4 Gene in C
Cervical Scrapess Is Highly Efficiient in Detectin
ng Cervical Carccinomas and Ad
dvanced CIN2//3 Lesions. Cancer Prevention Research 20144; 7: 1251‐1257
7. 20. de Strooper LMA, vaan Zummeren M
M, Steenbergenn RDM, Bleekerr MCG, Hesselin
nk AT, Wisman G
GB, Snijders PJF, Heideeman DAM, Meeijer CJLM. CAD
DM1, MAL and m
miR124‐2 meth
hylation analysis in cervical scrrapes to detect cervical and eendometrial can
ncer. J Clin Path
hol 2014; 67: 10067‐1071. 21. de Vu
uyst H, Mugo NR, Franceschi SS, McKenzie K, TTenet V, Njorogge J, Rana FS, Sa
akr SR, Snijders s PJF, Chung MH
H. Residual Diseaase and HPV Persistence after Cryotherapy foor Cervical Intraaepithelial Neop
plasia Grade 2//3 in HIV‐Positivve Women in Ken
nya. PLoS One 2014; 9: e111037. 22. Dijksttra MG, Snijderrs PJF, Arbyn M, Rijkaart DC, B erkhof J, Meijer CJLM. Cervica
al cancer screenning: on the wa
ay to a shift from cytology to full molecular scre
eening. Ann Onncol 2014; 25: 9
927‐935. 23. Dijksttra MG, van Nieekerk D, Rijkaarrt DC, van Kemeenade FJ, Heide
eman DAM, Snijders PJF, Meijeer CJLM, Berkhof J. Primaary hrHPV DNA Testing in Cervvical Cancer Scrreening: How to
o Manage Scree
en‐PositiveWom
men? APOBASC
CAMTrial Substtudy. Cancer Ep
pidem Biomar 2
2014; 23: 55‐633. 24. Domm
mering CJ, Mol BM, Moll AC, B
Burton M, Clooss J, Dorsman JC
C, Meijers‐Heijb
boer H, van der Hout AH. RB1 m
mutation specttrum in a comprehensive natio
onwide cohort oof retinoblastoma patients. J M
Med Genet 20114; 51: 366‐374
4. 25. Foliakki S, Brewer N, Pearce N, Snijd
ders PJF, Meijerr CJLM, Waqataakirewa L, Cliffo
ord GM, Francesschi S. Prevalen
nce of HPV infecttion and other risk factors in a
a Fijian populatiion. Infectious Agents and Can
ncer 2014; 9: 144. 26. Geraeets DT, Cuschieeri K, de Koning MNC, van Dooorn LJ, Snijders P
PJF, Meijer CJLM
M, Quint WGV, Arbyn M. Clinical Evalu
uation of a GP5++/6+‐Based Lum
minex Assay Haaving Full High‐R
Risk Human Pap
pillomavirus Geenotyping Capa
ability and an Intternal Control. J Clin Microbio
ol 2014; 58: 39996‐4002. 27. Gilliso
on ML, Castellsague X, Chaturvvedi A, Goodm an MT, Snijderss PJF, Tommasino M, Arbyn M
M, Franceschi S. Eurogin Roadmap: Comparative epidemiolo
ogy of HPV infeection and associated cancers of the head andd neck and cervvix. Int J Canceer 2014; 134: 4
497‐507. 28. Greutter MJE, Xu XM
M, Lew JB, Dekke
er E, Kuipers EJ , Canfell K, Meiijer GA, Coupe VMH. Modelingg the Adenoma
a and Serrated Pathway to
o Colorectal CAncer (ASCCA). RRisk Anal 2014; 34: 889‐910. M, Kooi EI, Massink MPG, Jorgeensen JAL, Rockkx DAP, Rooimans MA, de Wintter JP, Meijers‐‐Heijboer 29. Haitjeema A, Mol BM
H, Joeenje H, Dorsmaan JC. Coregulattion of FANCA aand BRCA1 in human cells. SprringerPlus 20144; 3: 381. 30. Heijsttek MW, Scherpenisse M, Groot N, Tacke C, SSchepp RM, Buisman AM, Berbers GAM, van der Klis FRM, W
Wulffraat NM. IImmunogenicitty and safety off the bivalent H PV vaccine in fe
emale patients with juvenile iddiopathic arthritis: a prosp
pective controllled observation
nal cohort studyy. Ann Rheum D
Dis 2014; 73: 15
500‐1507. 31. Hend
driks LEL, Smit EEF, Vosse BAH, M
Mellema WW, Heideman DAM
M, Bootsma GP,, Westenend M
M, Pitz C, de Vrie
es GJ, Houb
ben R, Grunbergg K, Bendek M, Speel EJM, Dinngemans AMC. EGFR mutated non‐small cell llung cancer pattients: Moree prone to deveelopment of bone and brain m
metastases?. Lun
ng Cancer 2014
4; 84: 86‐91. 32. Hes FFJ, Ruano D, Nieeuwenhuis M, T
Tops CM, Schruumpf M, Nielsen
n M, Huijts PEA, Wijnen JT, Waagner A, Garcia
a EBG, Sijmo
ons RH, Menko FH, Letteboer T
TGW, Hoogerbrrugge N, Harryvvan J, Kampman E, Morreau H
H, Vasen HFA, va
an Wezel T. Colorectal cancer risk variants on
n 11q23 and 155q13 are associated with unexxplained adenom
matous polyposis. J Med Geneet 2014; 51: 55‐60. 33. Hesseelink AT, Berkho
of J, van der Salm ML, van Spl unter AP, Geele
en TH, van Kem
menade FJ, Bleeeker MGB, Heideman DAM. Clinical Validaation of the HPV
V‐Risk Assay, a Novel Real‐Tim
me PCR Assay for Detection of H
High‐Risk Huma
an Papilllomavirus DNA by Targeting th
he E7 Region. J Clin Microbiol 2014; 52: 890‐8
896. 34. Hesseelink AT, Heideman DAM, Stee
enbergen RDM,, Gok M, van Ke
emenade FJ, Wilting SM, Berkhhof J, Meijer CJJLM, Snijdeers PJF. Methylation marker analysis of self‐ssampled cervico
o‐vaginal lavage
e specimens to o triage high‐risk HPV‐
positiive women for colposcopy. Intt J Cancer 20144; 135: 880‐886. 35. Hiddingh L, Raktoe R
RS, Jeuken J, Hu
ulleman E, Noskke DP, Kaspers GJ, Vandertop WP, Wesselingg P, Wurdinger T
T. Identtification of tem
mozolomide resistance factors in glioblastoma via integrative miRNA/mRNAA regulatory ne
etwork analyysis. Sci Rep 201
14; 4: 5260. 36. Hiddingh L, Tannouss BA, Teng J, Tops B, Jeuken J, Hulleman E, Bo
oots‐Sprenger S
SH, Vandertop W
WP, Noske DP, Kaspers GJL, W
Wesseling P, W
Wurdinger T. EFE
EMP1 induces ggamma‐secretase/Notch‐mediated temozolo mide resistance in gliobllastoma. Oncottarget 2014; 5: 363‐374. Annual Report V
VUmc CCA 2014 –
5 of 216 37. Holsttege H, Pfeiffer W, Sie DLS, Hulsman M, Nichoolas TJ, Lee CC, Ross T, Lin J, M
Miller MA, Ylstraa B, Meijers‐Heijboer HE, Brugm
man MH, Staal FJT, Holstege G
G, Reinders MJTT, Harkins TT, Le
evy S, Sistermans EA. Somatic mutations found in the healthy blood comp
partment of a 11
15‐yr‐old womaan demonstrate
e oligoclonal he
ematopoiesis. G
Genome Res 20
014; 24: 733‐7742. 38. Hubeers AJ, Brinkman
n P, Boksem RJ,, Rhodius RJ, W
Witte BI, Zwinderman AH, Heideman DAM, Duuin S, Koning R, Steen
nbergen RDM, SSnijders PJF, Sm
mit EF, Sterk PJ, Thunnissen E. Combined sputtum hypermethhylation and eN
Nose analyysis for lung can
ncer diagnosis. JJ Clin Pathol 20014; 67: 707‐711. 39. Hubeers AJ, van der D
Drift MA, Prinse
en CFM, Witte BBI, Wang YH, Sh
hivapurkar N, Stastny V, Bolijnn AS, Hol BEA, Feng ZD, Dekhuijzen PNR, Gazdar AF, Thunnissen E. Methyylation analysis in spontaneouss sputum for lu ng cancer diagn
nosis. Lung Canceer 2014; 84: 127‐133. 40. Hulseebos TJ, Kenter S, Siebers‐Rene
elt U, Hans V, W
Wesseling P, Flu
ucke U. SMARCB1 Involvementt in the Development of Leiom
myoma in a Patiient With Schw
wannomatosis. A
American Journ
nal of Surgical P
Pathology 2014;; 38: 421‐425. 41. Hulseebos TJM, Kenteer S, Verhagen WIM, Baas F, FFlucke U, Wesse
eling P. Premature terminationn of SMARCB1 translation may b
be followed by reinitiation in sschwannomatoosis‐associated schwannomas, but results in aabsence of SMA
ARCB1 expreession in rhabdo
oid tumors. ACT
TA Neuropathool 2014; 128: 43
39‐448. 42. Janseen M, Menko FH
H, Brosens LA, G
Giardiello FM, O
Offerhaus G. Esstablishing a clin
nical and moleccular diagnosis for hered
ditary colorectaal cancer syndro
omes: Present ttense, future perfect?. Gastrointest Endosc 22014; 80: 1145‐‐1155. 43. Johan
nnesma PC, Hou
uweling AC, van
n Waesberghe JJHTM, van Moo
orselaar RJA, Sttarink TM, Mennko FH, Postmus PE. The patho
ogenesis of pneeumothorax in Birt‐Hogg‐Dub, syndrome: A h
hypothesis. Respirology 2014; 19: 1248‐1250. 44. Johan
nnesma PC, Thu
unnissen E, Postmus PE. How rreliable are clin
nical criteria in d
distinguishing bbetween Birt‐Hogg‐Dube syndrrome and smokking as a cause for pneumothoorax?. Histopath
hology 2014; 64
4: 1045‐1046. 45. Johan
nnesma PC, Thu
unnissen E, Postmus PE. Lung Cysts as Indicattor for Birt‐Hog
gg‐Dube Syndroome. Lung 2014
4; 192: 215‐
216. nnesma PC, van
n den Borne BEM, Gille JJP, Naagelkerke AF, vaan Waesberghe
e JHTM, Paul MAA, van Moorselaar RJA, 46. Johan
Menkko FH, Postmuss PE. Spontaneo
ous pneumothoorax as indicato
or for Birt‐Hogg‐‐Dube syndrom
me in paediatric patients. BMC Pediatr 2014; 1
14: 171. 47. Khan SM, Greco D, M
Michailidou K, M
Milne RL, Mura nen TA, Heikkin
nen T, Aaltonen
n K, Dennis J, Boolla MK, Liu J, H
Hall P, Irwan
nto A, Humphreeys K, Li J, Czene K, Chang‐Clauude J, Hein R, R
Rudolph A, Seibo
old P, Flesch‐Jaanys D, Fletcherr O, Peto J, dos SSS, I, Johnson N,, Gibson L, Aitken Z, Hopper JLL, Tsimiklis H, B
Bui M, Makalic E
E, Schmidt DF, SSouthey MC, Ap
picella C, Stonee J, Waisfisz Q, Meijers‐Heijboer HE, Adank M
MA, van der Luijjt RB, Meindl A,, Schmutzler RKK, Muller‐Myhsok B, Lichtn
ner P, Turnbull C, Rahman N, C
Chanock SJ, Hu nter DJ, Cox A, Cross SS, Reed MW, Schmidt MK, Broeks A, vvan 't Veer LJ, Ho
ogervorst FB, Faasching PA, Sch
hrauder MG, Ekkici AB, Beckmann MW, Bojese
en SE, Nordestggaard BG, Nielse
en SF, Flyger H, Benitez J, ZZamora PM, Perez JI, Haiman CCA, Henderson BE, Schumache
er F, Le ML, Phaaroah PD, Dunn
ning AM, Shah M, Luben R, Brrown J, Couch FFJ, Wang X, Vacchon C, Olson JE
E, Lambrechts D
D, Moisse M, Paaridaens R, Christiaens MR, G
Guenel P, Truon
ng T, Laurent‐Puig P, Mulot C, Marme F, Burw
winkel B, Schne
eeweiss A, Sohnn C, Sawyer EJ, T
Tomlinson I, Kerrin MJ, Miller N,, Andrulis IL, Kn
night JA, Tchatcchou S, Mulligan
n AM, Dork T, B
Bogdanova NV, Easton DF, Nevvanlinna H. oRNA related polymorphisms and breast can cer risk. PLoS O
One 2014; 9: e109973. Micro
48. Knol JJC, de Wit M, A
Albrethsen J, Pie
ersma SR, Pham
m TV, Mongera S, Carvalho B, F
Fijneman RJA, M
Meijer GA, Jime
enez CR. Proteeomics of differrential extractio
on fractions enrriched for chrom
matin‐binding p
proteins from ccolon adenoma and carcin
noma tissues. B
Biochimica et Biiophysica Acta (BBA) ‐ Proteins and Proteomics 2014; 1844:: 1034‐1043. 49. Kuipeer JL, Heideman
n DAM, Thunnisssen E, Paul MA
A, van Wijk AW,, Postmus PE, S
Smit EF. Incidennce of T790M m
mutation in (sequ
uential) rebiopssies in EGFR‐mu
utated NSCLC‐p atients. Lung C
Cancer 2014; 85: 19‐24. 50. Kuipeer JL, Heideman
n DAM, Thunnisssen E, van Wijkk AW, Postmus PE, Smit EF. High‐dose, weekkly erlotinib is not an effecttive treatment in EGFR‐mutated non‐small ceell lung cancer‐‐patients with a
acquired extraccranial progresssive disease on standard
d dose erlotinib. Eur J Cancer 22014; 50: 1399‐1401. 51. Lacko
o M, Braakhuis BJ, Sturgis EM, Boedeker CC, SSuarez C, Rinald
do A, Ferlito A, Takes RP. Geneetic Susceptibility to Head and N
Neck Squamouss Cell Carcinoma. Int J Radiat O
Oncol 2014; 89:: 38‐48. 52. Luyteen A, Buttmann‐Schweiger N, LLuyten K, Maurritz C, Reinecke‐Luthge A, Pietralla M, Meijer CJLM, Petry KU
U. Early detecction of CIN3 an
nd cervical canccer during long‐‐term follow‐up
p using HPV/Pap smear co‐tessting and risk‐ad
dapted follow
w‐up in a locallyy organised screening program
mme. Internatio
onal journal of cancer Journal international d
du cancer 2014;; 135: 1408‐141
16. 53. Maffeei M, Mongera S, Terpstra L, D
Donadini A, Vooorham QJM, Me
eijer GA, Giaretti W, Carvalho B, Castagnola P
P. Chrom
mosome 20 abeerrations at the
e diploid‐aneupploid transition in sporadic colo
orectal cancer. Cytogenetic an
nd genome reseaarch 2014; 144: 9‐14. 54. Meijeer CJLM, Snijders PJF. Cervical cancer in 20133 screening com
mes of age and ttreatment proggress continues. Nature review
ws clinical onco
ology 2014; 11: 77‐78. 55. Menkko FH, Maher ER, Schmidt LS, Middelton LA, A
Aittomaki K, To
omlinson I, Richard S, Linehan W. Hereditary leiom
myomatosis and
d renal cell canccer (HLRCC): rennal cancer risk, surveillance an
nd treatment. FFam Cancer 201
14; 13: 637‐6644. Annual Report V
VUmc CCA 2014 –
6 of 216 56. Miok V, Wilting SM, van de Wiel MA, Jaspers A, vaan Noort PI, Braakenhoff RH, Sn
nijders PJF, Steeenbergen RDM, van Wieriingen WN. tigaR: integrative significance anaalysis of temporral differential g
gene expressionn induced by ge
enomic abnormalities. BMC Bioinformaticss 2014; 15: 327.. 57. Mol B
BM, Massink MPG, van der Ho
out AH, Dommeering CJ, Zaman
n JMA, Bosscha MI, Kors WA, M
Meijers‐Heijboe
er HE, Kaspeers GJL, te Rielee H, Moll AC, Cloos J, Dorsmann JC. High resolu
ution SNP array
y profiling identtifies variabilityy in retino
oblastoma geno
ome stability. G
Gene Chromosoome Canc 2014; 53: 1‐14. 58. Molleers M, Lubbers K, Spoelstra SK
K, Weijmar‐Schuultz WCM, Daem
men T, Westra TA, van der Sannde MAB, Nijman HW, de Melkeer HE, Tami A. Equity in human papilloma virrus vaccination uptake?: sexua
al behaviour, knnowledge and demo
ographics in a ccross‐sectional sstudy in (un)vacccinated girls in
n the Netherlan
nds. BMC Publicc Health 2014; 14: 288. 59. Molleers M, Vriend H
HJ, van der Sand
de MAB, Van Beergen JEAM, Kin
ng AJ, Lenselink
k CH, Bekkers RRLM, Meijer CJLLM, de Melkeer HE, Bogaards JA. Population‐ and Type‐Sppecific Clustering of Multiple HPV Types Acrosss Diverse Risk Populations in the N
Netherlands. Am
m J Epidemiol 2 014; 179: 1236
6‐1246. ous Melanoma"": Full‐fledged M
Melanoma or M
Melanoma Precu
ursor?. Adv Anaat Pathol 2014; 21: 181‐
60. Mooii WJ. "Lentigino
187. CL, Meijer CJLM
M, King AJ, Verh
hagen DWM, de
e vries HJC, Qui nt WGV, Molijn
n A, de 61. Mooiij SH, Boot HJ, SSpeksnijder AGC
Konin
ng MNC, van deer Sande MAB, vvan der Loeff M
MFS. Six‐Month Incidence and Persistence of Oral HPV Infecction in HIV‐N
Negative and HIV‐Infected Men Who Have Seex with Men. PLLoS One 2014; 9
9: e98955. 62. Mooiij SH, Landen O, van der Klis FR
RM, van der Sannde MAB, de M
Melker HE, Couttinho RA, van Eeeden A, van Rooijen MS, o evidence for a protective efffect of naturally
y induced HPV antibodies on Meijeer CJLM, van deer Loeff MFS. No
subseequent anogenital HPV infectio
on in HIV‐negattive and HIV‐infected MSM. J Infection 2014;; 69: 375‐386. 63. Mooiij SH, Landen O, van der Klis FR
RM, van der Sannde MAB, de M
Melker HE, Xiridou M, van Eedeen A, Heijman T
T, Spekssnijder AGCL, Snijders PJF, Sch
him van der Loeeff M. HPV Sero
oconversion Following Anal an d Penile HPV In
nfection in HIV‐N
Negative and HIV‐Infected MSM. Cancer Epiddem Biomar 201
14; 23: 2455‐24
461. 64. Orem
m J, Sandin S, Mbidde E, Mange
en FW, Middelddorp JM, Weide
erpass E. Epsteiin‐Barr Virus Viiral Load and Se
erology in Childhood Non‐Hodgkin's Lymphom
ma and Chronicc Inflammatory Conditions in U
Uganda: Implicaations for Disea
ase Risk and C
Characteristics. J Med Virol 2014; 86: 1796‐18803. 65. Osoriio A, Milne RL, Kuchenbaeckerr K, Vaclova T, PPita G, Alonso R
R, Peterlongo P,, Blanco I, de laa Hoya M, Duran M, Diez O, Caajal TRY, Konstantopoulou I, M
Martinez‐Bouzass C, Conejero RA
A, Soucy P, McG
Guffog L, Barrow
wdale D, van der Lee A, oman N, Ehrencrona H, Olopaade OI, Beattie MS, Domchek S
SM, Nathansonn K, Rebbeck TR, Arun BK, Arverr B, Rantala J, Lo
Karlan BY, Walsh C, Lester J, John E
EM, Whittemorre AS, Daly MB, Southey M, Ho
opper J, Terry M
MB, Buys SS, Jan
navicius R, Dorfling CM, van Rensburg EJ, Stee
ele L, Neuhauseen SL, Ding YC, H
Hansen TVO, Jo
onson L, Ejlertseen B, Gerdes AM
M, Infante M, Heerraez B, Moreno LT, Weitzel JJN, Herzog J, W
Weeman K, Man
noukian S, Peissel B, Zaffaroni D
D, Scuvera G, B
Bonanni B, Marieette F, Volorio SS, Viel A, Varescco L, Papi L, Otttini L, Tibiletti M
MG, Radice P, Y
Yannoukakos D,, Garber J, Ellis S, Frost D, Plattee R, Fineberg E,, Evans G, Lalloo
o F, Izatt L, Eelees R, Adlard J, D
Davidson R, Cole
e T, Eccles D, Coook J, Hodgson
n S, Brewer C, Tisschkowitz M, Do
ouglas F, Porteo
ous M, Side L, W
Walker L, Morriison P, Donaldson A, Kennedy y J, Foo C, Godw
win AK, Schm
mutzler RK, Wap
ppenschmidt B, Rhiem K, Engeel C, Meijers‐Heijboer EJ, Anton
niou AC, Beniteez J. DNA Glycossylases Involvved in Base Exccision Repair May Be Associateed with Cancer Risk in BRCA1 a
and BRCA2 Muttation Carriers.. PLoS Geneet 2014; 10: e10
004256. 66. Overw
water E, Smulders YM, van der Burg M, Lombbardi MP, Meije
ers‐Heijboer HE
E, Kuijpers TW, Houweling AC. The value of DN
NA storage and pedigree analyysis in rare diseaases: a 17‐year‐old boy with X
X‐linked lymphooproliferative disease (XLP) caused by a dee novo SH2D1A
A mutation. Eur J Pediatr 2014;; 173: 1695‐169
98. 67. Pinheeiro C, Garcia EA
A, Morais‐Santo
os F, Scapulate mpo‐Neto C, M
Mafra A, Steenbergen RDM, Booccardo E, Villa LL, Baltazar F, Longatto A. Lactate tran
nsporters and vvascular factors in HPV‐induced squamous ceell carcinoma off the uterin
ne cervix. BMC Cancer 2014; 1
14: 751. 68. Poddighe PJ, Wessels H, Merle P, W
Westers TM, Bhhola SL, Loonen A, Zweegman S
S, Ossenkoppelle GJ, Wonderggem MJ. Geno
omic amplificatiion of MYC as d
double minutess in a patient wiith APL‐like leuk
kemia. Molecullar cytogenetics 2014; 7: 67. n C, Obikoya‐Maalomo M, Kim SS, Chen Z, Florees‐Obando R, Gibbs D, Koriyam
ma C, Aguayo F,, Koshiol J, Capo
oraso NE, 69. Ragin
Carpaagnano GE, Ciottti M, Haka‐Akita H, Fukayamaa M, Goto A, Sp
pandidos DA, Gorgoulis V, Heiddeman DAM, va
an Boerd
donk RAA, Hiroshima K, Iwakawa R, Kastrinakkis NG, Kinoshitta I, Akiba S, Landi MT, Eugenee LH, Wang JL, Gehra R, Khurii FR, Lim WT, Owonikoko TK, R
Ramalingam S, SSarchianaki E, SSyrjanen K, Tsao
o MS, Sykes J, H
Hee SW, Yokota
a J, Zaravvinos A, Taioli E. HPV‐associate
ed lung cancerss: an international pooled analysis. Carcinogeenesis 2014; 35: 1267‐
1275. 70. Rietb
bergen MM, Braaakhuis BJM, M
Moukhtari N, Blooemena E, van d
den Brink A, Sie
e DLS, Ylstra B, de Jong RJB, Sn
nijders PJF, mans CR. No evvidence for activve human papillomavirus (HPV
V) in fields surro
rounding HPV‐p
positive Brakeenhoff RH, Leem
oroph
haryngeal tumo
ors. Journal of O
Oral Pathology and Medicine 2
2014; 43: 137‐1
142. 71. Rietb
bergen MM, Maartens‐de Kemp
p SR, Bloemena E, Witte BI, van den Brink A, d
de Jong RJB, Leeemans CR, Braa
akhuis actor for survivval in patients w
with human BJM, Brakenhoff RH. Cancer stem ccell enrichmentt marker CD98: A prognostic fa
papilllomavirus‐posittive oropharynggeal cancer. Eu r J Cancer 2014
4; 50: 765‐773.
Annual Report V
VUmc CCA 2014 –
7 of 216 72. Rietb
bergen MM, Snijders PJF, Beekkzada D, Braakhhuis BJM, van de
en Brink A, Heid
deman DAM, H
Hesselink AT, W
Witte BI, Bloem
mena E, Baaten
nburg de Jong R
RJ, Leemans CR,, Brakenhoff RH
H. Molecular characterization oof p16‐immuno
opositive but H
HPV DNA‐ negattive oropharynggeal carcinoma s. Int J Cancer 2
2014; 134: 2366
6‐2372. 73. Rios V
VE, Hoebers F, A
Aerts HJ, Rietbe
ergen MM, Braakenhoff RH, Leemans CR, Speel EJ, Straetma ns J, Kremer B, Lambin P. Exterrnally validated HPV‐based pro
ognostic nomoggram for oropharyngeal carcin
noma patients yyields more acccurate predictions than TNM staging. Radiother Oncol 20014; 113: 324‐3
330. 74. Rodriigo JP, Heidemaan DAM, Garcia
a‐Pedrero JM, FFresno MF, Brakkenhoff RH, Mo
olina JPD, Snijdeers PJF, Hermse
en MA. Time trends in the p
prevalence of HPV in oropharyyngeal squamou
us cell carcinom
mas in northern Spain (1990‐20
009). Int J Canceer 2014; 134: 4
487‐492. 75. Ronco
o G, Dillner J, Elfstrom KM, Tunesi S, Snijderss PJF, Arbyn M, Kitchener H, Se
egnan N, Gilham
m C, Giorgi‐Rosssi P, Berkh
hof J, Peto J, Meeijer CJLM. Efficcacy of HPV‐ba sed screening ffor prevention of invasive cervvical cancer: folllow‐up of four EEuropean rando
omised controlled trials. Lanceet 2014; 383: 524‐532. 76. Ronco
o G, Meijer CJLM, Segnan N, K
Kitchener H, Gioorgi‐Rossi P, Peto J, Dillner J. H
HPV‐based screeening for preve
ention of invasive cervical can
ncer Reply. Lanccet 2014; 383: 11295. 77. Rositcch AF, Mao L, H
Hudgens MG, M
Moses S, Agot K,, Backes DM, Nyagaya E, Snijders PJF, Meijer CJLM, Bailey R
RC, Smith JS. Rissk of HIV acquisition among ciircumcised andd uncircumcised
d young men with penile humaan papillomavirrus infecttion. AIDS 2014
4; 28: 745‐752. 78. Saadaatmand S, Vos JJR, Hooning MJ, Oosterwijk JCC, Koppert LB, de Bock GH, Aussems MG, van AAsperen CJ, Aalfs CM, Garcia EBG, Meijers‐Heijboer H, Ho
oogerbrugge N,, Piek M, Seynaeve C, Verhoef C, Rookus M, TTilanus‐Linthorsst MM. Relevvance and efficaacy of breast ca
ancer screeningg in BRCA1 and BRCA2 mutatio
on carriers abovve 60 years: A n
national cohorrt study. Int J Cancer 2014; 135: 2940‐2949.
79. Schuttze DM, Snijderrs PJF, ten Bosch L, Kramer D, Meijer CJLM, Steenbergen RD
DM. Differentiall In Vitro Immortalization Capaccity of Eleven, P
Probable High‐Risk Human Pa pillomavirus Tyypes. J Virol 201
14; 88: 1714‐17724. 80. Smit E. BRAF Mutatiions in Non‐Small‐Cell Lung Caancer. Journal o
of Thoracic Oncology 2014; 9: 1594‐1595. 81. Snelleenberg S, Cillessen SAGM, Van
n Criekinge W, tten Bosch L, Me
eijer CJLM, Snijders PJF, Steennbergen RDM. Meth
hylation‐mediatted repression o
of PRDM14 conntributes to apo
optosis evasion in HPV‐positivee cancers. Carccinogenesis 2014;; 35: 2611‐2618
8. 82. Steen
nbergen RDM, SSnijders PJF, He
eideman DAM, Meijer CJLM. C
Clinical implications of (epi)gennetic changes in
n HPV‐
inducced cervical preecancerous lesio
ons. Nat Rev Caancer 2014; 14:: 395‐405. 83. Sun C
C, Hobor S, Berttotti A, Zecchin D, Huang SD, G
Galimi F, Cottino F, Prahallad A
A, Grernrum W,, Tzani A, Schliccker A, Wesssels LFA, Smit EF, Thunnissen E
E, Halonen P, Li eftink C, Beijersbergen RL, Di Nicolantonio F,, Bardelli A, Tru
usolino L, Bernaards R. Intrinsicc Resistance to MEK Inhibition in KRAS Mutan
nt Lung and Colon Cancer throough Transcripttional Inducction of ERBB3. Cell reports 20
014; 7: 86‐93. 84. Than BLN, Goos JACM, Sarver AL, O
O'Sullivan MG, RRod A, Starr TK, Fijneman RJA,, Meijer GA, Zhaao L, Zhang Y, ott PM, Cormier RT. The role oof KCNQ1 in mo
ouse and human gastrointestinnal cancers. On
ncogene Largaaespada DA, Sco
2014;; 33: 3861‐3868
8. 85. Thom
mas LK, Bermejo
o JL, Vinokurova
a S, Jensen K, BBierkens M, Stee
enbergen RDM, Bergmann M,, Doeberitz M, Reuscchenbach M. Chromosomal ga
ains and losses in human papillomavirus‐asso
ociated neoplassia of the lowerr genital tract ‐ A systematic review and meta‐analysis. Eurr J Cancer 2014
4; 50: 85‐98. mo U, Francescchi S, Dorji D, Ba
aussano L, Teneet V, Snijders PJJF, Meijer CJLM
M, Bleeker MCG
G, Gheit T, Tomm
masino M, 86. Tshom
Cliffo
ord GM. Human
n papillomaviruss infection in Bhhutan at the moment of imple
ementation of aa national HPV vaccin
nation program
mme. BMC Infecct Dis 2014; 14:: 408. 87. Uijterrwaal MH, Kockken M, Berkhoff J, Bekkers RLM
M, Verheijen RH
HM, Helmerhorsst TJM, Meijer CCJLM. Posttreatment Assesssment of Wom
men at Risk of D
Developing Highh‐Grade Cervicaal Disease: Prop
posal for New G
Guidelines Based on Data From The Netherlan
nds. Journal of LLower Genital TTract Disease 20
014; 18: 338‐34
43. 88. Uijterrwaal MH, Verh
hoef VMJ, Snijders PJF, Meijer CJLM. Argume
ents in favor of HPV testing forr cervical screen
ning and post‐treatment CIN2
2+ monitoring. Expert review oof molecular diiagnostics 2014
4; 14: 245‐248. enade FJ, Rijkaaart D, Ridder R, Berkhof J, Balfo
oort‐van de Meeij GAMA, Bleekker MCG, 89. Uijterrwaal MH, Wittte BI, van Keme
Snijdeers PJF, Meijer CJLM. Triaging borderline/milld dyskaryotic P
Pap cytology with p16/Ki‐67 duual‐stained cyto
ology testin
ng: cross‐sectional and longitu
udinal outcome study. Brit J Caancer 2014; 110
0: 1579‐1586. 90. van A
Aar F, Mooij SH,, van der Sande
e MAB, Meijer CCJLM, King AJ, V
Verhagen DWM
M, Heijman T, Cooutinho RA, van
n der Loeff MF. TTwelve‐month iincidence and cclearance of oraal HPV infection
n in HIV‐negativ
ve and HIV‐infeected men who have sex with men: the H2M cohort study. B
BMC Infect Dis 22014; 14: 3845. 91. van B
Boerdonk RAA, Daniels JMA, Sn
nijders PJF, Grüünberg K, Thunn
nissen FBJM, va
an de Wiel M, YYlstra B, Postmu
us PE, Meijeer CJLM, Meijerr GA, Smit EF, Sutedja TG, Heiddeman DAM. DNA copy number aberrations in endobronchial lesions: a validated predicto
or for cancer. Th
horax 2014; 69:: 451‐457. Rijn VM, Mooij SSH, Mollers M, Snijders PJF, Sppeksnijder AGC
CL, King AJ, de vries HJC, van Eeeden A, van der Klis FRM, 92. van R
de Melker HE, van d
der Sande MAB,, van der Loeff MFS. Anal, Penile, and Oral High‐Risk HPV Inffections and HP
PV Serop
positivity in HIV
V‐Positive and H
HIV‐Negative M
Men Who Have SSex with Men. P
PLoS One 2014;; 9: e92208. Annual Report V
VUmc CCA 2014 –
8 of 216 93. van V
Vuurden DG, Arronica E, Hullem
man E, Wedekinnd LE, Biesmanss D, Malekzadeh A, Bugiani M,, Geerts D, Noske DP, Vandertop WP, Kasp
pers GJ, Cloos J, Wurdinger T, van der Stoop PM. Pre‐B‐cell leukemia homeeobox interacting protein 1 is overexpressed in astrocytoma and promotes ttumor cell grow
wth and migration. Neuro‐onccology 2014; 16
6: 946‐959. 94. Vasen
n HFA, Ghorban
noghli Z, Bourdeaut F, Cabarett O, Caron O, Duval A, Entz‐We
erle N, Goldberrg Y, Ilencikova D, Kratz CP, Laavoine N, Loefffen J, Menko FH
H, Muleris M, Seebille G, Colas C
C, Burkhardt B, Brugieres L, W
Wimmer K. Guide
elines for surveeillance of indivviduals with con
nstitutional mis match repair‐deficiency propo
osed by the Eurropean Consorttium "Care for CM
MMR‐D" (C4CM
MMR‐D). J Med Genet 2014; 5 1: 283‐293. 95. Verho
oef VMJ, Bosgraaaf RP, van Kem
menade FJ, Roz endaal L, Heide
eman DAM, Hessselink AT, Bekkkers RLM, Steenbergen RDM,, Massuger LFA
AG, Melchers W
WJG, Bulten J, Ovverbeek LIH, Be
erkhof J, Snijders PJF, Meijer CCJLM. Triage by meth
hylation‐markerr testing versus cytology in woomen who test HPV‐positive on self‐collectedd cervicovaginal specimens (PROHTEECT‐3): a random
mised controlleed non‐inferioriity trial. Lancet Oncol 2014; 155: 315‐322. 96. Verho
oef VMJ, Heideman DAM, van Kemenade FJ, Rozendaal L, B
Bosgraaf RP, Hessselink AT, Bekkkers RLM, Masssuger LFAG, Steenbergen RDM, Snijders P
PJF, Berkhof J, M
Meijer CJLM. M
Methylation marker analysis annd HPV16/18 ge
enotyping men with high g
grade CIN or ce rvical cancer. G
Gynecol in higgh‐risk HPV positive self‐sampled specimens tto identify wom
Onco
ol 2014; 135: 58
8‐63. 97. Vorm
mer TL, Wojciech
howicz K, Dekker M, de Vries SS, van der Wal A, zenne‐Goettte E, Naik SH, Soong JY, Dannen
nberg JH, Hanseen JB, te Riele H
H. RB Family Tu
umor Suppressoor Activity May Not Relate to A
Active Silencingg of E2F Target Genes. Canceer Res 2014; 74
4: 5266‐5276. 98. Vos C
CG, Dahele MR, de Koste JRV, SSenan S, Bahcee I, Paul MA, Thunnissen E, Smit EF, Harteminnk KJ. Semiautomated volum
metric responsee evaluation as an imaging bioomarker in supe
erior sulcus tum
mors. Strahlenthher Onkol 2014
4; 190: 204‐
209. 99. Vos JR, Teixeira N, van der Kolk DM
M, Mourits MJE,, Rookus MA, van Leeuwen FE, Collee M, vann Asperen CJ, Menssenkamp AR, Au
usems MGEM, van Os TAM, M
Meijers‐Heijboer HEJ, Gomez‐G
Garcia EB, Vasenn HF, Brohet RM
M, van der Hout AH, Jansen L, O
Oosterwijk JC, d
de Bock GH. Varriation in Mutation Spectrum Partly Explains Regional Differences in the B
Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands. Cancer Epidem BBiomar 2014; 2
23: 2482‐
2491. 100. Wessseling P. Embryo
onal tumor with multilayered rosettes (ETMR
R): signed, seale
ed, delivered. AACTA Neuropatthol 2014; 128: 3305‐308. 101. Wield
ders EAL, Hettin
nger J, Dekker R
R, Kets CM, Ligttenberg MJ, Me
ensenkamp AR, van den Ouweeland AMW, Prins J, Wagn
ner A, Dinjens W
WNM, Dubbink HJ, van Hest LPP, Menko F, Hogervorst F, Verhoef S, te Rielee H. Functional analysis of MSH22 unclassified vvariants found in suspected Ly nch syndrome patients reveals pathogenicityy due to attenuated mism
match repair. J M
Med Genet 2014; 51: 245‐253.. 102. Zanneette DL, van Eggermond MCJA
A, Haasnoot G, vvan den Elsen P
PJ. Simvastatin reduces CCL2 eexpression in m
monocyte‐
derived cells by indu
uction of a reprressive CCL2 chrromatin state. Hum Immunol 2014; 75: 10‐144. Scienttific publica
ations 1.
omes; in Harris on P, Gardiner C, Sargent IL, (e
eds): Extracelluular vesicles in h
health and Pegteel DM. The Bioggenesis of Exoso
disease. Pan Stanforrd Publishing. 2
2014 . Professsional publications 1.
2.
3.
E. Colorectaal ca
arcinoom in Neederland: situatie vóór en Elferink MA, van derr Vlugt M, Meijer GA, Lemmenns VE, Dekker E
na invvoering van hett landelijke bevvolkingsonderzooekNed Tijdschr Geneeskd 201
14158: . Kuitert PCJ, Abbink FFCH, Broers CJM
M, van der Valkk P, van Furth A
AM, van der Kuip M. Een Epsteein‐Barr‐virusinffectie met ernsttige gevolgenNeed Tijdschr Gen
neeskd 20141588: . Rietb
bergen MM. De rol van humaan papillomaviruus bij hoofd‐halskankerNed Tijjdschr Oncol 2001411: 255‐257
7. D
Dissertation
ns 1.
2.
3.
4.
Dijksttra MG. Toward
ds a more objecctive way of cerrvical cancer sccreening: cervical cancer screeening 2.0. 5/19//2014. (Co)p
promotor(es): M
Meijer CJLM, Snijders PJF, van Baal WM, van K
Kemenade FJ .
Graveeland AP. Molecular diagnosis of minimal ressidual head and
d neck cancer and field canceriization. 5/21/2014. (Co)p
promotor(es): B
Brakenhoff RH, Leemans CR ,Brraakhuis BJM, B
Bloemena E . Hubeers AJ. Moleculaar Analysis of Sp
putum for Lungg Cancer Diagno
osis. 11/13/201
14. (Co)promotoor(es): Meijer G
GA, Smit EF, Th
hunnissen FBJM
M, Heideman DA
AM . Marteens‐de Kemp SR. Towards perrsonalized and ttargeted treatm
ment of head an
nd neck cancer.. 3/19/2014. (Co)p
promotor(es): B
Brakenhoff RH, Leemans CR, Brraakhuis BJM, vvan Beusechem
m VW . Annual Report V
VUmc CCA 2014 –
9 of 216 5.
6.
7.
8.
Molleers M. Monitoring the impact of HPV vaccina tion: pre‐ and e
early post‐vaccination data. 4//22/2014. (Co)p
promotor(es): M
Meijer CJLM, de
e Melker HE .
Rietb
bergen MM. Thee Role of Huma
an Papillomaviruus in Head and Neck Cancer. 5
5/7/2014. (Co)ppromotor(es): B
Brakenhoff RH, Leemans CR, Snijders PJF, Bloemena E . overing epigenetic alterations oof tumour supp
pressor and vira
al genes during g HPV‐induced ccervical Snelleenberg S. Unco
carcin
nogenesis. 7/1//2014. (Co)prom
motor(es): Snijdders PJF, Meijerr CJLM, Steenbe
ergen RDM, vann Criekinge W .. Verho
oef VMJ. Impro
oving cervical ca
ancer screeningg by HPV self‐saampling. 12/10//2014. (Co)prom
motor(es): Meijer CJLM, Snijdeers PJF, van Kem
menade FJ, Rozzendaal L . Program 2 ‐
P
‐ Immunopa
athogenesiss Scientiffic papers re
efereed 1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
Abis G
GSA, Oosterlingg SJ, Stockmann
n HBAC, van de r Bij GJ, van Egmond M, Vandenbroucke‐Graauls CMJE, Bonjer HJ. Perio
operative selecttive decontamin
nation of the diigestive tract an
nd standard antibiotic prophy laxis versus standard antibiotic prophylaxxis alone in elective colorectal cancer patientss. Danish mediccal journal 20144; 61: A4695. Aleyd
d E, van Hout M
MWM, Ganzevle
es SH, Hoeben KKA, Everts V, Baakema JE, van E
Egmond M. IgA Enhances NETo
osis and Releaase of Neutroph
hil Extracellularr Traps by Polym
morphonuclearr Cells via Fc alp
pha Receptor I. JJ Immunol 2014; 192: 2374‐‐2383. Al‐Ku
uhlani M, Rothschild J, Pal S, de
e la Maza L, Ouuburg S, Morré SSA, Dean D, Ojccius DM. TRAIL‐‐R1 Is a Negativve Regulator of Pro‐Inflammatory Ressponses and Moodulates Long‐T
Term Sequelae Resulting from
m Chlamydia trachomatis Infecttions in Human
ns (vol 9, e93939, 2014). PLoS One 2014; 9: e93939. Arosio D, Chiodo F, R
Reina JJ, Marelli M, Penades SS, van Kooijk Y, Garcia Vallejo JJJ, Bernardi A. EEffective Targetting of DC‐
SIGN by alpha‐Fucossylamide Functionalized Gold Nanoparticles. Bioconjug Chem 2014; 25: 22244‐2251. Asnerr S, Morré SA, B
Bochud PY, Greub G. Host facttors and genetic susceptibility to infections d ue to intracellu
ular bacteeria and fastidio
ous organisms. Clin Microbiol Infec 2014; 20: 1246‐1253. Bakem
ma JE, van Egm
mond M. Fc rece
eptor‐dependennt mechanismss of monoclonall antibody theraapy of cancer. C
Curr Top Micro
obiol Immunol 2014; 382: 373‐392. Bastiaaansen KCJT, Ib
baÃ±ez A, Ramo
os JL, Bitter W, Llamas MA. The Prc and RseP proteases conttrol bacterial ce
ell‐surface signalling activity. En
nviron Microbio
ol 2014; 16: 24333‐2443. Beijer MR, Kraal G, d
den Haan JMM. Vitamin A andd dendritic cell d
differentiation. Immunology 22014; 142: 39‐4
45. Bitterr W, Kuijl CP. Taargeting bacterial virulence: thhe coming out o
of type VII secretion inhibitorss. Cell Host Microbe 2014; 16: 4330‐432. Bloem
m K, Vuist IM, vvan den Berk M, Klaver EJ, van Die IM, Knippe
els LM, Garssen
n J, Garcia Vallejjo JJ, van Vliet SSJ, van Kooijk Y. DCIR interaacts with ligand
ds from both enndogenous and pathogenic origin. Immunol LLett 2014; 158: 33‐41. N, Visser DH, So
olomons R, van
n Elsland SL, denn Hertog AL, vaan Furth AM. Lip
poarabinomannnan enzyme‐lin
nked Blok N
immu
unosorbent assay for early diagnosis of childhhood tuberculo
ous meningitis. International joournal of tuberculosis and lung d
disease 2014; 1
18: 205‐210. Bobo
osha K, Wilson LL, van Meijgaard
den KE, Bekele Y, Zewdie M, vvan dP, Abebe M
M, Hussein J, Khhadge S, Neupa
ane KD, Hagge DA, Jordanovva ES, Aseffa A, Ottenhoff THM
M, Geluk A. T‐Ce
ell Regulation in
n Lepromatous Leprosy. PLoS Negl Trop Dis 20014; 8: e2773. Bondt A, Rombouts Y, Selman MH, Hensbergen PJJ, Reiding KR, H
Hazes JM, Dolha
ain RJ, Wuhrer M
M. Immunoglobulin G (IgG) Fab Glycosylation Analysis Using a New Masss Spectrometric High‐throughput Profiling M
Method Reveals Pregn
nancy‐associateed Changes. Mo
olecular Cell 20014; 13: 3029‐30
039. Bosm
mann M, Russkaamp NF, Strobl B
B, Roewe J, Bal ouzian L, Pache
e F, Radsak MP,, van Rooijen N
N, Zetoune FS, SSarma JV, Nuneez G, Muller M, Murray PJ, Ward PA. Interrupption of Macrop
phage‐Derived IIL‐27(p28) Prodduction by IL‐10
0 during Sepsis Requires STAT3 but Not SOC
CS3. J Immunol 2014; 193: 566
68‐5677. Brankkovic I, Malogajjski J, Morré SA
A. Biobanking annd translation o
of human genettics and genom
mics for infectious diseases. Applied an
nd Translational Genomics 20114; 3: 30‐35. Broerrs CJM, Gemke RJBJ, Morré SA
A, Weijerman M
ME, van Furth AM. Increased production of in terleukin‐10 in children with Down syndrom
me upon ex vivo stimulation wiith Streptococccus pneumoniae
e. Pediatr Res 22014; 75: 109‐113. Bruzee M, Isaksson M
M, Gruvberger B
B, Andersen KE,, Goncalo M, Go
oossens A, Joha
ansen JD, Maibaach HI, Rustem
meyer T, Le Coz C
CJ, White IR. Pattch testing with
h methylchloroiisothiazolinone
e/methylisothia
azolinone 200â€€‰ppm aq. detects signifficantly more co
ontact allergy than 100â€‰pppm. A multicentre study within the Europeann Environmenta
al and Contaact Dermatitis R
Research Group
p. Contact Derm
matitis 2014; 71
1: 31‐34. Burgeer NB, Stuurman KE, Kok E, Konijn T, Schooneeman D, Niederrreither K, Coles M, Agace WW
W, Christoffels V
VM, Mebius RE, van de P
Pavert SA, Bekker MN. Involve ment of neuron
ns and retinoic acid in lymphaatic developmen
nt: new hts in increased
d nuchal translu
ucency. Prenataal Diag 2014; 34
4: 1312‐1319. insigh
Annual Report V
VUmc CCA 2014 –
0 of 216 19. Chiod
do F, Marradi M
M, Park J, Ram A
AFJ, Penades S, van Die I, Tefse
en B. Galactofuranose‐Coatedd Gold Nanoparticles Elicit a Pro‐inflammatory Response in Hu
uman Monocytte‐Derived Dendritic Cells and Are Recognizedd by DC‐SIGN. A
Acs chem
mical biology 2014; 9: 383‐389.. 20. Cho SSW, Soki FN, Ko
oh AJ, Eber MR, Entezami P, Paark SI, van Rooijjen N, McCaule
ey LK. Osteal maacrophages sup
pport physiologic skeletal remodeling and anabolic actioons of parathyrroid hormone in
n bone. P Nat; AAcad Sci USA 20
014; 111: 1545‐‐1550. 21. Croci DO, Cerliani JP
P, otto‐Moreno T, Mendez‐Hueergo SP, Mascaanfroni ID, rgan‐Dylon S, Toscaano MA, Caramelo JJ, Garcia Vallejo JJ, Ouyang J, Mesri E
EA, Junttila MR, Bais C, Shipp M
MA, Salatino M,, Rabinovich GAA. Glycosylation
n‐
Depeendent Lectin‐Receptor Interacctions Preservee Angiogenesis iin Anti‐VEGF Re
efractory Tumoors. Cell 2014; 1
156: 744‐
758. 22. Dalekke MH, Felix T, SSoprova Z, ten Hagen‐Jongmaan ten CM, ViksttrÃ¶m D, Majle
essi L, Beskers JJ, Follman F, de Punder K, van d
der Wel NN, Bau
umgarten T, Ph
ham TV, Piersmaa SR, Jimenez C
CR, van Ulsen P,, de Gier JW, Leeclerc C, Jong W
WS, Luirink S. Decoration of outter membrane vvesicles with m
multiple antigens using an autotransporter ap proach. Appl Envirol ob 2014; 80: 58
854‐5864. Micro
23. de Grroot A, Rustemeeyer T, Hissink D, Bakker M. CContact allergy tto capryloyl salicylic acid. Conttact Dermatitis 2014; 71: 185‐1187. 24. de la Durantaye M, Boulanger Piettte A, van Rooijeen N, Frenette JJ. Macrophage depletion reduuces cell proliferation and but increases thhe ultimate ten
nsile strength off injured Achillees tendons. J Orthop Res extracellular matrix accumulation b
2014;; 32: 279‐285. 25. de Maio F, Mauluccii G, Minerva M,, Anoosheh S, PPalucci I, Iantom
masi R, Palmierii V, Camassa S, Sali M, Sanguin
netti M, M, Delogu G. Im
mpact of protein domains on P
PE_PGRS30 polaar localization in Bitterr W, Manganellli R, de Spirito M
Myco
obacteria. PLoS One 2014; 9: e
e112483. 26. De Pu
uysseleyr K, De Puysseleyr L, D
Dhondt H, Geenns T, Braeckman
n L, Morré SA, C
Cox E, Vanromppay D. Evaluatio
on of the preseence and zoono
otic transmission of Chlamydiaa suis in a pig slaaughterhouse. BMC Infect Dis s 2014; 14: 560.. 27. den H
Haan JMM, Arens R, van Zelm MC. The activaation of the adaaptive immune system: Cross‐ttalk between antigen‐
preseenting cells, T ceells and B cells. Immunol Lett 2014; 162: 103
3‐112. 28. Dijxhoorn DN, Boutaall A, Mulder CJJJ, Ssebuufu R, Mall A, Kalungi S, Baigrie C, Go
oldberg PA. Collorectal cancer in patients from Uganda: A histtopathological sstudy. East and Central African
n Journal of Surrgery 2014; 19: 112‐119. n Fernholm AM
M, Rijnsburger M
MC, Ho‐dac‐Pan
nnekeet MM. Peeritoneal dialyssis‐
29. Dressselaars HF, Zwart B, Pettersson
assocciated peritonitis of zoonotic o
origin, when mi nor gets major. Neth J Med 20
014; 72: 551‐5553. 30. Fehrees CM, Bruijns SSCM, van Beele
en AJ, Kalay H, A
Ambrosini M, H
Hooijberg E, Ung
ger WWJ, de Grruijl TD, van Kooijk Y. Topiccal rather than intradermal application of thee TLR7 ligand im
miquimod leads to human derm
mal dendritic ce
ell maturation and CD8
8(+) T‐cell cross‐priming. Eur J Immunol 2014
4; 44: 2415‐2424
4. 31. Fehrees CM, Unger W
WWJ, Garcia Vallejo JJ, van Koooijk Y. Understaanding the biolo
ogy of antigen ccross‐presentattion for the desiggn of vaccines against cancer. FFrontiers in Miccrobiology 2014
4; 5: 149. 32. Filbeyy KJ, Grainger JR, Smith KA, Bo
oon L, van Rooijjen N, Harcus Y
Y, Jenkins S, Hew
witson JP, Maizzels RM. Innate and adapttive type 2 imm
mune cell responses in geneticcally controlled resistance to in
ntestinal helminnth infection. Im
mmunol Cell B
Biol 2014; 92: 436‐448. 33. Gül N
N, Babes L, Siegm
mund K, Kortho
ouwer R, Bögelss M, Braster R, Vidarsson G, te
en Hagen TLM, Kubes P, van Egmond M. Macrrophages elimin
nate circulating tumor cells aftter monoclonal antibody thera
apy. J Clin Invesst 2014; 124: 81
12‐823. 34. Gardiinassi LG, Dotz V, Hipgrave Ederveen A, de Allmeida RP, Nery Costa CH, Cossta DL, de Jesuss AR, Mayborod
da OA, Garcia GR, Wuhrer M
M, de Miranda Santos IK. Clini cal severity of vvisceral leishma
aniasis is associiated with chan
nges in immu
unoglobulin g fcc N‐glycosylatio
on. mBio 2014; 5: e01844. 35. Geldeerman KA, Drop
p ACAD, Trouw LA, Bontkes HJJ, Bouma G, van
n Hoogstraten IMW, von Blom
mberg BME. Serum autoaantibodies direccted against tra
ansglutaminasee‐2 have a low aavidity compare
ed with alloantiibodies againstt gliadin in coeliaac disease. Clin Exp Immunol 2
2014; 177: 86‐993. 36. Gerlin
ni A, Colomba LL, Furi L, Braccin
ni T, Manso AS,, Pammolli A, W
Wang B, Vivi A, T
Tassini M, van RRooijen N, Pozzzi G, Ricci S, Andreew PW, Koedel U, Moxon ER, Oggioni MR. Thhe Role of Host and Microbial Factors in the PPathogenesis of Pneumococcal Bacteeraemia Arisingg from a Single Bacterial Cell B
Bottleneck. PLoS
S Pathog 2014; 10: e1004026. 37. Glim JE, Everts V, Niessen FB, Ulrich
h MMW, Beeleen RHJ. Extracellular matrix com
mponents of orral mucosa diffe
er from skin aand resemble th
hat of foetal skin. Arch Oral Biiol 2014; 59: 10
048‐1055. 38. Gmellig‐Meyling FHJ, Meyaard L, M
Mebius R. 50 yeaars of Dutch immunology â€“ F
Founders, instittutions, highlights. Immu
unol Lett 2014; 162: 85‐94. 39. Gringghuis SI, Kaptein
n TM, Wevers B
BA, van der Vlisst M, Klaver EJ, van Die I, Vrien
nd LEM, de Jongg MAWP, Geijte
enbeek TBH. Fucose‐based P
PAMPs prime d
dendritic cells foor follicular T he
elper cell polarization via DC‐SSIGN‐dependen
nt IL‐27 produ
uction. Nature Communications 2014; 5: 50774. 40. Grosss S, Bakker SF, vvan Bodegraven
n AA, van Hooggstraten IMW, G
Gelderman KA, Bouma G, Muldder CJ, von Blomberg BME,, Bontkes HJ. Increased IgA Glyycoprotein‐2 Sppecific Antibodyy Titres in Refra
actory Celiac Diisease. Journal of Gastrrointestinal and
d Liver Diseasess 2014; 23: 127‐‐133. 41. Gül N
N, Babes L, Kubees P, van Egmond M. Macrophhages in the live
er prevent metastasis by efficiiently eliminating circullating tumor ceells after monocclonal antibodyy immunotherap
py. Oncoimmun
nology 2014; 3:: e28441. Annual Report V
VUmc CCA 2014 –
– Appendix 3: Scieentific output ‐ 31 of 216 42. Hiem
mstra IH, Beijer M
MR, Veninga H,, Vrijland K, Borrg EGF, Olivier B
BJ, Mebius RE, Kraal G, den Haaan JMM. The identtification and deevelopmental rrequirements off colonic CD169
9+macrophagess. Immunology 2014; 142: 269
9‐278. 43. Hiem
mstra IH, Klaver EJ, Vrijland K, K
Kringel H, Andreeasen A, Boumaa G, Kraal G, van Die I, den Ha an JMM. Excreeted/secreted TTrichuris suis products reduce barrier function and suppresss inflammatory cytokine produ
uction of intesttinal epithelial cells. Mol Immunol 2014; 60: 1‐7. 44. Houb
ben ENG, Korotkkov KV, Bitter W
W. Take five ‐ Tyype VII secretio
on systems of M
Mycobacteria. BBiochim Biophys Acta 2014;; 1843: 1707‐17
716. 45. Houthuijzen JM, Daeenen LGM, Roo
odhart JML, Oossterom I, van Jaaarsveld MTM, Govaert KM, Sm
mith ME, Sadattmand SJ, Rosin
ng H, Kruse F, Helms BJ, van Ro
ooijen N, Beijneen JH, Haribabu
u B, van de Lest CHA, Voest EE . Lysophospholipids secreeted by splenic macrophages in
nduce chemothherapy resistance via interfere
ence with the D
DNA damage ressponse. Naturre Communicattions 2014; 5: 5
5275. 46. Huijtss S, Boersma W
W, Grobbee D, G
Gruber W, Janseen K, Kluijtmanss JAJW, Kuiperss B, Palmen F, PPride M, Webbe
er C, Bonteen M. Predictin
ng pneumococcal community‐aacquired pneum
monia in the em
mergency deparrtment Evaluattion of clinical parameters. Clin Microbiol Infec 2014; 20:: 1316‐1322. 47. Isakssson M, Anderseen KE, Goncalo M, Goossens A
A, Gruvberger B
B, Johansen JD, Maibach HI, Ruustemeyer T, Le
e Coz CJ, Whitee IR, Bruze M. M
Multicentre pattch testing withh methylisothiazolinone by the
e European Envvironmental and
d Contact Derm
matitis Research
h Group. Contacct Dermatitis 20014; 70: 317‐32
20. 48. Jacob
bsen RN, Forristtal CE, Raggatt LJ, Nowlan B, BBarbier V, Kaur S, van Rooijen N, Winkler IG, PPettit AR, Levessque JP. Mobiilization with grranulocyte colo
ony‐stimulating factor blocks m
medullar erythropoiesis by deppleting F4/800(+)VCAM1(+)C
CD169(+)ER‐HR3
3(+)Ly6G(+) eryythroid island m
macrophages in the mouse. Expp Hematol 2014; 42: 547‐
561. 49. Kadouch DJ, Fortuin S, Kadouch JA,, Ovadia SA, Ka rim RB, de Rie MA. Improvement of efficacy in surgical man
nagement of faccial basal cell caarcinoma: an interdisciplinary pilot study in T
The Netherlands. European Jouurnal of Plastic Surgery 2014;; 37: 589‐594. 50. Kameeka AM, Haddadi S, Jamaldeen
n FJ, Moinul P, H
He XT, Nawazdeen FHP, Bonfie
eld S, Sharif S, vvan Rooijen N, Abdul‐
Careeem MF. Clodron
nate treatmentt significantly deepletes macrop
phages in chicke
ens. Canadian jjournal of veterrinary reseaarch 2014; 78: 2
274‐282. 51. Kapur R, la Valle L, SSonneveld M, Hipgrave Ederveeen A, Visser R, Ligthart P, de H
Haas M, Wuhreer M, van der Scchoot CE, nti‐RhD IgG‐Fc‐ffucosylation in pregnancy: a new variable pre
edicting severitty in haemolyticc disease Vidarrsson G. Low an
of thee fetus and new
wborn. Brit J Ha
aematol 2014; 1166: 936‐945.
52. Killoran KE, Miller AD, Uray KS, Weisbrodt NW, Paautler RG, Goye
ert SM, van Roo
oijen N, Conner r ME. Role of inn
nate unity and altereed intestinal mo
otility in LPS‐ annd MnCl2‐inducced intestinal in
ntussusception in mice. Am J P
Physiol immu
Gastrrointest Liver Ph
hysiol 2014; 306: G445‐G453.
53. Kluytmans v, Vos M,, Diederen B, Vandenbroucke‐‐Grauls C, Voss A, Kluijtmans JAJW. Dutch guiideline on the llaboratory 014; 33: 89‐1011. detecction of methicillin‐resistant Sttaphylococcus aureus. Eur J Clin Microbiol 20
54. Kock R, Becker K, Co
ookson B, van G
Gemert‐Pijnen JJE, Harbarth S, K
Kluijtmans JAJW
W, Mielke M, Peeters G, Skov RL, W, Friedrich AW
W. Systematic literature analysis and review off targeted prevventive Strueelens MJ, Tacconelli E, Witte W
meassures to limit heealthcare‐assocciated infection s by meticillin‐resistant Staphylococcus aureeus. Eurosurveillance 2014;; 19: 23‐49. 55. Korottkova N, Freire D, Phan TH, Um
mmels R, Creekkmore CC, Evanss TJ, Wilmanns M, Bitter W, Paarret AHA, Hou
uben ENG, Korottkov KV. Structu
ure of the Myco
obacterium tubberculosis type VII secretion sy
ystem chaperonne EspG(5) in co
omplex with PE25‐PPE41 dim
mer. Mol Micro
obiol 2014; 94: 367‐382. 56. Kosteen IJ, Rustemeyyer T. Generatio
on, subsets and functions of in
nducible regulattory T cells. Antti‐inflammatoryy & anti‐
allerggy agents in meedicinal chemisttry 2014; 13(3):: 139‐153. 57. Kraaijj MD, Koekkoekk KM, Gelderman KA, Van Koooten C. The NOX
X2‐mediated RO
OS producing ca
capacity of recip
pient cells is asssociated with reeduced T cell infiltrate in an exxperimental mo
odel of chronic renal allograft iinflammation. T
Transpl Immu
unol 2014; 30: 6
65‐70. 58. Lam R
RS, O'Brien‐Sim
mpson NM, Lenzzo JC, Holden JA
A, Brammar GC
C, Walsh KA, MccNaughtan JE, RRowler DK, van Rooijen N, Reyno
olds EC. Macrophage Depletio
on Abates Porphhyromonas gingivalis‐Induced Alveolar Bone Resorption in Mice. J Immu
unol 2014; 193:: 2349‐2362. 59. Lameeris R, Schneideers FL, de Gruijl TD, van der Vlieet HJ. Exploiting theCD1d‐iNKT
T cell axis for p otentiation of D
DC‐based canceer vaccines. Meethods Mol Biol 2014; 1139: 1555‐165. 60. Lanzi A, Fehres CM, de Gruijl TD, va
an Kooijk Y, Maastrobattista E. Effects of Antig
gen‐Expressing Immunostimullatory Liposomes on Chem
motaxis and Matturation of Denndritic Cells In V
Vitro and in Hum
man Skin Explannts. Pharmaceu
utical 516‐526. reseaarch 2014; 31: 5
61. Llamaas MA, van der Sar AM. Assesssing pseudomoonas virulence w
with nonmamm
malian host: zebbrafish. Method
ds Mol Biol 2014;; : 709‐721. 62. Luyai AE, Heimburg‐‐Molinaro J, Pra
asanphanich NSS, Mickum ML, Lasanajak Y, So
ong XZ, Nyame AAK, Wilkins P, R
Rivera‐
Marreero CA, Smith D
DF, van Die I, Se
ecor WE, Cumm
mings RD. Differrential expression of anti‐glycaan antibodies in
n schisttosome‐infecteed humans, rhesus monkeys annd mice. Glycob
biology 2014; 2
24: 602‐618. Annual Report V
VUmc CCA 2014 –
2 of 216 63. Maass KW, Biere SSA
AY, van Hoogstraten IMW, van der Peet DL, Cuesta MA. Imm
munological chaanges after minimally invasive or conventional esophageal resection forr cancer: a rand
domized trial. W
World J Surg 20114; 38: 131‐137
7. 64. Mafto
ouh M, Da Silvaa Aresta Belo va
an Wijk, Avan A
A, Funel N, Pete
ers GJ, Giovanne
etti E, van Die I . Galectin‐4 exp
pression is assocciated with redu
uced lymph nod
de metastasis aand modulation
n of Wnt/beta‐ccatenin signallinng in pancreatic adeno
ocarcinoma. On
ncotarget 2014
4; 5: 5335‐5349 . 65. Makaarov V, Lechartiier B, Zhang M, Neres J, van deer Sar AM, Raad
dsen SA, Hartko
oorn RC, Ryaboova OB, Vocat A
A, Decosterd LA, Widm
mer N, Buclin T, Bitter W, Andrries K, Pojer F, D
Dyson PJ, Cole S
ST. Towards a nnew combinatio
on therapy for tu
uberculosis with
h next generation benzothiazi nones. Embo M
Molecular Medicine 2014; 6: 3772‐383. 66. Maso
on S, Moutloatsse G, van Furth AM, Solomons RS, van Reenen M, Reinecke C, Koekemoer G
G. KEMREP: A N
New Qualiitative Method for the Assessm
ment of an Anaalystâ€™s Abilityy to Generate a
a Metabolomicss Data Matrix b
by Gas Chrom
matographyâ€““ Mass Spectrometry. Current Metabolomicss 2014; 2: 15‐26
6. 67. Mee‐‐Marquet N, Co
orvaglia A, Haen
nni M, Bertrandd X, Franck JB, K
Kluijtmans JAJW
W, Girard M, Quuentin R, Franco
ois P. Emerrgence of a novel subpopulatio
on of CC398 Staaphylococcus aureus infecting animals is a seerious hazard fo
or humans. Fronttiers in Microbiology 2014; 5: 652. 68. Meijeerink H, Wisaksana R, Iskandarr S, den Heijer M
M, van der Ven AJAM, Alisjahb
bana B, van Creevel R. Injectingg drug use is asssociated with a more rapid CD4
4 cell decline am
mong treatmen
nt naive HIV‐po
ositive patients in Indonesia. Jo
ournal of the in
nternational aid
ds society 2014; 17: 18844. 69. Mencckeberg C, Hol JJ, Simons‐Ooste
erhuis Y, Raatgeeep H, de Ruite
er L, Lindenberg
gh‐Kortleve D, KKorteland‐van M
Male A, El Aidy SS, van Lierop P,, Kleerebezem M
M, Groeneweg M, Kraal G, Elin
nk‐Schuurman B, de Jongste J,, Nieuwenhuis E, Samsom J. Hum
man buccal epithelium acquire
es microbial hyyporesponsiven
ness at birth, a rrole for secretoory leukocyte prrotease inhibitor. Immunolo
ogy 2014; 143: 2
24. 70. Muriss JJF, Scheper R
RJ, Kleverlaan CJJ, Rustemeyer TT, van Hoogstraaten IMW, von Blomberg BMEE, Feilzer AJ. Palladium‐
based
d dental alloys are associated with oral disea se and palladiu
um‐induced imm
mune responsees. Contact Derm
matitis 2014;; 71: 82‐91. 71. Notarri L, Riera DC, SSun R, Bohl JA, M
McLean LP, Ma dden KB, van R
Rooijen N, Vanuytsel T, Urban JJF, Zhao AP, Shea‐
Dono
ohue T. Role of Macrophages in the Altered EEpithelial Functiion during a Typ
pe 2 Immune RResponse Induced by Enterric Nematode In
nfection. PLoS O
One 2014; 9: e884763. 72. Oostvvogels R, Lokho
orst HM, Minnema MC, van e, van den Ouden
nalder K, Spierings E, Mutis T, Spaapen RM. Identtification of min
nor histocompa
atibility antigenss based on the 1000 Genomess Project. Haem
matol‐Hematol JJ 2014; 99: 1854‐‐1859. 73. Ottow
w MK, Klaver EJJ, van der Pouw
w Kraan CTM, H eijnen PD, Laan
n LC, Kringel H, Vogel DYS, Dijkkstra CD, Kooij G, van Die I. Thee helminth Trich
huris suis supprresses TLR4‐indduced inflammaatory responsess in human maccrophages. Gen
nes Immun 2014;; 15: 477‐486. 74. Overd
devest ITMA, vaan Heck M, van
n der Zwaluw K,, Huijsdens X, vvan Santen M, R
Rijnsburger MC,, Eustace A, Xu L, Hawkey P, Savvelkoul PHM, V
Vandenbroucke‐‐Grauls C, Willeemsen I, van de
e Ven J, Verhulst C, Kluijtmans JAJW. Extende
ed‐
specttrum beta‐lactaamase producin
ng Klebsiella sppp. in chicken meat and human
ns: a comparisoon of typing metthods. Clin Micro
obiol Infec 2014
4; 20: 251‐255. 75. Pereb
boom MTR, Speelten ER, Mannien J, Rours GIJ G, Morré SA, Schellevis FG, Hu
utton EK. Know
wledge and acce
eptability of Chlamydia tracho
omatis screening among pregnnant women an
nd their partnerrs; a cross‐sectioonal study. BMC Public 4. Healtth 2014; 14: 704
76. Peren
ncevich EN, Sko
ov R, Kluijtmanss JAJW. Identifyying Livestock‐A
Associated Methicillin‐Resistannt Staphylococccus aureus in thee United States. Jama internal medicine 20144; 174: 824‐825
5. 77. Peterrs RPH, Dubbinkk JH, van der Ee
em L, Verweij S P, Bos MLA, Ou
uburg S, Lewis D
DA, Struthers H
H, McIntyre JA, M
Morré SA. Crosss‐Sectional Stud
dy of Genital, Re
ectal, and Pharryngeal Chlamydia and Gonorrrhea in Womenn in Rural South Africa. Sex Transsm Dis 2014; 41
1: 564‐569. 78. Rabin
novich GA, Thijsssen VLJL. Introduction to Speccial Issue Galecctins Go with th
he Flow. Glycobbiology 2014; 24
4: 885. 79. Randall TD, Mebius RE. The development and funnction of mucossal lymphoid tissues: a balancinng act with miccro‐
nisms. Mucosal Immunology 2
2014; 7: 455‐46 6. organ
80. Rivera J, Sellers RS, ZZeng W, van Ro
ooijen N, Casad evall A, Goldmaan DL. Platelet‐‐activating Facttor Contributes to Bacillus anthrracis Lethal Toxxin‐associated D
Damage. J Biol CChem 2014; 289: 7131‐7141.
81. Romaano M, van de W
Weerd R, Brouw
wer FCC, Rovielllo GN, Lacroix R, Sparrius M, v
van Stempvoorrt G, Appelmelkk BJ, Geurttsen JJ, Berisio R. Structure an
nd Function of RRNase AS, a Polyadenylate‐Spe
ecific Exoribonuuclease Affectin
ng Myco
obacterial Viruleence In Vivo. Sttructure 2014; 222: 719‐730. 82. Roozeendaal APBR, R
Roozendaal R, R
Reijmers RM, Kooning JJ, Unger WW, Greuter M
M, Keuning ED, , Molenaar R, G
Goverse G, Sneeb
boer MMS, den
n Haan JMM, Bo
oes M, Mebius RE. Lymph nod
de stromal cells constrain imm
munity via MHC class II self‐aantigen presenttation. eLife 201
14; 3: e04433.
83. Ruben JM, van den A
Ancker W, Bonttkes HJ, Westerrs TM, Hooijberrg E, Ossenkopp
pele GJ, de Gruuijl TD, van de Loosdrecht Apoptotic blebs from leukemicc cells as a prefeerred source off tumor‐associated antigen forr dendritic cell‐based AA. A
nes. Cancer Immunol Immun 2
vaccin
2014; 63: 335‐3345. Annual Report V
VUmc CCA 2014 –
3 of 216 84. Sarkaar S, Doring A, ZZemp FJ, Silva C
C, Lun X, Wang XX, Kelly J, Hader W, Hamilton M
M, Mercier P, D
Dunn JF, Kinniburgh D, van R
Rooijen N, Robb
bins S, Forsyth P
P, Cairncross G,, Weiss S, Yong VW. Therapeutic activation of
of macrophagess and micro
oglia to suppresss brain tumor‐initiating cells. Nat Neurosci 2
2014; 17: 46‐55. 85. Schneeider C, Nobs SP, Heer AK, Kurrrer M, Klinke G
G, van Rooijen N
N, Vogel J, Kopff M. Alveolar M
Macrophages Are Essential for Prrotection from Respiratory Faiilure and Assocciated Morbidity following Influenza Virus Inffection. PLoS Pa
athog 2014;; 10: e1004053. 86. Solom
mons RS, van Elsland SL, Visserr DH, Hoek KGPP, Marais BJ, Schoeman JF, van
n Furth AM. Com
mmercial nucle
eic acid amplification tests in
n tuberculous m
meningitis‐a meeta‐analysis. Diagnostic microbiology and infe
fectious disease
e 2014; 78: 398‐4403. 87. Solom
mons RS, Wesseels M, Visser DH
H, Donald PR, M
Marais BJ, Schoe
eman JF, van Fu
urth AM. Uniforrm Research Ca
ase Defin
nition Criteria D
Differentiate Tub
berculous and BBacterial Menin
ngitis in Childre
en. Clin Infect D
Dis 2014; 59: 1574‐1578. 88. Szilaggyi K, Meijer AB
B, Neele AE, Verrkuijlen P, Leitgges M, Dabernat S, Forster‐Wa
aldl E, Boztug K,, Belot A, Kuijpe
ers TW, Kraal G, de Winther MPJ, van den B
Berg TK. PKC deelta is dispensib
ble for oxLDL up
ptake and foam
m cell formation
n by human murine macrophages. Cardiova
asc Res 2014; 1104: 467‐476. and m
89. te Raa GD, Pascutti MF, Garcia Vallejo JJ, Reinen EE, Remmerswaaal EBM, ten Berrge IJM, van Lieer RAW, Eldering E, van Oers MHJ, Tonino SH
H, Kater AP. CM
MV‐specific CD88(+) T‐cell functtion is not impaired in chronic lymphocytic leukemia. Blood
d 2014; 123: 71
17‐724. 90. Tefseen B, Grijpstra J, Ordonez S, Lammers M, van Die IM, Cock H
H. Deletion of th
he CAP10 gene of Cryptococcu
us neofo
ormans results in a pleiotropicc phenotype witth changes in e
expression of virulence factorss. Res Microbiol 2014; 165: 3399‐410. 91. Teodoro‐Morrison TT, Diamandis EP
P, Rifai N, Weetj
tjens BJC, Pennaazza G, de Boerr KHN, Bomers MK. Animal Olffactory Detecction of Diseasee: Promises and
d Pitfalls. Clin CChem 2014; 60: 1473‐1479. 92. Thijsssen VLJL, Rabinovich GA. Glyca
ans in vascular biology INTROD
DUCTION. Glyco
obiology 2014; 24: 1235‐1236
6. 93. Tiemeessen MM, Baeert MRM, Kok L, van Eggermonnd MCJA, van d
den Elsen PJ, Are
ens R, Staal FJTT. T Cell Factor 1
1 Repreesses CD8+ Effeector T Cell Form
mation and Funnction. J Immun
nol 2014; 193: 5
5480‐5487. 94. Tymo
oszuk P, Evens H
H, Marzola V, W
Wachowicz K, W
Wasmer MH, Datta S, Muller‐Holzner E, Fiegl H
H, Bock G, van Rooijen N, Theurl I, Doppler W.. In situ proliferration contributtes to accumulaation of tumor‐‐associated maccrophages in sponttaneous mamm
mary tumors. Eu
ur J Immunol 20014; 44: 2247‐2
2262. 95. Umm
mels R, Abdallah
h A, Kuiper V, Aa
ajoud A, Sparriuus M, Naeem R
R, Spaink HP, van Soolingen D, Pain A, Bitter W
W. Identtification of a no
ovel conjugativve plasmid in myycobacteria thaat requires both
h type IV and tyype VII secretio
on. mBio 2014;; 5: e01744‐14.. 96. van A
Aar F, de Moraees M, Morré SA, Van Bergen JEEAM, van der Klis FRM, Land JA
A, van der Sandde MAB, Van De
en Broek IVF. C
Chlamydia trach
homatis IgG serroprevalence inn the general po
opulation of the
e Netherlands iin 1996 and in 2
2007: differrential changes by gender and age. Sex Transsm Dis 2014; 90
0: 434‐440. 97. van B
Bloois L, Miller W
WG, Yee E, Bon
ndo JL, Rijnsburgger MC, Campe
ero C, Wagenaa
ar JA, Duim B. FFirst Closed Gen
nome Sequeence of Campylobacter fetus ssubsp. venerea lis bv. intermed
dius. Genome A
Announcementts 2014; 2: e012
246‐13. 98. van B
Bloois L, Miller W
WG, Yee E, Rijnsburger MC, W
Wagenaar JA, Du
uim B. Inconsisttency of Phenottypic and Geno
omic Charaacteristics of Caampylobacter fe
etus Subspecie s Requires Reevaluation of Current Diagnosttics. J Clin Micro
obiol 2014; 52: 4183‐4188. de Pavert SA, Feerreira M, Domingues RG, Ribeeiro H, Molenaaar R, Moreira‐Santos L, Almeidda FF, Ibiza S, Barbosa I, 99. van d
Goverse G, Labao‐Almeida C, Godin
nho‐Silva C, Konnijn T, Schoone
eman D, O'Toole
e TG, Mizee MRR, Habani Y, Haak E, Santo
ori FR, Littman DR, Schulte‐Me
erker S, Dzierza k E, Simas JP, M
Mebius RE, Veig
ga‐Fernandes H
H. Maternal retinoids contrrol type 3 innate lymphoid cellls and set the ooffspring immun
nity. Nature 2014; 508: 123‐1227. 100. van d
de Pavert SA, M
Mebius RE. Deve
elopment of Seccondary Lymph
hoid Organs in R
Relation to Lym
mphatic Vasculatture. Adv Anat Embryol Cel 20
014; 214: 81‐91
1. 101. van d
den Berg LM, Zijjlstra‐Willems E
EM, Richters CD
D, Ulrich MMW
W, Geijtenbeek T
TBH. Dectin‐1 acctivation induces prolifferation and miigration of hum
man keratinocyttes enhancing w
wound re‐epithe
elialization. Celll Immunol 2014; 289: 49‐
54. 102. Van D
Den Broek IVF, Land JA, Van Be
ergen JEAM, M orré SA, van de
er Sande MAB. Chlamydia tracchomatis Antibo
ody Testing in Vagginal Mucosal M
Material versuss Blood Sampless of Women Atttending a Fertility Clinic and aan STI Clinic. Ob
bstetrics and G
Gynecology Inteernational 2014
4; : 601932. 103. van d
den Broek LJ, Krroeze KL, Waaijman T, Breetveeld M, Sampat‐SSardjoepersad SC, Niessen FB,, Middelkoop E, Scheper RJ, Giibbs S. Differen
ntial Response o
of Human Adipoose Tissue‐Derived Mesenchymal Stem Cells,, Dermal Fibrob
blasts, and Kerattinocytes to Burrn Wound Exud
dates: Potentiall Role of Skin‐Sp
pecific Chemok
kine CCL27. Tisssue Engineeringg Part A 2014;; 20: 197‐209. 104. van d
der Woude AD, Stoop EJM, Stie
ess M, Wang Q
Q, Ummels R, van Stempvoort G
G, Piersma SR, CCascioferro A, JJimenez CR, H
Houben ENG, Lu
uirink J, Pieters J, van der Sar A
AM, Bitter W. A
Analysis of SecA2‐dependent suubstrates in Myco
obacterium marrinum identifiess protein kinasee G (PknG) as a virulence effecctor. Cell Microobiol 2014; 16: 2
280‐295. 105. van G
Gerven NM, Bakkker SF, de Boer YS, Witte BI, BBontkes H, van Nieuwkerk CM
M, Mulder CJ, Boouma G. Seroprrevalence of celliac disease in p
patients with au
utoimmune heppatitis. Eur J Gaastroen Hepat 2
2014; 26: 1104‐‐1107. Annual Report V
VUmc CCA 2014 –
4 of 216 106. van H
Heerden JH, Wo
ortel MT, Brugggeman FJ, Heijneen JJ, Bollen YJM, Planque R, H
Hulshof J, O'Tooole TG, Wahl A, Teusink B. Fattal attraction in
n glycolysis: how
w Saccharomycces cerevisiae m
manages sudden
n transitions to o high glucose. M
Microb Cell 2014;; 1: 103‐106. 107. van H
Heerden JH, Wo
ortel MT, Brugggeman FJ, Heijneen JJ, Bollen YJM, Planque R, H
Hulshof J, O'Tooole TG, Wahl SA
A, Teusink B. Losst in transition: start‐up of glycolysis yields suubpopulations of nongrowing cells. Science 22014; 343: 1245
5114. 108. van LLeeuwen LM, vaan der Kuip M, Y
Youssef SA, de Bruin A, Bitter W, van Furth A
AM, van der Sarr AM. Modelingg tuberrculous meninggitis in zebrafish
h using Mycobaacterium marinu
um. Disease Mo
odels and Mechhanisms 2014; 7: 1111‐
1122. 109. van R
Rijen MMI, Kluijjtmans JAJW. Adjustment of thhe MRSA Search and Destroy policy for outpaatients in the Netheerlands: a prospective cohort study with repeeated prevalen
nce measureme
ents. Antimicrobb Resist Infect C
Control 2014;; 3: 3. 110. van R
Rijen MML, Bosch T, Verkade E
EJM, Schouls L, Kluijtmans JAJW
W. Livestock‐Asssociated MRSAA Carriage in Pa
atients witho
out Direct Contact with Livesto
ock. PLoS One 22014; 9: e10029
94. 111. van SStrijp JAG, Bitter W. Pathogenss under stress. FFems Microbiology Reviews 2014; 38: 1089‐11090. Meijer J, Koudsstaal LG, Heidem
112. van W
Wanrooij RLJ, M
Muller DMJ, Nee
efjes‐Borst EA, M
man DAM, Bonttkes HJ, von Blo
omberg BME,, Bouma G, Mullder CJJ. Optimal Strategies too Identify Aberrant Intra‐Epithe
elial Lymphocyttes in Refractorry Coeliac Diseaase. Journal of cclinical immuno
ology 2014; 34: 828‐835. 113. Verkaade E, Kluytman
ns v, Benthem B
B, van Cleef B, vvan Rijen M, Bo
osch T, Schouls L, Kluijtmans JAAJW. Transmisssion of Meth
hicillin‐Resistantt Staphylococcu
us aureus CC3998 from Livestock Veterinarian
ns to Their Houssehold Members. PLoS One 22014; 9: e10082
23. 114. Verw
weij SP, Lanjouw
w E, Bax CJ, Quin
nt KD, Oostvogeel PM, Dorr PJ, Pleijster J, de v
vries HJC, Peters
rs RPH, Ouburg S, Morré SA. Seerovar D and E of serogroup B
B induce highestt serological responses in urog
genital Chlamyddia trachomatiss infecttions. BMC Infeect Dis 2014; 14
4: 3. 115. Verw
weij SP, Quint KD
D, Bax CJ, van Leeuwen AP, Muutsaers JAEM, JJansen CL, Oosttvogel PM, Oubburg S, Morré SA, Peters RPH. Serogroup disttribution of urogenital Chlamyydia trachomatis in urban ethn
nic groups in Thhe Netherlands.. Epidemiol Infectt 2014; 142: 40
09‐414. 116. Vink MA, Bootsma M
MCJ, Wallinga J. Serial Intervalls of Respiratory Infectious Disseases: A System
matic Review and Analyysis. Am J Epideemiol 2014; 180
0: 865‐875. 117. Vogel DYS, Glim JE, SStavenuiter AW
WD, Breur M, Heeijnen P, Amor S, Dijkstra CD, Beelen RHJ. Huuman macropha
age polarrization in vitro:: Maturation an
nd activation m
methods compared. Immunobiology 2014; 2199: 695‐703. 118. Vogelpoel LTC, Hanssen IS, Rispens T
T, Muller FJM, vvan Capel TMM
M, Turina MC, V
Vos JB, Baeten D
DLP, Kapsenberrg ML, de uman M2 Jong EC, den Dunnen J. Fc gamma receptor‐TLR crross‐talk elicits pro‐inflammatory cytokine prroduction by hu
macrophages. Naturre Communicattions 2014; 5: 55444. 119. von W
Wintersdorff CJ, Penders J, Sto
obberingh EE, laashof AM, Hoeb
be CJ, Savelkoul PHM, Wolffs PPF. High Rates o
of Antim
microbial Drug R
Resistance Gene Acquisition a fter Internation
nal Travel, the N
Netherlands. Em
merg Infect Dis 2014; 20: 649‐6657. 120. Walraaven M, Gouveerneur M, Middelkoop E, Beeleen RHJ, Ulrich M
MMW. Altered T
TGF‐beta signa ling in fetal fibrroblasts: Whatt is known abou
ut the underlyin
ng mechanismss?. Wound Repaair Regen 2014; 22: 3‐13. 121. Weissser SB, Kozicky LK, Brugger HK
K, Ngoh EN, Cheeung B, Jen R, M
Menzies SC, Sam
marakoon A, Muurray PJ, Lim CJJ, Johnson P, Boucher JL, van Rooijen N, Sly LM
M. Arginase acttivity in alternattively activated macrophages protects PI3Kp110 delta m sulfate induc ed intestinal inflammation. Eu
ur J Immunol 20014; 44: 3353‐3
3367. deficiient mice from dextran sodium
122. Werter IM, Schneideers FL, Scotet E, Verheul HMW
W, de Gruijl TD, van der Vliet HJ. Vgamma9Vggamma2‐T cells as antigen preseenting cells for iiNKT cell based cancer immunnotherapy. Oncoimmunology 2
2014; 3: e9553443. 123. Willemsen I, Nelson‐Melching J, He
endriks Y, Muldders A, Verhoefff S, Kluytmans‐V
Vandenbergh M
M, Kluijtmans JA
AJW. Meassuring the qualiity of infection control in Dutcch nursing home
es using a stand
dardized methood; the Infectio
on preveention RIsk Scan
n (IRIS). Antimiccrob Resist Infeect Control 2014; 3: 26. 124. Winkkelmann ER, Widman DG, Xia J, Johnson AJ, vaan Rooijen N, M
Mason PW, Bou
urne N, Milligann GN. Subcapsular sinus dissemination o
of West Nile viruus particles afte
er inoculation b
but are not esseential for the macrophages limit d
78‐289. devellopment of West Nile virus‐specific T cell respponses. Virologgy 2014; 450: 27
125. Wolf I, Bergervoet P
PWM, Sebens FW
W, van den Oevver HLA, Savelkkoul PHM, van d
der Zwet WC. TThe sink as a correctable sourcce of extended‐‐spectrum beta‐lactamase conntamination forr patients in the
e intensive caree unit. J Hosp In
nfect 2014; 87: 1226‐130. 126. Wolfss IMJ, Stoger JLL, Goossens P, P
Pottgens C, Gijbbels MJJ, Wijnan
nds E, van der V
Vorst EPC, van G
Gorp P, Beckerss L, Engel D, Bieessen EAL, Kraaal G, van Die I, D
Donners MMPCC, de Winther M
MPJ. Reprogram
mming macrophhages to an antii‐
inflam
mmatory pheno
otype by helmin
nth antigens re duces murine aatherosclerosis. FASEB J 2014; ; 28: 288‐299. 127. Woullfe JM, Gray MTT, Gray DA, Munoz DG, Middeeldorp JM. Hypo
othesis: A role ffor EBV‐inducedd molecular mimicry in Parkinson's disease. Parkinsonism Relat D 2014; 220: 685‐694. DT, Yazdani S, C
Celie JWAM, Aikkio M, Heljasvaaara R, Navis GJ, Pihlajaniemi TT, van den Born J. 128. Zaferrani A, Talsma D
Basem
ment Membran
ne Zone Collage
ens XV and XVIIII/Proteoglycan
ns Mediate Leuk
kocyte Influx in Renal Ischemia/Reperfusio
on. PLoS One 20
014; 9: e10673 2. Annual Report V
VUmc CCA 2014 –
5 of 216 129. Zaslona Z, Przybrano
owski S, Wilke C
C, van Rooijen N
N, Teitz‐Tennen
nbaum S, Osterrholzer JJ, Wilki nson JE, Moore
e BB, Peterrs‐Golden M. Reesident Alveola
ar Macrophagess Suppress, whe
ereas Recruited
d Monocytes Prromote, Allergic Lung Inflam
mmation in Murine Models of Asthma. J Imm
munol 2014; 193
3: 4245‐4253.
130. Zeesttraten ECM, Reimers MS, Saad
datmand S, Dekkker JW, Liefers GJ, van den Elssen PJ, van de VVelde CJH, Kupp
pen PJK. Comb
bined analysis o
of HLA class I, H
HLA‐E and HLA‐G
G predicts proggnosis in colon ccancer patientss. Brit J Cancer 2014; 110: 459‐4468. 131. Zhou ZN, Sharma VP
P, Beaty BT, Roh
h‐Johnson M, PPeterson EA, van Rooijen N, Ke
enny PA, Wiley HS, Condeelis JJS, Segall JE. Au
utocrine HBEGFF expression pro
omotes breast cancer intravassation, metasta
asis and macropphage‐independent invasion in vivo. Onccogene 2014; 33: 3784‐3793.
Scientific papers non
n‐refereed
1.
van TToorn R, Schaaf HS, Laubscher JA, van Elslandd SL, Donald PR,, Schoeman JF. Short Intensifieed Treatment in
n Children with Drug‐susceptib
ble Tuberculouss Meningitis. Peediatr Infect Diss J 2014; 33: 248
8‐252. Scienttific publica
ations 1.
Arrob
ba AI, varez‐Lindo N, van Rooijjen N, de la Rossa EJ. Microglia‐Müller Glia Cro
osstalk in the rdd10 Mouse Mo
odel of Retinitis Pigmentosaa; Retinal Degenerative Diseasses. New York, SSpringer, 2014:: 373‐379. Professsional publications 1.
2.
3.
4.
Bakkeer J, Rustemeyeer T. Fiddler's neckTijdschr Beddrijfs‐ Verzek G
Geneeskd 20142
22: 486‐487. Kraagg DE, Rustemeyyer T. Fototoxiscche en fotoalle rgische reacties in de dermato
ologieNederlannds Tijdschrift voor Allerggie en Astma 20
01414: 58‐61. Ogul E, Rustemeyer T. Diagnostiek en behandelingg van lichen scllerosusNederlands Tijdschrift vvoor Allergie en
n Astma 201414: 69‐74. van EEsch M, Rustem
meyer T. Allergie
e voor fresia, zeeldzaam of niet herkend?Nede
erlands Tijdschrrift voor Allergie en Astma 201414: 118‐120. Popu
ular publications 1. Mebius RE. Voedingg moeder bepaaalt afweer 20144.
D
Dissertation
ns 1.
2.
3.
4.
5.
6.
7.
opment, function, and collabooration. 3/4/2014. Beijer MR. Dendriticc cells and macrrophages in thee spleen: Develo
(Co)p
promotor(es): K
Kraal G, den Haa
an JMM . Hoeb
be EK. Epstein‐B
Barr virus encod
ded BARF1 prottein: immunopaathogenic role, transcriptionall regulation and
d diagn
nostic use in nassopharyngeal ccarcinoma. 5/8//2014. (Co)prom
motor(es): Midd
deldorp JM, Grreijer AE. Lindeenberg JJ. Targeeting skin associated DC subse ts and conferring resistance to
o tumor‐relatedd immune supp
pression. 11/244/2014. (Co)pro
omotor(es): de Gruijl TD, Scheeper RJ, van den
n Eertwegh AJM
M, Oosterhoff D
D . van d
der Steen LPE. Immunoglobulin
n A‐induced neeutrophil migrattion: How the Ig
gA receptor FcaaRI can aggrava
ate tissue damaage. 2/6/2014. (Co)promotor(e
es): Beelen RHJJ, van Egmond M
M, Bakema JE . Verw
weij SP. Chlamyd
dia trachomatiss in the Dutch ppopulation: epid
demiology, sero
ological responsses, and host genetics. 3/3/22014. (Co)prom
motor(es): Morré
é SA, Ouburg S,, Peters RPH .
Visser DH. Host imm
mune response to tuberculous meningitis. 12//11/2014. (Co)p
promotor(es): vvan Furth AM, SSchoeman JF . Mycobacterial vvirulence ‐ a de licate balance. 3/12/2014. (Co
o)promotor(es) : Bitter W, Weerrdenburg EM. M
Vandenbroucke‐Graauls CJME . Program 33 – Disease
e profiling Scientiffic papers re
efereed Annual Report V
VUmc CCA 2014 –
6 of 216 1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Aertss HJWL, Velazqu
uez ER, Leijenaa
ar RTH, Parmar r C, Grossmann P, Carvalho S, B
Bussink J, Monsshouwer R, Haibe‐Kains B, Rietveld D, Hoebers F, Rietbergen M
MM, Leemans CCR, Dekker A, Q
Quackenbush J, Gillies RJ, Lambbin P. Decodingg tumour nvasive imagingg using a quanti tative radiomiccs approach. Na
ature Communiications 2014; 5
5: 4006. phenotype by nonin
einin I, Alenttorn A, van Thuijl HF, Marie Y, Alshehhi H, Ca rpentier C, Boissselier B, Laigle‐Donadey F, M okhtari K, Sche
Wessseling P, Ylstra B
B, Capelle L, Ho
oang‐Xuan K, Saanson M, Delatttre JY, Reijneveld JC, Idbaih A. Clinical value o
of chrom
mosome arms 1
19q and 11p lossses in low‐gradde gliomas. Neu
uro‐oncology 2014; 16: 400‐4008. Alhan
n C, Westers TM
M, Cremers EMP, Cali C, Witte BI, Ossenkoppele GJ, van de LLoosdrecht AA. High flow cyto
ometric scorees identify adverse prognostic subgroups withhin the revised international p
prognostic scoriing system for myelo
odysplastic syndromes. Brit J H
Haematol 20144; 167: 100‐109. Alhan
n C, Westers TM
M, van der Helm
m LH, Eeltink C, Huls G, Witte B
BI, Buchi F, Santtini V, Ossenkooppele GJ, van d
de Loosd
drecht AA. Abseence of aberran
nt myeloid proggenitors by flow
w cytometry is a
associated withh favorable resp
ponse to azacittidine in higherr risk myelodysp
plastic syndrom
mes. Cytom Partt B‐ Clin CY 201
14; 86: 207‐215 . Almeida R, Ricano‐P
Ponce I, Kumar V
V, Deelen P, Szpperl A, Trynka G
G, Gutierrez‐Achury J, Kanteraakis A, Westra H
HJ, Franke L, Swertz MA, Platteeel M, Bilbao JR
R, Barisani D, Grreco L, Mearin LL, Wolters VM, Mulder CJJ, Maazzilli MC, Sood
d A, Cukro
owska B, Nunezz C, Pratesi R, W
Withoff S, Wijm enga C. Fine mapping of the celiac disease‐asssociated LPP lo
ocus reveaals a potential ffunctional variant. Hum Mol G enet 2014; 23: 2481‐2489. Attyggalle AD, Cabecaadas J, Gaulard P, Jaffe ES, de Jong D, Ko YH, Said J, Klapper W. Peripheral T‐cell and NK‐ccell lymphomas and their mimics; takin
ng a step forwa rd ‐ report on tthe lymphoma w
workshop of thhe XVIth meetin
ng of the pean Associatio
on for Haemato
opathology and the Society forr Hematopathology. Histopathhology 2014; 64
4: 171‐199. Europ
Bahcee I, Huisman MC, Verwer E, Oo
oijevaar R, Bou tkourt F, Vugts DJ, van Dongen GAMS, Boellaaard R, Smit EF. Pilot studyy of 89Zr‐bevacizumab positro
on emission tom
mography in pattients with advanced non‐smaall cell lung cancer. EJNM
MMI research 20
014; 4: 35. Baileyy DL, Barthel H,, Beuthin‐Baum
mann B, Beyer TT, Bisdas S, Boellaard R, Czernin J, Drzezga A, Ernemann U, FFranzius C, Guckeel B, Handgretinger R, Hartenb
bach M, Hellwigg D, Nadel H, N
Nekolla SG, Pflug
ger T, Pichler BJ
BJ, Quick HH, Sabri O, Sattleer B, Schafer J, SSchick F, Siegel BA, Schlemmeer HP, Schwenze
er NF, van den Hoff J, Veit‐Haiibach P, Wehrl HF. Comb
bined PET/MR: Where Are We
e Now? Summaary Report of the Second International Worksshop on PET/MR Imaging April 8‐12, 2013, Tub
bingen, Germany. Mol Imagin g Biol 2014; 16
6: 295‐310. Balaj L, Momen‐Herravi F, Chen W, Sivaraman S, Z hang X, Ludwigg N, Meese E, W
Wurdinger T, Nooske DP, Charesst A, Hochberg AH, Vandeertop WP, Skogg J, Kuo WP. De tection Of Hum
man c‐Myc and EGFR Amplificaations in Circula
ating Extracellular Vesiclees in Mouse Tum
mour Models. J ournal of Circulating Biomarke
ers 2014; 2014:: 6. Baraliakos X, Heldmann F, Callhoff J, Listing J, Apppelboom T, Bran
ndt J, Bosch F, B
Breban M, Burm
mester GR, Dou
ugados M, ewe R, Leirisalo‐Repo M, Siepeer J, de Vlam K, Pappas D, Emerry P, Gaston H, Grunke M, van der Horst‐Brui nsma IE, Lande
Kiltz U
U, van der Heijd
de D, von Braun
n J. Which spinaal lesions are associated with new bone form
mation in patien
nts with ankyllosing spondylittis treated with
h anti‐TNF agennts? A long‐term
m observationall study using M
MRI and conventtional heum Dis 2014;; 73: 1819‐18255. radiography. Ann Rh
n HBAC, van Die
emen PM, Bril H
H, Tijssen M, van Essen HF, Hey
ymans MW, Beelien JAM, Carva
alho B, Belt EEJT, Stockmann
Cillessen SAGM, Meeijer GA. Expression of Apopto sis Regulating P
Proteins Identiffies Stage II andd III Colon Cancer Patients With High Risk of Reecurrence. J Surrg Oncol 2014; 109: 255‐265.
O'Byrne KJ, Doooms C, Sejda A, Blackkhall FH, Peters S, Bubendorf LL, Dafni U, Kerr KM, Hager H, SSoltermann A, O
Hernaandez‐Losa J, M
Marchetti A, Savvic S, Tan Q, Th unnissen E, Spe
eel EJM, Cheney
y R, Nonaka D, de Jong J, Marttorell M, Letovvanec I, Rosell R
R, Stahel RA. Prevalence and CClinical Outcomes for Patients With ALK‐Posittive Resected Stage I to III Adenocarcinoma: Reesults From the
e European Thooracic Oncologyy Platform Lung
gscape Project. JJ Clin Oncol 2014; 32: 2780‐‐2787. Boellaaard R, Hofman
n MBM, Hoeksttra OS, Lammerrtsma AA. Accurate PET/MR Q
Quantification U
Using Time of Flight MLAA Imagee Reconstructio
on. Mol Imagingg Biol 2014; 16 : 469‐477. Bohtee AE, de Niet A,, Jansen L, Bipat S, Nederveenn AJ, Verheij J, T
Terpstra V, Sinkus R, van Nieuw
wkerk CMJ, de Knegt RJ, Baak BC, Jansen PLM
M, Reesink HW, Stoker J. Non‐ invasive evaluaation of liver fib
brosis: a compa rison of ultraso
ound‐based transient elastograp
phy and MR elasstography in paatients with viraal hepatitis B an
nd C. Eur J Radiiol 2014; 24: 63
38‐648. Boonstra K, Culver EEL, Wenniger LM
MD, van Heerdee MJ, van Erpeccum KJ, Poen AC, van Nieuwkeerk CMJ, Spanie
er BWM, Witteeman BJM, Tuynman HARE, va
an Geloven N, vvan Buuren H, C
Chapman RW, B
Barnes E, Beuerrs U, Ponsioen C
CY. Serum Immu
unoglobulin G4 and Immunoglobulin G1 for D
Distinguishing Immunoglobulin
n G4‐Associatedd Cholangitis From Primaary Sclerosing C
Cholangitis. Hep
patology 2014; 59: 1954‐1963. Both J, Krijgsman O, Bras J, Schaap JR, Baas F, Ylsttra B, Hulsebos TJM. Focal Chromosomal Coppy Number Aberrations Identtify CMTM8 and
d GPR177 as Ne
ew Candidate D
Driver Genes in Osteosarcoma. PLoS One 20144; 9: e115835. Brand
derhorst W, Bleezer ELA, Houtkkamp M, Ramakkers RM, van de
en Brakel JH, W
Witteveen H, vann der Have F, va
an Andel HAG, Vastenhouw B
B, Wu C, Stigter‐‐van Walsum M
M, van Dongen G
GAMS, Viergever MA, Bleekerr WK, Beekman FJ. Three‐
Dimeensional Histolo
ogic Validation o
of High‐Resoluttion SPECT of Antibody Distributions Within XXenografts. J Nu
ucl Med 2014;; 55: 830‐837. Annual Report V
VUmc CCA 2014 –
7 of 216 18. Bruijn
nen STG, Gent YYYJ, Voskuyl AE
E, Hoekstra OS, van der Laken CJ. Present Role of Positron Em
mission Tomoggraphy in the D
Diagnosis and M
Monitoring of Pe
eripheral Inflam
mmatory Arthrittis: A Systematiic Review. Arth ritis Care Res 2014; 66: 120‐1130. 19. Bruniing AHL, van Dijjk K, van Eijk HW
WM, Koen G, vaan Woensel JBM
M, Kruisinga FH
H, Pajkrt D, Wollthers KC. Evalu
uation of a rapid antigen detecttion point‐of‐ca
are test for resppiratory syncytial virus and influenza in a peddiatric hospitalizzed population in the Neetherlands. Diagnostic microb iology and infectious disease 2014; 80: 292‐2293. 20. Budding AE, Grasmaan ME, van Eck A, Bogaards JA
A, Vandenbroucke‐Grauls CMJE
E, van Bodegravven AA, Savelko
oul PHM. Rectaal Swabs for Analysis of the Inttestinal Microb iota. PLoS One 2014; 9: e1013
344. 21. Bultin
nk IEM, Lems W
WF. Performancce of vertebral ffracture assessm
ment in additio
on to dual energgy X‐ray absorp
ptiometry in pattients with rheu
umatoid arthrittis Useful or useeless?. Rheumaatology 2014; 53: 775‐776. 22. Burskka AN, Roget K, Blits M, Gomez LS, van de Looo F, Hazelwood
d LD, Verweij CLL, Rowe A, Goullielmos GN, van
n Baarsen LGM,, Ponchel F. Gen
ne expression a
analysis in RA: ttowards person
nalized medicine. Pharmacogeenomics J 2014; 14: 93‐
106. den Bos, van Kuuijk C, van Waesberghe JHTM. Magnetic resoonance imaging of deep 23. Busarrd MPH, van deen Pieters‐van d
infiltrrating endomettriosis: compariison of 2DT2‐ a nd 3DT2‐weigh
hted TSE sequen
nces. Journal off Endometriosiss and Pelvicc Pain Disorders 2014; 6: 34‐40. 24. Chatu
urvedi N, Meneezes R, Goeman
n JJ. Fused lassoo algorithm for Cox proportion
nal hazards and binomial logit models with aapplication to ccopy number profiles. Biometrrical journal 2014; 56: 477‐492
2. 25. Chiassserini D, van W
Weering JRT, Pie
ersma SR, Pham
m TV, Malekzade
eh A, Teunissen
n CE, de Wit H, Jimenez CR. Proteomic analyysis of cerebrospinal fluid extra
acellular vesiclees: A comprehe
ensive dataset. Journal of Prote
teomics 2014; 1
106: 191‐
204. 26. Coghill AE, Hsu WL, Pfeiffer RM, Juwana H, Yu KJ, Lou PJ, Wang C
CP, Chen JY, Che
en CJ, Middeldoorp JM, Hildesh
heim A. Epsteein‐Barr Virus Seerology as a Po
otential Screeni ng Marker for N
Nasopharyngea
al Carcinoma am
mong High‐Riskk Indiviiduals from Mu
ultiplex Familiess in Taiwan. Canncer Epidem Bio
omar 2014; 23:: 1213‐1219. 27. Cohen R, Vugts DJ, V
Visser GWM, Sttigter‐van Walsuum M, Bolijn M
M, Spiga M, Lazzzari P, Shankar SS, Sani M, Zand
da M, van Donggen GAMS. Deveelopment of No
ovel ADCs: Conjjugation of Tub
bulysin Analogues to Trastuzum
mab Monitored
d by Dual Radio
olabeling. Canceer Res 2014; 74
4: 5700‐5710. 28. Cree IA, Deans Z, Liggtenberg MJL, N
Normanno N, Eddsjo A, Rouleau
u E, Sole F, Thun
nnissen E, Timeens W, Schuurin
ng E, ueker E, Murrayy S, Dietel M, Grroenen P, van KKrieken JH. Guid
dance for laborratories perform
ming molecularr pathology Dequ
for caancer patients. J Clin Oncol 2014; 67: 923‐9311. 29. d'Ago
ostino MA, Boers M, Kirwan J, van der Heijdee D, Ostergaard M, Schett G, La
andewe RB, Maaksymowych W
WP, Naredo E, Dougados M, Iagn
nocco A, Bingha
am CO, Brooks PM, Beaton DE
E, Gandjbakhch F, Gossec L, Guuillemin F, Hew
wlett SE, Klopp
penburg M, March L, Mease PJJ, Moller I, Simoon LS, Singh JA,, Strand V, Wak
kefield RJ, Wellss GA, Tugwell P
P, Conaghan PG. Updating the OMERACT Filter: Imp lications for Im
maging and Soluble Biomarkerss. J Rheumatol 2
2014; 41: 1016‐‐1024. 30. Danieels L, Budding A
AE, de Korte N, van Eck A, Bogaaards JA, Stockmann HB, Conssten EC, Savelkooul PHM, Boerm
meester MA. FFecal microbiom
me analysis as a
a diagnostic tesst for diverticulitis. Eur J Clin M
Microbiol 2014; 33: 1927‐1936
6. 31. de Bo
oer KHN, de Meeij TGJ, Oort FA, Ben Larbi I, M
Mulder CJJ, van B
Bodegraven AA
A, van der Scheee MP. The Scent of Colorrectal Cancer: D
Detection by Vo
olatile Organic CCompound Anaalysis. Clin Gastrroenterol Hepaatol 2014; 12: 1085‐1089. 32. de Bo
oer YS, van Gervven NMF, Zwiers A, Verwer BJJ, van Hoek B, vvan Erpecum KJ, Beuers U, vann Buuren HR, Drrenth JPH, den O
Ouden JW, Verd
donk RC, Koek G
GH, Brouwer JTT, Guichelaar M
MMJ, Vrolijk JM, Kraal G, Muldeer CJJ, van Nieu
uwkerk CMJ, Fischer J, van d
den Berg T, Stickel F, Sarrazin CC, Schramm C, Lohse AW, Weiiler‐Normann CC, Lerch MM, Nauck M, Volzkke H, Homuth G
G, Bloemena E, V
Verspaget HW,, Kumar V, Zherrnakova A, Wijm
menga C, Franke
ke L, Bouma G. G
Genome‐
wide association stu
udy identifies va
ariants associatted with autoim
mmune hepatitis type 1. Gastrooenterology 20
014; 147: 443‐4452. 33. de Grroen FLM, Krijgsman O, Tijssen
n M, Vriend LEM
M, Ylstra B, Hoo
oijberg E, Meije
er GA, Steenberrgen RDM, Carvvalho B. Genee‐Dosage Depen
ndent Overexprression at the 113q Amplicon Id
dentifies DIS3 as Candidate Onncogene in Colo
orectal Canceer Progression. Gene Chromossome Canc 20114; 53: 339‐348. 34. de Jong MC, de Graaaf P, Noij DP, Goricke S, Maed er P, Galluzzi P,, Brisse HJ, Moll AC, Castelijns s JA. Diagnostic Perfo
ormance of Maggnetic Resonance Imaging andd Computed Tomography for A
Advanced Retinnoblastoma: A SSystematic Revieew and Meta‐an
nalysis. Ophthalmology 2014; 121: 1109‐1118. 35. de Meij TGJ, Ben Larrbi I, van der Scchee MP, Lentfeerink YE, Paff T,, Droste JSTS, M
Mulder CJ, van BBodegraven AA
A, de Boer KHN. Electronic nosee can discriminate colorectal ccarcinoma and advanced aden
nomas by fecal volatile biomarrker analyysis: proof of prrinciple study. In
nt J Cancer 20114; 134: 1132‐1138. 36. de Viron S, Morré SA
A, van Oyen H, Brand A, Oubu rg S. Genetic similarities betw
ween tobacco usse disorder and
d related como
orbidities: an exxploratory study. BMC Med Geenet 2014; 15: 85. 37. de Vrree PJP, de Wit E, Yilmaz M, de
e Heijning MV, Klous P, Verste
egen MJAM, Wa
an Y, Teunissenn H, Krijger PHL,, Geeven G, Eijk PP, Sie DLS, YYlstra B, Hulsma
an LOM, van Doooren MF, van ZZutven LJCM, va
an den Ouwelaand A, Verbeek S, van Dijk KW, C
Cornelissen M, Das AT, Ben B, Sikkema‐Raddaatz B, Berg E, van der Vlies P, W
Weening D, denn Dunnen JT, attusiak M, Lamkkanfi M, Ligtenb
berg MJL, ter Brrugge P, Jonkerrs J, Foekens JA,, Martens JW, v
van der Luijt R, van Amstel HKP, van Min Annual Report V
VUmc CCA 2014 –
8 of 216 38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
M, Sp
plinter E, de Laaat W. Targeted sequencing by proximity ligation for comprehensive variantt detection and
d local haplo
otyping. Nat Bio
otechnol 2014; 32: 1019‐1025 . de W
Wit M, Kant H, Piiersma SR, Pham
m TV, Mongeraa S, van Berkel M
MPA, Boven E, Ponten F, Meijeer GA, Jimenezz CR, Fijnem
man RJA. Colorrectal cancer candidate bioma rkers identified
d by tissue secre
etome proteom
me profiling. Jou
urnal of Proteeomics 2014; 99
9: 26‐39. Derkss S, Cleven AHG
G, Melotte V, Sm
mits KM, Brand es JC, Azad N, V
Van Criekinge W
W, de Bruine APP, Herman JG, vvan Engelland M. Emergiing evidence for CHFR as a canncer biomarker: from tumor biology to precission medicine. Cancer Metaast Rev 2014; 33
3: 161‐171. Diot Q
Q, Marks LB, Beentzen SM, Senan S, Kavanaghh BD, Lawrence MV, Miften M,, Palma DA. Com
mparison of Ra
adiation‐
Inducced Normal Lun
ng Tissue Densitty Changes for Patients From Multiple Institu
utions Receivingg Conventional or Hypo
ofractionated Trreatments. Int JJ Radiat Oncol 22014; 89: 626‐6
632. Drago
omir A, de Wit M, Johansson C
C, Uhlen M, Ponnten F. The Role of SATB2 as a
a Diagnostic Maarker for Tumorrs of Colorrectal Origin. Am
m J Clin Pathol 2014; 141: 6300‐638. Drahtt MXG, Smits KM, Tournier B, Jooste V, Chap usot C, Carvalho B, Cleven AHG, Derks S, Woouters KAD, Beltt EJTH, Stockkmann HBAC, Bril H, Weijenbe
erg MP, van denn Brandt PA, de
e Bruine AP, Herrman JG, Meijeer GA, Piard F, M
Melotte V, van EEngeland M. Pro
omoter CpG isla
and methylatioon of RET prediccts poor progno
osis in stage II ccolorectal cance
er patients. Molecular oncology 2014; 8: 679‐6
688. e J, Metselaar H
HJ, Kazemier G, van der Laan LLJW. The ins andd outs of micro
oRNAs as Farid WRR, Verhoevven CJ, de Jonge
disease and transplantation. TTransplant Interrnational 2014; 27: 1222‐12322. biomarkers in liver d
mos RA, V, Klopp W, Hoekstra O
OS, de Bree R. P
Practice variatioon in defining sentinel Flach GB, van Schie A, Witte BI, Olm
mphoscintigrams in oral cancerr patients. Eur JJ Nucl Med Mol I 2014; 41: 22449‐2256. lymph nodes on lym
bbing J, Jiao LR, Castellano L. AA microRNA me
eta‐
Frampton AE, Giovannetti E, Jamieson NB, Krell J, Gall TMH, Steb
enocarcinoma. Expert review o
of molecular dia
agnostics 2014;; 14: 267‐271. signature for pancreeatic ductal ade
M, Hoekstra OS,, Smit EF, Boellaaard R. Method
dological Fringss V, de Langen AJ, Yaqub MM,, Schuit RC, vann der Veldt AAM
Consiiderations in Qu
uantification off 3 '‐Deoxy‐3 '‐[[F‐18]Fluorothyymidine Uptake Measured withh Positron Emisssion Tomo
ography in Patieents with Non‐SSmall Cell Lung g Cancer. Mol Im
maging Biol 201
14; 16: 136‐1455. Fringss V, van Velden
n FHP, Velasque
ez LM, Hayes W
W, van de Ven PM, Hoekstra OS
S, Boellaard R. RRepeatability o
of Metaabolically Activee Tumor Volume Measuremennts with FDG PE
ET/CT in Advancced Gastrointesstinal Malignancies: A Multiicenter Study. R
Radiology 2014; 273: 539‐548.. Fringss V, Yaqub MM
M, Hoyng LL, Golla SSV, Windhoorst AD, Schuit RC, Lammertsm
ma AA, Hoekstrra OS, Smit EF, B
Boellaard R. Asssessment of Sim
mplified Metho
ods to Measure F‐18‐FLT Uptakke Changes in E
EGFR‐Mutated N
Non‐Small Cell Lung Canceer Patients Und
dergoing EGFR T
Tyrosine Kinasee Inhibitor Treatment. J Nucl M
Med 2014; 55: 11417‐1423. Gent Y, Ahmadi N, V
Voskuyl AE, Hoe
etjes N, van Kuijjk C, Britsemme
er K, Turkstra F, Boers M, Hoeekstra OS, van d
der Laken CJ. Deetection of Sub
bclinical Synovittis with Macropphage Targetingg and Positron E
Emission Tomoggraphy in Patie
ents with Rheumatoid Arthritiis without Cliniccal Arthritis. J RRheumatol 2014
4; 41: 2145‐215
52. Gent YYJ, Weijers K, Molthoff CFM,, Windhorst AD
D, Huisman MC,, Kassiou M, Jan
nsen G, Lammeertsma AA, van der Laken CJ. Prromising potenttial of new generation transloocator protein tracers providing enhanced conntrast of arthrittis imaging by po
ositron emission
n tomography in a rat model oof arthritis. Arth
hritis Res Ther 2
2014; 16: R70. Goos JACM, Hiemstrra AC, Coupe VMH, Diosdado B, Kooijman W, van Diemen P
PM, Karga C, Beelien JAM, van O
Oordt M, Geldof AA, M
Meijer GA, Hoekstra OS, Fijnem
man RJA. Epidermal growth factor receptor (EEGFR) and prosttaglandin‐
CWM
endoperoxide synthase 2 (PTGS2) a
are prognostic biomarkers for patients with rresected coloreectal cancer live
er metastases. Brit J Caancer 2014; 111
1: 749‐755. Gorteer RR, Heij HA, Eker HH, Kazem
mier G. Laparos copic appendectomy: State off the art. Tailoreed approach to
o the appliccation of laparo
oscopic append
dectomy?. Bailliiére's Best Pracctice and Research Clinical Gasstroenterology 2014; 28: 211‐2224. Grubb A, Horio M, H
Hansson LO, Bjo
ork J, Nyman U,, Flodin M, Larsson A, Bokenka
amp A, Yasuda YY, Blufpand H, Lindstrom V, Zeggers I, Althaus H, Blirup‐Jensen S, Itoh Y, Sjosstrom P, Nordin
n G, Christensso
on A, Klima H, SSunde K, Hjort‐
Christtensen P, Armb
bruster D, Ferre
ero C. Generatioon of a New Cystatin C‐Based Estimating Equuation for Glomerular Filtration Rate by Usse of 7 Assays SStandardized too the International Calibrator. Clin Chem 20144; 60: 974‐986.
Haan JC, Labots M, R
Rausch C, Koop
pman M, de Noooy‐van Tol J, Mekenkamp LJM, van de Wiel M
MA, Israeli D, va
an Essen HF, vaan Grieken NCTT, Voorham QJM
M, Bosch LJW, Q
Qu X, Kabbarah
h O, Verheul HM
MW, Nagtegaal ID, Punt CJA, Y
Ylstra B, Meijeer GA. (. Naturee Communicatio
ons 2014; 5: 54457. Hassaan C, Kester MG
GD, Oudgenoegg G, De Ru AH, JJanssen GMC, D
Drijfhout JW, Sp
paapen RM, Jim
menez CR, Heem
mskerk MHM
M, Falkenburg JH
HF, van Veelen PA. Accurate qquantitation of MHC‐bound pe
eptides by appliication of isotopically labeleed peptide MHC complexes. Jo
ournal of Proteeomics 2014; 10
09: 240‐244. Horew
weg N, Scholten ET, de Jong PA, van der Aalsst CM, Weeninkk C, Lammers JW
WJ, Nackaerts KK, Vliegenthart R, ten Haaf K, You
g HJ. Detection of lung cancer through usaf‐Khan UA, Heuvelmans MA, Thunnissen E, Oudkerk M, Mali W, Koning
low‐d
dose CT screeniing (NELSON): a
a prespecifi ed aanalysis of scre
eening test performance and innterval cancerss. Lancet Onco
ol 2014; 15: 134
42‐1350. Annual Report V
VUmc CCA 2014 –
9 of 216 57. Huijskens EGW, Rossen JWA, Kluijtmans JAJW, va n der Zanden A
AGM, Koopmans M. Evaluationn of yield of currrently availaable diagnosticss by sample typ
pe to optimize ddetection of resspiratory patho
ogens in patientts with a comm
munity‐
acquiired pneumoniaa. Influenza and
d Other Respiraatory Viruses 20
014; 8: 243‐249
9. 58. Hutajjulu SH, Kurnian
nda J, Tan IB, M
Middeldorp JM. Therapeutic im
mplications of Epstein‐Barr viruus infection for the treatm
ment of nasoph
haryngeal carcinoma. Therapeeutics and Cliniccal Risk Manage
ement 2014; 100: 721‐736. 59. Jimen
nez CR, Verheul HM. Mass spe
ectrometry‐baseed proteomics:: from cancer biology to proteein biomarkers, drug targeets, and clinical applications. American Societty of Clinical On
ncology educational book 20144; 2014: e504‐e
e510. 60. Jiwa LLS, van Diest PJJ, Hoefnagel LD, Wesseling J, W
Wesseling P, Mo
oelans CB. Upre
egulation of Claaudin‐4, CAIX and GLUT‐1 in disstant breast can
ncer metastasess. BMC Cancer 2014; 14: 864.
61. Joenssen O, Paff T, Haarman EG, Sko
ovgaard IM, Jennsen PO, Bjarnssholt T, Nielsen KG. Exhaled Brreath Analysis U
Using Electrronic Nose in Cystic Fibrosis an
nd Primary Ciliaary Dyskinesia P
Patients with Chronic Pulmonaary Infections. PLoS One 2014;; 9: e115584. 62. Johan
nnesma PC, van
n Moorselaar RJJA, Horenblas SS, van der Kolk LE, Thunnissen E, van Waesbeerghe JHTM, Me
enko FH, Postm
mus PE. Bilateraal renal tumourr as indicator foor birt‐hogg‐dub
be syndrome. C
Case reports in medicine 2014; 2014: 6186775. 63. Jong A, Kwee TC, dee Klerk JMH, Adam JA, de Keizeer B, Fijnheer R, Kersten MJ, Lu
udwig I, Jauw YYWS, Zijlstra JM, van den Bos IC
C, Stoker J, Hoeekstra OS, Nieve
elstein RAJ. Rel ationship betw
ween pretreatment FDG‐PET annd diffusion‐we
eighted MRI b
biomarkers in d
diffuse large B‐ccell lymphoma. Am J Nucl Med
d Mol Im 2014; 4: 231‐238. 64. Kaiseer AM, de Jong EE, Brugman SFM
M, Peppink JM, Vandenbrouckke‐Grauls CMJE, Girbes ARJ. Deevelopment of trigger‐
based
d semi‐automatted surveillance
e of ventilator‐aassociated pne
eumonia and central line‐assocciated bloodstream infecttions in a Dutch
h intensive care
e. Annals of Inteensive Care 201
14; 4: 40. 65. Krijgssman O, Bennerr C, Meijer GA, van de Wiel MA
A, Ylstra B. FocalCall: An R Pacckage for the Annnotation of Fo
ocal Copy Numb
ber Aberrationss. Cancer Inform
m 2014; 13: 1533‐156. 66. Krijgssman O, Carvalh
ho B, Meijer GA
A, Steenbergen RDM, Ylstra B. Focal chromossomal copy num
mber aberration
ns in canceer‐Needles in a genome haysta
ack. Biochim Biiophys Acta Mo
ol Cell Res 2014; 1843: 2698‐27704. 67. Labotts M, Buffart TEE, Haan JC, van Grieken NCT, TTijssen M, van d
de Velde CJH, Grabsch HI, Ylstrra B, Carvalho B
B, Fijneman RJA, V
Verheul HMW, Meijer GA. Higgh‐level copy nuumber gains of established and potential dru g target genes in gastric canceer as a lead for treatment deve
elopment and sselection. Cell O
Oncol 2014; 37:: 41‐52. 68. Labotts M, Schutte LM, van der Mun JC, Pham TV, Jimenez CR, Ve
erheul HMW. M
Mass Spectromeetry‐Based Seru
um and Plasm
ma Peptidome P
Profiling for Pre
ediction of Treaatment Outcom
me in Patients W
With Solid Maliggnancies. Oncologist 2014; 19: 10028‐1039. 69. Lalic D, Hackenberg M, Bijnsdorp IV
V, van Eijndhovven MAJ, Sadek P, Sie DLS, Zini N, Middeldorpp JM, Ylstra B, M
Menezes R, Wurd
dinger T, Meijerr GA, Pegtel DM
M. Nontemplateed Nucleotide A
Additions Distin
nguish the Smalll RNA Composiition in Cells from Exosomess. Cell reports 2
2014; 8: 1649‐11658. R, Boven E. Brea
ast cancer classsification by pro
oteomic techno
ologies: Currentt state of knowledge. 70. Lam SSW, Jimenez CR
Canceer Treat Rev 20
014; 40: 129‐138. 71. Lehou
ux S, Mi RJ, Aryyal RP, Wang YC
C, Schjoldager KKTBG, Clausen H
H, van Die I, Han YS, Chapman AB, Cummingss RD, Ju TZ. Identtification of Disttinct Glycoform
ms of IgA1 in Plaasma from Patie
ents with Immu
unoglobulin A (IIgA) Nephropatthy and Healtthy Individuals. Mol Cell Proteomics 2014; 133: 3097‐3113. 72. Lopezz‐Isac E, Bossini‐Castillo L, Gue
erra SG, Dentonn C, Fonseca C, Assassi S, Zhou
u XD, Mayes MD
D, Simeon CP, O
Ortego‐
Centeeno N, Castellvii I, Carreira P, G
Gorlova O, Bereetta L, Santanielllo A, Lunardi C, Hesselstrand R, Nordin A, Rie
emekasten G, Wiitte T, Hunzelm
mann N, Kreuterr A, Distler JHW
W, Voskuyl AE, de Vries‐Bouwsttra J, Koelemann BP, Herrick A, Worthington J, Radsstake TRDJ, Martin J. Identificaation of IL12RB1 as a novel sysstemic sclerosiss susceptibility locus. Arthrritis & rheumato
ology 2014; 66: 3521‐3523. 73. Lopezz‐Isac E, Bossini‐Castillo L, Simeon CP, Egurbi de MV, egre‐Saancho JJ, Calleja
as JL, Roman‐Ivvorra JA, Freire M, Beretta L, San
ntaniello A, Airo
o P, Lunardi C, H
Hunzelmann N,, Riemekasten G
G, Witte T, Kreu
uter A, Distler J HW, Schuerwe
egh AJ, Vonk MC, Voskuyl A
AE, Shiels PG, va
an Laar JM, Fonnseca C, Denton
n C, Herrick A, W
Worthington J, AAssassi S, Koele
eman BP, wide association
n study follow‐u
up suggests a p ossible role forr PPARG in Mayees MD, Radstake TRDJ, Martin J. A genome‐w
systemic sclerosis su
usceptibility. Arrthritis Res Therr 2014; 16: R6.
74. Louis DN, Perry A, Burger P, Ellison DW, Reifenberrger G, von Deimling A, Aldape
e K, Brat D, Colllins VP, Eberhart C, Figareella‐Branger D, Fuller GN, Gian
ngaspero F, Giaannini C, Hawkins C, Kleihues P
P, Korshunov A,, Kros JM, Lope
es MB, Ng HK, O
Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soyylemezoglu F, W
Wiestler O, Wessseling P. Intern
national Socieety of Neuropatthology‐Haarlem
m Consensus G uidelines for Nervous System Tumor Classificcation and Grad
ding. Brain Patho
ol 2014; 24: 429
9‐435. 75. Makrris NE, Boellaard
d R, Visser EP, d
de Jong JR, Vannderlinden B, W
Wierts R, van derr Veen BJ, Greuuter HJNM, Vuggts DJ, van Donggen GAMS, Lammertsma AA, H
Huisman MC. M
Multicenter Harm
monization of Z
Zr‐89 PET/CT Peerformance. J N
Nucl Med 2014;; 55: 264‐267. 76. Makrris NE, van Velden FHP, Huisman MC, Menke CW, Lammertssma AA, Boellaa
ard R. Validatioon of simplified dosimetry appro
oaches in (89) ZZr‐PET/CT: The use of manual vversus semi‐au
utomatic delineation methods to estimate orggan absorrbed doses. Meed Phys 2014; 4
41: 102503. Annual Report V
VUmc CCA 2014 –
0 of 216 77. Makssymowych WP, Naides SJ, Byke
erk V, Siminovittch KA, van Sch
haardenburg D, Boers M, Land ewe R, van derr Heijde D, Tak P
PP, Genovese M
MC, Weinblatt M
ME, Keystone ECC, Zhukov OS, A
Abolhosn RW, P
Popov JM, Britseemmer K, van K
Kuijk AW, Maro
otta A. Serum 14
4‐3‐3 eta is a Novel Marker thhat Complemen
nts Current Sero
ological Measurrements to Enh
hance Detecction of Patientts with Rheuma
atoid Arthritis. JJ Rheumatol 20
014; 41: 2104‐2113. 78. Markkusse IM, Dirven
n L, van den Bro
oek M, Bijkerk CC, Han KH, Ronday HK, Bolce R
R, Sasso EH, Kerrstens PJSM, Le
ems WF, Huizin
nga TWJ, Allaarrt CF. A Multibiomarker Diseasse Activity Scorre for Rheumato
oid Arthritis Preedicts Radiogra
aphic Joint Damaage in the BeSt Study. J Rheum
matol 2014; 41: 2114‐2119. 79. Mayees MD, Bossini‐C
Castillo L, Gorlo
ova O, Martin J E, Zhou XD, Che
en WV, Assassi S, Ying J, Tan FFK, Arnett FC, Re
eveille JD, Guerra S, Terue M, C
Carmona FD, Gregersen PK, Leee AT, Lopez‐Isaac E, Ochoa E, C
Carreira P, Simeeon CP, Castellvvi I, Padyukov L, arccon‐Riquelme M
M, Wijmenga C, Brown M, Bereetta L, Riemeka
asten G, Gonzalez‐Gay MA, ZZhernakova A, P
Voskuyl AE, Schu
uerwegh AJ, He
esselstrand R, N
Nordin A, Airo P
P, Lunardi Wittee T, Hunzelmann N, Kreuter A, Distler JHW, V
C, Shiiels P, van Laar JM, Herrick A, Worthington J,, Denton C, Wiggley FM, Humm
mers LK, Varga J,, Hinchcliff ME,, Baron M, Hudson M, Pope JE, Furst DE, Khan
nna D, Phillips KK, Schiopu E, Segal BM, Molitor JA, Silver RM,, Steen VD, Simms RW, BIJ, Frech TM, A
AlKassab F, Doccherty P, Kamin
nska E, Khalidi N
N, Jones HN, Maarkland J, Robin
nson D, Lafyatis RA, Fessler B
Broen
n J, Radstake TR
RDJ, Fonseca C,, Koeleman BP, Martin J. Immu
unochip Analyssis Identifies Muultiple Susceptibility Loci for Syystemic Sclerossis. Am J Hum G
Genet 2014; 94: 47‐61. 80. Mekeenkamp LJM, Haan JC, Israeli D
D, van Essen HFFB, Dijkstra JR, vvan Cleef P, Pun
nt CJA, Meijer G
GA, Nagtegaal ID, Ylstra B. Chrom
mosomal Copy Number Aberrations in Coloreectal Metastase
es Resemble Th
heir Primary Coounterparts and
d Differrences Are Typically Non‐Recu
urrent. PLoS Onne 2014; 9: e868
833. 81. Mercckel LG, Verkooijen HM, Peterss NHGM, Mannn RM, Veldhuis W
WB, Storm RK, Weits T, Duviviier KM, van Dallen T, Mali WPTM
M, Peeters PHM
M, van den Boscch MAAJ. The A
Added Diagnosttic Value of Dyn
namic Contrast‐‐Enhanced MRII at 3.0 T in Nonp
palpable Breast Lesions. PLoS O
One 2014; 9: e994233. 82. Merteens LS, Mir M, Scott AM, Lee SST, Fioole‐Bruinning A, Vegt E, V
Vogel WV, Man
necksha R, Boltoon D, Davies I, Horenblas S, van
n Rhijn BW, Law
wrentschuk N. FF‐18‐fluorodeoxxyglucose‐Posittron Emission T
Tomography/Coomputed Tomo
ography Aids SStaging and Preedicts Mortalityy in Patients Wiith Muscle‐invaasive Bladder Ca
ancer. Urology 2014; 83: 393‐3
398. 83. Merteens LS, Mir MC
C, van Rhijn BW,, Lawrentschukk N. F‐18‐fluorodeoxyglucose‐P
Positron Emissi on Tomo
ography/Compu
uted Tomograp
phy Aids Stagingg and Predicts M
Mortality in Pattients With Musscle‐invasive Bladder Canceer REPLY. Urolo
ogy 2014; 83: 39
99. 84. Moelans CB, van der Groep P, Hoeffnagel LD, van dde Vijver MJ, W
Wesseling P, We
esseling J, van dder Wall E, van Diest PJ. Geno
omic evolution ffrom primary breast carcinom
ma to distant me
etastasis: Few ccopy number chhanges of breasst cancer relateed genes. Canceer Lett 2014; 34
44: 138‐146. 85. Mooiij MG, van Duijn
n E, Knibbe CAJ, Windhorst AD
D, Hendrikse NH
H, Vaes WHJ, Sp
paans E, Fabriekk BO, Sandman
n H, Grosssouw D, Hanff LLM, Janssen PJJM, Koch BCP, TTibboel D, De W
Wildt SN. Pediatric Microdose SStudy of [C‐14] Paraccetamol to Stud
dy Drug Metabo
olism Using Acccelerated Mass Spectrometry: Proof of Conceept. Clinical Pharm
macokinetics 20
014; 53: 1045‐1
1051. 86. Nielseen K, Richir MC
C, Stolk T, van der Ploeg T, Mooormann G, Wiaarda B, Schreurss W. The Limiteed Role of Ultrasound in the D
Diagnostic Proceess of Colonic D
Diverticulitis. W
World J Surg 201
14; 38: 1814‐1818. 87. Nielseen K, Scheffer H
HJ, Pieters IC, van Tilborg AAJM
M, van Waesbe
erghe JHTM, Op
prea D, Meijerinnk MR, Kazemie
er G, Hoekkstra OS, Schreu
urs HWH, Sietse
es C, Meijer S, CComans EFI, van
n den Tol PMP. The use of PETT‐MRI in the follow‐up after radiofrequencyy‐ and microwa
ave ablation of colorectal liverr metastases. BMC Medical Im
maging 2014; 14
4: 27. DP, Boerhout EJJ, Bos I, Comans EFI, Oprea‐Laager D, Reinhard
d R, Hoekstra O
OS, de Bree R, dde Graaf P, Casttelijns JA. 88. Noij D
Wholle‐body‐MR imaaging including DWIBS in the w
work‐up of patiients with head
d and neck squaamous cell carcinoma: A feasib
bility study. Eurr J Radiol 2014; 83: 1144‐11511. 89. Noordman BJ, Comaans EFI, Lips PTA
AM, Rinkel RN. False‐Positive Uptake of I‐124
4 in a Laryngeall Cyst Mimickin
ng Thyroid Remn
nant After Thyroidectomy and I‐131 Therapy for Follicular T
Thyroid Carcinoma. Clin Nucl M
Med 2014; 39: 8
898‐899. 90. Obulkkasim A, van dee Wiel MA. Step
pwiseCM: An R Package for Ste
epwise Classificcation of Canceer Samples Usin
ng Multiple Heterrogeneous Dataa Sets. Cancer Inform 2014; 133: 1‐11. 91. Paff TT, Daniels JMA, Pals G, Haarma
an EG. Primary ciliary dyskinessia: From diagnosis to molecullar mechanismss. Journal of Pediatric Geneticss 2014; 3: 115‐127. 92. Patto
on S, Normanno
o N, Blackhall F,, Murray S, Kerrr KM, Dietel M,, Filipits M, Benlloch S, Popat SS, Stahel R, Thu
unnissen E. Assesssing standardizzation of moleccular testing forr non‐small‐cell lung cancer: re
esults of a worlldwide external quality assesssment (EQA) sccheme for EGFR
R mutation testting. Brit J Canccer 2014; 111: 4
413‐420. 93. Pena AS. Immunogeenetics of non celiac gluten sennsitivity. Gastro
oenterology and
d Hepatology frrom bed to ben
nch 2014; 7: 1‐55. 94. Piankko MJ, Terpos EE, Roodman GD,, Divgi CR, Zweeegman S, Hillen
ngass J, Lentzsch S. Whole‐Boddy Low‐Dose Co
omputed Tomo
ography and Ad
dvanced Imaging Techniques fo
for Multiple Myyeloma Bone Disease. Clin Canncer Res 2014; 2
20: 5888‐
5897. wit A, van de Loo
osdrecht AA, Be
ettelheim P, Broodersen LE, Burbury K, Cremers E, la Porta M
MG, Ireland R, Jo
ohansson 95. Porw
U, Maatarraz S, Ogataa K, Orfao A, Prreijers F, Psarra K, Subiraa D, V
Valent P, van de
er Velden VHJ, W
Wells D, Weste
ers TM, Kern W, Bene MC. R
Revisiting guidelines for integraation of flow cyytometry resultts in the WHO cclassification off
Annual Report V
VUmc CCA 2014 –
– Appendix 3: Scieentific output ‐ 41 of 216 myelo
odysplastic syndromes‐propossal from the Intternational/Eurropean Leukem
miaNet Working g Group for Flow
w Cytom
metry in MDS. LLeukemia 2014; 28: 1793‐17988. 96. Postm
ma ILE, Beenen LFM, Bijlsma T
TS, Berger FH, H
Heetveld MJ, Blo
oemers FW, Go
oslings JC. Radioological work‐up after mass casualty incideents: are ATLS gguidelines appliicable?. Eur J Raadiol 2014; 24: 785‐791. P, de Jongh DMC
C, Abdelrehim EE, Willemsen I, Kluijtmans JAJW
W, Savelkoul PH
HM, Vandenbro
oucke‐
97. Reulaand EA, Hays JP
Graulls CMJE, Al Naieemi N. Detectio
on and Occurre nce of Plasmid‐‐Mediated Amp
pC in Highly Ressistant Gram‐Negative Rods.. PLoS One 2014; 9: e91396. 98. Reuscchenbach M, W
Wentzensen N, D
Dijkstra MG, Dooeberitz MV, Arrbyn M. p16(INK4a) Immunohhistochemistry in Cervical Biopssy Specimens A Systematic Revview and Meta ‐Analysis of the
e Interobserver Agreement. Am
m J Clin Pathol 2014; 142: 767‐7772. 99. Robert J, Le Morvan
n V, Giovannettii E, Peters GJ. O
On the use of ph
harmacogenetics in cancer treeatment and clinical trials. Eur J Cancer 2014; 5
50: 2532‐2543. pstra V, Nederv een AJ, van Nie
euwkerk CMJ, d
de Knegt RJ, Baaak BC, Jansen P
PLM, Sinkus 100. Runge JH, Bohte AE,, Verheij J, Terp
oker J. Compariison of interobsserver agreemeent of magneticc resonance elastography withh histopathological staging R, Sto
of liveer fibrosis. Abdominal Imagingg 2014; 39: 2833‐290. 101. Sarhaadi VK, Lahti L, SScheinin I, Ellon
nen P, Kettunenn E, Serra M, Sccotlandi K, Picci P, Knuutila S. CCopy Number A
Alterations and N
Neoplasia‐Speciific Mutations in MELK, PDCD11LG2, TLN1, and PAX5 at 9p in
n Different Neopplasias. Gene Chrom
mosome Canc 2
2014; 53: 579‐5
588. 102. Schefffer HJ, Nielsen K, van Tilborg A
AAJM, Vieveenn JM, Bouwman
n RA, Kazemier G
G, Niessen HW M, Meijer S, va
an Kuijk C, van d
den Tol MP, Meeijerink MR. Ablation of coloreectal liver metasstases by irreve
ersible electropporation: resultss of the COLD
DFIRE‐I ablate‐and‐resect studyy. Eur J Radiol 22014; 24: 2467‐‐2475. 103. Scheiinin I, Sie DLS, B
Bengtsson H, va
an de Wiel MA, Olshen AB, van
n Thuijl HF, van Essen HF, Eijk PP, Rustenburgg F, Meijer GA, R
Reijneveld JC, W
Wesseling P, Pinkel D, Albertsoon DG, Ylstra B. DNA copy num
mber analysis of f fresh and form
malin‐fixed specimens by shallo
ow whole‐genom
me sequencing with identification and exclussion of problem
matic regions in the genome assembly. G
Genome Res 20
014; 24: 2022‐2 032. 104. Scholls RM, Lodewick TM, Bouvy ND
D, van Dam DA,, Meijerink WJH
HJ, van Dam GM
M, Dejong CHC,, Stassen LPS. N
Near‐
Infrarred Fluorescencce Laparoscopyy of the Cystic D
Duct and Arteryy in Pigs: Performance of a Preeclinical Dye. J Laparroendosc Adv SSurg Tech 2014;; 24: 318‐322.
105. Schoo
ok RM, Koudstaaal LG, Comans EFI, Postmus PPE, Grunberg K, Paul MA, Smit EF, Sutedja GTT. Benefit of a se
econd opinio
on: From metastatic disease to resectable lu ng cancer with sarcoid‐like reaction. Respirattory Medicine C
Case Reports 2014; 13: 26
6‐27. uten CS, de Breee R, van der Pu
utten L, Noij DPP, Hoekstra OS, Comans EFI, W
Witte BI, Doornaaert PA, Leeman
ns CR, 106. Schou
Casteelijns JA. Diffusion‐weighted EP
PI‐ and HASTE‐M
MRI and 18F‐FD
DG‐PET‐CT early during chemooradiotherapy iin advan
nced head and neck cancer. Q
Quantitative Imaaging in Medicine and Surgery
y 2014; 4: 239‐2250. 107. Shi J, van de Stadt LA
A, Levarht EWN
N, Huizinga TWJJ, Hamann D, vaan Schaardenburg D, Toes REM
M, Trouw LA. A
Anti‐
carbaamylated protein (anti‐CarP) antibodies preceede the onset o
of rheumatoid a
arthritis. Ann R heum Dis 2014
4; 73: 780‐
783. oeleman MW, vvan Moorsel MIH, van Essen H
HF, Eijk PP, Grunnberg K, van Grrieken NCT, 108. Sie DLS, Snijders PJFF, Meijer GA, Do
erformance of a
amplicon‐basedd next generatio
on DNA Thunnissen E, Verheeul HM, Smit EFF, Ylstra B, Heiddeman DAM. Pe
nostic gene mu
utation profilingg in oncopathology. Cell Oncol 2014; 37: 353‐‐361. sequeencing for diagn
109. Sissun
ng TM, Price DK
K, Del Re M, Leyy AM, Giovanneetti E, Figg WD,, Danesi R. Genetic variation: eeffect on prosta
ate cancer. BBA R
Reviews on Can
ncer 2014; 1846
6: 446‐456. 110. Slobb
be P, Windhorstt AD, Stigter‐van Walsum M, SSchuit RC, Smit EF, Niessen HG
G, Solca F, Stehl e G, van Donge
en GAMS, Poot AJ. Developmeent of [F‐18]afattinib as new TKKI‐PET tracer forr EGFR positive tumors. Nucl M
Med Biol 2014; 41: 749‐
757. 111. Smit M, de Stadt LAV
V, Janssen KMJ, van der Meerr B, Vissink A, vaan Winkelhoff A
AJ, Brouwer E, W
Westra J, van nst Porphyromoonas gingivalis iin seropositive arthralgia patieents do not pre
edict Schaaardenburg D. Antibodies again
devellopment of rheumatoid arthrittis. Ann Rheum
m Dis 2014; 73: 1277‐1279. 112. Snaeb
bjornsson P, Co
oupe VMH, Jona
asson L, Meijerr GA, van Grieke
en NC, Jonasson
n JG. pT4 stage e II and III colon cancers carry the worst proggnosis in a natio
onwide surviva l analysis. Shep
pherd's local peritoneal involveement revisited
d. Int J Canceer 2014; 135: 4
467‐478. 113. Steho
ouwer BL, Mercckel LG, Verkooijen HM, Peterss NHGM, Mann
n RM, Duvivier KM, Mali WPTM
M, Peeters PHM
M, Veldhuis WB, vvan den Bosch MAAJ. 3‐T brea
ast magnetic ressonance imagin
ng in patients w
with suspicious microcalcifications on mammography. Eur J Radiol 2014; 24: 603‐609. ma J, Grootendorst DC, van de
er Linden PWG.. CA 19‐9 As a M
Marker in Addition to CEA to M
Monitor Colorecctal 114. Stiksm
Canceer. Clin Colorecctal Cancer 2014
4; 13: 239‐244.. 115. Swan
nk HA, van Rossem CC, van Geloven AAW, in'tt Hof KH, Kazem
mier G, Meijerin
nk WJHJ, Langee JF, Bemelman WA. Endostapler or endo
oloops for securing the appenddiceal stump in
n laparoscopic a
appendectomy:: a retrospective cohort studyy. Surg Endosc 2
2014; 28: 576‐5
583. 116. Swartts DRA, van Suyylen RJ, den Bakkker MA, van O
Oosterhout MFM
M, Thunnissen E, Volante M, D
Dingemans AMC
C, Scheltinga MRM, Bo
ootsma GP, Pou
uwels HMM, va n den Borne BE
EEM, Ramaekerrs FCS, Speel EJ M. Interobservver Annual Report V
VUmc CCA 2014 –
2 of 216 Variability for the W
WHO Classification of Pulmonarry Carcinoids. A
American Journal of Surgical Paathology 2014;; 38: 1429‐
1436. 117. Temb
buyser L, Tack V
V, Zwaenepoel K, Pauwels P, M
Miller K, Bubend
dorf L, Kerr K, Schuuring E, Thuunnissen E, Deq
queker EMC. The Relevancee of External Qu
uality Assessmeent for Molecular Testing for A
ALK Positive No n‐Small Cell Lung Cancer: ow Room for Opptimization. PLo
oS One 2014; 9: e112159. Resullts from Two Pilot Rounds Sho
118. Terwijn M, Zeijlemaker W, Kelder A
A, Rutten AP, Snnel AN, Scholte
en WJ, Pabst T, V
Verhoef G, Low
wenberg B, Zwe
eegman S, Ossen
nkoppele GJ, Scchuurhuis GJ. Le
eukemic Stem CCell Frequency: A Strong Biom
marker for Cliniccal Outcome in Acute Myelo
oid Leukemia. P
PLoS One 2014; 9: e107587. 119. Teunis MAT, Spieksttra SW, Smits M
M, Adriaens E, EEltze T, Galbiati V, Krul C, Landsiedel R, Pieterrs R, Reinders J,, Roggen E, nternational ring trial of the eppidermal equivaalent sensitizer potency assayy: reproducibility and Corsini E, Gibbs S. In
predictive capacity. Altex 2014; 31: 251‐268. g JH, Dacic S, Geeisinger KR, Hirrsch FR, 120. Thunnissen E, Nogucchi M, Aisner S,, Beasley MB, BBrambilla E, Chirieac LR, Chung
Matsuno Y, Minaami Y, Moreira AL, Pelosi G, Pe
etersen I, Rogglli V, Travis WD,, Wistuba I, Ishikaawa Y, Kerr KM, Lantejoul S, M
Yatab
be Y, Dziadziuszzko R, de Witte B, Tsao MS, Niccholson AG. Re
eproducibility of Histopathologgical Diagnosis in Poorly Differrentiated NSCLC An Internatio
onal Multiobserrver Study. Jourrnal of Thoracicc Oncology 20144; 9: 1354‐1362
2. 121. Thunnissen E, van der Oord K, den Bakker MA. Proognostic and predictive bioma
arkers in lung caancer. A review
w. Virchows Arch 2014; 464: 347
7‐358. e Loo DMWM, Bierings MB, Bo
os C, Kollen WJW, Hop WCJ, Laanvers‐Kaminsky C, 122. Tong WH, Pieters R, Kaspers GJL, te
ng MV, Tissing W
WJE, van der Slu
uis IM. A prosppective study on
n drug monitoring of PEGasparraginase and Errwinia Rellin
asparraginase and assparaginase anttibodies in pediiatric acute lym
mphoblastic leuk
kemia. Blood 20014; 123: 2026‐‐2033. 123. van d
de Donk NW, Paalumbo A, Johnsen HE, Engelh ardt M, Gay F, Gregersen H, H
Hajek R, Kleber M, Ludwig H, M
Morgan G, Mustto P, Plesner T, Sezer O, Terpos E, Waage A, ZZweegman S, Einsele H, Sonneveld P, Lokhorsst HM. The cliniical relevaance and manaagement of monoclonal gamm
mopathy of undetermined significance and reelated disorderss: recom
mmendations from the Europe
ean Myeloma N
Network. Haem
matol‐Hematol J 2014; 99: 984‐‐996. 124. van d
de Wiel MA, Neerincx M, Buffa
art TE, Sie DLS, V
Verheul HM. Sh
hrinkBayes: a versatile R‐packaage for analysiss of count‐
based
d sequencing data in complex study designs. BMC Bioinform
matics 2014; 15: 116. 125. van d
den Ancker W, vvan Luijn MM, C
Chamuleau MEED, Kelder A, Fe
eller N, Terwijn M, Zevenbergeen A, Schuurhuis GJ, van Ham SM, Westers TM, Ossenkoppe
ele GJ, van de LLoosdrecht AA. High class II‐associated invariaant chain peptide ual leukemic ce
ells is associatedd with increased relapse risk in
n acute myeloidd leukemia. Leu
ukemia Res expreession on residu
2014;; 38: 691‐693. 126. van d
den Brand M, Peeters RPH, Catssburg A, Rubenjjan A, Broeke FJ, van den Dung
gen FAM, van W
Weissenbruch M
MM, van Furth
h AM, Koressaar T, Remm M, SSavelkoul PHM, Bos MP. Devellopment of a m
multiplex real‐tim
me PCR assay fo
or the rapid diagnosis of neeonatal late onset sepsis. J Mi crobiol Meth 2014; 106: 8‐15.. 127. van d
der Born D, Sew
wing C, Herscheid JDM, Windhoorst AD, Orru R
RVA, Vugts DJ. A
A Universal Proccedure for the [F‐
18]Trrifluoromethylaation of Aryl Iod
dides and Aryl BBoronic Acids w
with Highly Imprroved Specific AActivity. Angew
w Chem Int Ed En
ngl 2014; 53: 11
1046‐11050. 128. van d
der Marel J, van
n Baars R, Quintt WGV, Berkhoff J, Del Pino M, Torne A, Ordi JJ, Wentzensen N
N, Schiffman M
M, van de Sandtt MMV, Lindem
man J, Jenkins D
D, Helmerhorst TTJM, Verheijen RHM, ter Harm
msel B, Alonso II. The impact off human papilllomavirus geno
otype on colposscopic appearannce: a cross‐secctional analysis. BJOG‐Int J Obbstet Gyn 2014; 121: 1117‐‐1126. 129. van d
der Marel J, van
n Baars R, Rodriguez A, Quint W
WGV, van de Saandt MM, Berkh
hof J, Schiffmann M, Torne A, O
Ordi J, Jenkins D, Verheijen
n RHM, Helmerh
horst TJM, ter H
Harmsel B, Wen
ntzensen N, Del Pino M. The inncreased detecction of cerviccal intraepithelial neoplasia when using a seccond biopsy at colposcopy. Gy
ynecol Oncol 20014; 135: 201‐2
207. 130. van d
der Mijn JC, Mieer JW, Broxterm
man HJ, Verheu l HM. Predictive biomarkers in
n renal cell canccer: insights in drug resisttance mechanissms. Drug Resisst Update 2014;; 17: 77‐88. 131. van G
Grieken NCT, Ao
oyama T, Chambers P, Bottom
mley D, Ward L, Inam I, Buffart T, Das K, Lim T,
T, Pang B, Zhangg S, Tan I, Carvaalho B, Heidemaan DAM, Miyaggi Y, Kameda Y, Arai T, Meijer G
GA, Tsuburaya A, Tan P, Yoshi kawa T, Grabscch H, I. KRAS and BRAF muttations are rare and related too DNA mismatch
h repair deficiency in gastric caancer from the East and the W
West: Results fro
om a large international multiicentre study (vvol 108, pg 1495, 2013). Brit J CCancer 2014; 1
110: 546. 132. van H
Heerde MJ, Buijs J, Hansen BE, de Waart M, vvan Eijck CHJ, Kaazemier G, Pek CJ, Poley JW, BBruno MJ, Kuipe
ers EJ, van Buureen HR. Serum LLevel of Ca 19‐9
9 Increases Abil ity of IgG4 Testt to Distinguish Patients with AAutoimmune Pa
ancreatitis from Those with Pan
ncreatic Carcino
oma. Digest Diss Sci 2014; 59: 1
1322‐1329. 133. van LLuijn MM, van d
den Ancker W, vvan Ham SM, vaan de Loosdreccht AA. Class II‐associated invaariant chain pep
ptide as predictive immune m
marker in minim
mal residual dissease in acute m
myeloid leukem
mia. Oncoimmunnology 2014; 3: e941737. Rijssel MJ, Daheele M, Verbakel WFAR, Rosarioo TS. A critical aapproach to the
e clinical use of f deformable im
mage 134. van R
registtration software. In response tto Meijneke et al. Radiother O
Oncol 2014; 112
2: 447‐448. 135. van SSpronsen MF, O
Ossenkoppele GJ, Holman R, vaan de Loosdrecht AA. Improved risk stratificaation by the inte
egration of the reevised International Prognostiic Scoring Systeem with the Myyelodysplastic Syndromes Com
morbidity Index. Eur J Canceer 2014; 50: 3198‐3205. Annual Report V
VUmc CCA 2014 –
3 of 216 136. van SStein‐Callenfels D, Tan J, Bloem
mena E, van Vuggt RM, Voskuyl AE, Santana NT
TY, van der Wa al I. The role off a labial salivaary gland biopsyy in the diagnosstic procedure for Sjogren's syyndrome; a stud
dy of 94 cases. Medicina oral patologia oral yy cirugia bucal 2
2014; 19: E372‐‐E376. 137. van TThuijl HF, Schein
nin I, Sie DLS, Alentorn A, van Essen HF, Cordes M, Fleischeu
uer R, Beute G, van den Brink WA, Meijeer GA, Havenith
h M, Idbaih A, H
Hoang‐Xuan K, M
Mokhtari K, Verrhaak RGW, van
n der Valk P, vaan de Wiel MA, Heimans JJ, Aronica E, Reijnevveld JC, Wesseling P, Ylstra B. Spatial and tem
mporal evolutio
on of distal 10q deletion, a pro
ognostically unfavvorable event in
n diffuse low‐grrade gliomas. G
Genome Biol 20
014; 15: 472. 138. van TTurenhout ST, O
Oort FA, van der Hulst RWM, V
Visscher AP, Terrhaar sive Drostte JS, Scholten P, Bouman AA,, Meijer GA, M
Mulder CJJ, van Rossum LGM, Coupe VMH. Prrospective crosss‐sectional stud
dy on faecal im
mmunochemicall tests: sex specific cut‐off valuees to obtain equal sensitivity ffor colorectal caancer?. Bmc Ga
astroenterologyy 2014; 14: 217. 139. van TTuyl LHD, van deer Heijde D, Knol DL, Boers M.. Chronological reading of radiographs in rheeumatoid arthritis increaases efficiency and does not le
ead to bias. Annn Rheum Dis 20
014; 73: 391‐39
95. 140. van V
Veen‐Berkx E, B
Bitter J, Elkhuize
en SG, Buhre W
WF, Kalkman CJ, Gooszen HG, K
Kazemier G. Com
mment on Rese
earch Articlle Entitled "Variability of Subspecialty‐Specifiic Anesthesia‐C
Controlled Times at Two Acadeemic Institution
ns" as publisshed in J Med SSyst 2014; 38 (1
11). Journal of m
medical system
ms 2014; 38: 51.
141. van V
Veen‐Berkx E, B
Bitter J, Elkhuize
en SG, Buhre W
WF, Kalkman CJ, Gooszen HG, K
Kazemier G. Thee influence of anesthesia‐
contrrolled time on o
operating room
m scheduling in D
Dutch universitty medical centres. Canadian j ournal of anestthesia 2014;; 61: 524‐532. 142. van V
Velden FHP, Nisssen IA, Hayes W
W, Velasquez LM
M, Hoekstra OSS, Boellaard R. E
Effects of Reusiing Baseline Volumes of Intereest by Applyingg (Non‐)Rigid Im
mage Registratioon on Positron Emission Tomo
ography Responnse Assessmentts. PLoS One 22014; 9: e87167
7. 143. van V
Velden FHP, Nisssen IA, Jongsma F, Velasquez LM, Hayes W, LLammertsma AA, Hoekstra OSS, Boellaard R. T
Test‐Retest Variability of Various Quantitative Measures to Chharacterize Tracer Uptake and
d/or Tracer Upta
take Heterogeneity in 014; 16: 13‐18. Metaastasized Liver ffor Patients with Colorectal Caarcinoma. Mol IImaging Biol 20
144. van W
Wieringen WN, van de Wiel MA
A. Penalized diffferential pathw
way analysis of integrative onccogenomics stu
udies. Stat Appl Genet Mol 201
14; 13: 141‐158. 145. Veenemans J, Overd
devest IT, Sneld
ders E, Willemseen I, Hendriks Y
Y, Adesokan A, Doran G, Brusoo S, Rolfe A, Pettersson Fernh
holm AM, Kluijttmans JAJW. Ne
ext‐Generation Sequencing for Typing and De
etection of Resiistance Genes: Perfo
ormance of a Neew Commercial Method durinng an Outbreak of Extended‐Sp
pectrum‐Beta‐LLactamase‐Prod
ducing Escheerichia coli. J Clin Microbiol 20
014; 52: 2454‐24460. 146. Velth
huis S, Nieuwenhuis DH, Ruijter TEG, Cuesta M
MA, Bonjer HJ, Sietses C. Transsanal versus traaditional laparo
oscopic 4; 28: 3494‐349
99. total mesorectal exccision for rectal carcinoma. Su rg Endosc 2014
147. Venderbosch S, Naggtegaal ID, Maughan TS, Smith CG, Cheadle JP
P, Fisher D, Kaplan R, Quirke PP, Seymour MT, Richman SD, M
Meijer GA, Ylstraa B, Heideman DAM, de Haan AFJ, Punt CJA, Koopman M. M
Mismatch Repaiir Status and BR
RAF Mutaation Status in M
Metastatic Colo
orectal Cancer PPatients: A Pooled Analysis of the CAIRO, CAI RO2, COIN, and
d FOCUS Studies. Clin Cancer Res 2014; 20: 5
5322‐5330. oeven CJ, Farid WRR, de Jonge
e J, Metselaar H
HJ, Kazemier G, van der Laan LLJW. Biomarkers
rs to assess grafft quality 148. Verho
durin
ng conventionall and machine p
preservation in liver transplantation. J Hepatol 2014; 61: 6772‐684. 149. Verw
wer E, Bahce I, van Velden FHP,, Yaqub MM, Scchuit RC, Windh
horst AD, Raijm
makers P, Hoeksstra OS, Lamme
ertsma AA, Smit EF, Boellaard R
R. Parametric Methods for Quaantification of FF‐18‐FAZA Kinettics in Non‐Smaall Cell Lung Can
ncer d 2014; 55: 1772‐1777. Patients. J Nucl Med
150. Verw
wer E, Boellaard R, van der Veld
dt AAM. Positroon emission tom
mography to asssess hypoxia annd perfusion in lung canceer. World journal of clinical on
ncology 2014; 5 : 824‐844. 151. Vollebergh MA, Klijn
n C, Schouten P
PC, Wesseling J, Israeli D, Ylstraa B, Wessels LFA
A, Jonkers J, Linnn SC. Lack of G
Genomic Heterrogeneity at Higgh‐Resolution a
aCGH between Primary Breastt Cancers and T
Their Paired Lym
mph Node Meta
astases. PLoS One 2014; 9: e103177. 152. Vugtss DJ, Heuveling DA, Stigter‐van
n Walsum M, W
Weigand S, Berggstrom M, van D
Dongen GAMS, Nayak TK. Precclinical evalu
uation of Zr‐89‐labeled anti‐CD
D44 monoclonaal antibody RG7
7356 in mice and cynomolgus m
monkeys Prelud
de to Phasee 1 clinical stud
dies. MABS 2014
4; 6: 567‐575.
153. Wen BL, Brewer MA
A, Nadiarnykh O
O, Hocker J, Singgh V, Mackie TR
R, Campagnola PJ. Texture anaalysis applied to
o second harm
monic generation image data fo
or ovarian canccer classification
n. Journal of Bio
omedical Opticss 2014; 19: 096
6007. 154. Wierd
dsma NJ, Peters JHC, van Bokh
horst‐de van deer Schueren, Mulder CJJ, Metg
god I, van Bodeggraven AA. Bom
mb caloriimetry, the gold
d standard for a
assessment of iintestinal absorrption capacity: normative vallues in healthy ambulant adults. J Hum Nutr D
Diet 2014; 27: 5
57‐64. TM, Abbes AP, SStrunk A, Kuiper‐Kramer E, Pod
ddighe PJ, van dde Loosdrecht A
AA, 155. Wiggers TGH, Westrra G, Westers T
Cham
muleau MED. ZA
AP70 in B‐CLL Cells Related to the Expression in NK Cells is a Surrogate Marrker for Mutational Status. Cytom Part B
B‐ Clin CY 2014;; 86: 280‐287.
mans A, Kluijtm
mans JAJW. Evaluation of a com
mmercial real‐t ime PCR for the
e detection 156. Willemsen I, Hille L, Vrolijk A, Bergm
of exttended spectru
um beta‐lactamase genes. J Meed Microbiol 20
014; 63: 540‐54
43. 157. Wogn
num S, Heethuiis SE, Rosario TSS, Hoogeman M
MS, Bel A. Validation of deform
mable image reggistration algorrithms on CT im
mages of ex vivo
o porcine bladders with fiduciaal markers. Med
d Phys 2014; 41
1: 071916. Annual Report V
VUmc CCA 2014 –
4 of 216 158. Wond
dergem MJ, Herrmann K, Syrb
bu S, Zijlstra JM,, Hoetjes N, Ho
oekstra OS, Cille
essen SAGM, M oesbergen LM,, Buck AK, Vose JM, Juweid MEE. 18F‐fluorothyymidine uptakee in follicular lym
mphoma and error‐prone DNAA repair. EJNMM
MI reseaarch 2014; 4: 3. 159. Woutters R, Cucchi D
D, Kaspers GJL, SSchuurhuis GJ, Cloos J. Relevance of leukemic stem cells in aacute myeloid leukemia: heterrogeneity and in
nfluence on dissease monitorinng, prognosis and treatment design. Expert RReview of Hema
atology 2014;; 7: 791‐805. 160. Yick C
CY, Zwinderman
n AH, Kunst PW
W, Grunberg K, M
Mauad T, Chow
wdhury S, Bel EH
H, Baas F, Lutteer R, Sterk PJ. Gene expreession profiling of laser microd
dissected airwaay smooth musccle tissue in asthma and atopyy. Allergy 2014; 69: 1233‐
1240. mpt W, Reymen
n B, Even AJG, TTroost EGC, Olle
ers MC, Hoeberrs FJP, Houben RRMA, Eriksson J, 161. Zegerrs CML, van Elm
Wind
dhorst AD, Motttaghy FM, de Ruysscher D, Lam
mbin P. In Vivo Quantification of Hypoxic andd Metabolic Sta
atus of NSCLC Tumors Usingg [F‐18]HX4 and
d [F‐18]FDG‐PEET/CT Imaging. C
Clin Cancer Ress 2014; 20: 63899‐6397. urhuis GJ. Tumoor Heterogeneitty Makes AML a
a "Moving Targget" for Detection of 162. Zeijleemaker W, Grattama JW, Schuu
Resid
dual Disease. Cyytom Part B‐ Clin CY 2014; 86: 3‐14. Scientific papers non
n‐refereed
1.
2.
Bontkkes HJ. Serological biomarkerss for refractory celiac disease. Clinical Laboratory Internatioonal 2014; 37: 10‐11. de Brree R, Heuvelingg DA, van Donggen GAMS, Hoeekstra OS. Sentinel node biopsy in patients wiith early oral ca
ancer. New devellopments. Helleenic Surgical On
ncology 2014; 55: 9‐15. Scienttific publica
ations 1.
2.
3.
4.
5.
and non‐celiac gluten sensitivity; in Rodrigo LL, Pena AS, (edss): Celiac diseasse and Pena AS, Rodrigo L. Celiac disease a
non‐cceliac gluten seensitivity. Barcelona, OmniaSciience 2014: 25‐‐45. Perezz Villavicencio A
A, Lucke C, Pena
a AS. Perspectivves to take into
o account when
n studying celiacc disease in China an Centrral America; in Rodrigo L, Pena
a AS, (eds): Celiiac disease and non‐celiac glutten sensitivity. Barcelona, Spain, OmniiaScienc 2014: 61‐74. Riebleer A, Robinson MD, van de Wiiel MA. Analysiss of Next Generation Sequencing Data Using Integrated Nessted Laplace Approximation (INLA); in D
Datta S, Nettletoon D, (eds): Statistical Analysiss of Next Generration Sequencing Data. Switzzerland, Springeer Internationall Publishing 20114: 75‐91. Rodriigo L, Pena AS. Celiac disease a
and non‐celiac gluten sensitivity. Digital, OmniaScience 20114: . Schup
ppan D, Mulderr CJJ, Collin P, M
Murray JA. Villoous Atrophy; in Keuchel M, Hag
genmuller F, Taajiri H, (eds): Vid
deo Capsu
ule Endoscopy. Berlin Heidelberg, Springer 20014: 243‐249.
Professsional publications 1.
2.
3.
4.
5.
elaar RJA, Opsteelten W. Verlagging grenswaarde PSA voor veervolgdiagnostie
ek naar Blankker M, de Reijkee T, van Moorse
prosttaatcarcinoom iin NHG‐standaa
ardNed Tijdschrr Geneeskd 201
14158: . Heuvveling DA, van D
Dongen GAMS, de Bree R. De sschildwachtklierprocedure bij mondholtecarccinomen in een
n vroeg stadiu
um: huidige staand van zaken e
en mogelijkhed en tot verbeterringNed Tijdsch
hr Oncol 2014111: 224‐230. Krugeer DT, Linn SC, B
Beelen K, Sleijfe
er S, Jansen MPPHM, Jimenez C
CR, Boven E. De
e Biomarker Stuudy Everolimus: analyse van d
de PI3K‐Akt‐mTORroute om meer inzicht te v erkrijgen in de effectiviteit van everolimus inn combinatie met exem
mestaan bij gem
metastaseerd ma
ammacarcinoo m. Een studie vvan de Borstkan
nker Onderzoekk Groep (BOOG
G) NedeerlanNed Tijdsch
hr Oncol 20141
11: 250‐254. Nijeb
boer P, de Baaij LR, Cillessen SA
AGM, Mulder CCJJ, Bouma G, V
Visser O. Enteropathie‐geassoccieerd T‐cellymffoom: inzich
hten in behandeeling anno 2014
4Ned T Hematoologie 201411: 171‐175. ter Avvest MJ, Schook RM, Koudstaa
al LG, Grünbergg K, Paul MA, Sm
mit EF, Postmuss P. Nutzen eineer Zweitmeinung bei Broncchialkarzinom: Keine Nierenm
metastase, sond ern eine synchrone renale PrimÃ¤rneoplasieeKarger Kompasss Onko
ologie 20141: 10
02‐104. Popu
ular publications 1.
2.
3.
4.
Budding AE, Winterm
mans BB. 35.00
00 jaar oude ba cteriën uit een mammoet. Me
ed Contact 20144. Budding AE, Winterm
mans BB. Arts‐m
microbiologen ontleen mamm
moet.Tracer 201
14. Budding AE, Winterm
mans BB. Blij m
met prehistoriscche darmflora 2
2014. mans BB. Onde
erzoek VUmc oeeroue Siberische mammoet; N
Nu.nl 2014. Budding AE, Winterm
Annual Report V
VUmc CCA 2014 –
5 of 216 5.
6.
Budding AE, Winterm
mans BB. Woolly Mammoth, TThe autopsy; UK channel 2014
4. Krugeer DT, Beelen S,, Sleijfer MPHM
M, Jansen CR, Jim
menez CR, Linn
n SC, Boven E. B
Biomarker Studyy Everolimus, e
een studie van d
de Borstkanker Onderzoek Gro
oep NederlandKKanker Breed 20146. 7. Schep
pens MLM, Tho
olen ATR, Vande
enbroucke‐Gra uls CMJE. Micro
opia, the Utopia voor medischh (en moleculair) micro
obiologenMuseeumverslag NTM
MM 201422. 8. Winteermans BB, Bud
dding AE. Jagen
n op DNA uit pr ehistorie 2014.. 9. Winteermans BB, Bud
dding AE. Mammoet: binnensttebuiten gekee
erd; Radio De ke
ennis van NU raadio 5 VPRO 20
014. 10. Winteermans BB, Bud
dding AE. Mammoetbacterienn; De kennis van
n nu, VPRO 2014. D
Dissertation
ns 1.
2.
3.
4.
5.
6.
7.
8.
Fringss V. In vivo quaantification of proliferation andd glucose metaabolism in lung cancer patientss. 9/18/2014. (Co)p
promotor(es): B
Boellaard R, Smit EF . Heuvveling DA. Novel molecular ima
aging approachhes in the manaagement of head and neck canncer. 3/5/2014. (Co)p
promotor(es): d
de Bree R, van D
Dongen GAMS . Rodjaan F. Imaging off retinoblastom
ma patients: advvanced MRI tecchniques and asssociated morbbidity. 12/1/201
14. (Co)p
promotor(es): C
Castelijns JA, Mo
oll AC, de Graaff P . van R
Rijen MML. Stap
phylococcus aureus epidemiollogy and contro
ol: current challenges and costts analyses. 9/1
19/2014. (Co)p
promotor(es): K
Kluijtmans JAJW
W, Vandenbrouccke‐Grauls CMJE . van TTurenhout ST. EExploring Faecal Immunochem
mical Test Perforrmance for Colo
orectal Cancer SScreening: FIT is at its limit, take it to the n
next level. 11/26/2014. (Co)prromotor(es): Mulder CJJ, Meije
er GA, van Rosssum LG, Coupé VMH . Weyenberg SJB.. Minimally‐inva
asive imaging oof the small inte
estine. 9/26/2014. (Co)promottor(es): van Kuijk C, van W
Mulder CJJ, van Waeesberghe JHTM
M . Verkaade EJM. Characterization of liivestock‐associ ated MRSA CC3
398: detection, transmission aand virulence. 6
6/13/2014. (Co)p
promotor(es): K
Kluijtmans JAJW
W . Vosslamber S. The TType I Interferon System In Auttoimmune Dise
eases: Molecula
ar Markers For Heterogeneity And Theraapy Response P
Prediction. 5/26
6/2014. (Co)proomotor(es): Verrweij CL, van de
er Pouw Kraan CCTM, Voskuyl A
AE, Pegtel DM . Program 4 – Innovativve therapy
Scientiffic papers re
efereed 1.
2.
3.
4.
5.
6.
7.
Adem
ma AD, Floor K, Smid K, Honeyw
well RJ, Scheffeer GL, Jansen G,, Peters GJ. Ove
erexpression off MRP4 (ABCC4) and MRP55 (ABCC5) confeer resistance to
o the nucleosidee analogs cytarrabine and troxacitabine, but nnot gemcitabine. SpringerPlus 2014; 3
3: 732. Adham M, Stoker SD
D, Wildeman MA, Rachmadi L,, Gondhowiardjjo S, Atmakusumah D, Gatot D
D, Fles R, Greijer AE, Herm
mani B, Middeld
dorp JM, Tan IB.. Current statuss of cancer care
e for young patients with nasoopharyngeal carrcinoma in jakartta, indonesia. P
PLoS One 2014; 9: e102353. Allum
m WH, Bonavinaa L, Cassivi SD, C
Cuesta MA, Do ng ZM, Felix VN
N, Figueredo E, Gatenby PAC, H
Haverkamp L, Ibraev MA, Krasn
na MJ, Lambert R, Langer R, Le
ewis MPN, Nasoon KS, Parry K, P
Preston SR, Ruu
urda JP, Schaheeen LW, Tatum RP, Turkin IN, vaan der Horst S, van der Peet DL, van der Sluiss PC, van Hillege
ersberg R, Worm
mald JCR, Wu PPC, Zonderhuis BM. Surgiccal treatments for esophageal cancers. Ann N
NY Acad Sci 201
14; 1325: 242‐2
268. Al‐tom
ma A, Nijeboer P, Bouma G, Visser O, Mulderr CJJ. Hematopoietic stem cell transplantatioon for non‐maliggnant gastro
ointestinal diseeases. World J G
Gastroenterol 22014; 20: 17368
8‐17375. Andeersen CL, Bjorn M
ME, McMullin M
MF, Harrison C,, Samuelsson J, Ejerblad E, Zweegman S, Fernnandes S, Barefford D, Knapper S, Lofvenbeerg E, Linder O, Andreasson B,, Ahlstrand E, Je
ensen MK, Bjerrum OW, Vesteergaard H, Larse
en H, Klaussen TW, Mourits‐Andersen T, SSkov V, Thomasssen M, Kruse T
T, Gronbaek K, Hasselbalch HCC. Circulating YK
KL‐40 in patients with essenttial thrombocytthemia and polyycythemia veraa treated with the novel histonne deacetylase inhibitor vorinostat. Leukemia Res 2014; 38: 816‐821. Andeersson J, Abis G,, Gellerstedt M,, Angenete E, A
Angeras U, Cuessta MA, Jess P, Rosenberg J, Boonjer HJ, Haglin
nd E. Patient‐reported genitourinary dyssfunction after laparoscopic an
nd open rectal cancer surgery in a randomize
ed trial OR II). Brit J Surrg 2014; 101: 12
272‐1279. (COLO
Arend
ds S, Berden JH
HM, Grootscholtten C, Derksen RHWM, Bergerr SP, de Sevaux RGL, Voskuyl AAE, Bijl M. Inducction theraapy with short‐tterm high‐dose intravenous cyyclophosphamide followed by mycophenolatte mofetil in pro
oliferative lupuss nephritis. Neth J Med 2014; 7
VUmc CCA 2014 –
6 of 216 8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
Artibaani W, Ficarra V
V, Challacombe
e BJ, Abbou CC, Bedke J, Bosco
olo‐Berto R, Brausi M, de la Roosette JJ, Deger S, Denis L, Guazzzoni G, Guillonn
neau B, Heesakkkers JPFA, Jacqqmin D, Knoll T,, Martinez‐Pineiro L, Montorsi i F, Mottrie A, P
Piechaud PT, Raane A, Rassweiler J, Stenzl A, vvan Moorselaarr RJA, Van Velth
hoven RF, van P
Poppel H, Wirthh M, Abrahamsson PA, Parso
ons KF. EAU Policy on Live Surggery Events. Eu r Urol 2014; 66
6: 87‐97. Ashw
worth AB, Senan
n S, Palma DA, R
Riquet M, Ahn YYC, Ricardi U, C
Congedo MT, Go
omez DR, Wrighht GM, Melloni G, Milano MT, SSole CV, De Pas TM, Carter DL,, Warner AJ, Roodrigues GB. An
n Individual Patiient Data Metaaanalysis of Outtcomes and Progn
nostic Factors A
After Treatmentt of Oligometasstatic Non‐Small‐Cell Lung Can
ncer. Clin Lung CCancer 2014; 15: 346‐
355. Avan A, Adema AD, Hoebe EK, Huijts CM, Avan A, Veal GJ, Ruijte
enbeek R, Wosik
kowski K, Peterrs GJ. Modulatio
on of 15: 1312‐
Signaaling Enhances tthe Efficacy of tthe Combinatioon of Satraplatin and Erlotinib.. Current Drug TTargets 2014; 1
1321. Avan A, Avan A, Giovvannetti E, Pete
ers GJ. Calcium /Magnesium In
nfusion for Oxaliplatin‐Inducedd Neuropathy: Protective ot?. J Clin Oncol 2014; 32: 3341. or No
Avan A, Maftouh M,, Avan A, Tibald
di C, Zucali PA, G
Giovannetti E. SSNPs in PI3K‐PT
TEN‐mTOR and Brain Metastasses in NSCLC‐Letter. Clin C
Cancer Res 2014
4; 20: 3623‐36224. Avan A, Maftouh M,, Fiuji H, Giovan
nnetti E, Peters GJ. EZH2 (enhaancer of zeste h
homolog 2 (Droosophila)). Atlass of Geneetics and Cytogeenetics in Oncology and Haem
matology 2014; 18: 900‐906. Avan A, Maftouh M,, Funel N, Ghayyour‐Mobarhann M, Boggi U, Pe
eters GJ, Giovan
nnetti E. MET AAs a Potential Ta
arget for pper Gastrointe
estinal Cancers:: Characterization of Novel c‐M
Met Inhibitors ffrom Bench to B
Bed‐side. the Treatment of Up
Med Chem 201
14; 21: 975‐989. Curr M
Azijli K, Stelloo E, Peeters GJ, van den Eertwegh AJM
M. New Develo
opments in the T
Treatment of M
Metastatic Mela
anoma: Immu
une Checkpointt Inhibitors and Targeted Therrapies. Anticanccer Res 2014; 34
4: 1493‐1505. Azijli K, van Roosmalen IA, Smit J, P
Pillai S, Fukushim
ma M, de Jong S, Peters GJ, Bijnsdorp IV, Kruuyt FA. The nove
el thymidylate synthasse inhibitor trifluorothymidinee (TFT) and TRAIL synergistically eradicate nonn‐small cell lung cancer cells. Cancer Chemo
oth Pharm 2014
4; 73: 1273‐12883. Babaee N, Bourajjaj M
M, Liu Y, van Be
eijnum JR, Cerissoli F, Scaria PV,, Verheul M, van Berkel MPA, Pieters EHE, va
an Haastert RJ, Yo
ousefi A, Mastro
obattista E, Sto
orm G, Berezikoov E, Cuppen E, Woodle M, Sch
haapveld RQJ, PPrevost GP, Grifffioen AW, van N
Noort PI, Schiffeelers RM. Systemic miRNA‐7 d elivery inhibits tumor angioge
enesis and grow
wth in murine xenograft gliobllastoma. Oncottarget 2014; 5: 6687‐6700. Babu YR, Bhagavanrraju M, Reddy G
GD, Peters GJ, PPrasad VVSR. De
esign and Synth
hesis of Quinazoolinone Tagged
d Acridones as Cyytotoxic Agents and Their Effeccts on EGFR Tyrrosine Kinase. A
Arch Pharm 201
14; 347: 624‐6334. Bachaas C, Schuurhuiis GJ, Reinhardtt D, Creutzig U, Kwidama ZJ, Zw
waan CM, van den Heuvel‐Eibbrink MM, De Bont ESJM, Elitzu
ur S, Rizzari C, de Haas V, Zimm
mermann M, Clooos J, Kaspers G
GJL. Clinical rele
evance of moleecular aberratio
ons in paediatric acute myeloid leukaemia at first relapsse. Brit J Haemaatol 2014; 166: 902‐910. Oort IM, van denn Berg HP, Los M, Hamberg P, Coenen JL, vann den Eertwegh
h AJM, de Badrising S, van der Noort V, van O
Jong IJ, Kerver ED, van Tinteren H, Bergman AM. CClinical Activityy and Tolerabilitty of Enzalutam
mide ( MDV3100
0) in on‐ Resistant Prrostate Cancer Who Progress A
After Docetaxe l and Abiratero
one Patients With Metasstatic, Castratio
2014; 120: 968‐‐975. Treattment. Cancer 2
Bahcee I, Vos CG, Dickhoff C, Hartem
mink KJ, Dahelee MR, Smit EF, B
Boellaard R, Hoekstra OS, Thunnnissen E. Meta
abolic activiity measured byy FDG PET pred
dicts pathologiccal response in locally advance
ed superior sulccus NSCLC. Lungg Cancer 2014;; 85: 205‐212. Bajou
u K, Herkenne SS, Thijssen VLJL,, D'Amico S, Ngguyen NQN, Bou
uche A, Tabruyn S, Srahna M, Carabin JY, Nivelles O, Paques C, Cornelisseen I, Lion M, No
oel A, van Gils A
A, Vinckier S, De
eclerck PJ, Grifffioen AW, Deweerchin M, Martial JA, Carm
meliet P, Struman I. PAT‐1 mediates the antianngiogenic and p
profibrinolytic e
effects of 16K pprolactin. Nat M
Med 2014; 20: 7441‐747. Barrieentos G, Freitagg N, Tirado‐Gon
nzalez I, Unverddorben L, Jeschke U, Thijssen V
VLJL, Blois SM. Involvement off galectin‐1 in rep
production: passt, present and future. Humann Reproduction Update 2014; 2
20: 175‐193. Barrin
ngton SF, Mikhaeel NG, Kostakoglu L, Meignaan M, Hutchinggs M, Mueller SP, Schwartz LH,, Zucca E, Fishe
er RI, Trotm
man J, Hoekstraa OS, Hicks RJ, O
O'Doherty MJ, H
Hustinx R, Biggi A, Cheson BD. Role of Imaginng in the Stagingg and Respo
onse Assessment of Lymphom
ma: Consensus oof the International Conferencce on Malignantt Lymphomas Imaging Workking Group. J Clin Oncol 2014; 32: 3048‐3058 . Bautista‐Molano W,, Navarro‐Comp
pan V, Landewee RBM, Boers M
M, Kirkham JJ, van der Heijde D
D. How well are
e the ASAS/OMERACT Corre Outcome Setts for Ankylosinng Spondylitis im
mplemented in randomized cl inical trials? A ssystematic literature review. Clin Rheumatol 2
2014; 33: 1313‐‐1322. n BFAM, Christiianen MEMC, V
Vissink A, Beetzz I, Steenbakkerrs RJHM, Chouvvalova O, Leem ans CR, Doornaaert P, van Laan
Bijl HP, van Luijk P, LLangendijk JA. T
The QUANTEC ccriteria for paro
otid gland dose and their effi ccacy to preventt moderate a. ACTA Oncol 22014; 53: 597‐6
604. to sevvere patient‐rated xerostomia
Belcaaid Z, Lamfers M
MLM, van Beuse
echem VW, Hoeeben RC. Changging Faces in Virology: The Duttch Shift from O
Oncogenic to On
ncolytic Viruses. Hum Gene Ther 2014; 25: 8775‐884. Annual Report V
VUmc CCA 2014 –
7 of 216 28. Benard A, Janssen C
CM, van den Elsen PJ, van Eggeermond MCJA, Hoon DSB, van de Velde CJH, KKuppen PJK. Ch
hromatin status of apoptosis ggenes correlate
es with sensitiviity to chemo‐, immune‐ and ra
adiation therappy in colorectal cancer cell lines. Apoptosis 201
14; 19: 1769‐1778. 29. Bergh
hoff AS, Sax C, K
Klein M, Furtne
er J, Dieckmann K, Gatterbauer B, Widhalm G, Rudas M, Ziellinski CC, Bartscch R, Preussser M. Alleviattion of Brain Edema and Restooration of Functtional Independ
dence by Bevaccizumab in Brain
n‐
Metaastatic Breast Caancer: A Case R
Report. Breast ccare 2014; 9: 13
34‐136. 30. Bessee B, Adjei A, Baaas P, Meldgaard
d P, Nicolson M
M, Paz‐Ares L, Re
eck M, Smit EF,, Syrigos K, Stahhel R, Felip E, Peters S. 2nd EESMO Consensu
us Conference o
on Lung Cancerr: non‐small‐cell lung cancer first‐line/secondd and further lin
nes of treatm
ment in advancced disease. Ann Oncol 2014; 225: 1475‐1484.. 31. Biagi F, Schiepatti A,, Malamut G, M
Marchese A, Cel lier C, Bakker SSF, Mulder CJJ, V
Volta U, Zingonne F, Ciacci C, D'Odorico A, Andreealli A, Astegian
no M, Klersy C, Corazza GR. PRROgnosticating COeliac patieN
Nts SUrvivaL: Thhe PROCONSUL Score. PLoS One 2014; 9: e84163. ma MW, Blufpand HN, Kasperss GJL, Bokenkam
mp A. Why Pediatricians Fail to
o Diagnose Hyppertension: A M
Multicenter 32. Bijlsm
Surveey. J Pediatr 201
14; 164: 173‐17
77. 33. Bleekker FE, Lamba SS, Zanon C, Mole
enaar RJ, Hulseebos TJM, Troosst D, van Tilborg
g AA, Vandertoop WP, Leenstra
a S, van Noorden CJF, Bardelli A. Mutationa
al profiling of kiinases in glioblaastoma. BMC Cancer 2014; 144: 718. 34. Blufp
pand HN, Hes N,, Bokenkamp A
A, van de Weterring MD, Kaspers GJL. Diversity
y in Renal Functtion Monitoring and Dose Modiifications During Treatment fo
or Childhood Caancer: A Call forr Standardizatio
on. Pediatr Bloood Cancer 2014
4; 61: 337‐
344. ell carcinoma in patients twentty years of age or 35. Bodner L, Manor E, Friger MD, van der Waal I. Oraal squamous ce
nd analysis of 186 reported casses. Oral Oncoll 2014; 50: 84‐8
89. youngger ‐ Review an
36. Boekeema BKHL, Vligg M, Damink LO, Middelkoop EE, Eummelen L, Buhren AV, Ulrrich MMW. Effeect of pore size and cross‐
linkin
ng of a novel collagen‐elastin d
dermal substituute on wound healing. J Mater Sci‐Mater M 20014; 25: 423‐43
33. 37. Boerss M, Idzerda L, Kirwan JR, Beatton D, Escorpizoo R, Boonen A, Magasi S, Sinha I, Stucki G, Tuugwell P. Towarrd a Geneeralized Framew
work of Core Measurement Arreas in Clinical T
Trials: A Position Paper for OM
MERACT 11. J Rh
heumatol 2014;; 41: 978‐985. 38. Boerss M, Kirwan JR, Gossec L, Cona
aghan PG, d'Agoostino MA, Binggham CO, Brooks PM, Landew
we R, March L, SSimon L, Singh
h JA, Strand V, W
Wells GA, Tugw
well P. How to C hoose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Ap
pproves Filter 2
2.0. J Rheumato
ol 2014; 41: 10225‐1030. 39. Boerss M, Kirwan JR, Wells G, Beato
on D, Gossec L, d'Agostino MA
A, Conaghan PG, Bingham CO, Brooks P, Landewe R, Marcch L, Simon LS, SSingh JA, Strand
d V, Tugwell P. Developing Corre Outcome Me
easurement Setts for Clinical Trials: OMERACT Filter 2.0. J Clin Epidemiol 2014; 67: 7445‐753. 40. Bomeers MK, van Agttmael MA, Luik H, Vandenbrouucke‐Grauls CM
MJE, Smulders Y
YM. A detectionn dog to identifyy patients with C
Clostridium diffficile infection d
during a hospittal outbreak. J Infection 2014; 69: 456‐461. 41. Boons CCLM, Swart EL, Timmers L, van de Ven PM
M, Janssen JJWM
M, Hugtenburg JG. Study protoocol of the RAN
ND‐study: a multicenter, prospective cohort stu
udy investigatinng response and adherence to
o nilotinib treatm
ment in chronicc myeloid leukeemia. BMC Canccer 2014; 14: 24
47. 42. Boonstra K, Bokelaar R, Stadhoude
ers PH, Tuynma n HARE, Poen A
AC, van Nieuwk
kerk CMJ, Witteeman EM, Hama
ann D, Witteeman BJ, Beuerrs U, Ponsioen C
CY. Increased caancer risk in a large population
n‐based cohortt of patients witth primary biliaryy cirrhosis: follo
ow‐up for up to
o 36 years. Heppatology internaational 2014; 8:: 266‐274. 43. Boonstra K, Kunst AE, Stadhouderss PH, Tuynman HARE, Poen AC
C, van Nieuwkerrk CMJ, Wittem
man EM, Haman
nn D, Witteeman BJ, Beuerrs U, Ponsioen C
CY. Rising incideence and prevaalence of primary biliary cirrhoosis: a large pop
pulation‐
based
d study. Liver In
nternational 2014; 34: E31‐E388. 44. Borgsstein E, Kamiza S, Vujanic G, Pidini D, Bailey SS, Tomoka T, Baanda K, Kaspers G, Molyneux EE, Israels T. Wilm
ms Tumour in Maalawi: Surgical SStaging to Strattify Postoperati ve Chemotheraapy?. Pediatr Blood Cancer 20014; 61: 2180‐2184. 45. Bos W
WH, van de Stad
dt LA, Sohrabian A, Ronnelid J,, van Schaardenburg D. Develo
opment of anti ‐citrullinated protein antibody and rheum
matoid factor iso
otypes prior to the onset of rh
heumatoid arthritis. Arthritis RRes Ther 2014; 16: 405. Rappaport 46. Bots M, Verbrugge I, Martin BP, Salmon JM, Ghisi M, Baker A, Stanley K, Shortt J, Ossenkoppe le GJ, Zuber J, R
Atadja P, Lowe SSW, Johnstone RW. Differentiaation therapy fo
or the treatment of t(8;21) acuute myeloid leu
ukemia AR, A
usingg histone deacetylase inhibitorrs. Blood 2014; 123: 1341‐1352. 47. Boum
man MB, van Zeeijl MCT, Buncam
mper ME, Meijeerink WJHJ, van
n Bodegraven A
AA, Mullender M
MG. Intestinal Vagin
noplasty Revisitted: A Review o
of Surgical Tech niques, Complications, and Se
exual Function. Journal of Sexu
ual Medicine 2014; 11: 1835‐1847. 48. Bourggonje AM, Naviis AC, Schepenss JTG, Verrijp K,, Hovestad L, Hilhorst R, Harro
och S, Wesselingg P, Leenders W
WPJ, Hend
driks WJAJ. Intraacellular and exxtracellular dom
mains of protein
n tyrosine phossphatase PTPRZZ‐B differentially regulate gliom
ma cell growth aand motility. On
ncotarget 2014;; 5: 8690‐8702.. 49. Braatt AE, Pol RA, Oo
osterhuis JWA, de Vries JE, Meesker WE, Tollen
naar RAEM. Exccellent prognossis of node nega
ative patients after sentin
nel node proced
dure in colon caarcinoma: A 5‐yyear follow‐up sstudy. EJSO‐Eurr J Surg Oncol 2
2014; 40: 747‐7755. 50. Brastter R, O'Toole TTG, van Egmond
d M. Myeloid ceells as effector ccells for monocclonal antibody therapy of can
ncer. hods 2014; 65: 2
28‐37. Meth
Annual Report V
VUmc CCA 2014 –
8 of 216 51. Braun
n L, Kim PJ, Marrgolis D, Peters EJG, Lavery LA
A. What's new in
n the literature: An update of new research ssince the origin
nal WHS diabetic foot ulcer guidelines in 20066. Wound Repaair Regen 2014;; 22: 594‐604. 52. Brontte G, Rolfo C, Giovannetti E, Cicero G, Pauweels P, Passiglia F, Castiglia M, Rizzo S, Lo Vullo F, Fiorentino E
E, van Meerrbeeck J, Russo A. Are erlotinib
b and gefitinib iinterchangeablle, opposite or ccomplementaryy for non‐smalll cell lung canceer treatment? B
Biological, pharmacological annd clinical aspeccts. Crit Rev Oncol Hemat 20144; 89: 300‐313. 53. Buijs N, Brinkmann SSJH, Oosterink JJE, Luttikhold J,, Schierbeek H, Wisselink W, B
Beishuizen A, vaan Goudoever JJB, Houdijk APJ, vvan Leeuwen PA
AM, Vermeulen
n MAR. Intrave nous glutamine
e supplementattion enhances rrenal de nova a
arginine synth
hesis in humanss: a stable isotope study. Am J Clin Nutr 2014
4; 100: 1385‐1391. 54. Buis D
DR, Idema S, Feeller R, Vandertop WP. Standa rdization of Surgical Procedures: Beyond Cheecklists?. World
d neuro
osurgery 2014; 82: E376‐E377. 55. Bultin
nk IEM, Harvey NC, Lalmoham
med A, Cooper CC, Lems WF, van
n Staa TP, de Vrries F. Elevated risk of clinical ffractures and aassociated risk ffactors in patients with system
mic lupus erythe
ematosus versu
us matched conntrols: a popula
ation‐based studyy in the United Kingdom. Osteo
oporosis Int 20014; 25: 1275‐12
283. 56. Carettti V, Bugiani M, Freret M, Schellen P, Jansen MHA, van Vuu
urden DG, Kaspe
ers G, Fisher PG
G, Hulleman E, W
Wesseling P, Vogel H, Monje M
M. Subventricula
ar spread of difffuse intrinsic pontine glioma. ACTA Neuropaathol 2014; 128: 605‐607. 57. Carettti V, Sewing AC
CP, Lagerweij T,, Schellen P, Bu giani M, Jansen
n MHA, van Vuu
urden DG, Naviis AC, Horsman I, Vandertop WP, Noske DP, Wesselin
ng P, Kaspers G
GJ, Nazarian J, V
Vogel H, Hulleman E, Monje M
M, Wurdinger T. Human urine tumors. A
ACTA Neuropath
hol 2014; 127: 8
897‐909. pontiine glioma cellss can induce mu
eldof AA, Avan A, Cavaletti G, Peters GJ. Charracterization off and Protection
n from 58. Ceressa C, Avan A, Giiovannetti E, Ge
Neuro
otoxicity Induceed by Oxaliplatin, Bortezomib and Epothilone
e‐B. Anticancerr Res 2014; 34: 517‐523. 59. Chagaaluka G, Stanley C, Banda K, D
Depani S, Nijram
m'madzi J, Katan
ngwe T, Israels T, Bailey S, Mu kaka M, Molyneux E. Kaposi's sarcoma in children: An op
pen randomisedd trial of vincrisstine, oral etoposide and a com
mbination of vincristine and b
bleomycin. Eur JJ Cancer 2014; 50: 1472‐1481 . 60. Chaittanya P, Reddy GD, Varun G, Srikanth LM, Praasad VVSR, Ravindernath A. De
esign and Synthhesis of Quinazolinone Derivvatives as Anti‐inflammatory A
Agents: Pharma cophore Mode
eling and 3D QSAR Studies. Meedicinal chemisttry 2014; 10: 711‐723. 61. Chatu
urvedi N, Goem
man JJ, Boer JM,, van Wieringenn WN, Menezess R. A test for co
omparing two ggroups of samp
ples when analyyzing multiple o
omics profiles. B
BMC Bioinformaatics 2014; 15: 236. 62. Claveel CM, Paunescu
u E, Nowak‐Sliw
winska P, Griffiooen AW, Scopellliti R, Dyson PJ. Discovery of aa Highly Tumor‐‐Selective Organ
nometallic Ruth
henium(II)‐Aren
ne Complex. J M
Med Chem 2014
4; 57: 3546‐355
58. 63. Clavo
o B, Robaina F, JJorge IJ, Cabrerra R, Ruiz‐Egea E, Szolna A, Ote
ermin E, Llontop P, Carames M
MA, Santana‐Ro
odriguez N, Sminiia P. Spinal Cord Stimulation a
as Adjuvant Durring Chemotherrapy and Reirra
adiation Treatm
ment of Recurrent High‐
Gradee Gliomas. Integrative cancer therapies 20144; 13: 513‐519.
64. Cobben JM, Oostra RJ, van Dijk FS. Pectus excavattum and carinatum. Eur J Med
d Genet 2014; 557: 414‐417. an P, de Bree R,, Rinaldo A, Takkes RP, 65. Coca‐‐Pelaz A, Rodriggo JP, Triantafyllou A, Hunt JL, Fernandez‐Miranda JC, Stroja
Ferlito A. Chondrosaarcomas of the head and neckk. Eur Arch Oto‐‐Rhino‐L 2014; 2
271: 2601‐26099. CM, Stary J, Barruchel A, de Haaas V, Stam RW,, Reinhardt D, K
Kaspers GJL, renntsen‐Peters ST
TCJ, Meyer 66. Coenen EA, Zwaan C
Unique BHLHB33 overexpressio
on in C, Maarschalek R, Niggro LL, Dworzakk M, Pieters R, vvan den Heuvel‐Eibrink MM. U
pediaatric acute myeloid leukemia w
with t(6;11)(q277;q23). Leukem
mia 2014; 28: 15
564‐1568. 67. Coutiinho JM, Idemaa S, Vandertop W
WP. Decompre ssive craniectomy. J Neurosurrg 2014; 120: 5777. 68. Creuttzig U, Semmlerr J, Kaspers G, R
Reinhardt D, Zim
mmermann M. Re‐induction w
with L‐DNR/FLAAG Improves Response after AML Relapse, b
but not Long‐te
erm Survival. Kl in Padiatr 2014
4; 226: 323‐331. 69. Creuttzig U, Zimmerm
mann M, Dworzzak MN, Gibsonn B, Tamminga R, Abrahamsso
on J, Ha SY, Haslle H, Maschan A
A, Bertrand Y, Leverger G, von Neuho
off C, Razzouk BB, Rizzari C, Smissek P, Smith OP
P, Stark B, Reinhhardt D, Kasperrs GJL. The progn
nostic significan
nce of early trea
atment responsse in pediatric relapsed acute myeloid leukem
mia: results of tthe intern
national study R
Relapsed AML 2
2001/01. Haem
matol‐Hematol JJ 2014; 99: 1472‐1478. 70. Dafnii U, Karlis D, Sm
mit E, Peters S. SSecond line treaatment for EGFFR wild‐type adv
vanced NSCLC: The Jury is Stilll Out. Lung Canceer 2014; 84: 314‐315. 71. Dahm
men R, Buijsman
nn S, Siemonsm
ma PC, Boers M,, Lankhorst GJ, Roorda LD. Use
e and Effects off Custom‐Made
e Theraapeutic Footweear on Lower‐Exxtremity‐Relateed Pain and Activity Limitations in Patients wiith Rheumatoid
d Arthritis: A Pro
ospective Obserrvational Study of A Cohort. J RRehabil Med 20
014; 46: 561‐56
67. 72. Day J, Zienius K, Geh
hring K, Grossha
ans D, Taphoorrn MJ, Grant R, Li J, Brown PD. Interventions ffor preventing and ameliiorating cognitiive deficits in ad
dults treated w
with cranial irrad
diation. Cochrane Database Syyst Rev 2014; 2014: CD0111335. 73. de Bo
oer KHN, Lowen
nberg M, Hoenttjen F. Manage ment of Crohn's disease in poor responders tto adalimumab
b. Clinical and eexperimental gaastroenterologyy 2014; 7: 83‐922. 74. de Bo
oer KHN, van Bo
odegraven AA. Get the Best O ut of Thiopurin
ne Therapy. Gasstroenterology 2014; 146: 865
5. 75. de Brree E, Zoras O, H
Hunt JL, Takes R
RP, Suarez C, M
Mendenhall WM
M, Hinni ML, Rodrigo JP, Shahaa AR, Rinaldo A, Ferlito A, de Brree R. Desmoid tumors of the head and neck:: A therapeutic challenge. Hea
ad Neck‐J Sci Sppec 2014; 36: 15
517‐1526. 76. de Brruin EC, Cowell C, Warne PH, Jiang M, Saundeers RE, Melnick MA, Gettinger S, Walther Z, W
Wurtz A, Heyne
en GJ, Heideeman DAM, Go
omez‐Roman J, Garcia‐Castanoo A, Gong YX, Laadanyi M, Varm
mus H, Bernardss R, Smit EF, Politi K, Annual Report V
VUmc CCA 2014 –
9 of 216 77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
Down
nward J. Reduceed NF1 Expresssion Confers Reesistance to EGFFR Inhibition in Lung Cancer. CCancer discoverry 2014; 4: 606‐6619. de Cu
uba EMV, Verwaal VJ, de Hingh
h IHJT, van Menns LJJ, Nienhuijs SW, Aalbers A
AGJ, Bonjer HJ, te Velde EA. M
Morbidity Assocciated with Colo
ostomy Reversa
al After Cytoredductive Surgeryy and HIPEC. An
nn Surg Oncol 22014; 21: 883‐890. de Jong MC, Kors W
WA, de Graaf P, C
Castelijns JA, Kiivela T, Moll AC
C. Trilateral retin
noblastoma: a ssystematic reviiew and meta‐analysis. Lanceet Oncol 2014; 15: 1157‐1167 . de Jong T, Vosslamb
ber S, Jager W, R
Raterman H, Vooskuyl A, Gelde
erman K, Verwe
eij C. Serum Cyttokine Changes in Rituximab‐Treated R
Rheumatoid Artthritis Patients.. Ann Rheum Dis 2014; 73: A3. de Jong TD, Vosslam
mber S, Verweij CL. Moving tow
wards personalized medicine in rheumatoid aarthritis. Arthrittis Res Ther 2014; 16: 110. C, Rutten AP, P ouwels W, Schuurhuis GJ, Osssenkoppele GJ, Smit L. Attenua
ation of de Leeeuw DC, Denkeers F, Olthof MC
micro
oRNA‐126 Expreession That Drivves CD34(+)38 Stem/Progenitor Cells in Acutte Myeloid Leukkemia Leads to Tumor Eradication. Cancer Res 2014; 74: 2
2094‐2105. uiter RD, Gordijn MS, Gemke R
RJBJ, van den Boos CG, Bierings MB, Rotteveel J, Koper JW, Roossum EFC, Kasspers GJL. de Ru
Adren
nal insufficiencyy during treatm
ment for childhoood acute lymp
phoblastic leuke
emia is associatted with glucocorticoid recep
ptor polymorph
hisms ER22/23E
EK and BclI. Haeematol‐Hemato
ol J 2014; 99: E1
136‐E137. de Vo
os FY, Kaal SE, W
Wesseling P, Gijjtenbeek JM. Suuccessful third‐‐line chemotherapy for an aduult with recurrent medu
ulloblastoma. In
nternational Cancer Conferencce Journal 2014
4; 3: 32‐37. de Vrries MG, Ekkeleenkamp MB, Petters EJG. Are cl indamycin and ciprofloxacin a
appropriate for the empirical ttreatment of diaabetic foot infections?. Eur J Clin Microbiol 20014; 33: 453‐45
56. Decristoforo C, Penu
uelas I, Elsinga P, Ballinger J, W
Windhorst AD, V
Verbruggen A, V
Verzijlbergen F,, Chiti A. Radio
opharmaceuticaals are special, but is this recoggnized? The po
ossible impact o
of the new Cliniical Trials Regullation on the preparation of radiopharmaceu
uticals. Eur J Nuucl Med Mol I 2
2014; 41: 2005‐2007. ahyoid flap: A ccomprehensive review of an often overlookedd reconstructivve method. Deganello A, Leemans CR. The infra
Oral O
Oncol 2014; 50: 704‐710. den U
Uyl D, ter Wee M
M, Boers M, Ke
erstens P, Voskuuyl A, Nurmohaamed M, Raterm
man H, van Sch aardenburg D, van Dillen N, Dijjkmans BAC, Leems WF. A non‐inferiority trial of an attenuated combination
n strategy ('COBBRA‐light') com
mpared to the o
original COBRA sstrategy: clinica
al results after 226 weeks. Ann Rheum Dis 201
14; 73: 1071‐10078. dhar A, Reveille JD, Bosch F, vo
on Braun J, Burggos‐Vargas R, C
Caplan L, Clegg D
DO, Colbert RA,, Gensler LS, va
an der Deod
Heijde D, van der Ho
orst‐Bruinsma IE, Inman RD, M
Maksymowych W
WP, Mease PJ, Raychaudhuri SS, Reimold A, Rudwaleit M, Sieeper J, Weismaan MH, Landewe RBM. The Co ncept of Axial SSpondyloarthrittis. Arthritis & rrheumatology 2
2014; 66: 2649‐‐2656. Derkss J, Reijneveld JC, Douw L. Neu
ural network altterations underlie cognitive de
eficits in brain ttumor patients. Curr Opin Onco
ol 2014; 26: 627
7‐633. Dewint P, Hansen BEE, Verhey E, Old
denburg B, Hom
mmes DW, Pierrik M, Ponsioen CIJ, van Dullem
men HM, Russel M, van Bodegraven AA, van
n der Woude CJ. Adalimumab ccombined with ciprofloxacin is superior to addalimumab monotherapy in perianal fistula clo
osure in Crohn's disease: a ranndomised, doub
ble‐blind, placebo controlled ttrial (ADAFI). Gu
ut 2014; 63: 2992‐299. Dickh
hoff C, Hartemin
nk KJ, van de Ve
en PM, van Reijje EJF, Senan S,, Paul MA, Smitt EF, Dahele M. Trimodality therapy for stagee IIIA non‐small cell lung cance
er: Benchmarkinng multi‐disciplinary team deccision‐making a nd function. Lu
ung Cancer 2014;; 85: 218‐223. Dimo
opoulos MA, Lelleu X, Palumbo A, Moreau P, D
Delforge M, Cavvo M, Ludwig H
H, Morgan GJ, D
Davies FE, Sonne
eveld P, Scheyy SA, Zweegman S, Hansson M
M, Weisel K, Ma teos MV, Facon
n T, Miguel JFS. Expert panel cconsensus state
ement on the o
optimal use of p
pomalidomide in relapsed and refractory mulltiple myeloma. Leukemia 20114; 28: 1573‐1585. Ding XT, Liu WJ, Weiss A, Li YY, Wong I, Griffioen A
AW, van den Be
ergh H, Xu HQ, Nowak‐Sliwins ka P, Ho CM. Discovery of a low
w order drug‐cell response surfface for applicaations in person
nalized medicine. Physical Bioloogy 2014; 11: 0
065003. Dinm
mohamed A, van
n Norden Y, Vissser O, Posthum
ma E, Huijgens P
PC, Sonneveld P
P, van de Loosdrrecht AA, Jonge
en‐
Lavreencic M. The Usse of Medical Cllaims to Assess Incidence, Diaggnostic Procedures and Initial Treatment Am
mong Patients with Myelo
odysplastic Synd
dromes in the N
Netherlands. Haaematol‐Hemattol J 2014; 99: 992‐93. Dinm
mohamed AG, Visser O, van Norden Y, Huijgenns PC, Sonneveld P, van de Loo
osdrecht AA, Joongen‐Lavrencicc M. Trend
ds in incidence,, initial treatme
ent and survivall of myelodysplastic syndrome
es: A populationn‐based study o
of 5144 patients diagnosed iin the Netherlands from 2001 to 2010. Eur J Cancer 2014; 50: 1004‐1012. Domiinguez‐Soto A, de las Casas‐En
ngel M, Bragadoo R, Medina‐Echeverz J, ragoneses‐Fenoll L, M
Martin‐Gayo E, van Rooijen N, Berraond
do P, Toribio ML, Moro MA, Cuuartero I, Castriillo A, Sancho D
D, Sanchez‐Torrres C, Bruhns P, Sanchez‐
on S, Corbi AL. IIntravenous Immunoglobulin PPromotes Antittumor Responses by Modulati ng Macrophage
e Ramo
Polarrization. J Immu
unol 2014; 193: 5181‐5189. Alemany R, Meuulenberg JJM, vvan Beusechem
m VW. ORCA‐0100, a Novel Pote
ency‐
Dongg WL, van Ginkeel JWH, Au KY, A
Enhanced Oncolytic Adenovirus, Exxerts Strong An titumor Activity in Preclinical Models. Hum G
Gene Ther 2014
4; 25: 897‐
904. Annual Report V
VUmc CCA 2014 –
0 of 216 98. Dunscombe P, Grau C, Defourny N,, Malicki J, Borrras JM, Coffey M
M, Bogusz M, G
Gasparotto C, Sl otman B, Lieve
ens Y. Guideelines for equip
pment and stafffing of radiotheerapy facilities in the European
n countries: Finnal results of the
e ESTRO‐
HERO
O survey. Radiotther Oncol 2014; 112: 165‐1777. 99. Eekm
man DA, ter Weee MM, Coupe V
VMH, Erisek‐Deemirtas S, Kramer MH, Lems W
WF. Indirect costts account for h
half of the total costs of an osteeoporotic fracture: a prospecttive evaluation.. Osteoporosis Int 2014; 25: 1995‐204. 100. El‐Naaggar M, Ebbingg E, Bijnsdorp I, van den Berg JJ, Peters GJ. Rad
diosensitization
n by Thymidine Phosphorylase
e Inhibitor in Thyymidine Phosphorylase Negative and Overexxpressing Bladd
der Cancer Cell Lines. Nucleos N
Nucleot Nucl 2014; 33: 413‐4421. 101. Emmink BL, Laoukili J, Kipp AP, Kosster J, Govaert KKM, Fatrai S, Ve
erheem A, Steller EJA, Brigeliuss‐Flohe R, Jime
enez CR, Mass to Rinkees IHMB, Kranenburg O. GPx2 Suppression off H2O2 Stress Links the Formation of Differenntiated Tumor M
Metaastatic Capacity in Colorectal C
Cancer. Cancer RRes 2014; 74: 6
6717‐6730. 102. Esken
ns FALM, van Errpecum KJ, de JJong KP, van Deelden OM, Klum
mpen HJ, Verhoef C, Jansen PLLM, van den Bossch MAAJ, Romeero AM, Verheijj J, Bloemena E
E, de Man RA. H
Hepatocellular ccarcinoma: Dutch guideline forr surveillance, d
diagnosis and therapy. Neth J Med 2014; 72: 299‐304. 103. Flach GB, Bloemena E, Klop WMC, van Es RJJ, Scheepman KP, Hoe
ekstra OS, Caste
elijns JA, Leemaans CR, de Bree
e R. Sentinel lymph nodee biopsy in clinically N0 T1‐T2 staged oral can
ncer: The Dutch
h multicenter trrial. Oral Oncol 2014; 50: 1020‐‐1024. 104. Fosteer TL, Ferrantellli E, van Wier‐va
an de Schaaf, BBeelen RHJ. European Training and Research in Peritoneal Dialysis: scientific objectives,, training, imple
ementation andd impact of the programme. Jo
ournal of renal care 2014; 40: 34‐39. 105. Frampton AE, Castellano L, Colomb
bo T, Giovannettti E, Krell J, Jaccob J, Pellegrino
o L, Roca‐Alonsoo L, Funel N, Ga
all TMH, n DJ, Ahmad R, Habib NA, Coo
ombes RC, Harding V, Knosel T,
T, Stebbing J, Jia
ao LR. Giorggio A, Pinho FG,, Fulci V, Britton
Micro
oRNAs Cooperaatively Inhibit a Network of Tu mor Suppresso
or Genes to Promote Pancreat ic Tumor Grow
wth and Progrression. Gastroeenterology 201
14; 146: 268‐27 7. 106. Froklaage FE, Oosterb
baan LJ, Sizoo E
EM, de Groot M
M, Bosma I, Sancchez E, Douw L,, Heimans JJ, Reeijneveld JC, Lagerwaard FJ, Bu
uter J, Uitdehaaag BMJ, Klein M
M, Postma TJ. Ceentral neurotoxxicity of standarrd treatment inn patients with newly‐
diagn
nosed high‐grad
de glioma: a pro
ospective longittudinal study. J Neuro‐Oncol 2
2014; 116: 387‐‐394. 107. Gaillaard PJ, Appeldo
oorn CCM, van D
Dorland R, van Kregten J, Man
nca F, Vugts DJ, Windhorst AD,, van Dongen GAMS, de Vries HE, Maussang D, van Tellinge
en O. Pharmacookinetics, Brain Delivery, and E
Efficacy in Brainn Tumor‐Bearing Mice of Doxorubicin (2BB3‐101). PLoS O
One 2014; 9: e82
2331. Glutaathione Pegylated Liposomal D
108. Galvaani E, Toffalorio
o F, Peters GJ, D
De Pas T, Giovannnetti E. Pharm
macogenetics off Non‐small Celll Lung Cancer (NSCLC): Time to "Work it Ou
ut"?. Curr Pharm
m Design 2014; 20: 3863‐3874
4. ng the Role 109. Garajjova I, Le Large TYS, Frampton AE, Rolfo C, Vooortman J, Giovvannetti E. Molecular Mechannisms Underlyin
of MiicroRNAs in thee Chemoresistance of Pancreattic Cancer. Biom
med research in
nternational 20014; 2014: 6784
401. 110. Gardiien KLM, Middeelkoop E, Ulrich
h MMW. Progreess towards cell‐based burn wound treatmennts. Regenerativve medicine 2014; 9: 20
01‐218. 111. Gaud
dichon J, Milano
o F, Cahu J, DaC
Costa L, Marten s ACM, Renoir JM, Sola B. Dea
azaneplanocin AA Is a Promisingg Drug to Kill M
Multiple Myelom
ma Cells in Their Niche. PLoS O
One 2014; 9: e107009. 112. Gent YYJ, ter Wee M
MM, Ahmadi N, van Kuijk C, Vooskuyl AE, van d
der Laken CJ, Do
owling C, van d e Stadt LA, van
n Schaaardenburg D. Th
hree‐year cliniccal outcome fol lowing baseline
e magnetic reso
onance imagingg in anti‐citrullinated proteein antibody‐po
ositive arthralgia patients: an eexploratory study. Arthritis & rrheumatology 22014; 66: 2909‐2910. 113. Gholaamin S, Fiuji H, Maftouh M, Mirhafez SR, Hom
maei Shandiz F, Avan A. Targetting c‐MET/HGFF Signaling Path
hway in Uppeer Gastrointestinal Cancers: Ra
ationale and Proogress. Currentt Drug Targets 2
2014; 15: 1302‐‐1311. 114. Gielissse EAR, de Boeer KHN. Ipilimum
mab in a patiennt with known C
Crohn's disease
e: To give or nott to give?. Journ
nal of Crohn
n's and Colitis 2
2014; 8: 1742. 115. Gijezeen LC, Vernooijj M, Martens H,, Oduber CEU, H
Henquet CJM, SStarink TM, Prin
ns MH, Menko FH, Nelemans PJ, van Steen
nsel MAM. Topiical Rapamycin as a Treatmen t for Fibrofollicculomas in Birt‐Hogg‐Dube Synndrome: A Double‐Blind Placeebo‐Controlled Randomized Sp
plit‐Face Trial. PPLoS One 2014;; 9: e99071. 116. Gillett E, Alentorn A, Doukoure B, M
Mundwiller E, vaan Thuij H, Reijn
neveld JC, Medina JAM, Liou AA, Marie Y, Mokkhtari K, Hoan
ng‐Xuan K, Sanson M, Delattre JY, Idbaih A. TPP53 and p53 staatuses and their clinical impacct in diffuse low
w grade gliom
mas. J Neuro‐On
ncol 2014; 118: 131‐139. 117. Gingo
old H, Tehler D,, Christoffersen
n NR, Nielsen M
MM, Asmar F, Ko
ooistra SM, Christophersen NSS, Christensen LLL, Borre M, So
orensen KD, Andersen LD, And
dersen CL, Hulleeman E, Wurdin
nger T, Ralfkiaer E, Helin K, Groonbaek K, Omtoft T, Waszzak SM, Dahan O
O, Pedersen JS,, Lund AH, Pilpeel Y. A Dual Program for Translation Regulatioon in Cellular Prolifferation and Diffferentiation. C
Cell 2014; 158: 11281‐1292. 118. Giovaannetti E, Giacccone G. CYB5A a
and autophagy‐‐mediated cell death in pancre
eatic cancer. Auutophagy 2014
4; 10: 697‐
698. egies and Appliccations for Druggs Targeting EG
GFR and c‐Met. Current Drug T
Targets 119. Giovaannetti E, Leon LG. New Strate
2014;; 15: 1261‐1262
2. 120. Giovaannetti E, Wangg QY, Avan A, Funel N, Lagerw
weij T, Lee J, Caretti V, van der V
Velde A, Boggi U, Wang YS, Va
asile E, Peterrs GJ, Wurdingeer T, Giaccone G
G. Role of CYB5 A in Pancreaticc Cancer Progno
osis and Autophhagy Modulatio
on. J Natl Canceer I 2014; 106: djt346. Annual Report V
VUmc CCA 2014 –
– Appendix 3: Scieentific output ‐ 51 of 216 121. Gotin
nk KJ, Broxterman HJ, Honeyw
well RJ, Dekker H
H, de Haas RR, M
Miles KM, Adelaiye R, Griffioenn AW, Peters G
GJ, Pili R, Verheeul HMW. Acqu
uired tumor cell resistance to ssunitinib cause
es resistance in a HT‐29 humann colon cancer xxenograft mousse model witho
out affecting sun
nitinib biodistriibution or the tumor microvassculature. Oncooscience 2014; 1: 844‐853. 122. Gottrrup F, Apelqvistt J, Bjarnsholt T, Cooper R, Mooore Z, Peters EJJG, Probst S. An
ntimicrobials annd Non‐Healingg Wounds. Evideence, controverrsies and suggesstions‐key messsages. Journal o
of Wound Care 2014; 23: 477‐‐480. 123. Grau C, Defourny N,, Malicki J, Dunsscombe P, Borrras JM, Coffey M
M, Slotman B, B
Bogusz M, Gaspparotto C, Lieve
ens Y. Radio
otherapy equipment and depa
artments in the European coun
ntries: Final results from the EESTRO‐HERO survey. Radio
other Oncol 201
14; 112: 155‐16
64. 124. Griffioen AW. Angio
ostatic vaccines,, an underestim
mated approach
h of cancer therrapy. Oncotargeet 2014; 5: 109
961‐10962. 125. Griffioen AW, Thijssen VLJL. Galecttins in tumor anngiogenesis. Annals of translattional medicinee 2014; 2: 90. Winkel MTT, Nowak‐Sliwinska P. The emergin g quest for the optimal 126. Griffioen AW, Weisss A, Berndsen RH, Abdul UK, W
ostatic combinaation therapy. B
Biochem Soc T 22014; 42: 1608‐‐1615. angio
127. Griffioen GHMJ, Dah
hele M, de Haan PF, van de Veen PM, Slotman
n BJ, Senan S. High‐dose, conveentionally fracttionated on for lung tumo
ors. Lung Canceer 2014; 83: 356
6‐362. thoraacic reirradiatio
128. Griffioen GHMJ, Laggerwaard FJ, Haasbeek CJA, Slootman BJ, Senan S. A Brief Rep
port on Outcom
mes of Stereotacctic Ablattive Radiotherapy for a Second
d Primary Lung Cancer: Eviden
nce in Support o
of Routine CT S urveillance. Jou
urnal of Thoraacic Oncology 2
2014; 9: 1222‐1225. 129. Griffitth KA, Dorsey SSG, Renn CL, Zhu SJ, Johantgenn ME, Cornblath
h DR, Argyriou AA, Cavaletti G
G, Merkies ISJ, A
Alberti P, Postm
ma TJ, Rossi E, FFrigeni B, Bruna
a J, Velasco R, KKalofonos HP, P
Psimaras D, Rica
ard D, Pace A, G
Galie E, Briani C, la Torre C, Fab
ber CG, Lalisangg RI, Boogerd W
W, Brandsma D,, Koeppen S, He
ense J, Storey D
DJ, Kerrigan S, SSchenone A, Fab
bbri S, Valseecchi MG. Correespondence bettween neurophhysiological and
d clinical measurements of cheemotherapy‐ind
duced perip
pheral neuropatthy: secondary analysis of dataa from the CI‐PeriNomS study. J Peripher Nerrv Syst 2014; 19
9: 127‐135. 130. Groenendijk MR, Haartemink KJ, Dicckhoff C, Geera edts LMG, Terrra M, Thoral P, Hashemi SM. PPneumomediasttinum and (bilateral) pneumoth
horax after high
h energy traum
ma: Indications ffor emergency bronchoscopy. Respiratory Medicine Case Reports 2014; 13: 9‐11. 131. Grossso MJ, Matheuss V, Clark M, van Rooijen N, Ia nnotti CA, Stein
nmetz MP. Effe
ects of an Immuunomodulatory Therapy and C
Chondroitinase After Spinal Co
ord Hemisectionn Injury. Neurosurgery 2014; 7
75: 461‐471. 132. Gvozd
denovic E, Dirven L, van den B
Broek M, Han KH
H, Molenaar ET
TH, Landewe RB
BM, Lems WF, AAllaart CF. Intra
a articular injecttion with corticosteroids in patients with receent onset rheumatoid arthritiss: subanalyses ffrom the BeSt sstudy. Clin Rheumatol 2014; 33
3: 263‐267. 133. Gyorggy B, Fitzpatrickk Z, Crommentu
uijn MHW, Mu D, Maguire CA. Naturally enve
eloped AAV vecctors for shielding neutrralizing antibod
dies and robust gene delivery iin vivo. Biomate
erials 2014; 35:: 7598‐7609. 134. Halab
by T, Al Naiemi N, Kluijtmans JAJW, van der PPalen J, Vandenbroucke‐Graulss CMJE. Reply to
to "Colistin Resiistance durin
ng Selective Digestive Tract Decontamination Is Uncommon"". Antimicrob A
Agents CH 2014;
4; 58: 627. by T, Al Naiemi N, Vandenbrou
ucke‐Grauls CM
MJE. Reply to "Se
elective Digestiive Tract Deconntamination and Spread 135. Halab
of Co
olistin Resistancce: Antibiotic Prrophylaxis Is Noot a Substitute ffor Hygiene". Antimicrob Agennts CH 2014; 58
8: 3576‐
3578. ua MH, Krekel N
NMA, Jacobs GJJA, Zonderhuis BM, Bouman M
MB, Buncamperr ME, Niessen FFB, Winters HAH
H, Terwee 136. Halou
CB, M
Meijer S, van deen Tol MP. Cosm
metic Outcome Assessment following Breast‐‐Conserving Theerapy: A Compa
arison between BCCT.core Software and P
Panel Evaluatioon. Internationaal journal of bre
east cancer 20114; 2014: 71686
60. ua MH, Krekel N
NMA, Meijer S, van den Tol M P. Ultrasound‐gguided surgery for palpable brreast cancer: a historical 137. Halou
persp
pective. Expert Rev Anticancerr Ther 2014; 3: 4433‐439. 138. Hasheemi SMS, Daheele M, Daniels JMA, Smit EF. Coomplications off endoscopic ultrasound‐guideed needle aspiration. ACTA
A Oncol 2014; 53: 1265‐1268. 139. Hatem
mi G, Merkel PA
A, Hamuryudan
n V, Boers M, D ireskeneli H, Ayydin SZ, Yazici H
H. Outcome Meeasures Used in
n Clinical Trialss for Behcet Syn
ndrome: A Syste
ematic Review.. J Rheumatol 2
2014; 41: 599‐612. 140. Haverman TM, Rabeer‐Durlacher JE,, Rademacher W
WMH, Vokurka S, Epstein JB, H
Huisman C, Hazzenberg MD, de
e Soet JJ, matopoietic Ste
em Cell Recipien
nts: The Role off Inflammation. Mediat de Laange J, Rozema FR. Oral Complications in Hem
mm 2014; 2014
4: 378281. Inflam
141. Heiliggenberg M, Verrweij SP, Speksn
nijder AGCL, Moorré SA, de vrie
es HJC, Schim va
an der Loeff M.. No evidence for LGV transmission amongg heterosexualss in Amsterdam
m, the Netherlan
nds. BMC Resea
arch Notes 20144; 7: 355. 142. Heussschen R, Schulkkens IA, van Beiijnum J, Griffioeen AW, Thijssen
n VLJL. Endothe
elial LGALS9 spllice variant expression in endothelial cell biolo
ogy and angioggenesis. Biochim
m Biophys Acta Mol Basis Dis 2
2014; 1842: 2844‐292. 143. Hiligssmann M, Coop
per C, Guillemin
n F, Hochberg M
MC, Tugwell P, A
Arden N, Berenbaum F, Boers M, Boonen A, B
Branco JC, Mariaa‐Luisa B, Bruyeere O, Gasparikk A, Kanis JA, Kvvien TK, Martel‐‐Pelletier J, Pelletier JP, Pinedoo‐Villanueva R, Pinto D, Reiter‐Niesert S, Rizzoli R, Rovati LC
C, Severens JL, Silverman S, Re
eginster JY. A re
eference case foor economic evvaluations m the European
n Society for Clin
nical and Econoomic Aspects off in ostteoarthritis: An expert consensus article from
Osteo
oporosis and Ossteoarthritis (ESCEO). Semin A
Arthritis Rheu 2
2014; 44: 271‐28
82. 144. Hitzerd SM, Verbruggge SE, Ossenko
oppele GJ, Janseen G, Peters GJJ. Positioning off aminopeptidaase inhibitors in
n next generration cancer th
herapy. Amino Acids 2014; 466: 793‐808. Annual Report V
VUmc CCA 2014 –
2 of 216 145. Ho VK
KY, Reijneveld JJC, Enting RH, B
Bienfait HP, Robbe P, Baumert B
BG, Visser O. Ch
hanging incidennce and improved survival of glio
omas. Eur J Can
ncer 2014; 50: 2
2309‐2318. 146. Hoefn
nagels FWA, Haamer PD, Sanz‐A
Arigita E, Idemaa S, Kuijer JPA, Pouwels PJW, B
Barkhof F, Vanddertop WP. Differrentiation of ed
dema and gliom
ma infiltration: pproposal of a DTI‐based proba
ability map. J Neeuro‐Oncol 201
14; 120: 187‐1198. 147. Holtzer‐Goor KM, Bo
ouwmans‐Frijte
ers CAM, Schaaafsma MR, de W
Weerdtc O, Joossten P, Posthum
ma EFM, Witteb
bol S, Huijgens PC, Matthsssen EJM, Vreuggdenhil G, Visseer H, Peters WG
G, Erjavec Z, Wijermans PW, D
Daenen SMGJ, vvan der Hem KG, van Oers M
MHJ, Uyl‐de Gro
oot CA. Real‐woorld costs of chrronic lymphocy
ytic leukaemia i n the Netherlands. Leukeemia Res 2014; 38: 84‐90. 148. Hooijjberg JH, Jansen
n G, Kathmann I, Pieters R, Laaan AC, van Zanttwijk I, Kaspers GJL, Peters GJ. Folates provokke cellular effluxx and drug resisstance of substrates of the muultidrug resistan
nce protein 1 (M
MRP1). Cancer CChemoth Pharm
m 2014; 73: 911‐917. on TM, Perenteesis JP, Gamis AS, Alonzo TA, G
Gerbing RB, Ballard J, Adlard K,, Howard DS, Sm
mith FO, Jenkin
ns G, Kelder 149. Horto
A, Sch
huurhuis GJ, Moscow JA. A Phase 2 Study of Bortezomib Combined with Eiither Idarubicinn/Cytarabine orr Cytarrabine/Etoposid
de in Children w
with Relapsed, RRefractory or Secondary Acute
e Myeloid Leukkemia: A Reportt from the Children's Oncologyy Group. Pediatrr Blood Cancer 2014; 61: 1754
4‐1760. 150. Hugh
hes TP, Hochhau
us A, Kantarjian
n HM, Cervantees F, Guilhot F, N
Niederwieser D
D, le Coutre PD, Rosti G, Ossenkoppele obo C, Shibayam
ma H, Fan XL, M
Menssen HD, Keemp C, Larson R
RA, Saglio G. Saffety and efficaccy of switching to nilotinib GJ, Lo
400 m
mg twice daily ffor patients with chronic myel oid leukemia in
n chronic phase
e with suboptim
mal response orr failure on front‐‐line imatinib o
or nilotinib 300 mg twice daily.. Haematol‐Hem
matol J 2014; 99: 1204‐1211. 151. Hui K
KF, Leung YY, Yeeung PL, Middeldorp JM, Chianng AKS. Combin
nation of SAHA and bortezomi b up‐regulates CDKN2A and C
CDKN1A and ind
duces apoptosis of Epstein‐Ba rr virus‐positive
e Wp‐restricted
d Burkitt lymphhoma and lymphoblastoid cell lines. Brit J Haem
matol 2014; 167
7: 639‐650. da L, Rader T, TTugwell P, Boers M. Can We Deecide Which Ou
utcomes Should
d Be Measuredd in Every Clinical Trial? A 152. Idzerd
Scopiing Review of th
he Existing Conceptual Framew
works and Proccesses to Develop Core Outcom
me Sets. J Rheu
umatol 2014;; 41: 986‐993. 153. Israells T, Bailey S, Veerschoor R, Kasspers GJL, Kennnedy N, Molyneux EM. Manage
ement of Childrren with Wilmss Tumor in Africaa and Europe; TThoughts Aboutt Costs, Prioritiees and Collaborration. Pediatr Hemat Oncol 22014; 31: 395‐399. 154. Israells T, Molyneux EM. Collaboratting in Africa‐sm
mall steps to sustainable succe
ess. Nature revi ews clinical onccology 2014;; 11: 691‐692. 155. Jacob
bs JJL, Snackey C
C, Geldof AA, Characiejus D, vaan Moorselaar RJA, den Otter W. Inefficacy oof Therapeutic Cancer Vaccines and Propossed Improveme
ents. Casus of PProstate Cancerr. Anticancer Re
es 2014; 34: 26889‐2700. 156. Janjiggian YY, Smit EFF, Groen HJM, H
Horn L, Gettingeer S, Camidge D
DR, Riely GJ, Wa
ang BS, Fu Y, Chhand VK, Miller VA, Pao W. Du
ual Inhibition o
of EGFR with Afa
atinib and Cetuuximab in Kinase Inhibitor‐Resiistant EGFR‐Muutant Lung Cancer with and w
without T790M Mutations. Cancer discovery 2014; 4: 1036‐1045. 157. Janseen MHA, Kloet R
RW, van Vuurde
en DG, Veldhuijjzen van Zanten
n SEM, Witte BI, Goldman S, VVandertop WP, Comans EFI, H
Hoekstra OS, Bo
oellaard R, Kasp
pers GJL. 18F‐FD
DG PET standarrd uptake values of the norma l pons in children: estab
blishing a refereence value for d
diffuse intrinsic pontine gliomaa. EJNMMI rese
earch 2014; 4: 88. 158. Jansssens GO, Radem
makers SE, Terhaard CH, Doornnaert PA, Bijl HP
P, van den Ende
e P, Chin A, Takkes RP, de Bree R, nk J, Span PN, K
Kaanders JH. Im
mproved Recurre
ence‐Free Survival with ARCON
Patients Hooggsteen IJ, Bussin
N for Anemic P
with Laryngeal Canccer. Clin Cancer Res 2014; 20: 11345‐1354. 159. Jansssens GO, van Bo
ockel LW, Doorn
naert P, Bijl HP,, van den Ende P, de Jong MA,, van den Broekk GB, Verbist BM
M, Terhaaard CH, Span P
PN, Kaanders JH
H. Computed toomography‐bassed tumour volu
ume as a predicctor of outcome
e in larynggeal cancer: Reesults of the pha
ase 3 ARCON trrial. Eur J Cance
er 2014; 50: 111
12‐1119. 160. Jharaap B, de Boer KH
HN, Stokkers P, Hommes DW, Oldenburg B, D
Dijkstra G, van d
der Woude CJ, dde Jong DJ, Mu
ulder CJJ, van EElburg RM, van Bodegraven AA
A. Intrauterine eexposure and p
pharmacology o
of conventionall thiopurine the
erapy in pregn
nant patients w
with inflammato
ory bowel diseaase. Gut 2014; 6
63: 451‐457. 161. Johan
nnesma PC, Starink TM, van M
Moorselaar RJA, Postmus PE. Faacial Fibrofolliculomas as Indiccator for Renal Cell Canceer. Japanese Journal of Clinical Oncology 20114; 44: 609‐610. 162. Julsin
ng J, Peters GJ. M
Methylation of DNA repair gennes and the effficacy of DNA ta
argeted anticanncer treatment.. Oncology Disco
overy 2014; 2: 3
3. 163. Karaggozoglu KH, Dekkker HA, Rietve
eld D, de Bree RR, Schulten EAJM
M, Kantola S, Fo
orouzanfar T, vaan der Waal I. P
Proposal for a new staging system for osteoradionecrosis oof the mandible
e. Medicina oral patologia orall y cirugia bucal 2014; 19: E433‐‐E437. 164. Kaspeers G. How I treeat paediatric re
elapsed acute m
myeloid leukaemia. Brit J Haem
matol 2014; 1666: 636‐645. 165. Keldeerman S, Heemsskerk B, van Tin
nteren H, van dden Brom RRH, Hospers GAP, v
van den Eertweegh AJM, Kapite
eijn EW, de Groott JWB, Soeteko
ouw P, Jansen R
RL, Fiets E, Furneess AJS, Renn A
A, Krzystanek M
M, Szallasi Z, Lorrigan P, Gore M
ME, Schum
macher TNM, H
Haanen JBAG, Larkin JMG, Blannk CU. Lactate d
dehydrogenase
e as a selection criterion for ipilimumab treatm
ment in metasttatic melanoma
a. Cancer Immuunol Immun 201
14; 63: 449‐458
8. 166. Kerkh
hof MH, Ruiz‐Zaapata AM, Bril H
H, Bleeker MCG
G, Belien JAM, SStoop R, Helderr MN. Changes in tissue compo
osition of the vaginal wall of p
premenopausal women with pprolapse. Am J O
Obstet Gynecol 2014; 210: 1688. Annual Report V
VUmc CCA 2014 –
3 of 216 167. Kerkh
hofs TMA, Ettaieb MHT, Verho
oeven RHA, Kasspers GJL, Tissin
ng WJE, Loeffen
n J, van den Heuuvel‐Eibrink MM
M, de Krijgeer RR, Haak HR. Adrenocortical carcinoma in children: First p
population‐based clinicopathoological study w
with long‐
term follow‐up. Onccol Rep 2014; 32: 2836‐2844.
168. Kessleer SM, Simon YY, Gemperlein K
K, Gianmoena KK, Cadenas C, Zimmer V, Pokorny J, Barghash A, Helms V, van Rooijen N, Bo
ohle RM, Lammert F, Hengstler JG, Mueller R,, Haybaeck J, Kiiemer AK. Fatty
y Acid Elongatioon in Non‐Alcoh
holic Steattohepatitis and Hepatocellularr Carcinoma. Intt J Mol Sci 2014
4; 15: 5762‐577
73. 169. Kirsch
h M, Berben L, Johansson E, Calza S, Eeltink CCM, Stringer J, LLiptrott S, van d
der Geest S. Nuurses' practice p
patterns in relation to adherencce‐enhancing in
nterventions in stem cell transsplant care: a su
urvey from the Nurses Group of the Europ
pean Group forr Blood and Marrow Transplanntation. European Journal of Cancer Care 20114; 23: 607‐615
5. 170. Kirtscchig G, Kuik DJ. A Dutch Cohorrt Study Confirm
ms Familial Occurrence of Anogenital Lichen SSclerosus. Wom
men's Healtth Care 2014; 3: 209. 171. Kirwaan JR, Bartlett SSJ, Beaton DE, B
Boers M, Boswoorth A, Brooks P
PM, Choy E, de Wit MPT, Guill emin F, Hewlettt S, Kvien TK, Laandewe RB, Leo
ong AL, Lyddiatt A, March L, M
May J, Montie PL, Nikai E, Richa
ards P, Voshaarr MMJH, Smeetts W, Stran
nd V, Tugwell P, Gossec L. Updating the OMERRACT Filter: Implications for Patient‐reportedd Outcomes. J R
Rheumatol 2014;; 41: 1011‐1015
5. 172. Kirwaan JR, Boers M. Biological treatment in rheum
matoid arthritis: when to stop?
?. Lancet 2014;; 383: 288‐289. 173. Kirwaan JR, Boers M, Hewlett S, Bea
aton D, Bingham
m CO, Choy E, C
Conaghan PG, d'Agostino MA, Dougados M, FFurst DE, Guilleemin F, Gossec L, Van der Heijde DM, Kloppeenburg M, Kvien
n TK, Landewe R
RBM, Mackie SLL, Matteson EL, Mease PJ, Merkkel PA, Ostergaaard M, Saketkoo LA, Simon L, SSingh JA, Strand
d V, Tugwell P. Updating the O
OMERACT Filterr: Core Areass as a Basis for Defining Core O
Outcome Sets. JJ Rheumatol 20
014; 41: 994‐999. 174. Kirwaan JR, Boers M, Tugwell P. Upd
dating the OMEERACT Filter at OMERACT 11. JJ Rheumatol 20014; 41: 975‐977. 175. Kist JW
W, de Keizer B,, Stokkel MPM, Hoekstra OS, V
Vogel WV. Recu
urrent differenttiated thyroid ca
cancer: towardss perso
onalized treatm
ment based on e
evaluation of tuumor characteristics with PET ((THYROPET Stuudy): study prottocol of a multicenter observaational cohort study. BMC Canncer 2014; 14: 4
405. 176. Kneepkens EL, Plaseencia C, Krieckaert CLM, Pascu al‐Salcedo D, van der Kleij D, N
Nurmohamed M
MT, Lopez‐Casla MT, Wieriinga R, Rispens T, Wolbink G. G
Golimumab troough levels, antidrug antibodie
es and clinical reesponse in patients with rheum
matoid arthritiss treated in dailly clinical practiice. Ann Rheum
m Dis 2014; 73: 2217‐2219. 177. Koekkkoek JAF, Dirveen L, Reijneveld JC, Postma TJ, Grant R, Pace A
A, Oberndorferr S, Heimans JJ, Taphoorn MJB
B. Epilepsy in thee end of life phaase of brain tum
mor patients: a systematic revview. Neuro‐Oncology Practicee 2014; 1: 134‐1
140. 178. Koekkkoek JAF, Kerkh
hof M, Dirven L, Heimans JJ, Poostma TJ, Vos M
MJ, Bromberg JEC, van den Beent MJ, Reijneve
eld JC, Tapho
oorn MJB. With
hdrawal of antiepileptic drugs in glioma patie
ents after long‐term seizure fre
reedom: design of a prosp
pective observaational study. BMC Neurol 20114; 14: 157. 179. Konijn NPC, van Tuyyl LHD, Bultink IEM, Lems WF, Earthman CP, vvan Bokhorst‐de van der Schueeren. Making th
he invisible visible: bioelectrical impedance analysis demonst rates unfavourable body composition in rheuumatoid arthrittis patients in clin
nical practice. SScand J Rheuma
atol 2014; 43: 2273‐278. 180. Konin
ngs R, Lely RJ, N
Nurmohamed SA
A, Hoksbergen AWJ. Successfu
ul reversal of accute kidney fail ure by ultrasou
und‐
accelerated thrombolysis of an occcluded renal arttery. Case reports in medicine 2014; 2014: 2005646.. wen MIV, Hulshof MC, Bergmaan JJGH, van der Vliet HJ, Kapitteijn E, van Laarrhoven HWM, Richel DJ, 181. Kordees S, Henegouw
Klinkeenbijl JHG, Meijjer SL, Wilminkk JW. Preoperattive Chemoradiation Therapy in Combinationn With Panitumumab for Patients With Resecctable Esophage
eal Cancer: Thee PACT Study. In
nt J Radiat Onco
ol 2014; 90: 1900‐196. mza I. Control o
of metazoan heme homeostasiis by a conserve
ed 182. Korollnek T, Zhang J, Beardsley S, Sccheffer GL, Ham
multidrug resistancee protein. Cell M
Metabolism 20114; 19: 1008‐10
019. 183. Kotovv IN, van Olst E,, Knobel PA, van der Meulen‐M
Muileman I, Fellley‐Bosco E, va
an Beusechem VVW, Smit EF, Sttahel RA, Martii TM. Whole geenome RNAi scrreens reveal a ccritical role of R
REV3 in coping w
with replicationn stress. Molecu
ular oncollogy 2014; 8: 17
747‐1759. 184. Kuipeer JL, Smit EF. C
Challenges in the Managementt of EGFR‐Mutaated Non‐Small Cell Lung Canccer Patients with Acquired Resisttance to Tyrosine Kinase Inhib
bitors. Oncologyy‐ Basel 2014; 8
87: 83‐94. 185. Kusteers‐Vandeveldee HV, Willemsen
n AE, Groenen PPJT, Kusters B, Lammens M, W
Wesseling P, Djaafarihamedani M
M, Rijntjes J, Delye H, Willemseen MA, van Herpen CM, Blokx WA. Experimen
ntal treatment of NRAS‐mutatted neurocutan
neous melanocytosis with MEK162, a MEK‐inhibitor. Actta Neuropathologica Communinications 20144; 2: 41. 186. Kwon
n ED, Drake CG,, Scher HI, Fizazzi K, Bossi A, vann den Eertwegh
h AJM, Krainer M, Houede N, SSantos R, Maha
ammedi H, Ng S, Di Maio M, Fraanke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Ko
orbenfeld E, Senngelov L, Hanse
en S, Logotthetis C, Beer TTM, McHenry M
MB, Gagnier P, LLiu D, Gerritsen WR. Ipilimuma
ab versus place bo after radiotherapy in patients with metastatic castration
n‐resistant prosstate cancer thaat had progressed after docetaaxel chemotherrapy mised, double‐ blind, phase 3 ttrial. Lancet Oncol 2014; 15: 7700‐712. (CA1884‐043): a multticentre, random
187. Lahro
ouchi N, Bossch
ha MI, Moll AC. A Child With a White Pupil. JA
AMA‐J Am Med Accoc 2014; 3111: 1799‐1800. 188. Lal JA
A, Morré SA, Braand A. The overarching framew
work of translaation and integrration into heallthcare: a case ffor the LAL modeel. Personalized
d Medicine 2014
4; 11: 41‐62. 189. Lam SSW, de Groot SM, Honkoop AH
H, Jager A, ten TTije AJ, Bos MM
MEM, Linn SC, B
Bosch J, Kroep JJR, Braun JJ, van
n Tinteren H, Bo
oven E. Paclitaxeel and bevacizu
umab with or w
without capecitaabine as first‐lin
ne treatment foor HER2‐negativve locally Annual Report V
VUmc CCA 2014 –
4 of 216 recurrrent or metastatic breast canccer: A multicenntre, open‐labell, randomised p
phase 2 trial. Euur J Cancer 2014
4; 50: 3077‐‐3088. 190. Lam TTJ, van Bodegraaven AA, Felt‐Bersma RJF. Anoorectal complicaations and funcction in patientss suffering from
m inflam
mmatory bowel disease: a seriies of patients w
with long‐term follow‐up. Int JJ Colorectal Diss 2014; 29: 923‐‐929. 191. Lameeris R, de Bruin RC, Schneiders FL, Henegouw
wen PM, Verheu
ul HMW, de Gru
uijl TD, van der VVliet HJ. Bispeccific antibody platforms ffor cancer imm
munotherapy. Crrit Rev Oncol Hemat 2014; 92: 153‐165. 192. Lawleer M, Le Chevalier T, Banks I, C
Conte P, De Lor enzo F, Meunie
er F, Pinedo HM
M, Selby P, Murpphy MJ, Johnston PG. A Bill off Rights for patients with cancer in Europe. Laancet Oncol 20
014; 15: 258‐260
0. 193. Leon LG, Gemelli M,, Sciarrillo R, Avvan A, Funel N, Giovannetti E. Synergistic Activity of the c‐M
Met and Tubulin Inhibitor ntinib (ARQ197)) with Pemetrexxed in Mesotheelioma Cells. Cu
urrent Drug Targ
gets 2014; 15: 11331‐1340. Tivan
194. Lievens Y, Defourny N, Coffey M, Borras JM, Dunsscombe P, Slotm
man B, Malicki JJ, Bogusz M, Gaasparotto C, Grau C. Radio
otherapy staffin
ng in the Europe
ean countries: Final results fro
om the ESTRO‐H
HERO survey. RRadiother Oncol 2014; 112: 178‐186. C, Roig EM, Buil LCM, Christnerr SM, Beumer JJH, Wurdinger T
T, Beijnen JH, vaan Tellingen O. ABCB1, 195. Lin F, de Gooijer MC
ABCG
G2, and PTEN Determine the R
Response of Gliooblastoma to Temozolomide a
and ABT‐888 Thherapy. Clin Can
ncer Res 2014;; 20: 2703‐2713
3. 196. Lindeenberg JJ, van d
de Ven R, Ooste
erhoff D, Sombrroek CC, Loughe
eed SM, Stam A
AGM, Koenen H
HJPM, van den E
Eertwegh AJM, Scheper RJ, dee Gruijl TD. Indu
uction of dendriitic cell maturattion in the skin microenvironm
ment by soluble
e factors m Vacc Immunoother 2014; 10: 1622‐1632. derived from colon ccarcinoma. Hum
ulation Impact o
of Introducing SStereotactic Ab
blative 197. Louiee AV, Rodriguess GB, Palma DA,, Senan S. Meassuring the Popu
Radio
otherapy for Staage I Non‐Small Cell Lung Canccer in Canada. O
Oncologist 2014; 19: 880‐885.. 198. Louiee AV, Senan S. C
Computed Tomography Surveiillance of Patien
nts with Resected Lung Cancerr: Recurrence O
Or Second Primaary Lung Cancer?. J Thorac Carrdiov Sur 2014;; 147: 1715. 199. Louiee AV, Senan S, D
Dahele M, Slotm
man BJ, Verbakeel WFAR. Stereotactic Ablative
e Radiation Theerapy for Subce
entimeter Lung Tumors: Clinicaal, Dosimetric, a
and Image Guiddance Considerrations. Int J Radiat Oncol 20144; 90: 843‐849.. 200. Louiee AV, Senan S, P
Patel P, Ferket B
BS, Lagerwaard FJ, Rodrigues G
GB, Salama JK, Kelsey C, Palmaa DA, Hunink M
MG. When Is a B
Biopsy‐Proven D
Diagnosis Necesssary Before Steereotactic Ablative Radiothera
apy for Lung Caancer? A Decisio
on Analyysis. Chest (Ameer Coll Chest Ph
hys) 2014; 146: 1021‐1028. 201. Lu Y, Kham SKY, Arifffin H, Oei AMI, Lin HP, Tan AM
M, Quah TC, Yeo
oh AEJ. Host genetic variants oof ABCB1 and ILL15 influeence treatmentt outcome in pa
aediatric acute lymphoblastic leukaemia. Britt J Cancer 2014;; 110: 1673‐168
80. 202. Mafto
ouh M, Avan A,, Funel N, Frampton AE, Fiuji H
H, Pelliccioni S, Castellano L, Galla V, Peters G
GJ, Giovannetti E. Mir‐211 Modu
ulates Gemcitabine Activity Th
hrough Downreegulation of Rib
bonucleotide Re
eductase and Innhibits the Invasive Behavvior of Pancreaatic Cancer Cellss. Nucleos Nuclleot Nucl 2014; 33: 384‐393. 203. Mafto
ouh M, Avan A,, Funel N, Paolicchi E, Vasile E,, Pacetti P, Vacccaro V, Faviana P, Campani D, Caponi S, Mam
mbrini A, Boggi U, Cantore M,, Milella M, Peters GJ, Reni M,, Giovannetti E. A polymorphissm in the prom oter is associatted with EZH2 expression butt not with outco
ome in advanceed pancreatic ccancer patients. Pharmacogen omics 2014; 15
5: 609‐618. 204. Mafto
ouh M, Avan A,, Sciarrillo R, Grranchi C, Leon LLG, Rani R, Fune
el N, Smid K, Ho
oneywell RJ, Booggi U, Minutolo
o F, Peters GJ, Giovannetti E. Syynergistic intera
action of novel lactate dehydrrogenase inhibitors with gemccitabine againstt pancrreatic cancer ceells in hypoxia. Brit J Cancer 20014; 110: 172‐1
182. 205. Makh
haria GK, Muldeer CJJ, Goh KL, A
Ahuja V, Bai JC,, Catassi C, Gree
en PHR, Gupta SD, Lundin KEAA, Ramakrishna BS, Rawat R, Shaarma H, Sood A
A, Watanabe C, Gibson PR. Issuues associated with the emerg
gence of coeliacc disease in the
e Asia‐
Pacifiic region: A working party repo
ort of the Worl d Gastroentero
ology Organizattion and the Asiian Pacific Asso
ociation of Gastrroenterology. Jo
ournal of gastro
oenterology an d hepatology 2
2014; 29: 666‐677. 206. Mand
donnet E, VersÃ
Ã©lewel de Wittt Hamer PC, Paallud J, Bauchett L, Whittle I, Duffau H. Silent Diffuse Low‐Grrade Gliom
ma: Toward Screeening and Preventive Treatm
ment?. Cancer 2
2014; 120: 1758
8‐1762. 207. Matsuura E, Atzeni FF, Sarzi‐Puttini P, Turiel M, Loppez LR, Nurmoh
hamed MT. Is atherosclerosis aan autoimmune disease?. BMC Medicine 2014
4; 12: 47. onen SA, Huangg K, Ward AD, SSenan S, Palma DA. New techn
niques for assesssing response after hypofracttionated 208. Matto
radiotherapy for lun
ng cancer. Journ
nal of Thoracic Disease 2014; 6
6: 375‐386. 209. Matto
onen SA, Palmaa DA, Haasbeekk CJA, Senan S, W
Ward AD. Earlyy prediction of lung cancer reccurrence after stereotactic radiotherapy using ssecond order te
exture statisticss. SPIE Proceedings Series 2014; 9038: 903800T. 210. Matto
onen SA, Palmaa DA, Haasbeekk CJA, Senan S, W
Ward AD. Earlyy prediction of ttumor recurrennce based on CT
T texture changges after stereo
otactic ablative radiotherapy ((SABR) for lung cancer. Med Phys 2014; 41: 0033502. 211. Mei M
M, Wondergem
m MJ, Palmer JM
M, Shimoni A, H asenkamp J, Tssai NC, Simpson
n J, Nademaneee A, Raubitschek A, Forman SJ, Krishnan
n AY. Autologou
us Transplantatiion for Transformed Non‐Hodgkin Lymphom a Using an Yttrium‐90 Ibritu
umomab Tiuxettan Conditioning Regimen. Bioology of Blood aand Marrow Tra
ansplantation 22014; 20: 2072‐2075. 212. Meijeer RP, Mertens LS, van Rhijn BW
W, Bex A, van dder Poel HG, Meinhardt W, Kerst J, Bergman AM, Fioole‐Bru
uining A, van W
Werkhoven E, H
Horenblas S. Ind
duction Chemottherapy Followed by Surgery in Node Positivee Bladder Cancer. Urolo
ogy 2014; 83: 13
VUmc CCA 2014 –
5 of 216 213. Melero I, Gaudemacck G, Gerritsen W, Huber C, Paarmiani G, Scho
oll S, Thatcher N
N, Wagstaff J, Ziielinski C, Faulkkner I, Mellsstedt H. Therapeutic vaccines ffor cancer: an ooverview of clin
nical trials. Natu
ure reviews clinnical oncology 2
2014; 11: 509‐5524. 214. Melieef CJM, Scheperr RJ, de Vries IJM. Scientific coontributions tow
ward successful cancer immunnotherapy in Th
he Netheerlands. Immun
nol Lett 2014; 1
162: 121‐126. 215. Melleema WW, Hoekk D, Postmus PE
E, Smit EF. Retroospective evalu
uation of throm
mboembolic eveents in patients with non‐
small cell lung canceer treated with platinum‐base d chemotherap
py. Lung Cancerr 2014; 86: 73‐777. 216. Mequ
ue I, Dube K, Bierhuizen L, Zan
ngo A, Veldhuijzzen NJ, Cumbe F, Feldblum PJ, van de Wijgertt JH. Willingnesss to particcipate in futuree HIV prevention trials in Beiraa, Mozambique. Afr J AIDS Res 2014; 13: 393‐‐398. 217. Merccieca C, van der Horst‐Bruinsm
ma IE, Borg AA. PPulmonary, ren
nal and neurological comorbid ities in patientss with ankyllosing spondylittis; implicationss for clinical praactice. Current Rheumatology Reports 2014; 16: 434. 218. Merkkel PA, Aydin SZZ, Boers M, Corn
nell C, Direskenneli H, Gebhart D, Hatemi G, Lu
uqmani R, Mattteson EL, Milman N, Robso
on J, Seo P, Tom
masson G. Current Status of O
Outcome Measu
ure Developmen
nt in Vasculitis. J Rheumatol 2014; 41: 593‐5598. 219. Merteens LS, Meijer R
RP, de Vries RR, Nieuwenhuijzzen JA, van der Poel HG, Bex A, Rhijn BWG, M
Meinhardt W, Horenblas S. Prosttate Sparing Cysstectomy for Bladder Cancer: 20‐Year Single Center Experience. J Urology 22014; 191: 1250‐1255. 220. Merteens LS, Meijer R
RP, Meinhardt W, van der Poeel HG, Bex A, Ke
erst J, van der H
Heijden MS, Berrgman AM, Horrenblas S, van R
Rhijn BW. Occullt lymph node m
metastases in ppatients with caarcinoma invading bladder muuscle: incidence after neoadjuvant chemo
otherapy and cyystectomy vs aft
fter cystectomyy alone. BJU INT
T 2014; 114: 67‐‐74. 221. Merteens LS, Neuzilleet Y, Horenblas S, van Rhijn BW
W. TIMELINE Landmarks in non
n‐muscle‐invasiive bladder can
ncer. Naturre reviews urology 2014; 11: 4
476‐480. 222. Miran
nda RN, Aladily TN, Prince HM
M, Kanagal‐Sham
manna R, de Jon
ng D, Fayad LE, Amin MB, Haidderi N, Bhagat G
G, Brooks GS, Shifrin DA, O'Maalley DP, Cheah CY, Bacchi CE, Gualco G, Li SY
Y, Keech JA, Hocchberg EP, Cartty MJ, Hanson SSE, RL, Castillo JJ, BBeltran BE, de B
Boer JP, Musttafa E, Sanchez S, Manning JT, Xu‐Monette ZYY, Miranda AR, Fox P, Bassett R
Chakh
hachiro Z, Ye DJ, Clark D, Youn
ng KH, Medeiroos LJ. Breast Imp
plant‐Associated Anaplastic Laarge‐Cell Lymph
homa: Long‐‐Term Follow‐U
Up of 60 Patientts. J Clin Oncol 2014; 32: 114‐1
120. 223. Molenaar RJ, Verbaaan D, Lamba S, Zanon C, Jeukeen JWM, Boots‐‐Sprenger SHE, Wesseling P, H
Hulsebos TJM, T
Troost D, van TTilborg AA, Leen
nstra S, Vanderttop WP, Bardellli A, van Noord
den CJF, Bleekerr FE. The combiination of IDH1
1 mutations and M
MGMT methylaation status predicts survival inn glioblastoma better than eith
her IDH1 or MG
GMT alone. Neu
uro‐
oncollogy 2014; 16: 1
1263‐1273. 224. Moraabito F, Bringheen S, Larocca A, Wijermans P, M
Mateos MV, Gimsing P, Mazzo
one C, Gottardi D, Omede P, Zw
weegman S, Lah
huerta JJ, Zamb
bello R, Musto P
P, Magarotto V,, Schaafsma M,, Oriol A, Juliussson G, Cerrato CC, Catalano L, G
Gentile M, Turel AI, Liberati AM
M, Cavalli M, Rossi D, Passera RR, Rosso S, Bekssac M, Cavo M, Waage A, San Miguel J, Bocca
adoro M, Sonneveld P, Palumbo A, Offidani M
M. Bortezomib,, melphalan, prrednisone (VMP
P) versus melphhalan, prednisone, thalid
domide (MPT) in elderly newlyy diagnosed muultiple myelomaa patients: A retrospective casse‐matched study. Am J Hemaatol 2014; 89: 3
355‐362. 225. Mourrits DL, Hartongg DT, Moll AC, M
Mourits MP. Maanagement of P
Porous Orbital IImplants Requi ring Explantatio
on: A Cliniccal and Histopatthological Study. Ophthalmic pplastic and reco
onstructive surg
gery 2014; 30: 5528. 226. Mulder CJJ, van Asseeldonk DP, de B
Boer KHN. Drugg Rediscovery to
o Prevent Off‐Label Prescriptioon Reduces Hea
alth Care he Netherlands.. Journal of Gasstrointestinal an
nd Liver Diseasees 2014; 23: 12
23‐125. Costss: the Case of Tiioguanine in Th
227. Muth
huri SG, Venkateesan S, Myles P
PR, Leonardi‐Beee J, Al Khuwaittir TSA, Al Mamun A, Anovadiyya AP, zziz‐Baum
mgartner E, Baeez C, Bassetti M
M, Beovic B, Berrtisch B, Bonmaarin I, Booy R, B
Borja‐Aburto VH
H, Burgmann H,, Cao B, Carrata
ala J, Denh
holm JT, Domingguez SR, Duarte
e PAD, Dubnov‐‐Raz G, Echavarrria M, Fanella S
S, Gao ZC, Geraardin P, Giannella M, Gubb
bels S, Herberg JJ, Iglesias ALH, Hoger PH, Hu XXY, Islam QT, Jim
menez MF, Kan
ndeel A, Keijzerss G, Khalili H, Knight M, Kudo K, Kusznierz G,, Kuzman I, Kwa
an AMC, Aminee IL, Langenegger E, Lankarani KB, Leo YS, Linnko R, Liu P, Madanat F, Mayo
o‐Montero E, M
McGeer A, Memish Z, Metan G,, Mickiene A, M
Mikic D, Mohn K
KGI, Moradi A, N
Nymadawa P, O
Oliva ME, Ozkan
n M, Parekh D, Paul M, Polackk FP, Rath BA, RRodriguez AH, Sarrouf EB, Seale AC, Sertogullaarindan B, Siqueira MM, Skret‐Magierlo J, Steephan F, Talarek E, Tang JW, TTo KKW, Torres A, Torun SH, Trran D, Uyeki TM
M, van Zwol A, V
Vaudry W, Vidmar T, Yokota RTTC, Zarogoulidiss P, Nguyen‐Vann‐Tam JS. Effectiveness of neu
uraminidase inhhibitors in reduccing 1pdm09 virus in
nfection: a metaa‐analysis of ind
dividual mortaality in patientss admitted to hospital with inffluenza A H1N1
particcipant data. Lan
ncet respiratoryy medicine 20114; 2: 395‐404.
228. Naipaal KAT, Verkaik NS, Ameziane N, van Deurzenn CHM, ter Bruggge P, Meijers M
M, Sieuwerts AM
M, Martens JW
W, O'Connor MJ, V
Vrieling H, Hoeijjmakers JHJ, Jonkers J, Kanaarr R, de Winter JP, Vreeswijk MP, Jager A, van Gent DC. Functtional Ex Vivo A
Assay to Select Homologous R
Recombination‐‐Deficient Breasst Tumors for P
PARP Inhibitor TTreatment. Clin Cancer Res 22014; 20: 4816‐4826. 229. Narassaraju T, Yang EE, Samy R, Tan K
K, Moorthy A, PPhoon M, van R
Rooijen N, Choi H, Chow V. Com
mbination Therrapy with Hepatocyte Growth Factor and Ose
eltamivir Confeers Enhanced Prrotection Against Influenza Virral Pneumonia. Current molecular medicine 2014; 14: 690‐‐702. 230. Nedaaeinia R, Avan A
A, Manian M, Sa
alehi R, Ghayouur‐Mobarhan M
M. EGFR as a Pottential Target foor the Treatme
ent of Pancrreatic Cancer: D
Dilemma and Co
ontroversies. CCurrent Drug Targets 2014; 15:: 1293‐1301. Annual Report V
VUmc CCA 2014 –
6 of 216 231. Neefjjes ECW, van deer Vorst MJDL, Boddaert MSA,, Zuurmond WW
WA, van der Vliet HJ, Beeker AA, van den Bergg HP, van Groeningen CJ, Vrijaaldenhoven S, V
Verheul HMW. CClinical evaluattion of the efficacy of methyln altrexone in resolving consttipation induced by different o
opioid subtypess combined with laboratory an
nalysis of immuunomodulatory and antiangiogenic effeccts of methylnaltrexone. BMC Palliative Care 2014; 13: 42.
HJ, Vieveen JM,, van Tilborg AA
AJM, Meijer S, vvan Kuijk C, van
n den Tol MP, M
Meijerink MR, Bouwman 232. Nielseen K, Scheffer H
RA. A
Anaesthetic man
nagement durin
ng open and peercutaneous irreversible electrroporation. Britt J Anaesth 201
14; 113: 985‐9992. 233. Nieuw
wenhuijzen JA, de Vries R, van
n Tinteren H, Beex A, Poel H, Me
einhardt W, Ho
orenblas S. Folloow‐up after cysstectomy: Regularly scheduled
d, risk adjusted, or symptom guuided?: Pattern
ns of recurrence
e, relapse preseentation, and survival Oncol 2014; 40:: 1677‐1685. after cystectomy. EJSO‐Eur J Surg O
V, van Meerloo JJ, Kale AJ, Moo
ore BS, Assaraf Y
YG, Anderl JL, ZZweegman S, Ka
aspers GJL, 234. Niewerth D, Jansen G, Riethoff LFV
Mechanism of D
Drug Resistance
e to the Marine
e Salinispora troopica Proteasom
me Clooss J. Antileukemiic Activity and M
Inhibitor Salinosporaamide A (Marizzomib). Mol Phaarmacol 2014; 86: 12‐19. derl J, Blank JL, v
van de Ven PM , Zweegman S, Jansen G, 235. Niewerth D, Kasperss GJL, Assaraf YG, van Meerlooo J, Kirk CJ, And
Clooss J. Interferon‐ggamma‐induced
d upregulation oof immunoprotteasome subun
nit assembly oveercomes bortezzomib resisttance in human
n hematologicall cell lines. Jourrnal of hematology & oncology
y 2014; 7: 7. 236. Niewerth D, van Meeerloo J, Jansen G, Assaraf YG, Hendrickx TC, Kirk CJ, Anderl JL, Zweegrnan S, Kaspers GJL, Cloos J. 924. Anti‐lleukemic activitty and mechanisms underlyingg resistance to the novel immunoproteasom e inhibitor PR‐9
Bioch
hem Pharmacol 2014; 89: 43‐5
51. 237. Njugu
una F, Mostert S, Slot A, Langa
at S, Skiles J, Sittaresmi MN, van de Ven PM, M
Musimbi J, Muliiro H, Vreeman RC, Kaspeers GJL. Abando
onment of child
dhood cancer trreatment in We
estern Kenya. A
Arch Dis Child 20014; 99: 609‐61
14. 238. Ocio EM, Richardson
n PG, Rajkumarr SV, Palumbo A
A, Mateos MV, Orlowski R, Kum
mar S, Usmani SS, Roodman D, Niesvizky R, Ein
nsele H, Anderson KC, Dimopo
oulos MA, vet‐Looiseau H, Mellq
qvist UH, Turessson I, Merlini G
G, Schots R, McC
Carthy P, Bergssagel L, Chim CSS, Lahuerta JJ, SShah J, Reiman A, Mikhael J, Zw
weegman S, Lonial S, Comenzoo R, Chng WJ, M
Moreau P, Sonneveld P, Ludwigg H, Durie BGM
M, Miguel JFS. N ew drugs and n
novel mechanissms of action inn multiple myelo
oma in 2013: a report from the Internation
nal Myeloma W
Working Group ((IMWG). Leukemia 2014; 28: 5525‐542. 239. Oomeens MAEM, van
n der Waal I. Ep
pidemiology of ameloblastomaas of the jaws; A
A report from tthe Netherlands. Medicina oral patolo
ogia oral y ciruggia bucal 2014; 19: E581‐E583. anschot JJB, vann Hagen P, van Os R, van Rij CM, van der Sanngen MJ, Beukema JC, 240. Oppeedijk V, van der Gaast A, van La
Rutteen H, Spruit PH,, Reinders JG, R
Richel DJ, Heneggouwen MIV, H
Hulshof MCCM. Patterns of Reccurrence After Surgery Alonee Versus Preopeerative Chemorradiotherapy annd Surgery in th
he CROSS Trialss. J Clin Oncol 22014; 32: 385‐391. 241. Ossen
nkoppele GJ, Scchuurhuis GJ. M
MRD in AML: It iis time to changge the definitio
on of remission.. Best practice &
& research clinical haematologyy 2014; 27: 265‐271. 242. Oterd
doom LH, ten D
Dam SM, de Gro
oot SDW, Arjaanns W, van Bode
egraven AA. Lim
mited long‐term
m survival after in‐hospital intesttinal failure req
quiring total parrenteral nutritioon. Am J Clin Nutr 2014; 100: 1102‐1107. 243. Oudee Voshaar MAH, ten Klooster P
PM, Glas CAW, V
Vonkeman HE, Taal E, Krishnan E, Moens HJBB, Boers M, Terrwee CB, van R
Riel PLCM, van d
de Laar MAFJ. C
Calibration of thhe PROMIS Phyysical Function Item Bank in Duutch Patients w
with Rheumatoid Arthritiis. PLoS One 20
014; 9: e92367.
244. Overb
beek A, van den
n Berg MMHE, Louwe L, Wenddel E, ter Kuile M, Kaspers G, S
Stiggelbout A, vvan D, Hilders C
C. Practice, attitu
ude and knowleedge of Dutch p
paediatric oncollogists regardin
ng female fertiliity. Neth J Medd 2014; 72: 264‐‐270. 245. Paleri V, Drinnan M,, van den Breke
el MW, Hinni M
ML, Bradley PJ, W
Wolf GT, de Bree R, Fagan JJ, H
Hamoir M, Strojjan P, Rodriigo JP, Olsen KD
D, Pellitteri PK, Shaha AR, Gen den EM, Silver CE, Suarez C, Takes RP, Rinalddo A, Ferlito A. Vascu
ularized Tissue to Reduce Fistu
ula Following Saalvage Total Laryngectomy: A Systematic Revview. Laryngosccope 2014; 124: 1848‐1853. 246. Pallassch CP, Leskov I, Braun CJ, Vorrholt D, Drake A
A, Soto‐Feliciano YM, Bent EH, Schwamb J, Ili opoulou B, Kuttsch N, van Rooijen N, Frenzel LP, Wendtner CM
M, Heukamp L,, Kreuzer KA, Haallek M, Chen JZ, Hemann MT.. Sensitizing Pro
otective Tumo
or Microenviron
nments to Antib
body‐Mediatedd Therapy. Cell 2014; 156: 590‐602. 247. Palmaa DA, Salama JK
K, Lo SS, Senan S, Treasure T, G
Govindan R, We
eichselbaum R. The oligometaastatic state‐sep
parating truth from wishful thinking. Nature
e reviews clinicaal oncology 201
14; 11: 549‐557
7. 248. Palum
mbo A, Bringhen S, Kumar SK, Lupparelli G, U smani S, Waage A, Larocca A, van der Holt B,, Musto P, Offid
dani M, Petru
ucci MT, Evangeelista A, Zweegm
man S, Nooka A
AK, Spencer A, D
Dimopoulos MA
A, Hajek R, Cavoo M, Richardson P, Lonial S, Cicccone G, Boccad
doro M, Andersson K, Barlogie B, Sonneveld P
P, McCarthy PL. Second primarry malignanciess with lenaliidomide therap
py for newly dia
agnosed myelom
ma: a meta‐anaalysis of individual patient dataa. Lancet Oncol 2014; 15: 333‐3342. 249. Pathaak JL, Bravenbo
oer N, Verschue
eren P, Lems WFF, Luyten FP, Kllein‐Nulend J, B
Bakker AD. Inflaammatory facto
ors in the circullation of patien
nts with active rrheumatoid art hritis stimulate
e osteoclastogenesis via endoggenous cytokine
e produ
uction by osteo
oblasts. Osteopo
orosis Int 2014;; 25: 2453‐2463
3. 250. Peeteers CFW, Dziuraa J, van Wesel FF. Pathophysioloogical domains underlying the
e metabolic synndrome: an alte
ernative factor analytic strateegy. Ann Epidem
miol 2014; 24: 762‐770. 251. Peguret N, Dahele M
M, Lagerwaard FF, Senan S, Slottman B. A Brief Report of 10‐Year Trends in thhe Use of Stere
eotactic demic Medical CCenter. Journall of Thoracic On
ncology 2014; 99: 114‐117. Lung Radiotherapy aat a Dutch Acad
Annual Report V
VUmc CCA 2014 –
7 of 216 252. Peitscch WK, Orouji A
A, Starink TM, H
Hausser I, Figl RR, Goerdt S. Ann
nular Atrophic P
Plaques on the Face in a Fathe
er and a Son: C
Christianson's D
Disease, a Real Entity?. ACTA D
Derm‐Venereol 2014; 94: 100‐‐101. 253. Penne EL, Nurmohamed SA. Underrdosing of Prop hylactic Valgan
nciclovir Due to Inaccurate Estiimation of Glom
merular Filtration Rate Leadiing to Severe Cyytomegaloviruss Disease in a K
Kidney Transplant Recipient. Anntimicrob Agen
nts CH 2. 2014;; 58: 1271‐1272
254. Peterrs CP, Eshuis EJ,, Toxopeus FM, Hellemons MEE, Jansen JM, D'Haens GRAM, Fockens P, Stokkkers PCF, Tuyn
nman HAREE, van Bodegravven AA, Ponsioe
en CY. Adalimu mab for Crohn''s disease: Long
g‐term sustaineed benefit in a p
population‐
based
d cohort of 438
8 patients. Journ
nal of Crohn's aand Colitis 2014
4; 8: 866‐875. 255. Peterrs GJ. Novel Devvelopments in tthe Use of Anti metabolites. Nucleos Nucleot Nucl 2014; 33:: 358‐374. 256. Peterrs GJ, Avan A, G
Gallegos‐Ruiz MI, Orsini V, Ava n A, Giovannettti E, Smit EF. Prredictive Role oof Repair Enzym
mes in the Efficaacy of Cisplatin Combinations in Pancreatic annd Lung Cancerr. Anticancer Re
es 2014; 34: 43 5‐442. 257. Peterrs GJ, Honeywell RJ, Maulandi M, Giovannettti E, Losekoot N, Etienne‐Grimaldi MC, Milanoo G, Serdjebi C,, Ciccolini J. Selecction of the Best Blood Compartment to Mea sure Cytidine D
Deaminase Activ
vity to Stratify ffor Optimal Gemcitabine Or Cyytarabine Treatment. Nucleos Nucleot Nucl 22014; 33: 403‐412. 258. Peterrs S, Smit E. Pan
n‐HER inhibition
n in EGFR wild‐ttype non‐small‐cell lung cance
er. Lancet Oncool 2014; 15: 128
89‐1290. 259. Peterrs S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, W
Wrona A, Vansteeenkiste J, Felip
p E, Marcchetti A, Savic S, Lu S, Smit E, D
Dingemans AM,, Blackhall FH, B
Baas P, Camps C
C, Rosell R, Stahhel RA. Lungsca
ape: Oncology Reseccted Non‐Smalll‐Cell Lung Canccer Outcome byy Clinical and Pathological Parameters. Journnal of Thoracic O
2014;; 9: 1675‐1684.. 260. Porceelli L, Giovannettti E, Assaraf YG
G, Jansen G, Schheffer GL, Kathman I, Azzariti A
A, Paradiso A, PPeters GJ. The E
EGFR Pathw
way Regulates B
BCRP Expressio
on in NSCLC Cellls: Role of Erlottinib. Current Drug Targets 20114; 15: 1322‐13
330. 261. Radersma M, Muldeer CJJ, Tushuizen ME. A Rare CCause of Weightt Loss and Night Sweats. Gastrroenterology 20
014; 147: E11‐EE12. 262. Rajceevic U, Knol JC, Piersma S, Bougnaud S, Fack FF, Sundlisaeter E, Sondenaa K, Myklebust R, PPham TV, Niclou
u SP, Jimen
nez CR. Colorecctal cancer derivved organotypiic spheroids maaintain essential tissue charactteristics but ada
apt their metabolism in culture. Proteome SSci 2014; 12: 399. 263. Rajku
umar SV, Dimop
poulos MA, Palu
umbo A, Blade J, Merlini G, Mateos MV, Kum
mar S, Hillengasss J, Kastritis E, R
Richardson P, Lan
ndgren O, Paivaa B, Dispenzieri A, Weiss B, Lelleu X, Zweegmaan S, Lonial S, R
Rosinol L, Zamaggni E, Jagannath S, Sezer O, Kriistinsson SY, Caaers J, Usmani SSZ, Lahuerta JJ, Johnsen HE, Be
eksac M, Cavo M
M, Goldschmid t H, Terpos E, K
Kyle RA, Andeerson KC, Durie BGM, San Migu
uel JF. Internatiional Myeloma Working Group updated criteeria for the diaggnosis of multiple myeloma. LLancet Oncol 20
014; 15: E538‐EE548. ollen WJW, Me kelenkamp H, A
Abbink FCH, Kaspers GJL, Zom er‐Kooijker K, M
Molmans 264. Raphael MF, Laheij‐de Boer AM, Ko
BHW,, Tissing WJE. C
Caphosol, a therapeutic optionn in case of cancer therapy‐ind
duced oral mucoositis in childre
en? Results from a prospective m
multicenter dou
uble blind randdomized controlled trial. Suppo
ort Care Cancerr 2014; 22: 3‐6. h LA, van Bokho
orst‐de van der Schueren, van Thuyl LHD, Bulltink IM, Lems W
WF. Validity of a Calcium Intakke List to 265. Rasch
Estim
mate Calcium Inttake in Patientss with Osteopo rosis. Austin Jo
ournal of Nutritiion and Food scciences 2014; 2
2: 1019. 266. Reulaand EA, Al Naiemi N, Raadsen SA, Savelkoul PPHM, Kluijtmans JAJW, Vanden
nbroucke‐Graulls CMJE. Prevalence of ESBL‐‐producing Enteerobacteriaceae in raw vegetaables. Eur J Clin Microbiol 2014
4; 33: 1843‐18446. 267. Roberts RL, Wallace MC, Seinen ML, Krishnaprasaad K, Chew A, Laawrance I, Prosser R, Bamptonn P, Grafton R, Simms L, ord‐Smith G, An
ndrews JM, Barrclay ML. PACSI N2 Does Not In
nfluence Thiopu
urine‐Related To
Toxicity In Patients With Radfo
Inflam
mmatory Bowel Disease. Am J Gastroenterol 2014; 109: 925
5‐927. 268. Rodriigues G, Warneer A, Bauman G,, Senan S, Lage rwaard FJ. Systematic review of fractionatedd brain metastases radiotherapy. Journal of Radiation Oncology 20144; 3: 29‐41. 269. Rodriigues G, Warneer A, Zindler J, Slotman B, Lageerwaard F. A clin
nical nomogram
m and recursivee partitioning analysis to deterrmine the risk o
of regional failure after radiosuurgery alone fo
or brain metasta
ases. Radiotherr Oncol 2014; 111: 52‐58. 270. Rolfo
o C, Fanale D, Ho
ong DS, Tsimbe
eridou AM, Pihaa‐Paul SA, Pauw
wels P, van Mee
erbeeck JP, Caruuso S, Bazan V, Cicero G, Russo
o A, Giovannettti E. Impact of m
microRNAs in Reesistance to Ch
hemotherapy an
nd Novel Target
eted Agents in N
Non‐Small Cell LLung Cancer. Cu
urr Pharm Biote
ech 2014; 15: 4775‐485. 271. Rolfo
o C, Giovannettii E, Hong DS, Bivona T, Raez LEE, Bronte G, Bufffoni L, Reguartt N, Santos ES, G
Germonpre P, T
Taron M, Passigglia F, van Meeerbeeck JP, Russso A, Peeters M
M, Gil‐Bazo I, Pauwels P, Rosell R. Novel theraapeutic strategies for patients with NSCLC
C that do not respond to treatm
ment with EGFR
R inhibitors. Cancer Treat Rev 2014; 40: 990‐‐1004. 272. Ruben JM, Bontkes HJ, Westers TM
M, Hooijberg E, Ossenkoppele GJ, van de Loossdrecht AA, de Gruijl TD. In situ loading of skiin dendritic cellls with apoptotic bleb‐derivedd antigens for th
he induction of tumor‐directedd immunity. Onco
oimmunology 20
014; 3: e946360. 273. Ruijteer J, Broere L, M
Mulder MF, van der Ploeg AT, RRubio‐Gozalbo ME, Wortmann
n SB, Visser G, W
Wijburg FA. Gro
owth in patients with mucop
polysaccharidossis type III (Sanffilippo disease)). J Inherit Meta
ab Dis 2014; 377: 447‐454. h JHL, Schuit E, T
Trum H, van Drriel W, Mol BWJJ, Kenter GG, Buist MR. Develoopment and intternal 274. Rutteen MJ, Boldingh
validaation of a progn
nostic model fo
or survival afterr debulking surggery for epithelial ovarian canccer. Gynecol On
ncol 2014; 135: 13‐18. Annual Report V
VUmc CCA 2014 –
8 of 216 275. Rutteen MJ, Dijk F, Saavci‐Heijink CD, Buist MR, Ken ter GG, van de Vijver MJ, Jordanova ES. HLA‐‐G Expression Iss an Indep
pendent Predicttor for Improve
ed Survival in H igh Grade Ovarrian Carcinomas. Journal of im
mmunology rese
earch 2014; 2014: 274584. 276. Salen
ntijn EG, Peerdeeman SM, Boffa
ano P, van den BBergh B, Forouzanfar T. A ten‐‐year analysis oof the traumaticc maxilllofacial and braain injury patient in Amsterda m: Incidence and aetiology. J Cranio Maxill SSurg 2014; 42: 7
705‐710. 277. Samp
paio‐Barros PD, van der Horst‐‐Bruinsma IE. Addverse effects o
of TNF inhibitors in SpA: are thhey different frrom RA?. Best Pract Res Cl Rh 2014; 28: 747‐‐763. 278. Sandaahl JD, Coenen EA, Forestier E, Harbott J, Johhansson B, Kern
ndrup G, Adachi S, Auvrignon AA, Beverloo HB,, Cayuela JM, C
Chilton L, Fornerod M, de Haass V, Harrison CJ , Inaba H, Kasp
pers GJL, Liang D
DC, Locatelli F, M
Masetti R, Pero
ot C, Raimondi SC, Reinhaardt K, Tomizaw
wa D, von Neuhhoff N, Zecca M, Zwaan CM, va
an den Heuvel‐EEibrink MM, Ha
asle H. t(6;9))(p22; q34)/DEK
K‐NUP214‐rearranged pediatrric myeloid leukkemia: an intern
national study oof 62 patients. Haematol‐
Hemaatol J 2014; 99: 865‐872. 279. Santeegoets SJAM, Sttam AGM, Louggheed SM, Gall H, Jooss K, Sacks N, Hege K, Lo
owy I, Scheper RJ, Gerritsen W
WR, van den EEertwegh AJM, de Gruijl TD. M
Myeloid derived suppressor and dendritic cell subsets are rellated to clinicall outcome in pro
ostate cancer p
patients treated
d with prostate GVAX and ipilim
mumab. Journa
al for Immunothherapy of Cancer 2014; 2: 31. 280. Schafftenaar E, Gorp ECM, Meenken C, Osterhaus ADME, Remeijer L, Struthers HE, McIntyre JAA, Baarsma GS, Verjans GMGM, Peters RPH.. Ocular infectio
ons in sub‐Sahaaran Africa in th
he context of hiigh HIV prevaleence. Trop Med Int Health 4. 2014;; 19: 1003‐1014
281. Schefffer HJ, Nielsen K, de Jong MC,, van Tilborg AA
AJM, Vieveen JM
M, Bouwman RA, Meijer S, vann Kuijk C, van d
den Tol MP, Meijeerink MR. Irreveersible Electrop
poration for No nthermal Tumo
or Ablation in th
he Clinical Settiing: A Systemattic Review of Saffety and Efficaccy. Journal of va
ascular and inteerventional radiology 2014; 25
5: 997‐1011. 282. Scheiid C, Sonneveld
d P, Schmidt‐Wo
olf IGH, van derr Holt B, el Jarari L, Bertsch U, Salwender H, ZZweegman S, Blau IW, K, Pfreundschuh
h M, Jie KS, Nebben K, van der V
Velde H, Duehrsen U, Schaafsm
ma MR, Lindem
mann W, Vellenga E, Weisel K
Kersten MJ, Peter N, Hanel M, Croo
ockewit S, Marttin H, Wittebol S, Bos GMJ, van Marwijk‐Kooyy M, Wijermans P, Goldsschmidt H, Lokh
horst HM. Borte
ezomib before and after autologous stem cell transplantatioon overcomes tthe negattive prognostic impact of rena
al impairment inn newly diagno
osed multiple myeloma: a subggroup analysis ffrom the HOVO
ON‐65/GMMG‐‐HD4 trial. Haem
matol‐Hematol J 2014; 99: 148
8‐154. 283. Schep
pens B, Sedeyn K, Vande Ginstte L, De Baets SS, Schotsaert M, Roose K, Housspie L, Van Ran st M, Gilbert B,, van Rooijen N, Fiers W, P
Piedra P, Saelen
ns X. Protectionn and mechanissm of action of a novel humann respiratory syncytial virus vaccine candid
date based on th
he extracellularr domain of small hydrophobic protein. Emboo Molecular Me
edicine 2014;; 6: 1436‐1454.. 284. Scheu
urleer J, Koken PW, Wessel R. Potential inter operability problems facing m
multi‐site radiatiion oncology ce
enters in The N
Netherlands. J P
Phys Conf Ser 2014; 489: 0120080. 285. Schm
mitz MF, Otten H
HG, Franssen LE
E, van Dorp S, SStrooisma T, Lokkhorst HM, van de Donk NW. SSecondary mon
noclonal gamm
mopathy of und
determined sign
nificance after aallogeneic stem
m cell transplanttation in multipple myeloma. H
Haematol‐
Hemaatol J 2014; 99: 1846‐1853. 286. Schneeiders FL, Prodo
ohl J, Ruben JM
M, O'Toole TG, SScheper RJ, Bon
nneville M, Scottet E, Verheul H
HMW, de Gruijl TD, van der V
Vliet HJ. CD1d‐R
Restricted Antiggen Presentatioon by V gamma 9V delta 2‐T Ce
ells Requires Troogocytosis. Can
ncer immu
unology researcch 2014; 2: 732‐740. 287. Schollte JB, van Desssel HA, Linssen CF, Bergmans D
DC, Savelkoul PHM, Roekaerts PM, van Mookk WN. Endotraccheal aspiraate and bronch
hoalveolar lavagge fluid analysiss: interchangeable diagnostic modalities in suuspected ventilator‐
assocciated pneumon
nia?. J Clin Micrrobiol 2014; 52 : 3597‐3604. 288. Schollte JB, van Moo
ok WN, Linssen CF, van Dessel HA, Bergmans DC, Savelkoul P
PHM, Roekaertss PM. Surveillance cultures in intensivee care units: a nationwide survvey on current p
practice providing future persppectives. J Crit Care 2014; 29: 8885. 289. Schoo
ok RM, ter Avesst MJ, van Sette
en CH, de Man FS, Smit EF, Postmus PE. Lung
g Cancer Patientts Benefit from
m Second Opiniions by Improveement of Diagn
nosis and Theraapy. Cancer and
d Clinical Oncolo
ogy 2014; 3: 433‐57. 290. Schullkens IA, Heusschen R, van den
n Boogaart V, vvan Suylen RJ, D
Dingemans AMC
C, Griffioen AW
W, Thijssen VLJL. Galectin Expreession Profiling Identifies Galectin‐1 and Galeectin‐9 Delta 5 aas Prognostic Factors in Stage I/II Non‐Small Cell Lung Canceer. PLoS One 20
014; 9: e107988
8. 291. Sciarrrillo R, Minutolo
o F, Peters GJ, G
Giovannetti E. LLactate dehydrogenase acetylation adds anoother piece to th
he puzzle of meetabolic reprogramming in pan
ncreatic cancerr. Translational gastrointestina
al cancer 2014; 3: 64‐66. 292. Seineen ML, de Boer KHN, van Bode
egraven AA, Hannauer SB, Hoen
ntjen F. Allopuriinol‐thiopurine e combination therapy in inflam
mmatory bowel disease. Cliniccal Investigationn 2014; 4: 873‐8
879. 293. Senth
hi S, Dahele M, Slotman B, Sen
nan S. Investiga ting strategies to reduce toxiccity in stereotacctic ablative rad
diotherapy for ceentral lung tumors. ACTA Onco
ol 2014; 53: 3300‐335. 294. Senth
hi S, Senan S. Su
urgery for earlyy‐stage lung canncer: Post‐operrative 30‐day ve
ersus 90‐day moortality and pattient‐
centrred care. Eur J C
Cancer 2014; 50
VUmc CCA 2014 –
9 of 216 295. Sewin
ng ACP, Caretti V, Lagerweij T,, Schellen P, Jannsen MHA, van Vuurden DG, Id
dema S, Molthooff CPM, Vande
ertop WP, Kaspeers GJL, Noske DP, Hulleman E
E. Convection e nhanced delive
ery of carmustin
ne to the murinne brainstem: A
A feasibility studyy. J Neurosci Meeth 2014; 238: 88‐94. 296. Singh
h JA, Taylor WJ, Dalbeth N, Sim
mon LS, Sundy J,, Grainger R, Alten R, March L,, Strand V, Wel ls G, Khanna D,, McQueen F, Sch
hlesinger N, Boo
onen A, Boers M
M, Saag KG, Schhumacher HR, E
Edwards NL. OM
MERACT Endorssement of Mea
asures of Outco
ome for Studiess of Acute Goutt. J Rheumatol 2014; 41: 569‐5
573. 297. Slot K
KM, Verbaan D,, Uitdehaag BM
MJ, Wesseling P,, Sanchez E, Van
ndertop WP, Pe
eerdeman SM. Can excision off meningiomas be lim
mited to resectio
on of tumor andd radiologicallyy abnormal dura
a mater? Neuroonavigation‐guided biopssies of dural tail and seeminglyy normal dura m
mater, with a re
eview of the lite
erature. World neurosurgery 2
2014; 82: e832‐‐e836. 298. Smitss AJ, Giannakop
poulos GF, Zuide
ema WP. Long‐‐term results an
nd treatment m
modalities of connservatively tre
eated Brobeerg‐Morrey typ
pe 1 radial head
d fractures. Inju ry 2014; 45: 15
564‐1568. 299. Smoleen JS, Landewee R, Breedveld FFC, Buch M, Burrmester G, Dou
ugados M, Emerry P, Gaujoux‐VViala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit MPT, Aletaha D, Bettteridge N, Bijlssma JWJ, Boers M, Buttgereit F, Combe B, Cu
utolo M, Damjjanov N, Hazes JMW, Kouloum
mas M, Kvien TKK, Mariette X, Pavelka K, van Riel PLCM, Rubbbert‐Roth A, Sch
holte‐
Voshaaar M, Scott DLL, Sokka‐Isler T, Wong JB, van dder Heijde D. EULAR recomme
endations for thhe managemen
nt of rheum
matoid arthritiss with syntheticc and biologicall disease‐modiffying antirheum
matic drugs: 20113 update. Ann Rheum Dis 20014; 73: 492‐50
09. 300. Souveerein D, Boers SSA, Veenendaal D, Euser SM, KKluijtmans JAJW
W, Den Boer JW
W. Polyclonal Sppread and Outbreaks with ESBL Positive Gentamicin Resistantt Klebsiella spp.. in the Region Kennemerland, The Netherlannds. PLoS One 2
2014; 9: e1012212. 301. Soykaan EA, Butzelaaar L, de Kroon TL, Beelen RHJ, U
Ulrich MMW, vvan der Molens ABM, Niessen FB. Minimal extracorporeal circu
ulation (MECC) does not resultt in less hypertrrophic scar form
mation as comppared to conven
ntional ulation (CECC) w
with dexamethaasone. Perfusio
on 2014; 29: 249
9‐259. extracorporeal circu
302. Stewaardson AJ, Renzzi G, Maury N, V
Vaudaux C, Broossier C, Fritsch E, Pittet D, van
n Heck M, van dder Zwaluw K, R
Reuland EA, vaan de Laar T, Sn
nelders E, Vand
denbroucke‐Graauls C, Kluijtmans JAJW, Edderr P, Schrenzel J,, Harbarth S. Exxtended‐
Specttrum beta‐Lactaamase‐Producing Enterobacteeriaceae in Hospital Food: A Risk Assessment . Infect Cont Ho
osp Ep 2014;; 35: 375‐383. 303. Straatman J, Cuesta MA, Gisbertz SSS, van der Peett DL. Value of aa step‐up diagno
osis plan: CRP aand CT‐scan to diagnose and m
manage postoperative compliccations after m ajor abdominal surgery. Rev E
Esp Enferm Dig 2014; 106: 515
5‐521. 304. Straatman J, Harmseen AM, Cuesta MA, de Lange‐dde Klerk ES, van
n der Peet DL. T
The effect of geender, age and BMI on operative C‐reactive protein le
evels after majoor abdominal su
urgery. Journal of Current Surggery 2014; 4: 61
1‐69. posto
305. Stupp
p R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hoong YK, Aldape K
KD, Lhermitte B
B, Pietsch T, Gruujicic D, Steinba
ach JP, Wick W, Tarnawski R
R, Nam DH, Hau
u P, Weyerbrocck A, Taphoorn MJB, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, mann RD, Adam
mska K, McBain C, Brandes AA,, Tonn JC, Schne
ell O, Wiegel T, Kim CY, Naborrs LB, Reardon D
DA, van Kortm
den B
Bent MJ, Hicking C, Markivskyyy A, Picard M, W
Weller M. Cilengitide combined with standardd treatment for patients with newly diagnoseed glioblastoma
a with methylatted MGMT promoter (CENTRIC EORTC 260711‐22072 study):: a mised, open‐lab
bel, phase 3 triaal. Lancet Oncol 2014; 15: 1100
0‐1108. multicentre, random
W, Oosterkamp
p HM, Walenkamp AME, Dubbbink HJ, Beerepoot LV, Hanse M
MCJ, Buter J, Hoonkoop AH, Boerman D, 306. Taal W
de Vo
os FYF, Dinjens WNM, Enting R
RH, Taphoorn M
MJB, van den Be
erkmortel FWPJJ, Jansen RLH, BBrandsma D, Brromberg JEC, vvan Heuvel I, Veernhout RM, va
an der Holt B, vaan den Bent MJJ. Single‐agent bevacizumab oor lomustine versus a comb
bination of bevaacizumab plus lomustine in paatients with recurrent glioblasttoma (BELOB trrial): a randomiised contrrolled phase 2 ttrial. Lancet Onccol 2014; 15: 9443‐953. 307. Tack GJ, Waayenberrg P, de Boer KH
HN. Beneficial ppharmacologicaal interaction be
etween thiopurrine and mesala
azine ‐ Never change a winning team. Jourrnal of Crohn's and Colitis 201
14; 8: 1743‐1744. 308. Tackee ZCA, Eikelenboom MJ, Vermeulen RJ, van dder Knaap MS, E
Euser AM, van d
der Valk P, Kasppers GJL. Childh
hood Lymp
phomatoid Gran
nulomatosis: A Report of 2 Casses and Review
w of the Literatu
ure. J Pediat Heematol Onc 2014; 36: E416‐‐E422. 309. te Wiinkel ML, Pieterrs R, Hop WCJ, Roos JC, Bokkeerink JPM, Leeuw JA, de Bruin MCA, Kollen W
WJW, Veerman A
AJP, de Groott‐Kruseman HA
A, van der Sluis IM, van den Heeuvel‐Eibrink M
MM. Bone minerral density at diiagnosis determ
mines fractu
ure rate in child
dren with acute
e lymphoblasticc leukemia treatted according to the DCOG‐ALLL9 protocol. Bo
one 2014; 59: 2223‐228. 310. ten H
Have M, Mangen MJJ, van der Valk ME, Smeeets HM, van Bod
degraven A, Dijkstra G, Fidder HH, de Jong DJJ, Pierik M, Ponsiioen CY, Jong A
A, van der Woud
de CJ, van de M
Meeberg PC, Rom
mberg‐Camps M
MJL, Clemens CCHM, Jansen JM
M, Mahm
mmod N, Bolweerk CJM, Verme
eijden JR, Sierseema PD, Leende
ers M, Oldenbu
urg B. Effect of AAging on Healthcare Costss of Inflammato
ory Bowel Disea
ase: A Glimpse iinto the Future
e. Inflamm Bowel Dis 2014; 20:: 637‐645. 311. ter Avvest MJ, Schook RM, Koudstaa
al LG, Grunbergg K, Paul MA, Sm
mit EF, Postmuss PE. Benefit off a second opinion for lung ccancer: no mettastasis to the kkidney but a synnchronous prim
mary renal neop
plasm. Case repports in oncologgy 2014; 7: 122‐1125. 312. ter Heeine R, Lange R
R, Breukels OB, Bloemendal HJJ, Rummenie RG
G, Wakker AM, de Graaf H, Beeekman FJ, van der Westterlaken MML, Malingre MM, Wielders JPM, van den Berg LL, Hendrikse NH, de Klerk JMH.. Bench to bedsside Annual Report V
VUmc CCA 2014 –
0 of 216 devellopment of GM
MP grade Rheniu
um‐188‐HEDP, aa radiopharmaceutical for targ
geted treatmennt of painful bo
one metastases. International journal o
of pharmaceuticcs 2014; 465: 317‐324. 313. Thijsssen VLJL, Griffio
oen AW. Galecttin‐1 and‐9 in anngiogenesis: A sweet couple. G
Glycobiology 20014; 24: 915‐92
20. 314. Tol JP
P, Dahele M, Do
oornaert P, Slottman BJ, Verba kel WFAR. Tow
ward optimal org
gan at risk sparring in complex volum
metric modulated arc therapy:: An exponentiaal trade‐off with target volume
e dose homogeeneity. Med Phyys 2014; 41: 0221722. 315. Tol JP
P, Dahele M, Do
oornaert PA, Slo
otman BJ, Verbbakel WFAR. Diffferent treatme
ent planning prootocols can lead
d to large differrences in organ at risk sparing. Radiother Onccol 2014; 113: 2
267‐271. 316. Torrees RJ, Peters GJ,, Puig JG. Novell Developmentss in Metabolic D
Disorders of Purine and Pyrim idine Metabolism and Theraapeutic Applications of Their A
Analogs. Nucleoos Nucleot Nucll 2014; 33: 165‐‐173. 317. Trom
mp WG, van den
n Heuvel B, Dwa
ars BJ. A new acccurate method
d of physical examination for ddifferentiation of inguinal hernia types. Surg Endosc 2014; 28
8: 1460‐1464. M, Voskuyl AE. Long‐term eva luation of antim
malarials in a Dutch SLE cohort
rt: intolerance a
and other 318. Tsangg AS, Bultink IEM
reaso
ons for non‐usee. Clin Exp Rheumatol 2014; 322: 95‐100. 319. Tugw
well P, Boers M, d'Agostino MA
A, Beaton D, Bo onen A, Binghaam CO, Choy E, Conaghan PG, Dougados M, D
Duarte C, Furst DE, Guillemin F, Gossec L, Heiberg T, Van deer Heijde DM, H
Hewlett S, Kirwa
an JR, Kvien TK, , Landewe RB, M
Mease PJ, Osterrgaard M, Simo
on L, Singh JA, Strand V, Wells G
G. Updating the OMERACT Filtter: Implicationns of Filter 2.0 tto Select Outco
ome Instrumen
nts Through Asssessment of "Trruth": Content, Face, and Consstruct Validity. JJ Rheumatol 20
014; 41: 1000‐‐1004. 320. Uzun S, Djamin RS, K
Kluijtmans JAJW
W, Mulder PG, V
Van't Veer NE, E
Ermens AA, Pelle AJ, Hoogstedden HC, Aerts JG
G, van der omycin mainten
nance treatmennt in patients w
with frequent exxacerbations of f chronic obstru
uctive Eerdeen MM. Azithro
pulmonary disease ((COLUMBUS): a
a randomised, ddouble‐blind, placebo‐controllled trial. Lancett respiratory medicine 2014;; 2: 361‐368. 321. Valkeenet K, Trappen
nburg JCA, Gossselink R, Sosef M
MN, Willms J, R
Rosman C, Piete
ers H, Scheepers
rs JJG, de Heus SSC, Reyno
olds JV, Guinan
n E, Ruurda JP, R
Rodrigo EHE, N afteux P, Fontaaine M, Kouwen
nhoven EA, Ker kemeyer M, van der Peet DL, Hania SW, van H
Hillegersberg R, Backx FJG. Pre operative inspiratory muscle ttraining to prevvent postoperative pulmonary complicaations in patients undergoing eesophageal ressection (PREPAR
RE study): studyy protocol for a
a rando
omized controlled trial. Trials 2014; 15: 144.
322. van B
Berge L, Hamilto
on EMC, Linnan
nkivi T, Uziel G, Steenweg ME, Isohanni P, Wo
olf NI, Krageloh ‐Mann I, Brautaset NJ, Andreews PI, Jong BA
A, al Ghamdi M,, van Wieringenn WN, Tannous BA, Hulleman E, Wurdinger TT, van Berkel CG
GM, Polder E, Abbink TEM, Struyys EA, Scheper GC, van der Knnaap MS. Leuko
oencephalopath
hy with brainsteem and spinal ccord 137: 1019‐
involvvement and lacctate elevation: clinical and geenetic characterrization and target for therapyy. Brain 2014; 1
1029. 323. van C
Cleef BAGL, van Benthem BHB,, Verkade EJM, van Rijen M, Kluytmans v, Sch
houls LM, Duim
m B, Wagenaar JJA, Graveeland H, Bos MEH, Heederik D
D, Kluijtmans JAJ
AJW. Dynamics o
of methicillin‐re
esistant Staphyylococcus aureu
us and meth
hicillin‐susceptib
ble Staphylococccus aureus carrriage in pig farmers: a prospective cohort stuudy. Clin Microbiol Infec 2014;; 20: O764‐O77
71. 324. van d
de Kar AL, Hougge G, Shaw AC, d
de Jong D, van Belzen MJ, Peters DJM, Henne
ekam RCM. Kelloids in Rubinsttein‐Taybi syndrrome: a clinical study. Brit J De
ermatol 2014; 1171: 615‐621.
325. van D
Dellen E, Douw L, Hillebrand A,, Hamer PCD, BBaayen JC, Heim
mans JJ, Reijneveld JC, Stam CJ . Epilepsy surge
ery outco
ome and functio
onal network alterations in lonngitudinal MEG
G: A minimum spanning tree a nalysis. Neuroimage 2014;; 86: 354‐363. 326. van d
den Boezem PB,, Velthuis S, Lou
urens HJ, Cuestta MA, Sietses C
C. Single‐incision and NOTES CCholecystectom
my, Are Theree Clinical or Cossmetic Advanta
ages When Com
mpared to Conventional Laparo
oscopic Cholecyystectomy? A C
Case‐
contrrol Study Comparing Single‐inccision, Transvagginal, and Convventional Laparo
oscopic Techniqque for Chol. W
World J Surg 2014;; 38: 25‐32. 327. van D
Denderen JC, Visman IM, Nurm
mohamed MT, SSuttorp‐Schulte
en MSA, van der Horst‐Bruinsm
ma IE. Adalimum
mab Signifficantly Reducees the Recurrence Rate of Anteerior Uveitis in Patients with A
Ankylosing Sponndylitis. J Rheum
matol 2014;; 41: 1843‐1848
8. 328. van d
der Heijden JW, Assaraf YG, Ge
erards AH, Oerl emans R, Lemss WF, Scheper R
RJ, Dijkmans BAAC, Jansen G. Meth
hotrexate analo
ogues display en
nhanced inhibittion of TNF‐alph
ha production in whole blood from RA patien
nts. Scand J Rheumatol 2014; 43
3: 9‐16. 329. van d
der Horst‐Bruinssma IE, Zack D, Szumski A, Koeenig AS. Respon
nse to: 'Impact of gender on ooutcomes in ankkylosing spond
dylitis' by Feldtkeller et al. Ann
n Rheum Dis 20014; 73: E3. 330. van d
der Linden N, vaan Gils CWM, Pescott CP, Buteer J, Uyl‐de Groot CA. Cetuximab in locally addvanced squamous cell carcin
noma of the heead and neck: generalizability oof EMR 062202
2‐006 trial results. Eur Arch Otoo‐Rhino‐L 2014
4; 271: 1673‐‐1678. 331. van d
der Mijn JC, Sol N, Mellema W,, Jimenez CR, P iersma SR, Dekkker H, Schulte LLM, Smit EF, Brroxterman HJ, SSkog J, Tanno
ous BA, Wurdin
nger T, Verheul HM. Analysis oof AKT and ERK1/2 protein kinases in extrace llular vesicles issolated from blood of patien
nts with cancerr. Journal of Exttracellular Vesiccles 2014; 3: 25
VUmc CCA 2014 –
– Appendix 3: Scieentific output ‐ 61 of 216 332. van d
der Poel MWM,, Mulder WJM, Ossenkoppele GJ, Maartense E, Wijermans P
P, Hoogendoornn M, Schouten HC. Como
orbidity and treeatment decisio
on‐making in eldderly non‐Hodggkin's lymphom
ma patients: a suurvey among haem
matologists. Netth J Med 2014; 72: 165‐169. 333. van d
der Slegt J, Kluijtmans JAJW, M
Mulder PGH, Veeen EJ, Ho GH, vvan der Laan L. S
Surgical Site Inffection after Multiple Groin
n Incisions in Peeripheral Vascular Surgery. Surrgical infectionss 2014; 15: 752‐756. 334. van d
der Veldt AAM, Lammertsma A
AA. In Vivo Imagging as a Pharm
macodynamic M
Marker. Clin Canncer Res 2014; 20: 2569‐
2577. 335. van d
der Veldt AAM, Smit EF, Comans EFI, Lammerrtsma AA. Effeccts of chemothe
erapy on the paarotid and subm
mandibular gland
ds in head and n
neck cancer pattients treated w
with chemoradiiotherapy. Strahlenther Onkoll 2014; 190: 221
1‐222. 336. van d
der Veldt AAM, Smit EF, Lamm
mertsma AA. Do es Drug Accumulation in Bone
e Explain the Eff
fficacy and Toxicity of Docettaxel in Prostatte Cancer?. Clin
nical genitourinaary cancer 2014
4; 12: E63‐E64. 337. van d
mertsma AA. Pituuitary Gland: D
Do Anticancer Drugs Sit in the TTurkish Saddle??. J Clin Onco
ol 2014; 32: 851
1‐852. 338. van d
der Waal I. Oral potentially ma
alignant disordeers: Is malignan
nt transformatio
on predictable aand preventable?. Medicina oral patolo
ogia oral y ciruggia bucal 2014; 19: E386‐E390
0. 339. van D
Dijk FS, Sillence DO. Osteogene
esis imperfecta : Clinical diagno
osis, nomenclatture and severiity assessment. Am J Hum Geneet A 2014; 164: 1470‐1481. 340. van EEggermond AM,, Schaapveld M
M, Lugtenburg PPJ, Krol ADG, de Boer JP, Zijlstra JM, Raemaekkers JMM, Krem
mer LCM, Roesiink JM, Louwman MWJ, Alema
an BMP, van Leeeuwen FE. Riskk of multiple primary malignanncies following treatment of Ho
odgkin lymphom
ma. Blood 2014; 124: 319‐327.. 341. van G
Gerven NMF, Veerwer BJ, Witte
e BI, van Erpecuum KJ, van Buurren HR, Maijers I, Visscher AP, Verschuren EC
C, van Hoek B, Coenraad MJ, Beu
uers UHW, de M
Man RA, Drenthh JPH, den Oude
en JW, Verdonk
k RC, Koek GH, Brouwer JT, Gu
uichelaar MMJ,, Vrolijk JM, Mu
ulder CJJ, van N
Nieuwkerk CMJ,, Bouma G. Epid
demiology and clinical charactteristics of auto
oimmune hepattitis in the Neth
herlands. Scand
d J Gastroenterool 2014; 49: 1245‐1254. 342. van G
Groeningen I, Arnoldus J, Perenboom R, Voskkuyl AE. Red fistt and muscle we
eakness with a rare complicattion. BMJ Case Reports 2014; : . 343. van LLaar JM, Farge D
D, Sont JK, Nara
aghi K, Marjanoovic Z, Larghero J, Schuerwegh AJ, Marijt EWAA, Vonk MC, Schattenberg AV, M
Matucci‐Cerinic M, Voskuyl AE,, van de Loosdrrecht AA, Daike
eler T, Kotter I, S
Schmalzing M, Martin T, Liourre B, Weiner SM, Kreuterr A, Deligny C, D
Durand JM, Emeery P, Machold KR, Sarrot‐Reynauld F, Warnaatz K, Adoue DFFP, Consttans J, Tony HP, Del Papa N, Fa
assas A, Himsell A, Launay D, LLo Monaco A, Philippe P, Querre I, Rich E, Wessthovens R, Griffitths B, Saccardi R, van den Hoo
ogen FH, Fibbe WE, Socie G, Gratwohl A, Tyndall A. Autologoous Hematopoietic Stem Cell TTransplantation
n vs Intravenouss Pulse Cyclophhosphamide in D
Diffuse Cutaneo
ous Systemic Scclerosis A Randomized Cliniccal Trial. JAMA‐JJ Am Med Acco
oc 2014; 311: 24490‐2498. 344. van LLith SAM, Navis AC, Verrijp K, N
Niclou SP, Bjerkkvig R, Wesselin
ng P, Tops B, Molenaar R, van Noorden CJF, LLeenders WPJ. Glutamate as cchemotactic fue
el for diffuse gl ioma cells: Are they glutamate
e suckers?. BBAA Reviews on Ca
ancer 2014;; 1846: 66‐74. 345. van M
Maurik JFMM, SSchouten MEL, ten Katen I, vann Hal M, Peterss EJG, Kon M. Ultrasound Findiings After Surgical Decompression of th
he Tarsal Tunne
el in Patients W
With Painful Diabetic Polyneuro
opathy: A Prosppective Random
mized Studyy. Diabetes Caree 2014; 37: 767
7‐772. 346. van M
Maurik JFMM, vvan Hal M, van Eijk RPA, Kon M
M, Peters EJG. V
Value of Surgica
al Decompressioon of Compressed Nerves in thee Lower Extrem
mity in Patients w
with Painful Diaabetic Neuropaathy: A Random
mized Controlledd Trial. Plast Re
econstr Surg 2014; 134: 325‐332. 347. van M
Montfrans C, Stok MM, Geerke
ens M. Biology of chronic wou
unds and new trreatment strateegies. Phlebology 2014; 29: 1665‐167. 348. van R
Reij EJF, Dahele M, van de Ven PM, de Haan PPF, Verbakel WFAR, Smit EF, Slotman BJ, Senaan S. Changes in non‐
surgiccal managemen
nt of stage III no
on‐small cell lu ng cancer at a ssingle institutio
on between 20003 and 2010. AC
CTA Oncol 2014;; 53: 316‐323. 349. van R
Rijn S, Wurdingeer T, Nilsson J. M
Multiplex functtional biolumine
escent reporters using Gaussiaa luciferase fussed to epito
ope tags in an im
mmunobinding assay. Methodds Mol Biol 2014
4; 1098: 231‐24
47. 350. van TTilborg AAJM, Sccheffer HJ, Niellsen K, van Waeesberghe JHTM
M, Comans EFI, v
van Kuijk C, vann den Tol MP, M
Meijerink MR. TTranscatheter C
CT Arterial Portography and CTT Hepatic Arterriography for Liv
ver Tumor Visuualization duringg Percu
utaneous Ablatiion. Journal of vvascular and in terventional raadiology 2014; 2
25: 1101‐1111. 351. van TTuyl LHD, Lems WF, Boers M. M
Measurement oof stiffness in patients with rhe
eumatoid arthrritis in low disea
ase activity or rem
mission: a systeematic review. BMC Musculosskel Dis 2014; 15: 28. 352. van V
Veen‐Berkx E, Elkhuizen SG, Ka
alkman CJ, Buhrre WF, Kazemie
er G. Successful interventions tto reduce first‐‐case tardin
ness in Dutch university mediccal centers: Ressults of a nation
nwide operating
g room benchm
mark study. American Journ
nal of Surgery 2014; 207: 949‐9
959. 353. van V
Vollenhoven RF,, Mosca M, Berrtsias G, Isenbe rg D, Kuhn A, Le
erstrom K, Aringer M, Bootsm
ma H, Boumpas D, Bruce IN, Ceervera R, Clarkee A, Costedoat‐Chalumeau N, Czirjak L, Derkssen R, Dorner T, Gordon C, Graaninger W, Hou
ussiau F, Inancc M, Jacobsen SS, Jayne D, Jedryyka‐Goral A, Le vitsky A, Levy R
R, Mariette X, M
Morand E, Navaarra S, Neumann I, Rahm
man A, Rovensky J, Smolen J, V
Vasconcelos C, V
Voskuyl AE, Vosss A, Zakharova H, Zoma A, Schhneider M. Treat‐to‐
Annual Report V
VUmc CCA 2014 –
2 of 216 targeet in systemic lu
upus erythemattosus: recommeendations from
m an internation
nal task force. AAnn Rheum Dis 2014; 73: 958‐9967. 354. van W
Weyenberg SJB.. Esophageal intramural pseuddodiverticulosiss. Dig Liver Dis 2
2014; 46: 87. 355. van W
Weyenberg SJB.. Grading the Q
Quality of Bowell Preparation. V
Video Journal and Encyclopediia of GI Endosco
opy 2014; 1: 6155‐618. 356. van W
Weyenberg SJB,, Stam FJ, Marsman W. Successsful endoscopic closure of spo
ontaneous esopphageal rupture (Boerrhaave syndrom
me). Gastrointest Endosc 20144; 80: 162. 357. Vandenbroucke‐Graauls CMJE. Antim
microbial resisttance in the Netherlands: a natural experimeent?. Frontiers in public health 2014; 2: 5. ngomyelia. Neu
uropediatrics 20014; 45: 3‐9. 358. Vandertop WP. Syrin
no L, Dooms C, Douillard JY, Faaivre‐Finn C, Lim
m E, di Rocco G, Senan S, Van Schil P, Verone
esi G, 359. Vanstteenkiste J, Crin
Staheel R, Peters S, Feelip E. 2nd ESM
MO Consensus CConference on LLung Cancer: ea
arly‐stage non‐ssmall‐cell lung cancer conseensus on diagno
osis, treatmentt and follow‐up . Ann Oncol 2014; 25: 1462‐14
474. 360. Verhaagen HJMP, de Leeuw DC, Roe
emer MGM, Deenkers F, Pouwe
els W, Rutten A, Celie PH, Osseenkoppele GJ, SSchuurhuis GJ, Sm
mit L. IGFBP7 in
nduces apoptossis of acute myeeloid leukemia cells and synergizes with chem
motherapy in su
uppression of leu
ukemia cell survvival. Cell death
h & disease 20114; 5: e1300. 361. Verkaade E, Kluijtman
ns JAJW. Livestock‐associated Staphylococcu
us aureus CC398
8: Animal reservvoirs and huma
an infecttions. Infect Geenet Evol 2014; 21: 523‐530. 362. Verm
meer T, Orsini R,, Daams F, Nieu
uwenhuijzen G, Rutten H. Anasstomotic leakag
ge and presacraal abscess form
mation after locally advanced recctal cancer surggery: Incidence,, risk factors and treatment. EJJSO‐Eur J Surg O
Oncol 2014; 40: 1502‐
1509. 363. Verscchuren EC, Ong DE, Kamm MA
A, Desmond PV, Lust M. Inflam
mmatory bowel disease cancer surveillance in a tertiary referrral hospital: atttitudes and practice. Internal M
Medicine Journ
nal 2014; 44: 40
0‐49. 364. Verstteeg KS, Koninggs IRHM, Lagaayy AM, van de Looosdrecht AA, V
Verheul HMW. Prediction of trreatment‐relate
ed toxicity and o
outcome with ggeriatric assessm
ment in elderly patients with ssolid malignancies treated wit h chemotherap
py: a systematic review. A
Ann Oncol 2014
4; 25: 1914‐19118. 365. Vink L, Starink TM. B
Bullous acral lichen sclerosus w
with milia. Clin Exp Dermatol 2
2014; 39: 400‐4401. 366. Warm
mann SW, Godzzinski J, van Tintteren H, Heij H,, Powis M, Sand
dstedt B, Graf N
N, Fuchs J. Miniimally invasive nephrectomy for Wiilms tumors in children ‐ data from SIOP 2001. J Pediatr Surg 2014; 49: 15444‐1548. 367. Wefeers AK, Warmutth‐Metz M, Poschl J, von Buereen AO, Monoraanu CM, Seelos K, Peraud A, Toonn JC, Koch A, Pietsch T, Herolld‐Mende C, Mawrin C, Schouten‐van Meeteeren AYN, van V
Vuurden DG, von Hoff K, Rutkoowski S, Pfister SM, Kool M, Scchuller U. Subgrroup‐specific lo
ocalization of huuman medullob
blastoma based
d on pre‐operattive MRI. ACTA Neuro
opathol 2014; 1
127: 931‐933. 368. Wegn
ner I, Wilhelm A
AJ, Lambrechts DAJE, Sander J W, Lindhout D.. Effect of oral ccontraceptives on lamotrigine
e levels depends on comediccation. ACTA Neurol Scand 20014; 129: 393‐398. 369. Weisss A, Berndsen R
RH, Dubois M, M
Muller C, Schiblli R, Griffioen AW, Dyson PJ, Nowak‐Sliwinskaa P. In vivo anti‐tumor activiity of the organ
nometallic ruthe
enium(II)‐arenee complex [Ru(e
eta(6)‐p‐cymene)‐Cl‐2(pta)] (RRAPTA‐C) in hum
man 742‐4748. ovariaan and colorecttal carcinomas.. Chemical Sciennce 2014; 5: 47
370. Weisss A, van Beijnum
m JR, Bonvin D,, Jichlinski P, Dyyson PJ, Griffioe
en AW, Nowak‐‐Sliwinska P. Loow‐dose angiosttatic tyrosine kinase inhib
bitors improve photodynamic therapy for can
ncer: lack of vascular normalizzation. Journal of Cellular Molecular Mediicine 2014; 18: 480‐491. and M
371. Wellss G, Beaton DE, Tugwell P, Boe
ers M, Kirwan JRR, Bingham CO,, Boonen A, Bro
ooks P, Conaghaan PG, d'Agostiino MA, Douggados M, Furst D
DE, Gossec L, Guillemin F, Hellliwell P, Hewlettt S, Kvien TK, Landewe RB, Maarch L, Mease P
PJ, Osterrgaard M, Simo
on L, Singh JA, Strand V, Van deer Heijde DM. U
Updating the OMERACT Filter: : Discrimination
n and Feasibility. J Rheumaatol 2014; 41: 1
1005‐1010. 372. Wiggenraad R, Bos P
P, Verbeek‐de K
Kanter A, Nijehoolt GLA, van Santvoort J, Taphoorn M, Struikm
mans H. Pseudo‐
otherapy of braain metastases: lesion analysiss using MRI cinee‐loops. J Neuro
o‐Oncol progrression after steereotactic radio
2014;; 119: 437‐443.. 373. Wildee JCH, Aronson DC, Sznajder B, van Tinteren H
H, Powis M, Okkoye B, Cecchetto G, Audry G, Fuchs J, von Scchweinitz D, Heeij HA, Graf N, B
Bergeron C, Prittchard‐Jones K, van den Heuve
el‐Eibrink MM, di Carli M, Oldeenburger F, San
ndstedt B, de Krraker J, Godzinsski J. Nephron SSparing Surgeryy (NSS) for Unilaateral Wilms Tu
umor (UWT): Thhe SIOP 2001 Exxperience. Pediaatr Blood Canceer 2014; 61: 217
75‐2179. 374. Wilheelm AJ, den Burrger JCG, Swart EL. Therapeutiic Drug Monitoring by Dried Blood Spot: Proggress to Date an
nd Future Direcctions. Clinical P
Pharmacokinetics 2014; 53: 9661‐973. M, Savelkoul PHM, Masclee AA
A, Pierik MJ, Pen
nders J. Fecal M
Microbial Compoosition of Ulcerrative 375. Wills ES, Jonkers DM
Colitis and Crohn's D
Disease Patients in Remission aand Subsequen
nt Exacerbation. PLoS One 20114; 9: e90981. erwen B, Plug M
M, van der Wal A, zenne‐Goette E, Song JY, dde Vries S, Dekkker M, te 376. Wojciechowicz K, Caantelli E, Van Ge
Mismatch Repaair ‐ Deficient In
ntestinal Cryptss and Accelerate
es Riele H. Temozolomide Increases the Number of M
origenesis in a M
Mouse Model o
of Lynch Syndroome. Gastroentterology 2014; 1
147: 1064‐10722. Tumo
Annual Report V
VUmc CCA 2014 –
3 of 216 377. Wojtu
uszkiewicz AM,, Barcelos A, Du
ubbelman B, Abbreu R, Brouwer C, Bokkerink JJP, de Haas V, dde Groot‐Kruseman H, Janseen G, Kaspers GJL, Cloos J, Pete
ers GJ. Assessm
ment of Mercaptopurine (6Mp) Metabolites aand 6Mp Metab
bolic Key‐
Enzym
mes in Childhoo
od Acute Lymph
hoblastic Leukeemia. Nucleos N
Nucleot Nucl 20
014; 33: 422‐4333. 378. Wond
dergem MJ, Dijkstra FS, Visserr OJ, Zweegmann S, Ossenkoppele GJ, Witte BII, Janssen JJWM
M. Allogeneic transplantation afteer reduced‐inten
nsity conditioniing with fludaraabine‐CY for bo
oth indolent andd aggressive lym
mphoid maliggnancies. Bone Marrow Transp
pl 2014; 49: 5133‐518. 379. Wongg DR, Pierik M, Seinen ML, van
n Bodegraven A
AA, Gilissen LPL, Bus P, Bakker JA, Masclee AAAM, Neef C, Enggels LGJB, Hooyymans PM. The pharmacokinettic effect of adaalimumab on th
hiopurine metabolism in Crohnn's disease patiients. Journ
nal of Crohn's and Colitis 2014; 8: 120‐128. 380. Woutters MCA, Dijkggraaf EM, Kuijje
er ML, Jordanovva ES, Hollema H, Welters MJP
P, van der Hoevven JJM, Daeme
en T, Kroep JR, Niijman HW, van der Burg S. Inte
erleukin‐6 receeptor and its ligaand interleukin‐6 are oppositee markers for su
urvival and infiltrration with matture myeloid ce
ells in ovarian caancer. Oncoimm
munology 2014
4; 3: e962397. 381. Wurd
dinger T, Deumeelandt K, van der Vliet HJ, Wessseling P, de Grruijl TD. Mechanisms of intimaate and long‐disstance cross‐talk between gglioma and mye
eloid cells: How
w to break a vicious cycle. BBA
A Reviews on Caancer 2014; 184
46: 560‐
575. 382. Yang MY, Lee YB, Ah
hn CH, Kaye J, Fine T, Kashi R, O
Ohne O, Smid K
K, Peters GJ, Kim
m DJ. A Novel CCytidine Analog, RX‐3117, Show
ws Potent Efficacy in Xenograftt Models, even in Tumors thatt Are Resistant tto Gemcitabinee. Anticancer Re
es 2014; 34: 69951‐6959. 383. Yi H, Lanctot KL, Bon
nt L, Bloemers B
BLP, Weijermann M, Broers CJM
M, Li A, Kiss A, M
Mitchell I, Paes B. Respiratory Syncytial Virus Prophylaxis in Down Syndrom
me: A Prospectivve Cohort Stud
dy. Pediatrics 20
014; 133: 1031‐‐1037. an Noort PI, Schhaapveld RQJ, vvan Beijnum JR, Griffioen AW, Storm G, Schifffelers RM, 384. Youseefi A, Bourajjaj M, Babae N, va
Mastrobattista E. An
nginex lipoplexe
es for delivery oof anti‐angioge
enic siRNA. International journnal of pharmace
eutics 2014;; 472: 175‐184.. 385. Zaal A
A, Zweemer RP, Zikan M, Duse
ek L, Querleu D,, Lecuru F, Batss AS, Jach R, Sev
vcik L, Graf P, KKlat J, Dyduch G
G, von Menssdorff‐Pouilly S,, Kenter GG, Ve
erheijen RHM, CCibula D. Pelvic Lymphadenecttomy Improvess Survival in Pattients With Cervical Cancer With
h Low‐Volume Disease in the SSentinel Node A
A Retrospective
e Multicenter CCohort Study. In
nt J Gynecol Cancer 2014; 24: 303‐311.. 386. Zabriskie MS, Eide C
CA, Tantravahi SSK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, KKonopleva M, C
Cortes JE, ur EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, d
de Lange T, Hernnandez‐Boluda JC, Kantaarjian H, Jabbou
Ossen
nkoppele GJ, Prress RD, Chuah C, Goldberg SLL, Wetzler M, M
Mahon FX, Etienne G, Baccaranni M, Soverini S,, Rosti G, Roussselot P, Friedman R, Deiningerr M, Reynolds KKR, Heaton WL, Eiring AM, Pom
micter AD, Khorrashad JS, Kelle
ey TW, Baron
n R, Druker BJ, Deininger MW,, O'Hare T. BCRR‐ABL1 Compou
und Mutations C
Combining Key Kinase Domain
n Positions Confeer Clinical Resisstance to Ponattinib in Ph Chro mosome‐Positiive Leukemia. C
Cancer Cell 20144; 26: 428‐442.. 387. Zindleer JD, Slotman B, Lagerwaard FJ. Patterns of distant brain re
ecurrences afte
er radiosurgery alone for newly diagn
nosed brain metastases: Impliccations for salvaage therapy. Raadiother Oncol 2014; 112: 2122‐216. 388. Zweeegman S, Palum
mbo A, Bringhen
n S, Sonneveld PP. Age and aging in blood disorders: multiple myeloma. Hae
ematol‐
Hemaatol J 2014; 99: 1133‐1137. Scienttific publica
ations 1.
2.
3.
4.
5.
6.
7.
8.
9.
nduit Anastomo
osis; in Cuesta M
MA, Bonjer HJ, (eds): Case Bieree SSAY. Case on Cervical Leakagge of an Esophaago‐gastric Con
2014: 5‐8. Studies of Postoperaative Complicattions after Digeestive Surgery 2
Bieree SSAY. Case on Postoperative Hiatal Herniatioon After Esophageal Resection
n; in Cuesta MAA, Bonjer HJ, (eds): Case Studies of Postoperaative Complicattions after Digeestive Surgery 2
2014: 17‐21. n Anastomotic Problem After Esophageal Ressection for Canccer; in Cuesta M
MA, Bonjer Bieree SSAY. Case on Suspicion of an
HJ, (eeds): Case Studiies of Postoperative Complicattions after Dige
estive Surgery 2
2014: 1‐4. Blom RLGM, van derr Peet DL, van B
Berge Henegouuwen MI. Prevention and Treattment of Majorr Complicationss After hageal Surger; in Cuesta MA, B
Bonjer HJ, (eds)): Treatment off Postoperative Complications s After Digestive
e Surgery. Esoph
Springer 2014: 53‐73
3. Boerss M, Kirwan JR, Tugwell P. The
e OMERACT Hanndbook 2014: .
Busch
h ORC, Cuesta M
MA. Case on Co
omplication Afteer Surgical Treaatment of a Klatskin Tumor; inn Cuesta MA, Bo
onjer HJ, (eds): Case Studies o
of Postoperative Complicationns after Digestivve Surgery 2014
4: 211‐217. Clooss J, Niewerth D,, Jansen G. Precclinical studies oon the molecular basis of Borttezomib resistaance and modallities to overccome resistancee in hematological malignanci es; in Dou QP, (ed): Resistance
e to proteasom
me inhibitors in cancer 2014: 181‐204. meyer M, Guterrrez RA, Zaldivarr K, Crusius JBA
A, Pena AS. Celiaac disease in El Salvador; in Roodrigo L, Pena A
AS, (eds): Crom
Celiacc disease and n
non‐celiac gluten sensitivity. Baarcelona, Spain
n, OmniaScience
e. 2014: 75‐88. Cuestta MA. Case on Bile Leakage (a
and Portal Veinn Thrombosis) A
After Whipple P
Procedure; in Cuuesta MA, Bonjjer HJ, (eds): Case Studies o
VUmc CCA 2014 –
4 of 216 10. Cuestta MA. Case on Complications After Conservaatively Treated Appendicular P
Phlegmon; in C uesta MA, Bonjjer HJ, (eds): Case Studies o
4: 307‐310. 11. Cuestta MA. Case on Complications After ERCP andd Sphincterotomy; in Cuesta M
MA, Bonjer HJ, ((eds): Case Studies of Posto
operative Comp
plications after Digestive Surgeery 2014: 193‐1
198. 12. Cuestta MA. Case on Complications of Ileostomy; iin Cuesta MA, B
Bonjer HJ, (eds)): Case Studies oof Postoperativve Comp
plications after Digestive Surge
ery 2014: 501‐5506. 13. Cuestta MA. Case on Complications of Intestinal M
Malrotation; in C
Cuesta MA, Bon
njer HJ, (eds): CCase Studies of Posto
operative Comp
350. 14. Cuestta MA. Case on Fecal Incontine
ence After Delivvery; in Cuesta MA, Bonjer HJ, (eds): Case St udies of Postop
perative Comp
ery 2014: 529‐5531. 15. Cuestta MA. Case on Hepatic Abscess After Doublee Lesion (CBD and Right Hepattic Artery) Durinng Cholecystecttomy; in Cuestta MA, Bonjer H
HJ, (eds): Case SStudies of Postooperative Comp
plications after Digestive Surggery 2014: 171‐174. 16. Cuestta MA. Case on Impaction of E
Enteral (Bezoarss) During Enteral Feeding Afte
er Whipple Proccedure; in Cuesta MA, Bonjeer HJ, (eds): Casse Studies of Po
ostoperative Coomplications aftter Digestive Su
urgery 2014: 2339‐242. 17. Cuestta MA. Case on Intra‐abdomin
nal Bleeding witth Shock as Con
nsequence of Necrotizing Panccreatitis; in Cue
esta MA, Bonjeer HJ, (eds): Casse Studies of Po
urgery 2014: 2663‐266. 18. Cuestta MA. Case on Jaundice and H
Hepatic Failure After Major He
epatic Resection; in Cuesta MAA, Bonjer HJ, (eds): Case Studies of Postoperaative Complicattions after Digeestive Surgery 2
2014: 141‐145.
Pouch Anastom
mosis Fisteling (V
Vaginal and Perrineal); in Cuestta MA, Bonjer H
HJ, (eds): 19. Cuestta MA. Case on Late Ileoanal P
Case Studies of Posttoperative Com
mplications afterr Digestive Surggery 2014: 415‐‐420. 20. Cuestta MA. Case on Leakage After Ileoanal Pouchh Anastomosis; in Cuesta MA, Bonjer HJ, (eds ): Case Studies of Posto
operative Comp
370. 21. Cuestta MA. Case on Lost Stones in Abdomen Afteer Laparoscopic Cholecystectomy; in Cuesta M
MA, Bonjer HJ, (eds): Case Studies of Postoperaative Complicattions after Digeestive Surgery 2
2014: 192‐203.
22. Cuestta MA. Case on Postoperative Bleeding of a CColorectal Anasstomosis; in Cue
esta MA, Bonjeer HJ, (eds): Case Studies of Postoperative Complications after Digestive Suurgery 2014: 483‐486. 23. Cuestta MA. Case on Problems After Coloanal Ana stomosis (Stenosis Coloanal A
Anastomosis andd Frequent Stools and Soilin
ng); in Cuesta M
MA, Bonjer HJ, (eds): Case Studdies of Postoperative Complica
ations after Diggestive Surgery 2014: 401‐
405. 24. Cuestta MA. Case on Ureter Lesion During Laparosscopic Low Ante
erior Resection; in Cuesta MA,, Bonjer HJ, (ed
ds): Case Studies of Postoperaative Complicattions after Digeestive Surgery 2
2014: 407‐413.
HJ. Case Studiess of Postoperattive Complicatio
ons after Digesttive Surgery. Sppringer 2014: . 25. Cuestta MA, Bonjer H
26. Cuestta MA, Bonjer H
HJ. Case on Adrrenal Insufficienncy (Addison Syyndrome), Afterr Removal of ann Adenocarcino
oma of the Adren
nal Gland; in Cu
uesta MA, Bonjer HJ, (eds): Ca se Studies of Postoperative Co
omplications affter Digestive Surgery 2014: . 2014, pp 283
3‐286.. 27. Cuestta MA, Bonjer H
HJ. Case on Sple
enic and Portal Vein Thrombosis After Splene
ectomy; in Cuessta MA, Bonjer HJ, (eds): Case Studies of Posttoperative Com
mplications afterr Digestive Surggery 2014: 273‐‐278. HJ. Establishing the Pneumopeeritoneum and Closing the Tro
ocar Sites Durinng Laparoscopicc Surgery; 28. Cuestta MA, Bonjer H
in Cuesta MA, Bonjeer HJ, (eds): Treatment of Posttoperative Com
mplications After Digestive Surggery 2014: . 201
14, pp 319‐
321.. HJ. Prevention a
and Treatment of Major Comp
plications After Surgery of Klattskin Tumors; in Cuesta 29. Cuestta MA, Bonjer H
MA, B
Bonjer HJ, (eds)): Treatment off Postoperative Complications After Digestive
e Surgery. Sprinnger 2014: 161‐‐169. 30. Cuestta MA, Bonjer H
HJ. Treatment o
of Postoperativ e Complication
ns After Digestiv
ve Surgery. Spriinger 2014: . 31. Cuestta MA, Brosenss RPM. Case on Recurrence of Intestinal Obsttruction Because of Adhesionss; in Cuesta MA, Bonjer HJ, (eeds): Case Studiies of Postoperative Complicattions after Dige
estive Surgery 2
2014: 329‐334. 32. Cuestta MA, Gisbertzz SS. Case on Po
ostoperative Bleeeding After W
Whipple Procedu
ure; in Cuesta M
MA, Bonjer HJ, ((eds): Case Studies of Postoperaative Complicattions after Digeestive Surgery 2
2014: 219‐226.
opic 33. Cuestta MA, Mulder CJJ. Case on Late Stenosis of BBiliodigestive Anastomosis witth Cholangitis (AAfter Laparosco
Choleecystectomy); in Cuesta MA, B
Bonjer HJ, (eds) : Case Studies o
of Postoperative Complicationns after Digestivve Surgery 2014: 205‐209ñ. 34. Cuestta MA, Nijhof H
HW. Case on Ste
enosis After Low
w Anterior Rese
ection; in Cuestta MA, Bonjer H
HJ, (eds): Case SStudies of Posto
operative Comp
399. 35. Cuestta MA, Rodriguez M. Case on C
Carcinoid Discoovered in the Ap
ppendix; in Cue
esta MA, Bonjerr HJ, (eds): Case
e Studies of Postoperative Complications after Digestive Suurgery 2014: 299‐305. Care and Closurre of Open Abdomen Approach; in Cuesta MAA, Bonjer HJ, (eds): Case 36. Cuestta MA, Tuynmaan JB. Case on C
Studies of Postoperaative Complicattions after Digeestive Surgery 2
2014: 559‐563.
nt of Open Abdoomen Approach; in Cuesta MA
A, Bonjer HJ, (e ds): Treatmentt of 37. Cuestta MA, Tuynmaan JB. Treatmen
Posto
operative Comp
plications After Digestive Surgeery. Springer 20
014: 313‐317.
38. Cuestta MA, van der Peet DL. Case o
on An Acute Coomplication of tthe Wilkie Syndrome; in Cuestta MA, van der Peet DL, (eds): Case Studies o
VUmc CCA 2014 –
5 of 216 39. Cuestta MA, van der Peet DL. Case o
on Duodenal Leeakage After Re
esection of an Insulinoma of thhe Head of the Pancreas; in Cuesta MA, Bonjeer HJ, (eds): Casse Studies of Poostoperative Co
omplications aftter Digestive Suurgery 2014: 11
11‐115. 40. Cuestta MA, van der Peet DL. Case o
on Dysphagia A
After Laparoscopic Nissen Fund
doplication; in CCuesta MA, Bonjer HJ, (eds): Case Studies o
4: 49‐54. on Iatrogenic Essophageal Perfforation; in Cuesta MA, Bonjerr HJ, (eds): Case
e Studies of 41. Cuestta MA, van der Peet DL. Case o
Posto
operative Comp
0. 42. Cuestta MA, van der Peet DL. Case o
on Peritonitis A
After Unrecogniized Perforation
n Following Helller Myotomy a
and Dor Fundoplication for A
Achalasia; in Cuesta MA, Bonjeer HJ, (eds): Casse Studies of Po
ostoperative Coomplications aftter Digesstive Surgery 20
014: 61‐64. 43. Cuestta MA, van der Peet DL. Case o
on Small Bowell Ischemia During Neoadjuvant Chemotherappy for Gastroesophageal Juncttion Cancer; in C
Cuesta MA, Bon
njer HJ, (eds): CCase Studies of Postoperative Complications aafter Digestive Surgery 2014: 341‐344. orselaar RJA. Ca
ase on Rectoveesical Fistula Aftter LAR; in Cuessta MA, Bonjer HJ, (eds): Case Studies of 44. Cuestta MA, van Moo
Posto
operative Comp
437. 45. Cuestta MA, Veenhof AAFA, de Dioss Franco J. Casee on Perineal Prroblems After A
APR; in Cuesta M
2014: 439‐445.
46. Cuestta MA, Winterss HAH. Case on Anorectal Adennocarcinoma in
n Colorectal Cro
ohn's Disease; inn Cuesta MA, B
Bonjer HJ, (eds): Case Studies o
4: 421‐425. an Everdingen J , Faber W, Toonstra J, 47. de Riee MA. Academiic Medical Centter University oof Amsterdam; in Menke H, Va
van V
Vloten W, (eds): Dutch contributions to derm
matology. Overveen, Belvedere
e 2014: 27‐48. 48. Diepeenhorst GMP. C
Case on Compliccated Retainedd Stones in the C
Common Bile D
Duct After Multiiple Sphinctero
otomies by ERCP; in Cuesta MA,, Bonjer HJ, (eds): Case Studie s of Postoperattive Complicatio
ons after Digest
stive Surgery 20
014: 185‐
192. 49. Gisbeertz SS, Cuesta MA. Case Studies of Postoperaative Complicattions after Dige
estive Surgery 22014: 447‐453. 50. Gisbeertz SS, Straatm
man J, Cuesta MA. General Prinnciples of Recoggnition of Major Complication s Following Surrgery of the D
Digestive Tract; in Cuesta MA, Bonjer HJ, (edss): Treatment off Postoperative
e Complicationss After Digestive
e Surgery. Springer 2014: 27‐33
3. 51. Gutieerrez Moreno M
M, Tuynman JB, Cuesta MA. Caase on Leakage Distal Anastom
mosis After Low w Anterior Resecction (LAR) Witho
out Protective Ileostomy; in Cuesta MA, Bonjjer HJ, (eds): Caase Studies of P
Postoperative CComplications after Digesstive Surgery 20
014: 497‐500. 52. Gutieerrez Moreno M
M, Tuynman JB, Cuesta MA. Caase on Leakage Distal Anastom
mosis After Low w Anterior Resecction with Proteective Ileostomyy; in Cuesta MA
A, Bonjer HJ, (edds): Case Studie
es of Postopera
ative Complicattions after Digestive Surgeery 2014: . 53. Harteemink KJ. Case o
on Trachea‐gasstric Conduit Fisstula After Esop
phageal Resection; in Cuesta M
2014: 39‐44. 54. Konin
ngs R, Bonjer HJJ, Kazemier G. P
Prevention andd Treatment of Major Complica
ations after Surrgery of the Spleen, Adren
nal Glands, and
d Distal Pancrea
atectomy; in Cuuesta MA, Bonje
er HJ, (eds): Tre
eatment of Posttoperative Com
mplications After Digestive Surgery. Springer 20
014: 199‐207.
55. Lacy A
AM, Delgado S,, Cuesta MA. Is There Less Moorbidity After Laaparoscopic Surrgery?; in Cuestta MA, Bonjer H
HJ, (eds): Treattment of Postop
perative Complications After D
Digestive Surgery. Springer 2014: 35‐46. 56. Leem
mans CR. Commentary on: Rationale for electiive modified ne
eck dissection b
by Byers RM, W
Wolf PF and Balla
antyne AJ; in Shaah JP, (ed): A ceentury of progress in head andd neck cancer. N
New York, NY, U
USA, Jaypee Broos 2014: 175‐177. 57. Lelij R
RJ, Cuesta MA. Case on Gastricc Bleeding Caussed by a Necrottizing Pancreatiitis with Extenssive Pseudocystt Formation; in Cuestaa MA, Bonjer H
HJ, (eds): Case SStudies of Posto
operative Comp
ery 2014: 243‐2246. 58. Lelij R
RJ, Cuesta MA. Case on Reblee
eding After Initiial Coiling of Sp
pleen Trauma; in Cuesta MA, BBonjer HJ, (eds): Case Studies of Postoperaative Complicattions after Digeestive Surgery 2
2014: 279‐282.
RP, Brakenhoff R
RH, de Bree R, vvan Es RJJ. Nieu
uwe onderzoeksmethoden om
m occulte 59. Leusink FKJ, Takes R
n van mondkankker op te sporeen; Het tandhee
elkundig jaar 20
014 2014: 197‐2207. halskliermetastasen
uesta MA. Case
e on Complex RRecurrent Fistula‐in‐Ano; in Cuesta MA, Bonjeer HJ, (eds): Casse Studies 60. Martiinez Lopez S, Cu
of Postoperative Complications after Digestive Suurgery 2014: 523‐527. 61. Meijeerink WJHJ. Preevention and Treatment of Maajor Complicatio
ons After Laparoscopic Ileoceccal and Right Co
olectomy; in Cuesta MA, Bonjeer HJ, (eds): Treatment of Posttoperative Com
mplications After Digestive Surggery. Springer 2
2014: 217‐
228. dez C, Cuesta M
MA. Case on Reccto‐Vaginal Fisttula After LAR; in Cuesta MA, B
Bonjer HJ, (eds)): Case Studies of 62. Mend
Posto
operative Comp
431. 63. Metzger M, Wilimass JA, Harif M, Israels T. Wilms TTumour in Countries with Limited Resources;; in Pritchard‐Jo
ones K, hildhood. Berlinn Heidelberg, Springer 2014: 2
271‐281. Domee JS, (eds): Renal Tumors of Ch
AC, de Boer MR
64. Moll A
R, Bouter LM, SSingh N. Principples of Clinical E
Epidemiology; C
Clinical Ophthal mic Oncology. Berlin Heideelberg, Springer 2014: 1‐11. Annual Report V
VUmc CCA 2014 –
6 of 216 65. Nijho
of HW, Cuesta M
MA. Case on Lea
akage After LARR and Coloanal Anastomosis; in Cuesta MA, BBonjer HJ, (eds)): Case Studies of Postoperaative Complicattions after Digeestive Surgery 2
2014: 377‐383.
66. Nurm
mohamed MT. V
Vasculaire reum
matologie: een oonverwachte nieuwkomer; in van de Putte L,, Geurts M, Linsssen A, Moolenburgh T, (eds): Canon van d
de reumatologi e. Haarlem, DH
HCH 2014: 58‐60
0. man MM. Case on Recurrence of Acute Gallsttone Pancreatittis: When to Perform a Choleccystectomy?; in Cuesta 67. Poelm
MA, B
Bonjer HJ, (eds)): Case Studies of Postoperativve Complication
ns after Digestive Surgery 20114: 181‐184. 68. Poelm
man MM, Muld
der CJJ. Case on Distal Duoden al Perforation A
After Double Ba
alloon Endosco py (DBE); in Cuesta MA, Bonjeer HJ, (eds): Casse Studies of Po
urgery 2014: 1005‐109. 69. Sillevvis Smitt JH, van
n Everdingen JJE
E, Starink TM, vvan der Horst H
HE. Dermatoven
nereologie voorr de eerste lijn. Houten, Bohn Stafleu van Loghum 2014: . eductive Surgerry and Heated IIntraperitoneal 70. te Veelde EA, Verwaaal VJ. Case on Complications Foollowing Cytore
motherapy; in Cuesta MA, Bonjjer HJ, (eds): Caase Studies of P
Postoperative C
Complications aafter Digestive SSurgery Chem
2014: 479‐482. der Horst‐Bruinssma IE. EULAR online course ffor Rheumatolo
ogists: update chapter Medica l Treatment of 71. van d
Spondyloarthritis; Conceptrichtlijn NVR Update: bbiologicals in reumatoide artrittis, axiale SpA een artritis psoriatica 2014: . 72. van d
der Peet DL, Cueesta MA. Prevention and Trea tment of Comp
plications after Small Bowel Suurgery and Appeendicectomy; in Cuesta MA, Bo
onjer HJ, (eds): Treatment of P
Postoperative C
Complications AAfter Digestive SSurgery. Springer 2014: 209‐2
215. 73. van d
mertsma AA. Possitron emission
n tomography as a method for r measuring dru
ug delivery to tum
mors in vivo: th
he example of [11C]docetaxel;; in Marcucci F, Corti A, Berensson R, (eds): Wa
Ways to improve
e tumor uptakke and penetrattion of drugs in
nto solid tumorss. Frontiers Ressearch Topics 2014: 50‐56. 74. Veenhof AAFA. Casee on Presacral A
Abscess and Sinnuses After LAR; in Cuesta MA,, Bonjer HJ, (edds): Case Studies of operative Comp
390. Posto
75. Veenhof AAFA, Sietsses C, Cuesta M
MA. Postoperativve Consequencces of Surgical T
Trauma; in Cuessta MA, Bonjer HJ, (eds): Treattment of Postop
perative Complications After D
Digestive Surgery. Springer 2014: 1‐5. 76. Verm
meulen CFW, Beemelman WA, C
Cuesta MA. Is Thhere Less Morb
bidity After Fastt‐Track Surgeryy?; in Cuesta MA
A, Bonjer HJ, (eeds): Treatmentt of Postoperative Complicatioons After Digesttive Surgery. Sp
pringer 2014: 477‐52. 77. Verm
morken JB, Leem
mans CR, Gregoire V. Managem
ment fo recurre
ent and metasta
atic sqamous ceell carcinoma of the head and n
neck; in Kerr d, Haller D, van de Velde C, Baum
mann M, Saijo N, (eds): Oxford
d textbook of ooncology. Oxforrd Univeersity Press 201
14: 39‐55. 78. Vos C
CG. Case on Anaastomotic Leakage Following SSmall Bowel Resection; in Cuesta MA, Bonjerr HJ, (eds): Case
e Studies of Posto
operative Comp
314. 79. Wein RO, Chandra R
RK, Leemans CR
R, Weber RS. Dissorders of the H
Head and Neck; in Brunicardi FF, Anderson D, Bilar T, n D, Hunter J, M
Matthews J, Pollock RE, (eds): SSchwartz's princciples of surgerry. McGraw‐Hilll Publishers 201
14: 565‐
Dunn
604. dergem MJ, Klu
uin‐Nelemans JC
C, van den Bergg‐de Ruiter. Cyttologie, immuunfenotypering een cytogenetica; 80. Wond
Leerb
boek Hematologgie 2014: . 81. Zweeegman S, van deer Horst HE, Jan
nssen JJWM. Heematologie; in V
Van Everdingen
n J, Wiersma T, Schobben AFA
AM, (eds): Diagn
nose en therapiie 2015‐2016. B
Bohn Stafleu vaan Loghum 2014
4: 227‐273. Professsional publications 1.
2.
3.
4.
5.
6.
7.
Agca R, Turk S, Janseen D, Turkstra FF, Gerritsen M, Nurmohamed MT. Statine sto
oppen bij start ccolchine?Nederlands matologie 2014
4: 9‐16. Tijdscchrift voor Reum
Blufp
pand HN, Kaspers GJL, Bökenka
amp A. Nierfun ctie bij kindere
enTijdschr Kinde
ergeneeskd 2011482: 126‐133. Bonteen MJM, Kaspeers GJL, Bökenka
amp A. Infectioon prevention in
n Dutch hospita
alsNed Tijdschr Geneeskd 2014158: . Cham
muleau MED, dee Jong D, Kluin P
PM, Lugtenburgg PM, Kersten M
MJ, Veelken H, van Imhoff GW
W. De conseque
enties van de geenetische variattie van het diffu
uus grootcellig B‐cellymfoom vvoor het klinische beleidNed TT Hematologie 2
201411: 347‐3353. Crem
mers EMP, de Sw
wart L, Huls G, W
Wijermans P, Loowenberg B, Jo
ongen‐Lavrencicc M, de Greef G
GE, Muus P, van
n Marwijk Kooy R, Schaafsma R
R, van Maanen T, Deenik W, BBeeker A, Brouw
wer RE, Hoogendoorn M, Bree ms DA, Raaijma
akers HGP, Verho
oef GE, Schouteen HC, von dem
m Borne P, Kubaall J, Biemond B
BJ, Vellenga E, O
Ossenkoppele G
GJ, de Witte TJM
M, van de Loosd
drecht AA. Het myelodysplastiisch syndroom:: adviezen voorr ijzerchelatie bij secundaire heemochromatosseNed T Hemaatologie 201411: 215‐221. Dann
ner SA. Hiv‐1 inttegrase remmers, een goede aaanwinst voor h
het antiretrovirale arsenaalTijddschrift voor infecttieziekten 2014
49: 30‐36. de Brree E, de Bree R
R. Verbetering vvan afstandsmeetastasevrije en
n melanoomspe
ecifieke overlevving door toepa
assing van de schildwachtklierp
procedure bij patiënten met e en middeldik m
melanoom en occulte lymfeklieermetastasenN
Ned Tijdschr Onco
ol 201411: 176‐1
VUmc CCA 2014 –
7 of 216 8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
Deijen CL, Dunker M
MS. Zeldzame oo
orzaak perforattie ileostomaNe
ed Tijdschr Hee
elkd 201423: 488‐49. Geeraaedts LMG. Beh
handeling van ttraumapatienteen met levensbe
edreigend bloedverliesTijdschhrift voor Bloedtransfusie 201477: 49‐51. Gootjjes EC, Buffart TTE, Neerincx M, Offringa TJ, Veerhoef C, Verhe
eul HMW. De O
ORCHESTRA‐stuudie. Een onderzoek voor patiënten met uitgeezaaide darmkanker waarbij beehandeling mett een combinatie van chemothherapie en tum
mor‐
'debu
ulking' wordt veergeleken met b
behandeling meet alleen chemotherapieNed T
Tijdschr Oncol 2201411: 118‐12
21. Griffioen GHMJ, Dah
hele MR, Haasb
beek CJA, Slotm
man BJ. Radiothe
erapie bij oligom
metastasenNedd Tijdschr Onco
ol 201411: 51‐588. Jansssen JJWM, Corn
nelissen JJ, Posthuma EFM, Fal kenburg JHF, B
Biemond BJ, Boss GMJ, Petersenn EJ, Schattenberg AVMB, WM, Verhoef G
GEG, Vellenga E
E, Westerweel PPE, Ossenkoppe
ele GJ. Richtlijnen voor de behhandeling van chronische Smit W
myelo
oïde leukemie aanno 2014Ned T Hematologiee 201411: 185‐1
198. Knegtt CJ, Wintzen T,, Rustemeyer T
T. Contactallerg ie voor corticossteroiden: een overzicht als huulpmiddel in de
e prakttijkNed tijdschr dermatol vene
ereol 201424: 4449‐452. Koekkkoek JAF, Boddaert MSA, Taph
hoorn MJB. Glioomen: tot het e
einde in de aanv
val tegen epileppsie; toediening anti‐
epilep
ptica in de laatsste levensfaseN
Ned Tijdschr Geeneeskd 201415
58: . Linn A
AJ, van Weert JCM, Schouten BC, Smit EG, vaan Bodegraven AA, van Dijk L. Een communiccatietypologie vvoor het besprreken van theraapietrouwbarrièresPharm We ekbl 20148: . Lok C
CAR, Han SR, Tru
um JW, Ottevan
nger PB, Kuppeens SMI, Amantt F. Gynaecologische maligniteeit tijdens de gravid
diteitNed tijdscchr obstet gynaecol 2014127: 332‐336. Loweenberg B, Ossen
nkoppele GJ. De
e nieuwe AML‐sstudie voor volw
wassenen tot 6
66 jaar (HO132))Ned T Hematologie 201411: 368‐371. Menkko FH, Jacobs M
MAJM, Mager JJJ, Nicolai JJ, Meensenkamp AR, Aalfs CM. Een jjongeman met intestinale polyyposis en epistaaxisNed Tijdsch
hr Geneeskd 2014158: . Nieuw
wenhuis DH, Veelthuis S, Bonjer HJ, Sietses C. Transanale totale mesorectale excisie: een nnieuwe behandeling voor het reectumcarcinoomNed Tijdschr Geneeskd 20144158: . Niewerth D, Franke NE, Jansen G, vvan Meerloo J, ZZweegman S, d
de Haas V, Clooss J, Kaspers GJLL. Het voorspellen van de gevoeeligheid van kin
nderleukemiece
ellen voor proteeasoomremmersTijdschr Kindergeneeskd 2011482: 79‐88. Nurm
mohamed MT. B
BiosimilarsNede
erlands Tijdschrrift voor Reumaatologie 20141: 28‐30. Ossen
nkoppele GJ, Lo
owenberg B. HO
OVON 81: fase 22‐studie naar to
olerantie en efffectiviteit van dde toevoeging vvan bevaccizumab aan staandaardtherapie voor patiëntten met acute m
myeloïde leukem
mieNed T Hemaatologie 201411: 228‐
233. Ancker W, Wessters TM, Ossennkoppele GJ, de
e Gruijl TD, van de Loosdrecht AA. Actieve Ruben JM, van den A
immu
uuntherapie bij acute myeloïde leukemieNedd T Hematologie
e 201411: 91‐99. Schefffer HJ, Nielsen K, van Tilborg A
AAJM, Vieveenn JM, van den To
ol MP, Meijerin
nk MR. Irreversiibele elektropo
oratie: een nieuw
we vorm van beeeldgestuurde ttumorablatieNeed Tijdschr Gen
neeskd 2014158
8: . Terwijn M. Minimalee restziekte en leukemische sttamceldetectie bij acute myelo
oïde leukemie: nieuwe aanpak van mingNed T Hem
matologie 2014111: 177‐181. klinische besluitvorm
CLM, Hugtenburrg JG, Ossenkopppele GJ, Jansse
en JJWM. Chronische myeloÃˉˉde leukemie e
en Thieleen N, Boons CC
theraapietrouwNed TT Hematologie 2
201411: 241‐2447. Thieleen N, van der H
Holt B, Verhoef GEG, Ammerla an RAHM, Sonn
neveld P, Janssen JJWM, Deennik W, Falkenbu
urg JHF, Kersten MJ, Sinnige HAM, Schipperrus M, Schattennberg A, van Marwijk Kooy R, Smit WM, Chu IWT, Valk PJM,, Ossen
nkoppele GJ, Co
ornelissen JJ. Hoge dosis imatiinib versus hogge dosis imatinib
b in combinatiee met intermed
diaire dosis cytaraabine bij patiën
nten met nieuw
w gediagnosticeeerde chronisch
he myeloïde leu
ukemie: een gerrandomiseerde
e fase III‐
studiee van de Stichtiing HematoOnccologie voor Voolwassenen NNed T Hematologie 201411: 1133‐123. van B
Buijtenen JM, Po
oos HP. Snijden
n zonder grenzeen: Traumastagges in Kaapstad tijdens de opleeidingNed Tijdschr Heelkd 201423: 35‐37. van d
de Donk NWCJ, Palumbo A, Joh
hnsen HE, Engeelhardt M, Gay F, Gregersen H, Hajek R, Klebeer M, Ludwig H, Morgan G, Mu
usto P, Plesner T, Sezer O, Terpos E, Waage A
A, Zweegman S, Einsele H, Son
nneveld P, Lokhhorst HM. De kliinische relevaantie en aanpak van MGUS en
n MGUS‐gerelatteerde ziekten:: aanbevelingen
n van het 'Europpean Myeloma Netw
work'Ned T Hem
matologie 20141
11: 302‐317. van d
der Horst‐Bruinssma IE. Spondyyloartritis: nieuw
we naam voor o
oude bekenden
nNed Tijdschr G
Geneeskd 2014158: . van M
Montfrans C, Egggen C. Ulcus crruris: wat is nie uw en wat is efffectief?Ned tijd
dschr dermatoll venereol 2014
42014: 166‐1169. van M
Montfrans C, Qu
uint KD. Special EADV congress Building BridgesNed tijdschr dermatol vene reol 20142014: 1‐35. van R
Ruitenburg T, vaan Montfrans C
C. Een patiënt m
met een rood be
een; toepassing
g van de nieuwee richtlijn cellulitis/erysipelasN
Nurse Academyy 2014: . Vuurden DG. Aaanknopingspuntten voor nieuw
we therapieen te
egen hersentum
moren bij kindeerenOncology N
News van V
Intern
national 20148: 5. van W
Weert S, Karago
ozoglu KH. Delp
phian lymph nodde metastasis in oral squamou
us cell carcinom
maNed Tijdschr Keel‐, Neus‐ Oorheelkd 20
VUmc CCA 2014 –
8 of 216 36. Verbrrugge CSE. Therrapeutic targeting of protein ddegradation in aautoimmunity a
and cancerNedderlands Tijdsch
hrift voor Reum
matologie 20141
17: 25‐28. 37. Vis AN
N. Profylactisch
he tepelbestraliing bij bicalutam
midegebruik vaanwege prostaa
atkanker: kliniscche noodzaak?T
Tijdschrift voor Urologie 20144
4: 13‐17. daunorubicineKKinderarts en 38. Zwaan CM, Kaspers GJL. Recidief accute myeloide lleukemie: rol van liposomaal d
Weteenschap 20146:: 39. 39. Zweeegman S, Levin MD, van de Donk NWCJ, Ghideeyalemayehu W
W, Sonneveld P. 'Feasibility' enn effectiviteit va
an melfaalan‐prednison‐‐bortezomib (M
MPV) bij patiëntten > 75 jaar me
et een nieuw ge
ediagnosticeerdd multipel mye
eloom; een niet‐ggerandomiseerde fase II‐studieNed T Hematoologie 201411: 29‐32. D
Dissertation
ns 1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
d Monitoring of Nasopharyngeeal Carcinoma in
n Jakarta, Adham M. The Role of EBV Markerrs in Diagnosis, Treatment and
nesia. 9/25/201
15. (Co)promoto
or(es): Middelddorp JM, Tan IB
B, Hermani B, Greijer AE . Indon
Avan A. Genetic anaalyses and new models to imprrove therapeuttic strategies in pancreatic canncer. 1/13/2014
4. promotor(es): P
Peters GJ, Giova
annetti E, Würddinger T, Schuurrhuis GJ . (Co)p
Bachaas C. Characterization of relap
psed Acute Myeeloid Leukemia.. 11/11/2014. (Co)promotor(ees): Kaspers GJLL, Cloos J, Schuu
urhuis GJ . Glim JE. Dermal and
d oral wound he
ealing: Similarit ies and distincttions. 10/22/20
014. (Co)promot
otor(es): Beelen RHJ, nd M, Niessen FFB . Evertts V, van Egmon
Haan JC. Analysis of chromosomal copy number aaberrations in ggastrointestinal cancer. 3/17/22014. (Co)promotor(es): A, Ylstra B, Nagtegaal ID . Meijeer GA, Punt CJA
Huijskens EGW. Clinical microbiologist; the gatekeeeper of inform
mative diagnostics. 11/25/20144. (Co)promoto
or(es): oopmans M, Rossen JWA, Peetters MF . Kluijtmans JAJW, Ko
Lee P
P. New Applications of Broncho
oscopic Techniqques. 12/16/20
014. (Co)promotor(es): Postmuus PE Sutedja G
GT . Lo Gaalbo AM. Hypotthyroidism after treatment of laryngeal or hyypopharyngeal carcinoma. 10//22/2014. (Co)p
promotor(es): d
de Bree R, Leem
mans CR . Maass KW. Minimallyy invasive esophagectomy for cancer; beyond
d techniques. 2
2/12/2014. (Co))promotor(es): Cuesta MA, vvan der Peet DLL, Biere SSAY . Mafto
ouh M. New avvenues in pancrreatic cancer: Taargeting epigen
netics and meta
abolism. 6/11/22014. (Co)prom
motor(es): Peterrs GJ, Giovanneetti E . Meijeer RP. High risk bladder cancerr: staging, risk aassessment and
d treatment opttions. 1/23/20114. (Co)promotor(es): Horen
nblas S, Bex A . Merteens LS. Muscle‐‐invasive bladder cancer: stag ing and treatment. 5/2/2014. (Co)promotor((es): Horenblas S, Rhijn BWG . Niewerth D. Proteassome Inhibitorss in Acute Leukeemia. 11/14/20
014. (Co)promotor(es): Kasperrs GJL, Zweegman S, Cloos J, Jansen G . Posth
huma de Boer J. Towards targe
eted treatmentt for osteosarco
oma. 7/3/2014. (Co)promotor((es): van Royen
n BJ, Kaspeers GJL, Helder MN, van Beuse
echem VW . Senth
hi S. Treatment of early‐stage lung cancer: Cuure and survivo
orship. 9/24/201
14. (Co)promottor(es): Senan SS, Slotman BJ . van d
der Heuvel B. In
nguinal hernia surgery perspecctives beyond Lichtenstein. 2/2
28/2014. (Co)ppromotor(es): Bonjer HJ, Dwarrs BJ . van d
der Weijden MA
AC. The Paradoxx of Bone and BBeyond: Clinical studies of early Spondylarthrropathies. 12/1
17/2014. (Co)p
promotor(es): Lems WF, Dijkmans BAC, van dder Horst‐Bruinssma IE. van V
Vuurden DG. Inn
novative treatm
ment targets in pediatric high‐grade brain tum
mors. 3/17/20115. (Co)promoto
or(es): Kaspeers GJL, Vanderrtop WP, Cloos J, Hulleman E . Verbrrugge CSE. Therrapeutic targeting of protein ddegradation in aautoimmunity a
and cancer. 9/118/2014. (Co)p
promotor(es): Lems WF, Schep
per RJ ,Jansen G
G, de Gruijl TD .
Warm
moes MO. Proteeomics of experimental breastt cancer: Towarrds application of novel proteiin biomarkers in the clinic. 1/13/2014. (C
Co)promotor(ess): Boven E, Jim enez CR, Jonke
ers J . Program
m 5 – Qualitty of life Scientiffic papers re
efereed Annual Report V
VUmc CCA 2014 –
9 of 216 1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
Aaron
nson NK, Mattioli V, Minton O
O, Weis J, Johan sen C, Dalton SSO, de Leeuw IM
M, Stein KD, Alffano CM, Mehnert A, de Boer A, van de Poll‐FFranse L. Beyon
nd treatment ‐ Psychosocial an
nd behavioural issues in canceer survivorship research and p
practice. EJC Suppl 2014; 12: 54‐64. Alberrs G, Francke ALL, de Veer AJE, Bilsen J, Onwutteaka‐Philipsen
n BD. Attitudes of nursing stafff towards involvvement in medical end‐of‐life d
decisions: A nattional survey sttudy. Patient Ed
duc Couns 2014
4; 94: 4‐9. Alberrti P, Rossi E, Co
ornblath DR, Merkies ISJ, Postm
ma TJ, Frigeni B
B, Bruna J, Velasco R, Argyriouu AA, Kalofonos HP, Psimaaras D, Ricard D
D, Pace A, Galie E, Briani C, la TTorre C, Faber C
CG, Lalisang RI, Boogerd W, Brrandsma D, Koe
eppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G. Physician‐assesssed and patien
nt‐reported outco
ome measures in chemotherapy‐induced sennsory peripheraal neurotoxicity: two sides of thhe same coin. A
Ann Oncol 2014;; 25: 257‐264. Anqu
uinet L, Rietjenss J, Heide A, Bru
uinsma S, Jansseens MJPA, Delie
ens L, Addingto
on‐Hall J, Smithsson WH, Seymo
our J. Physicians' experien
nces and perspe
ectives regardinng the use of co
ontinuous sedattion until deathh for cancer pattients in ontext of psych
hological and exxistential sufferring at the end of life. Psycho‐oncology 2014;; 23(5): 539‐546. the co
Avan A, Avan A, Le LLarge TYS, Mam
mbrini A, Funel N
N, Maftouh M, Ghayour‐Moba
arhan M, Cantoore M, Boggi U, Peters GJ, Pacettti P, Giovannettti E. AKT1 and SELP Polymorpphisms Predict tthe Risk of Deve
eloping Cachexxia in Pancreaticc Cancer Patients. PLoS One 2
2014; 9: e10805
57. Blommestein HM, Franken MG, Ve
erelst SGR, van A
Agthoven M, Huijgens PC, Uyl‐de Groot CA. AAccess to expen
nsive e: Should we bee concerned?. Neth J Med 201
14; 72: 235‐2411. canceer drugs in Dutcch daily practice
Blommestein HM, Isssa DE, Pompen
n M, Ten Hoor G
G, Hogendoorn M, Joosten P, Zweegman S, H
Huijgens PC, Uyl‐de Groot CA. C
Cost‐effectiveneess of rituximab
b as maintenancce treatment fo
or relapsed follicular lymphom
ma: results of a population‐based sttudy. Eur J Haem
matol 2014; 92 : 398‐406. Boelee FW, de Leeuw
w IM, Cuijpers P
P, Reijneveld JC,, Heimans JJ, Klein M. Internett‐based guided self‐help for glioma patients with depresssive symptoms: design of a raandomized con
ntrolled trial. BM
MC Neurol 20144; 14: 81. Reijneveld JC, d
de Leeuw IM, H eimans JJ. Symptom managem
ment and qualitty of life in glioma Boelee FW, Klein M, R
patients. CNS Oncology 2014; 3: 37
7‐47. Boelee FW, Zant M, H
Heine ECE, Aaro
onson NK, Taphhoorn MJB, Reijneveld JC, Postma TJ, Heiman s JJ, Klein M. Th
he assocciation between
n cognitive funcctioning and heealth‐related qu
uality of life in low‐grade gliom
ma patients. Neuro‐
Onco
ology Practice 2014; 1: 40‐46. Bolt EEE, Heide A, On
nwuteaka‐Philip
psen BD. Reduccing questionnaire length did n
not improve phyysician responsse rate: a rando
omized trial. J C
Clin Epidemiol 2
2014; 67: 477‐4481. Botto
omley A, Tridello G, Coens C, R
Rolland F, Tesseelaar MET, Leem
mans CR, Huppe
erets P, Licitra LL, Vermorken JB
B, Van den Weyn
ngaert D, Truc G
G, Barillot I, Leffebvre JL. An Intternational Phaase 3 Trial in He
ead and Neck Caancer: Quality o
of Life and Symp
ptom Results. Cancer 2014; 120: 390‐398. Braam
mse AMJ, van M
Meijel B, Visser O, Huijgens PCC, Beekman ATFF, Dekker J. Distress, problems s and supportive
e care needs of patients treeated with auto
o‐ or allo‐SCT. BBone Marrow T
Transpl 2014; 49
9: 292‐298. Brinkkman‐Stoppelen
nburg A, Vergou
uwe Y, Heide A
A, Onwuteaka‐Philipsen BD. Ob
bligatory consulltation of an independent physician on euthan
nasia requests in the Netherlannds: What influ
uences the SCEN
N physicians juddgment of the llegal requirements of duee care?. Health Policy 2014; 1115: 75‐81. m L, Hopmans W
W, Pasman HRW
W, Timmermanss DRM, Widdersshoven GAM, O
Onwuteaka‐Phillipsen BD. Conggruence Brom
between patients' p
preferred and perceived particcipation in medical decision‐making: a review
w of the literature. BMC Making 2014; 1 4: 25. Medical Informatics and Decision M
Brom
m L, Pasman HRW
W, Widdershovven GAM, van dder Vorst MJDL,, Reijneveld JC, Postma TJ, Onw
wuteaka‐Philipsen BD. Patients' Preferencees for Participattion in Treatmeent Decision‐Maaking at the End
d of Life: Qualittative Interview
ws with Advanced Cancer Paatients. PLoS On
ne 2014; 9: e1000435. Bruin
nsma SM, Brown J Heide A, Deliens L, Anquineet L, Payne SA, Seymour JE, Rietjens JAC. Maaking sense of continuous sedattion in end‐of‐liife care for cancer patients: ann interview stud
dy with bereaved relatives in tthree European
n counttries. Supportivve Care in Cance
er 2014; 22(12)): 3243‐3252. Buskeermolen S, van Bokhorst‐de va
an der Schuere n, Verheul HMW
W, Langius JAE. 'Pre‐cachexia' : a non‐existingg phenomenon in cancer?. Ann Onco
ol 2014; 25: 16668‐1669. Cnosssen IC, Uden‐Krraan CF, Rinkel RN, Aalders IJ, de Goede CJ, d
de Bree R, Doornaert P, Rietveeld DHF, Langen
ndijk JA, Wittee BI, Leemans C
CR, de Leeuw IM
M. Multimodal gguided self‐help
p exercise program to preventt speech, swallo
owing, and shoullder problems aamong head an
nd neck cancer patients: a feassibility study. J Med Internet RRes 2014; 16: e7
74. Cohen J, van Wesem
mael Y, Smets T,, Bilsen J, Onwuuteaka‐Philipse
en BD, Distelmans W, Deliens LL. Nationwide ssurvey to evalu
uate the decisio
on‐making proce
ess in euthanassia requests in Belgium: do spe
ecifically traineed 2nd physicians improve qualitty of consultation?. BMC Health Serv Res 20114; 14: 307. Dagan M, Sandermaan R, Hoff C, Me
eijerink WJHJ, BBaas PC, van Haaastert M, Hage
edoorn M. The interplay between ners' responsiveeness and patie
ents' need for e motional expre
ession in couple
es coping with ccancer. J Behavv Med partn
2014;; 37: 828‐838. de Go
oede B, Eker HH
H, Klitsie PJ, van
n Kempen BJH, Polak WG, Hop
p WCJ, Metselaar HJ, Tilanus H
HW, Lange JF, Kazemier G. Incisional hernia afteer liver transpla
antation: risk faactors and health‐related quality of life. Clin TTransplant 2014; 28: 829‐
VUmc CCA 2014 –
0 of 216 23. de Ko
orte‐Verhoef M
MC, Pasman HRW
W, Schweitzer BBPM, Francke A
AL, Onwuteaka‐Philipsen BD, D
Deliens L. Burde
en for familyy carers at the end of life; a m
mixed‐method sttudy of the perrspectives of family carers andd GPs. BMC Palliative Care 2014;; 13: 16. 24. de Ko
orte‐Verhoef M
MC, Pasman HRW
Deliens L. General practtitioners' perspeectives on the a
avoidability of hhospitalizationss at the end of life: A mixed‐m
method study. Palliative Med 2014; 28: 949‐9
958. 25. de Ko
orte‐Verhoef M
MC, Pasman HRW
Deliens L. Reaso
ons for hospiitalisation at the end of life: diifferences betw
ween cancer and non‐cancer patients. Supporrt Care Cancer 2014; 22: 645‐6652. 26. de Leeeuw IM, Buffarrt LM, Heijmanss MW, Rietveldd DHF, Doornaert P, de Bree R,, Buter J, Aaronnson NK, Slotma
an BJ, Leem
mans CR, Langen
ndijk JA. The course of health‐ related quality of life in head and neck canceer patients treated with chem
moradiation: A p
prospective coh
hort study. Radiiother Oncol 20
014; 110: 422‐4
428. 27. De Ro
oo ML, Miccineesi G, Onwuteakka‐Philipsen BD
D, Den Noortgatte N, Block L, Bo
onacchi A, Donkker GA, Alonso JEL, Moreeels S, Deliens LL, Francke AL. A
Actual and Prefeerred Place of D
Death of Home‐‐Dwelling Patie nts in Four Euro
opean Countries: Making SSense of Qualityy Indicators. PLooS One 2014; 9
9: e93762. 28. De Vleminck A, Pard
don K, Beernaerrt K, Descheppeer R, Houttekier D, van Audenhove C, Delienss L, van der Sticchele R. Barrieers to Advance Care Planning in Cancer, Hearrt Failure and D
Dementia Patien
nts: A Focus Grooup Study on G
General Practitioners' Views and Experiences. PLoS One 20014; 9: e84905. don K, Beernaerrt K, Descheppeer R, Houttekier D, Van Audenhove C, Delienss L, van der Sticchele R. 29. De Vleminck A, Pard
Dementia Patien
nts: A Focus Grooup Study on G
General Barrieers to Advance Care Planning in Cancer, Hearrt Failure and D
Practitioners' Views and Experiences. PLoS One 20014; 9: e84905. 30. Deyaert J, Chambaere K, Cohen J, R
Roelands M, Deeliens L. Labellin
ng of end‐of‐life
e decisions by pphysicians.. Jou
urnal of Medical Ethics 2014
4; 40(7): 505‐507. 31. Dirveen L, Aaronson N
NK, Heimans JJ,, Taphoorn MJBB. Health‐relate
ed quality of life
e in high‐grade glioma patientts. Chinese journ
nal of cancer 20
014; 33: 40‐45. 32. Dirveen L, Reijneveld JC, Taphoorn M
MJB. Health‐Re lated Quality of Life or Quantity of Life: A Diffficult Trade‐Offf in Primaary Brain Tumo
ors?. Semin Onccol 2014; 41: 5441‐552. 33. Dirveen L, Taphoorn MJB, Reijneveld
d JC, Blazeby J, Jacobs M, Pusic A, La Sala E, S
Stupp R, Fayers P, Efficace F. T
The level of patient‐reported ou
utcome reportin
ng in randomiseed controlled trrials of brain tumour patients: A systematic review. Eur J Cancer 2014; 50: 2
2432‐2448. 34. Duijtss SFA, Egmond MP van, Spelte
en E, Muijen P vvan, Anema JR, Beek AJ van de
er. Physical andd psychosocial p
problems in canceer survivors beyyond return to w
work: a system
matic review. Psyycho‐oncology 2014; 23(5): 4881‐492. 35. Edieb
bah DE, Coens C
C, Zikos E, Quinten C, Ringash JJ, King MT, von
n Koch JS, Gotay
y C, Greimel E, FFlechtner H, W
Weis J, Reevee BB, Smit EF, TTaphoorn MJB, Bottomley A. D
Does change in health‐related quality of life sscore predict su
urvival? Analyysis of EORTC 08975 lung canccer trial. Brit J CCancer 2014; 11
10: 2427‐2433.
36. Efficaace F, Rees J, Faayers P, Pusic A, Taphoorn M, Greimel E, Reijneveld J, Whale
e K, Blazeby J. O
Overcoming barriers to the im
mplementation of patient‐reported outcomees in cancer clinical trials: the P
PROMOTION Reegistry. Health Qual Life Outco
omes 2014; 12:: 86. 37. Evanss N, Costantini M, Pasman HRW
W, Block L, Donnker GA, Miccin
nesi G, Bertolisssi S, Gil M, Boffiin N, Zurriaga O
O, Deliens L, Onwuteaka‐Philip
psen BD. End‐off‐Life Communi cation: A Retro
ospective Survey of Representaative General P
Practitioner works in Four Co
ountries. J Pain Symptom Mannag 2014; 47: 60
04‐619. Netw
38. Evanss N, Pasman HR
RW, Deeg DJH, Onwuteaka‐Ph ilipsen BD. How
w do general en
nd‐of‐life treatm
ment goals and values relatee to specific treeatment prefere
ences? A popul ation‐based stu
udy. Palliative M
Med 2014; 28: 11206‐1212. 39. Evanss N, Pasman HR
RW, Donker GA, Deliens L, Blocck L, Onwuteakka‐Philipsen BD. End‐of‐life carre in general prractice: A cross‐sectional, retrospective surve
ey of 'cancer', 'oorgan failure' aand 'old‐age/dementia' patientts. Palliative Med 2014; 28: 9665‐975. 40. Frankken MG, Gaultn
ney JG, Blomme
estein HM, Huijggens PC, Sonne
eveld P, Redeko
op WK, Uyl‐de G
Groot CA. Policyymaker, Pleasse Consider You
ur Needs Carefu
ully: Does Outcoomes Research in Relapsed or Refractory Muultiple Myeloma
a Reduce Policyymaker Uncertaainty Regardingg Value for Monney of Bortezom
mib?. Value Health 2014; 17: 2245‐253. 41. Geeleen E, Krumeich A, Schellevis FG
G, Akker M vann den. General p
practitioners' perceptions of thheir role in cancer follow‐
up caare: A qualitativve study in the N
Netherlands. Thhe European Jo
ournal of General Practice 20144; 20(1): 17‐24. 42. Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiaao ZJ, Slot S, Zw
weegman S, Sackmann F, Fuenttes AK, Hernandez‐
Maraaver D, Dohner K, Harrison CN,, Radia D, Muxi P, Besses C, Ce
ervantes F, Joha
ansson PL, And reasson B, Ram
mbaldi A, Barbu
ui T, Vannucchi AM, Passamon
nti F, Samuelssoon J, Birgegard G, Mesa RA. Distinct clusterinng of symptoma
atic burden amon
ng myeloprolifeerative neoplasm patients: ret rospective asse
essment in 1470
0 patients. Bloood 2014; 123: 3
3803‐3810. 43. Gunaawan S, Wolterss E, van Dongen
n J, van der Venn P, Sitaresmi M
M, Veerman A, M
Mantik M, Kasppers G, Mostertt S. Paren
nts' and Health‐‐Care Providerss' Perspectives on Side‐Effectss of Childhood C
Cancer Treatmeent in Indonesia
a. Asian Pacifiic Journal of Cancer Prevention 2014; 15: 35993‐3599. 44. Habeets EJJ, Kloet A, Walchenbach R
R, Vecht CJ, Kle in M, Taphoorn
n MJB. Tumour and surgery eff
ffects on cognitive functtioning in high‐ggrade glioma pa
atients. ACTA N
Neurochir 2014; 156: 1451‐145
59. Annual Report V
VUmc CCA 2014 –
– Appendix 3: Scieentific output ‐ 71 of 216 45. Habeets EJJ, Taphoorrn MJB, Nederend S, Klein M, D
Delgadillo D, Ho
oang‐Xuan K, Bottomley A, All geier A, Seute T
T, Gijten
nbeek AMM, dee Gans J, Entingg RH, Tijssen CCC, van den Bentt MJ, Reijneveld
d JC. Health‐relaated quality of life and cogniitive functioning in longterm a
anaplastic oligo dendroglioma and oligoastroccytoma survivo rs. J Neuro‐Onccol 2014; 116: 161‐168. on BA, Deliens L, Ferreira PL, TToscani F, Gysels M, 46. Higginson IJ, Gomess B, Calanzani N, Gao W, Bauseewein C, Daveso
n ST, Cohen J, Harding R. Prioriities for treatment, care and in
nformation if faaced with serious illness: Ceuleemans L, Simon
A com
mparative popu
ulation‐based su
urvey in seven European coun
ntries. Palliative
e Medicine 20144; 28(2): 101‐110. 47. Hopm
mans W, Damm
man OC, Timmerrmans DRM, Haaasbeek CJA, Slo
otman BJ, Sena
an S. Communiccating cancer trreatment inform
mation using th
he Web: utilizing the patient's perspective in website develo
opment. BMC M
Medical Informa
atics and Decission Making 201
14; 14: 116. 48. Keyzeer‐Dekker CM, d
de Vries J, Merttens MC, Roukeema JA, van der Steeg AFW. The impact of diiagnosis and tra
ait anxiety on pssychological disstress in women
n with early sta ge breast cance
er: A prospectiv
ve study. Brit J Health Psych 2014; 19: 783‐7794. 49. Ko W
W, Deliens L, Micccinesi G, Giusti F, Moreels S, D
Donker GA, Onwuteaka‐Philipsen BD, Zurriagga O, Lopez‐Ma
aside A, Blockk L. Care provideed and care settting transitionss in the last three months of life of cancer paatients: a nation
nwide monitoring study in four European countries. BMCC Cancer 2014; 14: 960. 50. Ko W
W, Miccinesi G, B
Beccaro M, Moreels S, Donkerr GA, Onwuteakka‐Philipsen BD, Alonso TV, Deeliens L, Block LL. Factors Assocciated with Fulffilling the Preference for Dyingg at Home amo
ong Cancer Patie
ents: The role oof general practtitioners. J Palliaat Care 2014; 30
0: 141‐150. 51. Koekkkoek JAF, Dirveen L, Reijneveld JC, Sizoo EM, PPasman HRW, P
Postma TJ, Delie
ens L, Grant R, McNamara S, G
Grisold W, Medicus E, Stockham
mmer G, Obern
ndorfer S, Flech l B, Marosi C, T
Taphoorn MJB, Heimans JJ. Endd of life care in high‐
gradee glioma patients in three Euro
opean countriees: a comparativve study. J Neuro‐Oncol 2014; 120: 303‐310. 52. Koekkkoek JAF, Dirveen L, Sizoo EM, Pasman HRW, H
Heimans JJ, Posstma TJ, Deliens L, Grant R, MccNamara S, Sto
ockhammer G, Meedicus E, Tapho
oorn MJB, Reijn
neveld JC. Sympptoms and medication manage
ement in the ennd of life phase of high‐
gradee glioma patients. J Neuro‐Onccol 2014; 120: 5589‐595. 53. Koldeenhof JJ, Wittevveen PO, de Vos R, Walraven M
M, Tillier CN, Ve
erheul HMW, Teunissen SCCM
M. Symptoms from treatm
ment with sunitinib or sorafen
nib: a multicentter explorative cohort study to
o explore the innfluence of patiient‐
reporrted outcomes on therapy deccisions. Supportt Care Cancer 2
2014; 22: 2371‐2380. 54. Koper I, Heide A, Jan
nssens MJPA, Sw
wart S, Perez RRSGM, Rietjens JAC. Consultation with speciallist palliative ca
are services in pallliative sedation
n: consideration
ns of Dutch phyysicians. Suppo
ortive Care in Ca
ancer 2014; 22((1): 225‐231. 55. Krebb
ber AMH, Buffaart LM, Kleijn G,, Riepma IC, de Bree R, Leemaans CR, Becker A
A, Brug J, van Sttraten A, Cuijpe
ers P, de Leeuw
w IM. Prevalence of depressio
on in cancer pattients: a meta‐aanalysis of diagnostic interview
ws and self‐report instru
uments. Psycho
o‐Oncol 2014; 2
23: 121‐130. 56. Langius JAE, Weijs P
PJM. Response tto the letter to the editor "The
e use of oral nu
utritional suppleements in patie
ents with hemo)radiotherrapy". Clin Nutrr 2014; 33: 369. head and neck canceer receiving (ch
57. Mosttert S, Njuguna F, Langat SC, Sllot AJM, Skiles JJ, Sitaresmi MN
N, van de Ven PM, Musimbi J, VVreeman RC, Kaspers GJL. overlooked con
ntributors to ab
bandonment of childhood canccer treatment in Kenya: parennts' social netwo
ork and Two o
experriences with ho
ospital retention
n policies. Psyc ho‐Oncol 2014; 23: 700‐707.
58. Mosttert S, Njuguna F, van de Ven P
PM, Olbara G, KKemps LJPA, Mu
usimbi J, Strother RM, Aluoch LM, Skiles J, Bu
uziba NG, man RC, Kasperrs GJL. Influenc e of Health‐Insurance Access a
and Hospital Reetention Policie
es on Sitareesmi MN, Vreem
Childhood Cancer Trreatment in Ken
nya. Pediatr Bloood Cancer 201
14; 61: 913‐918. 59. Oerleemans S, Issa DEE, van den Broe
ek EC, Nijziel M R, Coebergh JW
WW, Huijgens PC, Mols F, van dde Poll‐Franse L. Health‐
relateed quality of lifee and persisten
nt symptoms in relation to (R‐))CHOP14, (R‐)CHOP21, and othher therapies a
among patients with diffusee large B‐cell lymphoma: resullts of the popullation‐based PH
HAROS‐registry.. Ann Hematol 2014; 93: 1705‐‐1715. 60. Oerleemans S, Issa DEE, van den Broe
ek EC, Nijziel M R, Coebergh JW
WW, Mols F, van
n de Poll‐Fransee L. Impact of ttherapy and d
disease‐related symptoms on health‐related quality of life in
n patients with follicular lymphhoma: results o
of the population‐based PH
HAROS‐registryy. Eur J Haematool 2014; 93: 229‐238. 61. Olsman E, Leget C, O
Onwuteaka‐Philipsen BD, Willeems D. Should p
palliative care p
patients' hope bbe truthful, helpful or valuaable? An interprretative synthesis of literaturee describing heaalthcare professionals' perspeectives on hope of palliaative care patien
nts. Palliative M
Med 2014; 28: 559‐70. 62. Pivod
dic L, Block L, Paardon K, Miccin
nesi G, Alonso TTV, Boffin N, Do
onker GA, Cancian M, Lopez‐M
Maside A, Onwuteaka‐
Philip
psen BD, Delien
ns L. Burden on family carers a nd care‐related
d financial strain at the end of f life: a cross‐na
ational population‐based sttudy. Eur J Public Health 2014;; 24: 819‐826.
prangers MAG, Ringash J, Gotaay C, Bjordal K, Greimel E, Reeeve BB, Maringw
wa J, 63. Quintten C, Martinelli F, Coens C, Sp
Edieb
bah DE, Zikos E,, King MT, Osob
ba D, Taphoorn MJ, Flechtner H, Koch J, Weiss J, Bottomley AA. Global Analyssis of Multiitrial Data Invesstigating Quality of Life and Syymptoms as Pro
ognostic Factors for Survival inn Different Tum
mor Sites. Canceer 2014; 120: 302‐311. 64. Reich
h M, Leemans C
C, Vermorken J, Bernier J, Licitrra L, Parmar S, Golusinski W, LLefebvre J. Bestt practices in the manaagement of the psycho‐oncolo
ogic aspects of hhead and neck cancer patientss: recommendaations from the
e European Head and Neck Canccer Society Makke Sense Camp aign. Ann Onco
ol 2014; 25: 211
VUmc CCA 2014 –
2 of 216 65. Rinkeel NPM, de Leeu
uw IM, van den
n Brakel N, de BBree R, Eerenste
ein SE, Aaronson NK, Leemanss CR. Patient‐reported symp
ptom questionn
naires in larynge
eal cancer: Voicce, speech and swallowing. Oral Oncol 2014; 50: 759‐764. 66. Rooney AG, Brown P
PD, Reijneveld JJC, Grant R. De pression in glio
oma: a primer fo
or clinicians andd researchers. JJ Neurol Neuro
osur PS 2014; 8
85: 230‐235. 67. Ruijs CD, van der Waal G, Kerkhof AJJ, Onwuteaka‐PPhilipsen BD. Unbearable suffe
ering and requeests for euthanasia prosp
pectively studieed in end‐of‐life
e cancer patientts in primary caare. BMC Palliatt Care 2014; 133: 62. 68. Schaggen SB, Klein M
M, Reijneveld JC,, Brain E, Depreez S, Joly F, Sche
erwath A, Schra
auwen W, Wefeel JS. Monitorin
ng and optim
mising cognitivee function in can
ncer patients: PPresent knowle
edge and future
e directions. EJCC Suppl 2014; 12: 29‐40. 69. Schep
pers SA, Engeleen VE, Haverman L, Caron HN, Hoogerbrugge PM, Kaspers GJL, Egeler RM, G
Grootenhuis M
MA. Patient Reported Outcomess in Pediatric On
ncology Practicce: Suggestions for Future Usag
ge by Parents aand Pediatric Oncologists. Pediaatr Blood Canceer 2014; 61: 170
07‐1710. 70. Schoo
ok RM, Linssen C, Schramel FM
MNH, Festen JM
M, Lammers E, SSmit EF, Postmu
us PE, Westerm
man MJ. Why Do
o Patients and C
Caregivers Seekk Answers From
m the Internet a nd Online Lungg Specialists? A Qualitative Stuudy. J Med Interrnet Res 2014;; 16: e37. 71. Sizoo
o EM, Dirven L, Reijneveld JC, P
Postma TJ, Heim
mans JJ, Delienss L, Pasman HRW
W, Taphoorn M
MJB. Measuringg health‐
relateed quality of lifee in high‐grade glioma patientts at the end off life using a pro
oxy‐reported reetrospective questtionnaire. J Neu
uro‐Oncol 2014
4; 116: 283‐290 . 72. Sizoo
o EM, Grisold W
W, Taphoorn MJB. Neurologic aaspects of palliaative care: the e
end of life settinng. Handbook o
of Clinical Neuro
ology 2014; 121: 1219‐1225. 73. Sizoo
o EM, Koekkoekk JAF, Postma TJJ, Heimans JJ, PPasman HR, Deliens L, Taphoorn MJB, Reijnevveld JC. Seizures in patients with high‐ggrade glioma: a serious challennge in the end‐o
of‐life phase. BMJ Support Pal liative Care 201
14; 4: 77‐
80. 74. Sizoo
o EM, Pasman H
HRW, Dirven L, M
Marosi C, Grisoold W, Stockham
mmer G, Egeterr J, Grant R, Chaang S, Heimans JJ, Deliens L, Reiijneveld JC, Tap
phoorn MJB. The end‐of‐life phhase of high‐graade glioma patients: a system atic review. Support Care Canceer 2014; 22: 84
47‐857. 75. Slort W, Blankensteiin AH, Schweitzzer BPM, Delienns L, Horst HE vvan der. Effectiv
veness of the 'aavailability, currrent issues and aanticipation' (AC
CA) training pro
ogramme for geeneral practice trainees on communication w
with palliative care patients: a controlleed trial.. Patientt Education andd Counseling 20
014; 95(1): 83‐9
90. DL, Horst HE van der, Aaronson NK, Deliens LL. Effectiveness of the 76. Slort W, Blankensteiin AH, Schweitzzer BPM, Knol D
A) communication training proogramme for ge
eneral palliaative care 'Availability, Currentt issues and Antticipation' (ACA
practtitioners on patient outcomes:: A controlled trrial. Palliative M
Medicine 2014; 28(8): 1036‐10045. DL. Complexitiess in Euthanasia or Physician‐Assisted 77. Snijdeewind MC, van Tol DG, Onwutteaka‐Philipsenn BD, Willems D
Suicid
de as Perceived
d by Dutch Physsicians and Pati ents' Relatives.. J Pain Symptom Manag 20144; 48: 1125‐1134. 78. Stackk RJ, van Tuyl LH
HD, Sloots M, va
an de Stadt LA, Hoogland W, M
Maat B, Mallen CD, Tiwana R, Raza K, van Schaaardenburg D. Syymptom complexes in patientts with seropositive arthralgia and in patientss newly diagnossed with rheum
matoid arthritiss: a qualitative exploration of ssymptom development. Rheumatology 20144; 53: 1646‐1653. 79. Terwee CB, Roorda LD, de Vet HCW
W, Dekker J, Weesthovens R, van Leeuwen J, Cella D, Correia H, Arnold B, Pe
erez B, mish translation
n of 17 item ba nks from the Paatient‐Reported
d Outcomes Meeasurement Infformation Boerss M. Dutch‐Flem
Systeem (PROMIS). Q
Qual Life Res 2014; 23: 1733‐17741. 80. Timm
mers L, Boons CC
CLM, Kropff F, vvan de Ven PM , Swart EL, Smit EF, Zweegman S, Kroep JR, TTimmer‐Bonte JJNH, Boven E, Hugtenburg JG. Adherence and p
patients' experiiences with the
e use of oral antticancer agentss. ACTA Oncol 2
2014; 53: 259‐2267. 81. van B
Bruinessen IR, vvan Weel‐Baumgarten EM, Sni ppe HW, Gouw
w H, Zijlstra JM, van Dulmen S. Active Patient Particcipation in the Development o
of an Online Inttervention. J Me
ed Internet Ress 2014; 16: e59.. 82. van d
den Berg MH, vaan D, Overbeekk A, Ronckers C M, van Dorp W
W, Kremer LC, va
an den Heuvel‐EEibrink MM, Hu
uizinga GA, Looneen JJ, Versluys A
AB, Bresters D, Lambalk CB, Kaaspers GJL, van
n Leeuwen FE. F
Fertility studies in female child
dhood canceer survivors: selecting approprriate comparisoon groups. Reprrod Biomed Online 2014; 29: 3352‐361. 83. van d
den Berg‐Emonss RJG, van Ginn
neken BTJ, Nooiijen CFJ, Metselaar HJ, Tilanus HW, Kazemierr G, Stam HJ. Fa
atigue After Liver Transplantation: Effects of a R
Rehabilitation PProgram Including Exercise Tra
aining and Physsical Activity Co
ounseling. Phys Ther 2014; 94: 857‐865. 84. van d
der Kaaij MAE, vvan Echten‐Arends J, Heutte N
N, Meijnders P, beilard‐Lemoisson E, Spina M , Moser EC, Allggeier A, Meulemans B, Lugteenburg PJ, Alem
man BMP, Noorrdijk EM, Ferme
e C, Thomas J, S
Stamatoullas A, Fruchart C, Egh
hbali H, Brice P, Smit WGJM,, Sebban C, Doo
orduijn JK, Roessink JM, Gaillarrd I, Coiffier B, LLybeert MLM, CCasasnovas O, A
Andre M, Raem
maekers JMM, H
Henry‐Amar M, Kluin‐Nelemanns JC. Cryoprese
ervation, semen use and the liikelihood of fattherhood in maale Hodgkin lym
mphoma survivo
ors: an EORTC‐G
GELA Lymphom
ma Group cohort study. Hum RReprod 2014; 29
9: 525‐533. 85. van d
der Plas AGM, H
Hagens M, Pasm
man HRW, Schw
weitzer B, Duijstters M, Onwute
eaka‐Philipsen BBD. PaTz group
ps for primaary palliative caare: reinventingg cooperation bbetween generaal practitioners and district nuurses in palliativve care: an evalu
uation study com
mbining data frrom focus grou ps and a questiionnaire. BMC F
Fam Pract 20144; 15: 14. 86. van d
der Spek N, Udeen‐Kraan CF, Vo
os J, Breitbart W
W, Tollenaar RA
AEM, van Aspere
en CJ, Cuijpers P, de Leeuw IM
M. Mean
ning‐centered ggroup psychotherapy in cance r survivors: a fe
easibility study. Psycho‐Oncol 2014; 23: 827‐831. Annual Report V
VUmc CCA 2014 –
3 of 216 87. van d
der Spek N, Vos J, van Uden‐Krraan CF, Breitbaart W, Cuijpers P, Knipscheer‐K
Kuipers K, Willeemsen VWB, To
ollenaar RA, van Asperen CJ, de Leeuw IM. E
Effectiveness a nd cost‐effectivveness of mean
ning‐centered ggroup psychotherapy in canceer survivors: pro
otocol of a rand
domized controolled trial. BMC
C Psychiatry 201
14; 14: 22. 88. van d
der Valk ME, Maangen MJJ, Leenders M, Dijksttra G, van Bode
egraven AA, Fidder HH, de Jongg DJ, Pierik M, vvan der Woud
de CJ, Rombergg‐Camps MJL, C
Clemens CHM, JJansen JM, Mah
hmmod N, van de Meeberg PCC, Jong A, Ponsioen CY, Bolweerk CJM, Vermeeijden JR, Sierse
ema PD, van Oiijen MGH, Olde
enburg B. Healthcare costs of iinflammatory b
bowel disease have shifted
d from hospitaliisation and surggery towards anti‐TNF alpha therapy: results s from the COIN
N study. Gut 22014; 63: 72‐79. 89. van d
der Valk ME, Maangen MJJ, Leenders M, Dijksttra G, van Bode
egraven AA, Fidder HH, de Jongg DJ, Pierik M, vvan der Woud
de CJ, Rombergg‐Camps MJL, C
Clemens CHM, JJansen JM, Mah
hmmod N, van de Meeberg PCC, Jong A, Ponsioen CY, Bolweerk CJM, Vermeeijden JR, Sierse
ema PD, van Oiijen MGH, Olde
enburg B. Risk factors of work disability in pattients with inflam
mmatory bowel disease ‐ A Du
utch nationwidee web‐based su
urvey Work disa
ability in inflam matory bowel disease. Journ
nal of Crohn's and Colitis 2014; 8: 590‐597. 90. van d
der Weijden MA
A, Boonen A, va
an der Horst‐Br uinsma IE. Prob
blems in Work P
Participation annd Resource Usse Should Not B
Be Underestimaated in Patientss with Early Spoondyloarthritis. J Rheumatol 20
014; 41: 2413‐22420. 91. van LLitsenburg RRL, Huisman J, Pieters R, Verhaakk C, Kaspers GJ, Gemke RJ. Detterminants of qquality of life du
uring inducction therapy in
n pediatric acute lymphoblasti c leukemia. Sup
pport Care Cancer 2014; 22: 33235‐3242. 92. van LLitsenburg RRL, Kunst A, Huism
man J, Ket JC, Kaaspers GJ, Gemke RJ. Health Sttatus Utilities inn Pediatrics: A SSystematic Revieew of Acute Lym
mphoblastic Leu
ukemia. Med D ecis Making 20
014; 34: 21‐32.
93. van LLonden GJ, Donovan HS, Beckjo
ord EB, Cardy A
AL, Bovbjerg DH
H, Davidson NE, Morse JQ, Swiitzer GE, de Lee
euw IM, Dew MA. Perspectivves of postmeno
opausal breast cancer survivors on adjuvant endocrine therrapy‐related symptoms. Onco
ol Nurs Forum 2
2014; 41: 660‐668. 94. Van M
Muijen P van, SFA Duijts, K. Bo
onefaas‐Groeneewoud, van derr Beek AJ, Anem
ma JR. Factors a ssociated with work disab
bility in employeed cancer survivvors at 24‐monnth sick leave. B
BMC Cancer 201
14; 14: 236. 95. van N
Nieuwenhuizen AJ, Buffart LM,, Smit JH, Brakeenhoff RH, Braaakhuis BJ, de Bree R, Leemans C, de Leeuw IM
M. A comp
prehensive asseessment protoccol including pattient reported outcomes, physical tests, and biological sampling in newlyy diagnosed patients with hea
ad and neck canncer: is it feasib
ble?. Support Ca
are Cancer 20144; 12: 3321‐333
30. 96. van O
Oers HA, Haverm
man L, Limpergg PF, van Dijk‐Lookkart EM, Mau
urice‐Stam H, Grootenhuis MAA. Anxiety and D
Depression in Mo
others and Fath
hers of a Chroniically Ill Child. M
Maternal and ch
hild health jourrnal 2014; 18: 11993‐2002. 97. Vardii Y, Kitrey ND, M
Meuleman EJH, Scranton RE. EErectile Dysfuncction Diagnosis and Treatmentt as a Means to
o Improve Medication Adheren
nce and Optimize Comorbidityy Management. Journal of Sexual Medicine 22014; 11: 888‐890. M, Pasman HRW
W, Onwuteaka‐PPhilipsen BD. A
A comparison off drugs and proocedures of care
e in the 98. Westt E, Costantini M
Italian
n hospice and h
hospital settinggs: the final threee days of life for cancer patients. BMC Healtth Serv Res 201
14; 14: 496. 99. Westt E, Romoli V, Leeo S Di, Higginson IJ, Miccinesii G, Costantini M
M. Feasibility of assessing quaality of care at tthe end of life in
n two cluster triials using an aftter‐death approoach with multiple assessments. BMC Palliatiive Care 2014; 13: 36. 100. Wopkken K, van der SSchaaf A, Christtianen ME, Choouvalova O, Oossting SF, van de
er Laan BF, Rooddenburg JL, Lee
emans CR, Slotm
man BJ, Doornaeert P, Steenbakkkers RJ, de Leeeuw IM, Langendijk H. Develop
pment and validdation of a pred
diction modeel for tube feed
ding dependencce after curativee (chemo‐) radiiation in head a
and neck cancerr. PLoS One 201
14; 9: e948779. 101. Wopkken K, van der SSchaaf A, van der Laan HP, Choouvalova O, Ste
eenbakkers RJ, Doornaert P, S lotman BJ, Oossting SF, Christtianen ME, van
n der Laan BF, R
Roodenburg JL, Leemans CR, de Leeuw IM, Langendijk JA. Deevelopment of a multivariable normaal tissue complication probabi lity (NTCP) mod
del for tube fee
eding dependennce after curative radiotherapy/chemo
o‐radiotherapy in head and neeck cancer. Rad
diother Oncol 20
014; 2014: 95‐1101. Scientific papers non
n‐refereed
1.
van W
Wijmen MPS, Paasman HRW, W
Widdershoven G
GAM, Onwuteakka‐Philipsen BD
D. Motivations, aaims and comm
munication aroun
nd advance direectives A mixed
d‐methods studdy into the perspective of theirr owners and thhe influence of a current illness. Patient Educc Couns 2014; 95: 393‐399. Scienttific publica
ations 1.
2.
3.
ans CR. Evaluatiing the impact o
of cancer of the
e head and necck; in Ward EJ, vvan A, de Leeeuw IM, Rinkel RNPM, Leema
(eds): Head and neck cancer: treatm
ment, rehabilitaation and outco
omes. San Dieg
go, Plural Publisshing 2014: 29‐61. Kruizeenga HM, Wierrdsma NJ. Zakbo
oek dietetiek. A
Amsterdam, VU
U University Pre
ess Amsterdam 2014: . Wierd
dsma NJ, Kruizeenga HM, Muld
der CJJ. Voedingg bij maag‐, darrm‐ en leverziek
kten; in Kuiperss EJ, (ed): Leerb
boek Maag‐ darm
m‐ en leverziekteen. Utrecht, De Tijdstroom 20 14: . Annual Report V
VUmc CCA 2014 –
4 of 216 Professsional publications 1.
2.
3.
4.
5.
6.
Oncologie de Leeeuw IM, van Uden‐Kraan CF. ZZelfmanageme nt en eHealth in de psychosocciale oncologiePPsychosociale O
201422: 8‐9. Heidee A, van Delden
n JJ, Geijteman E, van Zuylen LL, van der Maas PM, Onwuteak
ka‐Philipsen BD
D. Frequentie en
n kenm
merken van gebruik van morfin
ne in de stervennsfase. Een dwaarsdoorsnede o
onderzoekNed TTijdschr Geneesskd 2014158: . Pasm
man HRW, Willems D, Onwutea
aka‐Philipsen B D. Wat gebeurtt er nadat een e
euthanasieverzzoek is afgew
wezen?Huisartss Wet 201457: 3
396‐399. Schuu
urhuizen CSEW
W, Verheul HMW
W, Braamse AM J, van der Linde
en MHM, Dekke
er J, Konings IRRHM. Nieuwe ASCO‐
richtlijn voor het signaleren en beh
handelen van anngst‐ en depresssieve klachten bij volwasseneen met kankerN
Ned Tijdscchr Oncol 201411: 278‐283. van d
de Poll‐Franse LL, Prins JB, de Le
eeuw IM. Ondeerzoek naar kwaaliteit van leven
n van kankerpattiënten; Leerbo
oek Onco
ologie 2014: . Van d
der Heide A, van Delden JJ, Geijteman E, van Zuylen L, van d
der Maas PM, O
Onwuteaka‐Phil ipsen. Frequen
ntie en kenm
merken van gebruik van morfin
ne in de stervennsfase. Een dwaarsdoorsnede‐o
onderzoekNedeerlands Tijdschrrift voor Geneeeskunde 20141
158: A6857. Popu
ular publications 1.
2.
3.
de Leeeuw IM. Genezzen maar niet b
beter 2014. de Leeeuw IM. Kankeer heb je samen
n 2014. Kaspeers GJL. Prinsess Maxima Centrrum voor Kindeeroncologie; Dicchtbij wat kan: sshared careAtteent 2014. D
Dissertation
ns 1.
CG. Superior Sulcus Tumors: Re
esponse Evaluaation & Quality of Life. 6/10/20
014. (Co)promootor(es): Dahele
e MR, Vos C
Harteemink KJ, Smit EEF . Annual Report V
VUmc CCA 2014 –
5 of 216 Appendix 4 ‐ Research programs A long‐term policy is developed for the programs, covering their focus, the need for personnel and materials, their budgets and their development. These long‐term plans constitute the basis of the long‐term policy of VUmc CCA. Research projects are evaluated on their (intrinsic) qualities and on their potential to strengthen the program as a whole. A list of all ongoing projects per program is shown in appendix 6. Program 1: Oncogenesis Program leaders: R.H. Brakenhoff (Otolaryngology‐ Head and Neck Surgery) R.D.M. Steenbergen(Pathology) E.J. Meijers‐Heijboer (Clinical Genetics) Program 1 covers both basic and translational research and is divided into two subthemes: 1. Viral oncogenesis, (pre)cancer genomics and early diagnostics 2. Genetic predisposition and cellular signaling A major common objective of the research brought together in this program is to identify and characterize viral and non‐
viral cancer genes, including microRNAs, involved in oncogenesis, as well as genes, responsible for inherited cancer predisposition. Their roles in oncogenic pathways are functionally evaluated in experimental models and descriptively analyzed in clinical material. In addition, molecular markers and drug‐able targets are sought that may be utilized for a) screening for cancer and precancerous lesions, b) risk assessment of precancerous lesions, c) cancer prevention, and d) cancer and precancer therapy. For the purpose of screening and risk assessment an integrated bench to bedside approach is followed encompassing: 1) marker identification and validation, 2) test development, clinical validation and up‐scaling by robotics, 3) risk group identification, 4) cost‐effectiveness modelling, and 5) public acceptance studies. Screening studies, either or not in the context of population‐based screening trials, are running for oral precancer, colorectal cancer and cervical cancer, in various risk groups. Viral oncogenesis, (pre)cancer genomics and early diagnostics This subtheme focuses on the role of human papillomaviruses (HPVs) and Epstein Barr virus (EBV) in the development of human cancers, including anogenital cancers, head and neck cancers, and lymphomas. Virus‐induced oncogenic progression is investigated using both in vitro models and clinically well‐defined patient material, and the genes involved in this process are identified and characterized. In line with the progression models for HPV‐mediated oncogenesis, models have been and are generated for head and neck cancer and gastrointestinal tumors. Viral and cellular candidate markers are being tested in screening and clinical trials for their capability to assess the risk of premalignant disease with an increased sensitivity and specificity compared to currently existing methods, and newly identified markers will be investigated likewise. Genetic predisposition and cancer genes Molecular mechanisms underlying the process of genomic destabilization, which is thought to be crucial for oncogenesis, are investigated in the context of both familial and sporadic cancer. Current focus is on the chromosomal instability disorders, in particular Fanconi anemia (FA; 15 genes so far identified) and the cohesinopathies (5 genes found), for which the molecular pathways are currently being unravelled and mouse models developed. It has been recognized that a subset of sporadic cancers may possess a cellular FA or cohesion‐deficient phenotype, which might be exploited through targeted therapeutic intervention based on synthetic lethality approaches. The possibility to sensitize (resistant) tumor cells by inhibition of the FA/BRCA pathway will also be explored. Other research lines involve 1) search for genes that contribute to genetic predisposition to breast/ovarian and colorectal cancer, 2) elucidation of mechanisms that tumor cells exploit when becoming resistant to reactive chemicals, including endogenous reactive oxygen species (as generated by hyperoxia) and cross‐linking agents, and 3) basic and translational research into retinoblastoma, both in patient material and mouse models. These approaches will increase fundamental insight into genome stability pathways and may provide important new leads to develop novel cancer treatment options. Besides the identification of cancer genes involved in inherited syndromes there is also active research to identify the genes and microRNAs causing sporadic head and neck, lung, colorectal, cervical and ovarian cancers. Well‐characterized cohorts of patients and state‐of‐the art high‐throughput methods for genetic, epigenetic, transcriptome, proteome, and metabolome analyses are utilized to classify the tumors and identify regions of interest and candidate genes and pathways in the subclassified tumors. In addition, functional genetic screens and genome editing approaches are carried out to Annual Report VUmc CCA 2014 ‐ Appendix 4: Research programs ‐ 76 of 216 identify candidate genes in relevant in vitro models, and the functional characterization of candidate genes is also analyzed in these models. Potential drug‐able genes and microRNAs are evaluated for treatment, mainly focused on secondary and tertiary prevention. Finally, we use functional genetic screens to identify genes and microRNAs that are lethal for tumors as well as genes and microRNAs modifying chemoradiation response. A strong aspect of the research brought together in this program is that patient‐oriented research is complemented by unique model systems that allows the study of the carcinogenic process in the laboratory. These model systems include: HPV‐transformed cultured keratinocytes mimicking cervical carcinogenesis (Pathology), conditionally immortalized oral keratinocytes allowing unraveling of the carcinogenic cascade mimicking head and neck carcinogenesis (ORL/HNS), organoids of gastrointestinal tumors, cell lines of tumors from patients with genetic instability syndromes and transgenic animals to study the role of genomic instability in the origin of cancer (Clinical Genetics). With the employment of Dr R Wolthuis at the Dept Clinical Genetics also regulation of the cell cycle became an important novel theme. Research highlights Program 1 within period 2008‐2014 1. Establishment that implementation of HPV testing in cervical screening leads to earlier detection of cervical (pre)cancerous lesions and that coverage can be increased by offering self‐sampling. As a result primary HPV testing and offering self‐sampling for non‐attendees will be introduced in population‐based screening in 2016. 2. Collection of evidence that high‐grade cervical premalignant lesions can be subdivided into potentially early and advanced lesions on the basis of their chromosomal profiles and that HPV positive women with clinically relevant cervical lesions can be recognised by hypermethylation of certain tumor suppressor genes. 3. Identification and clinical validation of DNA methylation markers as triage markers for HPV positive women in cervical screening using both scrapes and self‐sampled cervico‐vaginal specimens. 4. Establishment of HPV‐type dependent mechanisms of immortalization and transformation using newly developed in vitro models systems for eleven high‐risk HPV types. 5. Establishment of the role of EBV‐BARF1 protein in carcinogenesis and EBV‐LMP1 positive exosomes in lymphomagenesis. Insight in exosome biology and their potential as source for informative biomarkers.. 6. Development and validation of a novel test algorithm for archival formalin fixed paraffin‐embedded specimens to assess HPV involvement and establishment of the role of HPV in penile and head and neck cancer. 7. Assessment of time trend in the proportion of HPV‐induced head and neck cancer and development of prognostic risk models of oropharyngeal cancer 8. Generation of a unique in vitro model for head and neck cancer using conditionally immortalized oral keratinocytes that is exploited for functional screens. 9. Identification of tumor‐selective lethal microRNAs 10. Identification of radiation‐ and cisplatin‐sensitizing genes by functional genetic siRNA screens 11. Establishment of cell lines from precancer and of tumors from genetically predisposed patients. 12. Implementation of next generation sequencing for diagnostic and research purposes. 13. Identification of six novel Fanconi anemia genes: FANCB (responsible for an X‐linked form of FA), BRIP1/FANCJ (encoding a BRCA1‐interacting helicase), FANCM/Hef (encoding an evolutionary conserved DNA helicase), PALB2/FANCN (encoding a stabilizer and localizer of BRCA2), FANCI (encoding a binding partner of FANCD2) and SLX4/FANCN (encoding an organizer for endonucleases). 14. Development of a mouse models for FANCM and FANCF that establish a link between FANCM and FANCF deficiency and cancer predisposition. 15. Identification of the MYCN oncogene as one of the drivers of retinoblastoma with non‐mutated RB1 genes. 16. Identification of ESCO2 as the gene defective in Roberts syndrome and DDX11 as the gene defective in Warsaw Breakage syndrome, both rare disorders diagnostically overlapping with FA and featuring a specific type of chromosomal instability due to precocious centromere splitting. 17. Classification of CHEK2 as a high risk breast cancer gene in homozygous mutation carriers from breast cancer families and identification of several low risk breast cancer genes. 18. Identification of biomarkers for stool‐based and serum‐based colorectal cancer screening. 19. Establishment of organoid cultures covering the complete spectrum of colon cancer development. 20. Identification and validation of a chromosomal profile in endobronchial squamous metaplastic lesions that predicts lung cancer. 21. Insight in value of molecular biomarkers, such as DNA hypermethylation and DNA mutations, in sputum for the diagnosis of lung cancer. The activities of program 1 can further be inferred from the extra impulse by a large Center for Translational Molecular Medicine (CTMM) grant with the acronym DECODE to the research line on early detection of colorectal cancer, coordinated by VUmc (prof GA Meijer). A main focus of this 18.5 M€ program will be large‐scale validation of molecular markers for early detection of colorectal cancer. In addition, a second CTMM grant was obtained (AIRFORCE), and several other grants were awarded, amongst which an ERC advanced grant in 2012 (CJLM Meijer/PJF Snijders). Annual Report VUmc CCA 2014 ‐ Appendix 4: Research programs ‐ 77 of 216 In addition, within this program large, unique biobanks have been established. These include 200,000 cervical scrape samples and self‐collected cervico‐vaginal specimens from regular screening and triage cohorts, 15,000 brush samples of the oral cavity of various controls groups, Fanconi anemia patients, leukoplakia patients and treated oral cancer patients. We also have collected clinical information as well as tumor biopsies, mucosa biopsies, serum and plasma of over 450 head and neck and 200 lung cancer patients. In addition, 1,000 AFB‐guided bronchial biopsies of patients at risk of lung cancer, 600 sputum samples of lung cancer and COPD patients as well as 750 faeces samples of colorectal cancer cases and controls have been collected and stored. Finally, DNA from more than 700 breast cancer patients with suspected cancer predisposition is available. The total number of genetic subtypes in Fanconi anemia has now grown to 15. However, a unique collection of cell lines and material from Fanconi anemia families has been accumulated containing a sizable number of unclassifiable cell lines that still wait for their gene defects to be identified. This includes patients with ‘overlapping’ syndromes such as Seckel syndrome and cohesinopathies. In addition, a unique cell line panel of head and neck cancers from Fanconi anemia patients has been established. Perspectives In the five years to come we aim to demonstrate that, when proper test and device combinations are used. HPV testing on self‐sampled specimens in a screening popluation is non‐inferior to HPV testing on physician‐collected samples in terms of detecting cervical precancer and cancer. In addition, the most optimal molecular triage tool will be determined for HPV positive (self‐)samples. This paves the way for full molecular screening using self‐collected samples. Furthermore mechanisms of HPV induced carcinogenesis will be further unraveled. Novel genetic and epigenetic screening assays for oral cancer and precancer detection will be developed and further validated along with the health improvement and cost–effectiveness of population‐based screening programs. Function of several existing microRNAs and candidate‐cancer genes in head and neck, lung and cervical cancer will be elucidated. Novel genes involved in chromosome fragility syndromes (FA, cohesinopathies) or conditions associated with breast cancer predisposition, will have been mapped and/or identified. New mouse models for genome destabilization syndromes (including retinoblastoma) will have been generated and the role of genome stability genes in human cancers, sporadic and inherited, ascertained. In addition, targeted interference with the FA/BRCA pathway will be explored as a means to sensitize (resistant) tumor cells for chemotherapy. Furthermore, synthetic lethal interactions with the FA/BRCA and cohesion pathways will have been identified and explored for cancer therapy in sporadic cancer. In addition, we will have gained more insight in the carcinogenesis of retinoblastoma, have identified clinically relevant subgroups based upon molecular profiles and identified new drug targets. Finally we will have established cultures of premalignant cells and found drug‐able targets for tertiary prevention in head and neck cancer. Summary of the research aims for the coming 5 years: 1. Elucidation of specific genomic stabilisation mechanisms and the role of deficiencies in these mechanisms in the occurrence of cancer, both familial and sporadic. Interference with recognized targets will be explored as a means to sensitize (therapy‐resistant) tumor cells. Mechanisms underlying tumor cell resistance to therapeutic agents will be elucidated, including those based on endogenous (hyperoxia‐generated) oxygen radicals, which may provide novel clues for better cancer treatment. This approach includes in vitro model systems as well as animal models. 2. Improving insights into the exact mechanisms by which oncogenic viruses, in particular HPV and EBV, contribute to cancer development. This includes the identification of cancer genes and genetic and epigenetic alterations that occur during carcinogenesis. The roles of these (epi)genetic alterations in oncogenesis will be assessed, both in in vitro models and in the cancer patient. 3. Unraveling the carcinogenic process in squamous cell carcinoma of the upper aerodigestive tract, both in in vitro models, and in the cancer patient. This includes the recognition of the cancer genes and miRNAs that are most relevant in these tumors, and can be exploited for development of treatment strategies. This will be determined by a combination of descriptive research (microarray, sequencing, massively parallel sequencing) and functional genetic screens. 4. Detection of new markers to distinguish progressive precursor lesions of the cervix, head and neck, lung and ovary that may develop into carcinoma. 5. Development and improvement of high‐throughput molecular diagnostic methods for secondary prevention of cervical (i.e. scrapings and lavages), head and neck (i.e. scrapings and lavages), and lung (i.e. sputum) cancer. 6. Identification of drug‐able targets for cancer treatment and for tertiary prevention of premalignant oral lesions. 7. Comparison of hereditary with non‐hereditary retinoblastoma at the molecular level, to improve diagnostics and therapy. Collaboration This program is built around the three major departments that participate: Pathology, Otolaryngology/Head‐Neck Surgery, and Clinical Genetics. The collaboration not only involves common research interests, but also extends to the organization of the annual master course Oncogenesis. The program leaders meet at regular basis and visit each other’s work meetings to make optimal use of opportunities for collaboration, and this has led to a number of important papers. The recent Annual Report VUmc CCA 2014 ‐ Appendix 4: Research programs ‐ 78 of 216 development of an institution for early diagnosis and prevention of cancer (Cancer Center Amsterdam, in collaboration with VUmc CCA) has added new perspectives on a fruitful collaboration within and amongst the various programs. The establishment of a Familial Cancer Clinic with a separate Laboratory for Clinical Oncogenetics, will stimulate further collaboration within the program. Collaboration has been established with many outstanding groups, including those of the Netherlands Cancer Institute (Prof. R. Bernards, Prof. D. Peeper, Prof. R. Agami, Prof. S. Horenblas, Prof. A. Berns and Prof. H. Te Riele) and the Hubrecht laboratory is expected to pay off in the years to come. Both Profs. Peeper and Te Riele have been appointed as professors to VUmc, and are active participants within VUmc CCA. There are also intensive contacts with HPV, EBV and Fanconi anemia patient support groups all over the world. Means Modern technology such as genomics and proteomics technology, and functional genetic screens are needed to identify new biomarkers and candidate‐cancer genes that may be exploited as reliable risk‐predictors for the progression of premalignant lesions, especially in cervix, , the head & neck region, and the lung. In addition, biostatistical and bioinformatics support is warranted, as well as investment in high‐throughput robotics. Also next generation sequencing facilities are now in place at the Pathology and Clinical Genetics departments. Mouse models are accessible through Prof Te Riele. Program 2: Immunopathogenesis Program leaders: Tanja de Gruijl (Medical Oncology) Reina Mebius (Molecular Cell Biology and Immunology) Arjan van de Loosdrecht (Hematology) The VUmc CCA program 2 covers both fundamental and pre‐clinical, translational research in which immunological processes underlying homeostatic control, in relation with inflammatory diseases and cancer, form major topics of research. Program 2 is subdivided into three research lines: 1. Inflammation and immune modulation 2. Regulatory function of the (tumour) microenvironment 3. Immunotherapy and monitoring Program 2 studies the immune system, both its homeostatic control and its response towards micro‐organisms and tumours. Special focus of immune related questions in health and disease is on colon, skin, brain, lymph nodes, as well as in solid and leukemic tumours. We have identified the following key elements, which we regard as the major themes for the next five years. We will focus on these key elements and strengthen our program accordingly. Inflammation and immune modulation Main topics are: understanding the homeostatic control of the immune system and its dysregulation in cancer and inflammatory disorders, such as Rheumatoid Arthritis, Inflammatory Bowel Disease, Coeliac Disease, Multiple Sclerosis, and skin related diseases. Study of immune cell subsets and post‐translational modifications, in particular glycosylation, are major components of the research conducted on communication between immune cells, such as DC, neutrophils, macrophages and T cells. In relation to the induction of inflammatory processes (related to infections: bacterial, helminth, viral, or tumour‐related, or related to chronic inflammatory disorders like colitis, arthritis, or neurology‐ or wound‐related, or allergic contact dermatitis) we study innate and adaptive immune cell activation, receptor expression and function, and interactions with the (micro)environment. We aim to define at the molecular level anti‐inflammatory and protective activity of neutrophils, macrophages and dendritic cells. Understanding immune modulatory (activating) processes of pathogens on a molecular level will allow the design of novel immune‐stimulatory therapeutics for cancer. Furthermore, through our research on mycobacterial virulence, helminths and various viruses we aim to develop a better understanding of the immune suppression they establish. Also genetic and epigenetic processes that play a critical role in the regulation of the immune response in health and disease with a specific focus on antigen presentation, T cell activation and immune effector cell differentiation are studied. These studies will provide leads for therapeutic immune interventions, both by tolerance induction (under inflamed conditions) or by immune potentiation (in cancer). Regulatory function of the (tumour) microenvironment Central aim is to understand micro‐environmental modulation of the immune system in tumours and their draining lymph nodes (e.g. the function of antigen‐presenting cells (APC) like dendritic cells (DC) and macrophages), by soluble factors derived from tumours, through modifications of molecular and posttranslational signatures of stromal cells, or tumour antigens. Also epigenetic processes that account for silencing of antigen presentation functions of tumour cells will be studied. Moreover, the tissue microenvironment of brain, skin, joints and secondary lymphoid organs are studied in health Annual Report VUmc CCA 2014 ‐ Appendix 4: Research programs ‐ 79 of 216 and disease to discover central molecular players that delineate key molecular processes for therapeutic intervention in the micro‐environmental instruction of the immune system. The requirement for the formation of lymph nodes is studied in order to gain further insight in how these structures develop at sites of chronic inflammation. When involved in allowing the activation of autoimmune cells, these structures are unwanted. But when we could induce their formation at a tumour sites, they are considered beneficial for an anti‐tumour response. Furthermore, the central role of stromal cells and dendritic cell subsets in dictating the micro‐environment during lymph node development and the functioning of established lymph nodes, which a.o. is important for the induction of effector and regulatory T cells and the induction of homing receptors on T cells, is studied. Immunotherapy and immune monitoring For pre‐clinical immune therapy, our main lines of research for the next years will focus on 1) the in vivo modulation of DC phenotype and function and 2) Ab‐redirected effector cell therapies, including γδT cells, NKT cells, macrophages, neutrophilic granulocytes and Chimeric Antigen Receptor [CAR]‐modified T cells, and 3) the development of immune monitoring assays for implementation in the monitoring of clinical trials. Ad. 1) A major focus of research will remain the in vivo modulation of DC phenotype and function for tumour immunotherapeutic purposes, through immune potentiation with toll‐like receptor ligands (TLR‐L) and/or cytokines, (glyco‐
)liposomal technology, modified peptides, or adenovirus‐mediated genetic targeting, with a focus on skin resident DC or skin‐draining lymph nodes (in the context of the design of dermal tumor vaccines). By in‐vivo modulation of DC by local cytokine and/or TLR‐L administration, or the use of small molecule inhibitors as well as immune checkpoint inhibitors we aim to overcome the tumour‐induced immunosuppressive conditions, in order to optimize DC and anti‐tumour T cell activation. Aim is to develop widely applicable “off‐the‐shelf” therapeutics to boost anti‐tumour immunity in adjuvant settings, combined with other treatment modalities. Ad. 2) As separate strategy tumour targeting antibody/nanobody (VHH) treatment is being developed, in order to improve ADCC by macrophages, NK cells or effector T cell subsets. Also, activation of the innate NKT cells or neutrophils will form part of novel strategies to improve anti‐tumour immunotherapy. CAR modified T cell approaches will be explored in the context of B cell malignancies. Ad. 3) Immune monitoring assays for antigen specific T cell responses as well as (flowcytometric) immune subset analysis (Tregs, T cells, DC, myeloid derived suppressor cells [MDSC], macrophages) in tumours, their draining lymph nodes and blood are developed which allow for optimal monitoring of the immune status of patients who suffer from cancer or immune related diseases and undergo immune‐modulatory treatment modalities (which beside immunotherapy can also include conventional treatments like radio‐ and chemotherapy). This research should also lead to the identification of prognostic and predictive biomarkers for application in personalized therapy approaches. The major goals of Program 2 are to progressively acquire knowledge of the homeostatic control mechanisms of the immune system as well as their subversion in pathological situations like cancer and (chronic) inflammatory disorders. These insights should enable the identification of immunological parameters crucial for disease development and severity. The main objective is to lay the grounds for translational research programs for therapy of chronic inflammatory diseases, infections and cancer. This program combines the study of infectious diseases and cancer, based on common denominators in the immune system that may be modulated, either to enhance or to suppress the immune response. Importantly, several cancers are caused by viral infections such as EBV and HPV, linking pathogens to cancer development. The program aims to molecularly define how pathogens as well as developing tumours mitigate the immune system for their own benefit. We aim to develop strategies to overcome immune suppression and design vaccines and other immunotherapies to strengthen immune responses to eliminate tumour development and prevent inflammatory immune diseases. Strong focus within the 3 research lines is on the study of antigen presenting cells such as dendritic cells (DC) and macrophages, i.e. how they are suppressed by the tumour microenvironment (e.g. by stromal cells, chemokines, secretion of inhibitory factors, genetic factors) and pathogens, how these subvert immune responses, and induce regulatory T cells. Recognition of tumour antigens, such as MART‐1, gp100, Prame, WT1, NY‐ESO‐1, CEA, MUC1, and virally derived antigens, as well as post‐
translational modifications of tumours and pathogens, are major focus elements, employing a.o. proteomics and glycomics. Pre‐clinical immune therapeutic strategies encompassing in‐vitro and in‐vivo targeting of tumour antigens to DC and macrophages are fully explored as well as immune modulatory approaches aimed at activation and mobilisation of tumour‐
specific T cells. Both innate and adaptive components of the immune system in relation with their microenvironment such as stromal cells, that may steer immune responses during infectious diseases as well as tumour development, are studied. Perspectives For the next five years we aim to identify immune status‐related parameters, both on a molecular and a cellular level, that may provide therapeutic leads as well as prognostic or therapy predictive biomarkers for disorders such as chronic inflammation, tumour development and infection. We envisage that a solid combination of basic research and translational studies will form the basis of understanding immune escape mechanisms and will ultimately lead to innovative clinical strategies to achieve a more efficacious treatment of chronic inflammation, cancer and infectious diseases. In addition we Annual Report VUmc CCA 2014 ‐ Appendix 4: Research programs ‐ 80 of 216 anticipate that the two main lines of research on preclinical therapies, i.e. DC modulation and targeting and redirected effector cell therapy will have led to novel therapies ready for clinical implementation. The following key subjects of research and expertise were identified in program 2: 1. Strong DC and stromal cell biology and (pre)clinical knowledge and experimental settings, which have already led to successful clinical translation 2. Strong expertise in glycobiology, proteomics and related tools for research 3. Excellent setting for performing human immunology based research 4. Certified laboratory available for developing immune diagnostic and monitoring strategies (Medical Immunology) and various functional and phenotypic analyses developed (with Immunotherapy Lab of Medical Oncology) 5. Unique human skin model systems for pathogen infection, DC targeting and skin inflammation and wound healing 6. Presence of unique murine tumour‐models, tolerance induction models, as well as models of (auto‐immunity leading to) chronic inflammation 7. Strong expertise in lymphoid organ development and functioning 8. Strong expertise in mucosal immunity 9. Unique expertise in haematological and solid tumour biology and related immune editing 10. Flowcytometric and microscopy facilities and peptide synthesis facility 11. Unique setting for pathogen related research and technologies 12. Very strong expertise in (pre‐)clinical DC related therapy development Summary of the research aims for the next 5 years: 1. Within the next five years we envisage setting out strategic ways to target DC in‐vivo with tumour antigens (receptor‐
targeting, viral targeting, altered‐glycan‐targeting) with a special focus on improving treatment of colon carcinoma, breast cancer, melanoma, glioma and virally induced malignancies. Focus will be on targeting DC in‐vivo in such a way that both tumour specific CTL and T‐helper cells are induced, with a special focus on vaccine design in which local adjuvant combinations with in‐vivo targeting formulations will improve the mobilisation and antigen presentation capacity of skin DCs and DCs in skin‐draining lymph nodes. We also aim at redirecting NK cells, macrophages and high avidity cytotoxic T cell subsets against virally induced malignancies such as ano‐genital cancers, head and neck cancers and lymphomas, as well as against non‐virally induced malignancies. 2. In the field of infection/inflammation we will especially focus on the role of stromal cells in regulating defence mechanisms by innate cells and how this influx may be suppressed. Also our understanding on modulation of regulatory T and myeloid cells and effector T cells will help to design strategies to inhibit unwanted inflammatory reactions such as in IBD, RA and MS, and vice versa desirable reactions with therapeutic potential in cancer. 3. In the field of inflammation, we will focus on mechanisms of allergic contact dermatitis and skin wound healing in order to develop novel preventative as well as diagnostic strategies to prevent and treat skin related inflammation. In addition we will focus on the mucosal immune system and how the reciprocal interactions between food‐derived components, microflora, and immune cells determine the immune response locally as well as systemically both in health and disease. 4. Detailed delineation of molecular regulators that play a key role in tumour suppression and pathogen evasion. These studies will also include the role of extracellular vesicles (including exosomes) in these processes. Knowledge on these regulatory pathways may be further developed and incorporated into clinical applications, in particular into combinations with current treatments for cancer, inflammatory and infectious diseases Program 3: Disease profiling Program leaders: G.A.M.S. van Dongen (Radiology & Nuclear Medicine) C.R. Jimenez (OncoProteomics Laboratory, Medical Oncology) T. Würdinger (Neurosurgery) N. van Grieken (Pathology) Vacancy (Clinician) The VUmc CCA program 3 covers fundamental and translational research to identify new determinants for diagnosis, prognosis and tailored treatment for oncological and immunological diseases (solid tumors, hematological malignancies, chronic inflammatory diseases). Program 3 is subdivided in two biomarker‐oriented research lines that employ molecular and imaging technologies. The fields of molecular imaging and genomics provide new opportunities to unravel the unique biology of a specific disease in a specific patient. Integrating imaging and global molecular information with clinical data will allow for a model that may yield tremendously valuable indicators for the individual patient to personalize diagnosis and predictions. This program is a Annual Report VUmc CCA 2014 ‐ Appendix 4: Research programs ‐ 81 of 216 key connection in the line: target discovery ‐ ligand development ‐ molecular imaging – molecular diagnostics ‐ molecular targeted therapy. Imaging In all disease types, modern state‐of‐art CT and MRI‐machines enable imaging of anatomical details with high precision. In addition, imaging techniques like SPECT, PET, PET‐CT, PET‐MRI and optical imaging provide, non‐invasively, unique molecular and biological in vivo information at the tissue level (“molecular imaging”). For this purpose novel reporter probes (tracers) are being developed and evaluated in (pre)clinical studies making use of the unique facilities (cyclotrons, GMP facilities and licenses, animal and clinical PET‐CT and MRI‐CT machines) and expertise available at the campus. Tracers for monitoring key‐drivers of malignancy (hallmarks of cancer, e.g. energy metabolism, oxygenation, hypoxia, proliferation, apoptosis, angiogenesis, metastases formation are routinely used in clinical trials and sometimes part of routine clinical care. The same facilities can be used for the inert (radio)labelling of drugs, to enable their tracking throughout the human body by PET. Collaborations are ongoing with most of the large pharma companies to test their innovative targeted anti‐
cancer drugs, image‐guided, for the first time in man. VUmc recently decided the building of the VUmc Imaging Center Amsterdam (opening 2018/2019) in which all the preclinical and clinical imaging facilities of VU and VUmc will come together. This center will comprise the Tracer Center Amsterdam, and will also facilitate molecular imaging activities of Amsterdam Medical Center. Biomarkers Cancer is a disease caused by alterations in DNA that make cells grow in an uncontrolled way. Identifying the alterations in each tumor’s complete set of DNA – the genome and its epigenetic features – and its functionally relevant RNA and protein complement, the transcriptome and proteome, is expected to increase our understanding how such changes interact to drive the disease. This global molecular information will lay the foundation for improving cancer prevention, early detection and treatment. The VUmc Tumor Genome Analysis Core (TGAC) offers all Next Generation Sequencing (NGS) applications including, but not limited to, analysis of miRNA and mRNA expression, DNA copy number and mutation, with a specialisation in the analysis of clinical and archival materials of formalin fixed origin as well as blood‐based liquid biopsies. These genomic methods are increasingly being applied in studies to improve criteria for disease classification and to identify new prognostic and predictive markers, such as for colorectal, lung and head and neck cancer, lymphoma and other malignancies, and in chronic inflammatory diseases such as rheumatoid arthritis. The OncoProteomics Laboratory employs high resolution mass spectrometry‐based (phospho)proteomics and dedicated bioinformatics / statistics to enable biomarker discovery and validation in cancer cells, tissues and biofluids. The lab is specialized in label‐free analysis which offers a flexible study design that is advantageous for the analysis of large cohorts of clinical samples including formalin‐fixed samples. The infrastructure includes three nano‐liquid chromatography systems on‐line coupled to two high‐resolution tandem mass spectrometers (QExactive) for discovery proteomics and a QTrap 5500 platform for targeted mass spectrometry. Expertise includes global and targeted, multiplexed protein profiling of a variety of sample types (eg., cell/tissue lysates, exosomes, cell surface, secretome,sputum, cerebrospinal fluid, stool, urine, and platelets). These approaches are being applied to develop novel biomarkers in the context of cancer screening (colon cancer) and to enable personalized treatment (various solid tumors, AML). The glycoimmunology group at the Dept. of MCBI provides expertise in glycan profiling (glycomics) using mass spectrometry. Bioinformatics: Bioinformatics pipelines and the infrastructure to handle the NGS data are important points of attention that are centered in the Dry lab which was initiated in 2014. Future efforts will also focus on implementing/developing innovative data analysis strategies (eg., integrative data mining). In 2015 the Dry lab will require further integration in Program 3. Research highlights Program 3 within period 2010‐2015 1. Development of a test to predict therapy responsiveness in rheumatoid arthritis (Lubbers et al. Ann Rheum Dis 2013; Verweij et al. Nat Rev Rheumatol 2011) 2. Identification of peripheral blood biomarkers to predict responsiveness to IFN‐beta therapy in multiple sclerosis (Killestein et al. Nat Rev Neurol 2011) 3. Identification DNA copy number profiles associated with response to drug therapy in advanced colorectal cancer (Haan et al. Nat Communications 2014) 4. Identification temporal and spatial DNA copy number profiles associated with glioma (Van Thuijl et al. Genome Biol 2014; Hegi et al. Acta Neuropathologica 2012) 5. Identification of temporal and spatial DNA copy number profiles associated with lymphoma (Krijgsman et al. Heamatologica 2013) Annual Report VUmc CCA 2014 ‐ Appendix 4: Research programs ‐ 82 of 216 6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
Identification of (epi)genetic changes in HPV‐induced cervical cancer (Steenbergen et al. Nat Rev Cancer 2014; Verhoef et al. Lancet Oncol 2014; Meijer et al. Nat Rev Clin Oncol 2014; Ronco et al. Lancet 2014; Rijkaart et al. Lancet Oncol 2012; Gok et al. BMJ 2010) Identification of genetic profiles associated with head and neck cancer (Adham et al. Clin Cancer Res 2013; Leusink et al. Lancet Oncol 2012; Van Hooff et al. J Clin Oncol 2012; Schneiders et al. J Clin Oncol 2012; Leemans et al. Nat Rev Cancer 2011) DNA and RNA tissue profiling methods (Scheinin et al. Genome Res 2014; De Vree et al. Nat Biotech 2014; Naughton et al. Nat Struct Mol Biol 2013; Heideman et al. J Mol Diagnostics 2012) Novel protein biomarkers for colon cancer screening using stool/ fluid faecal immunochemical test (Bosch et al., Abstract 4523, Proceedings: AACR 103rd Annual Meeting 2012, Mar 31‐Apr 4, 2012; Chicago) Identification of blood platelets as a novel biosource for tumor‐derived nucleic acid biomarkers (Nilsson et al. Blood 2011; Best et al. Acta Neuropathologica 2015) Exosomes are carriers of functional miRNAs (Pegtel et al. PNAS 2010; Koppers‐Lalic et al. Cell Reports 2014) and proteins (Bijnsdorp et al. J Extracell Vesicles 2013; Van der Mijn et al. J Extracell Vesicles 2014) Protein signature for identification of homology repair deficient breast tumors with diagnostic and prognostic value (Warmoes et al. Mol Cell Prot 2012) Identification of protein biomarkers for (early) detection of colorectal cancer biomarkers (Albrethsen et al., Mol. Cell. Prot. 2010; Fijneman et al. Clin Cancer Res 2012; De Wit et al., Gut 2012; J. Prot. 2014) Development of immuno‐PET with long‐lived positron emitters 124I and 89Zr for navigation of antibody development and clinical applications: Worldwide distribution of technology. Development of TKI‐PET (PET with Tyrosine Kinase Inhibitors radiolabed with 11C or 18F) for navigation of TKI development and clinical applications (Slobbe et al. Drug Discovery Today 2012) Development of PET and optical tracers for SN and tumor detection (Heuveling DA et al. J Nucl Med 2013) Development of nanobody technology for targeting critical growth factors and their receptors: perspectives for imaging and therapy (Cohen et al. Nat Protoc 2013; Cohen et al. Cancer Res 2014) Monitoring response using FDG, H2O PET scanning and DCE‐MRI during treatment with EGFR and VEGF inhibitors in NSCLC (Bahce et al. Cancer Res 2013; Van der Veldt et al. Cancer Cell 2012) Development of PET methods in rheumatoid arthritis (Gent et al. J Rheumatol 2014) 19.
Perspectives Within the next five years we foresee the discovery of targets for, and development and (pre)clinical evaluation of several new SPECT and PET tracers for diagnosis, staging, treatment planning and response evaluation as well as the exploitation of PET, PET‐CT, MRI and PET‐MRI imaging in the development of novel therapeutics, and we predict an emergence in biomarker discovery and the development and implementation of new (non‐invasive) companion diagnostics tests. This should contribute to further individualization of treatment, e.g. by more accurate staging, prognostication and therapy response monitoring. PET(‐MRI) imaging will be further explored for early diagnostics and therapy monitoring of rheumatoid arthritis, ankylosing spondylitis and large vessel vasculitis. Breakthroughs are expected in the field of PET imaging in the development and application of novel anti‐cancer drugs, irrespective whether it are biologicals like monoclonal antibodies (mAbs), small molecules or cells (e.g. immune cells or stem cells). Confirmation of precise and optimal targeting in individual subjects and understanding the mechanism of action are key, especially because next generation targeted drugs are designed to be highly potent. The novel molecular imaging techniques have the promise to step beyond the classical TNM‐paradigm. Molecular profiling will yield tissue‐ and liquid biopsy‐based molecular signatures of disease subtypes e.g. in colon, brain, head and neck and lung cancer, lymphoma, and other malignancies, and in chronic inflammatory disease such as rheumatoid arthritis. The CCA Tumor Genome Analysis Core has always been at the forefront in implementation of new NGS applications. In the coming years new technologies will continue to develop rapidly. We aim to enable all researchers within the CCA to perform downstream data analysis and interpretation with state‐of‐the‐art IT facilities, while expanding the possibilities of NGS for archival samples. The continuing reduction in sequencing cost, will help achieve our goals and change the NGS approach towards targeted vs whole genome NGS. The OncoProteomics Laboratory is a pioneer in label‐free protein profiling by mass spectrometry‐based proteomics that enables high‐throughput, comprehensive protein inventories of cells, tissues and biofluids at low level. The integration of proteomic and genomic data by which MS/MS data is searched against customized databases of individual matched DNA/RNA sequence data, referred to as proteogenomics, provides a more comprehensive view of the molecular determinants that drive cancer than genomic analysis alone and may help identify the most important targets for cancer detection and intervention. Our participation in the Center for Personalized Cancer Treatment will enable to explore the value of phosphoproteomics for drug response prediction in a genomic context. The available expertise will allow for integrated application and assessment of imaging, sampling and profiling. Promising applications will be evaluated with respect to their clinical relevance and (cost) effectiveness. Efforts will be put on forming Annual Report VUmc CCA 2014 ‐ Appendix 4: Research programs ‐ 83 of 216 a link between molecular profiling and molecular imaging. A special field of interest will be the development of “radiomics” in which imaging features of a tumor obtained by any type of imaging modality will be evaluated along molecular markers for their potential to predict response to specific therapies, to identify early responders and to identify effective drugs at an early stage. Targets and markers discovered by molecular profiling will yield new molecular tests and the targets can be exploited in the development of disease specific contrast agents (e.g. using monoclonal antibodies, peptides or small molecules) for imaging as well as for therapy. Combined molecular profiling – molecular imaging approaches will be applied in several tumor types, e.g. colorectal, head and neck, lung, lymphoma and other malignancies, and in chronic inflammatory disease. Imaging will contribute to increased insight in tumor biology and pathophysiology, e.g. by pharmacokinetic and dynamic PET analysis. Also molecular interactions can be confirmed and elucidated, which might be of particular value in the development of new cutting‐edge therapeutic agents like monoclonal antibodies, peptides and small molecules that target the root causes of the disease. Emerging imaging innovations that are candidates for large‐scale clinical application will be further evaluated with respect to their (cost) effectiveness in clinical practice, as is presently done with several PET applications. Summary of the research aims for the coming 5 years: Opportunities for Imaging and Biomarkers can be found (but are not restricted) in the following areas: 1. Molecular profiling to identify disease signatures, markers and targets. These markers and targets will be exploited for the development of molecular tests and tracers for imaging. Focus point: integration of serial biopsying, longitudinal blood monitoring, and sequential imaging for early diagnostics and to monitor disease progression and therapy response and switching. 2. Characterization of molecular signatures of tumors (precurser lesions, established tumors, metastases) or immunological diseases, which are of value for selection of the proper therapeutic intervention. 3. Definition and integration of molecular profiles at various stages of development and progression, to provide a comprehensive view of the pathways involved in pathogenesis. 4. Development / implementation of bioinformatics pipelines to enable integrative mining of OMICS data. Focus point: how program 3 (biomarker identification by genetics, proteomics, and imaging analysis) can lead to next generation diagnostics, as well as leads for program 1, 2, 4, and 5. 5. Definition of tumor/pathogen and host interaction. 6. Validation of the predictive value of various biomarkers using either tissues (see above), body fluids and/or images of well defined patient groups who had well‐defined therapy with accurate follow‐up. 7. Development of novel in vivo imaging tools enabling non‐invasive biological and molecular disease characterization for individual patients. For example for early response monitoring or for prediction of poor response upon therapy (e.g. hypoxia and angiogenesis in case of cancer therapy) or for evaluation of the specificity of targeted drugs. Disease‐
specific contrast agents and software tools for quantification will be developed. 8. Initiation of clinical studies with molecular targeting agents to validate molecular targets, by taking tissue samples and or imaging, and to predict the efficacy of a given therapy. 9. Retrospective and prospective clinical studies with phosphoproteomics, targeted mass spectrometry and/or antibody‐
based methods to assess the biomarker potential in tumor biopsies or body fluids of disease‐related proteins and to establish values for sensitivity and specificity. 10. Clinical application studies of PET with specific markers for early diagnostics and therapy monitoring of various inflammatory rheumatic diseases. 11. Initiate discussion on formation of Liquid Biopsy Center and its potential complementarity to the Imaging Center, improving user‐friendlyness of the biobank, adaptation of clinical trials for longitudinal research. Collaboration In and outside VUmc: Projectleaders with projects in program 3 are based at several departments in the VUMC: Pathology, Otolaryngology/Head & Neck Surgery, Radiology & Nuclear Medicine, Molecular Cell Biology, Rheumatology, Hematology, Medical Oncology, Pulmonology, Gastroenterology, Radiology, Gynecology. Bilateral collaborations with leading national and international research groups have been established in the fields of genomics, proteomics, and molecular imaging. In these fields VUmc also participates in many strategic consortia (STW, TIPharma, CTMM, Alpes d’HuZes, ERC and NCI programs). In addition, many collaborations and preferred partnerships exist with leading innovative industries in the fields of molecular diagnosis, molecular imaging, and molecular targeted therapy. Valorisation Multiple patents have been submitted resulting in start‐up companies:  Self‐screen BV  thromboDx BV  Exbiome BV i.o.  Cyclotron BV  LinXis Annual Report VUmc CCA 2014 ‐ Appendix 4: Research programs ‐ 84 of 216 Means Research within VUmc CCA program 3 requires availability of various technology platforms, i.e. presence of state‐of‐the‐art facilities and know‐how. The following technology platforms are available, or planned to be available and in active operation within the coming year: 1. Tumor Genome Analysis Core 2. OncoProteomics Laboratory 3. Functional genomics unit 4. (Molecular) Imaging facilities 5. Research IT infrastructure and bio‐informatics (CCA dry lab) The technology platforms are organized as user‐groups or core facility. For each facility a business plan has been made. Program 4: Innovative therapies Program leaders: J.J.W.M. Janssen (Hematology) G.J. Peters (Medical Oncology) S. Senan (Radiation Oncology) H. van der Vliet (Medical Oncology) The VUmc CCA program 4 encompasses patient‐related translational research within oncology and immune‐mediated diseases. Both early and late‐stage clinical trials are performed in systemic therapy, including immunotherapy, radiotherapy and surgery. Researchers in program 4 include a number of recognized key opinion leaders in their field, with a track record of research leading to changes to standards of care in European and international guidelines. A number of clinical departments serve as national referral centers for diseases, thereby facilitating the design of novel clinical trials, access to new drugs, and established contacts with pharmaceutical companies. The available clinical research infrastructure includes a well‐equipped phase 1‐2 trials unit, dedicated team of research nurses and data managers, and an in‐house clinical research bureau for monitoring of clinical trials. By stimulating interactions within both the program and CCA activities, the program actively promotes the incorporation of novel translational research (such as biomarkers, imaging, immune function) and interventions into standard treatment modalities like radiotherapy, surgery and chemotherapy. The rapid diffusion of immunotherapy‐related research into clinical trials in a number of tumor sites is a clear example of the above. Selected highlights of the program in the period since the last site visit in 2009 are detailed below, in order to give the reader a feel of our strategy. Pioneered by the VUmc Hematology department, the flow cytometric identification of minimal residual disease in acute myeloid leukemia and its relevance for outcome has resulted in an important new risk‐based treatment algorithm that has recently been adopted by all other large AML treatment centers in the Netherlands, Belgium, Scandinavia and Switzerland. This work has resulted in several high impact papers, and, through collaboration between VUmc and the pharmaceutical industry, in a new clinical phase 1 study using a novel highly specific compound targeting leukemia stem cells, which will commence shortly. A key focus of research in systemic therapies has been exploring different clinical schedules for administering targeted therapies such as sunitinib and sorafenib, in ongoing clinical Phase I studies. In addition, the efficacy of combinations of small molecules and antibodies, both with each other and in combination with conventional therapy are in progress (CCR 2010). These studies incorporated extensive translational pharmacological research, and evaluated molecular markers of the targeted agents. Preclinical translational research has focused on downstream markers of the abovementioned drugs and combinations. Another research focus has been the elucidation of various novel resistance mechanisms of targeted therapy, such as mutations at the target domain and aberrant accumulation of drugs (JCO 2013; CCR 2013). Results of studies showing correlation of various miRNAs and single nucleotide polymorphisms (SNP) in relation to the efficacy targeted drugs and combinations with conventional therapy, appeared particularly promising (Ca Res 2010). Exciting results have emerged from translational immunotherapy studies, where the effect of local or systemic administration of immunomodulatory agents has been evaluated. A relevant example of such a study is a phase 1 study (Lancet Oncol. 2012) where the granulocyte‐macrophage colony‐stimulating factor‐transduced allogeneic prostate cancer cells vaccine (GVAX) was combined with ipilimumab, an antibody that blocks cytotoxic T‐lymphocyte antigen 4 (CTLA‐4), based on preclinical studies showing potent synergy with this combination. Apart from documenting the safety and tolerability of this combination, a > 50% decline in PSA values was observed in 25% of the patients. Extensive Annual Report VUmc CCA 2014 ‐ Appendix 4: Research programs ‐ 85 of 216 immunomonitoring demonstrated that a high CD4+CTLA‐4+ T cell frequency was a dominant predictor of survival, potentially allowing future selection of patients responding to therapy. An example of a practice changing surgical trial evaluating surgical techniques involving our principal investigators, is the published international COLOR II randomised trial in more than 1000 patients, showing that laparoscopic surgery in patients with rectal cancer was associated with rates of locoregional recurrence and disease‐free and overall survival similar to those for open surgery [NEJM 2015]. An example from the field of radiotherapy is the image‐guided stereotactic radiotherapy program in early‐stage lung cancer, the second‐largest experience in the world. Initial work in technical research and clinical outcomes were broadened to include published outcome studies in collaboration with the Netherlands Cancer Registry [JCO 2010], cost effectiveness studies in populations [Oncologist 2014], and a randomized study in operable patients [Lancet Oncol 2015]. Currently, we have 2 investigator‐initiated studies investigating immune‐biomarkers following stereotactic radiotherapy and surgery, and the program is accruing patients into three ongoing international trials evaluating the role of immune‐checkpoint inhibitors with chemo‐radiotherapy in locally‐advanced lung cancer. Perspectives and challenges As was pointed out during the previous site visit, the considerable diversity in the clinical departments comprising program 4 makes development of a coherent strategy a continuing challenge for the program leaders. The encouraging increase in measured quality of scientific output of program 4 since 2009 [CWTS reference] reflects in part the broader drive within the CCA to achieve more focus in research, and also vetting of new research proposals by the Scientific Research Committee (CWO) of the VUMC and the program leaders. Research falling outside the goals of the CCA framework are actively discouraged. A key drawback remains that the lack of financial resources available to program leaders to stimulate specific research lines that can facilitate inter‐disciplinary research, and our main instrument is the ability to facilitate good research proposals through positive evaluations. Three practical approaches are now in place in order to improve the quality of grant proposals. Firstly, leaders in program 4 will organise periodic brainstorming sessions with researchers who are planning to develop or submit proposals to both internal and external funding bodies. These sessions will serve to provide guidance on any shortcomings, or opportunities for synergies with ongoing research that could be incorporated into the proposals. Since 2013, clinical and research activities at the VUMC are increasingly organized along patient ´care paths´, with regular meetings now held for both clinicians and laboratory scientists in the tumour care path. We expect that this will further serve to increase opportunities for novel translational research. Finally, reducing the diversity of research will, in our view, improve interaction between researchers in program 4. In the coming period, we propose to exclude some areas of preclinical/fundamental research from the core of program 4, particularly if the likelihood of this research influencing clinical research or trial design in the short‐term is small. In this context we are specifically considering projects which fall into the gray area of pre‐clinical therapy, or translation from screening to therapy. Research aims for the coming 5 years: 1. More actively stimulate the implementation of novel clinical phase I,II and III trial designs that incorporate spin‐offs from on‐going lines of translational and immunological research by early interaction with researchers and clinicians. 2. A key challenge will be to strengthen links with researchers from the AMC (Alliantie partners), in order to identify and develop jointly high‐profile research lines that are internationally recognised. Collaboration In VUmc Currently, translational researchers in program 4 work in close collaboration with more basic researchers from programs 1‐
3 in order to allow the transition of bench‐to‐bedside research. Information on research meetings of all the departments in program 4 is disseminated via the VUmc CCA website to stimulate cooperation among the different departments. It is anticipated that this will increase the cross‐pollination of oncological and immunological research. Outside VUmc The partnerships with industry and with other academic centers in and outside the Netherlands will evolve given the increased scale offered by the VUMC‐AMC Alliantie. We anticipate an increasing focus on research conducted with pan‐
European consortia, and will aim to taking a leadership role in our selected areas of focus. Program 5: Quality of life Annual Report VUmc CCA 2014 ‐ Appendix 4: Research programs ‐ 86 of 216 Program leaders: J. Dekker (Rehabilitation/Psychiatry) B.D. Onwuteaka‐Philipsen (Occupational and Public Health) I.M. Verdonck‐de Leeuw (Otolaryngology–Head & Neck Surgery / VU Clinical Psychology) O. Visser (Hematology) The VUmc CCA program 5 encompasses research within the field of quality of life of cancer patients. Research on quality of life needs a strong interdisciplinary context. Therefore, the joint research program ‘Quality of life in cancer and immunology’ has been established, bridging the research institutes VUmc CCA and EMGO+. Research projects on quality of life in VUmc CCA have an excellent footing in oncology. Research projects on quality of life in EMGO+ have an excellent base in health and care research. The joint research program bridging VUmc CCA and EMGO+ is ideally suited to improve the interdisciplinary context of research on quality of life in cancer. The program “Quality of life” addresses four main topics: 1. Physical function, exercising, and nutrition 2. Psychosocial oncology 3. Communication and shared decision making 4. Palliative care In addition to traditional outcome measures like disease control and overall survival, quality of life has grown to become a standard outcome parameter in clinical studies. The general purpose of health‐related quality of life assessment is to evaluate both the short‐ and long‐term well‐being of individuals or groups of patients/survivors). It is known that self‐
reported health is related to mortality and morbidity and that it can be used to screen for high‐risk groups. Quality of life evaluation can also be used to improve clinical management of patients by obtaining real‐time feedback from individuals on quality of life issues. In addition, data from individual patient and proxy quality of life assessments can facilitate improved communication between patients and their clinicians. In general, tools to assess quality of life are questionnaires also called patient/proxy reported outcomes. Patients with oncological and immune‐mediated diseases and their families have to deal with adverse side‐effects of disease and treatment which may be both physical and psychological. These adverse side‐
effects may affect quality of life substantially both in the short and the long run. Approximately half of all adult cancer patients will survive the disease. Recent studies reveal that many cancer survivors continue to experience problems regarding physical and psychosocial functioning. These problems may occur during or shortly after treatment but also years after completion therapy in the so‐called long‐term survivors, particularly in those who experience adverse late effects. Supportive care is the prevention and management of these adverse effects from diagnosis through anticancer treatment to post‐treatment and palliative care in both patients and their relatives. Information technology has the potential to improve the efficiency of supportive care (e‐health). Physical function, exercising, and nutrition This research line focuses on physical condition, cognitive function, sexual functioning and fertility, and speech and swallowing. Also, studies on cancer rehabilitation and exercising aiming to improve physical functioning are included in this line of research. Nutrition and the nutritional status of cancer patients during and after treatment is directly related to quality of life. Nutrition research during treatment for instance focuses on biomarkers predicting pre‐cachexia and different aspects of malnutrition. Psychosocial oncology The research line Psychosocial oncology encompasses psychological and social aspects for both patients and their proxies of living with oncological and immune‐mediated diseases. Patients often have to deal with side‐effects of initial treatment, and the considerable threat to self‐image, confidence, and identity may be difficult to cope with and can be a cause of psychosocial problems also for patient‐proxies. Specific stressors as fear of death, interruption of life plans, and changes in quality of life often lead to cancer related fatigue and comorbid anxiety, depression, and insomnia. Current research is also investigating cost‐effectiveness of psychosocial care with a special focus on stepped care, self‐management and eHealth. Communication and shared decision making When confronted with cancer, patients’ needs for information can differ. In addition, treatment decisions need involvement of both physician and patient. Shared decision making is an approach where clinicians and patients communicate together using the best available evidence when faced with the task of making decisions. Shared decision making combines evidence‐based medicine with the preferences of patients. Some medical decisions are not strictly based on science, and patients have values that emphasize risks and benefits differently from their doctor. Shared decision making emphasizes the importance of communication in the process of making a decision and the use of decision support interventions. Research in this field contributes to the increasing interest in patient‐centredness and an increasing emphasis on recognising patient autonomy in health care interactions. Palliative care Annual Report VUmc CCA 2014 ‐ Appendix 4: Research programs ‐ 87 of 216 When possibilities for curative or life‐prolonging treatment get more limited, the need for palliative care increases. In palliative care the main focus is in maintaining or increasing the quality of life of patients. As quality of life is highly subjective, patient’s preferences are highly important in palliative care. In this research line research occurs on different main topics. From the perspective of public health there are studies that look at describing important characteristics (e.g. symptom burden, diagnoses, place of care, place of death, transitions and availability and use of palliative care services, end‐of‐life decision‐making) of the last phase of life in population‐based studies (i.e. throughout all health care settings). Another perspective is intervention studies aimed at improving quality of palliative care. Incurable ill patients often experience feelings of sadness, depression, hopelessness and spiritual distress, such as an evaluation of one's past and problems with finding a new meaning in life. In the daily practice of psychosocial care there is an urgent need for evidence‐
based psychosocial intervention methods enhancing the quality of life and dying and relieving the emotional distress in patients and their proxies. Finally, from the perspective of patients and the general populations there are studies on preferences on care and treatment in the last phase of life (and it’s relation with what perceived personal dignity). There is, among others, attention for possible changes in these preferences in the course of an illness process, and for the way physicians and other health care providers consider these preferences in advance care planning and actual care and treatment given in the last phase of life. All research on palliative care in the VUmc falls under the VUmc Expertise Center for Palliative Care that aims to improve palliative care on a national and international level through research, education, and care. Perspectives In the Netherlands, government policy statements and the guidelines “Cancer Rehabilitation” and “Screening for the need for psychosocial care” reflect broad scientific and social support for a structured, integrated approach to supportive care. Supportive care providers may improve the operational and organizational means to deliver care in a structured, comprehensive, and cost‐effective manner. Care can be organized according to stepped care principles in which several evidence‐based interventions are offered in a structured way while a care navigator carefully monitors the recovery of the patients. E‐health applications based on persuasive or motivational designs can be used as helpful tools and have the potential to improve the efficiency of care. At present, interventions are often practice‐based and scientific evidence is lacking regarding cost‐effectiveness. In the next five years, various specific patient‐tailored interventions and care strategies will be developed in a range of oncological and immunological diseases and cost‐effectiveness studies will be carried out. Besides improving and innovating care programmes, more insight will be obtained about quality of life by conducting large‐
scale prospective cohort studies. These ambitions require funding of specific issues as IT analists and consultancy, data storage and management, and care navigators to implement innovative supportive care solutions into clinical practice. Investing in the research lines of VUmc CCA programme 5 “Quality of life” has the potential to utilise market opportunities and to make concepts, knowledge, and supportive care innovations available to society. Research aims for the coming 10 years The common research aims of the four research lines in programme 5 are to generate improved knowledge about quality of life of childhood and adult patients with oncological and immune‐mediated diseases and their families and to conduct high quality innovative translational research into developments and readily available new supportive and palliative care strategies. Highlights of our priorities in the coming 5 years are 1. to perform large‐scale prospective cohort studies and generate improved knowledge about quality of life of patients and survivors, 2. to develop, evaluate and implement innovative (eHealth) interventions to improve supportive and palliative care. Collaboration In VUmc The existing expertise of the VUmc Cancer Center Amsterdam VUmc CCA Research Institute, the VU University Institute for Health and Care Research (EMGO+), the mental health institute GGZ InGeest, and the VUmc Expertise Center for Palliative Care will form a solid basis to facilitate the aims of programme 5. Quality of life researchers in program 5 are working in close contact with medical staff and allied health services to enable rapid implementation of research results into clinical practice and with biomedical researchers from programmes 1‐4 in order to allow large‐scaled cohort studies. Also, the large‐scale patient cohort studies will be tuned into running longitudinal cohort studies at EMGO+. Seminars will be organised at least twice a year in which senior scientists within the field of quality of life will be challenged to discuss their work. Furthermore, we aim at 6 meetings per year in which PhD students actively participate in discussions under supervision of at least one senior researcher. Information about the research of all the departments cooperating in program 5 has been collected and this will be made public on the VUmc CCA website to stimulate cooperation among the researchers working at the different departments. Outside VUmc Annual Report VUmc CCA 2014 ‐ Appendix 4: Research programs ‐ 88 of 216 Researchers in program 5 collaborate with researchers in other university and oncological expertise centers in and outside the Netherlands. There are also collaborations with the Academic Medical Center in Amsterdam and other (University) hospitals, the Netherlands Comprehensive Cancer Centers (IKNL), the Ingeborg Douwes Center for psychosocial care in Amsterdam, Trimbos Institute on Mental Health. Also, members of the various patient societies are involved in our research projects. This will be further exploited in the coming years. Annual Report VUmc CCA 2014 ‐ Appendix 4: Research programs ‐ 89 of 216 Append
dix 5 – Outputt indicators Research
h products for p
peers and societtal target groupss and outreach aactivities in 2014  Conttributions to a diirective, protoco
ol, or policy notee Author(s)/naame researcher(s)
Tittle/topic
Committee
Ang W Ad
dvice to ministry of Health
Ebola
Cornelissen JJ, Ossenkoppele G
ELN guidelines alloSCT
de Gruijl TD, van den Eertwegh AJM,, Drake CG et al. Meedical Treatment of Uro
ological Malignancies (M
MTUM): Immunotherapy
EAU‐ICUD Consu
ultation 2014 Committe
ee on Prostate Cancer ‐ Immunotherapyy de Keizer B, EEsser JP, Lam M, Oyen W
W, de Geus L, Hoekstra O
OS, Vogel W, de Klerk JMH, V
Veltman N Reecommendations: introd
duction therapeutic boneseeking rad
diopharmaceuticals NVNG
Decristoforo C, Penuelas I, Elsinga PH
H, Ballinger JR, Windhorrst AD, A, Verzijlbergen F, Chiti A Verbruggen A
Raadiopharmaceuticals aree special, but is this recognized? The possible im
mpact of the new Clinical Trials Regulation on the
e preparation of rad
diopharmaceuticals Drug developmeent committee EANM
Hastings R, V
Vanni R, Bown N, Betts D
D, Chatters S, Heim S, Zu
uzana Z, van den Berg‐de Ruiter E, Espinet B, Biletti M
M, Bernheim A, van Roy N
N, Ylstra B, Salido Galeote M, R
Roberts P, Teixeir M, Steevens‐Kroef M, Schoumaans‐Pouw J, Simons G Beest Practice Tumour Guid
delines
EU: EuroGentesst
Hoekstra OS Pro
ostate cancer
IKNL
Meelanoma
IKNL
FD
DG PET
EANM
Lymphoma imaging
ICML
Janssen J, Osssenkoppele G CM
ML HOVON/NVvH guidellines
Janssen JJWM
M Gu
uidelines for treatment o
of chronic myeliod leuke
emia anno 2014
HOVON leukemia working party
Maessen‐Vissch MB, van der Wegen‐‐Franken K, Neumann HA
AM, Halk AB, Eggen C, van
n Everdingen JJE, van Mo
ontfrans C, van Neer P, Munte K Gu
uidelines Venous patholo
ogy: Ulcus cruris
NVDV
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 91 of 216 Author(s)/naame researcher(s)
Tittle/topic
Committee
Meijerink MR
R Ree‐evaluation terminal ab
blation in colorectal liverr metastates
Zorginstituut Neederland
Stiichting DHCG
HCC werkgroep
Morre SA and RIVM Ch
hlamydia Screening, CSI
RIVM
Mostert S Ho
ospital Detention Practicces: Position Statement of a Global Task Force
SIOP PODC Glob
bal Task Force Onwuteaka‐P
Philipsen B Who are SCEN‐doctors? Iss there a relations betwe
een education, opinionss an
nd experience of SCEN do
octors and their activitie
es as a SCEN‐doctor. KNMG, SCEN bu
ureau
Functioning of the End of Live Clinic. Report of the
e research evaluation off the firsst year. End of Live Clinical
Ossenkoppelle G, Lowenberg B et al
AM
ML HOVON/NVvH guidelines
Savelkoul P Staandard of care for NF1
VSOP, NFVN, Medical experts Taphoorn MJJB Clinical Outcomes Assessm
ments for Brain Tumor T
Trials National Brain TTumour Society, FDA; Be
ethesda MD, October 15
5, 2014 Todde S, Win
ndhorst AD, Behe M, Bormans G, Decristoforo C
C, Faivre‐Chauvet A, Ferrari V, G
Gee AD, Gulyas B, Halldin C, Kolenc Peitl P, Koziiorowski J, Mindt TL, Sollini M,, et al EA
ANM guideline for the prreparation of an Investig
gational Medicinal Produ
uct Do
ossier (IMPD) Drug developmeent committee EANM
van de Donk N MM guidelines
EMN
van der Horsst‐Bruinsma IE (voorzitteer)
Gu
uidelines Diagnostics and
d Treatment of axial SpA
A
NVR Gu
uideline biologicals
NVR van Dorp W, van Dulmen‐den Broed
der E, van den Berg M, vaan den Heuvel‐
Eibrink MM, Dilorgio N, Levine J, Mu
ulder R, Kremer LCM, Hu
udson M, Haupt R, Wallace W
WH (order to be determined, in preparation) Female Guideline on femaale gonadotoxicity surve
eillance International Gu
uidelines Harmonisation
n Group
Zijlstra JM Lymfomen
Oncologisch Forrmularium 2014
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 92 of 216 Research
h products for p
peers and societtal target groupss and outreach aactivities in 2014  Research outputs other than publicaations Researcher Type of output
Nam
me of product
Short descripttion
Intended
d target of the product (specify scientificc peers or societal group) de Gruijl T Consultaancy
DCP
Prime BV
Development of an allogeneic DC‐bassed tumor vaccine platform Scientificc peers
Softwaree tools, designs or websites http://www.sitcancer.org//
Provides information on latest clinical developmentss in the field of cancer immunotherapy Scientificc peers
Eerenstein SE Softwaree tools, designs or websites ww
ww.hoofd‐halskanker.nl
Make Sense caampaign EHNS
General public
Fijneman RJA
A Softwaree tools, designs or websites http://chipster.ctmm‐trait..nl/
Chipster is an open‐source high‐throu
ughput data analysis softw
ware tool created and maaintained by the IT Center for Science (CSC, Finland), released for use in CTMM‐TraIT. A wo
orkflow for array‐Comparative Genomic Hybridizaation (aCGH) microaarray analysis Molecular Biologists & Bioinform
maticians Israels T Softwaree tools, designs or websites http://paedonc.wix.com/w
wilmsafricaproject Aims and proggress of project
Scientificc peers
Jimenez CR Softwaree tools, designs or websites ww
ww.oncoproteomics.nl
Provides information on the research strategies and activities, publications, infrastructure, collaborationss, and people of the OncoProteomics Laboratory of the VU
Umc Dept of Medical Oncology Scientificc peers
Softwaree tools, designs or websites Betta‐binomial test http://www.oncoproteomics.nl/index.php/resources#s
oftw
ware Dedicated stattistics in R for mass specctral count data Scientificc peers
Softwaree tools, designs or websites MaaxQuant Post‐processingg scripts
R scripts to extract relevant data from
m MaxQuant outtput and to present the results in an end‐user frriendly format Scientificc peers
Softwaree tools, designs or websites Dou
ublecheck
A software too
ol to analyze targeted m
mass spectrometry data Scientificc peers
Dataset
CSFF dataset, ProteomeXchaange with identifier PXD
D000608 Protein compo
osition of extracellular vvesicles isolated from pooled samples of human cerebrospinal fluid (CSF) Scientificc peers
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 93 of 216 Researcher Type of output
Nam
me of product
Short descripttion
Intended
d target of the product (specify scientificc peers or societal group) Kuijl C Softwaree tools, designs or websites Lab
bstore‐MMI
Web interfacee for GGO administration
n
MMI dep
partment
Consultaancy
O|22 integration
Creation of a ccomman workspace for VU/Vumc/AMC/UvA parties in O|2 in collaboration w
with Arno Sinjewel and Rogier de Jong O|2
Datasetss
Reggistry
Dutch Registryy for Irreversible Electro
oporation (IRE or NanoKnife) procedures Dutch IR
RE Cohort (DIRECT) ‐ Vum
mc, AMC, LUMC Consultaancy
Raaad van Advies SPKS
Raad van Adviies Stichting Patienten K
Kanker van het Spijsverterringsstelsel Patients
Consultaancy
Am
mbassador SBBvK
Ambassador SStichting Beeldgestuurdee Behandeling vvan Kanker Patients
Clinical ttrial guidance Clin
nical Trial Reviewer
Response Evalluation for Oncology Trials
BioClinicca BV
Menke‐van d
der Houven van Oordt Consultaancy
Meedical consultant for Rocche
Middeldorp JJM Clinical ttrial guidance Eud
dract nr: 2010‐022444‐220 Phase I‐II study of GCB and VPA plus G
GCV in patients with aadvanced NPC Medical Oncologists
Moll AC Other reesearch product not listeed above (please specify)
Weebsite
www.retinoblastoom.nl
To inform
m patients, family and h
health care workers
Molthoff CFM
M Consultaancy
Bio
omarker testing
Consultancy in
n the field of clinical app
plication of unlabeled monoclonal antibodies Ovarian cancer patients
Morré SA Valorizattion via SME Patthogen detection and tyyping
Diagnostic Asssay development
Medical Microbiology.
Mostert S Parentall education program Info
ormation booklet, DVD, medication diaries
Education matterials for parents of chiildren with cancer Provision
n to parents at diagnosis by medical doctor Onwuteaka‐P
Philipsen B Softwaree tools, designs or websites ww
ww.patz.nu
tools for impleementation of PaTz grou
ups
Health care professionals in prim
mary care Ossenkoppelle GJ Clinical ttrial guidance MR
RD Determination
MRD informs post remission therapy in AML in many Europeaan AML Trialgroups Snijders PJF Softwaree tools, designs or websites http://www.ecca.info/ga/ccampaigns/prehdict/
Provides information on prevention sttrategies for HPV relateed diseases in Europe Scientificc peers and health care professionals Softwaree tools, designs or websites http://www.hpvcentre.nett/prehdict/
Experimental data of FP7 project
Scientificc consortium members Softwaree tools, designs or websites http://www.coheahr.eu/
Information on cervical cancer preven
ntion in Europe Scientificc peers and CoheaHr pro
oject memberrs Meijerink MR
R Scientific peers
Nam
me of product
Short descripttion
Intended
d target of the product (specify scientificc peers or societal group) van der Laken J Datasetss
Ritu
uximab patient data and
d blood samples
For joint reseaarch in consortium of CTTMM TRACER Development of tools to predictt development and mon
nitor treatment of rheum
matoid arthritis
Datasetss
Pattient and blood sample d
data of patients Data of patien
nts subjected to PET scan
nning and radiolabeled n
new potential anti‐inflam
mmatory drug Contribu
ution to development off new anti‐
rheumattic drug van der Vliett JJ Consultaancy
NKTT Therapeutics, Inc. Walltham, MA, USA
Scientific and clinical advise
Scientificc peers
van Dulmen‐‐den Broeder E Research
h project http://www.vumc.nl/afdelingen/kinderoncologie‐
hem
matologie/onderzoek/laate‐effecten‐
ond
derzoek/VEVO‐onderzoeek/ Provides information about the backgground, aims and proggress of the DCOG‐LATER
R VEVO Study on repro
oductive function and risk of premature meenopause in female child
dhood cancer survivo
ors Health in
nformation https://www.skion.nl/voorr‐patienten‐en‐ouders/late‐
effeecten/530/zorg/ Provides information for patients and
d their parents on thee late effects of childhoo
od cancer Research
h project http://www.skionlaterstud
die.nl/
Provides information about currently ongoing large scale nattionwide DCOG‐LATER SStudy Research
h project http://www.pancarelife.eu
u/
Provides information about the currently ongoing Europ
pean study on fertility, o
ototoxicity and quality of life in survivors of childhood cancer van Furth AM
M Design w
website
ww
ww.kids2kidsafrica
Provides information concerning the w
work, research and p
publications of Kids2KidsAfrica van Tilborg A
AAJM Datasetss
Theermal ablation liver tumors
Treatment witth thermal ablation liverr tumors
Scientificc peers
Verdonck‐dee Leeuw IM Softwaree tools, designs or websites ww
ww.samenlevenmetkankker.nl
Provides information on research of the research group "Living with cancer" Research
hers and patients Softwaree tools, designs or websites ww
ww.triple‐ehealth.nl
Information on eHealth projects VU, V
Vumc, GGZ Ingeest Research
hers
Softwaree tools, designs or websites ww
ww. Oncokompas.nl
Public websitee on the OncoKompas
Patients
ww.polaris‐study.org
Information on POLARIS project
Research
hers
ww.kubusproject.nl
Information on NET‐QUBIC project
Research
hers and patients Softwaree tools, designs or websites ww
ww.halszaken‐vumc.nl
Intervention targeting exercises, head
d and neck cancer patientts Patients
Nam
me of product
Short descripttion
Intended
d target of the product (specify scientificc peers or societal group) Softwaree tools, designs or websites ww
ww.prostaatkankerkeuzeehulp.nl
Decision aid fo
or prostate cancer patients
Patients
ww.verderzonderstembaanden.nl
Intervention targeting laryngectomizeed patients
Patients
Voorman J Datasetss
Dattabase HNC patients
Establishmentt OpenClinical database local head and neck onco
ology patients Voskuyl AE Datasetss
DAiRE
National SLE register
Physician
ns, patients, researcherss, health economics of new drugs ww
ww.zakboekdietetiek.nl Background an
nd toolkid for 'zakboek d
dietetiek'
Health in
nformation
Instrumeents
Zeisss 200M Fluorescence Im
maging Robot
Automated Ceell Analysis Robot
CCA/VUm
mc Research Groups Other reesearch product not listeed above (please specify)
Meetamorph 7.1
Digital Image A
Analysis Software Packaages CCA/VUm
Gen
ne Silencing Reagents
Dharmacon on
n target plus RNAi sets
CCA/VUm
Anttibody Library
Reagents for W
Westerns, Immunofluoreescence, IPs CCA/VUm
mc Research Groups Wierdsma N Wolthuis R Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 96 of 216 Outreach activities for ssocietal target ggroups  Lectu
ures for health ccare professionals, general publiic and patients
Researcher Topic Audience
Date (dd‐mm‐yyyy)
Ang W Advice to ministry of Health abou
ut ebola
Politicians
Braamse A Problems and need of care after stemcell transplantation
n
Health care pro
ofessionals Brakenhoff R
R Targeted therapy in HNSCC
German FAsupp
port group 22‐1‐2014
Targeted therapy in HNSCC
Spanish FA support group Bultink, IEM Prednison
n and osteoporosis with SLE
Patients
10‐5‐2014
Carvalho B Biomarkeers in faeces for detectio
on of colon cancer
Nurses
7‐10‐2014
Biomarkeers in faeces for detectio
on of colon cancer
Nurses 6‐11‐2014
Molecular markers for early deteection of
colorectal cancer in stool Gastroenterolo
ogists 18‐11‐2014
de Gruijl T Tumor im
mmunity: how does it wo
ork?
Research nurse
es
17‐3‐2014
Dirven L Measuring instrumental activitiess of daily living in patien
nts with brain
n tumors Health care pro
ofessionals 25‐4‐2014
Measuress of functioning and HRQ
QOL in brain tumor patieents: use and limitations Health care pro
ofessionals (neurosurgeo
ons)
30‐5‐2014
Personalitty and behavioral changges in glioma patients
Health care pro
Collaboraative Wilms Africa Projecct Multi‐disciplina
ary medical professionals in Kampala, Uganda
4‐9‐2014
Israels T Collaboraative Wilms Africa Projecct Multi‐disciplina
ary medical professionals in Lilongwe, Malawi
10‐11‐2014
Lems WF Osteoporrosis Patient organization 8‐11‐2014
Meijerink MR
R Annual co
ongress Stichting Kankerr Actueel
Oncology patients 8‐11‐2014
Contact d
day Patients with cancerr of the gasteroentestinaal tract (SPK
KS) Oncology patients 1‐3‐2014
Menke‐van d
der Houven van Oordt
PET imagiing in cancer
Health Care Pro
Middeldorp JJM Many Facces of Epstein‐Barr virus infection
Health Care pro
ofessionals (MINC)
11‐12‐2014
Mostert S Workshop
p on "Compliance with cchronic diseases"
Clinicians, nurses in Semarang, Indonessia
June 2014
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 97 of 216 Researcher Topic Audience
Onwuteaka‐P
Philipsen B The end o
of live clinic: scientific evvaluation
Congres, End off live clinic as center of eexpertise, Utrecht
20‐3‐2014
Savelkoul P Studium G
Generale Universiteit Mastricht: Darmbacterien
n
General public
9‐10‐2014
Smit L Profession market / Barleas Gymnasium
Students Gymn
nasium 3‐6 1‐1‐2014
Snijders PJF Compatib
biliteit self test systems aand HPV tests
Expertmeeting new screening program
m BMHK, RIVM , Utrecht 18‐7‐2014
van der Horsst‐Bruinsma IE Patient m
meeting about Spondyloarthritis
Patients
30‐okt‐14
Advancess in Axial SpA, WEBCASTT
Rheumatologists (international)
10‐dec‐14
ACR revieew Rheumatologists (national)
9‐dec‐14
Editors in motion Journal patients with rheumatoid arthrritis
Prediction
n of RA by PET and macrrophae targeting
RA patients
January 2014
Detection
n of disease activity of Ankylosing Spondylitis
Ankylosing Spondylitis patients
1‐11‐2014
Survival aafter pediatric cancer
Psychologists, ssocial workers, gynaecollogist
17‐4‐2014
"Fertiliteit" in session paediatric ttumors
Medical specialists, genetici, immunolo
ogists, psychologists, pharmasists, on
ncology nurses, PhD stud
dents, social workers, patients 31‐10‐2014
van Schaardeenburg D Early artriitis: to identification and
d treatment . 4.6.2014, Ede
Day of study for physiotherapists
4‐6‐2014
van Tilborg A
AAJM Ablation o
of liver tumors
Radiodiagnosticc technicians
1‐2‐2014
Verheul HMW
W Angiogenesis inhibitors
Healthcare professionals 16‐1‐2014
Targeted therapy
NVvH Chirurgendagen 2014
HIPEC Healthcare professionals 10‐10‐2014
Update in
n oncology
Voskuyl AE Antiphosp
pholipd syndrome Patients / NVLE
E patient league
10‐5‐2014
Wierdsma N Intestinal failure
Dieticians
17‐4‐2014
Short bow
wel syndrome
Dieticians
29‐9‐2014
Hodgkin lymfoom; consideration
National contacct day for patients with Hodgkin lymphoma
13‐0‐2014
van der Laken J van Dulmen‐‐den Broeder E
Zijlstra JM Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 98 of 216 Outreach activities for ssocietal target ggroups  Conttributions, based
d on research, to
o post initial edu
ucation Researcher To
opic Audience
Boellaard R PEET physics
Clinical Phyysicists, EANM
20‐11‐2014
Kin
netic modeling
Clinical Phyysicists, EFOMP
14‐7‐2014
Kin
netic modeling
Scientists, INMIND 17‐11‐2014
Braamse A Selfmanagement in the co
ommon health care
Teachers, d
department 'Health, Spo
orts & Welfare', Inholland U
University of Applied Scieences 20‐3‐2014
Carvalho B Co
olorectal cancer screenin
ng
Bachelor biomedische wetenschap
p
3‐3‐2014
Cillessen S Experiences with working at a laboratory in the Vu
umc/hospital" HLO studen
nts 12‐2‐2014
Heideman DA
AM Working group Lung Onco
ology, NVALT (Dutch Asssociation of Chest Physicians), Lectu
ure entitled ‘Molecular diaagnostics: basic principlees.’ Chest physiicians March 2014
Mo
olecular diagnosis is to llook forward
Pathologistt, residents in pathology, KMBP(io), medical oncologists, chest physicians May 2014
Hensen EF Pre‐surgical imaging
ENT Specialists 19‐1‐2014
Hoekstra OS Lymphoma imaging guidelines
Radiologen
12‐9‐2014
Lymphoma imaging guidelines
Nuclear Geneeskundigen, Klin Fysicci
21‐11‐2014
PEET in lymphoma
Radiologen
4‐11‐2014
PEET in lymphoma
Radiologen
7‐11‐2014
im
maging biomarker develo
opment
EORTC imag
ging group (radiologists,, nucl med physicians)
22‐9‐2014
Do
osimetry in nuclear medicine
Invited lecture NVS 21‐03‐2014
Reecent developments in ccardial imaging with PETT
Invited lecture NVKF 18‐04‐2014
Jimenez CR (Ph
hospho)Proteomics Tow
wards novel (phospho)prrotein‐
baased biomarker strategiees for patient selection ffor tarrgeted therapy Health praccticioners, medical docto
ors dealing with Oncology patients (lecture in nasch
holingscursus organized by the Nederlanse Vereniging voorr Medische Oncologie) 15‐4‐2014
Mebius RE Lymphoid organ developm
ment
PhD studen
nts course "Advanced Im
mmunology"
30‐01‐2014
Huisman MC
C Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 99 of 216 Researcher To
opic Audience
Lymphoid organ developm
ment
Master and
d PhD students Institute pasteur, Paris
12‐10‐2014
Keeynote Lecture – Day forr Radiologists 2014 ‐
Tu
umorablation, challengess and possibilities for the inttervention radiologist off the future Radiologists
11‐9‐2014
Workshop Tumor Ablation
n ‐ Synergy, Miami, USA
A
Interventional Radiologists and Fellows
4‐11‐2014
Virral Oncogenesis (Organisor/Lecturer)
Master Students Febr. 03‐14, 2014
EB
BV oncogenesis (Lecture)
Master Students Sept. 12, 2014
Virral Oncogenesis (Organisor/Lecturer)
Master Students Febr. 03‐14, 2014
EB
BV oncogenesis (Lecture)
Master Students Sept. 12, 2014
Co
ourse grant writing
Medical Stu
udents June 2014
Co
ourse Hematology Medical Stu
udents June 2014
Su
upervising Internships
Biomedical Science students
During the year
Snijders PJF HP
PV BOP cursus Moleculaire diagnostieek NVVP voor arts‐
assistenten Pathologie 23‐5‐2014
Taphoorn MJJB Ch
hemotherapy, angiogeneesis inhibitors and small mo
olecules for gliomas Health care
e professionals, neurologgists South‐West Netherlands 25‐1‐2014
Up
pdate on new treatmentt for brain tumour patients
Health care
e professionals, neurologgists Apeldoorn, Deventer, D
Doetinchem 13‐2‐2014
Heealth‐related Quality of Life in Brain Tumour Pattients
Health care
e professionals, Biemond
d course Netherlands Society for Neurology 13‐3‐2014
Heealth‐related Quality of Life in Brain Tumour Pattients
Health care
e professionals, Biemond
d course Netherlands Society for Neurology 11‐12‐2014
Im
maging in rheumatology
Medical stu
udents (Immunology foccus education)
June 2014
RO
OIG: imaging in systemicc auto immune diseases
Internists in
n training June 2014
EA
ADV Specialist course Phlebology: Differential diiagnosis of leg ulcers International dermatologists
8‐nov‐14
Fu
uture academic dermato
ology: ways of solving a p
problem byy reference to zbcs of acaademic basic care Dutch derm
matologists 21‐nov‐14
Th
he added value of capillaair microscopy
Rheumatologists 25‐9‐2014
Meijerink MR
R Middeldorp JJM Smit L van der Laken J van Montfrans C Voskuyl AE Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 100 of 216 Researcher To
opic Audience
Sclerodermal care pathwaay
Rheumatologists 26‐9‐2014
Systemic sclerosis
Internal me
edicine 10‐10‐2014
Ylstra B OO
OA course ‐ Replication SStress and Chromosomaal Insstability PhD studen
nts OOA 20‐12‐2013
Zijlstra JM Neew guidelines for evaluaation of malignan lymphoma
Dutch socie
ety for Radiology
12‐9‐2014
Staaging and restaging malignant lymphoma
Sandwich course Radiology
4/11/2014; 7/11/2014
Neew Guidelines for evaluaation of malignant lymphoma
Dutch socie
ety for nuclear medicinee
23‐11‐2014
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 101 of 216 Outreach activities for ssocietal target ggroups  Media attention Researcher Topic Medium Name source
Date (dd‐
mm‐yyyy) URL Bitter W TBC: a persistan
nt Trojan horse ‐ intervieew with Wilbert Bitter
Newspaper (print)
BioNieuws
24‐10‐2014 Click here Brakenhoff R
R HPV (Trainee)
Television
RTL late night
Bultink, IEM Reumatoid artriitis
Cillessen S Researcher of th
he week de Gruijl T de Jong M RondReuma m
magazine
1‐3‐2014
Click here Other online sources (w
weblog, newsfeed, newsletter) KWF February 2014 Click here Succesfull vaccin
nation AML‐patiënts witth leukemic dendritic ceells
Magazine (online/printt)
OncologyUpTo
oDate
jan‐14
Click here “Active Immuun
ntherapy bij Acute Myeloïde Leukemia” Ruben, JW, van den Ancker W, Westers TM,, Ossenkoppele GJ, de G
Gruijl TD, van de Loosdreecht AA Magazine (online/printt)
Nederlands Tijdschrift voor Hematologgie
11‐9‐2014 Click here Trilateral retinoblastoma: a systematic review and meta‐analyssis
Newspaper (print)
Telegraaf
8‐8‐2014
Click here Trilateral retinoblastoma: a systematic review and meta‐analyssis
Newspaper (online)
Different onlin
ne newssites (in NL en BEE)
8‐8‐2014
Click here RTL news (ochtendbulletin)
8‐8‐2014
Trilateral retinoblastoma: a systematic review and meta‐analyssis
Television
Eerenstein SE Awareness Head
d&Neck cancer Other online sources (w
weblog, newsfeed, newsletter) Fijneman RJA
A Biomarkers for d
detection of colorectal ccancer
C2W Chemisch
h Weekblad
03‐07‐2014 Clickhere EGFR PTGS2 colorectal cancer prognosis Other online sources (w
weblog, newsfeed, newsletter) Oncologisch Onderzoek
02‐07‐2014 Click here Biomarkers for ccolorectal cancer Magazine (online/printt)
VUmc CCA Nieeuwsbrief #23
08‐05‐2014 Colorectal canceer sequencing Magazine (online/printt)
VUmc CCA Nieeuwsbrief #23
08‐05‐2014 Thesis Hubers
Other online sources (w
weblog, newsfeed, newsletter) Various
nov‐14
New HPV test
weblog, newsfeed, newsletter) GenomeWeb
jan‐14
Click here Heideman DA
AM sept 24‐28 2014 Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 102 of 216 Researcher Topic Medium Name source
Date (dd‐
mm‐yyyy) URL Lungcancer
weblog, newsfeed, newsletter) various
2014
Click here and here Lungcancer
Tracer 2014,23
3:9
2014
More than just b
blood
Magazine for professionals in chemistry, life sciences, laboratoratorry‐ and procestechnologgy C2W Life Scien
nces, issue 7 25‐04‐2014 Click here KWFgrant: Targeted therapy with triplee‐negative breastcancer
weblog, newsfeed, newsletter) Researcher of the week: Connie Jimenez; 2014
Click here CRC Bioscreen: Development of more eefficient screenings testss for colorectal cancer Other online sources (w
weblog, newsfeed, newsletter) Maag Lever Daarm Stichting
04‐11‐2014 Click here Leemans CR Make Sense Cam
mpaign Second Annual A
Awareness Week
weblog, newsfeed, newsletter) Youtube
11‐9‐2014 Click here Lems WF Osteoporosis
Newspaper (print) Telegraaf
aug‐14
Fractures in patients with rheumatic disseases
Newspaper (print)
Telegraaf
23‐12‐2014 Interview
Radio
Radio 5
20‐03‐2014 Click here Artikel Newspaper (print)
Volkskrant
20‐03‐2014 Looking for tracces of cancer in faeces Newspaper (print)
Parool
06‐14‐2014 New chairman W
WR KWF Other online sources (w
weblog, newsfeed, newsletter) Nieuwsbrief KW
WF
06‐16‐2014 Six million euross new funding for coloreectal cancer research
weblog, newsfeed, newsletter) Nieuwsbrief CTTMM
20‐12‐2014 Click here Healthy collectio
on samples? Radio
BNR Gezond
25‐11‐2014 New colorectal screening test ahead Other online sources (w
weblog, newsfeed, newsletter) Nu.nl, Volkskraant.nl, div andere sites
13‐3‐2014 Cllick here Researcher of th
he week Other online sources (w
weblog, newsfeed, newsletter) Nieuwsbrief KW
WF
1‐11‐2014 Stand up to cancer Dream Team Television
Stand up to cancer
19‐11‐2014 Stand up to cancer Dream Team Radio
Radio NPO1 / K
KRO/NCRV, De Ochtend
d 18‐11‐2014 Click here Jimenez CR Mebius RE Meijer GA Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 103 of 216 Researcher Meijerink MR
R Pegtel M Topic Medium Name source
Date (dd‐
mm‐yyyy) URL Gerrit Meijer leaads the new internation
nal Dream Team of KWF
weblog, newsfeed, newsletter) Arts en Apotheeker.nl
18‐11‐2014 Click here Improved coloreectal cancer research caan prevent many peoplee dying
Newspaper (print)
De Volkskrant
18‐11‐2014 Stand up to cancer Dream Team Other online sources (w
weblog, newsfeed, newsletter) Zorgvisie weekkoverzicht
21‐11‐2014 Biobanks need m
more strick rules Radio
Een Vandaag
2‐12‐2014 NanoKnife offerrs promising treatment ffor pancreatic cancer
Newspaper (print)
NoordHollandss Dagblad
16‐1‐2014 Click here NanoKnife offerrs promising treatment ffor pancreatic cancer
Newspaper (print)
Leidsch Dagblaad
16‐1‐2014 Click here NanoKnife offerrs promising treatment ffor pancreatic cancer
Newspaper (print)
Haarlems Dagb
blad
16‐1‐2014 Click here Zwervend RNA
Newspaper (print)
NRC
27‐09‐2014 Click here Exosomes
American Socieety Cell Biology
Secrete RNA outside the cell Other online sources (w
weblog, newsfeed, newsletter) Quanta magazzine
Click here Exosomes: "the next small thing" Other online sources (w
weblog, newsfeed, newsletter) Life technologies
Click here Zwervend RNA
Newspaper (print)
NRC
27‐09‐2014 Click here Television
ecancer
19‐11‐2014 Click here Quality criteria aas a stimulance for regio
onal networking
De Neuroloog
1‐4‐2014
Click here STOPHersentum
moren.nl awareness event Other online sources (w
weblog, newsfeed, newsletter) Beursgong Cerremonie, Beursplein 5, Amsterdam 9‐6‐2014
Click here Patiënt with braain tumor are victims in several ways
Medisch Contaact
1‐1‐2014
Click here Kwaliteitsdocum
ment voor neuro‐oncolo
ogie Magazine (online/printt)
Medische Oncologie
1‐4‐2014
Click here Thuistest; baarm
moederhalskanker Magazine (online/printt)
Radar+
Autumn 2014 (paages 58‐59) Peters GJ Reijneveld JC
C Snijders PJF Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 104 of 216 Researcher Topic Medium Name source
Date (dd‐
mm‐yyyy) URL van Egmond M Antibody therap
py of cancer Radio
Cancer radio U
US
27‐3‐2014 Financieren wijssheid vergt steeds meerr geluk
C2W Life Scien
nces
23‐10‐2014 Van Furth AM
M Familie in Wetenschap Radio
NPO‐ 1
20‐9‐2014 van Montfrans C Skin cancer day
Radio
Ritme van de sstad
25‐apr‐14 Click here Skin cancer day
Radio
Dit is de dag
17‐mei‐14 Click here EADV congres b
building bridges Magazine (online/printt)
Dermatology ttoday
okt‐14
EADV congres b
Special Nederlands Tijdschrift voor Dermatologie en Venereologie sep‐14
Click here Skin cancer day
weblog, newsfeed, newsletter) VUmc websitee
19‐mei‐14 Click here EADV congres b
EADV news nr 53 winter 2014‐
2015 Click here EADV congres b
EADV news nr 52 autumn 2014 Click here) EADV congres b
EADV news nr 51 summer 2014 Kanker heb je saamen
Newspaper (print)
Het Parool
2‐4‐2014
Genezen maar n
niet beter Magazine (online/printt)
ZIN
1‐2‐2014
Facts & Figures. Other online sources (w
weblog, newsfeed, newsletter) EORTC Qualityy of life group Newslette
er. Issue 14. 1‐12‐2014 Executive Comm
mittee Secretary Introdu
uction. Other online sources (w
weblog, newsfeed, newsletter) EORTC Qualityy of life group Newslette
er. Issue 14. 1‐12‐2014 SBS6 Broadcassting Company
29‐apr‐14 Verdonck‐dee Leeuw IM Wesseling P WHO's next? Brrain tumor classification conference
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 105 of 216 Use of reesearch productts  Interrnational collabo
oration *Type of collaboration 1. Use of dattasets, software tools, ettc. by peers 2. Use of reseearch faciliteit by peers
3. Use of reseearch faciliteit by societtal groups 4. Other use of products not listed above Type of Short description
n of the used collaboratio
on * product Ang W 1
1
1
1
1
1
1
1
Bakema J 1
Sharing materialss/cell lines
2
Sharing techniques (antibody engineering and production) 2
Sharing materialss and experiments/data. E. Breij Bijnsdorp IV
V 4
Collection of patiient samples
Boellaard R 1
SUV analysis toolls 1
SUV analysis toolls 1
Supervised clusteer analysis SW
1
Cardiac Vuer SW 2
PET/MR evaluatio
on & scans, use of PET/MR systems 2
Use of PET/CT for multicenter evaluation of Zr‐ccalibration 1
Boers M 1
1
1
1
1
1
EExternal collaborator (reesearch unit or societal group) ** K
K. Krogfelt, Statens Serum
m Institut
P
P.F. Teunis, Emory Univeersity
W
W. van Pelt, RIVM
H
H.A. Bijlmer, RIVM
H
H. Sprong, RIVM
M
M.M. Leeflang, AMC
R
R. Huits, Institute Tropicaal Medicine
TT.F. Wolfs, UMC Utrecht
TT. Valerius, University of Kiel
G
G. Vidarsson, Sanquin If applicable: name of the conssortium / research netw
work Place ** Country Copenhagen
Atlanta
Bilthoven
Bilthoven
Bilthoven
Amsterdam
Antwerpen
Utrecht
Kiel
Amsterdam
Denmark
USA
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
Belgium
The Netherlan
nds
Germany
The Netherlan
nds
G
Genmab Utrecht
The Netherlan
nds
J. Lammers van Buuren TT. de Reijke, Academical Medical Center
U
Univ. Of Cologne
U
Univ. Of Hasselt
G
Groningen Univ. MC
U
Uppsala PET Ctr
U
Univ. of Leipzig, Univ. of Zurich, Univ. of V
Vienna R
Radboud Univ MC Amsterdam
Cologne
Hasselt
Groningen
Uppsala
Leipzig, Zurich
h, Vienna Nijmegen
The Netherlan
nds
Germany
Belgium
The Netherlan
nds
Sweden
Germany, Swiss, Austria The Netherlan
nds
M. Yaqub M. Huisman, H. Harms P
P. Tugwell, G. Wells
P
P. Brooks
V
V. Strand
J. Kirwan
W
W. Maksymovich
J. Smolen
P
P. Wilkinson
U of Ottawa, C
CA
U of Brisbane
U of Stanford
U of Bristol
U of Edmonton, CA
U of Vienna
U of Liverpool
USA
Australia
USA
United Kingdo
om
USA
Austria
United Kingdo
om
Gran
nt CCA2013‐4‐03 Researcher Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 106 of 216 Braakhuis BJM Brakenhoff R Bultink IEM Type of collaboratio
on * 1
1
1
1
1
Short description
n of the used product Exchange of samples and analyses
Exchange of cell llines and knowledge
EExternal collaborator (reesearch unit or societal group) ** J. Blazeby
R
R. Christensen
A
A. Lanas
P
P. Golusinski
K
K. Hunter
1
4
4
1
Exchange of analyses MicroRNAs Gagomers Sharing of dataseet within the consortium Sharing of dataseet within the consortium Use of vitamin D receptor gene polymorphism asssessments in SLE by researchers within a research network Use of biomarkerrs for SLE by researchers within a research network Use of data on m
major outcomes in SLE patients from
m the Clinical Practice Research
h Datalink by researchers within a research network Sharing of dataseet within the consortium Sharing of dataseet within the consortium Sharing of dataseet within the consortium EE.J. Speel
In
nteRNA Technologies
Q
Quiet Therapeutics
SSanquin Research
1
1
1
1
1
Castelijns J 1
1
de Graaf P 1
Sharing of dataseet within the consortium 1
Sharing of dataseet within the consortium 1
Sharing MRI dataasets within the If applicable: name of the conssortium / research netw
work MiRa
acle MiRa
acle Sanq
quin Research/AMC/Vum
mc collaborative network on SLE Dutcch SLE Registry working p
party.
ZZiekenhuis Groep Twente
M
Maastricht University Meedical Center (Prof.dr. J.W. Cohen Tervvaert) U
University Medical Centeer Utrecht (Prof.dr. T.R.D.J. Radstakke) U
Utrecht Institute of Pharrmaceutical SSciences Place ** Country U of Bristol
U of Copenhaggen
U of Zaragoza
Poznan
Sheffield
United Kingdo
om
Denmark
Spain
Poland
United Kingdo
om
Maastricht
Utrecht
Tel Aviv
Sanquin Reseaarch, Amsterdam Ziekenhuis Gro
oep Twente, Almelo Maastricht Un
niversity Medical Centeer, Maastricht The Netherlan
nds
The Netherlan
nds
Israel
The Netherlan
nds
Researcher P.J. Snijders C.R. Leemanss, R.H. Brakenhoff R.H. Brakenhoff A.E. Voskuyl The Netherlan
nds
A.E. Voskuyl The Netherlan
nds
A.E. Voskuyl University Medical Center Utrecht, Utrecht Utrecht Institu
ute of Pharmaceuticaal Sciences, Utreecht The Netherlan
nds
A.E. Voskuyl The Netherlan
nds
W.F. Lems Erasmus MC, Rotterdam The Netherlan
nds
A.E. Voskuyl EErasmus MC
CHILL multicenter study
H
H.J. Brisse, Departementt of Radiology, In
nstitut Curie, Paris, Fran
nce P
P. Galluzzi, Neuroimaging and N
Neurointervention NINT,, Azienda O
Ospedaliera e Universitaria Santa Maria aalle Scotte, Siena, Italy SS. Göricke, Department o
of Diagnostic aand Interventional Radio
ology and N
Neuroradiology, University Hospital, EEssen, Germany P
P. Maeder, Department of Radiology and In
nterventional Radiologyy, CHUV, LLausanne, Switzerland U
University Hospital Essen
n (D), Curie Euro
opean Retinoblastoma Im
maging Colla
aboration (ERIC) opean Retinoblastoma Im
maging Euro
Colla
aboration (ERIC) P. de Graaf, A
A. Moll Euro
maging Colla
A. Moll Euro
maging Colla
A. Moll P. de Graaf, A
A. Moll Euro
maging Amsterdam
The Netherlan
nds
J.A. Castelijnss, M.C. de Jong, Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 107 of 216 Type of collaboratio
on * 1
1
de Jong M 1
1
1
1
den Haan JM
MM Dirven L Fijneman RJJA 2
1
1
1
1
1
VPH based predicctive model for oral cancer reoccuren
nce in the clinical practice Sharing MRI dataasets within the research networkk Multicenter collaaboration (pooling data, MRI data) Multicenter collaaboration (pooling data, MRI data) Multicenter collaaboration (pooling data, MRI data) Multicenter collaaboration (pooling data, MRI data) Use of microscop
pes Sharing of a dataset Sharing of a dataset EExternal collaborator (reesearch unit or societal group) ** In
nstitute Paris (F), CHUV Lausanne (CH), U
Universitaria Santa Mariaa alle Scotte, SSiena (I) U
University of Parma (I), If applicable: name of the conssortium / research netw
work Colla
aboration (ERIC); Cofoun
nder
OraM
Mod Parma
Italy
U
University of Barcelona
Euro
opean Retinoblastoma G
Group Barcelona
Spain
R.H. Brakenhoff, M.A. van der Wiel, S. M
Mes, C.R. Leemans, D. tte Beest A.C. Moll, W..A. Kors U
University Hospital Essen
n
Euro
maging Colla
aboration Euro
maging Colla
aboration Euro
maging Colla
aboration Euro
maging Colla
aboration Essen
Germany
S. Göricke, S. Sirin Siena
Italy
P. Galluzzi Paris
France
H. Brisse Lausanne
Switserland
P. Maeder Rotterdam
Rome
The Netherlan
nds
The Netherlan
nds
Italy
G. Kraal M.J.B. Taphoorn M.J.B. Taphoorn, J.C. Reijneveld USA
G.A. Meijer The Netherlan
nds
The Netherlan
nds
G.A. Meijer G.A. Meijer G.A. Meijer U
University Hospital, Siena
In
nstitut Curie
C
Centre Hospitalier Univeersitaire Vaudois (C
CHUV) SSanquin, Amsterdam
EErasmus MC
Ittalian Group for Adult H
Hematologic D
Diseases (GIMEMA), Data Center and H
Health Outcomes Researrch Unit Sharing of dataseet within consortium U
University of Minnesota
PROMOTION R.T. Cormier, T. Starr
Place ** Country U
UMCU
EErasmus MC
O. Krranenburg NGS‐‐ProToCol Duluth, MN & Minneapolis, M
MN Utrecht
Rotterdam
EErasmus MC, The Hyve, P
Philips
CTMM TraIT Amsterdam
The Netherlan
nds
Europe, Asia, America A
Amphia MC
C
Catharina MC
K
Kennemer Gasthuis
DeCo
oDe PET group
DeCo
oDe PET group
DeCo
oDe PET group
10 internation
nal laboratorys fro
om academia and industry Breda
Eindhoven
Haarlem
Gibbs S 1
Goos JACM 1
1
1
1
Datasets and tissue specimens
Jeeroen Bosch MC
DeCo
oDe PET group
Den Bosch
The Netherlan
nds
1
U
UMC
DeCo
oDe PET group
Utrecht
The Netherlan
nds
EE. Roggen (3Rs Managem
ment and C
Consultancy, Denmark)
Researcher A.C. Moll Sharing of dataseet within consortium
Sharing of softwaare tools and datasets within cconsortium Sharing of softwaare tools within consortium Pre‐Validation off the VUmc Epidermal equivaalent assay to distinguish sensittizers from non sensitizers Datasets and tissue specimens
1
Short description
n of the used product research networkk The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
J. Baas, A.M. Rijken M.W. van Beek, H.J. Pijpers H. Bril, H.B.A.C. Stockmann, A. Zwijnenbu
urg K. Bosscha, A
A.J. van den Brule, C.J. Ho
oekstra, J.C. van der Linden I.H. Borel Rinkes, P.J. van Diest, R. van Hillegersberg, Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 108 of 216 Short description
n of the used product EExternal collaborator (reesearch unit or societal group) ** If applicable: name of the conssortium / research netw
work Country Datasets and tissue specimens
M
Maxima MC
4
Research Networrk IA
ARC
4
Research Networrk V
Various
4
Research Networrk V
Various
4
Research Networrk V
Various
Interrnational HPV screening work
king group Various
various
4
Research Networrk V
Various
Dutcch RAS EQA initiative
various
The Netherlan
nds 2
Sharing of dataseet within consortium EE.G.E. de Vries
IMPA
ACT Groningen
The Netherlan
nds
2
Sharing of dataseet within consortium M
M. Meignan
PETR
RA_NHL Paris
France
2
2
2
Sharing of dataseet within consortium A
A.C. Dingemans
Sharing of dataseet within consortium D
D. Sullivan
Sharing of dataseet within consortium M
M. Morris
NVALT12 QIBA
A
GAP2
2
Maastricht
Durham
New York
The Netherlan
nds
USA
USA
4
4
Guideline PET in lymphoma
Guideline PET SS.F. Barrington
LLong list
ICMLL group EANM PET guideline group
London
United Kingdo
om
Huisman MC
C 4
P
Philips Medical Systems
Hulleman E 1
Devolpement of PCT workflow functionality Whole genome sequencing data
Hoekstra OSS DeCo
oDe PET group
Place ** 1
Heideman D
DAM Type of collaboratio
on * The Netherlan
nds
Lyon
France
Clinical Lung Cancer Genomee Proje
ect (CLCGP); Network Geenomic Medicine (NGM). PROHTECT, IMPROVE
Various
PMS, Clevelan
nd
SSt Jude Children's Researrch Hospital
Veldhoven
N.A.
Memphis
The Netherlan
nds
United States of America USA
Researcher O. Kranenburrg, M.G. Lam, N. Snoeren I.H. Liem, R.M
M. Roumen, W. Vening S. Vaccarella,, H. De Vuyst, M. Plummer,, S. Franceschi, T. Gheit, M. Tommasino, G.M. Clifford R. Thomas, M
MUMC, UMCG etc RadboudUMC
C (Massuger, H. Bulten, W. M
Melchers, R. Bekkers), ErasmusMC (Kemenade), Screening organisationss, RIVM G. Ronco, J. D
Dillner, K.M. Elfström, S. TTunesi, P.J. Snijders, M. A
Arbyn, H. Kitchener, N. Segnan, C. Gilham, P. Giorgi‐Rossi, J. Berkhof, J. Peeto, C.J. Meijer RadboudUMC
C (van Krieken, Ligtenberg), A
AMC, CWZ, NKI, UMCG, U
UMCU, etc H. Verheul, C
C.M. Menke, M.C. Huisman, R. Boellaard, G.A.M.S. van Dongen, D. Vugts J.M. Zijlstra, H
H.C.W. de Vet, R. Boellaard R. Boellaard, E.F. Smit R. Boellaard A. Lammertsm
ma, M. Yaqub, A.J. van den EEertwegh R. Boellaard, J.M. Zijlstra, A. Lammertsmaa M.M. Yaqub, R. Boellaard Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 109 of 216 Type of collaboratio
on * 4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
Jansen G 4
2
2
2
2
Jimenez CR 2
Short description
n of the used product DIPG cell line VUMC‐DIPG‐A
DIPG cell line VUMC‐DIPG‐A
EExternal collaborator (reesearch unit or societal group) ** SS. Venkataraman, Univerrsity of Colorado
D
D. Ziegler, Children’s Can
ncer Institute A
Australia for Medical Ressearch A
A. Montero Carcaboso, H
Hospital Sant Jo
oan de Déu Barcelona P
P. Yu, Brigham and Wom
men’s Hospital
K
K. Helin, BRIC
EE. Raabe, Johns Hopkins Hospital
M
M. Monje, Stanford Univversity
SS. Plasschaart, UMCG
DIPG cell lines HSSJD‐DIPG‐07, ‐08, ‐
12, and ‐13 LDN‐214117, ACV
VR1 inhibitor
Primary glioma tu
umor material
DIPG cell line JHH
H‐DIPG‐01
DIPG cell line SU__DIPG‐VI
Primary medullob
blastoma tumor material Primary high‐grad
de glioma and DIPG P
P. Johann, German Canceer Research cells: VUMC‐DIPG
G‐A, VUMC‐HGG‐1, C
Center (DKFZ) VUMC‐HGG‐3, an
nd VUMC‐HGG‐6 DIPG cell line VUMC‐DIPG‐A
M
M. Alonso, University Ho
ospital of N
Navarra Primary pediatricc brain tumor EE. Lopez, Centro Medico nacional siglo material and cell cultures X
XXI DIPG cell line VUMC‐DIPG‐A
O
O. Becher, Duke University Medical C
Center Primary high‐grad
de glioma cells: P
P. Murray, University of Birmingham
VUMC‐HGG‐1, an
nd VUMC‐HGG‐3 IL4‐PE compound
d R
R. Puri, FDA, Center for B
Biologics EEvaluation and Research Primary ependym
moma cells: VUMC‐
R
R. Grundy, University of Nottingham
EP‐1, ‐EP‐2, ‐EP‐3
3, ‐EP‐4, and ‐EP‐5 E98 Fluc‐mCherryy cells
SS. van Gool, University Hospital G
Gasthuisberg Medulloblastomaa cell culture
X
X‐N Li, Baylor College of Medicine
Lentiviral hTERT cconstruct
W
W. Böker, Klinikum der U
Universität M
München 3B‐101 liposomal doxorubicin
P
P. Gaillard, toBBB
3D modeling prottein modeling YY.G. Assaraf
facilities Experimental folaate based drugs and P
P.S. Low
imaging agents Experimental (im
mmuno) proteasome C
C.J. Kirk
inhibitors Proteasome inhib
bitors and J. Blank
proteasome analysis facilities Mass spectromettry‐based J.P. Medema, AMC
If applicable: name of the conssortium / research netw
work N.A.
N.A.
Place ** Country Boulder
Randwick
USA
Australia
Euro
opean DIPG network
Barcelona
Spain
N.A.
N.A.
Cure
e starts now DIPG consorrtium
Cure
e starts now DIPG consorrtium
N.A.
Boston
Copenhagen
Baltimore
Stanford Groningen
USA
Denmark
USA
USA
The Netherlan
nds
Euro
opean DIPG network
Heidelberg
Germany
Euro
opean DIPG network
Pamplona
Spain
N.A.
Mexico‐City
Mexico
N.A.
Durham
USA
N.A.
Birmingham
United Kingdo
om
N.A.
Bethesda
USA
N.A.
Nottingham
United Kingdo
om
Euro
opean DIPG network
Leuven
Belgium
N.A.
N.A.
Houston
München
USA
Germany
N.A.
The T
Technion, Israel Institute of Tech
hnology Purd
due University
Leiden
Haifa
The Netherlan
nds
Israel
J. Cloos, G.J. Peters West Lafayette
U.S.A.
C.J. van der LLaken Onyxx Pharmaceuticals
South San Fran
nsisco
U.S.A.
J. Cloos Take
eda Pharmaceuticals
Cambridge
U.S.A.
J. Cloos Conn
nection‐ Alpes d'HuZes
Amsterdam The Netherlan
nds
Researcher T. Wurdingerr D. Noske T. Wurdingerr Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 110 of 216 Type of collaboratio
on * Short description
n of the used product proteomics analyysis / 1 experiment in 2014 for a totaal of 488 hours of instrument time Mass spectromettry‐based proteomics analyysis / 1 experiment in 2014 for a totaal of 23 hours of instrument time Mass spectromettry‐based proteomics analyysis / 1 experiment in 2014 for a totaal of 216 hours of instrument time Mass spectromettry‐based proteomics analyysis / 1 experiment in 2014 for a totaal of 7.5 hours of instrument time Mass spectromettry‐based proteomics analyysis EExternal collaborator (reesearch unit or societal group) ** 2
Place ** Country M
M. Blijsma, AMC
nds
C
C. Garcia de Durango, Un
niversity of Madrid
Spain
EE. Braidot, University of Udine
Udine
Italy
C
C. Korth, Heinrich Heine Universität Dusseldorf
Germany
Mass spectromettry‐based proteomics analyysis D
D. Chasserini, Andrea Veelardi, University o
of Perugia Perugia
Italy
2
Mass spectromettry‐based proteomics analyysis SS. Rottenberg, NKI
nds
2
Mass spectromettry‐based proteomics analyysis O
O. van Tellingen, NKI
nds
2
Beta‐binomial tesst Newcastle
United Kingdo
om
2
Beta‐binomial tesst Erlangen
Germany
2
Beta‐binomial tesst Strasbourg
France
2
Beta‐binomial tesst Oullins
France
2
Beta‐binomial tesst K
K.A. Piróg, Institute of Geenetic Medicine, N
Newcastle University J. Milbradt, Institute for Clinical and M
Molecular Virology, Univversity o
of Erlangen‐Nuremberg
G
G. Schnell, Laboratoire de Spectrométrie d
de Masse BioOrganique, Institut P
Pluridisciplinaire Hubert Curien, U
Université de Strasbourgg A
A. Forterre, CarMeN Laboratory (INSERM 11060, INRA 1362, INSA) U
University of LLyon, Faculté de Médecine Lyon‐Sud V
V.A. Valdenegro‐Vega, N
NCMCRS, Locked B
Bag 1370, University of TTasmania Launceston
Australia
2
2
2
2
work Researcher 2 experimentts in 2014 for a total of 28 ho
ours of instrument tiime 1 experimentt in 2014 for a total of 12 ho
ours of instrument tiime Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 111 of 216 Kaspers GJL Type of collaboratio
on * 2
2
Short description
n of the used product Beta‐binomial tesst Beta‐binomial tesst 2
Beta‐binomial tesst 2
Beta‐binomial tesst 3
3
3
Sharing data Sharing data Sharing data 3
3
4
Sharing data 4
Sharing data 4
4
4
4
Sharing data Sharing data Sharing data Sharing data 4
Sharing data 4
Sharing data 4
4
4
4
Sharing data Sharing data 4
Sharing data EExternal collaborator (reesearch unit or societal group) ** SS. Pisanu, Porto Conte Riicerche
TT. King, Commonwealth Scientific and In
ndustrial Research Organisation FF.J. Sánchez‐Martín, Dep
partment of EEnvironmental Health an
nd Center for EEnvironmental Genetics,, University of C
Cincinnati College of Medicine C
Chawalit Kocharunchitt ,, Food Safety C
Centre, Tasmanian Institute of A
Agriculture, University off Tasmania G
Gottingen University Hosspital
work Place ** Country Alghero
North Ryde
Italy
Australia
Cincinnati
USA
Hobart
Australia
Germany
Europa
Indonesia
C. Kramm Amsterdam
Utrecht
Sydney
The Netherlan
nds
The Netherlan
nds
Australia
Leuven
Belgium
T. van den Beerg M.B. Bieringss R. Howman‐G
Giles, L. Dalla‐
Pozza J. Cools Ontario
Canada
A.D. Schimmeer BRIC
CS
AMLL‐BFM Group
Bonn
n University Medical Cen
nter
Germ
man BFM‐relapse ALL Study Grou
upx Germ
man Cancer Research Ceenter (DKF
FZ) Germ
man COALL Group
Aarhus
Denmark
Germany
Germany
Germany
H. Hasle, A. LLund U. Creutzig, D
D. Reinhardt B. Stoffel‐Waagner G. Henze, D. Stackelberg Germany
M. Kool Germany
I‐BFM
M‐SG London
Euro
opean DIPG network
U
Universitas Diponegoro,ccenter for b
biomedical research SSanquin
U
UMCU / Wilhelmina Kind
derziekenhuis
TThe Childrens Hospital, W
Westmead
C
Center for Human Genettics, Faculty of M
Medicine, KU Leuven P
Princess Margaret Hospital, Ontario C
Cancer Institute H
Hospital Skejby, Aarhus U
University
klin rresearch resea
arch In
nstitut für Humangenetik
M
Mainz University Medicaal Center
U
University of Wurzburg
G
Great Ormond Street Ho
ospital & U
University College Londeen Hospital R
Royal Hospital for Sick Ch
hildren
Researcher Bonn
Sultana, M.H. Faradz Mainz
United Kingdo
om
Germany
Germany
Wurzburg
London
Germany
United Kingdo
om
G. Escherich, G. Janka‐
Schaub D. Webb, M. Zimmerman D. Lohmann P. Kaatsch, J. Byrne, M.M. van den Heuvvel, L.C.M. Kremer, T. Laanger, G. Calaminus, C. Clissman M. Warmuth‐Metz D. Hargrave United Kingdo
om
W.H. Wallacee Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 112 of 216 Type of collaboratio
on * 4
4
4
Short description
n of the used product Sharing data Sharing data Sharing data 4
Sharing data 4
Sharing data 4
4
4
4
4
4
4
4
4
4
4
4
4
Sharing data Sharing data Sharing data Sharing data Sharing data Sharing data Sharing data Sharing data Sharing data Sharing data Sharing data Sharing data Sharing data 4
4
Sharing data 4
4
4
4
Sharing data 4
Sharing data EExternal collaborator (reesearch unit or societal group) ** If applicable: name of the conssortium / research netw
work UCHL
UK‐C
CCGL Place ** SSam Ratulangi Universityy, Dept of P
Pediatrics U
Universitas Diponegoro,d
dept of p
pediatrics U
Universitas Gadjah Madaa
U
Universitas Kristen Indon
nesia
U
University of Sumatera U
Utara
TTechnion‐Israel Institute of Technology
AIEO
OP M
MOI Teaching and Refferral Hospital
M
MTRH
H
HUKM University Kebanggsaan Malaysia
B
Blantyre
C
Centro Medico nacional siglo XXI
N
National University Hosp
pital Singapore
N
National University of Sin
ngapore
B
Baylor College of Medicine
B
Baylor College of Medicine/Texas C
Children's Cancer Centerr C
Childhood Oncology Group
D
Discovery, Millennium Ph
harmaceuticals, In
nc FFred Hutchinson Cancer Research Center
Eldoret
Houston
Country Researcher United Kingdo
om
United Kingdo
om
Indonesia
J. Bomanji P. Kearns, B. Gibson M.F.J. Mantikk, S. Gunawan Indonesia
A. Soemantri Indonesia
Indonesia
Indonesia
Israel
Italy
Kenia
Kenia
Maleisië
Malawi
Mexico
Singapore
Singapore
USA
USA
O. Sutaryo, E. Supriyadi, M.N. Sitaresm
mi, P.H. Widjajanto E. Pane B. Lubis Y.G. Assaraf A. Tésti, A. Peession L. Aluoch, C.N
N. Tenge F. Njuguna H. bt Alias E. Molyneux E. Lopez A. Eng‐Yuh Yeeoh W.J. Chng Xiao‐Nan Li T. Horton USA
USA
R. Aplenc L. Dick USA
S. Meshinch, D. MacPherson B.A. Tannouss J. Skiles, T. Viik, P. Loehrer H
Harvard Medical School
In
ndiana University, Ampaath Oncology In
nstitute N
N8Medical
O
Onyx Pharmaceuticals
O
Oregon Health and Scien
nce University (O
OHSU) USA
USA
SScripps Institution of Oceeanography & SSkaggs School of Pharmaacy and P
Pharmaceutical Sciencess, University of C
California SSt. Jude Children’s Reseaarch Hospital
USA
C. Genberg C.J. Kirk C. Keller, X‐N Li, J. Grill, E. Raabe, O. Becher, M. Monje, P. Speellman (PI's) B.S. Moore USA
R.R. Ribeiro, B. Razzouk, L. USA
USA
USA
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 113 of 216 Kuijl C Labots M Type of collaboratio
n of the used product EExternal collaborator (reesearch unit or societal group) ** 4
Sharing data 4
4
4
4
Sharing data Sharing data Sharing data Sharing data SStanford Institute for steem cell biology aand regenerative Medicine TThe Saban Research Institute
SSkåne University Hospitaal
A
AMC
EEKZ‐AMC
resea
arch resea
arch kwaliteit van leven
Amsterdam
Amsterdam
USA
Zweden
The Netherlan
nds
The Netherlan
nds
4
Sharing data EErasmus MC ‐ SKZ
lab +
+ klin research
Rotterdam
The Netherlan
nds
4
4
Sharing data Sharing data H
Hubrecht Instituut
IK
KNL
Utrecht
Amsterdam
The Netherlan
nds
The Netherlan
nds
4
4
Sharing data Sharing data LLUMC
N
NKI
lab research werk
kgroep kindertumoren Amstterdam resea
arch lab research Leiden
Amsterdam
The Netherlan
nds
The Netherlan
nds
4
4
4
4
4
4
4
Sharing data Sharing data Sharing data Sharing data Sharing data Sharing data Sharing data N
NNF
N
NVK/secie oncologie/hem
matologie
SSKION
TTo BBB
U
UMC Nijmegen
U
UMCG / Beatrix Kinderkliniek
U
UMCU/ Wilhelmina kinderziekenhuis
resea
arch Werkgroep benigne hemato
ologie
lab +
+ klin research
resea
arch multticenter onderzoek
lab research klin rresearch kwaliteit van leeven
Voorburg
Amsterdam
Den Haag
Nijmegen
Nijmegen
Groningen
Utrecht
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
2
1
G
Genentech
M
M. Carducci
South San Fran
ncisco
Baltimore
USA
USA
R
R. Pili
Buffalo
USA
Nijmegen
The Netherlan
nds
Den Bosch
The Netherlan
nds
1
Mouse Experiments Sharing of annotaated tissue samples and data Sharing of annotaated tissue samples and data Sharing of annotaated tissue samples and data Sharing of annotaated tissue samples and data Multicenter study Leiden
The Netherlan
nds
1
Multicenter study U
University Medical Centeer Maastricht
Maastricht
The Netherlan
nds
1
1
1
R Leemans CR
EE. Oosterwijk
work EURO
OTARGET R
R. Ruijtenbeek
U
University Medical Centeer Leiden
Verd
derZonderStembanden. L.A. van d
de Velden, T. Langeveld Verd
de Velden, T. Langeveld
Place ** Country Researcher USA
Robison M. Monje D. Cobrinik A. Grubb C. van den Bo
os H.N. Caron, A
A.Y.N. Schouten‐van
n Meeteren, M. Grootenhuis,, P. van der Spek, L.C.M. Kremer C.M. Zwaan, M. van den Heuvel‐Eibrin
nk, M.L. den Boer, R. Pieteers, P. van der Spek E. Cuppen M. Jansen‐Landheer, H.N. Caron D. Bresters H. te Riele, F..E. van Leeuwen C. Hilders nno
E. Sonneveld, V. de Haas P. Gaillard C.G. Gidding,, J.J. Loonen E.S.J.M. de Bo
ont, W. Tissing M. Bierings, A
A.B. Versluijs, S. Plasschaert G. Kolluman Johns Hopkin
ns Sidney Kimmel Canccer Center Roswell Park Cancer Institute Radboud University Medical Center PamGene BV
V I.M. Verdonck, S.E. Eerenstein I.M. Verdonck, S.E. Eerenstein Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 114 of 216 Martens AC
CM Type of collaboratio
on * 1
Short description
n of the used product Multicenter study EExternal collaborator (reesearch unit or societal group) ** U
University Medical Centeer Groningen
1
Multicenter study R
Radboud University Med
dical Center
1
Multicenter study U
University Medical Centeer Utrecht
1
Development of a humanized 3‐D drug screening syystem Humanized modeel model developed by Martens/Groeen Humanized modeel model developed by Martens/Groeen Humanized modeel model developed by Martens/Groeen Humanized modeel model developed by Martens/Groeen Sharing of dataseet within consortium
C
C.S. Mitsiades, DFCI, Bosston , USA
work NET‐‐QUBIC (The Netherland
ds Quality of Life and Biomediccal Coho
ort Studies). J.A. Langendijk, R. Take
es, C. Terhaard NET‐‐QUBIC (The Netherland
es, C. Terhaard n.a.
J.J. Schuringa
Sharing of dataseet within consortium
Sharing of softwaare tools and datasets within cconsortium Sharing of softwaare tools within consortium Thermal camera scanning of IRE in tissue model EBV exosomes, cell lines and miRNA profiling for PhD exchange research project EBV‐specific and proprietary monoclonal antib
bodies EBV specific synthetic peptides
Purified EBV‐DNA
A from tumor 4
4
4
4
Meijer GA 1
1
1
1
Meijerink M
MR 3
Menke‐van der n Oordt Houven van
1
1
1
2
Middeldorp
p JM 4
4
4
Place ** Country Researcher Groningen
The Netherlan
nds
I.M. Verdonck, R. de Bree, R. Brakenhofff, B. Braakhuis Nijmegen
The Netherlan
nds
I.M. Verdonck, R. de Bree, R. Brakenhofff, B. Braakhuis Utrecht
The Netherlan
nds
IM Verdonck, R de Bree, R Brakenhoff, B
B Braakhuis Boston
USA
R.W.J. Groen n.a
Groningen
The Netherlan
nds
R.W.J. Groen TT. Standal/A. Sundan
n.a.
Trondheim
Norway
R.W.J. Groen M
M. Garayoa
n.a.
Salamanca
Spain
RWJ Groen G
G. Huls/J. Jansen
n.a.
Nijmegen
The Netherlan
nds
R.W.J Groen U
University of Minnesota
R.T. Cormier, T. Starr
USA
R.J.A. Fijnemaan U
UMCU
EErasmus MC
O. Krranenburg NGS‐‐ProToCol Duluth, MN & Minneapolis, M
MN Utrecht
Rotterdam
The Netherlan
nds
The Netherlan
nds
R.J.A. Fijnemaan R.J.A. Fijnemaan EErasmus MC, The Hyve, P
Philips
CTMM TraIT Amsterdam
The Netherlan
nds
R.J.A. Fijnemaan D
Dutch IRE Cohort (DIREC
CT) ‐ Vumc, AMC, LLUMC U
UMCG
R
Radboud UMC
J. Bordet
C
C. Pientong
Dutcch IRE Cohort (DIRECT)
Amsterdam
The Netherlan
nds
IMPA
ACT IMPA
ACT ZEPH
HIR University of Khon Kaen
Groningen
Groningen Brussel
Khon Kaen
The Netherlan
nds
The Netherlan
nds
Belgium
Thailand
R.M. Verdaassdonk, J. Claessens H.M.W. Verheul H.M.W. Verheul H.M.W. Verheul J. Koskinen
ArcD
Dia Turku
Finland
D
D. Doolan
P
P. Farrell
QIMR
Sang
ger Genome Center
Brisbane
London
Australia
United Kingdo
om
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 115 of 216 Type of collaboratio
on * 4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
Moll C 4
1
4
Morré SA Short description
n of the used product material EBV‐specific and proprietary monoclonal antib
bodies EBV‐specific and proprietary monoclonal antib
EExternal collaborator (reesearch unit or societal group) ** If applicable: name of the conssortium / research netw
work Place ** Country D
D. Nadal
University Children's Hospitaal
Zurich
Switzerland
M
M. Luftig
Duke
e University
Durham U.S.A.
K
K. Lim
Korea
H
H‐J. Delecluse
Canccer research Instirute, Daejeon
Chun
ngnam National University Quee
en Mary Hospital, Univeersity of Hong Kong
Hong
g Kong Germ
man cancer research Cen
nter
Heidelberg
M
M. Masucci
MTC
C Karolinska Institute
Stockholm
Sweden
X
X. Zhang, H. Luo
Guan
ngdong Medical College
Zhanjiang
P.R.China
K
K. Luzariaga
Worcester
U.S.A.
EBV‐specific and proprietary monoclonal antib
EBV‐specific and proprietary monoclonal antib
Imaging, MRI, CTT scans
C
C.‐Ching Ng
Univ. Massachusetts Medicaal Scho
ool University of Malaya
Kuala Lkumpur
Malaysia
C
C. Münz
University of Zürich
Zürich
Switserland
J. Steitz
Yale University Medical Scho
ool
New Haven
U.S.A.
SS. Gottschalk
Baylo
or College of Medicine
Houston
U.S.A.
A
A. Moorman
LL. Frappier
Univ. Massachusetts
University Toronto
Worcester
Toronto
U.S.A.
Canada
J. Woulfe
Ottawa Hospital Research In
nstitute
Ottawa
Canada
J. van Beek
RIVM
M
Bilthoven
Euro
maging Essen, Paris, Siena, Colla
aboration Lausanne and Amsterdam Euro
opean Retinoblastoma G
Group
Argentina, Parris, Spain, German
ny, Italy, Swiss, U..K., etc The Netherlan
nds
France, Germany, Italy, Swiss Reum
matology, VUmc
Gastroenterology, VUmc
The Netherlan
nds
The Netherlan
nds
A
A. Chiang
European Retinoblastoma Group started in 2014 to
o collect data about diagnosis, treatm
ment and follow‐up of RB patients. Am
msterdam has WP late effects and Q
QoL 1
1
I.. van der Horst
A
A. van Bodegraven
Amsterdam
Amsterdam
Researcher P.R.China
Germany
Castelijns. dee Graaf, France, Spain, de Graaf, Korrs, Dorsman Germany, Italy, Swiss, U.K., etc B. Crusius B. Crusius Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 116 of 216 Pegtel M Peters GJ Type of collaboratio
on * 1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Open source softtware tool for analysis of RNA sequencing data 1
1
1
1
1 1
1
1
1
1 1
1
1
1
1
1
1 1 1
1
Short description
n of the used product EExternal collaborator (reesearch unit or societal group) ** J. Land
J. den Hartog, H Evers
SS. Bruisten, M. van der Lo
oeff
C
C. Hoebe, N. Dukers
M
M. van der Sande
H
H. de Vries
B
B. Xia
D
D. Dean, D Ojccius, L. de la Maza
220 partners
88 partners
J. Legitseme
J. Paavonen
H
H‐J. Surcel
220 partners
M
M. Hackenberg
work Gyna
aecology, UMCG
Gyna
aecology, UMCG
GGD Amsterdam
GGDZL RIVM
M
AMC
C
Wuh
han Hospital
California Universities
ICTI Consortium
Chlamydia Lab RIVM
CDC
University of Helsinki
Kaste
elli Centre EpiGenChlamydia
N
NKI
U
University of Twente
R
Rega Institute
EEORTC Tranlational reseaarch Division
M
Max‐Delbrück‐Center forr Molecular M
Medicine U
University of Pisa
U
University of Pisa
U
University of Pisa
N
National Cancer Institutee
U
University of Pisa ‐ Dept.. Pharmaceutical SSciences P
Parma Civic Hospital
U
University of Parma
EEuropean Institute of On
ncology
C
Cancer Center Humanitaas U
University of Roma ‐ Sap
pienza
A
Aix‐Marseille Univesite'
In
nstituto Canario de Inveestigación del C
Cáncer (ICIC) U
University of Barcelona, In
nstitute of Biomedicine and Oncology P
Programme U
Universidad de La Laguna
U
University of Bradford
Place ** Country Researcher Groningen
Maastricht
Amsterdam
Heerlen
Bilthoven
Amsterdam
Wuhan
LA, SF, Merced
d
NL, EU, USA
Amsterdam
Atlanta
Helsinki
Oulu
NL, EU, USA
Granada/Amstterdam
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
Ntherlnads
The Netherlan
nds
China
CA, USA
EU, USA
The Netherlan
nds
USA
Finland
Finland
EU, USA
Spain
S. Ouburg S. Ouburg S. Ouburg S. Ouburg S. Ouburg S. Ouburg B. Crusius S. Ouburg S. Ouburg S. Ouburg S. Ouburg S. Ouburg S. Ouburg S. Ouburg D. Koppers‐Laalic R. Be
ernards L. Moroni J. Balzarini J. Hall
I. Fichtner Amsterdam
Twente
Leuven
Brussels
Berlin‐Buch
The Netherlan
nds
The Netherlan
nds
Belgium
Belgium
Germany
E. Giovannettti E. Giovannettti R. Da
anesi N. Fu
unel A. Arrdizzoni A. Pa
aradiso EORT
TC‐PAMM grant. F. Minu
utolo
Pisa
Pisa
Pisa
Bari
Pisa
Italy
Italy
Italy
Italy
Italy
A. Arrdizzoni, M. Tiseo
P. Pe
etronini, R. Alfieri
F. Pe
eccatori A. Sa
antoro, P. Zucali
G. Co
odacci‐Pisanelli
J. Cicccolini J.M. Padron Parma
Parma
Milano
Milano
Roma
Marseille
Tenerife
Italy
Italy
Italy
Italy
Italy
France
Spain
M. Pastor‐Anglada
Barcelona
Spain
FP7 g
grant. L. Leon, J. Padron
n
R. Ph
hillips La Laguna
Bradford
Spain
om
United Kingdo
E. Giovannettti E. Giovannettti, E.F. Smit E. Giovannettti E. Giovannettti E. Giovannettti E. Giovannettti E. Giovannettti E. Giovannettti Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 117 of 216 Postma TJ Savelkoul P Smit L Snijders PJF Steenbergen
n RDM Taphoorn M
MJB Type of collaboratio
on * 1
Short description
n of the used product 1 1 1
1 1
1
4
4
4
1
1
4
4
1
1
1
1
1
1
Sharing of dataseet within the consortium Ispro software Polaris Blood systtem Ydilla POC system
m 1 1
1 1
1
1
Sharing of dataseets by consortium 1
Sharing of dataseets by consortium
1
2
1
1
Sharing datasets Use of in vitro mo
odels Sharing of a dataset Sharing of a dataset Sharing of dataseets by consortium EExternal collaborator (reesearch unit or societal group) ** A
Agricultural University
C
Center for Drug Design aand Discovery, SSVERI’s College of Pharm
macy TTechnion Institute
work S. Eriksson Y. Mayur Place ** Country Researcher Uppsala
Pandharpur
Sweden
India
E. Giovannettti Y. Asssaraf Haifa
Israel
B
Barbara Ann Karmanos C
Cancer Institute
G
Georgetown University
L.H. Matherly G. Giaccone Detroit
Washington D
DC
USA
USA
V
Vanderbilt‐Ingram Canceer Center
N
NCI
EEli Lilly &CO, European H
Head Quarters,
P
Pharmamar
C
Clavis Pharma
U
Universita di Milano, Bicocca
W. P
Pao G. Giaconne & V. Marquez
A. Ha
anauske C.M. Galmarini M. Sandvold Ci‐Pe
erinoms group
Nashville, TN
Bethesda, MD
D
Madrid
Oslo
Milano/Monzaa
USA
USA
Germany
Spain
Norway
Italy
CTMM MARS CTMM MARS R. Ke
erkhoven P. Ce
elie M. M
Maurice M. Jo
ongen‐Lavrencic
B. Blom P. Va
alk M. de Palma Amsterdam
Amsterdam
Amsterdam
Amsterdam
Amsterdam
Utrecht
Rotterdam
Amsterdam
Rotterdam
Lausanne
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
Zwitserland
D. Budding M. Bos M. Bos J. Ne
eefjes K. Ho
offmaster Amsterdam
Boston The Netherlan
nds
USA
B. Pang A. Myers, G. V
Vanasse Amsterdam
Stockholm
The Netherlan
nds
Sweden
E. Struijs C. Meijer, J. B
Berkhof Turin
Italy
C. Meijer, J. Berkhof Brussels
Belgium
C. Meijer, J. B
Berkhof Oslo
Leiden
Rotterdam
Rome
Norway
The Netherlan
nds
The Netherlan
nds
Italy
S.M. Wilting ISS Diagnostics
B
Biocartis
B
Biocartis
TThe Netherlands Cancer Institute
TThe Netherlands Cancer Institute
U
UMCU
EErasmus University A
Academic Medical Centeer
EErasmus University In
nstitut Suisse de Recherrche EExperimentale sur le Can
ncer ( ISREC) TThe Netherlands Cancer Institute
N
Novartis Institutes for Biochemical R
Research V
VU University Medical Ceenter K
Karolinska Institute (J. Diillner)
G. Sa
alomons PREH
HDICT (FP7 funded consortium) C
Città della salute e della scienza di Torino PREH
HDICT (FP7 funded (A
AOT) consortium) SScientific Institute of Pub
blic Health (M. PREH
HDICT (FP7 funded A
Arbyn) consortium) TThe Norwegian Radium H
Hospital
C
Crucell
EErasmus MC
Ittalian Group for Adult H
Hematologic PROMOTION D
Diseases (GIMEMA), Data Center and E. Giovannettti, H.M. Verheul, G. Jaansen E. Giovannettti, H.M. Verheul E. Giovannettti, E.F. Smit J.J. Heimans J. de Wit L. Dirven L. Dirven, J.C.. Reijneveld Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 118 of 216 Type of collaboratio
n of the used product 1
Sharing of a dataset EExternal collaborator (reesearch unit or societal group) ** H
Health Outcomes Researrch Unit
M
Medical Center Haagland
den
1
Sharing of a dataset EEORTC Brussels
Brussels
Belgium
1
1
2
2
2
M
Medical Center Haagland
den
M
M. Nawijn
(No: M. Wuhrer)
(YYes: D. Geerts)
A
Allergopharma
The Hague
UMCG
VU Amsterdam
m
Erasmus MC
Hamburg
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
Germany
D
Danone Research
O
ORCA Therapeutics
Utrecht
Nijmegen
The Netherlan
nds
The Netherlan
nds
C
CTMM TRACER consortiu
um
CTMM TRACER consortium
UMCU, dept o
of Rheumatologyy, Utrecht ETH, Zurich, Switserland/ Philogen Inc., Sienna, Italy Wellington
Manchester
Nantes
New York
The Netherlan
nds
C. Verwij, J.W
W.J. Bijlsma, S. Vosslamber Switzerland, Italy
G.A.M.S. van Dongen, D. Vugts van Beusech
hem VW 2
2
van der Lakeen J 1
Sharing of a dataset Murine graspolleen allergy model
Glycan analysis sh RNA for knockk down studies
Grasspollen allerggic patient derived immune cells Food allergic mou
use model
Use of research ffacilities and expertise Datasets, blood ssamples
1
Datasets, PET imaages, blood samples
EETH Zurich/Philogen Inc, Sienna, Italy
FP7 cconsortium PRIAT
1
1
1
1
V
Victoria University, U
University of Manchester
N
Nantes University
A
Albert Einstein College o
of Medicine
B. Stocker M. Exley M. B
Bonneville S. Po
orcelli, 1
2
2
2
4
4
Medical Medical di Sa
anto P. va
an Berge en Henegouwen
A. Bo
onvin J. Kuball 4
Medical P
Pasteur
U
Utrecht University U
Utrecht University U
Utrecht University R
Rijnstate ziekenhuis Arnh
hem SS. Teunissen, hoogleraarr Hospicezorg, U
UMC Utrecht K
K. Vissers, hoogleraar Pijn en Palliatieve zorg, Radboud LL.C.M. Kremer
Unger WWJ van der Vlieet JJ van der Vorst M van Dulmen
n‐den Broeder E 1 If applicable: name of the conssortium / research netw
work EKZ‐AMC Place ** Country Researcher The Hague
The Netherlan
nds
J.A.F. Koekko
oek, L. Dirven, J.C. Reijneveld, J.J. Heimans, T.J. Postma D. Ediebah, LL. Dirven, F. Galindo‐Garrre, B.M.J. Uitdehaag, J.C. Reijneveld L. Dirven Paris
Utrecht
Utrecht
Utrecht
Arnhem
Utrecht
Nieuw‐Zeelan
nd
United Kingdo
om
France
United States of America France
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
H.M.W. Verheul H.M.W. Verheul Nijmegen
The Netherlan
nds
H.M.W. Verheul Amsterdam
The Netherlan
nds
H.N. Caron, A
A.Y.N. Schouten‐van
n Meeteren, M. Grootenhuis,, H.J. van der Pal Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 119 of 216 van Furth AM Type of collaboratio
on * 1
Short description
n of the used product EExternal collaborator (reesearch unit or societal group) ** A
A.B. Versluijs
M
M.M. van den Heuvel‐Eib
brink
work UMC
CU/WKZ Erasm
musMC/SKZ
J.J. Loonen D
D. Bresters W
W. Tissing
FF.E. van Leeuwen
Place ** Country Researcher Utrecht
Rotterdam
The Netherlan
nds
The Netherlan
nds
UMC
CN LUMC UMC
CG The Netherlandss Kanker Insstituut (NKI)) NNF
Roya
al Hospital for Sick Childrren
Main
nz University Medical Ceenter
Nijmegen
Leiden
Groningen
Amsterdam
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
M. Bierings, JJ. Huisman S.J.C.M.M. Neeggers, J.J. Laven C.B. Beerendonck, H. Knoop M.M. ter Kuillen, L. Louwe A. Simons, G.. Huizinga Voorburg
Edinburg
Mainz
The Netherlan
nds
Scotland
Duitsland
Boyn
ne Research Institute Lim
mited
Pinta
ail Limited Universitätsklinikum Erlangeen
Charrité‐Universitätsmedizin Berlin
Universitätsklinikum Munsteer
Universität Bern
I.R.C.C.S Giannina Gaslini
University Hosptal Brno
Centtre Hospitalier Universitaaire de Saintt‐Etienne Kraeftens Bekaempelse
Moto
ol University Hospiutal
AvL
KU‐U
UZ Leuven St. Ju
udes Boyne
Brno
Saint‐Etienne
Ireland
Ireland
Germany
Germany
Germany
Switzerland
Italy
Czech Republic
France
Prague
Amsterdam
Leuven
Memphis
Cape Town
Denmark
Czech Republic
The Netherlan
nds
Belgie
USA
South Africa
1 1
1
1
1 1
1
1 1
1
1
1
1
1
1
1
1 1
1
1
1
1
1
1
1
J. Falck‐Winther
J. Kruseova
C
C. Lok
FF. Ammant LL. Robison TTygerberg Hospital, Stellenbosch U
University EElisabeth Ziekenhuis
U
Universiteit Maastricht
1
1
1
A
ANOVA institute
EESMID study group
U
Universiteit Maastricht
Mopani Districct
Bern
Maastricht
South Africa
Switserland
1
1
C
Centre for Human Metab
bolomics
K
Kilamanjaro Christian Meedical Center
Potchefstroom
m
Moshi
South Africa
Tanzania
1
TTijgerberg Hospital
Cape Town
South Africa
C
C. Hilders
W
W.H. Wallace
P
PanCareLIFE consortium (PanCareLIFE p
project: EU‐funded) P. K
Kaatsch J. Byrne
C
C. Clissman
TT. Langer
A
A. Borgmann‐Staudt
G
G. Calaminus
C
C. Kuehni
R
R. Haupt
TT. Kepak
C
C. Berger
Erlangen
Berlin
Munster
Bern
Tilburg
Maastricht
M.M. Hudson
n, D. Green D. Visser S.A. Morré O. El Tahir, S.. Ouburg, S.A. Morré F. van den Du
ungen, S.A. Morré, M.M. van Weissenbruch Y. Smulders, M. van Agtmael Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 120 of 216 van Montfraans C van Schaard
denburg D Verdonck‐de Leeuw IM Type of collaboratio
on * 1
4
4
4
4
4
4
4
1
1
Short description
n of the used product Multicenter study Multicenter study Multicenter study Multicenter study Multicenter study Multicenter study Multicenter study Sharing of dataseet within the consortium Multicenter study EExternal collaborator (reesearch unit or societal group) ** U
University of Michigan M
Medical school
C
C. Hebeda
M
M. Loots
H
H. Lam, G. Kuiters
W
W. Roest
J. Serrarens
SS. Beukers
M
M.C. Mooij
Jaan van Breemen researcch Institute / R
Reade O
Oslo University Hospital
1
Multicenter study U
University of Mainz
1
Multicenter study B
Bispebjerg Hospital
1
Multicenter study In
nnsbruck Medical Univeersity
work MOD
DIRA EORT
TC Quality of Life Group, Oral Health Module Developmen
nt Grou
up. M.J. Hjermstad, M. Bergenmar, S.E. Fisher, S. Montel, O. Nicolatou‐Galitis, J. Raberr‐
Durla
acher, S. Singer, I.M. Verd
donck‐de Leeuw, J. Weis, N. Yarom, B.B. Herlofson EORT
TC Quality of Life Group, Head and Neck Cancer Module Up
pdate up. S. Singer, J.I. Arraras,, I. Grou
Baum
mann, A. Boehm, W.C. C
Chie, R. Galalae J.A. Langendijk, O. Gunttinas‐Lichius, E. Hammerlid, M. Pinto
o, O. Nicolatou‐Galitis, C
C. Schm
malz, M. Sen, A.C. Sherm
man, K. Spieg
gel EORT
TC Quality of Life Group, Computerized Adaptive Testting Grou
up. Petersen MA, Aaronsson NK, A
Arraras JI, Chie WC, Conroy T, Costantini A, Giesinger JM, H
Holzner B, King MT, Singer S, Velikovva G, Verd
donck‐de Leeuw IM, You
ung T, Groe
envold M. EORT
TC Quality of Life Group, electtronic patient reported outcome assessment. B. Hollzner, J. Giesinger, M. Groenvold, M..A. Petersen, N.K. Aaronson, G. Velik
kova, I.M. Verdonck‐dee Leeuw
Place ** Country Researcher Ann Arbor, MII
Hengelo
Rotterdam
Zwolle
Almere
Amsterdam
Hoorn
Alkmaar
Reade Amsterrdam
USA
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
The Netherlan
nds
M. van der Ku
uip Oslo
Norway
Mainz
Germany
Copenhagen
Denmark
Innsbruck
Austria
J. v.d. Laken, W.F. Lems, C. Verweij Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 121 of 216 Verheul HM
MW Type of collaboratio
on * 1
Short description
n of the used product Multicenter study EExternal collaborator (reesearch unit or societal group) ** TTwente University
1
Multicenter study U
University Medical Centeer Leiden
1
Multicenter study U
University Medical Centeer Maastricht
1
Multicenter study U
University Medical Centeer Groningen
1
Multicenter study R
Radboud University Med
dical Center
1
Multicenter study U
University Medical Centeer Utrecht
1
Multicenter study V
VU University, Erasmus M
MC, Padjadjaran U
University 1
Multicenter study TTilburg University
1
M
M. Carducci
1
Sharing of annotaated tissue samples and data Sharing of annotaated tissue samples and data Sharing of annotaated tissue samples and data Sharing of annotaated tissue samples and data Sharing of annotaated tissue samples and data Sharing of annotaated tissue samples and data Sharing of annotaated tissue samples and data 1
H
H. El‐Gabalawy
1
1
1
1
1
1
Verweij CL If applicable: name of the conssortium / research netw
work KWF project. E.T. Bohlmeijerr, S. Drosssaert Verd
de Velden, T. Langeveld Verd
de Velden, T. Langeveld NET‐‐QUBIC (The Netherland
es, C. Terhaard KWF project. Passchier J, de Klerk, C, Sa
adarjoen SS Place ** Country Enschede
The Netherlan
nds
Leiden
The Netherlan
nds
Maastricht
The Netherlan
nds
Groningen
The Netherlan
nds
Nijmegen
The Netherlan
nds
C.R. Leemanss, R. de Bree, R. Brakenhoff, B
B. Braakhuis Utrecht
The Netherlan
nds
C.R. Leemanss, R. de Bree, R. Brakenhoff, B
B. Braakhuis Amsterdam, Rotterdam, Sumedang CZ project Shared Decision m
making Tilburg
in prrostate cancer. De Vries M, van Tol‐G
Geerdink J, van Uden‐Kraan CF.
Johns Hopkins Sidney Kimmeel Baltimore
Canccer Center Rosw
well Park Cancer Institute
Buffalo
The Netherlan
nds, Indonesia Researcher C.R. Leemanss, S.E. Eerenstein C.R. Leemanss, S.E. Eerenstein C.R. Leemanss, R. de Bree, R. Brakenhoff, B
B. Braakhuis The Netherlan
nds
J. van Moorseelaar, A. Vis, J. Nieuwenhuizzen USA
M. Labots USA
M. Labots The Netherlan
nds
M. Labots R
R. Ruijtenbeek
EURO
OTARGET, Radboud Univversity Nijmegen
Medical Center Pamgene BV Den Bosch
The Netherlan
nds
M. Labots U
UMCG
IMPA
ACT Groningen
The Netherlan
nds
W. Menke R
Radboud UMC
IMPA
ACT Groningen The Netherlan
nds
W. Menke J. Bordet
ZEPH
HIR Brussel
Belgium
W. Menke TTh. Aune
Vand
derbilt University School of Medicine University of Manitoba
Nashville
USA
Winnipeg
Canada
R
R. Pili
EE. Oosterwijk
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 122 of 216 Voskuyl AE Type of collaboratio
on * 1
1
Short description
n of the used product EExternal collaborator (reesearch unit or societal group) ** P
P. Emery, F. Pongel
X
X. Mariette
1
1
1
SS. Rantapaa‐Dahlvist
W
W. Robinson
TTh. Aune
1
1
1
H
H. El‐Gabalawy
P
P. Emery, F. Pongel
X
X. Mariette
1
1
1
W
W. Robinson
TTh. Aune
1
1
1
H
H. El‐Gabalawy
P
P. Emery, F. Pongel
X
X. Mariette
1
1
1
W
W. Robinson
Sharing of dataseet within consortium D
Dutch Autimmune Registter (DAiRE)
1
1
Sharing of dataseet within consortium
Sharing of dataseet within the consortium Sharing of dataseet within the consortium Use of vitamin D receptor gene polymorphism asssessments in SLE by researchers within a research network Use of biomarkerrs for SLE by researchers within a research network Combined GWASS analysis for breast cancer 1
1
1
Waisfisz Q 1
SSpanish scleroderma gro
oup
SSanquin Research
work University of Leeds
Hosp
pitaux Universiaires Paris‐Sud Universite Paris‐Sud INSERM
M U101
12 University Hospital Umea
Stanford University
Vand
University of Leeds
Hosp
M U101
Stanford University
Vand
University of Leeds
Hosp
M U101
Stanford University
Dutcch Autimmune Register ((DAiRE)
Span
nish scleroderma group
Sanq
quin Research/AMC/Vum
mc collaborative network on SLE CHILL multicenter study
EErasmus MC
M
Maastricht University Meedical Center (JJ.W. Cohen Tervaert) U
University Medical Centeer Utrecht (Prof.dr. T.R.D.J. Radstakke) C
Centre for Cancer Genetic Epidemiology, (BCA
AC) Breast Cancer Association D
Department of Public Heealth and Conssortium P
Primary Care, University of Cambridge, Place ** Country Researcher Leeds
Paris
Great Britain
France
Umea
California
Nashville
Sweden
USA
USA
Winnipeg
Leeds
Paris
Canada
Great Britain
France
Umea
California
Nashville
Sweden
USA
USA
Winnipeg
Leeds
Paris
Canada
Great Britain
France
Umea
California
Amsterdam
Sweden
USA
The Netherlan
nds
Granada
Sanquin Reseaarch, Amsterdam Erasmus MC, Rotterdam Maastricht Un
niversity Medical Centeer, Maastricht Spain
The Netherlan
nds
I.E. Bultink, M
M. Tsang‐a Sjoe The Netherlan
nds
I.E. Bultink, M
M. Tsang‐a Sjoe The Netherlan
nds
I.E. Bultink, M
M. Tsang‐a Sjoe University Medical Center Utrecht, Utrecht International
The Netherlan
nds
I.E. Bultink, M
M. Tsang‐a Sjoe International
H. Meijers‐Heeijboer, M. Adank I.E. Bultink, M
M. Tsang‐a Sjoe, J.W. Bijlsma Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 123 of 216 Type of collaboratio
n of the used product EExternal collaborator (reesearch unit or societal group) ** C
Cambridge, UK
A
Antoni van Leeuwenhoek, Amsterdam
1
National registry of familial breast and ovarian canccer cases Wierdsma N
N 1
V
VU university medical ceenter
Wolthuis R 1
Sharing of Dataseets B
Broad Institute, Harvard
Yaqub M 4
Philips PET/MRI P
Philips clinical science (A
Antonis Kalemis)
Ylstra B 1
U
UMCN
U
UMCU
1 1
1
1
1
1
1 1
1
1
1
N
NKI
A
AMC
A
AMC
A
AMC
U
University of Paris
U
UCSF
1 1
1
1
1
4 4
U
UCSF
C
CNIO
U
University of Edinburgh
U
University of Cambridge
D
Department of Cancer Th
herapeutics and SStratified Oncology, Genome Institute of SSingapore, Singapore, Sin
ngapore Cancer aand Stem Cell Biology Program, Duke‐
N
NUS Graduate Medical SSchool, SSingapore, Singapore Cancer Science In
nstitute of Singapore, National Uni M
MD Anderson Cancer Center
SStanford University
U
University of Minho
R
Royal College of Surgeon
ns in Ireland
M
Maastricht University
C
Cergentis
work Place ** Country Researcher Nationaal
Nationaal
H. Meijers‐Heeijboer, M. Adank Amsterdam
The Netherlan
nds
C.J.J. Mulder,, A.A. van Bodegraven, M.A.E. van Bokhorst‐de van der Schueren HFSP
P Project RGP0053, Annee Carp
penter Group exhib
bits Boston
US
VUmc, Amsterrdam
The Netherlan
nds
H. va
an Krieken, I. Nagtegaal
M. K
Koopman, P. van Diest, W
W. de Laat
S. Lin
nn, R. Kerkhof, P. Nederlof
C. Pu
unt R. Ve
ersteeg, J. Molenaar
F. Ba
aas, E. Aronica
A. Idbaih D. Pinkel. D. Albertson, H. Beng
gstton, A. Olshen J. Costello P. Re
eal N. Gilbert C. Ca
aldas, J. Brenton
P. Ta
an Nijmegen
Utrecht
NL
NL
Amsterdam
Amsterdam
Amsterdam
Amsterdam
Paris
San Francisco
NL
NL
NL
NL
Fr
USA
San Francisco
Madrid
Edinburgh
Cambridge
Singapore
USA
ES
UK
UK
Singapore
K.D. Aldape, R Verhaak
H.‐L. Ji P. Maciel A. Byyrne E.J. S
Speel, M. Van Engeland, H.I. Grab
bsch M. van Min Houston
Stanford
Braga
Dublin
Maastricht
USA
USA
PT
Ireland
NL
Utrecht
NL
(HEB
BON) Hereditair (=Erfelijke) Borst‐ en eierstokkanker Onde
erzoek The Netherlandss R. Boellaard, M. Hofman, O.S. Hoekstraa, A.A. Lammertsmaa, J. Castelijns P. Wesseling,, D. de Jong D. de Jong, G
G.A. Meijer, E. Thunnissen D. Heideman, G.A. Meijer G.A. Meijer P. Wesseling P. Wesseling G.A. Meijer, M
M.A. van der Wiel P. Wesseling,, D. de Jong N. van Griekeen P. Wesseling N. van Griekeen E. Thunnissen
n, G.A. Meijer Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 124 of 216 Zijlstra JM Type of collaboratio
on * 4
4
1
Short description
n of the used product Interim‐PET in maliganat lymphoma Re‐Analysis EExternal collaborator (reesearch unit or societal group) ** A
Agendia
SSomantix
LLYSA; NCRI; PETAL
work A. Gllas L. van de Flier PETR
RA Consortium
Place ** Country Amsterdam
Utrecht
Amsterdam
NL
NL
The Netherlan
nds
Researcher N. van Griekeen O.S. Hoekstraa, H.C.W. de Vet Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 125 of 216 Use of reesearch productts  Patents Researcherr Name
Auth
hor(s)
Description
Number
D
Date assigned Brakenhofff R PCT6037900‐US MiRNA for treatingg head and neck cancer..
Brakkenhoff RH, Van der Plass M, de Kemp SR. MiRNA for treating head and neck cancer PCT6037900‐‐US
de Gruijl T Immunoglo
obulins binding human V
Vγ9Vδ2 T cell receptors
van der Vliet HJ, de Gruijl TD
D, Verheul, HMW, de Bruin RC P31885NL00
pending The use of ccytostatics for the acceleerated differentiation off DC
van Wetering S, Kruisbeek A
AM, Scheper RJ, de Gruijjl TD, vvan de Ven R US8470789B2 25th June 2013 Jansen G Cyclopenta{{G}quinazoline derivativves for the treatment of rheumatoid arthritis or aacute myeloid leukaemiia Janssen, G. Jackman, A. US8466111 B
B2
18‐6‐2013 Pegtel M RNA nucleo
otide extension(s) determ
mine trafficking, activityy, sorting and release Pegttel, Koppers‐Lalic,Hackenberg,Wurdinger, Bijnssdorp P102178EP00
0
van Furth A
AM A method fo
or diagnosing tuberculo
ous meningitis
Cheggou NN, Walz G, van Furrth AM, Visser DH.
2014/02743
Wierdsma N Zakboek Dieetetiek
Kruizzenga HM, Wierdsma NJ
97890865967
747, NUR 893
1‐‐7‐2014 FR‐b targeted antiifolates
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 126 of 216 Demonsstrable marks off recognition  Inviteed lectures Researchers Boellaard R Name meeting (full name) Annual meeting of the European Association of Nuclear Medicine Annual meeting of the European Association of Nuclear Medicine Meeting of Austrrian Clinical Physicists Beyond FDG: mposiumon PET Tracers InternationalSym
in Oncology, Gro
oningen, April 2014 Tuebingen PET/M
MR workshop Boers M XIII Turku PET Syymposium 31st Internationaal Symposium “Radioactive Isottopes in Molecular Imaging” PET pharmacokin
netic course, INMIND PET pharmacokin
netic course, INMIND OMERACT 2014 conference OMERACT 2014 conference OMERACT 2014 conference OMERACT 2014 conference OMERACT 2014 conference EULAR 2014 annual conference EULAR 2014 annual conference Title/topic lecture
Co
ountry
Place
Date The EARL FDG‐PET/C
CT Accreditation Programme & Guideeline Developments: Resu
ults of more than 90 Successfully Accredited Sites and Future Perspectives
New Insights and Deevelopments for the Standardisation of Quantitative R. PET/CT and PET/MR
DG PET/CT studies: Quantification of FD
factors and artifacts affecting SUV. Standardisation and quantification, FDG and beyond weden
Sw
Gothe
enburg 20‐10
0‐2014
weden
Sw
Gothe
enburg 20‐10
0‐2014
Vienna
Austria
1‐9‐2014
NLL
Groningen 4‐4‐2014
Tu
uebingen
Germa
any 10‐2‐2014
Tu
urku
Zeell am See
Finlan
nd Austria
24‐5‐2014
20‐1‐2014
Am
msterdam
Am
msterdam
Bu
udapest
NL
NL
Hunga
ary 1‐2014
17‐11
17‐11
1‐2014
Bu
udapest
Bu
udapest
Hunga
ary Hunga
ary Bu
udapest
Hunga
ary Bu
udapest
Hunga
ary Paaris
France
e
Paaris
France
e
Quantification and SStandardisation: PET/CT versus PET/M
MR Cluster Input
Quantification With Images Only
Introduction of PET kinetic analysis. Parametric analysis methods
preconference workkshop on chronic pain: a brief overview
w of OMERACT Filter 2. opening session: Filtter 2.0
co‐chair, workshop o
on the OMERACT Handbook co‐chair, special inteerest group on patient perspective of remission in RA core side effects of gglucocorticoids, presentation in polyymyalgia rheumatica special interest group 90 minute workshop
p on scientific graphs, given twice
How to get indices aaccepted as outcome measures iin Clinical Trials Other colllaegues of the institute involved URL meeting/program Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 127 of 216 Researchers Name meeting (full name) EULAR 2014 annual conference EULAR 2014 annual conference Braamse A Brakenhoff R
R Bultink, IEM Carvalho B Cloos J De Bree R de Graaf P ASAS 2014 confeerence
Najaarsvergaderring KWF werkgemeenschap Psychosociale Oncologie ECHNO,
FA Support group
ESHG Annual meeting Spanish FA Association HPV conference,, Poznan IFHNOS, New Yo
ork (could not accept) ESP, London (cou
uld not accept) Boerhaave Nasch
holing Reumatologie Annual European
n Congress of Rheumatology EULAR 2014 OsteoRheumatology 2014 International Congress Translational gen
nomics in biomedicine First Internationaal Pediatric Oncology Congress 5th International Symposium on Folate Receptors and Transporters 6th International symposium on sentinel node bio
opsy in head and neck cancer Erasmus course on Magnetic resonance imaging; Central nervous system I Conference Courrse 2014: Case‐based Mastterclass in de Neuroradio
ologie ESHNR 2014 n 2014
Radiologendagen
Title/topic lecture
Co
ountry
Place
One‐year effects of gglucocorticoids on bone density. A metta‐analysis in cohorts of patients o
on high and low dose therapy OMERACT Method o
of Combined Reporting of Benefitt and Harm Applied to the Tear TTrial Keynote lecture on ttrial design
Hulpzoekgedrag van
n patiënten na behandeling met autologe stamceltransplantatie Summarizer
Targeted treatment
Non‐invasive detection
Targeted treatment
HPV molecular biolo
ogy
Osteoporose bij SLE
Multifactorial pathogenesis of osteoporosis in SLE
SLE and fractures
Paaris
France
e
Paaris
France
e
Geent
th
he Netherlands
Belgiu
um Utrech
ht UK
K
Geermany
Itaaly
Sp
pain
Po
oland
Liverp
pool Dusse
eldorf Milan
Sevilla
a
Pozna
an Neetherlands
Frrance
Amerssfoort Paris
10‐2‐2014
14‐6‐2014
Itaaly
Genoa
a
16‐10
0‐2014
DNA copy number changes in colorectal adenoma‐‐to‐carcinoma progression and early diagnosis of colorectal cancer. Molecular diagnosiss & new diagnostic methods in ALL and AML FPGS splicing and resistance in leukemia and lung cancer History of sentinel node biopsy
Sp
pain
Barcelona 13‐3‐2014
Iraan
Teheran 15‐5‐2014
Neetherlands
Heemskerk 1‐10‐2014
Beelgium
Brusse
els 23‐5‐2014
erdam Amste
19‐6‐2014
Aankleurende lesies in de apex orbitae Th
he Neetherlands Th
he Neetherlands Utrech
ht 21‐11
1‐2014
Orbital tumours in children
Pathologie gecentreerd rondom sella‐
Frrance
Th
he Marse
eile s Herttogenbosch
27‐9‐2014
12‐9‐2014
Diseases of the Orbit
Date Other colllaegues of the institute involved URL meeting/program 9‐10‐2014
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 128 of 216 Researchers de Gruijl T de Rie MA Name meeting (full name) International Orgganisation for the st
Immunotherapy of Cancer, 1 meeting, ITOC1 International Socciety for Cell and Gene Therapy of Canceer, ISGCT2014 th
50 Meeting of tthe Dutch Society for Immunology (NV
VvI) Domburg dagen
Eilanddagen
Brugge Dagen
Dekker J Japanese Societyy of Behavioral Medicine Society of Behavvioral Medicine den Haan JM
MM WIRMVIII
DC2014
Dirven L Society for Neuro
o‐Oncology Dorsman J ARVONED
Fijneman RJA
A 26th European C
Congress of Pathology 2014: Jointly Orgganised with the European Society of Pathology OASIS seminar
Gibbs S p ZonMW Expert Workshop
Kennis benuttingg voor TOP grant ZonMW Title/topic lecture
Co
ountry
sphenoid benaderd vanuit intracraniële hoek Biomarker developm
ment for ipilimumab and Prosstate GVAX: new leads Targeting Dendritic C
Cells for melanoma therapy Breaking the immun
ne suppressive status quo in solid tu
umors and their draining lymph nodees Udate systemische b
behandelingen voor psoriasis Screening van artritiis psoriatica, casuistiek Th17: bridging infecttions and psoriasis 67. Psychological disstress in patients with cancer: is screeening the effective solution ? Asssessment of com
morbidity: how and for which purpose ?
Splenic CD169+ maccrophages stimulate germinal ccenter B cell responses and deliveer Ag to FDCs Splenic CD169+ maccrophages stimulate germinal ccenter B cell responses and deliveer Ag to FDCs Personality and behaavioral changes in glioma patients Genomics to improvve diagnostics and care of retinoblastom
ma patients. DNA copy number aberration‐
associated breakpoint detection reveals novel candid
date driver genes for colorectal cancerr Colorectal cancer bio
omarker identification by gen
nomics and proteomics moleculaar profiling alternatieven voor d
dierpoeven
Kennisbenutting
Neetherlands
Place
Date Geermany
Municch 13‐3‐2014
Th
he Neetherlands Th
he Neetherlands Amste
erdam 26‐9‐2014
Kaatsh
heuvel 17‐12
2‐2015
Neetherlands
Domb
burg 15‐5‐2014
Neetherlands
Schierrmon nikoog
29‐6‐2014
Neetherlands
Santpoort 28‐8‐2014
Japan
Kyoto
March 2014
USSA
Philad
delphia 1‐4‐2014
witzerland
Sw
Davoss
22‐3‐2014
Frrance
Tours
18‐9‐2014
USSA
Miami, Florida 13‐11
1‐2014
he Th
Neetherlands UK
K
ht Utrech
28 11
1 2014
Londe
en 3/9/2
2014
Neederland
Amste
erdam 25‐04
4‐2014
Neederland
Neederland
den Haag den Haag 11‐2‐2014
16‐5‐2014
Other colllaegues of the institute involved URL meeting/program Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 129 of 216 Researchers Hensen EF Hoekstra OS Israels T Name meeting (full name) p Organ on a Chip KNAW workshop
Otorhinolaryngo
ological Researh Society spring meeting Title/topic lecture
Co
ountry
Place
Date Skin on a Chip
Head and neck paragangliomas. Genetics, heredity an
nd clinical characteristics. Update revisie melanoom richtlijn
PET biomarker statu
us
Collaborative Wilms Tumour Africa Project Collaborative Wilms Tumour Africa Project Collaborative Wilms Tumour Africa Project Physiologic and pharrmacologic role of drug efflux transp
porters in auto‐
immune disease Towards disease‐freee and treatment‐
free survival in CML
From (colon) cancer proteomics to biomarkers, drug tarrgets and clinical applications Neederland
Grreat Britain
Amste
erdam Londo
on 1‐12‐2014
14‐mrt‐14
NLL
USSA
Caanada
Nunsp
peet Washington Toronto 27‐11
1‐2014
22‐5‐2014
Oct 22nd 2014
Taanzania
Dar ess Salaam April 27 2014
Malawi
Blantyyre Hu
ungary
Budap
pest Septeember 17 2014
3‐4‐2014
Neetherlands
Zoetermeer 10‐11
1‐2014
pain
Sp
Madriid 10‐7‐2014
(Phospho)Proteomiccs, pathways, biomarkers USSA
Chicag
go 6‐3‐2014
Th
he Neetherlands Utrech
ht 10‐9‐2014
5th Workshop Peediatric Oncology (Phospho)Proteomiccs
complementing the CPCT genomics‐
based personalized ttreatment effort with the functionallyy relevant ‐OME Non‐Hodgkin Lymph
homas
Keenya
Eldore
et 5th Workshop Peediatric Oncology Oncological Emergen
ncies
Keenya
Eldore
et EuroNet Meetingg Hodgkin Lymophomas Amsterdams Sym
mposium intensive care verpleegkundigeen SKION dagen
New pediatric oncology structures in The Netherlands Oncologie in de neonatologie
Rotterrdam Amste
erdam 3‐2‐2014
Utrech
ht 6‐2‐2014
Landelijke bijscholingsdag voor Onderwijs vor kinderoncologie Th
he Neetherlands Th
he Neetherlands Th
he Neetherlands Th
he 14‐01
1‐2014 & 15‐01
1‐ 2014 14‐01
1‐2014 & 15‐01
1‐ 2014 31‐1‐2014
Utrech
ht 17‐4‐2014
WIN‐O QIBA annual meeeting
SIOP Renal Tumo
our Study Group Meeting SIOP Africa Meetting
Grand Round Meeeting
Jansen G Meet the Expert Transporter Conference 20144 Janssen JJWM
M Boerhaave cursu
us Leiden Jimenez CR 13th Human Pro
oteome Organisation Worl Congress*
*Invited speakerr and role as chair "Cancer Proteom
mics Session" 2014 ASCO Annu
ual Meeting** **Invited spreakker and role as chair "Educational Pro
oteomics Session" Symposium of th
he Center for Personalized Can
ncer Treatment (CPCT) Kaspers GJL Ontwikkelingen in A
AML
Other colllaegues of the institute involved URL meeting/program Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 130 of 216 Researchers Name meeting (full name) kinderoncologie verpleegkundigen Annual I‐BFM‐SG
G meeting Annual I‐BFM‐SG
G meeting Annual I‐BFM‐SG
G meeting Annual Fall meetting of Children’s Oncology Group
Annual Fall meetting of Children’s Oncology Group
3rd Congress on developments in Hematology and
d Oncology 3rd Congress on developments in Hematology and
d Oncology HiMMS Europe
ITCC/I‐BFM New
w Agents for Leukemia Meeting NOPHO‐DBH AM
ML group meeting Landelijk Shared Care Symposium Kluytmans JA
AJW AML committee meeting/I‐BFM‐SG Medilex: "Bacterriën onder de loep" Belgian Surgical W
Week
Antibiotic Stewardship op de Intensive nd en Vlaanderen Care in Nederlan
NVIC Congres
he German Society for Conference of th
Hygiene and Miccrobiology (DGHM) and the Association ffor General and Applied Microbiology (VA
AAM) iPrevent Sympossium; Infectiepreventie in de ouderenzorg Antibiotic Stewardship Symposium “Optimal use of antimicrobial therapy.” Advisory Board SSurgical Site Infections Title/topic lecture
Co
ountry
verpleegkundigen NL
How to introduce neew agents to de novo AML, Annual I‐‐BFM‐SG meeting APL
Neetherlands
Czzech Reepublique Czzech Reepublique Czzech Reepublique USSA
Chemotherapy backkbone in European Pediatric AML study 01 I‐BFM‐SG studies in relapsed AML
Place
Date Prague
26‐4‐2014
Prague
26‐4‐2014
Prague
26‐4‐2014
Dallass
17‐9‐2014
ICC APL Study 01 update and plans for ICC APL Study 02 Liposomal daunorub
bicin in acute myeloid leukemia Acute promyeloctic leukemia
USSA
Dallass
18‐9‐2014
Co
olombia
Cali
18‐10
0‐2014
Co
olombia
Cali
18‐10
0‐2014
Pediatric Oncology in The Netherlands: Shared
d Care Bortezomib phase II
Th
he Neetherlands Th
he Neetherlands Th
he Neetherlands Th
he Neetherlands USSA
Neetherlands
Beelgium
Amste
erdam 6‐11‐2014
Amste
erdam 7‐11‐2014
Amste
erdam 10‐11
1‐2014
Amste
erdam 21‐11
1‐2014
San Frrancisco Amerssfoort Spa
7‐12‐2014
16‐1‐2014
16‐5‐2014
Neetherlands
Rotterrdam 20‐5‐2014
Neetherlands
Geermany
Utrech
ht Dresden 18‐9‐2014
7‐10‐2014
BRMO, een hardnekkkig probleem
Neetherlands
Nijmegen 16‐10
02014
Resistance as a zoon
notic threat
Neetherlands
Groningen 10‐11
1‐2014
Compliance problem
ms in relation to Neetherlands
Amerssfoort 26‐11
1‐2014
Pediatric AML in Thee Netherlands
Shared care kinderoncologie in Nederland Pediatric high‐risk APL
Resistentie ‐ waar prraten we over?
Use&of&bundles&to
o&prevent&
Use of bundles to prrevent surgical site infections hip in de praktijk, Antibiotic stewardsh
Titel: SDD/SOD als sttewardship methode op de IC Isolation protects my patient
Hygiene – Quo Food and Hospital H
Vadis? Antimicrobial resistance: the role of antibiotic usee in animals Other colllaegues of the institute involved URL meeting/program Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 131 of 216 Researchers Name meeting (full name) Symposium Infecction diseases Kuijl C AIMMS
Labots M posium of the Melanoma symp
DutchWorking G
Group on Immunotherapy of Oncology oma symposium of the Renal cell carcino
DutchWorking G
Group on Immunotherapy of Oncology Positron Emissio
on Tomography: Technology and Application Positron Emissio
on Tomography: Technology and Application EFOMP School fo
or Medical Physics Experts (Nuclearr Medicine) EFOMP School fo
or Medical Physics Experts (Nuclearr Medicine) World Molecularr Imaging Congress Lammertsmaa AA World Molecularr Imaging Congress Annual Congresss of the European Association of Nuclear Medicine Annual Scientificc Meeting of the Japanese Societyy of Nuclear Medicine Leemans CR Annual Scientificc Meeting of the Japanese Societyy of Nuclear Medicine Annual Scientificc Meeting of the Japanese Societyy of Nuclear Medicine Postgraduate Seminar in Otolaryngology aand Head and Neck Surgery head and neck surgery Update Skills in h
and oncology ECHNO 2014
2nd Interdisciplin
nary congress of the Title/topic lecture
Co
ountry
Place
Date Neetherlands
Amste
erdam 16‐12
2‐2014
Neetherlands
Amste
erdam 15‐9‐2015
Neetherlands
Nunsp
peet November 27 2014
Neetherlands
Ede
March 27 2014
UK
K
Londo
on 11‐4‐2014
UK
K
Londo
on 11‐4‐2014
An overview update of plasma input models Reference tissue mo
odeling
Czzech Republic
Prague
10‐7‐2014
Czzech Republic
Prague
10‐7‐2014
Linearised models an
nd parametric imaging Modelling applicatio
ons in oncology studies Radiation safety asseessment of PET tracers for first‐in‐hu
uman studies Quantification versu
us simplification: searching for the optimal trade‐off between accuracy and clinical applicability Forward to the past: the role of digital PET PET in drug developm
ment
So
outh Korea
Seoul
17‐9‐2014
So
outh Korea
Seoul
17‐9‐2014
Sw
weden
Gothe
enburg 20‐10
0‐2014
Japan
Osaka
a
6‐11‐2014
Japan
Osaka
a
7‐11‐2014
Japan
Osaka
a
8‐11‐2014
How do Changing Paatterns of Epidemiology and Trreatments influence Head and Neck Surgery Primary and Salvagee Surgery in Different Sites Salvage Surgery
How do Changing Paatterns of witzerland
Sw
Lausanne 6‐3‐2014
Geermany
Leipzig
25‐3‐2014
Un
nited Kingdom
Ru
ussia
Liverp
pool Mosco
ow 24‐4‐2014
27‐5‐2014
the Care bundle
Centralisation of miccrobiology laboratories? Dissecting the functiional role of host proteins in the intracellular trafficking of bacteria oproteomics in The role of phospho
targeted therapy forr advanced cutaneous melanom
ma Phosphoproteomics for response prediction in patientts with metastatic renal cell carcinoma PET in Drug Discoverry and Development PET: Past, Present an
nd Future
Other colllaegues of the institute involved URL meeting/program Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 132 of 216 Researchers Name meeting (full name) head and neck
EHNS‐ESMO‐ESTTRO Teaching Course on Multidisciplinaryy Management of Head and Neck Oncolo
ogy EHNS‐ESMO‐ESTTRO Teaching Course on Multidisciplinaryy Management of Head and Neck Oncolo
ogy 5th World Congrress of International Federation of Heead and neck Oncologic Societies (IFHNO
OS)/Annual Meeting of the Americal Heaad and Neck Society (AHNS) Collegium Oto‐Rhino‐Laryngologicum m Amicitiae Sacrum
Rete Oncologica del Piemonte e della Valle d Aosta, GIC Testa‐Colla 7th European Heead and Neck Course 7th European Heead and Neck Course 7th European Heead and Neck Course 7th European Heead and Neck Course Head and Neck M
Multidisciplinary Symposium ‐ Turrkish Foundation of Fight Against Can
ncer (TKSV) International Sym
mposium on HPV Infection in Head
d and Neck cander III Congreso Nacional de la Sociedad Espanola de Cabeza y Cuello III Congreso Nacional de la Sociedad Title/topic lecture
Co
ountry
Place
Date Grreece
Athen
ns
29‐6‐2014
Management of the Neck Following Radiotherapy of Cheemo‐radiotherapy Grreece
Athen
ns
29‐6‐2014
Morbidity after Surggery
Grreece
Athen
ns
27‐6‐2014
Management of Reccurrent Tumours
Grreece
Athen
ns
27‐6‐2014
Robotic Head and Neck Surgery: Not as Good Value? Debate‐ Cost vs. Effectiveness of Novvel Surgical Treatments USSA
New Y
York 26‐7‐2014
Critical issues in seleection of patients with oropharyngeal cancer for treatment De‐escalaation trials Multidisciplinary Carre of the Patient with Head and Neckk Cancer: The Example of The Orop
pharynx Case Discussion on tthe Neck (moderator) Oral and Case Discussion on O
oropharyngeal Cancer Parapharyngeal Spacce Tumours
Salvage Following Ch
hemoradiation
Salvage Surgery for H
Head and Neck Tumours Itaaly
Rome
24‐8‐2014
Itaaly
Turin
19‐9‐2014
Po
oland
Pozna
an 1‐10‐2014
Po
oland
Pozna
an 1‐10‐2014
Po
oland
Po
oland
Tu
urkey
Pozna
an Pozna
an Istanb
bul 1‐10‐2014
1‐10‐2014
16‐10
0‐2014
oland
Po
Pozna
an 13‐11
1‐2014
Sp
pain
Oviedo
27‐11
1‐2014
Sp
pain
Oviedo
27‐11
1‐2014
Epidemiology and Trreatments influence Head and Neck Oncology nt of Squamous Surgical Managemen
Cell Cancer of the Orral Cavity Risk groups for surviival in HPV positive head and neeck squamous cell cancer How have changing patterns of epidemiology and trreatment sinfluenced head and neck oncology Salvage surgery afteer chemoradiation Other colllaegues of the institute involved URL meeting/program Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 133 of 216 Researchers Lems WF Name meeting (full name) Espanola de Cabeza y Cuello EULAR Osteorheumatology
Union European Geriatric Society EULAR Osteorheumatology
Union European Geriatric Society M Martens ACM
Mebius RE Meijer GA Annual meeting of the French Hematological So
ociety International Conference on Innate like lymphoid cells 9th ENII ‐ EFIS/EJJI Immunology Summer School WID Immunologie Expert meeting EMBO Conferencce on Innate Lymphoid Cells 2014 Annual biomarkeers conference WEO Colorectal Cancer Screening Committee Meeting NVMDL symposium
NVGE voorjaarsccongres Pathologendagen
TI Pharma springg meeting TI Pharma springg meeting HIMSS Amsterdaam Conference Meijerink MR
R Synergy 2014 ‐ A
A multidisciplinary approach to inteerventional oncology Radiologendagen
n
Middeldorp JJM 16th International EBV conference Title/topic lecture
Co
ountry
Place
Date Frrance
Itaaly
Neederland
Paris
Genua
a
17‐10
0‐‐2014
19‐9‐2014
Frrance
Itaaly
Neederland
Paris
Genua
a
17‐10
0‐‐2014
19‐9‐2014
Frrance
Paris
USSA
Irvine, California Lymphoid organ devvelopment
Itaaly
Lymphoid tissue form
mation in health and disease Innate Lymphoid Cells
Neetherlands
Porto Conte, Alghero, Sardinia Santpoort Frrance
Paris
Biomarker Research: A Clinician’s Perspective Novel protein biomaarkers
UK
K
Manchester March, 20‐21, 2014
7/2/2
2014 ‐
9/2/2
2014 5/5/2
2014 ‐
12/5//2014 11/6//2016 ‐
13/6//2014 29/9//2014 ‐
1/10‐‐2014 5‐2‐2014
Au
ustria
Vienna
17‐10
0‐2014
Am
msterdam
Nethe
erlands 16‐4‐2014
Veeldhoven
Zeeist
Nethe
erlands Nethe
10‐4‐2014
Am
mersfoort
Nethe
Am
mersfoort
Am
msterdam
Nethe
erlands Nethe
6‐11‐2014
USSA
Miami
15‐11
1‐2014
th
he Netherlands
Den Bosch 11‐9‐2014
Au
ustralia
Brisba
ane 16‐7‐2014
failure
Osteoporosis
Glucocorticoids and bone
Osteoarthritis, rheum
matology perspective Osteoporosis
Glucocorticoids and bone
Osteoarthritis, rheum
matology perspective A humanized mousee model to study hematological maliggnancies Innate like lymphoid
d cells
Standaardverslag co
olonpathologie, wat moet je weten? Introduction of CRC
Biobankieren met dee schatkamer van de pathologie MLD stichting; The case of VUmc/M
Health foundations aas partner to cross the ‘Valley of D
Death’ in translational medicin
ne Inleiding Medical IT Integration
Data integration as tthe centerpiece in translational researcch Radiofrequency ablaation, microwave ablation or irreversib
ble electroporation (Nan
noKnife) Keynote Lecture ‐ Interventional Oncology Cytolytic virus activaation therapy
Other colllaegues of the institute involved URL meeting/program Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 134 of 216 Researchers Moll AC Moorselaar R
RJA Name meeting (full name) 100 years retinoblastoma at MSKCC, New York Retinoblastoma Oogheelkunde in
n vogelvlucht 2014. European Retino
oblastoma Group, kick‐
off meeting State of the Art U
Urology op herhaling Dutch Oncoforum
m
4e Symposium N
Niercelcarcinoom ESU course: Surggery or radiotherapy for localised and loccally advanced prostate cancer ESU course: Surggery or radiotherapy for localised and loccally advanced prostate cancer Prostaatkanker. Bayer
ESU course: Earlyy diagnosis of prostate cancer and treattment of localised prostate cancer
ESU course: Earlyy diagnosis of prostate cancer and treattment of localised prostate cancer. The national congress of the Slovak Asssociation of Urology. 5 juni 2014, Nitra, Slovakia ESU course: Earlyy diagnosis of prostate cancer and treattment of localised prostate cancer. The national congress of the Slovak Asssociation of Urology Update in Urologgy
Workshop Oncollogie. The European Urrology Residents Education Prograamme (EUREP), 12th EUREP Course The European Urrology Residents Education Prograamme (EUREP), 12th EUREP Course Urology State of the Art U
Title/topic lecture
Co
ountry
Place
Date High risk retinoblasttoma
U..S.A.
New Y
York 18‐9‐2014
MRI screening for seecond primary malignancies in irrad
diated RB patients Retinoblastoom
Diagnosis, late effects and quality of life Opening door de daggvoorzitter
Prostaat‐ en blaascaarcinoom: rol van de uroloog. Gelokaliseerd nierceelcarcinoom: behandelen of afwachten? How and when to usse nomograms and networks Geermany
Essen
21‐11
1‐2014
th
he Netherlands
Frrance
Amste
erdam Paris
17‐1‐2014
4‐3‐2014
NLL
NLL
Wolfh
heze Amste
erdam 8‐2‐2014
18‐2‐2014
NLL
s Herttogenbosch
27‐3‐2014
Zw
weden
Stockh
holm 13‐4‐2014
Adjuvant therapies ffollowing radical prostatectomy: Whaat is the standard and what is new? Lunch and learn
Unique education op
pportunity for urologists. Zw
weden
Stockh
holm 13‐4‐2014
NLL
Slo
ovakia
Mijdre
echt Nitra
22‐4‐2014
5‐6‐2014
Does early diagnosiss mean early treatment? Slo
ovakia
Nitra
5‐6‐2014
Radiotherapy in the treatment of localised prostate caancer. Slo
ovakia
Nitra
5‐6‐2014
Prostaatcarcinoom: de willekeur voorbij. osis and Testis cancer: Diagno
treatment of stage I disease. NLL
Domb
burg 27‐6‐2014
NLL
Czzech Republic
Domb
burg Prague
27‐6‐2014
5‐9‐2014
Renal Cancer. Management of locally advanced and metasstatic disease. Czzech Republic
Prague
5‐9‐2014
Inleiding sprekers + onderzoek binnen NLL
Garde
eren 11‐10
0‐2014
Other colllaegues of the institute involved URL meeting/program Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 135 of 216 Researchers Name meeting (full name) Donateursdag PrrostaatKankerStichting Oncologie TV
Oncoforum Summary Meeting ECDC‐meeting, SSTI and HIV Genetic Retraite, ROL‐DUC ESCA science dayy, IARC‐WHO ESHG Nurmohameed MT Symposium at Diponogero University ESH 2ndinternational Multiple ng Myeloma meetin
Fifth International Immunology Summit 9th Int Spondylarthropathy Congress 9th GuangDong ––Hong Kong Rheumatology Seminar & 20th Annual ng of the Hong Society Scientific Meetin
of Rheumatologyy 3e Cardiovasculaaire Conferentie Oprea‐Lager DE NVMBR Congresss
State of the Art U
Urology (SOTA) Ossenkoppelle GJ Acute Leukemia Forum CML Expert meeeting ELN meeting Maannheim Bd Investigators meeting 3th International meeting on AML ELN Frontiers
matology Swiss Socity hem
German Austrian
n Swiss annual Oncology meetin
ng Hematologie Nasscholing Rotterdam European Society of Gene and Cell therapy association Pegtel M Title/topic lecture
het VUmc. Een als maar oplopeend PSA. Perspectieven pre‐chemo: nieuwe therapieopties? PC. Current Management of CRP
guidelines and 2014 highlights. Chlamydia Late complications
Entrepreneurship
Entrepreneurship
Chlamydia host geneetics
Compliance with chrronic diseases
antiapoptotic signallling in MM
Managing cardiovascular comorbidities in patients with inflammatory arthrittis. CV Risk and Other Risk Factors: A View of Axial SpA, RA
A, and SLE Cardiovascular como
orbidity in rheumatic diseases: is early diagnosis and prevention posssible? Vascular risk manageement in Rheumatoid patients with/without inflammatory activitty PET/MRI a new imagging technic
Hybrid imaging in prrostate cancer‐an update MRD in Aml
Stop TKI in CML
new drugs in AML
MRD/LSC in AML
MRD/LSC in AML
Standard treatment in AML
MRD in AML
New drugs in AML
Mrd in hematology
Exosomes RNA
Co
ountry
Place
Date NLL
NLL
Ede
Hilverrsum 0‐2014
29‐10
10‐11
1‐2014
Frrankrijk
Parijs
29‐11
1‐2014
Crroatia
Neetherlands
Frrance
Itaaly
Dubro
ovnic Kerkra
ade Lyon
Milan
Indonesia
Grreece
Semarrang Athen
ns
20‐21
1 May 2014
10‐March‐2014
11‐4‐2014
31‐may till 3 June 2014 June 2014
7‐9 no
oVember 2014
Beelgium
Gent
23‐10
0‐2014
ong Kong
Ho
Hong Kong 23‐11
1‐2014
NLL
Ermelo
6‐3‐2014
th
he Netherlands
th
he Netherlands
Zwolle
e
Garde
eren 16‐5‐2014
11‐10
0‐2014
USSA
Po
ortugal
Geermany
USSA
Itaaly
Geermany
Sw
wiss
Geermany
San Frrancisco Estoril
Mannheim San Frrancisco Portoffino Berlin
Zurich
h
Berlin
April 25th
March 14th
Feb 3
3th
June 3th
May 2
22th
Oct 18th
Oct 24th
Oct 11th
Neederland
Th
he Neetherlands Rotterrdam The Hague Oct 9th
23/10
0/2014
Other colllaegues of the institute involved URL meeting/program Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 136 of 216 Researchers Peters GJ Name meeting (full name) Regional Nephro
ology Symposim Title/topic lecture
Co
ountry
Place
Date EBV‐RNA in Nephritiis
Amste
erdam 10‐7‐2014
Vall' D'Hebron In
nstiute
Exosome in diagnosttics of prostate cancer n of RX‐3117: Mechanism of action
Role of DNA Methylttransferases and nucleoside kinases.
The role of folate traansporters in the sensitivity of antifolates and modulation by l‐
leucovorin. deaminase for The role of cytidine d
gemcitabine toxicityy. Th
he Neetherlands Sp
pain
Barcelona 7‐1‐2014
USSA
San Diego April 6,2014
USSA
San Diego April 6,2014
Geermany
Bonn
June 27, 2014
The effect of different leucovorin isomers on the efficaacy of novel antifolates; role of the Reduced folate Carrier and Proton Coupled Folate Transporter. he Th
Neetherlands Heemskerk Octob
ber 1, 2014
Sp
pain
Tenerife orters in drug Role of drug transpo
resistance. Sp
pain
Tenerife Octob
ber 14, 2014
Octob
ber 17, 2014
Frontiers of pharmacokinetics and metabolism in canceer research. pain
Sp
Barcelona Research meetin
ng Philips A new era in Medicaal Microbiology
NLL
KNVM Symposiu
um
Boerhaave nasch
holingscursus Tijd voor een richtlijn typeren. Analysis of the humaan and animal microbiome, reservo
oirs of antimicrobial resistaance. How rapid molecular diagnosis helps in the management of outbreaks. Diagnostiek op maatt
Molecular Diagnostics in the 21st century Analysis of the humaan and animal microbiome, reservo
oirs of Rexahn Satellite meeting at the American Association for Cancer Research Rexahn Satellite meeting at the American Association for Cancer Research Annual meeting of CESAR, (Central Europeaan Society for Anticancer Drug Research) 5th International Symposium on Folate Receptors and Transporters Joint EORTC‐Drug Discovery Committee and EU‐COST meeeting Centro de Investtigaciones Biomedicas de Canaria (CIBIC
CAN) conference; University of La LLaguna th
Interview duringg the 26 EORTC‐NCI‐
AACR meeting in
n Barcelona Savelkoul P ESCMID Post graaduate Education Course Yakult Symposium
Qiagen symp[osiium
International Sep
psis Forum November 19, 2014
14‐1‐2014
NLL
NLL
Eindhoven High Tech C
Campus Universiteit Utrecht
LUMC
C
FR
R
Lyon
1‐7‐2014
NLL
NLL
Houte
en Eindhoven 7‐10‐2014
8‐10‐2014
FR
R
Parijs
2‐12‐2014
Other colllaegues of the institute involved URL meeting/program http://ecancer.org/viideo/search.p
hp?page=5 30‐1‐2014
17‐1‐2014
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 137 of 216 Researchers Name meeting (full name) Schuurhuizen
n C Thema‐avond Essperanz
Snijders PJF Roche Tage 20144
Symposium Imprroving cervical cancer prevention, Erasmus MC Steenbergen
n RDM Taphoorn MJJB Internation Papillomavirus meeting 2014 European Association for Neuro‐
Oncology Indian Society off Neuro‐Oncology Indian Society off Neuro‐Oncology UK Brain Tumour Charity Meeting Asian Society of Neuro‐Oncology Unger WWJ Intl Workshop Lu
ungfunds van Beusechem VW 16 meeting of tthe RNAi Global Initiative and Sem
minar Series on RNAi for Functional Sccreening th
th
12 annual meetting of the International Socciety for Cell and Gene Therapy of Canceer (ISCGT) van de Donk N Saudi Society of Blood and Marrow Transplantation
Janssen Pharmacceuticals European Myelo
oma Network (EMN) Janssen Pharmacceuticals Light chain confeerence van den Eertwegh AJM
M Targeted therapyy (TAT) Meeting of the D
Dutch Society of Medical Oncologgy Title/topic lecture
Co
ountry
Place
Date Th
he Neetherlands Geermany
Ouden
ndijk 6‐3‐2014
Mannheim 2‐7‐2014
Neetherlands
USSA
Seattle
How to best deal witth quality of life evaluation in brain ttumours? Long‐term cognitive deficits in low‐
grade glioma Health‐related quality of life in glioma
Measuring Quality o
of Life in brain tumour patients Low‐grade glioma: ccognition and health‐related qualitty of life Glycan modification of antigens to modulate immune responses A genome‐wide siRN
NA screen in human NSCLC cells identifies multiple components of the R
RNA splicing machinery as regulators of p53 tumor suppressor activity.
Functional genomicss screening identifies orphan G‐protein coupled receptor 27 as radiation susceptibility gene in prostate can
ncer Hematology Year Reeview
Itaaly
Torino
o
11‐10
0‐2014
India
Lucknow 11‐4‐2014
India
Un
nited Kingdom
Lucknow Londo
on 12‐4‐2014
21‐5‐2014
Tu
urkey
Istanb
bul 12‐9‐2014
NLL
Amsersfoort 24‐26
6‐01‐2014
Geermany
Heidelberg 20‐5‐2014
Neetherlands
Amste
erdam 27‐9‐2014
Saaudi arbaia 1.1.20
014
Daratumumab in Myyeloma
Treatment protocol primary plasma cell leukemia Daratumumab in Myyeloma
MGUS en Smolderin
ng Multiple Myeloma Immunotherapy is taargeted therapy
Immunotherapy in o
oncology
Beelgium
Itaaly
1.1.20
014
1.1.20
014
USSA
Beelgium 1.1.20
014
1.1.20
014 antimicrobial resistaance Coloncarcinoom
Strategies for HPV sccreening in Europe and USA Methylation analysiss serves as traige marker for hrHPV po
ositive women at risk of cervical canceer development. Neetherlands
Neetherlands
Amste
erdam Veldhoven Other colllaegues of the institute involved URL meeting/program 15‐4‐2014
18‐19
9 November 2014 Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 138 of 216 Researchers van der Horsst‐
Bruinsma IE Name meeting (full name) WIN‐O multidiscciplinary symposium Melanoma Dutch Institute o
of Clinical Auditing congress Dutch Society off Hospital Pharmacists Dutch Society off Oncology IGAS th
35 Scandinavian Congress of Rheumatology 18th Belgian Con
ngress on Rheumatology International Forrum on Spondylarthritis 15th EULAR Posttgraduate Course ASAS educationaal workshop van der Laken J Nuclear Medicine meeting International Follate receptor meeting van der Vorst M Europese Geriatrrie Congres MSD academy paalliatieve zorg Nationaal Congrees Palliatieve Zorg van Dulmen‐‐
den Broeder E Point‐dag
NVvO congres
van Egmond M University of Texxas
University of Sou
uthampton Gordon conferen
nce on rare cells in circulation Duke University
Joint HighGlycan
n/IBD‐BIOM meeting Title/topic lecture
Co
ountry
Place
Date Targeted therapy of melanoma
Neetherlands
Nunsp
peet 27‐no
ov‐14
A revolution in the treatment of metastatic melanom
ma Treatment of Metastatic Melanoma
Tumor‐immunology and Immunotherapy in o
oncology Determinants of treaatment response and resistence to bio
ologics in AS Modern managemen
nt of ankylosing spondylitis Treat to target in Axxial Spondyloarthritis mendations in the ASAS/EULAR recomm
use of TNF inhibitorss in AS Ankylosing Spondylittis – modern management ifestations and Extra‐articular manif
SpA: Ps, IBD, UA” ondyloathritis
Management of Spo
Positron Emission To
omography (PET) of inflammatory rheumatic diseases Folate PET imaging o
of rheumatoid arthritis Delirium at the end of life
Delirium at the end of life
Nieuwe ontwikkelinggen in de palliatieve zorg Kinderkansen na kinderkanker
Fertiliteit
Neetherlands
Amste
erdam Neetherlands
Neetherlands
de Me
een Ellecom 12‐13
3 June 2014
24‐4‐2014
13‐Mar‐20104
Ch
hina
Shang
ghai Sw
weden
Stockh
holm 11‐13
3 april 2014 23‐seep‐14
Brrussels
Belgiu
um 25‐seep‐14
Paalermo
Sicilie
3‐okt‐14
Prrague
Tsechie 14‐15
5 okt 2014
Brrussels Belgiu
um 22‐okkt‐14
NLL
aanvu
ullingen: Amste
erdam zie bijjlage!!!
24‐3‐2014
NLL
Heemskerk 2‐10‐2014
th
he netherlands
th
he netherlands
th
he netherlands
rotterrdam Heeze
e
lunterren 18‐9‐2014
23‐1‐2014
26‐11
1‐2014
neederland
neederland
17‐4‐2015
31‐10
0‐2014
Myeloid cells as effeector cells for mAb therapy of cancer ADCP by macrophagges prevents surgery‐induced metastasis. Macrophages elimin
nate circulating tumor cells after mo
onoclonal antibody therapy Myeloid cells as effeector cells for mAb therapy of cancer mmation
IgA in chronic inflam
USS
Rotterrdam Amste
erdam, Rode Hoed
Austin
n
UK
K
Southampton 1‐7‐2014
USS
South Hadley 6‐8‐2014
USS
Durha
am 8‐8‐2014
Neetherlands
Leiden
n
11‐9‐2014
Other colllaegues of the institute involved URL meeting/program 11‐6‐2014
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 139 of 216 Researchers van Furth AM
M Name meeting (full name) Center of Researrch for inflammation Bichat Medical SSchool
Amsterdam kind
dersymposium 2014 Title/topic lecture
Co
ountry
Place
Date Myeloid cells in canccer treatment
IgA system in inflammation
Projecten in de derd
de wereld
Paris
Paris
Amste
erdam 3‐12‐2014
3‐12‐2014
6‐2‐2014
Scientific spring meeting KNVM & NVMM 2014 Modelling tuberculo
ous meningitis in zebrafish using Myco
obacterium marinum. The impact of host ggenetic factors in addition to a currentt prediction model for hearing lo
oss after bacterial meningitis. Diagnostic performaance of the Multiplex PCR comp
pare to blood culture for 78 monomicrobial infections. Antiretroviral treatm
ment is associated with increased arterrial stiffness in sub‐saharan African HIV‐1‐infected patients: A cross‐secctional study. Respiratory syncytiaal virus prophylaxis in down syndrome: A
A prospective cohort study. A Pragmatic approacch to improve care of HIV+ children
n on antiretroviral therapy (ART) in Sou
uth Africa (SA). Influence of HIV‐1 an
nd antiretroviral therapy on surrogate markers for cardiovascular risk liike carotid intima‐
media thickness and
d lipid profile: a systematic of observvational studies. Frrance
Frrance Th
he Neetherlands Th
he Neetherlands Papen
ndal, Arnhem, The Netherlands 16‐4‐2014
Th
he Neetherlands Kerkra
ade 20‐03
3‐2014, 21‐
03‐20
014 Sp
pain
Barcelona 10‐05
5‐2014 t/m 13‐05
5‐2014 Sp
pain
Barcelona 10‐05
5‐2014 t/m 13‐05
5‐2014 Caanada
Montrreal 31‐05
5‐2014 t/m 04‐06
6‐2014 Au
ustralia
Melbo
ourne 20‐07
7‐2014 t/m 25‐07
7‐2014 Sp
pain
Barcelona 10‐05
5‐2014 t/m 13‐05
5‐2014 Th
he Neetherlands Th
he Neetherlands K
UK
Amste
erdam 4‐4‐2014
Amste
erdam 4‐4‐2014
Londo
on 14‐1‐2014
Beelgium
Gent
25‐6‐2014
Prrotugal
Lissab
bon 25‐5‐2014
Genetics Retreatt ECCMID
ECCMID
th
ISPOR 19 annuaal international meeting th
AIDS 2014 20 In
nternational AIDS Conference ECCMID
Onderzoeksconferentie Reproduction & Development
Martin Luther King Jr. Lecture. van Kooyk Y DIIID Seminar Seeries
Workshop 'Vacciines: from Immunology to Registration'
EMBO Workshop
p Glycobiology and Glycochemistry Glycans for immune inhibitory and stimulatory instructiion of DC Glycan‐induced imm
mune responses and implications for vaccine development Lycans in the respon
nse of DC for the treatment of cancerr Other colllaegues of the institute involved URL meeting/program Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 140 of 216 Researchers van Montfrans C Name meeting (full name) 50th Anniversaryy Congress 2014’ Dutch Society for Immu
unology 18th European V
Vascular Course Dermatologen dagen
23rd European A
Academy of Dermatology and
d Venereology Werkgroep immunotherapie Nederland voor Oncologie
van urg Schaardenbu
D van Tuyl LHD
D 15th EULAR Posttgraduate Course van Vliet SJ NVVI 50‐year lusstrum conference OMERACT
Joint meeting IB
BD‐BIOM and HighGlycan Vandenbrouccke
‐Grauls CMJEE Symposium Typeeren (KNvM & NVMM) Huisartsen Symp
posium GGD 24th ECCMID
ALTANT Symposium
AIMMS Star Sym
mposium AMC Scholierenssymposium Verdonck‐dee Anatomische Less Mesures subjecttives en santé et Title/topic lecture
Co
ountry
Place
Date The good and the bad of glycans in immunity Biology of chronic w
wounds & novel treatment strategiess Ulcus cruris: wat is n
nieuw & wat is effectief? Evaluation and manaagement of venous ulcers: Updaate of the Dutch guideline venous ulcers Behandeling Lentigo
o Maligna. Hoe ver moeten wij gaan? Neederland
Kaatsh
heuvel 17‐12
2‐2014
Th
he Neetherlands Th
he Neetherlands Th
he Neetherlands Maasttricht 14‐May‐14
Papen
ndal 11‐Ap
pr‐14
Amste
erdam 10‐Occt‐14
Th
he Neetherlands Nunsp
peet Czzech Republic
Prague
27‐No
ov‐14
0‐2014
12‐10
Hu
ungary
Budap
pest 7‐5‐2014
Neetherlands
Kaatsh
heuvel 17‐12
2‐2014
Neetherlands
Leiden
n
11‐9‐2014
Neederland
Utrech
ht 30‐1‐2014
Neederland
Amste
erdam 1‐4‐2014
Sp
panje
Neederland
Barcelona Utrech
ht 11‐5‐2014
14‐5‐2014
Neederland
Amste
erdam 30‐11
1‐2014
Neederland
Amste
erdam 6‐11‐2014
Neederland
Frrance Amste
erdam Paris
13‐11
1‐2014
21‐11
1‐2013
Prediction and treatment of RA and: How to design a clinical trial in rheumatic diseases
The Patient perspecttive on remission in RA Tumor‐associated gllycans trigger the C‐type lectin MGL on
n dendritic cells to dampen anti‐tumor immunity The immunosuppresssive function of mucin‐type glycosylaation in colorectal cancer ESBL's: typisch iets vvoor nieuw beleid? Resistentie door Extended‐Spectrum Beta‐Lactamasen (ESSBL) The year in Infection
n Control
Antibiotic resistancee: a tragedy of the commons Antibiotic resistancee: a tragedy of the commons Antibiotica resistenttie of Hoe wondermiddelen heet wonder vernietigen Inleiding lezing prof.. M. Blaser
Monitoring quality o
of life in clinical Other colllaegues of the institute involved URL meeting/program Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 141 of 216 Researchers Leeuw IM Name meeting (full name) recherché en psyycho‐onologie, EORTC Meeting
op
MASCC Worksho
Verheul HMW
W Visser O Voskuyl AE Vugts DJ Wesseling P The changing pro
ospects of cancer: new models of aftercare for patient with and beyond canccer 5th International Meeting on Angiogenesis WIN‐O‐symposiu
um
Transplant meetting Turku FINLAND European lupus ccongress LEAP Post ‐EULAR
8th International conference on isotopes and Exp
po RADIOMI annuall meeting Int. Soc. Neuropaathology Int. Soc. Neuropaathology Int. Soc. Neurpatthology Wierdsma N Wolthuis R Ylstra B Clinical Genetics Science Day ON SEQUENCING, NEXT GENERATIO
approaches and applications EMBO ‐ 10th Golden Helix mics Day Pharmacogenom
1st Internationall workshop on Cancer Genetic & Cytogenetic Diagnostics Title/topic lecture
Co
ountry
Place
Date Itaaly
USSA
Venice
e
Miami
17‐9‐2014
25‐6‐2014
UK
K
Manchester 4‐4‐2014
Angiogenesis and bio
omarkers
Neetherlands
Amste
erdam 14‐3‐2014
SURE: sunitinib rechallenge in patients with metasttatic renal cell carcinoma ECP topics
Treat to target in SLEE
Treat to target in SLEE
Systeemziekten
Zr‐89: from productiion to clinical application 89Zr‐immuno‐PET: ffrom production to clinical application Angiogenesis in high
h‐grade gliomas; prominent, but prom
mising? The rise, shine and ffuture of GBM‐O
Practice changes upd
dates; Tumors in adults Comprehensive nutrritional status of patients with (complicated) celiac disease and EATL at presentation. Genomic Screens
on of mutations NGS for the detectio
and copy number ab
berrations in DNA isolated from FFPE ssolid tumor specimens Intratumoral heterogeneity in low‐
grade gliomas by shaallow whole genome sequencingg Intratumoral heterogeneity in low‐
grade gliomas by shaallow whole genome sequencingg Neetherlands
Ede
27‐3‐2014
Fin
nland
Grreece
Geermany
Neetherlands
USSA
athens
berlin
Utrech
ht Chicag
go 2014
May 2
25‐4‐2014
24‐5‐2014
24‐6‐2014
27‐8‐2014
NLL
Amste
erdam 3‐11‐2014
Brrazil
Rio de
e Janeiro Sept. 15, 2014
Brrazil
Brrazil
Rio de
e Janeiro Rio de
e Janeiro Sept. 17, 2014
Sept. 18, 2014
he Th
Neetherlands Veldhoven 21‐3‐2014
Neetherlands
ortugal
Po
AMC A
Amsterdam
Braga
19‐11
1‐2014
17‐6‐2013
Neetherlands
Amste
erdam (RAI)
23‐9‐2013
Neetherlands
Nijmegen 22‐3‐2013
practice and innovatting supportive care. Quality of life in clinical practice
ho‐oncology and Innovations in psych
speech pathology: do they really help? An international perrspective. Other colllaegues of the institute involved URL meeting/program P. Nijeboer, M.A.E. de van der n, G. Bouma, A.A. van Schueren
Bodegravven, C.J.J. Mulder http://www.ecsaude.uminho.pt/D
&pageid=943&l
efault.aspx?tabid=8&
ang=pt‐PT D. Sie
http://www.goldenheelix.org/index.
php/news/latest‐new
ws http://www.paoheyeendael.nl/nl/bi
j‐en‐nascholing/aanb
bod/ Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 142 of 216 Researchers Name meeting (full name) Joint Meeting off the Pathological Society of Great Britain & Ireland and the Dutch Pathological Society (NVVP) Title/topic lecture
Co
ountry
Place
Date Implementing NGS o
on FFPE Tumour‐
Derived DNA for Mu
utation Analysis in Routine Diagnostic P
Pathology Neetherlands
Utrech
ht 8‐1‐2013
nnovative diagnostic Symposium on In
and therapeutic approaches in oncology Jaarvergadering;; De Nederlandse Vereniging voor Neurologie Intratumoral heterogeneity in low‐
grade gliomas by shaallow whole genome sequencingg Subclonal copy number aberrations ue in diffuse low‐
with prognostic valu
grade gliomas Intratumoral heterogeneity in low‐
grade gliomas by shaallow whole genome sequencingg Neetherlands
Maasttricht 19‐12
2‐2013
Neetherlands
Utrech
ht 15‐9‐2013
Neetherlands
Nijmegen 28‐3‐2014
panje
Sp
Malag
ga 13‐5‐2014
http://www.isco2014
4.com Grreece
Aegina
12‐9‐2014
Intratumoral heterogeneity in low‐
grade gliomas by shaallow whole genome sequencingg PET‐based decisionss in non Hodgkin’s lymphoma” Imaging decisions in haematological malignancies Brrazil
Barrettos 19‐9‐2014
http://www.goldenheelix.org/index.
php/education/goldeen‐helix‐
conferences/summerr‐
schools/upcoming‐su
ummer‐
schools barretos.com.
http://www.hcancerb
br/home‐iep/eventoss Sp
pain
Sp
pain
2nd Internationaal workshop on Cancer Genetic & Cytogenetic Diagnostics ISCO2014 ‐Intern
national Society of Cellular Oncologgy Pharmacogenom
mics and Genomic Medicine ‐ Bridgging research and the clinic IV International SSymposium on Translational Oncology Zijlstra JM European Society of Medical Oncology European Society of Medical Oncology Other colllaegues of the institute involved D. Sie, Drr. D. Heideman
URL meeting/program huijl, Dr. J.Reijneveld, H. Van Th
Prof. Dr. P. Wesseling http://www.neurologgie.nl/publiek/
nvn/werkgroepen/neeuro‐
oncologie/ http://www.paoheyeendael.nl/nl/bi
j‐en‐nascholing/aanb
bod/ http://pathsoc.org/files/meetings/
scientificMeetings/uttrecht2012/67
73%20PreN(Wint13‐
Utrecht)%20v10%20[[web150].pdf http://www.grow‐um
m.nl/ Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 143 of 216 Demonsstrable marks off recognition  Awarrds Researcher Name award/h
honor
Scientifc/public
Awarded by
Datte (dd‐
mm
m‐yyyy) Place Cerem
mony
Al‐Itejawi H Value Based Heealthcare Prize Public
Value Based Healthcaare Center Europe 10‐‐4‐2014
Nijkerk, The
e Netherlands
Bitter W appointed Desm
mund Tutu Professor Scientific
VU 1‐8‐2014
Amsterdam
m
Boellaard R Most cited papeer
Scientific
Springer/EANM
20‐‐10‐2014
Gothenburgg
PET center of exxcellence award Scientific
PET COE
1‐6
6‐2014
Amsterdam
m
Fijneman RJA
A Best oral presen
ntation (1st prize) Scientific
European Congress o
of Pathology
3‐9‐2014
Londen
Heideman DA
AM Member Taakgroep Richtlijn moleculaire diagnostiek in de patthologie
Scientific
NVVP 201
14
nvt
Hensen EF Heinsius Houbo
oldt Stipendium Scientific
stichting het Heinsiuss Houboldt Fonds
1‐3‐2014
Israels T SIOP poster award
Scientific
SIOP 26‐‐10‐2014
Toronto
Lammertsmaa AA Certificate of Ap
ppreciation Scientific
Japanese Society of N
Nuclear Medicine
6‐11‐2014
Osaka
Leemans CR Elected Presideent European Head and N
Neck Society
Scientific
European Head and N
Neck Society
201
14
Awarded I.J. Sendulskii Commemorativve Medal for outstanding contribution to Russiaan oncology and su
urgery and international multidisciplinary scientific cooperation Scientific
Russian Society of Heead and Neck Cancer 201
14
Meijerink MR
R Kanker in Beeld
d Award Public
Stichting Beeldgestuu
urde Behandeling van Kanker (SBBvK) 7‐1‐2014
Vumc
Morré SA Deskundighiedss verklaring Scientific
Officier van Justitie
4‐8‐2014
nvt
Mostert S Invitation to wrrite Personal View Scientific
The Lancet Oncology
Julyy 2014
not applicab
ble
Onwuteaka‐
Philipsen B ZonMw Parel fo
or PaTz project (palliatieeve thuiszorg)
Scientific
ZonMW 26‐‐11‐2014
opening cerremony of the National Congress Palliative Caare (Lunteren, 26‐28 novvember) Taphoorn MJJB Abihjit Guha Aw
ward
Scientific
Indian Society for Neuro‐Oncology
12‐‐4‐2014
Lucknow, In
ndia
van de Donk N UMC Utrecht Research Talent Scientific
UMC Utrecht
201
14
van der Laken J Aspire award
Scientific
Pfizer Jun
ne 2014
Papendal se
ept 2014
van Kooyk Y van Loghem lau
ureate
Scientific
Dutch society of Imm
munology
17‐‐‐12‐2014
Kaatsheuvel
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 144 of 216 Researcher Name award/h
honor
Scientifc/public
Awarded by
Datte (dd‐
mm
m‐yyyy) Place Cerem
mony
van Montfrans C De Gouden Leeuw 2014 Public
Dutch Dermatologistss/Leo Pharma
28‐‐11‐2014
Nijmegen
van Tilborg A
AAJM Kanker in Beeld
d Award Public
Stichting Beeldgestuu
urde Behandeling van Kanker (SBBvK) 7‐1‐2014
Vumc
van Tuyl LHD
D Pfizer Inflammaation Competitive Reseaarch Program
Scientific
Pfizer 1‐5‐2014
Papendal, N
NVR
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 145 of 216 Demonsstrable marks off recognition  Orgaanization of conggresses Researchers Name congress/conff/symp
City
Country
Bitter W NVMM/KNVM voorjaaarsvergadering
Papend
dal Nederland
14‐4‐‐2014 ‐ 16‐04‐2014 Boellaard R EFOMP summer scho
ool Prague
Tsech republiic
10‐7‐‐2014
EANM trends in PET m
methodologies
Vienna
Austria
20‐11
1‐2014
Boers M 12th OMERACT Intern
national consensus confference
Budape
est Hungary
May 2
2014
de Gruijl T ISCGT2014, Intl. Socieety for the Cell and Genee Therapy of Cancer
Amsterrdam The Netherlands
25‐9‐‐2014
Annual Meeting of th
he Dutch Tumor Immuno
ology Working Party
Breuke
elen The Netherlands
7‐6‐2014
Dermatologendagen Arnhem
m
The Netherlands
10‐04
4‐2014 / 11‐04‐2014 Domburg dagen Dombu
urg The Netherlands
15‐05
5‐2014 / 16‐05‐2014 Dekker J International Congresss of Behavioral Medicin
ne
Groningen The Netherlands
Augustus 2014
Dorsman J Dutch HD Meeting Amsterrdam The Netherlands
23‐5‐‐2014
Gibbs S 2nd Annual Meeting of the Center of Regeneerative Medicine Amsterrdam The Netherlands
9‐10‐‐2014
International Federattion for Adipose Therapeeutics and Science
13/16
6‐11‐2014
Heideman DA
AM ‘Moleculaire diagnosttiek is vooruitzien’
Utrecht
The Netherlands
May 2
2014
Hensen EF Vlaam Nederlands Ottologisch Gezelschap Amsterrdam The Netherlands
28/29
9‐03‐2014
Israels T SIOP PODC Programm
ma Toronto
Canada
Oct 2
22 ‐ 25, 2014
Collab SIOP Africa Wilms Tumour Work Meetting
Dar es Salaam Tanzania
April 24 2014
Jansen G 5th International Sym
mposium on Folate Receptors and Transporters
Heemskerk The Netherlands
30‐6‐‐2014 to 4‐10‐2014 Jimenez CR 14th Annual Fall Meeeting of the Netherlandss Proteomics Platform Rotterd
dam The Netherlands
14‐11
1‐2014
Kaspers GJL Fifth Workshop on Peediatric Oncology
Eldorett
Kenia
14‐01
1‐2014 & 15‐01‐2014 Landelijke (6‐daagse)) bij‐ en nascholing verpleging kinderoncologie
Utrecht
The Netherlands
09‐20
014 en 10‐2014
NOPHO‐DBH meetingg on pediatric AML
10‐11
1‐2014 & 11‐11‐2014 Infectiepreventie voo
or AIOS medische microb
biologie
Oisterw
wijk The Netherlands
20‐01
1‐2014/24‐01‐2014 ECCMID 2015 ‐ Programme Committee
Copenh
hagen Denmark
24‐06
6‐2014/25‐06‐2014 de Rie MA Kluytmans JA
AJW Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 146 of 216 Researchers Name congress/conff/symp
City
Country
ESCMID‐SHEA Coursee in Hospital Epidemiology
Phukett
Thailand
20‐10
0‐2014/22‐10‐2014 NeuroReceptor Mapp
ping 2014
Egmond aan Zee The Netherlands
21‐5‐‐2014 tot 24‐5‐2014 PET Pharmacokinetic Course
19‐5‐‐2014 tot 21‐5‐2014 INMiND Course PET TTracer Pharmacokineticss and Data Analysis Proccedures
17‐11
1‐2014 tot 19‐11‐2014 ECHNO 2014 Liverpo
ool United Kingdo
om
24‐4‐‐2014
7th European Head and Neck Course
Poznan
n
Poland
01‐10
0‐2014 ‐ 03‐10‐2014 International Sympossium on HPV Infection in
n Head and Neck canderr
Poznan
n
Poland
13‐11
1‐2014 ‐ 14‐11‐2014 EULAR scientific Committee
Paris
France
08 tot 12 june 2014
ECTS scientific Comm
mittee Praag
Tjechie
17 en
n 20 mei 2014
NVReumatologie (weetenschappelijk secretarris)
Papend
dal The Netherlands
25 en
n 26 september 2014 EULAR scientific Committee
Paris
France
08 tot 12 june 2014
ECTS scientific Comm
mittee Praag
Tjechie
17 en
n 20 mei 2014
NVReumatologie (weetenschappelijk secretarris)
Papend
dal The Netherlands
25 en
n 26 september 2014 Meijerink MR
R Radiologendagen Den Bo
osch the Netherlan
nds
11‐9‐‐2014
Morré SA Annual Amsterdam C
Chlamydia Meeting
7‐2‐2014
Nurmohameed MT NVVG Jaarsymposium
m 'De oudere patiënt meet hart‐ en vaatziekten"
Scheve
eningen The Netherlands
28‐11
1‐2013
Onwuteaka‐P
Philipsen B Fourth EAPC (European Association of Palliattive Care) Research Sem
minar
16/17
7‐10‐2014
Vlaams‐Nederlands O
Onderzoeksforum Palliattieve Zorg
Antwerrpen Belgium
27‐3‐‐2015
Palliative Care 2020, Final Conference EUROIIMPACT and IMPACT
Brussels
Belgium
15‐10
0‐2014
ELN Frontiers Berlin
Germany
16‐19
9 Oct
ELN Mannheim Annu
ual meeting
Mannh
heim Germany
2‐4 Fe
eb
Pegtel M ISEV 2014 Rotterd
dam The Netherlands
Peters GJ 5th International Sym
mposium on Folate Receptors and Transporters
Heemskerk The Netherlands
30 Se
ept ‐ 4 October 2014 Winter EORTC ‐ PAMM meeting
Munste
er Germany
febru
uary 2014
Winter EORTC ‐ PAMM meeting
Marseille France
Januaary 2015
CIBICAN Conference o
on Molecular Pharmaco
ology and Mechanisms o
of New Puerto de la Cruz, Tenerife
Spain
14‐15
5 October 2014
Lammertsmaa AA Leemans CR Lems WF Ossenkoppelle GJ Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 147 of 216 Researchers Name congress/conff/symp
City
Country
th
25‐09
9‐2014 ‐ 27‐09‐2014 22 Annual Meeting of the European Societyy of Gene and Cell Theraapy
th
The Hague The Netherlands
23‐10
0‐2014 ‐ 26‐10‐2014 van der Laken Imaging session by naational working group IR
RON
Arnhem
m
The Netherlands
26‐9‐‐2014
van Montfrans C 23rd European Acadeemy of Dermatology and
d Venereology
9 until 12‐10‐2014
van Velden FF Klifopdag symposium
m 2014
3‐10‐‐2014
van Vliet SJ NVVI 50‐year lustrum
m conference
Kaatsheuvel The Netherlands
17/19
9‐12‐2014
Verdonck‐dee Leeuw IM Workshop at EORTC A
Autumn meeting
Venice
Italy
17‐9‐‐2014
Workshop at the MASSCC congress
Miami
USA
25‐6‐‐2014
Verheul HMW
W Targeted Therapy 201
14 Amsterrdam The Netherlands
15‐4‐‐2014
Wesseling P WHO's next; a colloquium to guide next step
ps in brain tumor classificcation and grading Haarlem
m The Netherlands
1‐3 M
May 2014
Scientific Program Intt. Congress Neuropathology
Rio de Janeiro Brazil
15‐18
8 Sept. 2014
Wierdsma N Pitactief post graduatte Nutrition in GI diseases
Utrecht
The Netherlands
15‐09
9‐2014; 29‐09‐2014; 10‐‐11‐2014; Wolthuis R Clinical Genetics Science Day
19‐11
1‐2014
Ylstra B Replication stress and
d chromosomal instabiliity
08‐01
1‐2014 to 09‐01‐2014 ISCO2014 ‐International Society of Cellular O
Oncology
Malaga
a
Spain
11‐5‐‐2014 to 14‐5‐2014 International Worksh
hop on PET in Lymphomaa
Menton
France
18‐9‐‐2014
Anticancer Drugs van Beusechem VW Zijlstra JM 12 annual meeting o
of the International Sociiety for Cell and Gene Th
herapy of Cancer (ISCGT) Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 148 of 216 Demonsstrable marks off recognition  Mem
mberships of scieentific committeees, editorial boaards and civil advvisory bodies Researcher Type of me
embership
Name of the
‐ scientific commiittee; ‐ book/journal; or ‐ civil society advisory body Position/function P
(rreviewing activities are not relevant) Ang W Membersh
hip of an editorial board
Nederlands Tijdscchrift voor Geneeskundee
M
Member
Membersh
hip of a scientific committee
Committe of "Kno
owledge sharing" Dutch Society for Medical Chair
C
Microbiology Membersh
ISEV
M
Member
Membersh
AACR
M
Member
Bitter W Membersh
FEMS Microbiolog
gy Reviews A
Associate editor
Boellaard R Membersh
EANM Physics C
V
Vice chair
Membersh
EORTC imaging grroup M
Member
Membersh
EJNMMI Physics
M
Member of board
Membersh
HOVON imaging g
group M
Member
Membersh
RSNA QIBA FDG P
PET/CT technical C
M
Member
Membersh
RSNA UPICT FDG PET/CT working group
M
Member
Membersh
EANM Research LLtd (EARL) S
Scientific advisor
Membersh
Arthritis and Rheu
umatism A
Associate Editor
Membersh
Letter to the Edito
or in Rheumatology
A
Associate Editor
Membersh
Annals of Rheuma
atic Diseases
B
Board member and grap
hical design advisor Membersh
Journal for Clinica
al Epidemiology (Policy A
Advisory Board)
B
Board member
Membersh
Journal of Rheumatology B
Board member
Membersh
OMERACT
Ambassador for non‐rheumatological conditionss. (see A
w
www.omeract.org) Membersh
e on conduct and reportting of long‐term EULAR Committee
extension studies in rheumatology C
Co‐chairman
Bijnsdorp IV Boers M Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 149 of 216 Researcher Type of me
embership
Name of the
‐ scientific commiittee; ‐ book/journal; or ‐ civil society advisory body Membersh
EULAR Committee
e on monitoring of gluco
ocorticoid therapy in Member
M
rheumatoid arthritis. Membersh
e on guidelines for treattment of rheumatoid Member
M
EULAR Committee
arthritis Membersh
OMERACT Task Fo
orce on imaging in rheum
matoid arthritis
Membersh
OMERACT Speciall Interest Group on coree set for polymyalgia Member
M
rheumatica Membersh
on patient‐reported rem
mission in rheumatoid Co‐chairman
C
OMERACT group o
arthritis Membersh
ASAS, international consensus group on gguidelines for es in ankylosing spondylitis outcome measure
M
Member
Membersh
Trial Steering Com
mmittee: ZIPP (zoledronaate in prevetion of Paget) trial. P.I. S Ralston, Edinburgh, UK
C
Chair
Membersh
COMET Steering G
Group. International inittiative to create measurement corre sets for trials across d
diseases M
Member
Braakhuis BJM Membersh
Oral Oncology
M
Member
Brakenhoff R
R Membersh
Clinical cancer ressearch A
Associate editor
Membersh
Current Cancer Th
herapy Reviews A
Associate editor
Membersh
Oral Oncology A
Associate editor
Membersh
Reports of Practiccal Oncology and Radiotherapy A
Associate editor
Membersh
SLE working partyy of the Dutch Society off Rheumatology
M
Member working party
Membersh
Osteoporosis worrking party of the Dutch Society of Rheumatology M
Member working party
Membersh
Interdisciplinary w
working party on osteop
porosis
M
Member
Membersh
American Society for Bone and Mineral R
Research
M
Member
Membersh
International Oste
eoporosis Foundation
M
Member
Membersh
European Calcified Tissue Society
M
Member
Bultink, IEM Position/function P
(rreviewing activities are not relevant) M
Member
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 150 of 216 Researcher Type of me
embership
Name of the
(rreviewing activities are not relevant) Buter J Membersh
Head and Neck Grroup EORTC
M
Member of the steering commitee
Membersh
NWHHT
M
Member
Membersh
Hoofdredactieraad Nederlands Tijdschriftt voor Oncologie
C
Chairman
Membersh
IFHNOS hoofdhalss congres New York
C
Chairman
Membersh
Dutch society of R
Radiology: M
Member Plenaire Visitat
ie‐commissie ((2004‐hed
den) Membersh
Dutch society of R
Radiology: M
Member Concilium Radio
ologicum (2004‐ heden) Membersh
Orde van Medisch
he Specialisten
P
Plv. Member RSG (2012 ‐
‐ heden)
Membersh
European Society of Head and Neck Radio
ology:
M
Member Executive Comm
mittee (1998– heden) Membersh
European Society of Head and Neck Radio
ology:
C
Chairman of the Researc
h Committee (1999‐hed
den). Membersh
European Society of Radiology
Member Research Comm
M
mittee ofthe European Society of R
Radiology (2010‐ ..) Membersh
European Retinob
blastoma Imaging Collab
boration (E.R.I.C.)
F
Founder and Chairman (2
2009‐ …)
Membersh
European Archive
es of Otorhinolaryngologgy
M
Member
Membersh
The Open Otorhin
nolaryngology Journal
M
Member
Membersh
Oral Oncology
M
Member
Membersh
Nederlands Tijdscchrift voor Oncologie
M
Member
Membersh
Cochrane Ear, Nose & Throat Disorders G
Group
M
Member
Membersh
European Retinob
blastoma Group
M
Member
Membersh
European Retinob
blastoma Imaging Collab
boration C
Cofounder Membersh
Grant Review Com
mmittee Melanoma Reseearch Alliance, USA
C
Committee member and
advisor
Membersh
KWF wetenschappleijke raad
C
Committee member and
ad hoc advisory board member Membersh
Cancer Immunolo
ogy Research
A
Associate editor
Membersh
DCPrime BV
S
Scientific advisory board
Membersh
Society for the Im
mmunotherapy of Cancerr (SITC)
M
Member advisory comm
ittee external communications Membersh
NVDV
M
Member
Castelijns J De Bree R de Graaf P de Gruijl T de Rie MA Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 151 of 216 Researcher Type of me
embership
Name of the
(rreviewing activities are not relevant) Membersh
NascholingsCie
C
Chair
Membersh
EADV
M
Member
Membersh
Finance Cie EADV
M
Member
Membersh
AAD
M
Member
Membersh
ESDR
M
Member
Membersh
hip of a civil society advisory body
Chanfleury van Ijssselsteijn Stichting
C
Chair
Membersh
Rene Touraine Fondation M
Member
Member of editorial board
Dermatology
E
Editor
Case reports in De
ermatology
E
Editor
Dermatology and Therapy E
Editor
Latin American Jo
ournal of Psoriasis and Pssoriatic Arthritis
E
Editor
Membersh
International Society of Behavioral Mediccine P
President
Membersh
Member of the Sttanding Committee on SScience VUmc
M
Member
Membersh
Netherlands Beha
avioral Medicine Federattion M
Member
Membersh
Health Council of the Netherlands M
Member
Membersh
Netherlands Health Professionals in Rheu
umatology C
Chair
Membersh
Dutch Cancer Society M
Member
den Haan JM
MM Membersh
NWO ZONMW VIDI committee
S
Selection of VIDI candida
ates
Dirven L Membersh
EORTC Quality of Life Group A
Active member
Membersh
European Association of Neuro‐Oncologyy
M
Member
Membersh
BMC Gastroenterology A
Associate editor
Membersh
Dataset papers in Science A
Associate editor
Gibbs S Membersh
Centre for Transla
ational Regenerative Meedicine
M
Member of core team
Heideman DA
AM Membersh
Committee Moleccular Diagnostics in Path
hology, Dutch Society Board member
B
for Pathology (CM
MDP NVVP) Dekker J Fijneman RJA
A Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 152 of 216 Researcher Type of me
embership
Name of the
Committee Qualitty Control of WMDP‐NV
VVP (QC committee CMDP NVVP) C
Chairmen
Membersh
Foundation for Qu
uality Medical Laboratorry Diagnostics (Stichting Kwaliteitsbewaking Medische Laboratoriumdiag
gnostiek, SKML) ‐ section
n Pathology B
Board member
Membersh
CCKL/RvA E
External auditor Membersh
AACR: American A
Association for Cancer R
Research
M
Member
Membersh
IASLC: Internation
nal Association for the Sttudy of Lung Cancer Member
M
Membersh
NVGE: Dutch Society for Gastroenterologgy (Nederlandse Vereniging voor G
Gastroenterologie) M
Member Membersh
NVVP Dutch Socie
ety for Pathology (Nederrlandse Vereniging voor Pathologie)
M
Member
Membersh
VMDG: Society Molecular Diagnostics in H
Health Care (Vereniging tot Moleculaire Diagnostiek in de Gezondheidszorg)) M
Member
Membersh
LNVH: National Network of Female Professors (Landelijk Netwerk Vrouwelijke Hoogleraren) M
Member
Hensen EF Membersh
Nederlands Tijdscchrift voor KNO
A
Associate editor
Hoekstra OS Membersh
ZON‐MW EEK
M
Member
Membersh
The Oncologist
S
Section editor
Membersh
SNM review board
M
Member
Membersh
FNIH biomarker group A
Advisor
Huisman MC
C Membersh
Frontiers in biome
edical Physics
E
Editor
Hulleman E Membersh
International Society of Pediatric Oncologgy
M
Member
Membersh
European DIPG Network M
Member and co‐founder
r
Membersh
DCOG
M
Member discipline group
p Molecular Research Membersh
Project Committe
ee World Child Cancer
M
Member
Israels T Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 153 of 216 Researcher Jansen G Jimenez CR Kaspers GJL Type of me
embership
Name of the
DCOG Renal Tumo
our Protocol Committeee
M
Member
Membersh
SIOP PODC WG ad
dapted treatment regim
mens
M
Member
Membersh
SIOP PODC WG su
upportive care
M
Member
Membersh
SIOP PODC
C
Co‐chair
Membersh
Open Arthritis Jou
urnal A
Associate Editor
Membersh
Folate Receptor Society M
Member executive board
d
Membersh
Journal of Proteom
mics M
Member
Membersh
Molecular and Cellular Proteomics
M
Member
Membersh
Proteomics
M
Member
Membersh
BBA Proteins and Proteomics
G
Guest Editor
Membersh
Netherlands Prote
eomics Platform
M
Member Steering Comm
ittee
Membersh
Dutch Tech Centre for Life Science
M
Member of scientific Adv
visory Committee Membersh
Human Proteome
e Organisation
M
Member of Board of Dire
ectors
Membersh
European Proteom
mics Assocation
G
General Council Member
r
Membersh
Journal of Oncology M
Member
Membersh
Expert Reviews off Anticancer Therapy
M
Member
Membersh
Therapy
M
Member
Membersh
DCOG Disease Committee Myeloid Malignancies
C
Chair
Membersh
Onderzoekscomm
missie, SKION
M
Member
Membersh
Taakgroep "shared care", DCOG
C
Chair
Membersh
"International Outreach Program", SKION
N
C
Chair
Membersh
Protocol Commisssie "Relapsed AML 1999
9/2001" en "Pediatric Chair
C
APL", SKION Membersh
Protocol Commisssie ALL‐10 en AML2007 (DB‐AML01), SKION
M
Member
Membersh
"Quality of Life" vvan VUmc CCA, VU medisch centrum
P
Programma co‐leider
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 154 of 216 Researcher Kluytmans JA
AJW Type of me
embership
Name of the
IKNL ‐ Werkgroep kindertumoren Amsterrdam C
Co‐chair
Membersh
Raad van Toezichtt SKION M
Member
Membersh
Protocol commisssie initiele AML, NOPHO‐DBH‐ AML‐2012
C
Chair
Membersh
"Stichting Vumc K
Kinderstad" 2011 onward
ds
B
Board member
Membersh
Stichting Ronald M
MC Donald huis VUmc
B
Board member, vice‐cha
ir per December 2013 Membersh
AML Relapse Worrking Group, Internation
nal BFM Study Group Chair
C
Membersh
SIOP Scientific Pro
ogramme Advisory Committee
M
Member
Membersh
Plos One
M
Member
Membersh
Infection
M
Member
Membersh
Antimicrobial Resistance and Infection
C
Co‐chair
Membersh
NVMM
M
Member
Membersh
NVI
M
Member
Membersh
ESCMID
M
Member
Membersh
ASM
M
Member
Membersh
IDSA
M
Member
Membersh
Fellow of SHEA
M
Member
Membersh
FRCPE
M
Member
Membersh
hip of an advice counsil
Amphia Ziekenhuis Breda/Oosterhout
Consultant Microbiologisst and Head of the Dep. Of Inf. C
C
Control Membersh
St. Elisabeth Zieke
enhuis Tilburg
Consultant Microbiologisst and supervisor educattion medical C
m
microbiology Membersh
TweeSteden Zieke
enhuis Tilburg
C
Consultant Microbiologis
st
Membersh
Vumc untill May 2
2014 P
Prof. of Medical Microbio
ology and Infectioncontrol Membersh
Julius Center, UMCU, Utrecht
P
Prof. of Medical Microbio
ology and Infectioncontrol Membersh
Infection Control Committee Amphia Ziekkenhuis, C
Chairman
embership
Name of the
(rreviewing activities are not relevant) Breda/Oosterhout
Lammertsmaa AA Membersh
Nederlandse Vere
eniging voor Medische M
Microbiologie
C
Chairman
Membersh
NVMM guideline committee: detection o
of Highly Resistant
C
Chairman
Membersh
Verpleeghuis Elisa
abeth, Breda
M
Member Infection Contro
ol Committee
Membersh
Amphia Ziekenhuis Breda/Oosterhout
M
Member Committee pro
moting science
Membersh
CDC guideline com
mmittee for the preventtion of surgical site infections M
Member
Membersh
Orde van Medisch
h Specialisten (OMS)
M
Member
Membersh
Concilium Microbiologicum Medical Micrrobiology
M
Member
Membersh
Provinciaal kennissnetwerk zoonosen
M
Member
Membersh
Publications Committee SHEA
M
Member
Membersh
European Advisorry Board 3FM
M
Member
Membersh
Int. Steering Committee Staphyloccus aurreus vaccine Pfizer
M
Member
Membersh
RIVM / Outbreak Management Team
M
Member
Membersh
ZIEN
F
Founder and member
Membersh
European Course on Hospital Epidemiology and Infection Control C
Chairman and member f
aculty
Membersh
Molecular Imaging and Biology
In
nternational associate e
editor
Membersh
Nuklearmedizin
S
Section editor
Membersh
International Jourrnal of Molecular Imagin
ng
A
Ad hoc editor
Membersh
Journal of Cerebra
al Blood Flow and Metabolism
M
Member
Membersh
European Journal of Nuclear Medicine an
nd Molecular Imaging Member
M
Membersh
American Journal of Nuclear Medicine an
nd Molecular Imaging Senior member
S
Membersh
Clinical and Translational Imaging
M
Member Membersh
Current Medical Imaging Reviews
M
Member Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 156 of 216 Researcher Leemans CR Type of me
embership
Name of the
BMC Medical Physics M
Member Membersh
OA Molecular Onccology M
Member Membersh
Journal of Radiolo
ogy Research and Practicce
M
Member Membersh
PET/MRI COST acttion M
Member management co
ommittee
Membersh
Stichting Opleidin
ng Klinisch Fysicus
M
Member college van ber
oep
Membersh
Center for Integra
ated Oncology Köln‐Bonn
M
Member scientific adviso
ory board
Membersh
Dutch Imaging Hu
ub M
Member steering commi
ittee
Membersh
Medical Research Council UK
M
Member grant assessme
nt panel
Membersh
Nederlands Tijdscchrift voor keel‐Neus‐Oo
orheelkunde (Netherlands Jourrnal of Otorhinolaryngollogy) M
Member
Membersh
European Archive
es of Oto‐Rhino‐Laryngology Head and Neck
M
Member
Membersh
Oral Oncology
M
Member
Membersh
Head & Neck
M
Member
Membersh
Oral Diseases
M
Member
Membersh
Surgical Oncologyy
M
Member
Membersh
Italian Journal of Maxillofacial Surgery
M
Member
Membersh
Acta Otorrinolarin
ngologia Espanola
M
Member
Membersh
Acta Otorhinolaryyngoiatrica Italica
M
Member
Membersh
Reports of Practiccal Oncology and Radiotherapy
M
Member
Membersh
Dutch Head and N
Neck Oncology Cooperattive Group (NWHHT) General board member
G
Membersh
Netherlands Socie
ety for Otorhinolaryngollogy and Cervico‐
Facial Surgery M
Member Membersh
Netherlands Socie
ety of Oncology
M
Member Membersh
Head and Neck Ca
ancer Cooperative Group of the European Organization for R
Research and Treatmentt of Cancer (EORTC) C
Chair subcommittee Surg
gery
embership
Name of the
Working Party Head and Neck Surgery of the Netherlands Society for Otorhinolaryngology and Cervvico‐Facial Surgery P
President
Membersh
American Head an
nd Neck Society
M
Member
Membersh
American Academ
my of Otolaryngology‐Heead and Neck Surgery Member
M
Membersh
Concilium Oto‐rhino‐laryngologicum in th
he Netherlands
M
Member
Membersh
British Association
n of Head and Neck Onccologists
M
Member
Membersh
European Head an
nd Neck Society
P
President
Membersh
Eruopean Rhinolo
ogical Society
M
Member
Membersh
International Acad
demy of Oral Oncology
F
Founding fellow
Membersh
Collegium Oto‐rhiino‐laryngologicum Amicitiae Sacrum (CORLAS) M
Member credentials com
mmittee
Membersh
European Salivaryy Gland Society (ESGS)
M
Member
Membersh
Spanish Society off Otorhinolaryngology‐H
Head and Neck Surgery (Sociedad
d Espanola de Otorrinolaaringologia y Pathologia Cervico‐Facial; SEORL‐PCF) M
Member
Membersh
Merck Serono
A
Advisory committee
Mebius RE Membersh
LSBR
M
Member
Meijer E Membersh
Dutch Hematology Congress
C
Chairman
Meijer GA Membersh
National Committtee for Implementation of Colorectal Cancer Member
M
Screening, RIVM
Membersh
Dutch Cancer Society (KWF) C
Chairman of the Scientifi
ic Board
Membersh
Maag, Lever, Darm
mstichting M
Member Scientific Adviso
ory Committee Colorecttal Cancer Membersh
eTRIKS
M
ory Board
Membersh
EATRIS
N
National co‐director
Membersh
ZonMW Committee Personalised Medicin
ne
D
Deputy Chairman Membersh
TranSMART Foundation B
Board member
embership
Name of the
(rreviewing activities are not relevant) Meijerink MR
R Membersh
Interventional Oncology 360
M
Member
Membersh
World Journal Clin
nical Oncology
M
Member
Membersh
ASCO
M
Member
Membersh
ESMO
M
Member
Membersh
NVMO
M
Member
Membersh
Bijniernetwerk
M
Member
Membersh
J.Virol.Methods
A
Associate editor
Membersh
J.Clin.Virology
A
Associate editor
Membersh
International EBV Association
B
Board member
Membersh
Nasopharyngeal C
Carcinoma Society
B
Board Member
Membersh
J.Virol.Methods
A
Associate editor
Membersh
J.Clin.Virology
A
Associate editor
Membersh
International EBV Association
B
Board member
Membersh
Nasopharyngeal C
Carcinoma Society
B
Board Member
Membersh
Essen Retinoblastoma Center
In
nternational board mem
mber
Membersh
European Retinob
blastoma Group
P
Project leader WP late ef
ffects and QoL
Membersh
Public Health Gen
nomics M
Member
Membersh
World Journal of G
Gastroenterology
M
Member
Membersh
SIOP PODC Working Group on Treatmentt Abandonment
M
Member Membersh
Global Taskforce o
on Hospital Detention Practices
M
ittee
Membersh
Annals of the Rheumatic Diseases
M
Member
Membersh
Arthritis Research
h Therapy M
Member
Membersh
Plos One
A
Academic Edictor
Membersh
Nederlands veren
niging voor vasculaire geeneeskunde (NVVG)
B
Board Member (Secretar
ry)
Menke‐van d
der Houven van Oordt
Middeldorp JJM Moll AC Morré SA Mostert S Nurmohameed MT Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 159 of 216 Researcher Type of me
embership
Name of the
(rreviewing activities are not relevant) Onwuteaka‐P
Philipsen B Membersh
BMC Geriatrics
A
Associate editor
Membersh
KNMG Advisory Board SCEN M
Member advisory board
Membersh
VENI ZonMW
M
Member
Membersh
European J Heamtology S
Section Editor
Membersh
Eueropean Hemattology association
B
Board member
Membersh
European Leukem
mia Net C
Chair AML WP
Pegtel M Membersh
JEV
M
Member
Peters GJ Member of editorial board
American Journal of Cancer research
S
Senior editor
Amino Acids M
Member
Annals of Oncolog
gy M
Member
Applied Scientific Reports M
Member
Cancer Chemothe
erapy and Pharmacologyy
M
Member
Cancer Therapy
M
Member
Chemotherapy Re
esearch and Practice
M
Member
Chinese Journal of Clinicians M
Member
Clinical Colorectal Cancer M
Member
Current Drug Resiistance S
Section editor
European Journal of Cancer M
Member
Experimental Hem
matology and Oncology
M
Member
Expert Opinion on
n Drug Metabolism and Toxicology
M
Member
Gastrointestinal C
Cancer Reviews
M
Member
International Jourrnal of Oncology
M
Member
Journal of Cancer Research and Treatmen
nt
E
Editor in chief
Journal of Chemotherapy M
Member
Ossenkoppelle GJ Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 160 of 216 Researcher Type of me
embership
Name of the
(rreviewing activities are not relevant) Member of editorial board
Journal of Chinese
e Clinical Medicine
M
Member
Journal of Epithelial Biology and Pharmaccology
M
Member
Journal of Pharma
acology and Toxicology
M
Member
Journal of Tumor M
Member
Journal of Zhejian
ng University‐SCIENCE B (JZUS‐B) M
Member
Nucleosides, Nucleotides and Nucleic Acids
M
Member
Oncology Discove
ery E
Editor in chief
Pteridines
M
Member
The Open Lung Ca
ancer Journal
E
Editor‐in Chief
World Journal of C
Clinical Oncology
S
Strategy Associate Editor
r‐in‐Chief
World Journal of G
Gastrointestinal Oncologgy
M
Member
World Journal of G
Gastrointestinal Pharmaacology and Therapeutics M
Member
World Journal of Pharmacology
M
Member
Membersh
European Organizzation for Research and treatment of Cancer Member
M
Membersh
EORTC General Asssembly M
Member
Membersh
EORTC Pharmacology and Molecular Mecchanisms Group
M
Member of Steering Com
mmittee (1990‐) Chair (Ju
uly 2009‐) Membersh
EORTC Drug Disco
overy Committee NCI co
ompounds task force
C
Chair (2009‐)
Membersh
EORTC‐Translational Research Advisory C
Committee (TRAC)
M
Member
Membersh
American Association for Cancer Research M
Member
Membersh
Purine and Pyrimiidine Society (PPS) S
Secretary/treasurer
Membersh
Steering Committtee IMBRAIN, an EU fund
ded program for Outermost Region
ns of the EU, Canaryy Islands, Spain (2012‐)
A
Advisory boards
Membersh
Kucera Pharmaceuticals, Winston‐Salem, NC, USA
A
Advisory boards
embership
Name of the
Salzburg Therapeutics, Winston‐Salem, NC, USA
A
Advisory boards
Membersh
Taiho Pharmaceuticals, Tsukuba, Japan
A
Advisory boards
Membersh
Review Committe
ee UICC for Translational Cancer Research Funds (TRCF) and ACSBI (1998‐) M
Member
Membersh
Fonds Wetenscha
appelijk Onderzoek (FWO
O) Vlaanderen (2013‐ Member Expert panel M
M
edisch Onderzoek; Med
d4 (“Cancer ) T
Therapy and biology”). Membersh
Agency for health Quality and Assessmen
nt of Catalonia (Cahta Panel member La Marato
P
o de TV3 call on Cancer (2013‐) Research) Membersh
26th EORTC‐NCI‐A
AACR meeting on drug d
development; Barcelona, Spain, November 2014; M
Member
Reijneveld JC
C Membersh
EORTC Quality of Life Group M
mittee
Savelkoul P Membersh
CMI
M
Member
Membersh
ESCMID
C
Chairman European stdu
uy Group on Molecular D
Diagnostics Membersh
KNVM
C
Chairman Divisie Molecu
ulaire typering
Membersh
ESCMID
M
ory Board
Membersh
NVMM
M
Member
Membersh
ASM
M
Member
Membersh
Neurofibromatose
e vereniging NL
M
Member Medische Advie
es raad, vrijwilliger Membersh
Vereniging voor m
moleculair diagnostici in de gezondheidszorg Chair
C
Smit L Membersh
AACR
A
Active member
Snijders PJF Membersh
International Papillomavirus Society (IPVSS) M
d
Membersh
Journal of Clinical Virology A
Associate Editor
Membersh
International Jourrnal of Oncology
M
Member
Membersh
Sub‐committee HPV of the Workgroup M
Molecular Diagnostics Member
M
MDP) in Pathology (WM
Membersh
BMC Cancer
Steenbergen
n RDM A
Associate editor
embership
Name of the
International Papillomavirus Society
M
Member
Membersh
CCA V‐ICI
M
Member
Membersh
Eurogin
M
Member
Membersh
EORTC Quality of Life Group A
Active member
Membersh
European Association of Neuro‐Oncologyy
B
Board Member
Membersh
EORTC Brain Tumor Group A
Active member
Membersh
European CanCer Organization (ECCO)
B
Board Member
Membersh
Neuro‐Oncology
M
Member
Membersh
Neuro‐Oncology P
Practice A
Associate editor
Membersh
Expert Reviews Ph
harmacoeconomic Outcomes Research
M
Member
Membersh
UK Brain Tumour Charity M
Member
Membersh
Cancer Research U
UK M
ory board
Membersh
ALS foundation Th
he Netherlands
M
ory board
Membersh
National Brain Tumour Society USA
M
ory board
Unger WWJ Membersh
CWO CCA/Vumc
M
Member
van Beusechem VW Membersh
NVGCT Science co
ommittee C
Chairman
Membersh
NVGCT board
B
Board Member
Membersh
Human Gene Therapy E
Editor
Membersh
Genetics Research
h International
E
Editor
Membersh
Medicines Evaluation Board expert group
p on Advanced al Products Therapy Medicina
E
External advisor
Membersh
HOVON Myeloma
a group S
Secretary
Membersh
ASH
M
Member
Membersh
EHA
M
Member
Membersh
NTVH
E
Editor Taphoorn MJJB van de Donk N Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 163 of 216 Researcher Vandenbrouccke‐Grauls CMJE
van den Eerttwegh AJM van der Horsst‐Bruinsma IE van der Laken J Type of me
embership
Name of the
EMN
M
Member
Membersh
Royal College of P
Physicians (UK)
F
Fellow
Membersh
Frontiers in Publicc Health, Section Infectio
ous Diseases
A
Associate editor
Membersh
VUMC CCA Scienttific review committee
C
Chairman
Membersh
WIN‐O melanoma
a group C
Chairman
Membersh
Scientific board Dutch Melanoma Treatm
ment Registry (DMTR) Chairman
C
Membersh
Dutch Melanoma Treatment Registry (DM
MTR)
B
Board Member
Membersh
WIN‐O
B
Board Member
Membersh
Working group metastatic prostate canceer of the Dutch Uro‐
Oncology B
Board Member
Membersh
Study group (DUO
OS) B
Board Member
Membersh
Dutch Society of M
Medical Oncology
M
Member
Membersh
WIN‐O
M
Member
Membersh
Cancer Immunoth
herapy Consortium M
Member
Membersh
Tumorfocus group
p melanoma
M
Member
Membersh
EORTC melanoma
a group M
Member
Membersh
Dutch Society for Immunology (NVVI) M
Member
Membersh
ASAS
M
d
Membersh
IGAS
M
ittee
Membersh
NVR werkgroep SpA richtlijn C
Chair (national)
Membersh
NVR werkgroep biologicals M
Member (national)
Membersh
National working group Imaging Rheumatology Organisaton of the Netherland
ds (IRON) B
Board member: Treasure
er
Membersh
Standing committte of imaging of the EULAR
M
Member
Membersh
European working
g group risk factors for rrheumatoid arthritis Member
M
embership
Name of the
European working
g group Imaging of spon
ndyloarthritis
M
Member
Membersh
International Scho
olarly Research Notices
M
Member
Membersh
Cancer and Clinica
al Research
M
Member
Membersh
European Association of Palliative Care [EEAPC]
M
Member
Membersh
ESMO
M
Member
Membersh
Nederlandse Internisten Vereniging [NIV]]
M
Member
Membersh
Dutch Childhood Oncology Group‐LATER Taskgroup
E
Executive Board membe
r
Membersh
International Guid
deline Harmonisation Grroup Member and work group
M
p leader within Female FFertility G
Guideline van Egmond M Membersh
PeerJ
A
Academic editor
van Furth AM
M Member editorial board
BMC Infectious Diseases M
Member
Member editorial board
"Purple pages" Pe
ediatric Infectious Diseasses Journal
M
Member
Membersh
Advisory commite
ee Royal Tropical Institutte
M
Member
Membersh
NVK wetenschapsscommissie
M
Member
Membersh
Commissie weten
nschappelijk onderzoek V
Vumc Kindergeneeskunde M
Member
Membersh
Interne Auditcommissie (IAC)
M
Member
Membersh
NVVI
M
Member
Membersh
American Society of Immunology
M
Member
Membersh
Advisory board TW
WINCORE M
Member Advisory board
Membersh
IMMUUN
E
Editor
Membersh
Scientific program
mming committee EADV
M
Member
Membersh
PR committee Dutch Society of Dermatology and Venereology Chair
C
Membersh
Ethics of Live Surg
gery Committee, Europeean Association of Urology van der Vliett JJ van der Vorst M van Dulmen‐‐den Broeder E
van Kooyk Y van Montfrans C van Moorselaar RJA M
Member
embership
Name of the
European School of Urology (ESU)
B
Board member
Membersh
Medical Innovatio
on Board, TNO
M
Member
Membersh
Steering Committtee Guidelines on Prostaate Cancer, Dutch Urological Associa
ation M
Member
Membersh
Subgroup Minima
al Invasive Oncology SWEN, Dutch Urological Chairman
C
Association Membersh
Urology Committe
ee, comprehensive canccer center Amsterdam C
Chairman
Membersh
Dutch Urological O
Oncological Study Group
p (DUOS)
M
Member Board
Membersh
Lid Werkgroep On
ncologische Urologie: NV
VU
M
Member
Membersh
European Board o
of Urology B
Board member
Membersh
Examination Committee EBU
M
Member
Membersh
Association of Aca
ademic European Urologgists
M
Member
Membersh
hoofdredactieraad Ned. Tijdschrift voor O
Oncologie
M
Member
van Schaardeenburg D Membersh
Arthritis Rheumattol A
Advisory editor
van Vliet SJ Membersh
Consortium for Fu
unctional Glycomics
P
PI
Membersh
Dutch Society for Immunology
M
Member
Membersh
Club Francophone
e des Cellules dendritiqu
ues (CFCD, French Dendritic Cell Society) M
Member
Membersh
Ducth society for Glycobiology
M
Member
Membersh
Cancer
C
Consulting editor
Membersh
Psycho‐Oncology
C
Consulting
editor
Membersh
Folia Phoniatrica Logopedica
C
Consulting editor
Membersh
Oral Oncology
C
Consulting editor
Membersh
World Journal of C
Clinical Oncology
M
Member Membersh
Supportive Care in
n Cancer C
Consulting editor
Verdonck‐dee Leeuw IM Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 166 of 216 Researcher Verheul HMW
W Verweij CL Type of me
embership
Name of the
EORTC Quality of Life Group M
mittee
Membersh
MASCC Study Gro
oup on Cancer Survivorsh
hip and Rehabilitation C
Chair
Membersh
CCA and EMGO Research Program Quality of Life in Cancer
C
Chair
Membersh
NIVEL patient pan
nel Living with Cancer
M
Member Advisory Board
Membersh
Pink Ribbon
M
Member Advisory Board
Membersh
Foundation "Klankbord", patient organizaation Head and Neck Member Advisory Board
M
cancer Membersh
ASCO
M
Member
Membersh
AACR
M
Member
Membersh
ESMO
M
Member
Membersh
Current angiogenesis M
Member
Membersh
The Open Rheumatology Journal
M
Member Membersh
nity Genes and Immun
A
Associate editorial board
d member
Membersh
Frontiers in immu
unology M
Member Membersh
Frontiers in innate
e immunology
A
d member
Membersh
Arthritis
M
Member
Membersh
Recent Patents an
nd Biomarkers
M
Member Membersh
Arthritis Research
h and Therapy
M
Member Membersh
BioScience Biomarker summit symposium
m
Member advisory committee
M
Membersh
Dutch Arthritis Asssociation M
ory Board Membersh
International Society for Translational Meedicine (ISTM)
M
Member
Membersh
European Association for Predictie and Peersonalised Medicine Member
M
(EPMA) Membersh
M
Member
embership
Name of the
Genes and Immun
nity A
d member
Membersh
Frontiers in immu
unology M
Member Membersh
Frontiers in innate
e immunology
A
d member
Membersh
Arthritis
M
Member Membersh
Recent Patents an
nd Biomarkers
M
Member Membersh
Arthritis Research
h and Therapy
M
Member Membersh
m
M
Membersh
ory Board Membersh
M
Member
Membersh
M
(EPMA) Membersh
M
Member Membersh
nity Genes and Immun
A
d member
Membersh
Frontiers in immu
unology M
Member Membersh
Frontiers in innate
e immunology
A
d member
Membersh
Arthritis
M
Member
Membersh
Recent Patents an
nd Biomarkers
M
Member
Membersh
Arthritis Research
h and Therapy
M
Member
Membersh
m
M
Membersh
ory Board Membersh
M
Member
Membersh
M
(EPMA) Voortman J Membersh
World journal clin
nical oncology
M
Member
Voskuyl AE Membersh
Lupus and medicine M
Member
embership
Name of the
Stichting registrattie systeemziekten Nedeerland
P
President
Membersh
National SLE werk
kgroup S
Secretary / vice presiden
nt
Membersh
National werkgroup sclerodermie
M
Member
Membersh
Treat to target in SLE, European taskforcee
M
Member
Membersh
gue NVLE, patient leag
P
President of medical adv
visory board
Membersh
NVLE‐FONDS
M
Member
Membersh
Reumafonds, implementatie
M
Member
Membersh
EULAR studygroup
p on SLE M
Member
Membersh
EULAR studygroup
p on microvascularisatio
on in rheumatic diseases M
Member
Membersh
Acta Neuropathollogica A
Advice
Membersh
Neuro‐Oncology
A
Advice
Membersh
Brain Pathology
A
Advice
Membersh
Neuro‐Oncology P
Practice A
Advice
Membersh
STOPbraintumorss Foundation
A
Advice
Membersh
Koppie‐AU Foundation A
Advice
Wierdsma N Membersh
ECCO
D
Dietician member in D‐E
CCO executive board Windhorst AD Membersh
TOPIM
D
Define scientific program
m
Membersh
ISRS2015
D
m
Membersh
ESRR2014
D
m
Membersh
Nuclear Medicine & Biology A
Advisor
Membersh
J. Labelled Compn
nd & Radiopharm
E
Editor
Membersh
Frontiers in Nucle
ear Medicine
A
Advisor
Membersh
Current radiopharrmaceuticals
A
Advisor
Membersh
NWO ALW VIDI co
ommittee M
Member executive pane
l
Wesseling P Wolthuis R Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 169 of 216 Researcher Type of me
embership
Name of the
(rreviewing activities are not relevant) Ylstra B member off editorial board
Cellular Ooncolog
gy
M
Member
Membersh
International Society of Cellular Oncologyy (ISCO)
C
Chair
Membersh
American Association of Cancer Research
h (AACR)
M
Member
Membersh
Nederlandse Vere
eniging voor Oncologie (NVvO)
M
Member
Membersh
Research Foundattion Flanders (FWO)
3‐year member apointment FWO Expertpanalistt Med4: 3
C
Cancer Research Membersh
Genomics Core, U
University Leuven and an
nd University hospital Scientific Advisory Board
S
d member
Leucven (BE) Membersh
Fundação para a C
Ciência e a Tecnologia, I.P. (FCT), the Portuguese publicc funding agency for R&D S
Scientific Advisory Board
d member
Annual Report VUmc CCA 2014 – Appendix 5: Output indicattors ‐ 170 of 216 Appendix 6 – Ongoing research projects
Program 1 – Oncogenesis Breast cancer o
o
Genomic profiles for inherited breast cancer M. Massink, S. van Mil, J.P. de Winter, Q. Waisfisz, H. Meijers‐Heijboer Department of Clinical Genetics, VU University Medical Center, Amsterdam Grant: NWO VIDI Meijers‐Heijboer Towards targeted treatment of (familial) breast cancer J.L. Bakker1, S. van Mil1, A.B. Oostra1, H.M.W. Verheul2, H. Meijers‐Heijboer1, Q. Waisfisz1, J.P. de Winter1 1Department of Clinical Genetics and 2Department of Medical Oncology, VU University Medical Center Grant: VUmc CCA Cancer o
Sister chromatid cohesion: lessons from yeast, mice and man R. Wolthuis, H.van Attikum, H. te Riele Department of Clinical Genetics, VU University Medical Center, Amsterdam Grant: NWO TOP‐GO Cancer mouse models o
Stop osteosarcoma S.R. Baglio, D.M. Pegtel Department of Neurosurgery and Pathology, VU University Medical Center Amsterdam Grant: I‐Care Marie Curie Cervical cancer o
o
o
o
Comparison self‐collection of specimens for HPV testing (self‐sampling) with physician‐based HPV screening in a population‐based screening setting N. Polman, C.J.L.M. Meijer, P.J.F. Snijders, D.A.M. Heideman, G. Kenter, J. Berkhof Department of Pathology, Department of Epidemiology and Biostatistics, Centre for gynaecologic Oncology Amsterdam Grant: FP7, Coheahr Improving cervical cancer screening by finding new, objective biomarkers M. van Zummeren, C.J.L.M. Meijer, P.J.F. Snijders, G. Kenter Department of Pathology, Centre for gynaecologic Oncology Amsterdam Molecular Self Screening for Cervical Cancer Prevention C.J.L.M. Meijer Department of Pathology, VU University Medical Center, Amsterdam Grant: EU Screening for cervical cancer: triage strategies in high‐risk HPV positive women R. Luttmer, C.J.L.M. Meijer, P.J.F. Snijders, D.A.M. Heideman, G. Kenter Department of Pathology, Department of Epidemiology and Biostatistics, Centre for gynaecologic Oncology Amsterdam Colorectal cancer o
o
o
o
CRCbioscreen B. Carvalho, R. Fijneman, C. Jimenez, G.A. Meijer Department of Pathology and Medical Oncology, VU University Medical Center, Amsterdam Grant: CTMM Datamanagement voor moleculaire vroegdiagnostiek en therapieselectie bij darmkanker J. Beliën, G.A. Meijer Department Of Pathology, VU University Medical Center, Amsterdam Grant: Stichting Avanti STR Development of an improved molecular test for population‐wide colorectal cancer screening A.C. Hiemstra, B. Carvalho, R.J.A. Fijneman, C.R. Jimenez, C.J. Mulder, G.A. Meijer Department of Pathology, Medical Oncology and Gastroenterology, VU University Medical Center, Amsterdam Grant: Vrienden van het CCA Development of screening tests for early detection of CRC Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 171 of 216 o
L. Bosch1, B. Carvalho1, M. van der Wiel1, V. Coupé1, M. van Engeland4 Y. van der Burgt5, W. van Criekinge6, C.R. Jimenez2, R. Fijneman1, C.J. Mulder3, G.A. Meijer1 1Department Of Pathology, 2Department Medical Oncology (OncoProteomics Laboratory), 3Department Gastroenterology, VU University Medical Center, 4MUMC, 5LUMC, MdXHEalth, 6Univ Gent Grant: CTMM Structural chromosomal rearrangements in colorectal cancer E. van den Broek, R.J.A. Fijneman, G.A. Meijer Department Of Pathology, VU University Medical Center, Amsterdam Grant: VUmc Cancer Center Amsterdam Fanconi anemia o
o
o
o
Compensatory survival mechanisms in head and neck cancer from Fanconi anemia patients: novel targets for cancer therapy? C. Pennings, J.C. Dorsman, R. Wolthuis, V.W. van Beusechem, R.H. Brakenhoff, H.P.J. te Riele Department of Clinical Genetics, VU University Medical Center, Amsterdam Grant: KWF Fanconi anemia: a genomics approach A. Haitjema, Joenje H, Dorsman JC Department of Clinical Genetics, VU University Medical Center, Amsterdam Human genes essential for the defence against oxygen toxicity M. Corbin, Joenje H, Dorsman JC Department of Clinical Genetics, VU University Medical Center, Amsterdam Identification of pathway(s) compensating for Fanconi anemia gene defects K. Roohollahi, Joenje H, Dorsman JC Department of Clinical Genetics, VU University Medical Center, Amsterdam Head and neck cancer o
o
o
o
o
o
o
Clinical and genetic aspects of hereditary paragangliomas J.A. Rijken, E.F. Hensen, C.R. Leemans Department of Otolaryngology and Head‐Neck Surgery VU University Medical Center Clinical significance of human papillomavirus infection in oropharyngeal squamous cell carcinoma M. Rietbergen1, C.R. Leemans1, P.J.F. Snijders2, B. Witte3, R.J. Baatenburg de Jong4, B.J.M. Braakhuis1, E. Bloemena2, R.H. Brakenhoff1 Departments of 1Otolaryngology ‐ Head and Neck Surgery, 2Pathology, 3Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, 4Otolaryngology – Head and Neck Surgery, Erasmus Medical Center, Rotterdam Grant: KWF Development of a personalized targeted treatment of head and neck cancer A. van Harten, B.J.M. Braakhuis, C.R. Leemans, R.H. Brakenhoff Department Otolaryngology and Head‐Neck Surgery, VU University Medical Center, VU University Medical Center, Amsterdam Grant: VUmc Cancer Center Amsterdam Early detection of primary and recurrent nasopharyngeal carcinoma (NPC) using (anti‐) EBV based tumor markers and options for using photodynamic therapy (PDT) in the treatment of local disease I.B. Tan, S.M. Haryana, J.M. Middeldorp Department of Pathology, VU University Medical Center Amsterdam, AKI‐AvL, Amsterdam, UGM, Yoguakarta, Indonesia Grant: KWF Fanconi anemia: course of disease in rthe Dutch patient cohort and early recognition of cancer S. Smetsers1,2, A. Brink1, R.H. Brakenhoff1 Departments of 1Otolaryngology ‐ Head and Neck Surgery VU University Medical Center, Amsterdam, 2Paediatrics, University Medical Center Utrecht Grant: Kika Identification of oncogenic microRNAs and cancer genes involved in head and neck squamous cell carcinoma by a functional genomics approach M. Lindenbergh‐van der Plas, B.J.M. Braakhuis, C.R. Leemans, R.H. Brakenhoff Section Tumor Biology, Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam Grant: VUmc Cancer Center Amsterdam Improving molecular staging of surgically treated head and neck cancer patients: towards rationalized adjuvant treatment A.P. Graveland1, M. de Maaker1, E. Bloemena2, B.J.M. Braakhuis1, C.R. Leemans1, R.H. Brakenhoff1 Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 172 of 216 o
o
o
o
o
Departments. 1Otolaryngology/Head‐Neck Surgery and 2Pathology, VU University Medical Center, Amsterdam, University Utrecht Grant: NKB/KWF Molecular diagnosis of head and neck squamous cell carcinoma B.J.M. Braakhuis1, W. van Wieringen2, B. Ylstra3, O. Krijgsman3, Q. Voorham3, C.R. Leemans1, R.H. Brakenhoff1 Departments 1Otolaryngology ‐ Head and Neck Surgery, 2Epidemiology and Biostatistics, 3Pathology, VU University Medical Center, Amsterdam Novel tumor‐selective lethal miRNAs for the treatment of head and neck cancer ("MIRacle") S. Martens‐de Kemp, M. Buijze, R.H. Brakenhoff Department of Otolaryngology and Head‐Neck Surgery VU University Medical Center, Amsterdam Grant: EU‐FP7‐SME Targeted therapy of precancerous fields in head and neck mucosa D.V. de Boer1, M. Stigter‐van Walsum1, B.J.M. Braakhuis1, V.W. van Beusechem2, R.H. Brakenhoff1 Department of 1Otolaryngology ‐ Head and Neck Surgery, 2Medical Oncology, VU University Medical Center, Amsterdam Grant: VUmc Cancer Center Amsterdam Targeted treatment of oral cancer and precancer in FA S. Martens‐de Kemp1, V.W. van Beusechem2, R.H. Brakenhoff1 Department of 1Otolaryngology ‐ Head and Neck Surgery, 2Medical Oncology, VU University Medical Center, Amsterdam Grant: Fanconi Anemia Research Fund VPH based predictive model for oral cancer reoccurrence in the clinical practice ("ORAMOD") S. Mes1, B.J.M. Braakhuis1, A. Brink1, E. Bloemena2, P. de Graaf3, W. van Wieringen4, B. Ylstra2, M. van de Wiel4, O. Krijgsman2, C.R. Leemans1, B.R.H. Brakenhoff1 Department 1Otolaryngology ‐ Head and Neck Surgery, 2Pathology, 3Radiologie & Nuclear Medicine, 4Epidemiology and Biostatistics, VU University Medical Center, Amsterdam Grant: EU‐FP7‐ICT HPV‐induced tumors o
o
o
o
Clinical evaluation of methylation markers for risk assessment of high‐risk HPV‐positive women for cervical cancer and its high grade precursors L. de Strooper, C.J.L.M. Meijer, P.J.F. Snijders, D.A.M. Heideman Department Of Pathology, VU University Medical Center Amsterdam Grant: KWF Comprehensive molecular characterisation of a longitudinal in vitro model of high‐risk HPV‐mediated transformation V. Miok1, S.M. Wilting1, R.D.M. Steenbergen1, W.N. van Wieringen2, P.J.F. Snijders1 Department Pathology1 and Epidemiology & Biostatistics2, VU University Medical Center Amsterdam Grant: St. VUmc CCA Discover and validation of molecular triage markers to stratify women with hrHPV positive self‐samples for colposcopy directed biopsy by the gynaecologist B.C. Snoek, R.D.M. Steenbergen, D.A.M. Heideman, C.J.L.M. Meijer, P.J.F. Snijders Department of Pathology, VU University Medical Center Amsterdam Discover and validation of molecular triage markers to stratify women with hrHPV positive self‐samples for colposcopy directed biopsy by the gynaecologist W. Verlaat, R.D.M. Steenbergen, D.A.M. Heideman, C.J.L.M. Meijer, P.J.F. Snijders Department of Pathology, VU University Medical Center Amsterdam Immunotherapy o
Physiological role of EBV‐LMP1 in MHC‐II+exosomes for tumor immune escape across the immunological synaps: Implications for prognosis and immunotherapy F. Verweij, E. Hooijberg, J.J.C. Neefjes, J.M. Middeldorp, D.M. Pegtel Department of Pathology, VU University Medical Center Grant: KWF Lung cancer o
o
Finding molecular derangements in carcinoids S. Duin, B. Ylstra, D. Sie, F.B.J.M. Thunnissen Department of Pathology, VU University Medical Center Amsterdam Genomic profiling for risk assessment of preneoplastic endobronchial lesions R.A.A. van Boerdonk, P.J.F. Snijders, E.F. Smit, D.A.M. Heideman, Department of Pathology1 and Pulmonology2, VU University Medical Center, Amsterdam Grant: KWF Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 173 of 216 o
o
Histologic reproducibility lung cancer E Thunnissen 1), M Noguchi 2), S. Aisner 3), M Beasley 4), E Brambilla 5), LR Chirieac 6), JH Chung 7), S. Dacic 8), K Geisinger 9), Fred.Hirsch 10), Y Ishikawa 11), KM Kerr 12), S. Lantejoul 13), Y Matsuno 14), Y Minami 15), AL Moreira 16), G Pelosi 17) , I Petersen 18), V Roggli 19), WD Travis 20), I Wistuba 21), Y Yatabe 22), R . Dziadziuszko, Department of Oncology and Radiotherapy, Medical University of Gdańsk, Poland 23), B. Witte 24), M. Tsao 25), AG Nicholson 26) Lungscape ETOP S. Duin, F.B.J.M. Thunnissen Department of Pathology, VU University Medical Center Amsterdam Retinoblastoma o
o
Genomics to improve diagnostics and care of retinoblastoma patients E.I. Kooi1,5, B.M. Mol1, T. van Harn2, A.C. Moll3, J. Cloos4,5, G.J.L. Kaspers5, H. te Riele1,2, J.C. Dorsman1 Departments of 1Clinical Genetics, 3Opthalmology, 4Hematology, 5Pediatric Oncology/ Hematology, VU University Medical Center, Amsterdam, The Netherlands. 2Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam Grant: Stichting KIKA Kinderen Kankervrij The molecular carcinogenesis of retinoblastoma B.M. Mol1, E.I. Kooi1, A.C. Moll2, D.A.P. Rockx1, W.A Kors3, M.I. Bosscha2, C. Dommering1, H. Joenje1, H. te Riele1,5, J. Cloos3,4, J.C. Dorsman1 Departments. of 1Clinical Genetics, 2Ophthalmology, 3Pediatric Oncology/Hematology, 4Hematology VU University Medical Center, Amsterdam and 5Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam Grant: VUmc CCA Stichting Avantie STR (round 2008) Other o
o
o
o
o
o
Clinical and molecular evolution of progressive and recurrent glioma F.B. Barthel, R. Verhaak, P. Wesseling Depts of Genomic Medicine, MD Anderson Cancer Center, Cambridge, Houston, USA and Pathology, VU University Medical Center Amsterdam Grant: Research funds Dr. Roel Verhaak, MDACC Vulvar carcinogenesis: assessment of molecular alterations in vulvar SCC and precursor lesions M. Bleeker Department of Pathology, VU University Medical Center Amsterdam Grant: CGOA Grant: CCA A multiparameter radiogenomics‐based decision support system for personalized treatment of advanced stage head and neck cancer patients M. van den Brekel en C. Vens C, NKI, Terhaard en Willems UMCU, Lambin en Hoebers MUMCaa, C.R. Leemans, R.H. Brakenhoff Departments of EBS, Otolaryngology ‐ Head and Neck Surgery and Med. Oncol Grant: KWF‐Alpe d'huzes Construction and clinical validation of a miRNA marker panel for triage in HPV‐based cervical cancer screening I. Babion, R.D.M. Steenbergen, S.M. Wilting, P.J.F. Snijders Department of Pathology, VU University Medical Center Amsterdam Grant: HPV in head and neck cancer R.H. Brakenhoff, Snijders PJ, Leemans CR Department of Otolaryngology ‐ Head and Neck Surgery, and Pathology, VU University Medical Center, Amsterdam Grant: Tumor classification and identification of synthetic lethal interactions by functional genomics vacature, R. Menezes, R.H. Brakenhoff, V. van Beusechem Department of Otolaryngology ‐ Head and Neck Surgery Program 2 – Immunopathogenesis Cancer o
Antibody based therapeutic intervention in Head and Neck Squamous Cell Carcinoma J.E.Bakema1, S.H.Ganzevles1, B.J.M. Braakhuis1, C.R. Leemans1, R.H. Brakenhoff1, C.Tuk2, M.van Egmond2, L. P.E. van der Steen2 ,W.Unger2, A.A. van de Loosdrecht3, G.Vidarsson 4, T.Valerius5, and E. Breij6. Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 174 of 216 o
o
o
o
o
o
o
o
o
o
o
1Department Otolaryngology – Head and Neck Surgery, 2 Department of Molecular Cell biology and Immunology, 3 Department of Haematology, VU University Medical Center, Amsterdam, the Netherlands. 4Department of Experimental Immunohematology, Sanquin Blood Supply Foundation, Amsterdam, the Netherlands. 5 Christian‐
Albrechts‐Universität zu Kiel, Kiel, Schleswig‐Holstein, Germany. 6Genmab B.V., Utrecht, The Netherlands Development of a HOVON Lymphoma Biobank Facility D. Kluin (UMCG), M.E.D. Chamuleau, D. de Jong Department of Pathology, VU University Medical Center Amsterdam Grant: KWF Development of a rapid and effective prime‐boost vaccination strategy for melanoma D. van Dinther, H. Veninga, Y. van Kooyk, J.M.M. den Haan Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam Glycan modification of tumor vaccins enhancing anti‐tumor responses S.K. Horrevorts, T.D. de Gruijl, A. van de Loosdrecht, Y. van Kooyk Departments of Molecular Cellular Biology and Immunology, Medical Oncology and Hematology, VU University Medical Center, Amsterdam iNKT and Vγ9Vδ2‐T cell based immunotherapies for solid tumors R.C. de Bruijn1, F.L. Schneiders1, R. Lameris, R.J. Scheper2, A.J.M. van den Eertwegh1, G.A.M.S. van Dongen3, R.C. Roovers4, P.M. van Bergen en Henegouwen5, H.M.W. Verheul1, T.D. de Gruijl,1 H.J. van der Vliet1. Departments of 1Medical Oncology, 2Pathology, and 3Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam and 4 Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, and 5Cell Biology, Department of Biology, Utrecht University, Utrecht, The Netherlands Grant: ZonMw Clinical Fellowship, KWF Clinical Cancer Research Fellowship Macrophages and tumour development R. Braster1, R.H.J. Beelen2, M. van Egmond1,2 Departments. of 1Surgery and, 2Molecular Cell Biology and Immunology, VU University Medical Center Grant: Eerste geldstroom via MCBI Macrophages as effector cells for monoclonal antibody therapy of cancer N. Gül1, R. Braster1, M. van Egmond1,2 Departments of 1Molecular Cell Biology and Immunology and 2Surgery VU University Medical Center Grant: Eerste geldstroom via MCBI and KWF Novel strategies for antibody therapy of cancer L. van der Steen1,2, C. Tuk2, A. van de Loosdrecht3, J. Bakema4, M. van Egmond1,2 Departments of 1Surgery, 2Molecular Cell Biology and Immunology, 3Hematology and 4Otolaryngology/Head‐Neck Surgery, VU University Medical Center Grant: Stichting VUmc CCA Promoting antitumor immunity by specific tumor‐targeting of iNKT cells J.J. van der Vliet1, T.D. de Gruijl1, G.A.M.S. van Dongen2 1Department Of Medical Oncology and 2Otolaryngology/Head‐Neck Surgery, VU University Medical Center, Amsterdam Grant: ZonMw Surgery induced development of liver metastases S. Grewal1,2, N. Gül1, R.H.J. Beelen1, J. Bonjer2, M. van Egmond1,2 Departments. of 1Molecular Cell Biology and Immunology, and 2Surgery, VU University Medical Center Grant: NWO, Mozaiek The role of galectin‐4 in progression of pancreatic cancer A. Belo1, Mina Maftouh2, E. Giovannetti2, I.M. van Die1 1Department of Molecular Cell Biology and Immunology and 2Dept of Medical Oncology, VU University Medical Center, VUmc, Amsterdam Grant: Portuguese FCT to A. Belo Towards the implementation of personalized treatment of diffuse large B‐cell lymphoma in the Netherlands; preparations for a biomarker‐based Bayesian trial P.J. Lugtenburg (ErasmusMC), Zijlstra JM, D. de Jong Department of Pathology, VU University Medical Center Amsterdam Grant: KWF Cancer ‐ Dendritic cells o
Dendritic cell targeting using nanovesicles to improve anti‐cancer therapy W.W.J. Unger, M. Verstege, S. Engels Y. van Kooyk Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam Grant: SENTERNOVEM, NanoNext Initiative Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 175 of 216 o
o
o
Dissecting the molecular mechanisms that drive expression of immunoregulatory glycans in epithelial cancers of the lung and colon S.J. van Vliet, Y. van Kooyk Department of Molecular Cell Biology and Immunology and Pulmonary Diseases, VU University Medical Center, Amsterdam Grant: KWF In situ targeting and modulation of dendritic cells for immunotherapy: reversal of suppression in tumor‐draining lymph nodes R. van de Ven1, A.G.M. Stam1, K.M. Van Pul1, S.M. Lougheed1, V.W. van Beusechem1, E. Bloemena2, P. van den Tol3, C.R. Leemans4, D.T.C. Curiel5, B.A. Fox6, W.Urba6, A.J.M. van den Eertwegh1, T.D. de Gruijl1 Depts. of 1Medical Oncology, 2Pathology, 3Surgical Oncology, 4 Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam, 5Center for Biotherapeutics, Washington Ubiversity, MO and 6Providence Cancer Center, Earle A. Chiles Research Insstitute OR, USA Grant: KWF Fund Fellowship Interactions between CD169+ macrophages and dendritic cells H. Veninga, E. Borg, H. Kalay, Y. van Kooyk, G. Kraal, J.M.M. den Haan Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam Grant: KWF Dermatology o
o
o
Novel in vitro assays for detection of sensitizers S.W. Spiekstra1, T. Rustemeyer1, S. Gibbs1 Departments of 1Dermatology, VU University Medical Centre The development of an immune‐competent skin‐on‐a‐chip L. Bergers1, T.D. de Gruijl2, A. van de Stolpe3, R. Dekker4, S. Gibbs1 1Department of Dermatology and 2Medical Oncology VU medisch centrum, and 3Philips Research, Eindhoven and 4Institute for Microelectronics and Submicron Technology, TU Delft. Grant: MKMD NWO The development of immuno‐competent human skin and oral mucosa equivalents and their use in determining factors involved in T cell skewing and imprinting I. Kosten1, S.W. Spiekstra1, B.M.E. von Blomberg2, T. Rustemeyer1, R.J. Scheper2, T.J. De Gruijl2, S. Gibbs1 Departments of 1Dermatology and 2Pathology, VU University Medical Center Grant: VUmc CCA OIO Gastroenterology o
o
o
Exploration of novel therapeutic options for refactory CD (RCD) and EATL S. Cillessen, M. von Blomberg, H.J. Bontkes, G. Bouma, C. Mulder Department Of Pathology and Gastroenterology, VU University Medical Center, Amsterdam Grant: Celiac Disease Consortium (CDC/NGI) IgA and intestinal inflammation M. Bogels, E. Aleyd, S. Pouw, M. van Egmond Department Mol Cell biol and Immunol & Surgery, VU University Medical Center, Amsterdam Grant: NWO VICI Protection against inflammatory bowel diseases by glycan antigens E.J. Klaver1, G. Bouma2, G. Kraal1, I.M. van Die1 1Department of Molecular Cell Biology & Immunology, VUmc, Amsterdam; 2Department Gastroenterology, VU University Medical Center, Amsterdam Grant: the Broad Medical Research Program of the Broad Foundation (USA) Hematology o
o
o
A humanized engineered bone marrow model for myeloma and leukemia A.C. Martens, R.W.J. Groen, C.S. Mitsiades1 Department Of Hematology, VU University Medical Center, Amsterdam, (1) DFCI, Boston, USA Grant: Leukemia and Lymphoma Society, USA DC subsets in MDS pathogenesis N. Kerkhoff1, T.M. Westers1, H.J. Bontkes2, R. Mebius3, S. Kordasti4, T.D. de Gruijl5, A.A. Van de Loosdrecht1 Departments of 1Hematology, 2Pathology, 3Molecular Cell Biology and Immunology, and 5Medical Oncology, VU medisch centrum and 4Kings College London Grant: CCA Individualizing myeloma treatment with BET bromodomain inhibitors A.C. Martens, R.W.J. Groen, C.S.Mitsiades1 Department Of Hematology, VU University Medical Center, Amsterdam, (1) DFCI, Boston, USA Grant: Leukemia and Lymphoma Society, USA Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 176 of 216 o
Unraveling interactions in the hematopoietic niche in multiple myeloma H. Prins, A.C. Martens, R.W.J. Groen, R. Raymakers1 Department Of Hematology, VU University Medical Center, Amsterdam (1) UMC Utrecht dept Hematology Grant: KWF Host pathogen interaction o
o
o
o
o
o
o
o
o
o
o
EBV‐MicroRNA containing exosomes: Trojan vesicles carrying hostile message D.M. Pegtel, D.A. Thorley‐Lawson, J.M. Middeldorp Department of Pathology, VU University Medical Center and Tufts University, Boston, USA Grant: NWO‐Veni, ZonMW2008 Enteroviral infections in children S. de Crom 1, Dr. Ch. Obihara 1, M. Peeters 2, S.A. Morré 3 , A. M. van Furth 4 1Department of Pediatrics, St. Elisabeth Ziekenhuis, Tilburg; 2 Department of Medical Microbiology , St. Elisabeth Ziekenhuis, Tilburg; 3Laboratory of Immunogenetica, Department of Medical Mirobiology and Infection Control,VUmc, Amsterdam; 4Department of Pediatric Infectious Diseases, Immunology, and Rheumatology, VUmc, Amsterdam Genetic profiling in bacterial meningitis O. El Tahir, S. Ouburg1 , S.A. Morré1 , A.M. van Furth2 1Laboratory of Immunogenetica, Department of Medical Mirobiology and Infection Control,VUmc, Amsterdam; 2Department of Pediatric Infectious Diseases, Immunology, and Rheumatology, VUmc, Amsterdam Grant: FP7 Immunogenetic, pharmacological and neurodevelopmental aspects of nosocomial sepsis and meningitis in preterm AGA and SGA infants F. van den Dungen1 , S.A. Morré2, P. Savelkoul3, M. M. van Weissenbruch1, A.M. van Furth4 1Department of Neonatology, VUmc, Amsterdam 2 Laboratory of Immunogenetica, Department of Medical Mirobiology and Infection Control,VUmc, Amsterdam; 3Department of Medical Microbiology, VUmc, Amsterdam, 4Department of Pediatric Infectious Diseases, Immunology, and Rheumatology, VUmc, Amsterdam Immunogenetics and environmental factors in infectious diseases S. Ouburg1, H.J.C de Vries2, Y. Pannekoek3, S. Verweij1, M. Singer1, J. Land4, C. Hoebe5, P.H. Savelkoul1, C.M.J.E. Vandenbroucke‐Grauls1, M. van Furth 6,, J.B.A. Crusius1, A.S. Peña1, S.A. Morre 1Laboratory Immunogenetics, Department of Medical Mirobiology and Infection Control,, 2GGD Amsterdam, 3AMC Med Microbiol, 4 UMCG, Groningen, 5MUMC+, Department Med Microbiol, 7Periacts, VUmc Grant: Eurotransbio Improving early diagnosis of tuberculous meningitis in children R. Solomons1, J. Schoeman1, A.M. van Furth2 Departments. of 1Tijgerberg Hospital, Cape Town, SA; 2Pediatric Infectiology, Immunology and Rheumatology, VU University Medical Center, Amsterdam, The Netherlands Inflammatory host defense in children with Down syndrome C.J.M. Broers1, M.E.Wijerman1,2 ; R.J.B.J. Gemke1 , A.M. van Furth3,4 1Department of Pediatrics, VU medical center, 2Department of Pediatrics, Diaconesseziekenhuis, Leiden; 3 Department of Pediatric Infectious Diseases‐Immunology and Rheumatology, VU University Medical Center, Amsterdam; 4Laboratory of Experimental Internal Medicine, Academical Medical Center, Amsterdam Metabolomics Study of Tuberculous Meningitis in Children S. Mason1, R.Solomons2, J.Schoeman2,R.Wevers3, C.Reinecke1, A.M. van Furth4 Departments. of 1Centre for Human Metabolomics, Potchefstroom, SA; 2 Tijgerberg Hospital, Cape Town, SA; 3 Clinical Chemistry, UMC, Nijmegen; 4Pediatric Infectiology, Immunology and Rheumatology, VU University Medical Center, Amsterdam, The Netherlands Predictionmodels in bacterial meningitis O. El Tahir, S.A. Morré, A.M. van Furth Department of Paediatrics and Medical Microbiology, VU University Medical Center, Amsterdam Grant: FP7 The effect of HIV infection and AZT‐3TC‐NVP/EVF therapy on vascular and metabolic changes in patienst with HIV T.Msoka1, Y.Smulders2, M.van Agtmael2, J.Bartlett3, A.M. van Furth4 Departments. of 1Centre for Human Metabolomics, Potchefstroom, SA; 2 VUmc, Amsterdam, The Netherlands; 3 John Hopkins, Baltimore, USA; 4Pediatric Infectiology, Immunology and Rheumatology, VU University Medical Center, Amsterdam, The Netherlands The role of the granulomaformation in tuberculous meningitis in zebrafish L. van Leeuwen, M. van der Kuip, A. van der Sar, W. Bitter, A.M. van Furth Department of Paediatrics and Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam Immunology ‐ Dendritic cells o
Signaling pathways in homeostasis and function of dendritic cells Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 177 of 216 M. Beijer, G. Goverse, R.E. Mebius, G. Kraal and J.M.M. den Haan Department of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam Grant: NWO‐ALW Meervoud to J.M.M. den Haan Liquid biopsy o
Circulating EBV biomarkers in SLE D.M. Pegtel, N. Masoumi, A. Voskuijl, J. Middeldorp Depts of Rheumatology, Pathology, Nephrology and Dermatology, VU University Medical Center, Amsterdam Grant: Rheumafonds Rheumatology o
o
o
o
A phase 0 single dose study to evaluate the pharmacokinetics/‐dynamics and specific targeting properties of 124‐I‐
F8IL10 in patients with active rheumatoid arthritis Y. Gent1, M. Tsang a Sjoe1, O.S. Hoekstra2, G.A.M.S. van Dongen2, D. Vugts2, L. Giovanonni3, D. Neri4, C.J. van der Laken1 Depts of 1Rheumatology, 2Radiology and Nuclear Medicine, VU University Medical Center, 3PHILOGEN S.p.A. , Sovicille (SI), Italy, 4ETH, Zurich, Switzerland Grant: FP7 Health program Biomarkers in systemic lupus erythematosus J. Jacobs, M.W.P. Tsang‐A‐Sjoe, L‐A. Korswagen, B.A.C. Dijkmans, I.E.M. Bultink, A.E. Voskuyl Department of Rheumatology, VU University Medical Center Circulating microvesicles containing inflammatory viral RNA (EBER1) as indicators of SLE activity and organ involvement N. Masoumi Kouhestani, M. Pegtel, A. Voskuyl, J. Middeldorp Department of Pathology and Rheumatology, VU University Medical Center Amsterdam Immunoglobulin A Fc receptor (Fc‐alpha‐RI)‐induced inflammatory diseases E. Aleyd1, S. Pouw1, J.E. Bakema, M. van Egmond Departments. of Molecular Cell Biology and Immunology, and Surgery, VU University Medical Center Grant: NWO, Agentschap NL, MaagLeverDarmStichting Other o
o
o
o
o
o
o
o
A national registry for systemic erythematosus (SLE) in The Netherlands M. Tsang a Sjoe, I.E. Bultink, A.E. Voskuyl Department of Rheumatology, VU University Medical Center, Amstedam Grant: ZonMw Biobanking of systemic sclerosis I.E. Bultink, A.E. Voskuyl Department of Rheumatology, VU University Medical Center, Amstedam DC‐targeted autophagosomes and immunity to melanoma T.H.D. Eisden1, R. van de Ven1, A.G.M. Stam1, C.Ribeiro2, Th. Geijtenbeek2, T.D. de Gruijl1 1Dept Medical Oncology VU medisch centrum and 2Dept Exp. Immunology, AMC, Amsterdam, The Netherlands Grant: VUmc/AMC alliantie De rol van microbiële darmflora in relatie tot chronische darmontstekingen en maligniteiten M.E. Grasman, C.M.J.E. Vandenbroucke‐Grauls, A.A. van Bodegraven, P.H.M. Savelkoul, C.J.J. Mulder Department of Gastroenterology and Medical Microbiology and Infection, VU University Medical Center Amsterdam Dendritic cells and antigen sources in acute myeloid leukemia J.M. Ruben, T.D. de Gruijl, T.M. Westers, H.B. Bontkes, G.J. Ossenkoppele, A.A. van de Loosdrecht 1Department Of Hematology and Medical Oncology, VU University Medical Center, Amsterdam. Grant: Stichting VUmc CCA Developing diagnostic criteria for the differentiation between large vessel vasculitis and atherosclerosis using 18‐
FDG PET/CT M. van Kanten, K.J. Lensen, A.E. Voskuyl, C.J. van der Laken, E. Comans, M. Boers, Y.M. Smulders Department of Reumatology, VU University Medical Center, Amsterdam Grant: Reumafonds Development of a rapid and effective prime‐boost vaccination strategy for melanoma H. Veninga, D. van Dinther, Y. van Kooyk, J.M.M. den Haan Department of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam Dissecting the heterogeneity of myelodysplastic syndromes: a pathophysiological approach M. Spronsen, T.M. Westers, J. de Koning, G.J. Ossenkoppele, G.J. Schuurhuis, T. de Gruijl, R.E. Mebius, A.A. van de Loosdrecht Department of Hematology, Medical Oncology, Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam Grant: Vumc CCA Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 178 of 216 o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
Exploring crosstalk between CLR and TLR R.J.E. Li, J. Garcia‐Vallejo, W. Unger Department of Molecular Cell Biology, VU University Medical Center Amsterdam Generation of a novel syngeneic in vivo model of head and neck squamous cell carcinoma vacature, M. van Egmond, B.J.M. Braakhuis, J.E. Bakema Department of Otolaryngology/Head‐Neck Surgery and Molecular Cel Biology and Immunology, VU University Medical Center Grant: CCA HLA‐DQ genotype distribution in Celiac Disease in European and non‐European countries J.B.A. Crusius 1, R, Heijmans1, S.A. Morré, M. Cromeyer2, Luis Rodrigo3, A.S. Peña 1 Laboratory of Immunogenetics,Department of Medical Mirobiology and Infection Control, VU University Medical Center, Amsterdam, The Netherlands. 2Hospital de Dignostico, Service of Pathology and Gatroenterology,, San Salvador, El Salvador, 3Department of Gastroebterology and Medicine, Univer5sity of Oviedo, Oviedo, Spain. Grant: Human Myelodysplastic syndromes osteoprogenitor functie en leukemische evolutie M. Raaijmakers, A.A. van de Loosdrecht Department Of Hematology, VU University Medical Center, Amsterdam Grant: ZonMw Image guided treatment optimalization with cetuximab for patients with metastatic colorectal cancer: IMPACT ‐ CRC E. van Helden, C. Menke, O. Hoekstra, M. Huisman, D. Vugts, G. van Dongen, G.A.P. Hospers, S.Radema, I. Desar, A. Brouwens, H. Hendrikse, W. Oyen, LF de Geus‐Oei, E.G.E de Vries, W.T.A van der Graaf, H.M.W. Verheul Department of Medical Oncology and Radiology and Nuclear Medicine, VU University Medical Center Amsterdam Immuno‐monitoring of alitretinoine treatment T. Rustemeyer Department of Dermatology, VU University Medical Center Amsterdam Grant: Allmiral Peri‐implantitis, implant loss and radio‐osteonecrosis in head and neck tumor patients H. Dekker, E. Bloemena, B. Schulten, N. Bravenboer Departments of Maxillofacial Surgery, Pathology, and Endocrinology VU University Medical Center Amsterdam Grant: ACTA IOT, Straumann, MKA Protection to diabetes mellitus by Schistosoma mansoni M. Wolde Gebre1,2, A. Tsegaye2, L.C. Laan1, G. Kooij1, C.D. Dijkstra1, I. van Die1 1Department of Molecular Cell Biology & Immunology, VUmc, Amsterdam; 2Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Ethiopia Grant: Noord‐Zuid grant van CIS‐VU Specific CD1d targeting in Multiple Myeloma and solid tumors using nanobody technology R. Lameris1, R.C. De Bruin1, H.M.W. Verheul1, S. Zweegman2, T.D. de Gruijl1, J.J. van der Vliet1 1Department Of Medical Oncology and 2Hematology, VU University Medical Center, Amsterdam Grant: AICR and CCA Study the immunomodulatory effect of lymph node stromal cells in rheumatic disease R. Nadafi, L. van Baarsen, R.E. Mebius Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam Tackling underdiagnosis of Large Artery Giant Cell Arteritis: A Prevalence and Phenotype Study K.J. Lensen, A.E. Voskuyl, C.J. van der Laken, E. Comans, Y.M. Smulders Department of Reumatology, VU University Medical Center, Amsterdam Visualization of vitamin A metabolism M.N. Erkelens, R. E. Mebius Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam Grant: UL ICI A bitter sweet symphony: how tumor glycans orchestrate immune evasion L.A.M. Cornelissen, J. den Haan, S.J. van Vliet, W.W.J. Unger, Y. van Kooyk Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam Control of chemokine signaling by stromal cell‐associated heparan sulfate proteoglycans R. Reijmers, R.E. Mebius Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam Grant: NWO Effect evaluation of home treatment program TBM, Cape Town, South Africa S. van Elsland1; P. Springer2; J. Schoeman2; A.M. van Furth1 Departments. of 1Pediatric Infectiology, Immunology and Rheumatology, VU University Medical Center, Amsterdam, The Netherlands; 2 Tijgerberg Hospital, Cape Town, SA Helminth glycoproteins: a new therapeutic option to prevent or ameliorate MS? Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 179 of 216 o
o
G. Kooij, L. Laan, C.D. Dijkstra, I. van Die Department of Molecular Cell Biology & Immunology, VUmc, Amsterdam Grant: the Dutch Foundation MS Research Spatial dynamics of lectin‐carbohydrate interactions S.J. van Vliet and Y. van Kooyk Department of Molecular Cellular Biology and Immunology, VU University Medical Center Amsterdam Grant: VENI NWO The IgA Fc receptor (FcaRI) in health and disease M.H. Heineke, JE Bakema, M. van Egmond Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam Program 3 – Disease profiling Brain cancer o
o
o
o
o
o
o
o
Advanced glioma and correlation with histological and molecular characteristics P. de Witt Hamer1, O. Hoekstra2, R. Boellaard2, F. Barkhof2, P. Wesseling3, J.C. Reijneveld4 Department of 1Neurosurgery, 2Radiology & Nuclear Medicine, 3Pathology, 4Neurology, VU University Medical Center Amsterdam Grant: VUmc Cancer Center Amsterdam Expression of HER2 and other biomarkers in meningiomas: prediction of biological behaviour and potential targets for therapy M. Coenen, S.M. Peerdeman, W.P. Vandertop Department of Neurosurgery, VU University Medical Center, Amsterdam Grant: stichting Stophersentumoren.nl Identification of clinically relevant genetic aberrations in pediatric glioneuronal tumors B. Ylstra1, P. Wesseling1, E. Aronica2, Schouten2 Department Of Pathology, 1VU University Medical Center Amsterdam, 2Amsterdam Medical Center Grant: Edli Foundation Ontwikkeling celtherapie voor kinderen met wittestofziektes S. Dooves1,2, J. Wortel1, C. van der Meer1, L. Thoolen1, T. Lagerweij3, C. Molthoff4, I. de Greeuw4, M. Verlaan4, V. Heine1,2 Departments of 1Pediatrics and 2CNCR, 3Neuro‐oncology Research Group, 4 Radiology & Nuclear Medicine, Vumc, Amsterdam Grant: NWO Pediatric meningiomas in the Netherlands. Biomarkers as predictors for biological behaviour N. Thuijs, S.M. Peerdeman, W.P. Vandertop Deparment of Neurosurgery, VU University Medical Center, Amsterdam Pilot study on the determination of tumor concentrations of protein kinase inhibitors in patients with newly diagnosed high‐grade glioma M. van Linde1, K.E. Hovinga, P.C. de Witt Hamer2, T. Wurdinger2, M. Labots1, J. Buter1, G.J. Peters1, R. Honeywell1, C.R. Jimenez1, J.C. Reijneveld3, P. Wesseling4, F.J. Lagerwaard5, J. Berkhof6, WP Vandertop2, H.M.W. Verheul1 Department of 1Medical Oncology, 2Neurosurgery, 3Neurology, 4Pathology, 5Radiotherapy, 6Epidemiology and Biostatistics, VU University Medical Center Amsterdam Radiological aspects in meningioma surgery M. Slot, S.M. Peerdeman, W.P. Vandertop Deparment of Neurosurgery, VU University Medical Center, Amsterdam Targeting growth factor‐induced signal transduction in Diffuse Intrinsic Pontine Glioma M.H. Meel 1,2, D.G. van Vuurden1,2, P. Wesseling2,3,4, W.P. Vandertop5, D.P. Noske2,5, T. Wurdinger2,5,6, G.J.L. Kaspers1, E. Hulleman1,2 Departments of 1Pediatric Oncology/Hematology, 2Neuro‐oncology research group, Cancer Center Amsterdam, Department of 3Pathology, VU University Medical Center Amsterdam, Department of 4Pathology, Radboud University Nijmegen Medical Center, 5Neurosurgery, 6Molecular Neurogenetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA6 Grant: Semmy Foundation Colorectal cancer o
Building data bridges and services between biological and medical infrastructures in Europe R. Voorham, J. van Denderen, J. Beliën, J.W. Boiten, G.A. Meijer Department of Pathology, VU University Medical Center Amsterdam Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 180 of 216 o
o
Grant: EU‐KP7 Molecular imaging of early stage disease colorectal cancer M. de Wit,2, R. Fijneman2, J. Verbeek1, A.D. Windhorst1, R. Lamerichs 3,4, C. Sio3, K. Donato3, J. Stoker4, G.A. Meijer2 Departments of 1Radiology & Nuclear medicine, 2Pathology, Vumc, 3 department of biomolecular imaging philips research, 4department of radiology AMC Grant: CTMM, DeCoDe Personalized therapy in recurrent colorectal cancer J. Goos1, R. Fijneman1, A.A. Geldof2, O.S. Hoekstra2, L. Perk3, G.A. Meijer1 Department of 1Pathology, 2Nuclear Medicine & PET reserach, VU University Medical Center, Amsterdam, 3BV Cyclotron Grant: CTMM CRC proteomics o
Improving clinical management of colon cancer through CONNECTION, a nation‐wide Colon Cancer Registry and Stratification effort TV Pham, E Fessler, L Vermeulen, RJA Fijneman, GA Meijer, HMW Verheul, JP Medema, CR Jimenez VUmc Dept. Medical Oncology and Dept. Pathology; AMC Lexor Grant: Alpe d’HuZes/KWF Genetic profiling o
o
o
o
o
o
o
DCR1 and its role in response of colorectal cancer patients to irinotecan treatment L. Bosch Department of Pathology, VU University Medical Center Amsterdam Grant: KWF DNAseq/RNAseq prostate and CRC R.J.A. Fijneman, Ylstra B, Meijer GA Department Of Pathology, VU University Medical Center Amsterdam Grant: CTMM Metastatic colorectal molecular laboratory tests B. Ylstra1, B. Carvalho1, M. van Engeland2, W. Corver3, B. Janssen4, W. van Criekinge5, G.A. Meijer1 Department Of 1Pathology, VU University Medical Center, Amsterdam, 2MUMC, 3LUMC, 4ServiceXS, MDXHEalth, Univ. Gent Grant: CTMM Molecular stool test for post‐polypectomy surveillance E. Dekker (AMC), M. Engeland (UMCM), G.A. Meijer Department of Pathology, VU University Medical Center Amsterdam Grant: KWF Next Generation Sequencing: from Prostate to Colorectal cancer R.J.A. Fijneman, Ylstra B, Meijer GA Department of Pathology, VU University Medical Center Amsterdam Grant: CTMM Predictive genomic biomarker methods for combination Bevacizumab (Avastin) therapy in metastatic colorectal cancer B. Ylstra Department of Pathology, VU University Medical Center Amsterdam Grant: EU TRACER Genomic biomarkers to predict development of RA (VERA, ERA), and therapy responsiveness (ESRA) (WP5) J. Lübbers, E. Mantel, A.E. Voskuyl, R. Out, C. Verweij Dept. of Pathology, Dept. of Rheumatology, Flexgen Grant: CTMM Head and neck cancer o
FALCON ‐ Intra‐operative fluorescent parathyroid glands localization A.F. Engelsman1, C.F.M. Molthoff2, A.D. Windhorst2, I. de Greeuw2, W.A. Adamzek2, M. Verlaan2, G.A.M.S. van Dongen2 1Dept. of Surgery, AMC medical center and 2Dept. of Radiology&Nuclear Medicine, Vumc Amsterdam Grant: AMC Hematology o
EBV markers in CLL cases from Spain De Sanjose, J.M. Middeldorp Department Of Pathology, VU University Medical Center Amsterdam Imaging Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 181 of 216 o
o
o
o
o
o
o
o
o
Carbon‐11 labelled peptodes as PET tracers A. Pekosak, AJ Poot, AD Windhorst Department Radiology & Nuclear Medicine Grant: EU ITN Design and production of anti‐body drug conjugates (ADC), anti‐body tracer conjugates (ATC) and other disease‐
targeted devices D. Waalboer, G.A.M.S. van Dongen Department of Otolaryngology/Head‐Neck Surgery, Radiology & Nuclear Medicine, VU University Medical Center Grant: LinXis FLT PET and DW MRI as markers of proliferation: technical validation 1G.E.M. Kramer, 1IC Pieters‐van den Bos, 2JPA Kuijer, 1OS Hoekstra, 2EF Smit, 3CW Menke‐van den Houven v Oordt, 1R Boellaard Departments of 1Radiology & Nuclear Medicine, 2Physics & Medical Technology, 3Pulmonology, 4Medical Oncology, VUmc Grant: EU IMI project Quic‐Concept In vivo imaging of Epstein Barr Virus Activation by cytolytic antiviral therapy in nasopharyngeal carcinoma cell lines and xenograft models Z. Novalic1, M. Verlaan2, J. Eersels2, C.F.M. Molthoff2, A.E. Greijer1, J.M. Middeldorp1 Depts. of 1Pathology and 2Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam Grant: ZonMW, KWF Measurement of tumor kinase inhibitor concentrations using PET imaging in patients with advanced solid malignancies (PIKTURE) L. Mammatas, C. Menke,A.A. Lammertsma, A.D. Windhorst, N.H. Hendriks, H.M.W. Verheul Department of Medical Oncology and Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam Multimodal imaging of orthotopic tumors: validation study C.F.M. Molthoff1, A. Avan2, E. Giovanetti2, T. Lagerweij3, R. Bergstra1, I. de Greeuw1, G.J. Peters2, T. Würdinger3, D. Fuchs4, P. Trochet4, J. Jose4 Departments. of 1Radiology & Nuclear Medicine, 2Medical Oncology, 3Neuro‐oncology Research Group, VU University Medical Center, Amsterdam and 4VisualSonics Europe, Amsterdam Multiparametric PET‐MRI imaging in Breast cancer K.M. Duvivier, P. de Graaf, O.S. Hoekstra, C. Jimenez, I.R.H.M. Konings, C.W. Menke‐van der Houven van Oordt, E.A. te Velde Department Of Radiology & Nuclear Medicine, Vu University Medical Center, Amsterdam Quantitative imaging in cancer: connecting cellular processes with therapy: Data and Image Analysis (WP4) L.L. Hoyng, M. Yaqub, F. van Velden, R. Boellaard Department Of Radiology & Nuclear Medicine, Vu University Medical Center, Amsterdam Grant: IMI EU project QuicConcept (EORTC, CR‐UK, EFPIA) Technical validation of DW‐MRI, FLT and ICMT‐PET as read‐outs of proliferation and apoptosis in drug development G.E.M. Kramer1, L. Hoyng1, JPA Kuijer2, IC Pieters1, R Boellaard1, EF Smit3, W Menke‐van den Houven v Oordt4, OS Hoekstra1 Department of 1Radiology & Nuclear Medicine, 2Physics & Medical Technology, 3Pulmonary Oncology, 4Medical Oncology, VU University Medical Center, Amsterdam Grant: IMI EU project QuicConcept (EORTC, CR‐UK, EFPIA) Imaging ‐ Antibodies o
Pharmacokinetic modelling of PET tracers in oncology E Verwer, AA Lammertsma, EF Smit, OS Hoekstra, R Boellaard Departments of Pulmonology, Radiology & Nuclear Medicine, VUmc Grant: CTMM AiRForce Imaging ‐ Brain tumours o
The effect of dexamethasone on the biodistribution of [3‐N‐11C‐methyl]temozolomide in glioblastoma multiforme patients; a pilot study M. van Linde1, H.M.W. Verheul1, B.N.M. van Berckel, M.Yaqub2, J.Eriksson, C.H. Polman3, A.A. Lammertsma2, J.J. Heimans3, N.H. Hendrikse4, E.A.M Froklage2, J.C. Reijneveld3 Department of 1Medical Oncology, 2Radiology and Nuclear Medicine, 3Neurology, 4Pharmacy, VU University Medical Centerl Amsterdam Imaging ‐ Colorectal cancer o
Development validation of predictive PET tracers in patients with colorectal cancer liver metastases J.A.C.M. Goos1,2, R. Fijneman2, J. Verbeek1, M.P. van den Tol3, H.M.W. Verheul4, A.D. Windhorst1, A.A. Geldof1, O.S. Hoekstra1, G.A. Meijer2 Departments of 1Radiology & Nuclear medicine, 2Pathology, 3Surgery, 4Medical Oncology, Vumc Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 182 of 216 Grant: CTMM DeCoDe Imaging ‐ Head and neck cancer o
o
o
o
o
o
o
Detection of residual neck disease after chemoradiation by PET‐CT S. Hakim1, O.S. Hoekstra2, R. de Bree1 Department of 1Otolaryngology/Head‐Neck Surgery, and 2Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam Evaluation and prediction of response C.S. Schouten1, O.S. Hoekstra2, J.A. Castelijns2, C.R. Leemans1, R. de Bree1 Departments. of 1Otolaryngology/Head and Neck Surgery, 2Radiology & Nuclear Medicine, 3Oral and Maxillofacial Surgery, 4Pathology, VU University Medical Center Grant: ZonMw and CCA FDG‐PET for avoidance of futile direct laryngoscopies under general anasthesia with taking op biopsies in patiens with suspicion on recurrent laryngeal carcinoma after radiotherapy L. van der Putten1, I. van der Waal3, O.S. Hoekstra2, E. Bloemena4, C.R. Leemans1, R. de Bree Depts. of 1Otolaryngology ‐ Head and Neck Surgery, 2Radiology & Nuclear Medicine 3Oral and Maxillofacial Surgery, 4Pathology, VU University Medical Center, Amsterdam Grant: ZonMw and CCA Response evaluation after chemoradiation for advanced oropharyngeal cancer using PET‐CT and MRI C.S. Schouten1, J.A. Castelijns2, O.S. Hoekstra2, R. de Bree1 Department of 1Otolaryngology/Head and Neck Surgery, 2Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam Grant: ZonMw Screening for distant metastases and second primary tumors with FDG‐PET (The school study) A. Senft1, J.A. Castelijns2, R. de Bree1, O.S. Hoekstra2, C.R. Leemans1 Depts. of 1Otolaryngology/Head and Neck Surgery, 2Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam Grant: ZonMw Doelmatigheidsonderzoek The predictive value of PET‐DW‐MRI early during chemoradiotherapy for locoregional control of advanced stage head and neck cancer D. Noij, C.S. Schouten, P. de Graaf, T. Marcus, J.Kuijer, M.Yaqub, R.Boellaard, O.Hoekstra, R. de Bree, J.A.Castelijns Departments of Radiology & Nuclear Medicine, Otolaryngology/Head and Neck Surgery, VUmc, Amsterdam Grant: Guerbet Ultrasound guided fine needle aspiration cytology and sentinel node biopsy in the detection of occult lymph node metastases of early oral and oropharyngeal cancer G.B. Flach, I.J. den Toom, J. Castelijns, O.S. Hoekstra, A. van Schie, E. Bloemena, G.A.M.S. van Dongen, I. van der Waal, C.R. Leemans, R. de Bree Department Otolaryngology/Head and Neck Surgery, Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam Grant: ZonMw Imaging ‐ Paediatric tumours o
Development of pediatric brain tumor. Diffuse intrinxic pontine glioma (DIPG) models for improvement of imaging and therapy P. Wesseling1, T. Würdinger2, E. Hulleman3, G.J. Kaspers3 Departments of 1Pathology, 2Neurooncology Research Group, 3Pediatric Oncology/ Hematology, VU University Medical Center, 4VU University RNC, 5Massachusetts General Hospital and Harvard Medical School, Boston, MA Grant: Stichting Kika Imaging ‐ Retinoblastoma o
Epidemiology and imaging of retinoblastoma M. de Jong1, P. de Graaf1, H.J. Brisse MD2, P. Galluzzi3, S. Göricke4, Ph. Maeder5, A.C. Moll6, J.A. Castelijns1 1Dept. of Radiology, VU University Medical Center, Amsterdam,2Dept. of Radiology, Institut Curie, Paris, France, 3 Dept. of Neuroimaging and Neurointerventional (NINT), Azienda Ospedaliera e Universitaria Santa Maria alle Scotte Siena, Italy , 4Dept. of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany, 5 Dept. of Radiology, University Hospital, Lausanne, Switzerland, 6Dept. of Ophtalmology, VU University Medical Center, Amsterdam Grant: ODAS Stichting Imaging ‐ Rheumatoid diseases o
Detection of subclinical synovitis with (R)‐11C‐PK11195 positron emission tomography in treated Rheumatoid Arthritis patients without clinical synovitis Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 183 of 216 o
Y.Y.J. Gent, N. Ahmadi2, A.E. Voskuyl1, N.Hoetjes2, C. van Kuijk2, K. Bristsemmer3, F. Turkstra3, M. Boers4, O.S. Hoekstra2, C.J. van der Lakenl1 Depts of 1Rheumatology, 2Radiology and Nuclear Medicine, and 4Clinical Epidemiology & Biostatistics, Amsterdam VU University Medical Center, 3Department of Rheumatology, Jan van Breemen Research Institute Institute | Reade, Amsterdam Development of imaging markers, using PET(‐CT), for early detection of RA and therapy monitoring Y.Y.J. Gent1, K. Weijers1, I. de Greeuw2, M. Verlaan2, B. Windhorst2, A.A. Lammertsma2, O.S. Hoekstra2, B.A.C. Dijkmans1, G. Jansen1, C.F.M. Molthoff2, C.J. van der Laken1 Departments. of 1Rheumatology, 2Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam Liquid biopsy o
o
o
CANCER‐ID D.M. Pegtel, G. Jenster, L. Terstappen Department of Pathology, VU University Medical Center Amsterdam Grant: STW Lymphoma monitoring D.M. Pegtel, van Eijndhoven, J. Zijlstra, D. de Jong Department of Pathology and Hematology, VU University Medical Center Amsterdam Grant: VUmc CCA miRNA liquid biopsy D.M. Pegtel Department of Pathology Grant: KWF cancer award Phosphoproteomics o
Phosphoproteomics for personalized treatment of Colorectal Cancer with kinase inhibitors R. Beekhof, M. Labots, N. Van Grieken, CR Jimenez, HMW Verheul Department of Medical Oncology, VU University Medical Center Amsterdam Grant: Aegon International Scholarship in Oncology, VUmc‐Cancer Center Amsterdam Prediction lung cancer o
Non Small Cell Lung Cancer (NSCLC) ALK IHC positive, registry study A.C. Hiemstra, F.B.J.M. Thunnissen Department of Pathology, VU University Medical Center Amsterdam Grant: Pfizer Proteomics ‐ Brain tumours o
Phosphoproteomics of glioblastoma cells: ΔEGFR targets and erlotinib effects J.C. van der Mijn1*, R. Piersma2*, Thang V. Pham3, Tom Wurdinger3, H.M.W. Verheul1*, and Connie R. Jimenez2* 1Angiogenisis Laboratory, 2OncoProteomics Laboratory, Department of Medical Oncology, 3Department Neurosurgery, VU University Medical Center, Amsterdam, the Netherlands. *Equal contribution. Grant: VUmc Cancer Center Amsterdam and the Moller Foundation Proteomics ‐ Breast cancer o
o
o
Immunohistochemical validation in human breast cancer of selected protein members of the mouse 45 protein BRCA1 deficiency signature P. van der Groep1,2, M. Warmoes3, J. Lam3, Y. Smolders2, E. Boven3, S. Rottenburg4, J. Jonkers4, E. van der Wall1, P. van Diest2, C. Jimenez3 1Division of Internal Medicine and Dermatology and 2Department of Pathology, University Medical Center Utrecht, Utrecht, 3Oncoproteomics Laboratory, Department of Medical Oncology, VU University Medical Center, Amsterdam, 4Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands Proteomics of mouse BRCA1‐deficient and proficient mammary cell line secretomes reveals candidate biomarkers for non‐invasive testing M. Warmoes¹*, S.W. Lam1*, T.V. Pham1, S.R. Piersma1, S. Rottenberg2, E. Boven1, P. van der Groep3, P.J. van Diest3, P. Nederlof2, J. Jonkers2, C.R. Jimenez1 1 Oncoproteomics Laboratory, Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands; 2 Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 3Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. *Equal contribution. Grant: VUmc Cancer Center Amsterdam Role of flowcytometry in the diagnosis of cytopenia of unknowsn significance and myelodysplastic syndromes D.T. Kruger1, S. Linn2, S. Sleijfer3, C. Jimenez4, E. Boven1. In cooperation with Dutch Breast Cancer Trialists' Group, Amsterdam 1Dept of Medical Oncology, VU University Medical Center. 2NKI‐AvL, Amsterdam. 3Erasmus Medical Center, Rotterdam. 4Head of OncoProteomics Laboratory, VU University Medical Center Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 184 of 216 Proteomics ‐ Colorectal cancer o
o
o
o
o
o
Colorectal cancer tissue spheroids: an in‐depth proteomics analysis U. Rajcevic1, J.C. Knol2, S. Piersma2, S. Bougnaud1, T.V. Pham2, E. Sundlisaeter3, P. Enger3, R. Bjerkvig1,3, S.P. Niclou1 and C.R. Jimenez2 1NorLux Neuro‐Oncology, CRP‐Santé, Luxembourg, 2OncoProteomics Laboratory, Department Medical Oncology, VU University Medical Center, Amsterdam; 3Department of Biomedicine, University of Bergen, Bergen, Norway Grant: Fonds National de la Recherche (FNR) of Luxembourg and the VUmc Cancer Center Amsterdam Deciphering signaling pathways in a panel of colorectal cancer cell lines by label‐free titanium‐oxide‐based phosphoproteomics B.K. Sampadi1, S.R. Piersma1, M. Labots2, J.A.C.M. Goos3, B. Carvalho3, G.A. Meijer3, R.J.A. Fijneman3, H.M.W. Verheul2, C.R. Jimenez1 1Oncoproteomics Laboratory, Dept. Medical Oncology, 2Angiogenesis laboratory, Dept. Medical Oncology; 3Tumor Profiling Unit, Dept. Pathology, VU University Medical Center, Amsterdam, The Netherlands Grant: VUmc Cancer Center Amsterdam Proteome profiling of proximal fluids from human colon cancer tissue reveals novel candidate biomarkers for early diagnosis M. de Wit1,2, H. Kant2, S. Piersma2, T. Pham2, S. Mongera1, M.P.A. van Berkel2, E. Boven2, G.A. Meijer1, R.J.A. Fijneman1**, C.R. Jimenez2***Shared corresponding authors 1Department of Pathology (Tumor Profiling Unit), 2Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands.*Shared last author Grant: Aegon International Scholarship in Oncology, VUmc‐Cancer Center Amsterdam Proteomics of exosomes secreted by cancer cell lines and primary cells reveals oncogenic signaling and biomarker potential M. de Wit1, R.J.A. Fijneman2 , M. Lavaei1, H. de Wit3, J. van de Wetering3, J.C. Knol1, S.R. Piersma1, T.V. Pham1, R. Steenbergen2, G.A. Meijer2, H.M.W. Verheul1, M. Pegtel2, C.R. Jimenez1 1Dept. Pathology, 2Dept. Medical Oncology, 3NCA‐VU, VU University Medical Center Grant: VUmc‐Cancer Center Amsterdam Stool proteomics reveals novel candidate biomarkers for colorectal cancer screening L.J.W. Bosch1*, M. de Wit2*, G. Oudgenoeg2, A.C. Hiemstra1, S. Mongera1, S.R. Piersma2, T.V. Pham2, J.S. Terhaar sive Droste3, F.A. Oort3, S.T. van Turenhout3, I. Ben Larbi3, C.J.J. Mulder3, B. Carvalho1, C.R. Jimenez2, R.J.A. Fijneman1, G.A. Meijer1 *These authors have contributed equally to this work. 1Department of Pathology, 2Medical Oncology and 3Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands Grant: VUmc Cancer Center Amsterdam and CTMM‐DeCoDe Tumor‐specific protein biomarkers for early detection of colorectal cancer M.A. Komór, R.J.A. Fijneman, C.R. Jimenez, G.A. Meijer Department of Pathology and department of Medical Oncology, VU University Medical Center Amsterdam Grant: KWF Proteomics ‐ Generic o
o
Label‐free phosphoproteomics: evaluation of workflow performance at normal and low protein input levels M. Labots1, K. van der Mijn1, S. Piersma2, R. de Haas1, I. de Reus2, J. Knol2, T. Pham2, N. van Grieken3, G. Meijer3, H.M.W. Verheul1, C. Jiménez2 1Department of Medical Oncology, VU University Medical Center, 2OncoProteomics Laboratory, Department of Medical Oncology, VU University Medical Center, 3Department of Pathology, VU University Medical Center Grant: VUmc Cancer Center Amsterdam Pilot study on the determination of intratumoral concentrations of kinase inhibitors in patients with advanced solid malignancies (ICK) M. Labots, M. Neerincx, J. van der Mijn, G. Peters, H.M.W. Verheul et al Department of Medical Oncology, VU University Medical Center Amsterdam Grant: Proteomics ‐ Hematology o
o
Phosphoproteomics for personalized treatment of acute myeloid leukemia with kinase inhibitors J.J.W.M. Janssen*, C. van Alphen, J. Cloos, G.J. Schuurhuis, G.J. Ossenkoppele, H.M.W. Verheul, C.R. Jimenez* 1.Dept. Hematology; 2. Dept. Medical Oncology of the VU University Medical Center. *shared senior authors Grant: VUmc Cancer Center Amsterdam Protein Composition of exosomes yields new insights into the endosomal‐exosomal pathway of B cells during infection and malignant transformation D. Koppers‐Lalic1, J. Knol2, T.V. Pham2, F. Verweij1, S. Piersma2, J. Middeldorp1, C.R. Jimenez2*, M. Pegtel1* *Shared corresponding authors 1Dept. of Pathology, VUmc, 2OncoProteomics Laboratory, Dept. Medical Oncology, VU University Medical Center Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 185 of 216 o
Grant: VUmc Cancer Center Amsterdam Transfer of regulatory protein networks via extracellular vesicles as a possible mechanism of AML resistance to apoptosis A. Wojtuszkiewicz1,2, F. Kessler2, S. Zweegman2, G.J. Schuurhuis2, G. Jansen3, S. Piersma4, J. Knol4, Y.G. Assaraf5, G.J.L. Kaspers1, J. Cloos1,2, C.R. Jimenez4 1Dept of Pediatric Oncology/Hematology, 2Dept. of Hematology, 3Dept. of Rheumatology, 4Dept. of Medical Oncology VU University Medical Center, The Netherlands, 5Dept. of Biology, Technion‐Israel Institute of Technology, Haifa, Israel Grant: VUmc Cancer Center Amsterdam Proteomics ‐ Lung cancer o
Novel candidate biomarkers for cisplatin response prediction and monitoring in NSCLC T.B.M. Schaaij‐Visser1, N. Proost2, R. Nagel3, S.R. Piersma1, T.V. Pham1, R.H. Brakenhoff3, F.B.J.M. Thunissen4, E.F. Smit5, A. Berns2, C.R. Jimenez1 1OncoProteomics Laboratory, Department of Medical Oncology, 2Division of Molecular Genetics and Centre for Biomedical Genetics, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 3Department of Otolaryngology/Head and Neck Surgery, 4Department Pathology, 5Department Pulmonology, VU University Medical Center, Amsterdam, The Netherlands Grant: CTMM Airforce Proteomics ‐ Prostate cancer o
From prostate cancer cell exosome proteomics to urine‐based biomarkers I.V. Bijnsdorp1*, A.A. Geldof1, M. Lavaei2, S.R. Piersma2, R.J.A. van Moorselaar1, C.R. Jimenez2 1. Department of Urology;2. OncoProteomics Laboratory, Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands Grant: VUmc Cancer Center Amsterdam Rheumatology o
o
o
o
o
Acceleration, synchronisation and validation of experimental spondyloarthritis in HLA‐B27+huB2m++ transgenic rats L. van Duivenvoorde1, I. de Greeuw2, M. Verlaan2, R. Bergstra2, J. van der Laken3, C.F.M. Molthoff2, D.L.P. Baeten 1Dept. of Reumatology, AMC medical center, 2Dept. of Radiology&Nuclear Medicine and 3Reumaotology, VUmc Amsterdam Grant: AMC B cells in the preclinical phase of rheumatoid arthritis J. Lubbers, H. Bontkes, C.L. Verweij Department of Pathology, VU University Medical Center Amsterdam Grant: Reumafonds Molecular Diagnostics in Rheumatoid Arthritis C. Verweij, S. Vosslamber, H. Bijlsma Dept. of Pathology, Dept. of Rheumatology, Flexgen Grant: ZonMW Towards a molecular understanding of the preclinical phase and therapy responsiveness in rheumatoid arthritis C. Verweij, S. Vosslamber, T. de Jong Dept. of Pathology, Dept. of Rheumatology, Flexgen Grant: Reumafonds TRACER Protein arrays and metabolite biomarkers to predict development of RA and response to therapy (WP8) J. Wesseling, A.E. Voskuyl, P. van der Putte, C. Verweij Dept. of Pathology, Dept. of Rheumatology, Flexgen Grant: CTMM Other o
o
o
CTMM algemeen M. van Engeland1, C.J.H. van de Velde2, G.A. Meijer2 Department of Pathology, MUMC1, VU University Medical Center Amsterdam2 Grant: CTMM Diagnostic monitoring of NPC and building a second center of expertise in Indonesia Gondowiyardjo S1, L. Adham1, A.N. Kurniawan1, J.M. Middeldorp2 1Univ Indonesia, Jakarta, 2Department of Pathology, VU University Medical Center, Amsterdam Grant: KWF Dutch National Tissue Portal C. Steegers, F. van Kemenade, G.A. Meijer Department Of 1Pathology, VU University Medical Center, Amsterdam, 2MUMC, 3LUMC, 4ServiceXS, MDXHEalth, Univ. Gent Grant: BBMRI‐NL Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 186 of 216 o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
ICT and data analysis J. Beliën, G.A. Meijer Department Of Pathology, VU University Medical Center, Amsterdam Grant: CTMM Identifying the epileptogenic zone in the absence of epileptiform discharges: bias‐free network analysis applied to interictal MEG recordings I. Nissen1,2, E. van Dellen1, L. Douw1, J.J. Heimans1, J.C. Baayen4, P.C. de Witta Hamer3, G. Visser5, C.J. Stam2, J.C. Reijneveld1,4 A. Hillebrand2 Departments of 1Neurology, 2Clinical Neurophysiology, 3Neurosurgery, VU University Medical Center, 4Department of Neurology, Academic Medical Center, Amsterdam, 5Department of Clinical Neurophysiology, Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede Grant: Epilepsie Fonds Medical technology assessment C. Uyl, V. Coupé, G.A. Meijer Department Of Pathology, VU University Medical Center, Amsterdam Grant: CTMM Multiplex NPC families in Taiwan A. Hildesheim2, J.M. Middeldorp1 1Department Of Pathology, VU University Medical Center Amsterdam, 2 NCI‐NIH, USA Grant: RTI, USA Regulation of interferon acitivity by rituximab in rheumatoid arthritis C. Verweij Department of Pathology, VU University Medical Center Amsterdam Grant: Rheumafonds TRACER ICT S. de Ridder, J. Beliën, C. Verweij Department of Pathology and Reumatology, VU University Medical Center Amsterdam [18F]Choline Reproducibility in prostate cancer D.E. Oprea‐Lager, R. Boellaard, O.S. Hoekstra, R.J.A. van Moorselaar, A.J.M. van den Eertwegh Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam Bone disease in MM J.C. Regelink, J.M. Zijlstra, P.H.M.G. Raijmakers, S. Zweegman Department of Hematology, VU University Medical Center, Amsterdam CCA Drylab C. Rausch Department of Pathology, VU University Medical Center Amsterdam Grant: CCA foundation Detectie van colorectale tumoren met behulp van een fluorescent en radioactief gelabeld gehumaniseerd anti‐CEA antilichaam labetuzumab M. Ankersmit, I. de Greeuw, M. Verlaan, R. Vos, W.A. Adamzek, C.F.M. Molthoff, G.A.M.S. van Dongen, W.J.H.J. Meijerink Department of Surgery and Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam Diagnosis of vital tumor tissue by OCT and MRI in retinoblastoma patients O. Nadyarnykh, J. de Boer, P. de Graaf, M.I. Bosscha, Moll AC Department op Ophthalmology, VU University Medical Center and Laser Lab, VU Grant: KIKA Disease profiling of reumatic diseases: Ankylosing spondylitis and rheumatic arthritis genetics J.B.A. Crusius, I. van der Horst‐ Bruinsma, S.A., Morré 1Laboratory Immunogenetics, Department of Medical Mirobiology and Infection Control,, 2GGD Amsterdam, 3UMCG, Groningen Myelofibrosis; from demographics to pathophysiological characterisation S. Slot, J.M. Zijlstra, P.H.M.G. Raijmakers, N.W. van de Donk, S. Zweegman Department of Hematology, VU University Medical Center, Amsterdam Positron Emission Tomography (PET) for detection of histologic transformation of indolent non‐Hodgkin's lymphoma M.J. Wondergem, S. Zweegman, J.M. Zijlstra, O.S. Hoekstra, M.E.D. Chamuleau, S.A.G.M. Cillessen Department of Hematology, Nuclear Medicine and Pathology, VU University Medical Center, Amsterdam To treat or not to treat, prostate cancer prostasome diagnostics I.V. Bijnsdorp1, D. Koppers‐Lalic2, D.M. Pegtel2, M. Hackenberg3, A. Vis1, R.J.A. van Moorselaar1 1. Department of Urology;2. OncoProteomics Laboratory, Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands Towards Personalized medicine: defining the role of the bone marrow microenvironment in multiple myeloma Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 187 of 216 o
o
R. Groen Department of Hematology, VU University Medical Center, Amsterdam Grant: Marie Curie fellowship Validation of interim PDG PET in lymphoma‐ a study on optimal fining, response criteria, therapy interference and cost‐effectiveness C.M. Burggraaff, J.M. Zijlstra, H.C.W. de Vet, O.S. Hoekstra, S. Zweegman Department of Hematology and Nuclear Medicine, VU University Center, Amsterdam Grant: KWF Women’s Reproductive Health: prediction of tubal pathology on the basis of host genetic markers S. Ouburg1, H.J.C de Vries2, S. Verweij1, M. Singer1, J. Land3, S.A. Morre1 1Laboratory Immunogenetics, Department of Medical Mirobiology and Infection Control,, 2GGD Amsterdam, 3UMCG, Groningen Grant: Eurostars Program 4 – Innovative therapy Bladder cancer o
Improving therapy of blader cancer: the development of novel bcg M.J. Burggraaf, C. Kuijl, C.F.M. Molthoff, W. Bitter Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam Grant: Diamond program. VUmc CCA Brain cancer o
o
o
o
o
o
Drug distribution and local drug delivery in diffuse intrinsic pontine glioma S.E.M. Veldhuijzen van Zanten, D.G. van Vuurden, M.H.A. Jansen, W.P. Vandertop, G.J.L. Kaspers 1Pediatric Oncology/ Hematology, VU University Medical Center, Amsterdam, The Netherlands; 2 Neurosurgical Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands Grant: Stichting Semmy Monitoring of treatment response to EGFRvIII‐targeted treatment in patients with glioblastoma through blood profiling N. Sol1,2, T. Würdinger2, H.M.W. Verheul3, J.J. Heimans1, B. Ylstra4, P. Wesseling4, J.C. Reijneveld1,3 Departments of 1Neurology, 2Neurosurgery, 3Medical Oncology and 4Pathology, VU University Medical Center, Amsterdam, Department of 5 Neurology, Academic Medical Center, Amsterdam Grant: KWF Kankerbestrijding Prediction of response to radiotherapy with concomitant and adjuvant Temozolomide in glioblastoma patients with serum proteomics M.E. Van Linde1, J.C. van der Mijn1, T.V. Pham1, J.C. Knol1, L.E. Wedekind3, J. Buter1, T. Wurdinger3, C.R. Jimenez1, J.C. Reijneveld2, H.M.W. Verheul1 Departments. of 1Medical Oncology, 2Neurology and 3Neurosurgery of the VU University Medical Center Amsterdam Targeted therapy in pediatric brain tumors D.G. van Vuurden1,4, E. Hulleman2,4, P. van der Stoop2,4, T. Wurdinger2,4, M. Irandoust1,3, G.J.L. Kaspers1, J. Cloos1,3 Departments of 1Pediatric Oncology/ Hematology, 2Neurosurgery, 3Hematology and 4Neuro‐Oncology Research Group, VU University Medical Center, Amsterdam Grant: VONK Treatment strategies and new diagnostic tools for malignant pontine gliomas M.H.A. Jansen1, D.G. van Vuurden1, W.P. Vandertop2, G.A.M.S. van Dongen3,4, O.S. Hoekstra4, G.J.L. Kaspers1 1Department Pediatrics, Pediatric Oncology/‐Hematology, 2Department Neurosurgery, 3Department Otolaryngology/Head and Neck Surgery and 4Radiology & Nuclear Medicine, 4Department Nuclear Medicine, VU University Medical Center, Amsterdam Grant: Semmy Foundation Unravelling diffuse pontine glioma E. Hulleman1,2, P.J. van der Spek3, G.J.L. Kaspers1 Department of 1Pediatric oncology / 2Neuro‐oncology Research Group Cancer Center Amsterdam, VU University Medical Center Amsterdam, 3 Bioinformatics Center ErasmusMC, Rotterdam Grant: Complete Genomics Cancer vaccine o
Harnessing glioma exosomes Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 188 of 216 J. Garcia‐Vallejo, T. Wurdinger, D.M. Pegtel Department of Molecular Cell Biology, Neurosurgery and Pathology, VU University Medical Center Amsterdam Grant: Colorectal cancer o
Innovations in local treatment and imaging of colorectal liver metastases K. Nielsen1, H.J. Scheffer2, M.P. van den Tol1, E.F.I. Comans2, M.R. Meijerink2, S. Meijer1 Departments of 1Surgery, 2Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam Grant: Donation Head and neck cancer o
o
o
o
Epstein barr virus activation and cytolytic antivirual therapy in nasopharyngeal patients O. Ramayanti1, A.E. Greijer1, I.B. Tan2, J. Kurnianda3, J.M. Middeldorp1 1Department of Pathology, VU University Medical Center, 2Department Of Head and Neck Surgery & Medical Oncology, NKI, Amsterdam, 3Department Medicine, Gadjah Mada University Grant: KWF Improvement of treatment of head and neck cancer. General aspects R. de Bree1, D.A. Heuveling1, S. Hakim1, C.S. Schouten1, S. van Weert1, P. Doornaert2, K.H. Karagozoglul3, J. Buter4 , O.S. Hoekstra5, J.A. Castelijns5, C.R. Leemans1 Depts. of 1Otolaryngology‐Head and Neck Surgery, 2Radiation Oncology, 3Oral and Maxillofacial Surgery, 4 Medical Oncology, 5 Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam Grant: ZonMw New therapy for Epstein‐Barr virus driven tumours by targeting the virus itself Z. Novalic1, A.E. Greijer1, I.B. Tan2, J.P. de Boer2, J.M. Middeldorp1 1Department of Pathology, VU University Medical Center, 2Department Of Head and Neck Surgery & Medical Oncology, NKI, Amsterdam Grant: ZonMw Salvage treatment after (chemo)radiation L. van der Putten, C.R. Leemans, R. de Bree Department of Otolaryngology/Head and Neck Surgery VU University Medical Center, Amsterdam Grant: Hematology o
o
o
o
o
o
Application of bortezomib in pediatric acute lymphoblastic leukemia D. Niewerth1,2, J. van Meerloo1, S. Zweegman2, G.J.L. Kaspers1, G. Jansen3, J. Cloos1,2 Departments. of 1Pediatric Oncology/Hematology, 2Hematology and 3Rheumatology, VU University Medical Center, Amsterdam Grant: Stichting KIKA Clonal evolution of acute myeloid leukemia stem cells R. Wouters1,2, C. Bachas1,2, Z.J. Kwidama1,2, E. Sonneveld3, L. Smit2, G.J. Ossenkoppele2, G.J.L. Kaspers1 G.J. Schuurhuis2, J. Cloos1,2. Departments. of 1Pediatric Oncology/ Hematology and 2Hematology, VU University Medical Center, Amsterdam, 3Dutch Childhood Oncology Group, The Hague Grant: VONK Combination treatment of Daratumumab with Ibrutinib, YM155 and ATRA for treatment of multiple myeloma A.C. Martens, T. Mutis, R.W.J. Groen, H. Lokhorst, N. van de Donk Department Of Hematology, VU University Medical Center, Amsterdam Grant: Janssen R&D, USA Cytogenetics and treatment response in pediatric acute myeloid leukemia K. Klein, V. de Haas, G.J.J. Kaspers Department of Pediatric Oncology/ Hematology, VU University Medical Center, Amsterdam Grant: VONK Daratumumab (DARA) for the treatment of multiple myeloma (MM); Preclinical in vivo and in vitro studies A.C. Martens, R.W.J. Groen, H. Lokhorst, N. van de Donk Department Of Hematology, VU University Medical Center, Amsterdam Grant: Janssen R&D, USA Drug resistance in childhood leukemia N.E. Franke1, J. van Meerloo1,2, D Niewerth1,2, S.E. Verbrugge3, R.X. de Menezes4, W.J. Chng6, B.A.C. Dijkmans3, Y.G. Assaraf7, G.J.L. Kaspers1, G. Jansen3, J. Cloos1,2 Depts. of 1Pediatric Oncology/Hematology, 2Hematology, 3Rheumatology and 4Epidemiology and Biostatistics , VU University Medical Center, Amsterdam, 4Dept. of Medicine, National University of Singapore, 7Dept of Biology, Technion‐Israel Institute of Technology, Haifa, Israel Grant: Stichting Translation Research and ZonMw Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 189 of 216 o
o
o
o
o
o
o
o
o
o
o
o
Identification of targeted therapies for aOnaplastic large cell lymphoma based on apoptosis expression profiles C.J.L.M. Meijer, G.J. Ossenkoppele, S. Cillessen Department of Pathology en Hematology, VU University Medical Center, Amsterdam Grant: KWF Identification of under‐treated and over‐treated acute myeloid leukemia patients, using minimal residual disease and leukemia stem cell frequency D.W. Hanekamp, G.J. Schuurhuis, J. Cloos, G.J. Ossenkoppele Department of Hematology, VU University Medical Center, Amsterdam Mechanismen en therapeutisch modulatie van microomgeving gerelateerde immuun escape in multiple myeloom L.C. Holthof, N. v.d. Donk, R. Groen, T. Mutis, S. Zweegman Department Of Hematology, VU University Medical Center, Amsterdam PET‐CT of biodistribution of rituximab in relation to therapeutic outcome and histological response of lymphoid tissue in rheumatoid arthritis patients S.T. Bruijnen1, A.E. Voskuyl1, G. Jansen1, G.A.M.S. van Dongen2, M.C. Huisman2, O.S. Hoekstra2, A.A. Lammertsma2, P.P. Tak3, Boumans J.H.M., C.J. van der Laken1. Departments of 1Rheumatology, 2Radiology & Nuclear Medicine, VU University Medical Center, Department of Rheumatology & Immunology3, Academic Medical Center, Amsterdam Prediction of achievement of deep molecular responses to combination treatment with nilotinib and pegylated interferon‐alpha in chronic myeloid leukemia J.J.W.M. Janssen, M. Koppes, G.J. Schuurhuis, G.J. Ossenkoppele Department of Hematology, VU University Medical Center Grant: Novartis Netherlands Predictive value of stem cell enumeration for the response to nilotinib in newly diagnosed CML patients N. Thielen, A. Zevenbergen, B. van Kuijk, W. Pouwels, G.J. Schuurhuis, G.J. Ossenkoppele, J.J.W.M. Janssen Department of Hematology, VU University Medical Center Grant: Novartis The identification of microRNAs specific for leukemic stem cells in acute myeloid leukemia D. de Leeuw1, H. Verhagen1, F. Denkers1, A. Rutten1, W. Pouwels1, R.Kerkhoven2, I de Rink2, M. de Palma3, P. Valk4, R. Menezes5, C. Jimenez6, G.J. Schuurhuis1, G. Ossenkoppele1, L. Smit1 1Department of Hematology, 5Department of Biostatistics, 6Proteomic Facility, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands. 2Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands, 3Institut Suisse de Recherche Experimentale sur le Cancer ( ISREC), Lausanne, Swiss. 4Department of Hematology, Erasmus University, Rotterdam, The Netherlands. Grant: Interna (2008‐2009), AICR (2008‐2011) and KWF (2015‐2019 The potential of Wnt pathway inhibition to eradicate acute myeloid leukemia (stem) cells R. Hendrix1, K. Hoffmaster2, A. Myers2, M. Al1, H. Verhagen1, A. Rutten1, G.J. Schuurhuis1, J. Cloos1, G. G. Vanasse2, Ossenkoppele1 and L. Smit1 1 Department of Hematology University Medical Center, Amsterdam, The Netherlands and 2 Novartis Institutes for Biomedical Research, Cambridge MA, USA Grant: Novartis The role of impaired FPGS splicing in methotrexate response in childhood acute lymphoblastic leukemia A.M. Wojtuszkiewicz1,2, G.J. Peters3, G. Jansen4, Y.G. Assaraf5, G.J.L. Kaspers1, J. Cloos1,2 2Depts. of 1Pediatric Oncology/Hematology, 2Hematology, 3Medical Oncology and 4Rheumatology, VU University Medical Center, Amsterdam, 5Department of Biology, Technion‐Israel Institute of Technology, Haifa, Israel Grant: Stichting KIKA (kinderen kankervrij) The role of minimal residual disease, and leukemic stem cells herein, in clinical decision making W. Zeijlemaker, G.J. Ossenkoppele, GJ. Schuurhuis Department Of Hematology, VU University Medical Center, Amsterdam Grant: Hematology Foundation The therapeutic potential of IGF1R inhibition and IGFBP7 in the specific eradication of leukemic stem cells in acute myeloid leukemia H. Verhagen1, D. de Leeuw1, F. Denkers1, P. Celie2, R. Kerkhoven3, I. de Rink3, M. Terwijn1, A. Rutten1, W. Pouwels1, B. Ylstra4, R. Menezes5, G. Ossenkoppele1, G.J. Schuurhuis1 and L. Smit1 1Department of Hematology, 4Department of Pathology, 5Department of Biostatistics, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.2Protein facility, 3Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands Grant: VUmc Cancer Center Amsterdam (2011‐2015) + KWF (2015‐2019) Therapeutic target identification specific for leukemic stem cells of chronic myeloid leukemia M. Smit1, M. Koppes1, H. Verhagen1, F. Denkers1, R. Kerkhoven2, I. de Rink2, A. Rutten1, W. Pouwels1, G.J. Schuurhuis1, L. Smit1 and JJ Janssen1 Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 190 of 216 o
o
1Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands. 2Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Grant: Novartis Therapeutic target indentification specific for leukemic stem cells of acute myeloid leukemia H. Verhagen1, D. de Leeuw1, F. Denkers1, P. Celie2, R. Kerkhoven3, I. de Rink3, M. Terwijn1, A. Rutten1, W. Pouwels1, B. Ylstra4, R. Menezes5, G. Ossenkoppele1, G.J. Schuurhuis1 and L. Smit1 1Department of Hematology, 4Department of Pathology, 5Department of Biostatistics, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.2Protein facility, 3Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands Grant: VUmc Cancer Center Amsterdam Therapeutic targeting of EVI‐1 positive acute myeloid leukemia stem cells B. Venniker‐Punt, H. Verhagen, M. Smit, A. Rutten, P. Merle, G. Ossenkoppele, G.J. Schuurhuis, J. Janssen and L. Smit Department of Hematology University Medical Center, Amsterdam, The Netherlands Grant: St. Vu Steunfonds Hematologie Immunotherapy o
o
o
Development of DCOne and novel AML‐derived cell lines for DC‐based allogeneic tumor vaccination J.M. Ruben1, N. Kerkhoff1, W. Van den Ancker1, S.J.A.M. Santegoets2, M. Koppes1, P.J.G.T.B. Wijnands3, A. Reurs3, M. Meerendonk3, J. Kaspers3, S. van Wetering3, A.J.M. van den Eertwegh2, Rik J. Scheper2,4, G.J. Ossenkoppele1, A.M. Kruisbeek3, A.A. van de Loosdrecht1, T.D. de Gruijl2 Departments of 1Hematology, 2Medical Oncology, 3DC Prime BV, and the Department of 4Pathology, VU University Medical Center, Amsterdam, The Netherlands Grant: ZonMW Translationeel Research Grant, DCPrime BV Immune correlates of clinical response and survival in castration resistant prostate cancer patients treated with Prostate GVAX and anti‐CTLA4 immunotherapy S.J.A.M. Santegoets2, A.J.M. van den Eertwegh1, A.G.M. Stam2, S.M. Lougheed1, H. Gall1, P.E.T. Scholten2, B.M.E. von Blomberg2, E. Hooijberg2, K. Jooss4, N. Sacks4, K. Hege4, I. Lowy5, R.J. Scheper2, W.R. Gerritsen1, T.D. de Gruijl1 Departments of 1Medical Oncology and 2Pathology of the VU University medical center, Amsterdam, The Netherlands; 3Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA; 4Cell Genesys Inc.,South San Francisco, CA; 5Medarex, Bloomsbury, NJ Grant: Prostate Cancer Foundation Research Award, Dutch Cancer Society Translating immune characteristics of metastatic tumour cells into therapeutic targets for cervical cancer A.M. Keessen‐Heeren, E. Jordonova, T.D. de Gruijl, G. Kenter Department of Obstetrics and Gynaecology and Medical Oncology, VU University Medical Center Amsterdam Interventional Oncology ‐ Tumor ablation o
o
o
Clinical validation of Irreversible Electroporation L. Vroomen1, A.A.J.M. van Tilborg1, H.J. Scheffer1, K. Nielsen2, M.P. van den Tol2, M.R. Meijerink1 1Department of Radiology & Nuclear Medicine, 2 Department of Surgery, VU University Medical Center, Amsterdam, The Netherlands Current status, recent advances and future prospectives of image‐guided liver tumor ablation, expanding the horizon A.A.J.M. van Tilborg1, H.J. Scheffer1, K. Nielsen2, M.P. van den Tol2, M.R. Meijerink1 1Department of Radiology & Nuclear Medicine, 2 Department of Surgery, VU University Medical Center, Amsterdam, The Netherlands Grant: SBBvK Irreversible electroporation: a novel image‐guided tumor ablation technique H.J. Scheffer1, A.A.J.M. van Tilborg1, K. Nielsen2, M.P. van den Tol2, M.R. Meijerink1 1Department of Radiology & Nuclear Medicine, 2 Department of Surgery, VU University Medical Center, Amsterdam, The Netherlands Grant: NFtK Oncolytic adenovirus o
o
Enhancement of the oncolytic potency of conditionally replicative adenoviruses W. Dong1, K.Y. Au1, A. Gros2, J.W.G. van Ginkel1, M. Cascallo2, W.R. Gerritsen3, R. Alemany2, J.J.M. Meulenberg1, V.W. van Beusechem1,3 1ORCA Therapeutics, Amsterdam, The Netherlands; 2Translational Research Laboratory, IDIBELL‐Institut Català d’Oncologia, Barcelona, Spain; and 3Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands Exploiting miRNA to enhance oncolytic adenovirus potency V.W. van Beusechem1,2, J. Hodzic1, T. Gupta1, H. Kristyanto1, A. Vermeulen3, J. Karpilow3, J.J.M. Meulenberg2 1Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands; 2ORCA Therapeutics, Amsterdam, The Netherlands; 3Thermo Fisher Scientific, Dharmacon RNAi Technologies, Lafayette, CO, USA Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 191 of 216 o
Virotherapy of glioblastoma multiforme using an infectivity‐enhanced selectively replication‐competent adenovirus V.W. van Beusechem1, M.L.M. Lamfers2, J.M. Amado de Azevedo1, I.H. van der Meulen‐Muileman1, S. Idema3, W.R. Gerritsen1, W.P. Vandertop3, D.P. Noske3, C.M.F. Dirven2 Departments. of 1Medical Oncology and 3Neurosurgery, VU University Medical Center, Amsterdam; 2Department Neurosurgery, Erasmus MC, Rotterdam Grant: ZonMw Translationeel Gentherapeutisch Onderzoek Pancreatic cancer o
Phosphoproteomics and the prediction of outcome and treatment of pancreatic cancer T.Y.S. Le Large, E. Giovannetti, M. Bijlsma, C. Jimenez, H.M.W. Verheul Department of Medical Oncology, VU University Medical Center Amsterdam Grant: VUmc‐AMC alliantie AIO Pediatric cancer o
o
o
o
o
o
A formula based on cystatin C for individual carboplatin dosing in children H.N. Blufpand1, G.J.L. Kaspers1, F.C.H. Abbink1, A.J. Wilhelm2, R.J. Honeywell3, G.J. Peters3, B. Stoffel‐Wagner5, A. Bökenkamp4 Department of 1Pediatric Oncology/Hematology, 2Clinical Pharmacology and Pharmacy, 3Medical Oncology, 4Pediatric Nephrology all VU University Medical Center, Amsterdam, The Netherlands. 5Clinical Chemistry and Clinical Pharmacology, University of Bonn ‐ Medical Center, Bonn, Germany Grant: VUmc Research on Childhood Cancer ‐ VONK and Fonds NutsOhra A medication diary‐book for childhood cancer patients in Kenya G. Olbara1, F. Njuguna1, P.M. van de Ven2, J. Skiles3 , G.J.L. Kaspers4 , S. Mostert4 1 Department of Pediatrics, Moi Teaching and Referral Hospital, Eldoret, Kenya, 2 Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands, 3 Department of Hematology‐Oncology and Academic Model Providing Access to Healthcare (AMPATH) program, Indiana University School of Medicine, Indianapolis, United States of America, 4 Department of Pediatric Oncology‐Hematology and Doctor 2 Doctor program, VU University Medical Center, Amsterdam, the Netherlands Carboplatin dosing in children using estimated glomerular filtration rate: equation matters H.N. Blufpand1, G.J.L. Kaspers1, F.C.H. Abbink1, A.J. Wilhelm2, R.J. Honeywell3, G.J. Peters3, B. Stoffel‐Wagner5, L.M. Buffart6, A. Bökenkamp4 Department of 1Pediatric Oncology/Hematology, 2Clinical Pharmacology and Pharmacy, 3Medical Oncology, 4Pediatric Nephrology and 5EMGO Institute for Health and Care Research and the department of Epidemiology and Biostatistics, VU University Medical Center Grant: VUmc Research on Childhood Cancer ‐ VONK and Fonds NutsOhra Compliance with childhood cancer treatment in Kenya F. Njuguna1, P.M. van de Ven2, J. Skiles3 ,G.J.L. Kaspers4, S. Mostert4 1 Department of Pediatrics, Moi Teaching and Referral Hospital, Eldoret, Kenya, 2 Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands, 3 Department of Hematology‐Oncology and Academic Model Providing Access to Healthcare (AMPATH) program, Indiana University School of Medicine, Indianapolis, United States of America 4 Department of Pediatric Oncology‐Hematology and Doctor 2 Doctor program, VU University Medical Center, Amsterdam, the Netherlands Grant: SIOP International Fellowship Elucidation and interference of resistance to temozolomide in pediatric and adult gliomas L. Hiddingh1,2,3, D.P. Noske1,3, W.P. Vandertop1, P. Wesseling4,5 G.J.L. Kaspers2, T. Wurdinger1,3,6 Departments of 1Neurosurgery and 2Pediatric oncology / 3Neuro‐oncology Research Group, Cancer Center Amsterdam, Department of 4Pathology, VU University Medical Center Amsterdam, Department of 5Pathology, Radboud University Nijmegen Medical Center, Molecular Neurogenetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA6 Grant: KiKa, Stichting Stophersentumoren.nl The role of epigenetics in the treatment of pediatric brain tumors S.E. Mir1, E. Hulleman1,2, D. Biesman1, M. Smits2, S. Pons4, T. Wurdinger2, D. Noske2, G.J.L. Kaspers1, J. Cloos1,3 Departments of 1Pediatric Oncology/ Hematology, 2Neurosurgery, and 3Hematology, VU University Medical Center, Amsterdam, 4Department of Cell Death and Proliferation, Institute for Biomedical Research of Barcelona Grant: Mozaiek, KWF fellowship Personalized medicine o
A randomized multicenter clinical trial for patients with multi‐ORgan, Colorectal cancer metastases comparing the combination of cHEmotherapy and maximal tumor debulking versuS chemoTheRapy Alone: ORCHESTRA. E. Gootjes, D. Poel, J. Voortman, M. Neerincx, T. Buffart, E.van Meerten, P. van den Tol, J.W.A Burger, M.R. Meijerink, N. Haasbeek, J.J. Nuyttens, P. van de Ven, C.R. Jimenez, A.J. Ten Tije, L. te Velde, S. Dwarkasing, O.S. Hoekstra, G.A. Meijer, K. Biermann, D. W. Albeda, C. Verhoef, H.M.W. Verheul Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 192 of 216 o
o
o
o
o
o
Department of Medical Oncology, Pathology and Radiology & Nuclear Medicine, VU University Medical Center Amsterdam Clinical evaluation of the underlying mechanisms of targeted therapy related toxicities Rovithi1, H. Berkhof2, T.D. de Gruijl1, C.R. Jimenez1, M.Labots1, G.A. Meijer3, G.J. Peters1, S.Santegoets1, A.A. van Bodegraven4, N.C.T van Grieken3, C. van Montfrans5, A.J.M van den Eertwegh1, H.M.W. Verheul1 Departments of 1Medical Oncology, 2Biostatistics, 3 Pathology, 4 Gastroenterology and 5 Dermatology of the VU University Medical Center Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients (PRESPECT) J. van der Mijn, M. Labots, G.J. Peters, A.J.M. van den Eertwegh, T.D. de Gruijl, C.R. Jimenez, T. Pham, S. Piersma, G.A. Meijer, D.L. van der Peet, M.R. Meijerink, J.Berkhof, H.M.W. Verheul Department of Medical Oncology, Surgery, Epidemiology and Biostatistics and Pathology, VU University Medical Center Amsterdam Targeting epigenetic and RNA deregulation: the 11th hallmark of cancer M. Blijlevens, E.F. Smit, V.W. van Beusechem Department of Medical Oncology and Pulmonology, VU University Medical Center, Amsterdam Grant: Stichting CCA / Walter Bruckerhoff Stiftung Towards novel anti‐cancer drugs directed against G‐protein coupled receptors to improve treatment of prostate, lung and brain tumors J. van Offenbeek1, J. Hodzic1, R. Leurs2 , M. Smit2, H. Vischer2, T. Wurdinger3, I de Esch2, V.W. van Beusechem1 Department of 1Medical Oncology, 3 Neurosurgery, VU University Medical Center, Amsterdam and 2Division of Medicinal Chemistry, faculty of Science VU University Amsterdam Grant: Stichting CCA Towards patient tailored cancer treatment supported by molecular imaging IMPACT: Imaging Patients for Cancer drug selecTion ‐ Metastatic Breast Cancer (IMPACT breast) E. van Helden, C. Menke, F. Bensch, G.A.P. Hospers, J.A. Gietema, E. Boven, O. Hoekstra, M. Huisman, D. Vugts, G. van Dongen, H. Hendrikse, C. van Herpen, I. Desar, C.P. Schroder, W.T.A van der Graaf, H.M.W. Verheul, E.G.E de Vries Department of Medical Oncology and Radiology and Nuclear Medicine, VU University Medical Center Amsterdam Watchful waiting in patients with good and intermediate risk metastatic renal cell carcinoma; an imaging guided observational approach E. van Helden, C.Menke, H.M.W. Verheul, E.G.E. de Vries, I.M.E. Desar, W.T.A van der Graaf Department of Medical Oncology, VU University Medical Center, Amsterdam Radiotherapy o
o
o
o
Development of automated treatment planning strategies, including applications to individualized and adaptive radiotherapy J. Tol, M. Dahele, B.J. Slotman, W.F.A.R. Verbakel Department of Radiation Oncology, VU University Medical Center, Amsterdam Grant: Varian Medical Systems, Palo Alto, USA Diagnosis, cost‐effectiveness of local therapies for early‐stage non‐small celllungcancer H Tekatli, A.V. Louie, Verbakel FJ.Lagerwaard, D.A. Palma2, G. Rodrigues2, M.G. Hunink3, M Dahele, B.J. Slotman, JJM Takkenberg 3, S Mokhles 3, APWM Maat 3 K Stephans 4, G Videtic 4, S. Senan Departments of Radiation Oncology, VU University Medical Center, Amsterdam, 2Department of Radiation Oncology, London Regional Cancer Program, London, Ontario, Canada, 3 Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, Netherlands Grant: Varian Medical Systems, Palo Alto, USA, CARO‐Elekta Research Fellowship (2013), Detweiler Travelling Fellowship of the Royal College of Physicians and Surgeons of Canada (2014) Innovative techniques for intracranial stereotactic radiotherapy Lagerwaard FJ, Meijer OWM, Haasbeek CJA, Vandertop WP, Baaijen JC, van den Berg R, Postma TJ, Leemans CR, Slotman BJ Departments. of Radiation Oncology, Neurosurgery, Radiology & Nuclear Medicine, Otolaryngology/Head and Neck Surgery and Neurology, VU University Medical Center, Amsterdam Grant: Varian ‐ RapidArc Study on the interaction between angiogenesis inhibition and radiotherapy E.A. Kleibeuker1, K. Castricum1, A.W. Griffioen2, H.M.W. Verheul2, B. Slotman1, S. Senan1, V.L.J.L. Thijssen1,2 Departments. of 1Radiation Oncology, VU University Medical Center, and 2Medical Oncology, VU University Medical Center (Stichting VUmc Cancer Center Amsterdam Grant: Stichting VUmc Cancer Center Amsterdam Resistance to therapy o
Identification of genes involved in resistance of lung cancer cells to cisplatin E. Siebring‐van Olst1, R.X. de Menezes2, E.F. Smit1, V.W. van Beusechem3 Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 193 of 216 o
o
o
o
Departments. of 1Pulmonary Diseases, 2Epidemiology and Biostatistics, and 3Medical Oncology, VU University Medical Center, Amsterdam Grant: Stichting CCA / Walter Bruckerhoff Stiftung Identification of genes involved in resistance of prostate cancer cells to irradiation J. Hodzic1, B. van Triest2, A. Geldof3, R.X. de Menezes4, W.R. Gerritsen1, M. Verheij2, V.W. van Beusechem1,5 Departments of 1Medical Oncology, 3Urology, 4Epidemiology and Biostatistics and 5RNA Interference Functional Oncogenomics Laboratory, VU University Medical Center, Amsterdam; 2Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam Grant: Stichting CCA Phase II study of sunitinib rechallenge in patients with metastatic renal cell carcinoma (SURE) M. Labots, C. Huijts, K.J. Gotink, T. de Gruijl, G.J Peters, C.R. Jimenez, A.J.M. van den Eertwegh, J.J. van der Vliet, H.M.W. Verheul Department of Medical Oncology, VU University Medical Center Amsterdam Targeted therapy of osteosarcoma J. Posthuma de Boer1, M. N. Helder1, V.W. van Beusechem2, G.J.L. Kaspers3,B.J. van Royen1 1 Department of Orthopaedic Surgery, VU University Medical Center, 2 Department of Medical Oncology, VU University Medical Center and 3 Department of Pediatric Oncology/Haematology, VU University Medical Center Grant: The Strategic Regeneration Network, Aarhus University Hospital, Denmark; VONK and the department of Orthopaedic Surgery, VU University Medical Center, Amsterdam Targeting resistance to radio‐chemotherapy by inhibition of the PI3Kinase‐Akt signaling pathway R.S. Narayan1, L.J.A. Stalpers2, B. G. Baumert3,6, M.E. van Linde4, N.A.P. Franken2, J. van den Berg1, J. Theys3, B.J. Slotman1, T. Wurdinger5, P. Sminia1 Departments. 1Radiation Oncology, 4Medical Oncology,5Neuro‐Oncology Research Group, VU University Medical Center; Department 2Radiation Oncology, Academic Medical Center, Amsterdam; 3Department Radiation Oncology Maastricht Universitair Medisch Centrum; 6Mediclin Robert‐Janker‐Clinic & University of Bonn Medical Centre, Cooperation Unit Neurooncology, Bonn, Germany Grant: KWF Rheumatoid diseases o
Imaging and targeting of macrophage folate receptor‐beta in rheumatoid arthritis Chandrupatla, Durga1, K. Weijers1, Y.Y.J. Gent1, G. Jansen1, C.F.M. Molthoff2, A.D. Windhorst2, J.W. van der Heijden1, A. Voskuyl1, P.S. Low3, M. Ratnam4, Y.G. Assaraf 5, A.A. Lammertsma2, B.A.C. Dijkmans1, and C.J van der Laken1 Departments. of 1Rheumatology and 2PET‐Center/Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands, 3Endocyte, West Lafayette, IN, USA, 4Department of Biochemistry and Molecular Biology, Medical University of Toledo, Toledo, OH. U.S.A., 5Department of Biology, The Technion, Israel Institute of Technology, Haifa, Israel Grant: Nationaal Reumafonds Rheumatology o
Molecular basis of sensitivity/resistance for folate antagonist and experimental targeted drugs G. Jansen1, J.W. van der Heijden1,2, M.C. Al1, R.J. Scheper3, J. Cloos4, N.E. Franke4, S.E. Verbrugge1, R. de Jonge5, G.L. Scheffer3, C.L. Verweij1,3, C.F.M. Molthoff6, G.J. Peters7, C.J. van der Laken1, Y.G. Assaraf 8 and W.F. Lems1 Depts. of 1Rheumatology, 2Nephrology, 3Pathology, 4Pediatric Oncology, 6PET‐Center/Nuclear Medicine, 7Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands, 5Dept. of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands, 8Dept. of Biology, The Technion, Israel Institute of Technology, Haifa, Israel Grant: Eerste geldstroom Reumatologie Other o
o
o
CD38 CART cell therapy of Multiple Myeloma 2013‐2017 T.Mutis, H.Lokhorst, N.vd Donk Department Of Hematology, VU University Medical Center, Amsterdam Grant: various Chronological or random reading of radiographs in long term follow‐up studies of Rheumatoid Arthritis? L. Van Tuyl,1,2 D.M.F.M van der Heijde, 3 M. Boers (PI)1,2 1. Dept of Clinical Epidemiology and Biostatistics; 2. Dept of Rheumatology; VUmc; 3. Dept of Rheumatology, Leiden UMC Grant: Reumafonds C‐Met inhibitors in novel ortothopic pancreatic tumors from primary cells A. Avan, N. Funel2, R.J. Honeywell1, T. Lagerweij3, O. H.M.W. Verheul1, G.J. Schuurhuis4, U. Boggi2, G.J. Peters1, T. Würdinger3, E. Giovannetti1 1Department of Medical Oncology, VU University Medical Center, VUmc, Amsterdam, The Netherlands; 3Neuro‐
oncology Research Group, 4Department of Hematology, VUmc Grant: NWO‐Veni and CCA Foundation Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 194 of 216 o
o
o
o
o
o
o
o
o
o
o
o
COBRA cohort study and patient reported remission outcomes L. Van Tuyl,1M. Boers 1,2,3, WF Lems1, AE Voskuyl1, D van Schaardenburg1,3, P Kerstens 3,4, M Nurmohamed1,3 1. Dept of Clinical Epidemiology and Biostatistics; 2. Dept of Rheumatology; VUmc; 3. Reade/Jan van Breemen Research Institute Amsterdam; 4. WestFries Gasthuis in Hoorn Grant: Pfizer Combination therapy of Daratumumab (DARA) for the treatment of Multiple Myeloma H.Lokhorst, N.vd. Donk, T.Mutis Department Of Hematology, VU University Medical Center, Amsterdam Grant: Johnsson pharmacotherapeutics Development of novel lactate dehydrogenase inhibitors for the treatment of mesothelioma L.G. Leon1,2, R. Sciarrillo,3 F. Minutolo4, GJ. Peters1, E. Giovannetti1 1Department Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands, 2Instituto de Tecnologias Biomedicas, Center for Biomedical Research of the Canary, 3Department of Hematology, VUmc, 4 Departemtn of Pharmaceutical Sciences, University of Pisa, Pisa, Italy Grant: Mesothelioma Applied Research Foundation (US) Development of preclinical pediatric brain tumor imaging models L. Hiddingh1,2,3, V. Caretti1,2,3, T. Lagerweij1,2,3, E. Hulleman1,2,3, G.J. Kaspers1, W.P. Vandertop2, C. Molthoff4, B.A. Tannous4, D. Noske2,3, T. Wurdinger2,3,5 Departments of 1Pediatric Oncology/ Hematology, 2Neurosurgery, 3Neurooncology Research Group, VU University Medical Center, 4VU University RNC, 5Massachusetts General Hospital and Harvard Medical School, Boston, MA Grant: Stichting KiKa Development of a therapeutic vaccine approach to anti‐angiogenesis in oncology M.Q. Wentink, J.J. van der Vliet, H.M.W. Verheul Department of Medical Oncology VU University Medical Center Amsterdam Effect of specific inhibitors of PI3K/Akt/mTOR pathway in squamous cell carcinoma of the lung with reduced PTEN levels A. Cavazzoni,1 R.R. Alfieri,1 E. Giovannetti,2 P.G. Petronini,1 G.J. Peters1 1 University of Parma, Department of Experimental Medicine, Italy; 2Department of Medical Oncology, VU University Medical Center, VUmc, Amsterdam, The Netherlands; Grant: AIRC (Italian Association for Cancer Research) Epigenetic therapies in pediatric high‐grade glioma S.J.E. Veringa,1,2, D.G. van Vuurden1,2, P. Wesseling2,3, W.P. Vandertop5, D.P. Noske2,4, T. Wurdinger2,4, G.J.L. Kaspers1, E. Hulleman1,2 Departments of 1Pediatric Oncology/Hematology, 2Neuro‐oncology research group, 3Pathology and, 4Neurosurgery, VU University Medical Center, Amsterdam Grant: VUmc Research on Childhood Cancer – VONK / Stichting Egbers EVIDENCE: European observational study on the burden of disease associated with the use of NSAIDs in rheumatology A. Lanas, M. Boers Dept of Clinical Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, Zaragoza, Spain Grant: AstraZeneca International Fighting pancreatic cancer: from research to innovative treatment through microRNA analysis T. Le Large1,2, N. Funel3, A.E. Frampton4, H.M.W. Verheul1, E. Giovannetti1, G. Kazemier2 1Department of Medical Oncology, VU University Medical Center, VUmc, 2Department of Surgery, VUmc, 3 Department of Surgical Pathology, Pisa University, Pisa, Italy; 4HPB Surgical Unit, Department of Surgery, Imperial College, London, UK Grant: Bennink Foundation GLORIA ‐ The Glucocorticoid Low‐dose Outcome in RheumatoId Arthritis Study Comparing the cost‐effectiveness and safety of additional low‐dose glucocorticoid in treatment strategies for elderly patients with rheumatoid arthritis M. Boers,1,2 H. Bijlsma,2 F. Buttgereit,3 J. da Silva,4 M. Cutolo,5 #. J. Rovensky,6 Z. Scekanecz,7 R. Ionescu.8 1. Dept of Clinical Epidemiology and Biostatistics; 2. Dept of Rheumatology; VUmc; 3. Berlin; 4. Coimbra; 5. Genova; 6. Piestany; 7. Debrecen; 8. Bucharest. Grant: Horizon 2020 Knowledge based treatment planning strategies, including knowledge of historical plans and correlations between plan dosimetry and toxicity J. Tol, M. Dahele, B.J. Slotman, S. Senan, W.F.A.R. Verbakel Grant: Varian Medical Systems, Palo Alto, USA Microenvironment‐Mediated Immune suppression Mechanisms in Multiple Myeloma T. Mutis, R. Groen, M. Minnema Department Of Hematology, VU University Medical Center, Amsterdam Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 195 of 216 o
o
o
o
o
o
o
o
o
o
o
Grant: AICR MicroRNAs in Pancreatic Adenocarcinomas and Pancreatic Intraductal Papillary Mucinous Neoplasms: prognostic and predictive role N. Funel1, T. Le Large2, S. Caponi2, A.E. Frampton4, E. Vasile2, H.M.W. Verheul1, G. Kazemier5, E. Giovannetti1 1Department of Surgical Pathology, Pisa University, Pisa, Italy; 2Unit Medical Oncology‐2, Pisa, Italy; 4HPB Surgical Unit, Department of Surgery, Imperial College, London, UK; 5Department of Surgery, VUmc, 1Department of Medical Oncology, VU University Medical Center Grant: ITT (Tuscany Tumor Foundation) Minor H antigen UTA2‐1‐loaded DC dendritic cells (DC)as vaccines to improve the therapeutic effect of donor lymphocyte infusions in B cell malignancies T. Mutis, H. Lokhorst Department Of Hematology, VU University Medical Center, Amsterdam Grant: ZonMW Monoclonal antibody related targeted therapies P. Noordhuis P, L. Smit L, J. van Meerloo Department Of Hematology, VU University Medical Center, Amsterdam Grant: Pharmaceutical Industries NF‐κB drives acquired resistance to a novel T790M‐mutant selective EGFR inhibitor L.G. Leon1,2, E. Galvani2, R. Sciarrillo,3 D.A.M. Heideman4, R. Bernards5, E.F. Smit15, W. Pao6, G.J. Peters1, E. Giovannetti1 1Department Medical Oncology, VU University Medical Center, VUmc, Amsterdam, The Netherlands, 2Instituto de Tecnologias Biomedicas, Center for Biomedical Research of the Canary, 4Department of Hematology, VUmc, 5Department of Pathology, VUmc, 5NKI, 6Vanderbilt‐Ingram Cancer Center, Nashville, TN 37232, US Grant: FP7‐REGPOT‐2012‐2013 Novel planning and delivery approaches for stereotactic radiotherapy of cranial and extracranial (vertebral and abdominal) lesions W.F.A.R. Verbakel, B.J. Slotman, S. Senan, M. Dahele Department of Radiation Oncology, VU University Medical Center, Amsterdam Grant: Varian Medical Systems Oxaliplatin, bortezomib and epothilone‐B induced neurotoxicity: characterization and protection Abolfazl Avan1,2 Cecilia Ceresa3,*, Elisa Giovannetti1, Albert A. Geldof4, Amir Avan1, Guido Cavaletti2, Godefridus J Peters1 1Department of Medical Oncology, VU University Medical Center, VUmc, 2Department of Neurology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; 3Department of Surgery and Interdisciplinary Medicine, University of Milano‐Bicocca, Monza, Italy; 4Department of Urology, VUmc Grant: Mashhad University of Medical Sciences grant Personalized therapy in lymphatic malignancies; role of (immune‐)PET monitoring YWS Jauw, MC Huisman, GAMS van Dongen, OS Hoekstra, S Zweegman, JM Zijlstra Department Of Hematology and Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam Grant: KWF Phase II randomixed trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first‐line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor S.W. Lam, C. Jimenez, H.J. Guchelaar, H. van Tinteren, E. Boven Depts of Medical Oncology, VU University Medical Center Amsterdam, Dept. Of Clinical Pharmacy & Toxicology, Leiden, Dept. Of Statistics, NKI‐AVL, Amsterdam Grant: Industry Preclinical and phase 1 evaluation of an alternative treatment schedule with weekly or every other week of high dose sunitinib in patients with advanced solid tumors to increase its antitumor activity M. Rovithi, J. Voortman, R. de Haas, R. Honeywell, M. Labots, D. Poel, G.J. Peters, A.W. Griffioen, H.M.W. Verheul Depts of Medical Oncology, VU University Medical Center Amsterdam Prospective Validation of Soluble Biomarkers as Predictors of Structural Damage in Rheumatoid Arthritis (BIODAM) OMERACT Biomarker working group: Walter P. Maksymowych (Canada), Désirée van der Heijde (Netherlands), Robert Landewé (Netherlands), Members: George Wells (Canada), Joan Bathon (USA), Clifton Bingham (USA), Vivien Bykerk (Canada), Mikkel Ostergaard (Denmark), Tore Kvien (Norway), Maarten Boers (Netherlands), Daniel Aletaha (Austria), Paul‐Peter Tak (Netherlands), Oliver Fitzgerald (Ireland), Chris Ritchlin (USA), Philip Mease (USA), Hani El‐Gabalawy (Canada), Willem Lems (Netherlands), Dirk‐jan van Schaardenburg (Netherlands), Hilde Berner Hammer (Norway), Marina Backhaus (Germany), Bernard Combe (France), Gianfranco Ferraccioli (Italy) Grant: Unrestricted research grant: Abbott, Inc Real‐time non‐invasive monitoring of patient and target position during high‐precision radiotherapy C. Hazelaar, M. Dahele, H. Mostafavi*, J van Sornsen de Koste, S. Senan, B. Slotman, W. Verbakel Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 196 of 216 o
o
o
o
o
o
o
Department of Radiation Oncology, VU University Medical Center, Amsterdam, *Varian Medical Systems, Grant: Varian Medical Systems Risk and Benefit of Glucocorticoid Therapy in Rheumatoid Arthritis: A systematic review and GRADE approach to the body of evidence from prospective studies S. Tarp Jensen1,2, E.M Bartels1, H. Bliddal1,3,4, M. Boers5, D.E. Furst6, J.R. Kirwan7, B. Danneskiold‐Samsøe1,3,4, M. Rasmussen2, R. Christensen1,8 1. The Parker Institute: Musculoskeletal Statistics Unit (MSU), Copenhagen University Hospital at Frederiksberg, Copenhagen F, Denmark, 2. The Faculty of Pharmaceutical Sciences: Department of Pharmacology and Pharmacotherapy Section of Clinical Pharmacy, University of Copenhagen, Copenhagen, Denmark, 3. Center for Sensory‐Motor Interaction, Aalborg University, Aalborg, Denmark, 4. Faculty of Health & Science, University of Copenhagen, Denmark, 5. Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, Netherlands, 6. University of California at Los Angeles, Los Angeles, USA, 7. University of Bristol, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK, 8. Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense M, Denmark. Grant: Unrestricted research grant Mundipharma International Role of flowcytometry in the diagnosis of cytopenia of unknowsn significance and myelodysplastic syndromes Cremers EMP, C. Alhan, TM Westers, GJ Ossenkoppele, AA van de Loosdrecht Department Of Hematology, VU University Medical Center, Amsterdam Grant: Celgene/HOVON Role of flowcytometry in the predictionof response to IMids in low risk myelodyspalstic syndromes C. Alhan, Cremers EMP, TM Westers, GJ Ossenkoppele, AA van de Loosdrecht Department Of Hematology, VU University Medical Center, Amsterdam Grant: Celgene/HOVON Splicing alterations as novel mechanism of drug resistance R. Sciarrillo1,2, E. Giovannetti3, Jansen G4, G.J. Peters3, S. Zweegman2, G.J.L. Kaspers1, J. Cloos1,2 Departments. of 1Pediatric Oncology/Hematology, 2Hematology, 3Medical Oncology and 4Rheumatology, VU University Medical Center, Amsterdam Grant: VUmc CCA Stichting Avantie STR Systematic review of longitudinal studies of bone loss in RA M. Baak, L. van Tuyl, M. Voskuyl‐Lodder, W. Lems, M. Boers. Dept of Clinical Epidemiology and Biostatistics, VU University Medical Center, Amsterdam Testing novel treatment modalities for diffuse intrinsic pontine glioma (DIPG) in in vivo animal models A.C.P. Sewing1,2, D.G. van Vuurden1,2, D.P. Noske2,3, T. Wurdinger2,3,4, W.P. Vandertop3, G.J.L. Kaspers1, E. Hulleman1,2 Departments of 1Pediatric oncology, 2Neuro‐oncology Research Group Cancer Center Amsterdam, 3Neurosurgery, VU University Medical Center Amsterdam, and 4Molecular Neurogenetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA Grant: KiKa, Children‐Cancer‐free The OMERACT Handbook M. Boers, J. Kirwan3, P. Tugwell4, D. Beaton5, C.O. Bingham III6, P.G.Conaghan7, M.‐A. D'Agostino8, M. de Wit9, L. Gossec10, L. March11, L.S. Simon12, J.A. Singh13, V. Strand14, G. Wells15 1: Dept of Clinical Epidemiology and Biostatistics; 2. Dept of Rheumatology; VUmc; 3: Bristol, UK; 4,15: Ottawa, Canada; 5: Toronto, Canada; 6: Baltimore, USA; 7: Leeds, UK; 8, 10: Paris, France; 9: Amsterdam; 11: Sydney, Australia; 12: Boston, USA; 13: Birmingham, USA; 14: Palo Alto, USA Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 197 of 216 Program 5 – Quality of life Child o
o
o
o
o
o
Compliance with childhood cancer treatment in Yogyakarta, Indonesia D. Susilawati1, M.N. Sitaresmi2, S. Mostert3, E. Supriyadi4, I.L. Gamayanti1, P.H. Widjajanto4, G.J.L. Kaspers3 1 Psychology, Dr Sardjito Hospital, Yogyakarta, Indonesia, 2 Social Pediatrics, Dr Sardjito Hospital, Yogyakarta, Indonesia, 3Oncology‐Hematology, VU University Medical Center, Amsterdam, the Netherlands, 4 Oncology‐
Hematology, Dr Sardjito Hospital, Yogyakarta, Indonesia Fertility impairment in a pan‐European cohort of female 5‐year survivors of childhood cancer (PanCareLIFE) M. van Dijk, E. van Dulmen‐den Broeder, M. van den Berg, G.J. Kaspers Department of Pediatrics, VU University Medical Center Amsterdam Grant: Netherland4s Organization for Scientific Research Reducing vincristine‐induced peripheral neuropathy in children with acute lymphoblastic leukemia by one‐hour infusions instead of bolus injections (the VINCA study) M.E. van de Velde, F. Abbink, M.H. van den Berg, G.J. Kaspers Departments of Pediatric Oncology/Hematology, VU University Medical Center Grant: ZonMw (Gooed Gebruik Geneesmiddelen) SLAAP studie: Sleep in children with Acute leukemia and Additional cost to the parents: a study into the effect on quality of life R.R.L. van Litsenburg1, M.S. Gordijn2, M.A. Grootenhuis3, G.J.L. Kaspers1 Department of 1 Pediatric Oncology‐hematology, VU University Medical Center Amsterdam, 2 Pediatrics, VU University Medical Center Amsterdam, 3 Psychosocial department, Emma Children’s Hospital AMC Amsterdam Sleep in children with acute lymphoblastic leukemia and its effect on quality of life, fatigue and parental functioning L.M.H. Steur, R.R.L. van Litsenburg, M.A. Grootenhuis, G.J.L. Kaspers Departments. of Pediatric Oncology/ Hematology, VU University Medical Center, Amsterdam Sleep, fatigue and quality of life in survivors of childhood acute lymphoblastic leukemia M.S. Gordijn1, R.R.L. van Litsenburg1, RJ.B.J. Gemke1, J. Huisman2, M.B. Bierings3, P.M. Hoogerbrugge5, G.J.L. Kaspers1 Departments. of 1Pediatrics and Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, 2 Medical Psychology, VU University Medical Center, Amsterdam / Pediatric Psychology & Social Work, University Medical Center Utrecht, 3Pediatric Hematology/Oncology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, 4Pediatric Hemato‐Oncology, Radboud University Nijmegen Medical Center Grant: KWF Exercise o
o
o
A combined physical exercise and psychosocial training program to improve physical fitness in children with cancer K.I. Braam1, E.M. van Dijk2, E. van Dulmen‐den Broeder1, M.A. Veening1, M. Bierings3, J. van der Net3, J.H.M. Merks4, M.A. Grootenhuis4 G. Sinnema3, M. Chinapaw5, M.M. van den Heuvel‐Eibrink6, I. Streng6, T. Takken3, J. Huisman2, G.J.L. Kaspers1 1Pediatric Oncology/ Hematology, VU University Medical Center, and 2Department of medical Psychology VU university medical center; 3Wilhelmina Children’s Hospital, University Medical Center Utrecht; 4Academic Medical Centre, Amsterdam; 5EMGO institute, VU University Medical Center, 6Erasmus MC/Sophia Childrens Hospital, Rotterdam Grant: Alpe d’HuZes/KWF Development of a new questionnaire to measure instrumental activities of daily living (IADL) in patients with primary brain tumors L. Dirven1, S.A.M. Sikkes2, J.C. Reijneveld1,3, N.K. Aaronson4, B.M.J. Uitdehaag1, M.J.B. Taphoorn1,5 1 Department of Neurology VU University Medical Center, 2 Department of Epidemiology and Biostatistics, 3 Department of Neurology, Amsterdam Medical Center, 4 Division of Psychosocial Research and Epidimiology, Netherlands Cancer Institute, 5 Department of Neurology, Medical Center Haaglanden Grant: DEVON Exercising in head and neck cancer. Netherlands Quality of Life and Biomedical Cohort Studies in Head and Neck Cancer (NET‐QUBIC_HNC) A van Nieuwenhuizen1, C.R. Leemans1, L. Buffart2,I.M. Verdonck‐de Leeuw1 Department of 1Otolaryngology ‐ Head and Neck Surgery, 2Epidemiology and Biostatistics, VU University Medical Center, Amsterdam Grant: KWF, Alpe‐ d'Huzes Gastrointestinal and nutritional quality of life aspects Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 198 of 216 o
o
Prevalence and biomarkers of pre‐cachexia and cachexia in advanced cancer patients scheduled for treatment with chemotherapy S. Blauwhoff‐Buskermolen, D.L. van der Peet, J.A.E. Langius, E.F. Smit, M.J.D.L van der Vorst, L.C.W. Neefjes, C.R. Jimenez, M.E. von Blomberg, H.J. Bontkes, M. Diamant, P.A.M. van Leeuwen, H.M.W. Verheul, M. A.E van Bokhorst‐ de van der Schueren Departments of Nutrition and Dietetics, Surgery, Pathology, Pulmonology and Medical Oncology, VU University Medical Center Amsterdam VUMC: VU University Medical Center Grant: Nuts Ohra Zorgsubsidies The effect of individualized NUTritional counselling on muscle mass and treatment outcome in patients with metastatic COLOrectal cancer undergoing chemotherapy (COLONUT) A. van der Werf, M.J.D.L van der Vorst, K.S. Versteeg, L.C.W. Neefjes, S. Blauwhogg‐Buskermolen, J.Berkhof, H.M.W. Verheul, J.A.E Langius, M.A.E de van der Schueren. Department of Nutricion and dietics, Epidemiology & Biostatistics and Medical Oncology, VU University Medical Center Amsterdam Hematology o
Short trial: long versus short antibiotic treatment for febrile neutorpenia in hematological malignancies N.A. de Jonge, J. Sikkens, S. Zweegman, M. Kramer, M.A. van Agtmael, J.J.W.M. Janssen Department of Internal Medicine and Hematology, VU University Medical Center Amsterdam Late effects after childhood cancer o
o
Cancer related fatigue in Childhood Cancer Survivors: a DCOG LATER Study J. Loonen5, H.Knoop, E.van Dulmen‐den Broeder1, M.H. van den Berg1, LCM Kremer2, MM van den Heuvel‐Eibrink3, W. Tissing4, , B. Versluys6, D. Bresters7, FE van Leeuwen8, M. Grootenhuis2 1Department of Paediatrics, Division of Paediatric Oncology/Haematology, VU University Medical Center, Amsterdam, 2Department of Paediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, 3Department of Paediatrics, Division of Paediatric Oncology/Haematology, ErasmusMC University Medical Center Rottrdam, 4Department of Paediatric Oncology, Beatrix Children's Hospital/University Medical Center Groningen, 5Department of Paediatric Oncology, Radboud University Nijmegen Medical Center, Nijmegen, 6Department of Paediatric Oncology, Wilhelmina's Children's Hospital, University Medical Center, Utrecht, 7Willem‐Alexander Children's Hospital, Leiden University Medical Center 8Department of Epidemiology, Netherlands Cancer Institute Amsterdam, 9Dept of Internal Medicine VU University Medical Center Amsterdam, 10 Dept of Medical psychology, EKZ/AMC, Amsterdam The DCOG‐LATER (Late effects after Childhood cancer)‐ study E.van Dulmen‐den Broeder1, M.H. van den Berg1, LCM Kremer2, MM van den Heuvel‐Eibrink3, W. Tissing4, J.Loonen5, , B. Versluys6, D. Bresters7, FE van Leeuwen8, M.Jaspers2, CR Ronckers2, MA Veening1, J. Kooter9, M. Grootenhuis10, 1Department of Paediatrics, Division of Paediatric Oncology/Haematology, VU University Medical Center, Amsterdam, 2Department of Paediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, 3Department of Paediatrics, Division of Paediatric Oncology/Haematology, ErasmusMC University Medical Center Rottrdam, 4Department of Paediatric Oncology, Beatrix Children's Hospital/University Medical Center Groningen, 5Department of Paediatric Oncology, Radboud University Nijmegen Medical Center, Nijmegen, 6Department of Paediatric Oncology, Wilhelmina's Children's Hospital, University Medical Center, Utrecht, 7Willem‐Alexander Children's Hospital, Leiden University Medical Center 8Department of Epidemiology, Netherlands Cancer Institute Amsterdam, 9Dept of Internal Medicine VU University Medical Center Amsterdam, 10 Dept of Medical psychology, EKZ/AMC, Amsterdam Grant: SKION LATER/KWF/KiKa/VONK/Stichting QOL Late effects of tumor treatment o
Pediatric acute lymphoblastic leukemia: quality of life and cost‐effectiveness of treatment R.R.L. van Litsenburg¹, J. Huisman², C. Verhaak³, G.J.L. Kaspers4, R.J.B.J. Gemke¹ Department of ¹Pediatrics VU University Medical Center, ²medical psychology UMC Utrecht, ³medical psychology, UMC Nijmegen, 4Pediatric oncology‐hematology VU University Medical Center Grant: AGIKO Patient reported outcome o
o
Complications, functional, and cosmetic results in patients treated for retinoblastoma in the Netherlands D.L. Mourits, D.T. Hartong, M. Bosscha, J.S. Remmers, F. Bak, H.S. Tan, A.C. Moll Department of Ophthalmology, VU University Medical Center Grant: ODAS OncoKompas 2.0: Development and pilot testing of an e‐health self‐management platform to optimise supportive care in cancer patients C.F. van Uden‐Kraan1,2, S. Lubberding1, H. Melissant2, C.R. Leemans1, P. Cuijpers2, I.M. Verdonck‐de Leeuw1,2 1. Otolaryngology, Head and Neck Surgery, VUmc, 2. Clinical Psychology, VU University Grant: Dutch Cancer Society (KWF), Pink Ribbon, SAG Foundation, NDDO Foundation Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 199 of 216 o
o
o
o
OncoQuest: touch screen computer based screening of health related quality of life and distress I.M. Verdonck‐de Leeuw1, R. de Bree1, A. Houffelaar1, C.F. van Uden‐Kraan1, P. Doornaert2, C.R. Leemans1 1. Otolaryngology, Head and Neck Surgery, VUmc, 2. Radiotherapy, VU University Medical Center, Amsterdam Grant: Fonds NutsOhra, Dept Otolaryngology, Head and Neck Surgery Participation in decision‐making to improve quality of life of cancer patients and their proxies: implementation of advance care planning L. Dirven1, H.R.W. Pasman2, J.C. Reijneveld1,4, B. Philippsen‐Onwuteaka2, O. Visser3, M.J.B. Taphoorn1,5 Departments of 1Neurology, 2EMGO+, 3 Hematology, VU University Medical Center, Amsterdam, 4Department of Neurology, Academic Medical Centre, Amsterdam,5Department of Neurology, Medical Centre ‘Haaglanden’, Den Haag Grant: DEVON Patient reported speech and swallowing outcome in head and neck cancer R.N.P.M. Rinkel1, I.M. Verdonck‐de Leeuw1, N.K Aaronson2, C.R. Leemans1 1. Otolaryngology, Head and Neck Surgery, Vumc, 2. Psychosocial research, The Netherlands Cancer Institute Grant: VUmc, Otolaryngology, Head and Neck Surgery Shared decision making in early‐stage lung cancer W. Hopmans, D.R.M. Timmermans, O.C. Damman, L. Zwaan, C.J.A. Haasbeek, K. Hartemink, E.F. Smit, B.J. Slotman, S. Senan Departments. of Radiation Oncology, Public and Occupational Health and the EMGO+ Institute for Health and Care Research, Surgical Oncology, Pulmonology, VU University Medical Center Psychosocial aspects o
o
o
o
o
o
o
Distress and quality of life of patients treated with autologous stem cell transplantation A. Braamse1, B. van Meijel2, O. Visser3, P.C. Huijgens3, A. Boenink1, P. Cuijpers4, P. van Oppen1 , A.T.F. Beekman1, J. Dekker1 1 Department of Psychiatry VU University Medical Center, 2 Research Group Mental Health Nursing, Inholland University, 3 Department of Hematology VU University Grant: VU University Medical Center and Inholland University Help‐seeking behavior after autologous stem cell transplantation A.M.J. Braamse1, O.Visser2, B. van Meijel3, P.C. Huijgens2, A.T.F. Beekman1, J.Dekker1,4 Departments of 1Psychiatry, 2 Hematology, 4 Rehabilitation Medicine, VU University Medical Center, 3 Inholland University of Applied Sciences, Amsterdam Grant: VU University Medical Center and Inholland University of Applied Sciences Internet‐based treatment of low‐grade glioma patients with depression and fatigue; randomized controlled trial F. Boele1, M. Klein1, J.C. Reijneveld2,3, I. Verdonck4,5, J.J. Heimans2, P. Cuijpers5, Departments of 1Medical Psychology, 2Neurology, VU University Medical Center, 3Neurology, Academic Medical Center, 4Head‐Neck Surgery, VU University Medical Center, 5Clinical Psychology, VU University, Amsterdam Grant: KWF (Alpe d'Huzes) Screening and treatment of psychological distress in colorectal cancer with metastasized disease (TES) C. Schuurhuizen, S. Vrijaldenhoven, A. Beeker, C.J van Groeningen, R. Rietbroek, J. Brakenhoff, A. van Bochove, H.J. Bloemendal, M. Los, A. Wymenga, M. Polee, M. Van der Vorst, C. Tromp, E. Department of Medical Oncology, Otolaryngology/Head and Neck Surgery and Medical Psychology, VU University Medical Center Amsterdam Grant: Alpe d’Huzes en KWF Kankerbestrijding Stepped care to improve symptoms of anxiety and depression in cancer patients A.M.H. Krebber1, F. Smit2, P. Cuijpers2, A. van Straten2, A.T.F. Beekman3, A. Becker4, EF Smit4, C.R. Leemans1, I.M. Verdonck‐de Leeuw1,2 1. Otolaryngology, Head and Neck Surgery, VUmc, 2. Clinical Psychology, VU University, Faculty of Psychology and Education, 3. Psychiatry, VUmc, 4. Pulmonary Disease, VUmc Grant: ZonMW Structured life review using autobiographical retrieval practice in depressed palliative head and neck cancer patients G. Kleijn1, R. de Bree2, C.R. Leemans2, A.Becker3, E.F. Smit3, C. Eeltink4, D. Rietveld5, P. Doornaert5, M. van der Vorst6, M. van den Brekel7, B. Steunenberg8, E.T. Bohlmeijer9, V. Willemsen10, P. Cuijpers1, I.M. Verdonck‐de Leeuw1,2 1. Clinical Psychology, VU University, 2. Otolaryngology, Head and Neck Surgery, VUmc, 3. Pulmonary Disease, VUmc, 4. Hematology, VUmc, 5. Radiotherapy, VUmc, 6. Medical Oncology, VUmc, 7. Otolaryngology, Head and Neck Surgery, Netherlands Cancer Institute, 8. Julius Center, UMCU, 9. Mental Health, University Twente, 10. Ingeborg Douwes Center, Amsterdam Grant: ZonMw The development, implementation and evaluation of the meaning‐centered group psychotherapy 'Living Meaningfully with Cancer' in the Netherlands Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 200 of 216 N. van der Spek1, K. Holtmaat1, C.F. van Uden‐Kraan1, R. Tollenaar2, P. Cuijpers1, B Breitbart3, I.M. Verdonck‐de Leeuw1,4 1. Clinical Psychology, VU University, 2. Surgery, LUMC, 3. Psychiatry, Memorial Sloan Kettering Cancer Center, New York, 4. Dept Otolaryngology, Head and Neck Surgery, VU University Medical Center Grant: Duch Cancer Society / Alpe d’HuZes Foundation Psychosocial oncology o
o
o
o
o
o
Effectiveness of methodically writing L. Post, J. Delver, I.M. Verdonck‐de Leeuw 1. Spiritual Care, 2. VU Clinical Psychology, VU Universtiy Medical Center, Amsterdam Grant: Addesium Foundation Improving quality of life in glioma patients F. Boele1, J. Heijmans1, M. Klein2, I.M. Verdonck‐de Leeuw3 1. Neurology, 2. Medical Psychology, 3. VU Clinical Psychology Grant: Dutch Cancer Society / Alpe d’HuZes Foundation Positive psychological changes in cancer patients K. Holtmaat1, N. van der Spek1, P. Cuijpers1, I.M. Verdonck‐de Leeuw1,4 1. Clinical Psychology, VU University, 4. Dept Otolaryngology, Head and Neck Surgery, VU University Medical Center Grant: Duch Cancer Society / Alpe d’HuZes Foundation Sexual life beyond hematological cancer C.M. Eeltink3, I.M. Verdonck‐de Leeuw2, S. Zweegman! 1. Hematology, VU Clinical Psychology, 2. Otolaryngology, Head and Neck Surgery, VUmc, 3. Clinical Psychology, VU University Shared decision making in prostate cancer Al‐Itejawi, van Uden‐Kraan, Vis, van Nieuwenhuizen, Verdonck‐de Leeuw, van Moorselaar 1. Urology, 2. VU Clinical Psychology, VU University Medical Center, Amsterdam The information needs of patients with a hematological malignancy J. Rood, I.M. Verdonck‐de Leeuw, S. Zweegman P.C. Huijgens, O. Visser, F. van Zuuren, F. Stam Otolaryngology, Hemato‐oncology and Clinical Psychology, VU University Medical Center, Amsterdam Retinoblastoma: Late‐effects o
Early‐detection of quality of life problems in children with Retinoblastoma M.I. Bosscha1J. van Dijk2, J. A. Frankfoorder1, G. Buurmans‐Kool1, A. Kors3, E. van Dulmen‐den Broeder5, M.A. Grootenhuis4, A. Houffelaar5, I.M. Verdonck‐de Leeuw5 and A.C. Moll1 Departments. of 1Ophthalmology, 2Pedriatic Psychology, 3Pediatric Oncology, 5ENT/Head and Neck, VU University Medical Center, and 4Clinical Psychology, Free University, and Psychosocial Department, Pediatrics, University Hospital of Amsterdam Grant: NutsOhra Voice, speech, and swallowing in head and neck cancer o
o
Efficacy of voice therapy in patients with voice problems after treatment for early glottic cancer C.D.L. van Gogh1, I.M. Verdonck‐de Leeuw1, R.N. Rinkel1, J.A. Langendijk2, P. Doornaert3, H.F. Mahieu1 1Department Otolaryngology/Head‐Neck Surgery, VU University Medical Center, 2Department Radiotherapy, University Medical Center Groningen, 3Department Radiotherapy, VU University Medical Center, Amsterdam Grant: KWF Dutch Cancer Society RUG2008‐3983, Fonds NutsOhra 080T‐043, Eureka 2614 GGN371, VAZ/CVZ Doelmatigheid 00143 LARINX: a web‐based self‐help programme for laryngectomized patients during and after treatment I.C. Cnossen1, C.F. van Uden‐Kraan1, S.E. Eerenstein1, R. de Bree1, Leemans1, Verdonck‐de Leeuw1 1. Otolaryngology, Head and Neck Surgery, VUmc. Grant: Michel Keijzer Fonds / the Netherlands Society of Laryngectomees Other o
o
Compliance with childhood cancer treatment in Manado, Indonesia S. Gunawan,MD2, PM van de Ven,MSc,PhD3 , MN Sitaresmi,MD,PhD4 , M Mantik,MD2, GJL Kaspers,MD,PhD1 ,S Mostert,MD,PhD1 1Department of Pediatric Oncology‐Hematology, Prof Dr RD Kandou Hospital, Manado, Indonesia, 2 Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands, 3 Department of Pediatrics, Dr Sardjito Hospital, Gadjah Mada University, Yogyakarta, Indonesia, 4 Department of Pediatric Oncology‐Hematology, VU University Medical Center, Amsterdam, the Netherlands Grant: SMALL Foundation Glucocorticoid induced HPA axis suppression in childhood acute lymphoblastic leukaemia and lymphoma M.S. Gordijn1, R.J.B.J. Gemke1, J. Rotteveel1, M.B. Bierings2, C. van den Bos3, G.J.L. Kaspers1 Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 201 of 216 o
o
o
o
o
o
o
o
o
Departments. of 1Pediatrics and Pediatric Oncology/Hematology, VU University Medical Center, 2Pediatric Hematology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, 3Pediatric Oncology/Hematology, Emma’s Children Hospital / Academic Medical Center Grant: Dutch Cancer Society, grant VU Malnutrition in patients with head and neck cancer during (chemo)radiotherapy; concepts and clinical implications J.A.E. Langius1, C.R. Leemans2, P. Doornaert3, M.H.H. Kramer4, H.M. Kruizenga1, I.M. Verdonck‐de Leeuw2, J.A. Langendijk5, P.J.M. Weijs1 Departments. of 1Nutrition and Dietetics, Internal Medicine; 2Otolaryngology/Head and Neck Surgery; 3Radiation Oncology, 4Internal Medicine, VU University Medical Center, Amsterdam and 5Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands Grant: CCA 2011‐1‐02 Predicting OptimaL Cancer Rehabilitation and Supportive Care (POLARIS) J. Kalter, J. Brug, I.M. Verdonck‐de Leeuw, L.M. Buffart Department Epidemiology and Biostatistics and Department Otolaryngology, VU University Medical Center Amsterdam Grant: Bas Mulder Award, granted to L.M. Buffart by the Alpe d’HuZes/KWF Fund (VU 2011‐5045). Quality of life and neurocognitive functioning in meningioma patients D. van Nieuwenhuizen1, S.M. Peerdeman2, L.J.A. Stalpers5, W.P. Vandertop2,6, , M. Waagemans1,3, J.J. Heimans1, M. Klein3, J.C. Reijneveld1,4 Department of 1Neurology, 2Neurosurgery, and 3Medical Psychology, VU University Medical Center, Amsterdam, Department of 4Neurology, 5Radiotherapy, and 6Neurosurgery, Academic Medical Center, Amsterdam Signaleren en behandelen van psychologische distress in de oncologie J. Dekker, F.J. Snoek, H.M.W. Verheul, J.A. Stoker, M. van Linde, J.M. Balcombe, A. Boenink, A.M.J. Braamse, E.H. Collette, F.J.M. Eskens, K. Hilverda, A. Hoogendoorn, I.R.H.M. Konings, M. van der Linden, J. ter Veen Dept. Medical Oncology, Dept. Medical Psychology, Dept. Psychiatry Grant: VUmc, InGeest Structured follow‐up by mobile phones for childhood acute lymphoblastic leukemia patients in Yogyakarta, Indonesia K. Handayani1, D. Susilawati2, M.N. Sitaresmi3, E. Supriyadi1, I.L. Gamayanti2, P.H. Widjajanto1, G.J.L. Kaspers4,S. Mostert4 1Department of Oncology‐Hematology, Dr Sardjito Hospital, Yogyakarta, Indonesia, 2 Department of Psychology, Dr Sardjito Hospital, Yogyakarta, Indonesia, 3 Department of Social Pediatrics, Dr Sardjito Hospital, Yogyakarta, Indonesia, 4Department of Oncology‐Hematology, VU University Medical Center, Amsterdam, the Netherlands Grant: Programma Noord‐Zuid Supportive care needs in patients treated with autologous or allogeneic hematopoietic stem cell transplantation A.M.J. Braamse1, O. Visser 2, B. van Meijel3, P.C. Huijgens2, A.T.F. Beekman1, J. Dekker1,4 Departments. Of 1Psychiatry, 2 Hematology, 4 Rehabilitation Medicine, VU University Medical Center, 3 Inholland University of Applied Sciences, Amsterdam Grant: VU University Medical Center and Inholland University of Applied Sciences The patient perspective on remission in rheumatoid arthritis L. Van Tuyl1, M. Boers 1,2,3, D van Schaardenburg1,3, M Scholte‐Voshaar4, Wijnanda Hoogland4, Josef Smolen5, George Wells6, John Kirwan7, Sarah Hewlett7 1. Department of Rheumatology; 2. Department of Clinical Epidemiology and Biostatistics; VUmc; 3. Reade/Jan van Breemen Research Institute Amsterdam; 4. Patient partners, VUmc, The Netherlands; 5. Medical University of Vienna, Austria; 6. University of Ottawa, Canada; 7. University of Bristol, United Kingdom Grant: EULAR28 Cost evaluation of supportive care in head and neck cancer. Netherlands Quality of Life and Biomedical Cohort Studies in Head and Neck Cancer (NET‐QUBIC_HNC) F. Jansen1, C.R. Leemans1, C. Coupé2, I.M. Verdonck‐de Leeuw1 Department of 1Otolaryngology ‐ Head and Neck Surgery 2Epidemiology and Biostatistics, VU University Medical Center, Amsterdam Grant: KWF, Alpe‐ d'Huzes Health‐related quality of life in high‐grade glioma patients and their partners in the end‐of‐life phase E.M. Sizoo1, J.J. Heimans1, M. Klein2, T.J. Postma1, L. Dirven1, J.A.F. Koekkoek1, R. Grant6, W. Grisold7, C. Marosi 8,G. Stockhammer9, H.R.W. Pasman3, L. Deliens3 J.C. Reijneveld1,4, M.J.B. Taphoorn1,5 Departments of 1Neurology, 2Medical Psychology, and 3EMGO+, VU University Medical Center, Amsterdam, 4Department of Neurology, Academic Medical Centre, Amsterdam, 5Department of Neurology, Medical Centre ‘Haaglanden’, Den Haag, 6Department of Neurology, Western General Hospital, University of Edinburgh, United Kingdom, 7Ludwig Bolzman Institute for Neuro‐Oncology, Kaiser Franz Josef Hospital, Vienna, 8Department of Internal Medicine, Medical Univeristy, Vienna, and 9Department of Neurology, Neuro‐Oncology Group, Medical University of Innsbruck, Austria Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 202 of 216 o
o
o
Grant: Jacobus Stichting Grant: DEVON Netherlands Quality of Life and Biomedical Cohort Studies in Head and Neck Cancer (NET‐QUBIC) I.M. Verdonck‐de Leeuw1,2, A.J. van Nieuwenhuizen1, L. Korsten1, R.H. Brakenhoff1, J. Smit2, L.M. Buffart3, S. Kleiterp1, R. de Bree1, J.A. Langendijk4, R. Takes5, Chr. Terhaard6, C.R. Leemans1 1. Otolaryngology, Head and Neck Surgery, VUmc, 2. Clinical Psychology, VU, 3. Epidemiology and Biostatistics, VUmc, 4. Radiotherapy, UMCG, 5. Otolaryngology, Head and Neck Surgery, UMC Radboud, 6. Radiotherapy, UMCU Grant: Dutch Cancer Society / Alpe d’HuZes Foundation Seizures in glioma patients J.A.F. Koekkoek1, L. Dirven1, J.J. Heimans1, T.J. Postma1, M. Vos2, J.C. Reijneveld1,3, M.J.B. Taphoorn1,2 1 Department of Neurology, VU University Medical Center, 2 Department of Neurology, Medical Center Haaglanden,3 Department of Neurology, Amsterdam Medical Center Grant: Jacobus Stichting, ZOLEON, Chanrone The course of quality of life in head and neck cancer patients L. Korsten, C.R. Leemans, I.M. Verdonck‐de Leeuw Department of Otolaryngology/Head‐Neck Surgery VU University Medical Center Annual Report VUmc CCA 2014 ‐ Appendix 6: Ongoing research projects ‐ 203 of 216 Appendix 7 – Scientific Research Committee Clinical protocols that need approval of the medical ethical committee (METC) of the VUmc are first evaluated by the scientific research committee (CWO), see appendix 4 for the participating members. In 2014 a total of 97 clinical protocols were evaluated, with specific attention to the quality and feasibility of the proposed protocol. In addition, the CWO evaluated a total of 114 research projects/grant proposals in 2014. New research projects were firstly checked by the executive board for embedding in one of the five VUmc CCA research programs. Animal related protocols that need approval of the animal ethical committee (DEC) of the VUmc were first evaluated by the CWO‐DEC committee, see appendix 1 for the participating members. In 2014, a total of 37 animal‐related protocols were evaluated and approved. Clinical protocols Applicant Title Ankersmit M Advanced imaging in laparoscopic HIPEC for peritoneal carcinomatosis of colorectal origin to improve cytoreduction; a feasibility study Bouma G Double‐blind, double‐dummy, rondomised, placebo‐controlled, multi‐centre phase III study on the efficacy and tolerability of a 8‐week treatment with 9 mg budesonide vs. 3 g mesalazine vs. Placebo in patients with lymphocytic colitis Bouma G Randomised, double‐blind, placebo‐controlled, multi‐centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitis Bouma G Een fase 2A open‐label onderzoek ter beoordeling van de voorspelling van de respons op Golimumab met behulp van een transcriptomisch profiel bij patienten met matig tot ernstige actieve colitis ulcerosa Bouma G Tacrolimus suppositories versus beclomethasone suppositories for the treatment of protitis refractory to local 5‐ASA Brakenhoff R Towards targeted therapy of genetically altered preneoplastic lesions in the oral cavity
Bruynzeel AME Postoperative local stereotactic radiotherapy versus observation following complete resection of a single brain metastatis Buter J An Open‐Label, Randomized Phase 3 Clinical Trial of Nivolumabs vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum‐refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) Chamuleau M HOVON 130 NHL: A phase II study evaluating the effect of the addition of lenalidomide to R‐CHOP for patients with newly diagnosed MYC positive DLBCL and BCL‐U Chamuleau M CC‐5013‐DLC‐002: Phase 3 randomized, double‐blind, placebo controlled, multicenter to compare the efficacy and safety of Lenalidomide (CC‐5013) plus R‐CHOP Chemotherapy (R2‐CHOP) versus placebo plus R‐CHOP Chemotherapy in subjects with previously untreated activated B‐cell type diffuse large B‐cell lymphoma Chamuleau ME GO28667: A Multicenter, Phase III, Open‐Label, Randomized Study in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia To Evaluate The Benefit of GDC‐0199 (ABT‐
199) Plus Rituximab Compared with Bendamustine plus Rituximab. Chamuleau ME HOVON 124 WM: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenström's macroglobulinemia; a HOVON/Greek Myeloma Study Group study. Chamuleau MED HOVON 127 BL: Randomized phase II study comparing R‐CODOX‐M/R‐IVAC versus dose‐
adjusted EPCH‐R (DA‐EPOCH‐R) for patients with newly diagnosed high risk Burkitt lymphoma Chamuleau MED GO27878: A phase IB/II, open‐label study evaluating the safety and pharmacokinetics of GDC‐0199 (ABT‐199) in combination with rituximab ® or Obinutuzumab (G) plus Annual Report VUmc CCA 2014 – Appendix 7: Scientific Research Committee ‐ 204 of 216 Applicant Title cyclofosfamide, doxorubicin, vincristine and prednisone (CHOP) in patients with B‐cell Non‐
Hodgkin's lymphoma (NHL) and DLBCL de Boer KHN A Phase 2b, Multicenter, Randomised, Double‐blind, Placebo‐controlled, Parallel‐group, Dose‐response Study Evaluating the Effecacy and Safety of JNJ‐54781532 in subjects with Moderately to Severely Active Ulcerative Colitis de Bree R Validation study of sentinel node biopsy in laryngeal carcinoma using freehand SPECT
de Jonge NA SHORT‐trial: Short versus extended antibiotic treatment with a carbapenem for high‐risk febrile neutropenia in hematology patients with Fever of Unknown Origin: a randomized multicenter open‐label non‐inferiority trial de Langen AJ Immunological profiling of hilar and mediastinal lymph nodes in lung cancer patients
de Langen AJ A Randomized Open‐Label Phase III Trial of MK‐3475 versus Platinum based Chemotherapy in 1L Subjects with PD‐L1 Strong Metastatic Non‐Small Cell Lung Cancer de Langen AJ A Phase III, Open‐Label, Randomized Study of AZD9291 versus Platinum‐Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non‐Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbor a T790M mutation within the Epidermal Growth Factor Receptor Gene (AURA‐3) Duvivier KM Pilot study: the use of PET‐MRI in work‐up of breast cancer patients Haarman E Randomized controlled trial (RCT) to determine the efficacy and safety of azithromycin (AZN) maintenance therapy for 6 months in subjects with PCD, a double‐blind, parallel group study Hashemi SMS A Randomized, Double‐Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Placlitaxel Versus Placebo Plua Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non‐Small Cell Lung Cancer (NSCLC) Hoekstra OS Technical validation of simplified quantitative methods for 3'deoxy‐3' [18F]fluorothymidine ([18F]FLT) PET in liver metastases of colorectal cancer patients' Hugtenburg JG Effect of food on the pharmacokinetics of nilotinib in chronic myeloid leukemia: assessment of a tailored dose reduction Jager DHJ Implantology and Sjögren's syndrome: a multicenter propective cohort study Janssen JJWM A multi‐center Phase 3 Randomized, Open‐Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Janssen JJWM HOVON 112 MSC: Treatment of severe acute GVHD after allogeneic hematopoietic stem cell transplantation with steroids versus MSC and steroids; a prospective double‐blind placebo‐controlled randomized phase III trial Kaspers GJL A multi‐center, open label, non‐controlled phase II study to evaluate efficacy and safety of oral nilotinib in pediatric patients whith newly diagnosed Ph+ chronic myelogenous leukemia (CML) in chronic phase (CP) or with Ph+ CML in CP or accelerated phase (AP) resistant or intolerant to either imatinib or dasatinib Kaspers GJL International randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia, Pediatric Relapsed AML 2010/01 Kaspers GJL An open label, multi‐center nilotinib roll‐over protocol for patients who have completed a previous Novartis‐sponsored nilotinib study and are judged by the investigator to benefit from continued nilotinib treatment Konings IRHM Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer ‐ the TRAIN‐2 study Konings IRHM Validatie van de Steep Ramp Test (SRT) voor het beoordelen van inspanningstolerantie bij patiënten met kanker die chemotherapie ondergaan (START) Konings IRHM A randomized double‐blind, placebo‐controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2‐negative, advanced breast cancer who received no prior therapy for advanced Annual Report VUmc CCA 2014 – Appendix 7: Scientific Research Committee ‐ 205 of 216 Applicant Title disease‐ the MONOLEESA‐2 (CLEE011A2301)
Konings IRHM A Randomized, Placebo‐Controlled, Double‐Blind, Phase 3 Study Evaluating Safety and Effecacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage riple Negative Breast Cancer (TNBC) Meijer CJLM A randomized, double‐blinded, controlled with GARDASIL (Human Papillomavirus Vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)), phase 3 clinical trial to study the immunogenicity and tolerability of V503 (9‐valent Human Papillomavirus [HPV] L1 virus‐like particle [VLP] vaccine) in 12‐ 26‐year‐old men Meijer E HOVON 116 AML studie: A phase I/II feasibility study of the combination of panobinostat and decitabine prior to donor lymphocyte infusion in recipients of allogeneic stem cell transplantation with poor and very poor‐risk AML Meijer E HOVON 113 MSC: treatment of severe steroid‐refractory acute GvHD with mesenchymal stromal cells. A phase III randomized double‐blind multi‐center HOVON study Meijer E GS‐US‐218‐018: A Phase 2b, Randomized, Double‐Blind, Placebo‐Controlled Multi‐Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS‐5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract Meijer E GS‐US‐218‐1502: A Phase 2b, Randomized, Double‐Blind, Placebo‐Controlled Multi‐Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS‐5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract Mellema W Randomized phase I/II study of regorafenib and erlotinib compared to decetaxel in patients with advanced KRAS mutation positive Non‐Squamous NSCLC that failed at least one line of platinum‐based chemotherapy Menke‐ van der Houven van Oordt CW An open label positron emission tomography (PET) imaging study using 89Zirconium to investigate the biodistribution of anti_HER3 monoclonal antibody (mAb) GSK2849330 and characterize its dose receptor occupancy relationship in subjects with advanced HER3‐
positive solid tumors Menke‐ van der Houven van Oordt CW Towards patient tailored cancer treatment supported by molecular imaging ‐ IMPACT: Imaging Patients for Cancer drug selecTion ‐ Metastatic Breast Cancer Menke‐ van der Houven van Oordt CW Watchful waiting in patients with good and intermediate risk metastatic renal cell carcinoma; an imaging guided observational approach Menke‐ van der Houven van Oordt CW Estrogen and Androgen Receptor Imaging in Metastatic Breast Cancer patients Ossenkoppele GJ HOVON 132 AML/ SAKK 30/13: randomized study with a run‐in dose‐selection phase to assess the added value of lenalidomide in cmbination with standard remission‐induction chemotherapy and post‐remission treatment in patients aged 18‐65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS‐R risk score > 4,5), a multicenter phase III study Ossenkoppele GJ SOPRA (Selinexor in Older Patients with Relapsed AML): A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT‐330) versus Specified Physician's Choice in Patients ≥ 60 Years Old with Relapsed/Refractory Acute Myeloid Leukemia (AML) Who are Ineligible for Intensive Chemotherapy and/or Transplantation Ossenkoppele GJ Een open‐label gerandomiseerde studie van fase 3 naar monotherapie met quizartinib (AC220) versus salvage chemotherapie bij patiënten met FLT3‐ITD‐positieve acute myeloïde leukemie (AML) die refractair is voor of recidiveerde na eerstelijnsbehandeling met of zonder hematopoëtische stamceltransplantatie (HSCT) als consolidatiebehandeling Ossenkoppele GJ B1871039: A Phase 4 Safety and Efficacy Study of Bosutinib (Bosulif®) in Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with One Or More Tyrosine Kinase Inhibitors Platek EE A phase 2, randomized, double‐blind, placebo‐controlled, dose‐range study of safety of Tofacitinib in subjects with active ankylosing spondylitis (AS) Annual Report VUmc CCA 2014 – Appendix 7: Scientific Research Committee ‐ 206 of 216 Applicant Title Ramsoekh D A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK‐5172/MK‐8742 in Subjects who have Failed Prior Treatment with Pegylated Interferon and Ribavirin (P/R) with Chronic HCV GT1, GT4, GT5 and GT6 Infection Rustemeyer T Efficacy of a skin barrier repair cream (Dermalex Eczema) in atopic dermatitis patients (EDAD) Rustemeyer T A Double‐Blind, Randomised, Placebo‐Controlled, Multi‐Center Field Study to Assess the Efficacy and Safety of HDM‐SPIRE in Subjects with a History of House Dust Mite‐Induced Rhinoconjunctivitis. Scheffer HJ COLDFIRE‐II study: Clorectal metastatic liver disease, efficacy of irreversible electroporation ‐ a phase II clinical trial Smit EF A Phase II Double‐Blind, Randomised, Placebo‐Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244, ARRY‐142886) (Hyd‐Sulfate) in Combination with Docetaxel, Compared with Placebo in Combination with Docetaxel, in Patients receiving second line treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB‐IV) (D1532C00064) Smit EF Paclitaxel‐trastuzumab in EGFR‐mutated NSCLC patients after progression on TKI‐
treatment; a pilot‐study Smit EF TIGER‐2: Een fase 2, openlabel onderzoek in meerdere centra naar de veiligheid en doeltreffendheid van orale CO 1686 als 2e‐lijns EGFR‐gerichte TKI bij patiënten met niet‐
kleincellige longkanker (NSCLC) door gemuteerde EGFR met de T790M‐resistentiemutatie Smit EF A Phase 2, Multicenter, Single‐arm Study of Oral AP26113 in Patients with ALK‐positive, Locally Advanced or Metastatic Non‐small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated with Crizotinib (ARIAD ALK studie) Straatman J The STOMACH trial. Surgical Technique; Open versus Minimally invasive gastrectomy After Chemotherapy [N.B. handtekening afdelingshoofd in protocol signature sheet] Straatman J the PRECious trial. A Step‐up approach: CRP first followed by CT‐scan imaging to ensure Quality Control after Major Abdominal Surgery Tuynman JB TESAR TRIAL: Rectal preserving treatment for early rectal cancer. A multicentred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancers. van de Donk N CC‐4047‐MM‐013: A phase 2 multicenter, open‐label study to determine the efficacy and safety of Pomalidomide (CC‐4047) in combination with low‐dose dexamethasone in subjects with relapsed of refractory multiple myeloma and moderate or severe renal impairment including subjects undergoing hemodialysis. van de Loosdrecht AA Protocol Celgene AZA‐MDS‐003 tudie: A Phase 3, Multicenter, Randomized, Double‐blind Study to Supportive Care in Subjects with Red Blood Cell Transfusion‐dependent Anemia and Thrombocytopenia due to IPSS Lower‐risk Myelodysplastic Syndromes van de Loosdrecht AA Study 200170: A Rollover Study to Provide Continued Treatment with Eltrombopag (NL48025.029.14) van Delft F Acute biliary Pancreatitis: early ERC plus sphincterotomy versus Conservative treatment ‐
The APEC‐trial van den Eertwegh AJM A Phase Ib/II Study of GDC‐0068 or GDC‐0980 with Abiraterone Acetate Versus Abiraterone Acetate in Patients wit Castration‐Resistant Prostate Cancer Previously Treated with Docetaxel‐Based Chemotherapy van den Eertwegh AJM A randomised Phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium van den Eertwegh AJM A Randomized, Double Blind, Multicenter, Parallel‐Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy van den Eertwegh AJM EORTC 18081: Adjuvant Pegylated‐Interferon‐alpha2b (SylatronTM) for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2‐
Annual Report VUmc CCA 2014 – Appendix 7: Scientific Research Committee ‐ 207 of 216 Applicant Title 4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. van den Eertwegh AJM A phase 2, Randomized, Double‐Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects with Metastatic Chemotherapy‐Naïve Castration Resistant Prostate Cancer Who are Asymptomatic or Minimally Symptomatic van den Eertwegh AJM A Phase II, Open‐Label, Multicenter Study of Vemurafenib plus Cobimetinib (GDC‐0973) in Unresectable Stage IIIc of Stage IV Melanoma ‐ Response Monitoring and Resistance Prediction with Positron Emission Tomography and Tumor Characteristics (REPOSIT). van den Tol MP MISSFIRE: mammacarcinoma IRE Surgery study, non‐thermal ablation using irreversible Electroporation (IRE) to treat breast cancer van der Vorst MJDL A Phase 3, Randomized, Double‐blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib van Moorselaar RJA Optical biopsy to improve the diagnosis of kidney cancer: a prospective, observational, multicentre, invivo study (OCT‐study) van Moorselaar RJA Urine protocol Nanopil studie
van Moorselaar RJA PCMM prostate cancer molecular medicine
Veening MA International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Veening MA 30‐day, open‐label, active‐controlled, randomized study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations of venous thrombosis (IMP 14374) Veening MA Multicenter, open‐label, active‐controlled, randomized study to evaluate the efficacy and safety of an age‐and body weight‐adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism (IMP 14372) Verdonck‐de Leeuw IM Efficacy of a guided self‐help exercise program targeting speech, swallowing and shoulder problems in laryngectomized patients: a randomized controlled trial Verheul HMW An Open‐Label, Non‐randomised, Parallel Group, Multicentre, Phase I Study to Assess the Safety and the Effect of Olaparib at Steady State on the Pharmacokinetics of the Anti‐
hormonal Agents Anastrozole, Letrozole and Tamoxifen at Steady State, and the effect of the Anti‐hormonal Agents on Olaparib, Following Administration in Patients With Advanced Solid Cancer Verheul HMW CORRELATE ‐ Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings
Verheul HMW Treatment strategies in colorectal cancer patients with initially unresectable liver‐only metastases CAIRO5 a randomised phase 3 study of the Dutch Colorectal Cancer Group (DCCG) Verheul HMW A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 211 Administered as Continuous Intravenous Infusion in Subjects with Relapsed/Refractory Gastrointestinal Adenocarcinoma Vis AN The use of indocyanine green for accurate sentinel node detection and removal in a group of high‐risk nodal metastasis prostate cancer patients Voortman J A phase I, open‐label, multi‐center, dose escalation study of oral BGJ398, a pan FGF‐R kinase inhibitor, in adult patients with advanced solid malignancies Zijlstra JM Phase I/II feasibility study combining brentuximab vedotin with second line salvage chemotherapy (DHAP) in Hodgkin lymphoma patients refractory to first lne chemotherapy or in first relapse who are eligible for high dose treatment followed by autologous peripheral blood stem cell transplantation (Transplant BRaVE) Zijlstra JM SOPHIA study: Study Of menopause in ex‐Patients of Hodgkin lymphoma: influence on long‐term Adverse effects Zweegman S A Randomized, Open label phase 3 Study of Carfilzomib, Melphalan and Prednisone versus Bortezomib, Melphalan and Prednisone in Transplant‐ ineligible patients with newly diagnosed Multiple Myeloma Annual Report VUmc CCA 2014 – Appendix 7: Scientific Research Committee ‐ 208 of 216 Applicant Title Zweegman S Protocol OPZ006: A Phase 1b/2, multicenter, open‐label study of Oprozomib, Melphalan and Prednisone in transparant ineligible patients with newly diagnosed multiple myeloma Zweegman S Millennium C16019: A Phase 3, Randomized, Placebo‐Controlled, Double‐Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant Zweegman S HOVON 126 MM/ NMSG 21.13: Ixazomib citrate‐thalidomide‐low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trial Zweegman S The role of 15O‐water and 18F‐fluoride‐PET/CT and MRI‐DCE and ‐DWIBS in characterizing the bone marrow environment in advanced‐stage myelofibrosis and the additive value in response monitoring during ruxolitinib treatment Zweegman S HOVON 129 PCL: Carfilzomib and lenalidomide‐based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients. A European Intergroup Trial of the European Myeloma Network EMN (EMN12/HO129 PCL) Zweegman S The BEAMY study: Characterizing the Bone marrow Evironment in Advanced‐stage Myelofibrosis. A PET/MRI study Zweegman S 54767414MMY3003 (POLLUX) study: Phase 3 study comparing daratumumbab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in subjects with relapse or refractory multiple myeloma Zweegman S Selvedex KPT‐330: A Phase II study of Selinexor (KPT‐330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive of refractory Multiple Myeloma. Grant Applicant Title
Bas Mulder Veringa S Epigenetics in the treatment of pediatric malignant glioma EU‐Innovative Training Networks (ITN) van Kooyk Y Selective Carbohydrate Immunomodulators targeting C‐type Lectin Receptors on Antigen Presenting Cells‐IMMUNOSHAPE Huijgens PhD position Vumc CCA
Ruhe E Dissecting the Heterogeneity of Myelodysplastic Syndromes: A Patholphysiological Approach Huijgens PhD position Vumc CCA
Ruhe E Improving therapy of bladder cancer: the development of novel BCG
KWF Bakema JE Antibodies paying Toll to improve their therapeutic efficacy: Improving antibody‐mediated anti‐cancer treatment via co‐activation of Toll‐like receptors and Fc‐receptors KWF Bijnsdorp IV Towards minimally‐invasive detection of aggressive prostate cancer
KWF Bleeker MCG
Vulvar carcinogenesis: assessment of molecular alterations in vulvar squamous cell carcinoma and precursor lesions KWF Bleeker MCG
Vulvar carcinogenesis: assessment of molecular alterations in vulvar squamous cell carcinoma and precursor lesions KWF Braakhuis BJM
Molecular pathology of squamous cell carcinoma of the oral cavity in young adults KWF de Gruijl TD A randomized Phase 2 trial of local low‐dose anti‐CTLA4 administration combined with an NY‐ESO‐1 vaccine in early‐stage melanoma patients KWF Griffioen AW
Rapid stochastic optimization of drug combination for optimal angiostatic cancer therapy KWF Griffioen AW
A vaccine against the tumor vasculature
KWF Klein M Long‐term oncological and functional outcome after surgery and radiotherapy in patients with diffuse low‐grade gliomas Annual Report VUmc CCA 2014 – Appendix 7: Scientific Research Committee ‐ 209 of 216 Grant Applicant Title
KWF Kwakman R Responspredictie van hypertherme intraperitoneale chemotherapie voor peritoneale metastasen van het colorectaal carcinoom KWF Meijerink MR
PANFIRE‐2 study: Locally advanced pancreatic carcinoma: efficacy of irreversible electroporation (IRE) – a phase II clinical trial KWF Meijerink WJHJ
Detection of colorectal cancer by using a tumorspecific radioactive and fluorescent tracer KWF Moll AC Second primary malignancies in hereditary retinoblastoma patients
KWF Mutis T Generation of safe and efficient, off the shelf, chimeric antigen receptor (CAR)‐engineered T cells for broad application KWF Mutis T Unraveling and Therapeutic Targeting of Microenvironment‐Mediated Immune Escape Mechanisms in Multiple Myeloma KWF Pegtel DM Circulating small RNAs for non‐invasive remission monitoring in Lymphoma
KWF Pegtel DM Extracellular miRNAs for monitoring Lymphoma patient treatment response KWF Ramsoekh D Immunochemical faecal occult blood test followed by colonoscopy in individuals at increased risk for colorectal cancer; a multicenter study comparing test performance of OC‐sensor and FOB‐Gold KWF Scheffer HJ COLDFIRE‐2 study: Colorectal metastatic liver disease: efficacy of irreversible electroporation (IRE) – a phase II clinical trial KWF Schuurhuis GJ
Identification of under‐treated and over‐treated acute myeloid leukemia patients, using minimal residual diseas and leukemia stem cell frequency KWF Schuurhuis GJ
Identification of therapy surviving leukemia initiating cells in acute myeloid leukemia KWF Smit L The role of microRNAs in persistence of acute myeloid leukemia stem cells
KWF Straatman J STOMACH trial: Surgical Technique; Open versus Minimally invasive gastrectomy After Chemotherapy KWF Thijssen VLJL
Galectin‐targeted therapy to sensitize anti‐VEGF resistant tumors KWF Thijssen VLJL
Regulation of tumor progression via galectin‐cytokine interactions; opportunities for the development of new anti‐cancer therapies KWF van Montfrans C
Surgical excision versus imiquimod versus radiotherapy for the treatment of lentigo maligna: an open label non‐inferiority randomized controlled trial KWF Veening MA Very long‐term renal effects in Dutch survivors of childhood cancer
KWF Verheul HMW
Improved treatment with tyrosine kinase inhibitors by alternative treatment dosing and scheduling KWF Vis A Unravelling mechanistic features between cholesterol metabolism and prostate cancer progression KWF Westerman A
The GlioINTEGRATE project: from glioblastoma data integration to therapy
KWF Wolthuis R Exploiting Sister Chromatid Cohesion Defects in Breast Cancer KWF Würdinger T mRNA sequencing of tumor‐educated platelets for multi‐class cancer diagnostics KWF Alpe d'HuZes Klein M Reducing the psychological burden of primary brain tumors: an innovative approach aimed at sustaining independence of patients and their informal caregivers KWF Kanker en Ouderen Slee‐Valentijn MS
COMMODO; Communicatie over Ouderen in de Oncologie KWF Kanker en Ouderen Slee‐Valentijn MS
Prehab: een gerandomiseerde studie naar prehabilitatie bij ouderen met Annual Report VUmc CCA 2014 – Appendix 7: Scientific Research Committee ‐ 210 of 216 Grant Applicant Title
colorectaal kanker
KWF Secundaire Preventie van Kanker Bontkes HJ / Cillessen SAGM Prospective analysis of and validation of biomarkers for the development of Pr‐EATL and EATL KWF Secundaire preventie van Kanker Heideman DAM / Snijders PJF Improvement of HPV‐based cervical cancer screening by methylation marker triage testing KWF Secundaire preventie van Kanker Mulder CJ European Consortium for Epidemiology and Treatment Protocol for (Pr‐
)EATL and Enteropathy Associated T‐cell Lymphoma Seventh Framework Program HEALTH EU van Dulmen‐den Broeder E Fertility impairment in a pan‐European cohort of female 5‐year survivors of childhood cancer (project acronym: PanCareLIFE) Stichting Nutsohra Straatman J the STOMACH trial: Surgical Technique: Open versus Minimally invasive gastrectomy After CHemotherapy Stichting Semmy Meel H Targeting growth factor‐induced signal transduction in Diffuse Intrinsic Pontine Glioma Stichting Semmy Veringa S Epigenetic therapies in pediatric high‐grade glioma VENI Prins H‐J Understanding hematopoietic‐stromal interactions in myelofibrosis
VENI Xi Wen Zhao Glioblastoma immune‐conversion by inhibition of tumour‐derived extracellular vesicles VIDI Giovannetti E
Visualizing and profiling tumor‐host crosstalk for the individualized selection of effective drugs against metastatic pancreatic cancer VIDI van der Vliet JJ
Taking immune checkpoint blockade to the next level VUmc van de Wiel MA
Targeted and personalized cancer therapy development by high‐
demensional data analysis VUmc van Vuurden DG
Molecular Drug Imaging in Childhood Brain Tumours Vumc CCA Foundation Bakema JE Generation of a novel syngeneic in vivo model of head and neck squamous cell carcinoma Vumc CCA Foundation Berenguer J Targeting chemokine receptors: a novel anti‐cancer systems biology approach Vumc CCA Foundation Bleeker MCG
Identification of molecular alterations in HPV‐induced vulvar carcinogenesis for tailored management of women with vulvar intraepithelial neoplasia Vumc CCA Foundation Bonjer HJ Rectal cancer; risk assessment and novel rectal cancer treatment strategies for better quality of life without compromise in oncological outcome Vumc CCA Foundation Braakhuis BJM
Gene expression in peripheral blood cells: value as biomarker for head and neck squamous cell carcinoma Vumc CCA Foundation Braakhuis BJM
Intra‐tumor genetic heterogeneity in head and neck squamous cell carcinoma Vumc CCA Foundation Buffart T MiR expression based clinical test for optimal treatment selection in patients with advanced colorectal cancer Vumc CCA Foundation Cover KS Differentiating between pseudoprogression and true progression in glioblastoma using color intensity projections of MRI perfusion Vumc CCA Foundation de Graaf P Multimodality and multi‐parametric PET/MRI analysis for enhancing diagnosis, prognosis and response prediction in advanced stage head and neck cancer. Vumc CCA Foundation de Graaf P Development of a radiomics pipeline for head and neck cancer Annual Report VUmc CCA 2014 – Appendix 7: Scientific Research Committee ‐ 211 of 216 Grant Applicant Title
Vumc CCA Foundation de Graaf P Early multiparametric PET‐MRI in conjunction with tumor protein profiling for early response prediction and characterisation in neoadjuvant chemotherapy for breast cancer Vumc CCA Foundation de Langen AJ
Mapping the immune microenvironment in non‐small cell lung cancer –
biomarker exploration Vumc CCA Foundation den Haan JMM
Does synergy of the humoral and cellular immune system predict or protect against colorectal cancer development in inflammatory bowel disease patients? Vumc CCA Foundation Derks S Immune checkpoint inhibition in esophageal adenocarcinoma; investigating the regulation of PD‐L2 in cancer cells and its role in modulating immune evasion Vumc CCA Foundation Dirven L Improving participation of brain cancer and hematological cancer patients in clinical decision‐making: a randomized clinical trial on the implementation of facilitated advance care planning Vumc CCA Foundation Dorsman JC A new approach for translational Retinoblastoma research Vumc CCA Foundation García Vallejo JJ
Harnessing extracellular vesicles for dendritic cell immunotherapy against glioblastoma Vumc CCA Foundation Heideman DAM
Mutation profiling of premalignant lesions of endobronchial squamous cell carcinoma Vumc CCA Foundation Houweling AC
Clinical, histological and molecular studies of renal cell cancer in Birt‐Hogg‐
Dubé Syndrome (BHD) Vumc CCA Foundation Hulleman E Development and validation of a new method for the ultra‐sensitive blood‐
based detection of point mutations in pediatric oncology Vumc CCA Foundation Jimenez CR Targeted kinome pathway activity assay by mass spectrometry (MS) to enable personalized treatment of cancer with kinase inhibitors Vumc CCA Foundation Jordanova ES
Cracking carbohydrate cues in cervical cancer Vumc CCA Foundation Kazemier G MicroRNA (miRNA) profiling of ductal and duodenal fluids to improve the differential diagnosis and optimize therapeutic strategies for cholangiocarcinoma and pancreatic cancer Vumc CCA Foundation Koppers‐Lalic D
Transfer RNAs (tRNAs) as novel class of cancer biomarkers Vumc CCA Foundation Meijerink MR
COLDFIRE‐2 study: Colorectal metastatic liver disease: efficacy of irreversible electroporation (IRE) – a phase II clinical trial Vumc CCA Foundation Meijerink MR
PANFIRE II – Chemoradiation using SBRT versus chemoablationusing irreversible electroporation (IRE) to treat locally advanced pancreatic carcinoma (LAPC) – a randomized phase III clinical trial Vumc CCA Foundation Meijerink WJHJ
Improvement of sentinel lymph node identification in early colon cancer
Vumc CCA Foundation Menezes R Tumor classification by functional genomics
Vumc CCA Foundation Pegtel DM Standardizing collection, processing and biobanking of blood specimens from patients with cancer to facilitate Liquid Biopsy testing at the VUmc‐
CCA Vumc CCA Foundation Rubina Baglio S
Mesenchymal stem cell‐induced drug resistance in cancer Vumc CCA Foundation Schuurhuis GJ
The characterization of minimal residual disease of acute myeloid leukemia to tailor personalized therapy Vumc CCA Foundation Sie D Initial steps towards Bed Side Sequencing for personalized cancer therapy
Vumc CCA Foundation Sminia P Conjugated biodegradable polymersomes for local delivery of anti‐cancer therapeutics to brain tumours Vumc CCA Foundation Smit L The role of epigenetic mechanisms and stemness in heterogeneity of Annual Report VUmc CCA 2014 – Appendix 7: Scientific Research Committee ‐ 212 of 216 Grant Applicant Title
myeloid leukemia and the consequence for chemotherapy sensitivity
Vumc CCA Foundation Steenbergen RDM
High‐throughput functional validation of altered microRNAs associated with HPVinduced anchorage independent growth Vumc CCA Foundation Stoker JA Supporting Resilience and Case Finding – Evaluation of an Innovative Procedure for Detecting and Treating Psychological Distress in Patients with Cancer Vumc CCA Foundation te Velde EA Molecular determinants for efficacy of HIPEC of colon cancer Vumc CCA Foundation Thunnissen E
RNAseq for the identification of driver gene‐fusions in pulmonary carcinoids Vumc CCA Foundation van Beusechem VW Targeting epigenetic and RNA deregulation: the 11th hallmark of cancer
Vumc CCA Foundation van de Ven R
Characterizing a new immune checkpoint in HPV negative head and neck cancers: exploring prognostic and therapeutic value' Vumc CCA Foundation van den Heuvel B
FIT FOR SURGERY
Vumc CCA Foundation van der Steen LPE
Granulocytic myeloid‐derived suppressor cells (G‐MDSC): suppressors or future effectors? Vumc CCA Foundation van Die IM Exploring galectin 4 as a novel molecular target for prognostic and therapeutic purposes in pancreatic cancer Vumc CCA Foundation van Litsenburg RRL Quality of life, sleep and cost‐effectiveness of treatment in pediatric acute myeloid leukemia Vumc CCA Foundation van Vuurden DG
Radiolabeled Erlotinib and Dasatinib for PET imaging in children with high‐
grade glioma and diffuse intrinsic pontine glioma, a diagnostic feasibility study Vumc CCA Foundation Volders JH MISS‐FIRE ( Mammacarcinoma IRE Surgery Study a Feasibility study of IRrevisible Electoporation) Vumc CCA Foundation Voortman J Let the tumor speak: microRNA profiles for clinical outcome prediction in laryngohypopharyngeal cancer patients treated with chemoradiation Vumc CCA Foundation Waalboer D Combining highly potent synthetic tubulysins with in‐house developed platinum‐based linker‐technology; breaking the monopoly of big pharma with next generation Antibody‐Drug Conjugates (ADCs) Vumc CCA Foundation Wesseling P Deciphering intratumoral heterogeneity by in situ RNA‐seq for optimal combination therapy Vumc CCA Foundation Westerman B
The Cancer Synergy Atlas Platform (CSAP): An integrated bioinformatics platform to classify and target tumor subclasses using tailored synergistic multidrug cocktails Vumc CCA Foundation Wilting SM Improving classification of molecular tumour profiles from impure clinical material by the use of co‐data Vumc CCA Foundation Wurdinger T Imaging the Imaginary: 3D CLARITY visualisation of whole (tumor) tissues
Vumc CCA Foundation Wurdinger T Evaluation of a novel tumor suppressor discovery tool and development of a tumor suppressor CRISPR/Cas9 knock out library VUmc CCA PhD position Gibbs S Investigation of innate and adaptive T cell responses in skin and oral mucosa VUmc CCA PhD position Le Large T Integrative microRNAs and functional profiling of resistance patterns to foster novel therapeutics in pancreatic ductal adenocarcinoma VUmc CCA PhD position van Kooyk Y A bitter sweet symphony: how tumor glycans orchestrate immune evasion
VUmc CCA PhD position Wolthuis R The Signaling Pathways of Folliculin (FLCN): a Tumor Suppressor in Birt‐
Hogg‐Dubé Hereditary Kidney Cancer with Connections to Ras and p53 Annual Report VUmc CCA 2014 – Appendix 7: Scientific Research Committee ‐ 213 of 216 Grant Applicant Title
VUmc research into childhood cancer Klein K Cytogenetics and treatment response in pediatric acute myeloid leukaemia
ZonMw van de Velde M
Vincristine‐induced peripheral neuropathy in children with acute lymphoblastic leukemia: comparing one‐hour infusions with bolus injections (the VINCA study) ZonMw van den Berg M
Reducing Vincristine‐Induced peripheral Neuropathy in Children with Acute lymphoblastic leukemia by one‐hour infusions instead of bolus injections (the VINCA study) ZonMW van Kooyk Y Exploration of crosstalk between CLRs and TLRs using single molecule vaccine modalities ZonMW van Kooyk Y Turning tumor glycans into anticancer vaccines single molecule vaccine modalities Annual Report VUmc CCA 2014 – Appendix 7: Scientific Research Committee ‐ 214 of 216 CWO DEC: Animal related protocols Applicant Title Aleyd E De rol van interacties tussen immunoglobulin A (IgA) met de IgA Fc receptor (Fc RI) op neutrofielen in mucosale ontsteking van het darmstelsel Aleyd E Het genezen en voorkomen van blaarvorming in een Linear IgA Bullous Disease (LABD) muizenmodel Ankersmit M / van Dongen GAMS
Detectie van colorectale tumoren met behulp van een fluorescent en radioactief gelabeld gehumaniseerd anti‐CEA antilichaam labetuzumab Bar‐Ephraim J Rol van CD62L bij recirculatie van innate lymphoid cells (ILCs)
Bijnsdorp I Osteoclasten en prostaatmetastases – Pilot: injectie route
Braakhuis B Tumorselectieve therapie van hoofd‐halskanker met een nieuw antikanker middel in combinatie met bestraling en in vergelijking met chemoradiatie: (KNO – 14‐xx) Braakhuis B Tumorselectieve therapie van hoofd‐halskanker met een nieuw antikanker middel in combinatie met bestraling en in vergelijking met chemoradiatie : drug X (KNO – 14‐xx) Cornelissen L Tumor specifieke Siaalzuren en Tn antigens en de onderdrukking van de anti‐tumor immuun response den Haan J Leidt eliminatie van Siglec1+/CD169+ macrofagen tot verminderde immuunresponsen en minder lange antigen presentatie na antigen targeting? Ferrantelli E The effect of Alanine‐Glutamine dipeptide on preserving membrane function in rodent peritoneal dialysis model Griffioen A Vaccinatie tegen eiwitten in de tumorbloedvaten als een methode ter behandeling van solide tumoren en de ontwikkeling van een vaccin tegen Ewing sarcoom Gül N Effecten van TLR liganden op de lever na behandeling met tumorspecifiek antilichaam Hooijberg E / Carvalho B Colorectal adenoma to carcinoma progression; the role of AURKA and TPX2 Ilarregui JM Study of contact hypersensitivity response in different lectin KO mice Keuning E Dierproeven ten behoeve van onderwijs aan medewerkers van de afdeling Moleculaire Celbiologie en Immunologie (MCBI) van het VU medisch centrum (al dan niet in opleiding). Koning J De rol van retinolzuur in de ontwikkeling van lymfatisch endotheel op moleculair niveau Lagerweij T Analyse van immunotoxines gebaseerd op antilichaam fragmenten uit lama’s in in vivo hersentumormodellen Lagerweij T Hersentumoren: Modellen, behandelingen, beeldvorming en diagnostiek. Lagerweij T Study of the role of mesenchymal stem cells conditioned with osteosarcoma exosomes in the development of osteosarcoma metastases Legler J Establishing a universal zebrafish adipogenesis standard (positive control) for obesity research
Reijmers RM Bestuderen van dermatan sulfaat in het functioneren van de lymfeklier Schetters S Nieuwe dendritische cel‐gemedieerde vaccin formuleringen tegen solide tumoren Sciarrillo R Development of malignant mesothelioma (MM) mouse models from primarycultures as new tools for therapeutics discovery Thijssen V Optimalisation of combination of angiostatic drugs and radiotherapy van der Sar A Onderzoek naar de rol van PPE38 en LipY in virulentie van Mycobacterium marinum in zebravissen van der Steen L Chirurgie‐geïnduceerde levermetastases
van der Steen L Optimalisatie van monoklonale anti‐CD20 antilichaamtherapie door het bundelen van de kracht van IgG met de activatie van de IgA Fc receptor Fc RI Annual Report VUmc CCA 2014 – Appendix 7: Scientific Research Committee ‐ 215 of 216 Applicant Title van der Stoop P Het bepalen van het effect van uitschakelen van COPB2 door RNAi of chemische interventie met Prazosin op de stralingsgevoeligheid, groei en migratie van diffuus infiltratieve glioomcellen van der Vliet JJ Anti‐tumor effectiviteit en biodistributie van een bespecifiek anti‐EGFR‐anti‐V 9V 2 TCR nanobody van Dinther D Het belang van CD4+ T cel activiteit en antilichaam productie bij het in stand houden van een goede cytotoxische T cel respons. van Dongen GAMS Evaluation of the pharmacokinetic profile of Zr‐labeled antibody‐tracer conjugates prepared by conjugation to reduced inter‐chain disulfides or by random conjugation van Dongen GAMS PET‐imaging en biodistributie met [ C]vemurafenib gecorreleerd aan de effectiviteit van behandeling met vemurafenib, een BRAF‐V600E selectieve kinase remmer in melanoom en colorectaal tumoren van Dongen GAMS Therapie respons voorspelling door middel van PET imaging met gelabelde TKIs [ F]afatinib 11
and [ C]erlotinib van Dongen GAMS Tumor targeting performance of a Zr‐labeled anti‐CD27 antibody Veninga H Duur van antigen presentatie na targeting van antigenen naar macrofaag en DC subsets Veninga H Leidt de targeting van tumor antigenen naar siglec‐1+ macrofagen tot vermindering van uitgroei van tumoren? Vila Cuenca M Effect of Paricalcitol on Klotho expression and its distant effects in Vitamin D deficient and uremic rat 89
11
18
89
Annual Report VUmc CCA 2014 – Appendix 7: Scientific Research Committee ‐ 216 of 216

PDF bestand Page 1. Page 2. Appendix Annual Report Vumc CCA

Transcription

Similar documents

De afdeling Medische Oncologie, eerder afdeling

65. Annual Report 2010 20 februari 2016 — PDF bestand Page 1

PDF bestand VUmc Cancer Center Amsterdam (VUmc CCA)

PDF bestand Page 1. VUmc Cancer Center Amsterdam VUmc CCA

PDF bestand Page 1. VUmc Cancer Center Amsterdam

Year Report Julius Center 2007

HPV - Gezondheidsraad

NAA: A2478, KRAMER J M M

deel 3 deel 4

Hoofd-Hals Journaal 39 oktober 2008